
<html lang="en"     class="pb-page"  data-request-id="10d14b29-4b3d-4021-acc4-59989f0f3b0c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00761;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-23"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Development Process for Discovery and Clinical Advancement of Modern Antimalarials" /></meta><meta name="dc.Creator" content="Trent D.  Ashton" /></meta><meta name="dc.Creator" content="Shane M.  Devine" /></meta><meta name="dc.Creator" content="Jörg J.  Möhrle" /></meta><meta name="dc.Creator" content="Benoît  Laleu" /></meta><meta name="dc.Creator" content="Jeremy N.  Burrows" /></meta><meta name="dc.Creator" content="Susan A.  Charman" /></meta><meta name="dc.Creator" content="Darren J.  Creek" /></meta><meta name="dc.Creator" content="Brad E.  Sleebs" /></meta><meta name="dc.Description" content="Malaria is a devastating disease caused by Plasmodium parasites, resulting in approximately 435000 deaths in 2018. The impact of malaria is compounded by the emergence of widespread resistance to c..." /></meta><meta name="Description" content="Malaria is a devastating disease caused by Plasmodium parasites, resulting in approximately 435000 deaths in 2018. The impact of malaria is compounded by the emergence of widespread resistance to c..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 6, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00761" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00761" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00761" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00761" /></link>
        
    
    

<title>The Development Process for Discovery and Clinical Advancement of Modern Antimalarials | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00761" /></meta><meta property="og:title" content="The Development Process for Discovery and Clinical Advancement of Modern Antimalarials" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0030.jpeg" /></meta><meta property="og:description" content="Malaria is a devastating disease caused by Plasmodium parasites, resulting in approximately 435000 deaths in 2018. The impact of malaria is compounded by the emergence of widespread resistance to current antimalarial therapies. Recently, a new strategy was initiated to screen small molecule collections against the Plasmodium parasite enabling the identification of new antimalarial chemotypes with novel modes of action. This initiative ushered in the modern era of antimalarial drug development, and as a result, numerous lead candidates are advancing toward or are currently in human clinical trials. In this Perspective, we describe the development pathway of four of the most clinically advanced modern antimalarials, KAE609, KAF156, DSM265, and MMV048. Additionally, the mechanism of action and life–cycle stage specificity of the four antimalarials is discussed in relation to aligning with global strategies to treat and eliminate malaria. This perspective serves as a guide to the expectations of modern antimalarial drug development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00761"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00761">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00761&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00761&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00761&amp;href=/doi/10.1021/acs.jmedchem.9b00761" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10526-10562</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00683" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b01562" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Development Process for Discovery and Clinical Advancement of Modern Antimalarials</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Trent D. Ashton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Trent D. Ashton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia</div><div class="loa-info-affiliations-info">Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Trent+D.++Ashton">Trent D. Ashton</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shane M. Devine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shane M. Devine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shane+M.++Devine">Shane M. Devine</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8727-7392" title="Orcid link">http://orcid.org/0000-0001-8727-7392</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jörg J. Möhrle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jörg J. Möhrle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%B6rg+J.++M%C3%B6hrle">Jörg J. Möhrle</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benoît Laleu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benoît Laleu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beno%C3%AEt++Laleu">Benoît Laleu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeremy N. Burrows</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeremy N. Burrows</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy+N.++Burrows">Jeremy N. Burrows</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan A. Charman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan A. Charman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+A.++Charman">Susan A. Charman</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Darren J. Creek</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darren J. Creek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>For D.J.C.: phone, +61 3 9903 9249; E-mail, <a href="/cdn-cgi/l/email-protection#7612170404131858150413131d361b191817051e58131203"><span class="__cf_email__" data-cfemail="4d292c3f3f2823632e3f2828260d2022232c3e2563282938">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darren+J.++Creek">Darren J. Creek</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7497-7082" title="Orcid link">http://orcid.org/0000-0001-7497-7082</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Brad E. Sleebs</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brad E. Sleebs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia</div><div class="loa-info-affiliations-info">Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3052, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>For B.E.S.: phone, +61 3 9345 2718; E-mail, <a href="/cdn-cgi/l/email-protection#d0a3bcb5b5b2a390a7b5b8b9feb5b4a5feb1a5"><span class="__cf_email__" data-cfemail="b1c2ddd4d4d3c2f1c6d4d9d89fd4d5c49fd0c4">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brad+E.++Sleebs">Brad E. Sleebs</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9117-1048" title="Orcid link">http://orcid.org/0000-0001-9117-1048</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00761&amp;href=/doi/10.1021%2Facs.jmedchem.9b00761" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10526–10562</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 6, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 May 2019</li><li><span class="item_label"><b>Published</b> online</span>6 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00761" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00761</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10526%26pageCount%3D37%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTrent%2BD.%2BAshton%252C%2BShane%2BM.%2BDevine%252C%2BJ%25C3%25B6rg%2BJ.%2BM%25C3%25B6hrle%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D23%26contentID%3Dacs.jmedchem.9b00761%26title%3DThe%2BDevelopment%2BProcess%2Bfor%2BDiscovery%2Band%2BClinical%2BAdvancement%2Bof%2BModern%2BAntimalarials%26numPages%3D37%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10562%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00761"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2834</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00761" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Development Process for Discovery and Clinical Advancement of Modern Antimalarials&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Trent&quot;,&quot;last_name&quot;:&quot;D. Ashton&quot;},{&quot;first_name&quot;:&quot;Shane&quot;,&quot;last_name&quot;:&quot;M. Devine&quot;},{&quot;first_name&quot;:&quot;Jörg&quot;,&quot;last_name&quot;:&quot;J. Möhrle&quot;},{&quot;first_name&quot;:&quot;Benoît&quot;,&quot;last_name&quot;:&quot;Laleu&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;N. Burrows&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;A. Charman&quot;},{&quot;first_name&quot;:&quot;Darren&quot;,&quot;last_name&quot;:&quot;J. Creek&quot;},{&quot;first_name&quot;:&quot;Brad&quot;,&quot;last_name&quot;:&quot;E. Sleebs&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10526-10562&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00761&quot;},&quot;abstract&quot;:&quot;Malaria is a devastating disease caused by Plasmodium parasites, resulting in approximately 435000 deaths in 2018. The impact of malaria is compounded by the emergence of widespread resistance to current antimalarial therapies. Recently, a new strategy was initiated to screen small molecule collections against the Plasmodium parasite enabling the identification of new antimalarial chemotypes with novel modes of action. This initiative ushered in the modern era of antimalarial drug development, and as a result, numerous lead candidates are advancing toward or are currently in human clinical trials. In this Perspective, we describe the development pathway of four of the most clinically advanced modern antimalarials, KAE609, KAF156, DSM265, and MMV048. Additionally, the mechanism of action and life–cycle stage specificity of the four antimalarials is discussed in relation to aligning with global strategies to treat and eliminate malaria. This perspective serves as a guide to the expectations of modern antimalari&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00761&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00761" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00761&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00761" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00761&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00761" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00761&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00761&amp;href=/doi/10.1021/acs.jmedchem.9b00761" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00761" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00761" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00761%26sid%3Dliteratum%253Aachs%26pmid%3D31385706%26genre%3Darticle%26aulast%3DAshton%26date%3D2019%26atitle%3DThe%2BDevelopment%2BProcess%2Bfor%2BDiscovery%2Band%2BClinical%2BAdvancement%2Bof%2BModern%2BAntimalarials%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D23%26spage%3D10526%26epage%3D10562%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291528" title="Parasites">Parasites</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/jmcmar.2019.62.issue-23/20191212/jmcmar.2019.62.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Malaria is a devastating disease caused by <i>Plasmodium</i> parasites, resulting in approximately 435000 deaths in 2018. The impact of malaria is compounded by the emergence of widespread resistance to current antimalarial therapies. Recently, a new strategy was initiated to screen small molecule collections against the <i>Plasmodium</i> parasite enabling the identification of new antimalarial chemotypes with novel modes of action. This initiative ushered in the modern era of antimalarial drug development, and as a result, numerous lead candidates are advancing toward or are currently in human clinical trials. In this Perspective, we describe the development pathway of four of the most clinically advanced modern antimalarials, KAE609, KAF156, DSM265, and MMV048. Additionally, the mechanism of action and life–cycle stage specificity of the four antimalarials is discussed in relation to aligning with global strategies to treat and eliminate malaria. This perspective serves as a guide to the expectations of modern antimalarial drug development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The World Health Organization (WHO) estimates that around 3.5 billion people, about half of the world’s population, live at risk of malaria.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In 2018, there was an estimated 219 million cases of malaria and 435000 deaths occurred globally, with 92% of cases in Africa and 5% in South East Asia. Children under the age of 5 are most at risk and account for about 61% of deaths worldwide.</div><div class="NLM_p">Malaria in humans is caused by five <i>Plasmodium</i> species. <i>Plasmodium falciparum</i> (Pf) is the most prevalent species and accounts >99% of cases in Africa and 63% of cases in South East Asia, while <i>Plasmodium vivax</i> (Pv) is common in South East Asia and accounts for 72% of cases in the Americas.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Pf is the most lethal of the <i>Plasmodium</i> species and is responsible for approximately 90% of all malaria related deaths globally. Pv is responsible for recrudescent infection via activation of dormant liver-stage hypnozoites that re-establish the clinical blood stage of infection. Although <i>Plasmodium malariae</i> and <i>Plasmodium ovale</i> may cause milder symptoms than Pf or Pv,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> these parasites can be part of mixed species infections and, as such, are usually not detected. Nevertheless, mixed populations of <i>Plasmodium</i> parasites are a significant public health threat.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a><i>Plasmodium knowlesi</i> is known to cause deaths in humans and is now considered the most common cause of malaria in Malaysia and is becoming increasingly widespread throughout South East Asia.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Within the context of developing novel antimalarials to tackle elimination, it is preferred for compounds to have activity against all five human-infecting <i>Plasmodium</i> species.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">The malaria parasite has a complex lifecycle with several morphogenesis events.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> For human infection to take place, an infected female <i>Anopheles</i> mosquito takes a blood meal and injects saliva filled with anticlotting agents and sporozoites. Sporozoites travel through the skin and into the bloodstream and finally reach the liver, where they invade hepatocytes and replicate over 5–6 days to produce schizonts filled with 10–30000 merozoites. The merozoites egress from the schizonts into the bloodstream where the merozoites invade host erythrocytes. Here, the parasites self-replicate over multiple asexual stages, causing erythrocyte depletion, new merozoites are released into the blood, and sequestration of infected erythrocytes in blood vessels resulting in the symptomatic signs of malaria. On occasion, the parasite will commit to gametocytogenesis. Here, the parasites sexually differentiate to produce mature male and female gametocytes. The mature gametocytes are then transmitted to the <i>Anopheles</i> mosquito via a blood meal and in the midgut immediately transform to male and female gametes. These forms of the parasite fuse to form a diploid zygote. These zygotes develop into motile ookinetes that invade and embed themselves in the basal lamina beneath the midgut, forming an oocyst. The oocyst then divides by meiosis to produce many haploid sporozoites, which travel to the salivary glands where the parasites can be transmitted to another human host. The multifaceted lifecycle of the malaria parasite makes studying the parasite and designing new preventative measures and treatments a challenging task.</div><div class="NLM_p">There are two ways to combat malaria: prevention and treatment. Preventative measures to control the vector such as insecticide laced bed-nets have greatly reduced the incidence of infection, however, this has not completely curtailed the spread of malaria.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> RTS,S/AS01 or Mosquirix is the first registered antimalarial vaccine targeting a circumsporozoite protein epitope in Pf, and although it only offers limited protection,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> it represents a significant advancement in the field. Several promising vaccines targeting different parasite protein epitopes are currently advancing through clinical trials,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> but the level of protection offered by these vaccines in a large diverse population is currently unknown. Chemoprophylactic treatments are an important control measure, particularly for travelers to malaria endemic regions, and are also important in mitigating the spread of resistance. There are currently two classes of prophylaxis, suppressive and causal. Suppressive prophylactics such as chloroquine (CQ), mefloquine (MQ) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), azithromycin, and doxycycline are used as single agents and must be continually taken 2–4 weeks after the subject has left the endemic area, as the agents are only effective at treating the erythrocytic or asexual stage of the parasite lifecycle.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Causal prophylactics, such as atovaquone–proguanil (Malarone), tafenoquine, and primaquine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), can stop being taken after several days of visiting an endemic area because they target both asexual and liver stages.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of currently used antimalarials and the ozonides, arterolane and artefenomel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are a number of products that are effective at curing malaria, most of which contain two or more drugs used in combination. The combination strategy was primarily implemented to deliver a cure and curb the emergence of resistance by ensuring that any resistant parasites emerging are killed by the partner drug within the combination. There are currently two types of combination therapies used, nonartemisinin combinations and artemisinin (ART) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) combination therapies (ACTs).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Non-ART combinations are comprised of sulfadoxine–pyrimethamine in combination with either CQ, amodiaquine, or MQ (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, in recent years, the WHO stopped recommending the use of these combination therapies due to the emergence of resistance against these treatments.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">ACTs are now the only recommended frontline malaria treatment. The WHO currently recommends five ACTs for treatment of uncomplicated malaria and has strict compliance guidelines for the application of each of these therapies.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Artemether and lumefantrine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) (Coartem) is recommended for children but is not recommended for pregnant women due to limited safety data in this population. The combination therapy chlorproguanil–dapsone–artesunate was an encouraging ACT, but development ceased when the increased risk of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency was discovered during the phase III program. Pyronaridine and artesunate (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) (Pyramax) is the only treatment recommended by a stringent regulatory authority for both Pv and Pf infections. The most recent data suggests ACTs have overall efficacy rates at day 28 greater than 99% outside the Greater Mekong subregion,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> but the current arsenal of clinically used ACTs are under threat due to the emergence of resistance. Resistance to ART, which is manifested as a decreased parasite clearance rate due to lower efficacy against resistant ring stage parasites, was first reported on the Thai–Cambodian border in 2008,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and as of 2017, ART resistance has been reported in four Greater Mekong subregion countries.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Furthermore, resistance to all the partner antimalarials used in ACTs has also been extensively reported (reviewed in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>). To date, there have been only limited reports of resistance to ACTs in the clinic,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> but concerningly resistance to the front line therapy for malaria is progressively spreading.</div><div class="NLM_p">Compounding the issue of resistance, there has not been a new class of antimalarial registered since atovaquone at the turn of the century. Tafenoquine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was the most recent antimalarial to advance to registration.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> But rather than representing a new chemotype, tafenoquine is an iteration of primaquine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), an 8-aminoquinoline developed in the 1940s.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The recently introduced arterolane (OZ277) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and the structural analogue artefenomel (OZ439) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) currently under late stage clinical assessment possess the same endoperoxide architecture of ART.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> These peroxides are completely synthetic, and artefenomel has an extended half-life of over 2 days compared to 1–2 h for ARTs.<a onclick="showRef(event, 'ref1 ref20'); return false;" href="javascript:void(0);" class="ref ref1 ref20">(1,20)</a> Although artefenomel likely acts with a similar mode of action as ART, it still shows good activity against the same Kelch13 mutant resistance strains in vitro and in patients, and its longer half-life is an additional distinct differentiation<a onclick="showRef(event, 'ref17 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref17 ref21 ref22">(17,21,22)</a> (reviewed in ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>). Common mechanism of action traits between many antimalarial clinical candidates highlights a problem with “me too” chemotypes. Quinolines, phenanthrenes, and antifolate chemotypes (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) are historically the mainstay of what could now be considered as “old world antimalarials”.</div><div class="NLM_p">The issues and limitations with current antimalarial chemoprophylactics and treatments have been informative in constructing the current set of guidelines for new chemical entities entering the clinic.<a onclick="showRef(event, 'ref1 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref5">(1,5)</a> The guidelines were created by multiple stakeholders including WHO and Medicines for Malaria Venture (MMV) to align new chemical entities with the global strategy of malaria elimination and eradication. The target product profile (TPP) encompasses the attributes of a combination therapy of two or more single agents. The TPPs are aligned with two underlying strategies: treatment and chemoprotection (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), or more particularly, single exposure radical cure (SERC) and single exposure chemoprotection (SEC), respectively. The target candidate profiles (TCPs) for single agents, summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, are generally aligned with the stage of the parasite’s lifecycle. Other factors such as pharmacokinetics, parasite killing kinetics, and drug–drug interactions are also considered when determining the inclusion of single agents in a combination therapy. The TPP and TCP terminologies will be referred to throughout this Perspective.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of Antimalarial Target Product and Target Candidate Profiles Recommended by the Medicines for Malaria Venture<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target product profile</th><th class="colsep0 rowsep0" align="center">target candidate profile</th><th class="colsep0 rowsep0" align="center">parasite stage</th><th class="colsep0 rowsep0" align="center">purpose</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 treatment (SERC)</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">asexual</td><td class="colsep0 rowsep0" align="center">treatment of acute malaria symptoms</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">liver hypnozoite (Pv)</td><td class="colsep0 rowsep0" align="center">treatment of relapse</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">transmission (gametocytes)</td><td class="colsep0 rowsep0" align="center">mass drug administration for treatment and transmission blocking</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">transmission (mosquito)</td><td class="colsep0 rowsep0" align="center">chemoprevention in endemic areas</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2 chemoprotection (SEC)</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">liver schizont</td><td class="colsep0 rowsep0" align="center">chemoprotection in endemic areas–particularly saving children’s lives in seasonal malaria chemoprevention or protecting vulnerable populations from outbreaks</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">asexual</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div><div class="NLM_p">Identifying new chemotypes with novel modes of action against different stages of the parasite lifecycle are now recognized as the defining traits of modern antimalarial drug discovery. Over the last 20 years, there has been renewed support and funding from multiple philanthropic institutions and governments for antimalarial research and development. In particular, the public private partnership MMV has played a key role in leading, coordinating, and mobilizing the development of novel antimalarial chemical entities. This has been achieved through collaborations involving MMV, industry, and academia. Key early successes came from phenotypic based high throughput screening of vendor comprised and proprietary compound libraries of partners such as Novartis, GSK, and St Jude Children’s Research Hospital. These screens were primarily conducted on the asexual stage of the parasite lifecycle,<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34">(24−34)</a> but since the advent of new parasite culturing techniques and assays, high throughput screens have also been undertaken on pre-erythrocytic and transmission stages of the lifecycle.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38 ref39 ref40">(35−40)</a> Protein targets identified as essential to multiple stages of the malaria parasite by way of genetic studies were also screened against large compound collections (examples given in refs <a onclick="showRef(event, 'ref41 ref42 ref43 ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44 ref45 ref46 ref47">(41−47)</a>). Collectively, the initiative resulted in the discovery of thousands of unique starting points for antimalarial development. Many of these chemotypes are publicly disclosed and are now under investigation, while several compound classes developed by industry or academia or in partnership have now progressed to lead development phase or advanced to clinic trials (reviewed in ref <a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a>). The most advanced of these antimalarials, KAE609, KAF156, DSM265, and MMV048, are currently in phase II clinical trials (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of antimalarial clinical candidates that are the focus of this Perspective.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this Perspective, we highlight the development of the four most advanced modern antimalarials in clinical trials. The chemical starting points that ultimately led to KAE609, KAF156, and MMV048 were discovered through two independent high throughput phenotypic screens against the Pf asexual stage parasite,<a onclick="showRef(event, 'ref32 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref32 ref49 ref50">(32,49,50)</a> while the chemical starting point that led to DSM265 was identified from a target-based screen against <i>Plasmodium</i> dihydroorotate dehydrogenase (DHODH),<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> an enzyme essential for pyrimidine biosynthesis and malaria parasite survival. The four antimalarial candidates potently inhibit the asexual stage parasite but possess differing activities against pre-erythrocytic and transmission stages of the parasites. KAF156, DSM265, and MMV048 are characterized as having plasma half-lives of several days and low clearance in keeping with the likelihood of a single dose cure or preventive therapy. Most importantly, each of these compounds have a novel mechanism of action and they are not susceptible to resistance mechanisms of existing antimalarial classes. Parasite lifecycle stage activities, parasite reduction rate (PRR), pharmacokinetic profiles, dose size, formulation and, critically, safety and tolerability are all factors that will ultimately determine the end use of these agents in a therapy. Herein, we describe in detail the identification and development of the four most promising modern antimalarials, with the goal to inform the research community of the malaria models required to characterize new chemical entities but to also underscore the qualities desirable in a new antimalarial agent.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">KAE609 (NITD609, Cipargamin)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Hit Identification</h3><div class="NLM_p">KAE609 was identified as part of a phenotypic high-throughput screen of ∼12000 natural products and natural product-like synthetic compounds.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> This screen identified 275 primary hits which displayed submicromolar growth inhibition of Pf parasites. Triaging these primary hits using a mammalian cellular cytotoxicity screen with a cutoff of >50% viability at 10 μM, gave 17 hits. Of the 17 hits, the singleton spiroazepineindole <b>1</b> displayed potent activity against wild-type (NF54) and CQ-resistant (K1) strains of Pf, with EC<sub>50</sub>s of 0.090 and 0.080 μM, respectively.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The synthesis of compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) gives a mixture of the four possible enantiomers, with the <i>trans</i>-diastereomers formed in favor of the <i>cis</i>-products in a ratio of ∼9:1.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The <i>trans</i>-isomers were resolved by chiral chromatography and compound <b>2</b> (the 1<i>R</i>,3<i>S</i> isomer of <b>1</b>) potently inhibited NF54 (EC<sub>50</sub> 0.020 μM) and K1 (EC<sub>50</sub> 0.030 μM) parasite growth. The 1<i>S</i>,3<i>R</i> isomer <b>3</b> was inactive at 5.0 μM against both parasite lines (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compound <b>1</b> was also efficacious in a proof-of-concept Pb blood-stage mouse model, demonstrating 96% clearance of parasitemia after a single 100 mg/kg dose.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The spiroazepineindole <b>1</b> exhibited promising parasite efficacy, pharmacokinetic, and physical properties suitable for hit-to-lead optimization.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hit compound and resynthesized and resolved isomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Lead Identification and Optimization</h3><div class="NLM_p">Investigation of the structure–activity relationship (SAR) began with exploration of halogen substituents on the indolinone ring. Replacement of the 5′-bromo substituent in <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) with a chlorine atom ((±)-<b>4</b>) gave equipotent Pf parasite activity (NF54 EC<sub>50</sub> 0.084 μM).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Expanding the seven-membered ring of (±)-<b>4</b> to an eight-membered ring was detrimental to activity, whereas potency was maintained against NF54 parasites when the 3-methyl substituent was absent from (±)-<b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The tetrahydro-β-carboline derivative (±)-<b>5</b> displayed improved potency against parasites compared with (±)-<b>4</b> with an EC<sub>50</sub> of 0.027 μM. As with the original screening hit, the stereochemistry was crucial for antimalarial activity. The (1<i>R</i>,3<i>S</i>)-enantiomer <b>6</b> exhibited enhanced activity against NF54 parasites (EC<sub>50</sub> 0.009 μM) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), while the (1<i>S</i>,3<i>R</i>)-enantiomer was considerably less active (EC<sub>50</sub> > 5.0 μM).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Additional halogen substituents on the indolinone moiety failed to improve parasite growth inhibitory activity.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of spiroindoles in lead identification phase including clinical candidate KAE609.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Variations made to the C3-substituent of (±)-<b>5</b> were not well tolerated and typically resulted in >5-fold decreases in efficacy; deletion the 3-methyl substituent or 3,3-dimethyl substitution were detrimental modifications. Replacing the 3-methyl substituent of <b>6</b> with a trifluoromethyl group also decreased potency against Pf NF54 (EC<sub>50</sub> of 0.054 μM).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Extending the 3-methyl group to a propyl chain or oxidation of the methyl substituent also led to reduced Pf parasite activity. Methylation of N9 of (±)-<b>5</b> was also tolerated but was ∼2-fold less potent against Pf NF54 (EC<sub>50</sub> 0.017 μM). The lactam carbonyl was found to be necessary for potency as the reduced form of the spiro-lactam exhibited micromolar potency.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">The active 1<i>R</i>,3<i>S</i> enantiomer <b>6</b> displayed moderate clearance (CL 50 mL/min/kg) in mice (dosed at 5.4 mg/kg by iv) and also inhibited CYP2C9 (IC<sub>50</sub> 1.5 μM).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The metabolic stability of the active 1<i>R</i>,3<i>S</i> enantiomer was addressed while investigating SAR around the indole motif of (±)-<b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Specifically, halogenation led to potency gains and improved pharmacokinetics, presumably by blocking metabolically susceptible sites. Inclusion of a 6-fluoro substituent (<b>7</b>) did not impact the inhibition of CYP2C9 (EC<sub>50</sub> 1.7 μM), but it did result in a modest improvement in potency against NF54 parasites (EC<sub>50</sub> 0.003 μM) and in vivo clearance in mice was markedly improved (CL 24 mL/min/kg). The addition of the 7-chloro moiety in <b>8</b> impacted potency in a similar manner (NF54, EC<sub>50</sub> 0.004 μM) and decreased CYP2C9 inhibition (IC<sub>50</sub> 4.1 μM). However, in isolation, the 7-chloro substituent of <b>8</b> proved unfavorable with respect to clearance in mice (CL 60 mL/min/kg). In combination (KAE609), these two additions resulted in slightly decreased CYP2C9 inhibition (IC<sub>50</sub> 5.4 μM), improved clearance in mice (CL 9.8 mL/min/kg), and subnanomolar potency against NF54 parasites (EC<sub>50</sub> 0.0009 μM). Similarly, the 6,7-difluoro analogue was also highly efficacious against NF54 parasites (EC<sub>50</sub> 0.0002 μM), displayed low clearance in mice (CL 8.5 mL/min/kg) and reduced inhibition of CYP2C9 (IC<sub>50</sub> 7.4 μM). Interestingly, the gains in potency achieved through the metabolic blocking strategy was replicated for the enantiomers. For example, the enantiomer of KAE609 displayed reasonable potency against the NF54 line (EC<sub>50</sub> 0.077 μM), low clearance in mice (CL 2.6 mL/min/kg), and no CYP2C9 inhibition at 10 μM.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p last">The changes incorporated in the spiroindolone scaffold culminated in the preclinical candidate, KAE609.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> After iv dosing to mice (5.4 mg/kg), KAE609 displayed moderate steady-state volume of distribution (<i>V</i><sub>ss</sub> 2.11 L/kg), good exposure (AUC<sub>inf</sub> 23.88 μM·h), moderate clearance (CL 9.75 mL/min/kg), and a half-life of 3.44 h. Upon oral administration at 24.6 mg/kg to mice, KAE609 was rapidly absorbed (<i>T</i><sub>max</sub> 1 h), displayed good exposure (AUC<sub>inf</sub> 138.65 μM·h), a moderate half-life of 10.0 h, and excellent oral bioavailability (<i>F</i> 100%). After an iv dose of 5.0 mg/kg and oral dose of 23.7 mg/kg to rats, exposure levels were high (AUC<sub>inf</sub> 61.32 and 524.15 μM·h, respectively), with a long half-life (<i>T</i><sub>1/2</sub> 10.69 and 27.73 h for iv and po, respectively), low clearance (CL 3.48 mL/min/kg), and excellent oral bioavailability (<i>F</i> 100%).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The PK profile of KAE609 suggested that once a day dosing was a suitable dosing regimen for malaria efficacy models.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Mechanism of Action</h3><div class="NLM_p">KAE609 displays moderate to slow-killing activity in vitro against asexual blood stages of Pf as measured in the PRR assay.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The compound does not exhibit cross-resistance with any of the clinically used antimalarials, suggesting that the spiroindolones act by a novel mechanism of action.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Current evidence indicates that the primary target is the ATP-dependent Na<sup>+</sup> channel, PfATP4 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. homology model of PfATP4. Cartoon representation of PfATP4 showing mutations (magenta) that confer resistance to KAE609,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and mutations, orange, that confer resistance to KAE678, a structurally related analogue of KAE609. Spiroindolones are cross resistant to parasites that possess these mutations.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The previously described homology model of PfATP4 was recreated with SWISS-MODEL based on the crystal structure of the rabbit SERCA pump (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2C88">2C88</a><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The predicted transmembrane region of PfATP4 is shown by the dotted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The mechanisms of action and resistance were initially determined by generation of resistant parasites in vitro, which required 3–4 months of continuous exposure to sublethal concentrations of KAE609 to provide low levels of resistance, indicated by EC<sub>50</sub> values 7–24-fold greater than the parental strain.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Genomic analysis of six drug-resistant clones identified 11 nonsynonymous mutations in the <i>Pfatp4</i> gene, and confirmation of the role of <i>Pfatp4</i> in KAE609 susceptibility was provided by transgenic expression of two mutant <i>Pfatp4</i> alleles (D1247Y or double mutant I398F/P990R) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) in a wild-type parasite, resulting in elevated EC<sub>50</sub> values.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In addition to providing a mechanism for resistance, it is proposed that PfATP4 is also the molecular target of KAE609.</div><div class="NLM_p">The <i>Pfatp4</i> gene was annotated as a cation-transporting P-type ATPase and was previously thought to play a role in Ca<sup>2+</sup> transport.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> However, more recent studies have confirmed a primary role in the maintenance of intraparasitic Na<sup>+</sup> levels, consistent with a function as an ATP-dependent Na<sup>+</sup>/H<sup>+</sup> antiporter.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> This transporter plays a critical role in parasite survival by pumping Na<sup>+</sup> out of the intracellular parasite in order to maintain a low intraparasitic Na<sup>+</sup> concentration in the context of high Na<sup>+</sup> levels in the infected red blood cell (RBC) cytosol. Direct analysis of the impact of spiroindolones (KAE246 and KAE139) on Na<sup>+</sup> homeostasis revealed a rapid and extensive increase in intracellular Na<sup>+</sup> concentration immediately after drug addition, consistent with inhibition of PfATP4 function.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Furthermore, baseline intracellular Na<sup>+</sup> concentrations were moderately higher in <i>Pfatp4</i> mutant KAE609-resistant parasites (11.9 and 14.8 μM) compared to their parental wild-type strains (8.4 and 7.2 μM), suggesting that resistance-associated mutations modify the Na<sup>+</sup>-transporting function of PfATP4. Importantly, the inhibition of Na<sup>+</sup> homeostasis by the spiroindolone (KAE246) was significantly impaired in <i>Pfatp4</i> mutant strains, consistent with a key role for PfATP4 in the mechanism of action of the spiroindolones.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p">While the spiroindolones were the first class of novel antimalarials shown to target PfATP4, a wide range of antimalarial chemotypes have subsequently been identified with the same resistance marker and phenotype. Sequencing of resistant strains generated by prolonged in vitro drug pressure has identified mutations in <i>Pfatp4</i> associated with antimalarial dihydroisoquinolones (including the preclinical candidate SJ-733),<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> aminopyrazoles (including GNF-Pf4492),<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> pyrazolamides (including PA21A092),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> MMV772,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and two compounds from the MMV malaria box.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Furthermore, analysis of Na<sup>+</sup> homeostasis revealed 28 chemically diverse compounds from the MMV malaria Box,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and 11 from the MMV pathogen box<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> that appear to inhibit PfATP4.</div><div class="NLM_p">The findings that so many structurally diverse compounds target PfATP4 raises the question of whether the mode of action involves direct inhibition of PfATP4, or whether PfATP4 is a secondary target downstream of a range of primary targets that regulate Na<sup>+</sup> homeostasis. Unfortunately, to date it has not been possible to heterologously express PfATP4 in order to directly demonstrate drug binding. However, analyses of ATPase activity in parasite plasma membrane preparations have confirmed that KAE609 and a range of other PfATP4 inhibitors directly inhibit the Na<sup>+</sup>-dependent ATPase activity in membrane fractions,<a onclick="showRef(event, 'ref54 ref61'); return false;" href="javascript:void(0);" class="ref ref54 ref61">(54,61)</a> thereby ruling out a potential role of cellular targets in other compartments that might modulate PfATP4 activity and confirming that these compounds act directly on PfATP4 itself or on a membrane-associated interacting partner. In addition, the inhibition of PfATP4-associated ATPase activity in membrane fractions by KAE609 was attenuated in <i>Pfatp4</i> mutant strains that demonstrated KAE609 resistance.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> These findings, and the extensive cross-resistance observed between different PfATP4-targeting molecules associated with various mutations in the <i>Pfatp4</i> gene, strongly suggest that KAE609, and a range of other novel antiparasitic compounds, act by direct inhibition of PfATP4.<a onclick="showRef(event, 'ref49 ref54 ref55 ref57 ref58 ref61'); return false;" href="javascript:void(0);" class="ref ref49 ref54 ref55 ref57 ref58 ref61">(49,54,55,57,58,61)</a></div><div class="NLM_p">Unfortunately, the inability to obtain purified PfATP4 protein (to date) has prevented direct measurement of drug–target interactions and structural analysis of the ligand binding site. A majority of the resistance-associated PfATP4 mutations occur in the transmembrane domain (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), suggesting that the binding site of KAE609 is likely within this transmembrane domain.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> A comparative genomics study investigating the mechanisms of action and resistance of KAE609 in modified <i>Saccharomyces cerevisiae</i> identified the primary target as ScPMA1, a P-type ATPase proton pump with homology to <i>Pfatp4.</i><a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In silico docking studies for KAE609 in the yeast protein structure revealed a putative binding site containing resistance-associated mutations in a region with high homology to <i>Pfatp4</i>, thereby providing a hypothetical binding site for KAE609 (and dihydroisoquinolones) in PfATP4, although further work is required to determine the structure of PfATP4 in order to better understand drug binding.</div><div class="NLM_p last">The mechanism of cell death that follows from inhibition of PfATP4 is not entirely clear. The elevated intraparasitic Na<sup>+</sup> concentration that results from inhibition of Na<sup>+</sup> extrusion could have direct effects on metabolic functions within the parasite or could inhibit processes that rely on the plasma membrane electrochemical gradient (such as inorganic phosphate uptake) or could lead to osmotic imbalance and subsequent cell swelling or bursting.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Metabolomic profiling of KAE609 and other PfATP4 inhibitors demonstrated significant inhibition of metabolic pathways involved in nucleotide, hemoglobin, and central carbon metabolism.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> Compound KAE609 has been shown to dramatically inhibit protein translation within 1 h of treatment<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and to induce accumulation of cholesterol in the parasite plasma membrane within 2 h.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Morphological changes similar to merozoite formation were observed following KAE609 exposure,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> while other studies observed swelling, increased rigidity, and membrane blebbing that may indicate eryptosis.<a onclick="showRef(event, 'ref55 ref60 ref67'); return false;" href="javascript:void(0);" class="ref ref55 ref60 ref67">(55,60,67)</a> There are conflicting reports about whether or not PfATP4 inhibitors induce phosphatidylserine exposure, which is indicative of eryptosis.<a onclick="showRef(event, 'ref55 ref67'); return false;" href="javascript:void(0);" class="ref ref55 ref67">(55,67)</a> However, multiple studies have demonstrated cell swelling and increased rigidity,<a onclick="showRef(event, 'ref55 ref60 ref67'); return false;" href="javascript:void(0);" class="ref ref55 ref60 ref67">(55,60,67)</a> which has been attributed to Na<sup>+</sup>-induced osmotic stress.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> These properties likely enhance the clearance of infected RBCs by the spleen,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> which may provide an explanation for the higher rate of parasite clearance observed in vivo compared to the rate of parasite killing measured in vitro.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Antimalarial Activity</h3><div class="NLM_p">KAE609 has potent asexual Pf activity with EC<sub>50</sub> values in the range of 0.0005–0.0014 μM for multiple strains.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> KAE609 also has similar potency against variety of multidrug resistant parasite lines, implying KAE609 is not susceptible to the same drug resistance mechanism as known drugs, such as CQ, MQ, and ART (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). These results are consistent with PfATP4 inhibition as the mechanism of action for KAE609. KAE609 displays single-digit nanomolar activity against Pv,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> however, <i>P. knowlesi</i> is less sensitive to KAE609 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> This phenomenon was also observed for other PfATP4 inhibitors.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">KAE609 possesses potent activity in asexual ring, trophozoite, and schizont stages at low nanomolar (EC<sub>50</sub> < 10 nM) concentrations.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In an in vitro pulsed exposure parasite assay, KAE609 (100 × EC<sub>50</sub>) exhibited significant inhibition of growth in ring, trophozoite, and schizont stages after 1 h. Growth inhibition at nanomolar concentrations was observed over the 24 h assessment period.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Furthermore, KAE609 in the asexual PRR assay was found to have a moderate rate of action (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The sexual inhibition profile is consistent with the expression of PfATP4 across all intraerythrocytic stages.</div><div class="NLM_p">KAE609 exhibits potential as a transmission blocking agent with dose-dependent activity against gametocytes and potentially inhibits oocyst development (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Significant disruption of stage II gametocyte development was also observed at 5 nM KAE609. The development of stage V gametocytes was inhibited by KAE609 in a dose dependent manner at 5, 50, and 500 nM. In addition, there was a dose dependent reduction in oocyte number in mosquitos in a standard membrane feeding assay (SMFA) following treatment of KAE609 at a concentration of 500 nM. The authors postulate that KAE609 may have further inhibition affecting the fertilization of the remaining gametocytes or ookinete and oocyst production. KAE609 is not effective against pre-erythrocytic malaria in vitro. Additionally, oral administration of KAE609 to mice at doses of 15 and 30 mg/kg, 1–3 h before injection of <i>P. berghei</i> (Pb, the mouse-specific <i>Plasmodium</i> species) sporozoites into mice failed to offer protection against infection, also suggesting KAE609 is not effective against liver stage malaria.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The stage specificity of KAE609 suggests this antimalarial is an attractive asset for treating severe malaria (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">Early studies showed that KAE609 was efficacious in the Pb malaria mouse model. After a single oral treatment, the effective dose to achieve 99% reduction in parasitemia was 5.3 mg/kg while the ED<sub>90</sub> and ED<sub>50</sub> were 2.7 and 1.2 mg/kg, respectively.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> A single oral dose of 10 mg/kg of KAE609 achieved a clearance of 99.6% reduction in parasitemia and a mean survival of 13.3 days. A dose of 30 mg/kg increased survival to 24.1 days with 50% of mice cured (no parasites present at day 30). At a single 100 mg/kg oral dose, parasitemia was reduced by 99.2% with survival of >30 days and 100% cure rate (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Under the same dosage regimen, the reference drugs (ART, CQ, and MQ) failed to cure infection. A three day 10, 30, or 50 mg/kg qd dosing regimen of KAE609, resulted in 50%, 90%, and 100% cure rate of Pb infected mice.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Collectively, the pharmacokinetic, parasite kinetic and stage specificity data suggested that KAE609 could be used as a fast acting partner agent in a SERC therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Synthesis</h3><div class="NLM_p">During medicinal chemistry optimization, led by Thierry Diagana and Bryan Yeung at the Novartis Institute for Tropical Disease, the synthesis of KAE609 and analogues was conducted using a Pictet–Spengler reaction between a tryptamine derivative and an isatin building block (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref52 ref70'); return false;" href="javascript:void(0);" class="ref ref52 ref70">(52,70)</a> The diastereoselective nature of the Pictet–Spengler reaction allows for the synthesis of the active enantiomer of KAE609 from the enantiopure tryptamine <b>15</b>. The synthesis of <b>15</b> began from accessing the ketone <b>14</b> by two pathways (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The first started with the addition of acetone to 5-chloro-6-fluoroisatin (<b>9</b>) using a catalytic Et<sub>2</sub>NH and K<sub>2</sub>CO<sub>3</sub> to give <b>10</b> in high yield.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Acetal protection of the ketone <b>10</b> afforded <b>11</b>, which is then converted to <b>14</b> by Red-Al reduction and subsequent treatment with HCl. Alternatively, aldehyde <b>12</b> can be converted to the nitroalkene <b>13</b> by condensation with EtNO<sub>2</sub> in the presence of NH<sub>4</sub>OAc.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Hydrogenolysis of <b>13</b> using Pt/C and H<sub>2</sub> afforded an intermediate oxime which is converted to <b>14</b> upon treatment with NaHSO<sub>3</sub>.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>2</sub>NH (10 mol %), K<sub>2</sub>CO<sub>3</sub> (10 mol %), acetone, 56 °C, 2 h, 84%; (b) (EtO)<sub>3</sub>CH, <i>p</i>-TsOH·H<sub>2</sub>O, ethylene glycol, 40–50 °C, 2 h, 95%; (c) (i) Red-Al, THF, 3 h, (ii) 20% HCl, 20 min, 75% (over two steps); (d) EtNO<sub>2</sub>, NH<sub>4</sub>OAc, 100 °C, 4 h, 97%; (e) (i) 5% Pt/C, H<sub>2</sub>, EtOAc, 21 °C, (ii) NaHSO<sub>3</sub>, H<sub>2</sub>O, EtOH, 80 °C, 60% (over two steps).<a onclick="showRef(event, 'ref52 ref71'); return false;" href="javascript:void(0);" class="ref ref52 ref71">(52,71)</a></p></p></figure><div class="NLM_p">Treating indole ketone <b>14</b> with an engineered transaminase ATA256<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> and <i>i</i>-PrNH<sub>2</sub>·HCl as an amine source in the presence of P5P in triethanolamine buffer, adjusted to pH 7 using aqueous NaOH, afforded the chiral amine which was isolated as the (+)-CSA salt <b>15</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Spiroindoline formation is then achieved by treating the amine salt <b>15</b> with 5-chloroisatin and Et<sub>3</sub>N. Addition of (+)-CSA was followed by solvent exchange with EtOH/EtOAc (1:14) to yield the spiroindole (+)-CSA salt <b>16</b> in high yield. Neutralization of <b>16</b> was affected using Na<sub>2</sub>CO<sub>3</sub> in EtOH/H<sub>2</sub>O (3:1), followed by particle filtration and recrystallization affording KAE609 as a hemihydrate.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) <i>i</i>-PrNH<sub>2</sub>·HCl, ATA256, P5P, PEG-200, triethanolamine buffer pH 7, NaOH<sub>(aq)</sub>, 50 °C, 24 h, (ii) (+)-CSA, <i>i</i>-PrOAc, 89 °C then cooled to 0 °C, 84% (over two steps); (b) (i) Et<sub>3</sub>N, 5-chloroisatin, <i>i</i>-PrOH, 83 °C, 24 h, (ii) (+)-CSA, (iii) solvent exchange to EtOH/EtOAc (1:14), 77 °C then cooled to 0 °C for 24 h, 86%; (c) (i) Na<sub>2</sub>CO<sub>3</sub>, EtOH/H<sub>2</sub>O (3/1), 58 °C, (ii) recrystallization, 91%.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></p></p></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Preclinical Assessment</h3><div class="NLM_p">ADME profiling of <sup>14</sup>C-labeled KAE609 in rats and dogs was undertaken as part of preclinical assessment.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In the ADME study, KAE609 was the major component found in plasma and excreta after intravenous and oral administration. On intravenous dosing (5 mg/kg for rats, 1 mg/kg for dogs), KAE609 displayed low clearance (0.252 L/h/kg in rats and 0.201 L/h/kg in dogs), moderate volume distribution (3.18 L/kg in rats and 2.17 L/kg in dogs), and a moderate half-life (8.2 in rats and 10.9 h in dogs). On oral dosing, KAE609 (10 mg/kg for rats, 3 mg/kg for dogs) was slowly absorbed in rats (<i>C</i><sub>max</sub> 1210 ng/mL observed at <i>T</i><sub>max</sub> 5.3 h) but efficiently absorbed in dogs (<i>C</i><sub>max</sub> 868 ng/mL observed at <i>T</i><sub>max</sub> 1.7 h). The estimated oral bioavailability was 85% in rats and 68% in dogs. Combined with human in vitro metabolism data, it was predicted that KAE609 had a pharmacokinetic profile suitable for once a day dosing in humans.</div><div class="NLM_p">In ADME and safety studies in rats and dogs, KAE609 and several major metabolic products were primarily excreted in the feces. Of the metabolites identified, <b>M18</b> was the major metabolite identified in plasma of rats and dogs (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). <b>M17</b> and <b>M19</b> were the major metabolites detected in rat and dog feces, respectively. The <b>M17</b> metabolite was also the major metabolite formed during incubation of KAE609 in the presence of human hepatocytes. Characterization of the metabolites revealed the structure of <b>M17</b> was a result of a novel ring expansion biotransformation mediated by CYP3A4 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The CYP3A4 oxidative biotransformation is proposed to proceed via a C–C bond cleavage by a single electron transfer to produce an isocyanate intermediate. The isocyanate intermediate then undergoes nucleophilic attack from the tetrahydro carboline nitrogen, affording the ring closure product <b>M17</b>. Subsequent oxidation by CYP3A4 and CYP1A2 produced metabolites <b>M18</b> and <b>M19</b>, respectively. <b>M19</b> was further hydroxylated to produce <b>M20</b>, which was also detected as a trace metabolite. The major metabolites were synthesized and were inactive against Pf in vitro and importantly were nontoxic in human cellular assays.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed mechanism for the formation of metabolite <b>M17</b> and the metabolic pathway of major metabolites detected in humans and preclinical species after oral dosing of <sup>14</sup>C-labeled KAE609.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vitro safety profiling established that KAE609 was nontoxic (CC<sub>50</sub> > 10 μM) to a variety of human neural, renal, hepatic, or monocytic cell lines.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> KAE609 was screened against a panel of high-risk human receptors and ion channels in a biochemical format and revealed KAE609 did not inhibit any of these targets at a therapeutically relevant concentration (IC<sub>50</sub>s all >30 μM). Importantly, negligible inhibition of the hERG ion channel (IC<sub>50</sub> ≥ 30 μM) was observed by patch clamp and binding assay methods, indicating a low risk of cardiotoxicity. KAE609 was also nonmutagenic in an Ames assay suggesting a low risk of genotoxicity.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p last">In exploratory toxicology studies, rats were dosed with KAE609 daily for 14 days and showed plasma exposure levels (AUC<sub>0–24h</sub>) after this period that were 10–20 times higher than the dose required to clear parasitemia in a Pb mouse model (ED<sub>99</sub> 5.3 mg/kg).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Additionally, KAE609 was well tolerated, with no adverse events recorded and normal histopathology. Further safety data in other preclinical species have not been reported. Collectively, the preclinical assessment established that KAE609 was well tolerated and has a safety profile suitable for dosing in humans.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Clinical Trial Progress</h3><div class="NLM_p">A phase I trial was undertaken to assess the pharmacokinetics, safety, and tolerability of KAE609 in healthy individuals (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In the first component of the trial, a single dose of KAE609 was administered to cohorts at escalating doses from 1 to 300 mg. In part two of the phase I trial, three once-daily doses of KAE609 ranging from 10 to 150 mg were administered over three consecutive days to different study cohorts. In part one and part two trial arms, bioanalysis sampling occurred at multiple time points to assess the pharmacokinetic profile over 96 and 144 h postdosing. In the single dose study, the systemic exposure of KAE609 increased in a dose-proportional manner. At a 300 mg single oral dose of KAE609, the <i>T</i><sub>max</sub> was 8 h and with an average <i>C</i><sub>max</sub> of approximately 2000 ng/mL. The systemic exposure of KAE609 (AUC<sub>0–24h</sub>) was 36 μg·h/mL, the elimination half-life was approximately 24 h and the apparent clearance was 5.5 L/h. In part 2 of the trial, KAE609 dosed at 150 mg over 3 days, showed increased plasma exposure from day 1 (<i>C</i><sub>max</sub> 1170 ng/mL, AUC<sub>0–24h</sub> 15 μg·h/mL) to day 3 (<i>C</i><sub>max</sub> 1770 ng/mL, AUC<sub>0–24h</sub> 29.4 μg·h/mL). The extent of exposure was not affected by food intake.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Overview of KAE609 Clinical Trials Completed or in Progress</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">phase/study</th><th class="colsep0 rowsep0" align="center">study population</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">end point and outcome</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, PK and tolerability</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">arm 1: single dose from 1 to 300 mg</td><td class="colsep0 rowsep0" align="left">primary measure: tolerability</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 2: daily single dose from 10 to 150 mg for 3 days</td><td class="colsep0 rowsep0" align="left">secondary measure: PK</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: half-life, 19–24 h; AUC<sub>0–24</sub>, 0.13–36.0 (μg·h/mL); <i>T</i><sub>max</sub>, 1–5.4 h; <i>C</i><sub>max</sub>: 14.1–2090 ng/mL</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">no serious adverse events</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, PK and tolerability</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">300 mg of the <sup>14</sup>C labeled KAE609</td><td class="colsep0 rowsep0" align="left">primary measures: PK and metabolite identification</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: identified and characterized major and trace metabolites with no safety liabilities</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">      </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, tolerability with partner agent</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">5 arms: 75 mg KAE609 and 320 mg PPQ, 25 mg KAE609 and 1280 mg PPQ; 25 mg KAE609 alone, 320 mg PPQ alone, 1280 mg PPQ alone</td><td class="colsep0 rowsep0" align="left">primary measures: PK, drug–drug interaction and tolerability</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measure: cardiotoxicity</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: coadministration did no effect PK or tolerability profile of either single agent; combination of KAE609 and KAE609 did not affect the QT parameters of PPQ</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase IIa, efficacy</td><td class="colsep0 rowsep0" align="left">uncomplicated Pf infected adults from Thailand and Vietnam</td><td class="colsep0 rowsep0" align="left">single dose range 300 to 75 mg</td><td class="colsep0 rowsep0" align="left">primary measure: cure rate by blood count at day 28</td><td class="colsep0 rowsep0" align="center">NCT01860989</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: 75 mg, 64% cure rate at day 28 (<i>n</i> = 11)</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">hepatobiliary disorder in 27% of subjects; increased levels of AST and ALT in 36 and 45% of subjects</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">no results for doses >75 mg</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase IIa, determination of MIC</td><td class="colsep0 rowsep0" align="left">uncomplicated Pf infected adults from Vietnam</td><td class="colsep0 rowsep0" align="left">single dose range of 30–10 mg</td><td class="colsep0 rowsep0" align="left">primary measure: MIC up to day 8</td><td class="colsep0 rowsep0" align="center">NCT01836458,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measures: parasite clearance up to 72 h and cure rate by qPCR at days 28, 25, and 42</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: predicted median MIC, 0.126 ng/mL</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">cure rate: 30 mg, 57% (<i>n</i> = 7); 20 mg, 15 mg 14% (<i>n</i> = 7); 50% (<i>n</i> = 4); 10 mg, 29% (<i>n</i> = 7).</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase IIa, efficacy</td><td class="colsep0 rowsep0" align="left">healthy adults infected with either Pv or Pf asexual parasites</td><td class="colsep0 rowsep0" align="left">30 mg daily dose for 3 days</td><td class="colsep0 rowsep0" align="left">primary measure: parasite clearance up to day 5</td><td class="colsep0 rowsep0" align="center">NCT01524341,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measures: tolerability and PK</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: 100% clearance for Pv and Pf 12 h median Pf and Pv parasite clearance</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">no serious adverse events; nausea in 67% of subjects</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">half-life of KAE609 was 20.8 h</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase IIa, tolerability and efficacy</td><td class="colsep0 rowsep0" align="left">uncomplicated Pf infected adults from multiple sites in Africa</td><td class="colsep0 rowsep0" align="left">single dose and multiple daily doses over 1–3 days</td><td class="colsep0 rowsep0" align="left">primary measure: AST and ALT for liver function</td><td class="colsep0 rowsep0" align="center">NCT03334747</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measures: parasite clearance (12, 24, and 48 h post dose) and recrudescence (day 15 and 28)</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcome expected Sep 2019</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div><div class="NLM_p">In both arms of the KAE609 trial, no serious adverse events were observed. Mild adverse events were observed in <10% of KAE609 treated individuals and included diarrhea, nausea, and dizziness. One noted physiological effect was the yellow discoloration of semen from KAE609 treated participants. Analysis of the semen revealed several KAE609 metabolites, while the parent KAE609 was not detectable. The main metabolite detected, <b>M19</b>, has a yellow coloration, and it was reasoned that this metabolite was responsible for the semen discoloration. The concentrations of the KAE609 metabolites detected were inactive against Pf in vitro, nontoxic to human hepatic cells, and did not physiologically affect semen. The <b>M19</b> metabolite was also the major metabolite observed across several preclinical species.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p">To further confirm the safety profile of KAE609 in humans, 300 mg of the <sup>14</sup>C labeled compound was orally administered to healthy individuals to investigate the distribution of KAE609 metabolites (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The major constituent of plasma was the parent KAE609 accounting for 75% of the total <sup>14</sup>C radioactivity. The plasma concentration of KAE609 was high compared with whole blood, consistent with KAE609 displaying a high plasma protein binding of >99.7%. Approximately 85% of the dose (based on total radioactivity) was recovered in feces with less than 5% of the total dose in urine.</div><div class="NLM_p">The two major circulating metabolites were <b>M18</b> and <b>M19</b> (shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) comprising 8 and 12%, respectively, of plasma radioactivity. Other trace metabolites (<3% of total radioactivity) were detected and were consistent with the metabolites detected in preclinical studies.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The 25 h half-life of the <b>M19</b> metabolite was similar to the 33 h half-life of the parent KAE609 (in the <sup>14</sup>C labeled study). KAE609 and <b>M19</b> were present in feces at levels of 32% and 36% of the dose, respectively. The major metabolite <b>M19</b> and other trace metabolites were confirmed to be present in semen, consistent with observations from the tolerability clinical trial.</div><div class="NLM_p">While metabolite profiling in humans revealed that the same metabolites were present as previously observed in rats and dogs,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> the proportion of metabolites differed between species. For example, <b>M17</b> was the major metabolite in rats, compared with <b>M19</b> being the major metabolite in dogs and humans. The differences in metabolite distribution are likely explained by the expression levels and the type of CYP450 enzymes and transporters present in each species. Ultimately, metabolite profiling revealed the metabolites of KAE609 were nontoxic and did not preclude further dosing of KAE609 in humans.</div><div class="NLM_p">A potential combination partner for KAE609 was considered to be piperaquine (PPQ) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). PPQ is known to prolong the cardiac QT interval,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> and in combination with other partner antimalarials adverse events have been reported.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> During clinical trials there have been no reports of QT prolongation by KAE609, however, a comment on unpublished preclinical data has linked KAE609 to potential cardiac risk: “<i>preclinical studies (in vitro and in animals) have suggested a potential risk for QTc prolongation</i>”.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Another potential risk of the KAE609 and PPQ combination is that PPQ is a substrate and an inhibitor of CYP3A4, while KAE609 is metabolized by CYP3A4. A clinical trial in healthy volunteers was undertaken to assess the tolerability and safety associated with coadministering KAE609 and PPQ (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The major findings from this trial indicate the antimalarial partner combination was well tolerated with no serious adverse events reported. KAE609 alone did not affect electrocardiographic parameters, while expectedly PPQ alone displayed an exposure correlated increase in QT interval. Dosing KAE609 in combination with PPQ did not affect the QT parameters of PPQ. Co-administration of PPQ did not affect the systemic exposure of KAE609 but did reduce the <i>C</i><sub>max</sub> by 17%. Conversely, KAE609 did not have a statistically relevant dose dependent effect on the exposure of PPQ. Ultimately, the outcome of the study demonstrated KAE609 and PPQ are well tolerated combination partners and indicated KAE609 could be potentially be administered safely in the presence of other CYP3A4 inhibitors.</div><div class="NLM_p">A phase IIa clinical trial (NCT01860989),<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> to date not reported in literature, was undertaken to evaluate efficacy of KAE609 in individuals infected with asexual Pf (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Here, individual cohorts of infected patients were orally administered descending doses of KAE609 (300, 225, 150, and 75 mg) to determine the effective dose. After a single 75 mg dose of KAE609, 64% of Pf-infected individuals cleared the infection by day 6 of the study and without subsequent recrudescence within 28 days. Individuals administered a single 75 mg dose of KAE609 reported several adverse events; 27% reported hepatobiliary disorders defined by increased levels of either aspartate aminotransferase, alanine aminotransferase, or both. Other physiological abnormalities included fatigue, nausea, headaches, and dizziness. This clinical trial assisted in determining the dosing regimen for subsequent phase II studies.</div><div class="NLM_p">Another dose ranging phase IIa trial (NCT01836458) was conducted in individuals with an uncomplicated asexual Pf infection with the primary goal to determine the minimal inhibitory concentration (MIC) of KAE609 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> To determine the MIC, parasite clearance rate and recrudescence was recorded in patient cohorts orally administered a subtherapeutic single dose of either 30, 20, or 15 or a 10 mg dose of KAE609. In this trial, the rate of parasite clearance was dose-dependent and plateaued at a dose of 30 mg. At a single 30 mg dose, the parasite clearance time (PC<sub>99</sub>) was 10 h and approximately 50% of patients were cured (defined as no parasite recrudescence post 28 days of dose). The average calculated in vivo MIC for KAE609 was 0.126 ng/mL. The pharmacokinetic and pharmacodynamic data from this study was important in predicting the most effective minimal dose in subsequent trials.</div><div class="NLM_p">The efficacy of KAE609 to treat either uncomplicated Pv or Pf malaria was investigated in another phase 2 trial (NCT01524341) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In this trial, a 30 mg daily dose of KAE609 was orally administered for three consecutive days to patients infected with either Pv or Pf and parasitemia monitored until day 5 (end point). The median parasite clearance time was 12 h in patients with either Pv or Pf infection, and 100% parasite clearance from patients was achieved at 30 h for Pv infection and 16 h for Pf infection. The median Pv and Pf parasite clearance half-life was approximately 0.9 h (calculated using the Worldwide Antimalarial Resistance Network parasite clearance estimator)<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> after the administration of KAE609 in the Pf cohort. This is the fastest recorded parasite clearance in humans of any antimalarial to date, including the ART derivatives. Four patients were infected with Pf parasites possessing single point kelch mutations (N537I, G538V, or C580Y) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), linked to ART resistance, and responded equally as well to KAE609 as individuals infected with parasites without the kelch mutation. Gametocytes were detected in five patients infected with Pv malaria. The gametocytes in these individuals were cleared within 8 h of treatment with KAE609. KAE609 is known to have Pf gametocytocidal activity in vitro and in standard membrane feeding assays,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> but this is the first evidence for activity of KAE609 against Pv gametocytes. No serious adverse events related to the effect of KAE609 were observed. Consistent with earlier clinical trials, increased levels of alanine aminotransferase and aspartate aminotransferase occurred in two individuals. Alanine aminotransferase and aspartate aminotransferase are related to liver dysfunction, but these patients did not show increases in bilirubin or display physiological signs of jaundice. No changes in cardiac function assessed by electrocardiography were recorded. Overall, KAE609 administered orally at 30 mg daily for 3 days in this trial was well tolerated and effective against both Pf and Pv.</div><div class="NLM_p last">Phase II trials with KAE609 are ongoing, most notably a study across multiple sites in Africa investigating the efficacy and safety of single and multiple doses of KAE609 in adults infected with Pf (NCT03334747) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The results of this trial are expected in the second quarter of 2019 and will give an indication of future clinical dosing regimens in a combination therapy.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">KAF156 (GNF156, Ganaplacide)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Hit Identification</h3><div class="NLM_p">The Genomics Institute of the Novartis Research Foundation, via a HTS of 1.7 million compounds led by Prof. Elizabeth Winzeler, identified 6000 molecules from >530 different scaffolds active against Pf 3D7 in a cell-based proliferation assay.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The team led by Thierry Diagana and Arnab Chatterjee interrogated the data to identify a novel scaffold that had attractive features for further development including: (a) potency (EC<sub>50</sub> < 1 μM against sensitive and resistant cell lines), (b) safety (>20-fold, toxicity panel against six cell lines), and (c) synthetic tractability. One such scaffold was the imidazolopiperazine class, whereby GNF-Pf-5069, GNF-Pf-5179, and GNF-Pf-5466 (<b>21</b>–<b>23</b>) were identified (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The imidazolopiperazine class (<b>21</b>–<b>23</b>) demonstrated good activity against Pf wild-type (3D7) and drug resistant (W2) strains and >20-fold selectivity window over the Huh7 cell line. Additionally, <b>21</b> was highly aqueous soluble (>175 μM at pH 6.8) and did not have cytochrome P450-mediated effects associated with other hit compounds. The imidazolopiperazine chemotype is distinct from known antimalarial scaffolds and appeared an ideal class for optimization.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Hit compounds in the imidazolopiperazine class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Lead Identification and Optimization</h3><div class="NLM_p">The imidazolopiperazine scaffold, although considered an ideal starting point for medicinal chemistry, was not without risk, including potential metabolic soft spots on the aryl groups and the presence of a toxicophoric methylenedioxy aryl motif. Compound <b>21</b> demonstrated low hERG susceptibility (IC<sub>50</sub> 19 μM),<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> low oral plasma exposure with <i>C</i><sub>max</sub> 320 nM and AUC<sub>(0–5h)</sub> 972 h·nM,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> and low bioavailability when dosed orally in rodents.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Optimization of the imidazolopiperazine class first aimed to enhance asexual parasite potency while addressing metabolic liabilities. This was achieved by investigating the amino acid moiety (A), the 2-phenyl moiety (B), and the aniline substituent (C) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Modifications to optimize the imidazolopiperazine core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first-generation compounds designed by Wu et al.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> demonstrated that substitution on the secondary amine (A-position, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was necessary for antiparasitic activity. For example, the glycine derived <b>24</b> and dimethyl analogue <b>25</b> were the most potent analogues with EC<sub>50</sub> values of 20 nM against 3D7 Pf when <i>p</i>-fluorophenyl groups were attached at the other key positions (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Modifying the B-position (see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) to include the 3-fluorophenyl (<b>26</b>) group led to a 2-fold improvement in Pf activity (EC<sub>50</sub> 10 nM) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). However, electron donating groups on the aryl ring-B (eg, 4-methyl and 4-methoxy) were less advantageous, demonstrating EC<sub>50</sub> values >2000 nM. Many substituents were tolerated on the aryl ring-C, for example, the 3,4-difluorophenyl (<b>27</b>) analogue inhibited parasite growth with an EC<sub>50</sub> of 60 nM (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), but the most potent derivative was the 3-fluoro-4-chloro substituents (<b>28</b>) in combination with the <i>N</i>-glycine and 4-fluorophenyl groups at positions A and B, respectively, exhibiting an EC<sub>50</sub> of 3 nM (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Key SAR for the first-generation imidazolopiperazine series with activity against NF54 parasites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The SAR from this first series was fine-tuned to enhance the physicochemical properties when coupled with the incorporation of changes to the 5-, 6-, and 8-positions of the piperazine ring. These changes were required, as without further modifications at these positions, potent molecules such as <b>26</b> resulted in reduced oral exposure and inferior in vivo efficacy. Another factor that was a prerequisite for piperazine modification was the identification of inactive metabolites (<b>M29</b> and <b>M30</b>) after oxidation of the unsubstituted piperazine ring of the 3,4-difluoroaniline derivative (<b>27</b>) and relative chemical instability (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Major metabolites resulted from chemical instability and C8-oxidation of <b>M29</b>, leading to inactive compounds.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although activity gains were achieved with 5- and/or 6-position modification to the piperazine ring, the greatest benefit was seen when 8-substitution was examined. The addition of a methyl substituent at either the 5-position (<b>31</b>) or 6-position (<b>32</b>) of the piperazine ring resulted in reduced activity with EC<sub>50</sub> values of 80 and 82 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Incorporation of a substituent at the 8-position resulted in abrogation of the unwanted oxidation profile by blocking the benzylic position, and the chirality at this position was unimportant for activity. The <i>gem</i>-dimethyl substituent was the most synthetically attractive as it avoided the incorporation of a stereogenic carbon and gave the most potent analogues. The combination of 8-dimethyl substituent on the piperazine ring, <i>N</i>-glycine substitution, 4-fluorophenyl group, and 4-fluoroaniline produced the additive effect of KAF156 with an EC<sub>50</sub> value of 10 nM against Pf 3D7 parasites. In general, the imidazolopiperazines were Lipinski rule-of-five compliant and highly soluble in aqueous media.</div><figure id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effect of methyl substitution on the imidazolopiperazine series.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Key compounds in the series were evaluated for permeability in the Caco-2 and PAMPA assays.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> A range of permeability values exist across the series, with no apparent correlation between Caco-2, PAMPA, and cLogP values. Compounds with cLogP values higher than 4.5 were required for high percentage absorbed values in the PAMPA assay. In these assays, KAF156 exhibited a 52% absorption by the PAMPA assay and permeability coefficients of 1.26 (apical to basolateral) and 2.99 (basolateral to apical) × 10<sup>–6</sup> cm/s in the Caco-2 cell assay. The introduction of the carbonyl group adjacent to the piperazine nitrogen, thereby eliminating the basicity of the nitrogen, resulted in improved microsomal stability in mouse and human liver microsomes. The in vitro hepatic extraction ratio for KAF156 was intermediate (0.48, 0.66, and 0.49 in mouse, rat, and human liver microsomes, respectively). The PK profile of KAF156 following iv administration at 5 mg/kg to male Balb/c mice showed a high volume of distribution (<i>V</i><sub>d</sub> 10.2 L/kg), moderate clearance (49.2 mL/min/kg), short half-life (<i>T</i><sub>1/2</sub> 2.0 h), and AUC<sub>0–24h</sub> of 4119 h·nM. After oral administration at a dose of 20 mg/kg, the maximal concentration (<i>C</i><sub>max</sub>) was 1538 nM at 1.0 h, the half-life was modest (<i>T</i><sub>1/2</sub> 4.35 h), and there was good exposure (AUC<sub>0–24h</sub> of 12155 h·nM) and good oral bioavailability (<i>F</i> 74%).</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Mechanism of Action</h3><div class="NLM_p">The mechanism of action of KAF156 has not been clearly defined. In vitro directed evolution studies using KAF156 produced resistant parasites with a range of mutations in the <i>Pfcarl</i> gene that demonstrated up to 700-fold resistance to KAF156.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> The role of five <i>Pfcarl</i> mutations in drug resistance was confirmed using CRISPR-Cas9 gene editing to introduce the mutations into wild-type parasites.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The PfCARL protein contains seven transmembrane domains and is localized to the cis-Golgi region,<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> and while the biological function of PfCARL has not been characterized, a homologous protein in yeast plays a role in protein folding.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The critical role of <i>Pfcarl</i> mutations in KAF156 resistance raises the likelihood that PfCARL is the direct target of KAF156. However, other structurally unrelated compounds have also been shown to induce <i>Pfcarl</i> mutations following drug pressure, raising the possibility that PfCARL represents a nonspecific resistance protein.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a></div><div class="NLM_p last">An alternative resistance selection strategy, aiming to allow selection of mutations that confer a fitness cost, identified mutations in two other resistance-associated genes, <i>Pfact</i> and <i>Pfugt</i>.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> These genes encode an acetyl-CoA transporter (<i>Pfact</i>) and a UDP-galactose transporter (<i>Pfugt</i>) that reside on the ER membrane of the parasite, and their role in drug resistance was confirmed by CRISPR-Cas9 gene editing. Mutations in the acetyl-CoA transporter were also identified in KAF156 resistant Pb selected by directed evolution in the murine in vivo model.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Interestingly, cross-resistance was observed with the chemically unrelated compounds that were associated with <i>Pfcarl</i>-based cross-resistance, suggesting that all three proteins, PfCARL, PfACT, and PfUGT, can mediate resistance to a selection of antimalarial compounds.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> It has been proposed that these drugs may exert their action in the ER/Golgi apparatus and that mutations in these three proteins may limit access of the drugs to this organelle, in a manner similar to the impact of <i>Pfcrt</i> mutations on accumulation of CQ in the digestive vacuole. However, direct evidence for this proposed mechanism of resistance is lacking, and further work is necessary to elucidate the mechanism of action of KAF156.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Antimalarial Activity</h3><div class="NLM_p">KAF156 displays potent Pf asexual activity against 3D7 (EC<sub>50</sub> 10 nM) and W2 (EC<sub>50</sub> 6 nM) strains (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The Pv asexual antimalarial activity was determined by an ex vivo schizont maturation assay utilizing field isolates from the Thai–Myanmar border and Indonesia (Papua). In this assay, KAF156 displayed activity against Pv and Pf, with EC<sub>50</sub> values of 5.5 and 12.6 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><div class="NLM_p">In addition to asexual activity, KAF156 demonstrates potent multistage activity with single-digit nanomolar EC<sub>50</sub> values against liver and gametocyte stages (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The 4-chloroanilino variant of KAF156 arrested <i>Plasmodium yoelii</i> exoerythrocytic forms (EEFs).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Early stage gametocytes treated with KAF156 demonstrated a substantial dose-dependent reduction in total numbers of mature gametocytes (stage V) after the induction of gametocytogenesis.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> When 5 nM of KAF156 was fed to mosquitoes in a SMFA, no oocysts were detected in the mosquito midgut. This evidence demonstrates KAF156 blocks pre-erythrocytic development and transmission to the mosquito and implies KAF156 is suitable for the TCP 1, 4, and 5 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">KAF156 was evaluated in a Pb mouse survival model treated orally 1 day post infection.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> At doses of 1 × 30, 1 × 100, or 3 × 30 mg/kg, the average parasitemia reduction was 99.5% at 16.3 d, 99.4% at 14.0 d, and 99.8% at 17.7 d survival (untreated control mice survive 6–7 days), respectively (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The effective dose giving 99% reduction in parasitemia (ED<sub>99</sub>) was 2.2 mg/kg. These results were more favorable than for the known antimalarials: CQ and artesunate. After iv dosing to rats, KAF156, showed a high volume of distribution (<i>V</i><sub>d</sub> 13.7 L/kg), high clearance (67.5 mL/min/kg), moderate half-life (<i>T</i><sub>1/2</sub> 4.6 h), and reduced AUC<sub>0–24h</sub> of 1831 h·nM. The maximal concentration (<i>C</i><sub>max</sub>) was 91 nM at 1.5 h, half-life (<i>T</i><sub>1/2</sub> 4.7 h), AUC<sub>0–24h</sub> of 974 h·nM, and oral bioavailability (<i>F</i> 20%) at 10 mg/kg, whereas these values increased to <i>C</i><sub>max</sub> 580 nM at 4.3 h, half-life (<i>T</i><sub>1/2</sub> 8.4 h), AUC<sub>0–24h</sub> of 34885 h·nM, and oral bioavailability (<i>F</i> 57%) at a dose of 100 mg/kg.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis</h3><div class="NLM_p">The synthesis of KAF156 begins with the base-mediated alkylation of Cbz-protected 2-amino-2-methylpropionic acid <b>33</b> with 4-fluorophenacyl bromide (<b>34</b>) to give ester <b>35</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Condensation of <b>35</b> with NH<sub>4</sub>OAc affords the imidazole <b>36</b> in good yield. The imidazole <b>36</b> was then alkylated using ethyl 2-bromoacetate under basic conditions, followed by hydrogenolysis of the benzyl carbamate to give lactam <b>37</b> in high yield. Reduction of the lactam and HATU-mediated coupling with <i>N</i>-Boc-glycine furnished imidazolopiperazine <b>38</b>. Treatment of <b>38</b> with Br<sub>2</sub> gives quantitative conversion to bromide <b>39</b>, which can then be converted to KAF156 using a Buchwald–Hartwig amination with 4-fluoroaniline and Boc-deprotection.</div><figure id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 4 h, 84%; (b) NH<sub>4</sub>OAc, toluene, 111 °C, 3 h, 88%; (c) (i) ethyl 2-bromoacetate, K<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 2.5 h, 83%, (ii) H<sub>2</sub>, Pd/C, EtOH, 25 °C, 3 d, 91%; (d) (i) BH<sub>3</sub>–THF, THF, 66 °C, 16 h, 95%, (ii) 2-(<i>tert</i>-butoxycarbonylamino)acetic acid, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 8 h, 70%; (e) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 30 min, 100%; (f) (i) 4-fluoroaniline, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 25 °C, 15 min, then 120 °C, 8 h, 89%, (ii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 2 h, 52%.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></p></p></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Preclinical Assessment</h3><div class="NLM_p">KAF156 was assessed for in vitro toxicology as a component of preclinical evaluation.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> KAF156 was noncytotoxic in a panel of hematopoietic, epithelial, laryngeal, hepatoma, and human and mammalian cell lines at physiologically relevant concentrations (CC<sub>50</sub> > 12 μM). KAF156 had IC<sub>50</sub> values >6 μM against a panel of cytochrome P450s and panel screening against high risk adverse targets revealed KAF156 inhibited hERG with an IC<sub>50</sub> value of 13.4 μM, 170-fold above the efficacious plasma concentration (<i>C</i><sub>max</sub> 75 nM) of KAF156 dosed (2 mg/kg) in a mouse model of malaria, suggesting a low risk of cardiotoxicity. In an Ames and a micronucleus assay KAF156 was negative, suggesting a low risk of genotoxicity in humans.</div><div class="NLM_p">ADME profiling of <sup>14</sup>C- and <sup>13</sup>C-labeled KAF156 in rats was undertaken as part of the preclinical assessment studies.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The primary goal was to pharmacokinetically characterize KAF156 and identify metabolites that may display toxicity. In this study, KAF156 was dosed orally and intravenously to rats at 10 and 3 mg/kg, respectively. After iv dosing, KAF156 exhibited a half-life of 6.6 h, high plasma clearance (CL 5.4 L/h/kg), and a very high volume of distribution (<i>V</i><sub>ss</sub> 29.5 L/kg). After oral dosing, KAF156 was absorbed efficiently with a <i>C</i><sub>max</sub> of 139 ng/mL at 2 h and displayed a half-life of 5.7 h with an estimated oral bioavailability of 48%. After both iv and oral dosing to rats, KAF156 was extensively metabolized and metabolites were excreted in urine and feces. Three major polar metabolites of KAF156 (including <b>M41</b>) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), and several minor metabolites (including <b>M40</b>) were detected in rat urine, accounting for 24–37% of the intravenous or oral dose, while five major metabolites (including <b>M40</b>) were detected in feces. The characterized metabolites revealed KAF156 was oxidatively metabolized, underwent oxidative defluorination, oxidative deamination, hydroxylation and ring opening, and acetylation. <i>O</i>-Sulfonation by sulfotransferases gave further byproducts of these metabolites. The <b>M40</b> metabolite, present in both urine and feces, was also a major product formed upon incubation of KAF156 with rat or human hepatocytes. The ketoamide metabolite <b>M40</b> was not a result of an oxidative transformation with any of the 19 CYP450 isoforms, therefore it was proposed that KAF156 is metabolized to the ring opened product, <b>M40</b>, by way of two hydrolytic events. These metabolism events were proposed to proceed via hydrolytic cleavage of the imidazole ring followed by amide hydrolysis to form <b>M41</b> and 4-fluoroaniline, which is subsequently hydroxylated, O-sulfonated, acetylated, and oxidatively defluorinated, producing several metabolites (<b>M42</b>–<b>M45</b>) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Overall, the in vitro toxicology data and dosing in rodent models suggested that KAF156 was well tolerated. Limited toxicology data in preclinical species was published at the time of writing this review, however, KAF156 was advanced to human trials.</div><figure id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Proposed mechanism for the formation of metabolite <b>M40</b> and the metabolic pathway of major metabolites detected in rats after oral and intravenous dosing of <sup>14</sup>C-labeled KAF156.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Clinical Trial Progress</h3><div class="NLM_p">A phase I trial was undertaken to determine the safety, tolerability, and pharmacokinetics of KAF156 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> In this trial, KAF156 was studied in two arms, the first was a single-ascending dose from 10 to 1200 mg; the second arm included multiple ascending doses of 60 to 600 mg once daily for 3 days. KAF156 was well tolerated in both single and multiple dose cohorts, with no serious adverse events observed. The most common adverse events reported were headache, nausea, and dizziness. Gastrointestinal disorders appeared to be more frequent with increasing dose of KAF156. No liver-related issues or significant cardiac QTc prolongations were detected. A single dose of KAF156 was quickly absorbed with a <i>T</i><sub>max</sub> between 1 and 6 h. The systemic circulation of KAF156 was dose-dependent, with <i>C</i><sub>max</sub> values ranging from 7.6 to 2720 ng/L and AUC<sub>0–24h</sub> ranging from 83 to 31000 mg·h/mL for 10–1200 mg doses, respectively. The apparent clearance decreased from 35 to 16 L/h, and the volume of distribution decreased from 2410 to 1610 L with an increase in dose from 10 to 1200 mg, suggesting possible saturation of metabolism enzymes. The half-life of the KAF156 ranged from 47 to 70 h for 10 to 1200 mg doses. The absorption profile of KAF156 was not significantly affected when administered with food compared to fasted, although the <i>T</i><sub>max</sub> was extended to 6 h with food compared to 3 h fasted. After multiple doses of KAF156, the systemic exposure on day 3 increased more than the increase in dose.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> In summary, the study demonstrated that KAF156 well tolerated and suitable for single or multiple dose administration, although a pharmacodynamic study was required to determine the effective dose and dosing regimen necessary to treat humans infected with <i>Plasmodium</i>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Overview of KAF156 Clinical Trials Completed or in Progress</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">phase/study</th><th class="colsep0 rowsep0" align="center">study population</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">end point and outcome</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, PK and tolerability</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">arm 1: single dose from 10 to 1200 mg</td><td class="colsep0 rowsep0" align="left">primary measure: PK</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 2:60 to 600 mg daily dose for 3 days</td><td class="colsep0 rowsep0" align="left">secondary measure: tolerability</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: half-life: 43–72 h; AUC<sub>0–24h</sub>, 83–31000 mg·h/mL; <i>T</i><sub>max</sub>, 1–6 h; <i>C</i><sub>max</sub>, 7.6–2720 ng/L</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">no serious adverse events, few mild adverse symptoms</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, tolerability with partner agent</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">single dose for Arm 1:800 mg KAF156 and 1280 mg PPQ</td><td class="colsep0 rowsep0" align="left">primary measures: PK and tolerability up to 61 days</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 2, 800 mg KAF156; arm 3, 1280 mg PPQ.</td><td class="colsep0 rowsep0" align="left">secondary measure: cardiotoxicity up to 48 h</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: KAF156/PPQ combination did not alter AUC</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">KAF156 did not affect the QT parameters of PPQ; frequency of mild adverse events, 87.5, 79.2, and 58.3% for KAF156 + PPQ, PPQ, and KAF156</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase IIa</td><td class="colsep0 rowsep0" align="left">Pv or Pf monoinfected adults from Vietnam and Thailand</td><td class="colsep0 rowsep0" align="left">arm 1: daily doses of 400 mg for 3 days</td><td class="colsep0 rowsep0" align="left">primary measures: arm 1, Pf and Pv parasite clearance at day 5; arm 2, Pf parasitemia at day 28</td><td class="colsep0 rowsep0" align="center">NCT01753323,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 2: single dose of 800 mg.</td><td class="colsep0 rowsep0" align="left">secondary measures: PK</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: arm 1:45 h median Pf parasite clearance (<i>n</i> = 10); 24 h median Pv parasite clearance (<i>n</i> = 10); arm 2:, 4 h median Pf parasite clearance (<i>n</i> = 21) and 67% cure rate at day 28; arm 1, half-life 44 h</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">symptomatic sinus bradycardia in 63% of patients and hypokalemia in 50% of patients; AST and ALT elevated in 33% patients</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase IIb, efficacy and tolerability with partner agent</td><td class="colsep0 rowsep0" align="left">infected patients part A > 12 yrs age; part B > 2 to <12 yrs age; from Vietnam, Thailand, and multiple sites in Africa (<i>n</i> = 512)</td><td class="colsep0 rowsep0" align="left">combinations of KAF156 200, 400, and 800 mg with 480 and 960 mg lumefantrine single daily dose ranging 1 day to 3 days</td><td class="colsep0 rowsep0" align="left">primary measure: parasite clearance at day 28</td><td class="colsep0 rowsep0" align="center">NCT03167242</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measures: PK to day 15; safety to day 42; recrudescence at days 14, 28, and 42</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcome expected April 2020</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div><div class="NLM_p">PPQ (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was considered as a potential antimalarial combination partner of KAF156, and therefore a phase I clinical trial was performed to determine drug–drug interactions between KAF156 and PPQ in healthy individuals (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Both PPQ and KAF156 are substrates and inhibitors of CYP3A4. Leong et al. report that both KAF156 and PPQ inhibit CYP3A4 with a <i>K</i><sub>i</sub> of 156 and 90 nM, respectively<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> (although this is inconsistent with previous reports that KAF156 does not inhibit CYP3A4<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a>). Thus, it was important to compare the pharmacokinetic and safety profile in healthy individuals of the two antimalarials dosed as single agents and in combination.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The pharmacokinetic profile for KAF156 (800 mg dose) as a single agent was consistent with the previous clinic data,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> and this was relatively unchanged when it was coadministered with PPQ (800 and 1280 mg doses for KAF156 and PPQ, respectively). However, the <i>C</i><sub>max</sub> of both KAF156 and PPQ increased 1.2- and 1.7-fold, respectively, compared to the <i>C</i><sub>max</sub> when either was dosed alone. The reason for the change in the absorption is unknown. KAF156 and PPQ either alone or in combination were well tolerated and no serious adverse events were recorded. The frequency of adverse events was not significantly different between the PPQ alone and KAF156 and PPQ combination cohorts. Consistent with the previous clinical trial for KAF156, the most common side effects reported were nausea and headache. Importantly, there was no evidence of a synergistic increase in QT interval compared to the QT interval when PPQ was dosed alone. In summary, the trial demonstrated there were no safety issues or drug–drug indications that would prevent the use of KAF156 and PPQ in a combination therapy for treatment of malaria.</div><div class="NLM_p">To determine the antimalarial efficacy of KAF156 in humans a phase II trial was undertaken across sites in South East Asia (NCT01753323) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The trial was conducted in two parts. The first treated adults infected with either Pf or Pv with multiple doses of KAF156 (400 mg once daily for 3 days), and in the second cohort, adults infected with Pf were treated with a single 800 mg dose of KAF156. The half-life of KAF156 in malaria infected patients in this trial was approximately 44 h, consistent with the long half-life in earlier clinical trials.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> KAF156 was generally well tolerated, and there were no serious adverse events. Approximately 23% of all patients experienced a drug-related increase in aspartate aminotransferase levels, a key indicator of liver dysfunction. Other adverse events reported were likely related to malaria infection and were not directly attributed to KAF156.</div><div class="NLM_p">In this phase II trial, KAF156 cleared Pf infection efficiently, with median parasite clearance times of 45 h for a multiple dose regime and 49 h for treatment with a single dose of. Clearance of Pv with a multiple dose regime of KAF156 was significantly quicker than for Pf, with a median parasite clearance time of 24 h. The median parasite clearance half-life (calculated using the Worldwide Antimalarial Resistance Network parasite clearance estimator<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a>) was between 1.9 h for Pv and approximately 3.5 h for Pf. In comparison, this is a slightly slower clearance rate than seen with ART derivatives but significantly slower than for KAE609.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Of the patients treated with a single dose of KAF156, 67% were cured at day 28 (blood smear), while 33% had recrudescent infections. Gametocytes were detected in independent Pf and Pv infections of four patients. Gametocytes were cleared by 16 h for Pv and between 54 and 74 h post-treatment for Pf consistent with in vitro gametocytocidal activity of KAF156<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> and suggesting a possible use for KAF156 in a transmission blocking therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">Of the patients infected with Pf in the phase II trial, 14 patients had parasites with single-nucleotide polymorphisms (SNPs) in the K13 gene, 10 of which possessed the C580Y variant strongly associated with ART resistance.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> In infections with or without this mutation the parasite clearance rates were the same, suggesting KAF156 is not susceptible to the same resistance mechanism as ART. Patients infected with Pf parasites harboring mutations in the <i>Pfmdr</i> and <i>Pfcrt</i> genes associated with aminoquinoline resistance<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a> also responded to treatment with KAF156 equally as well compared to patients infected with Pf without these genetic perturbations. Of the 31 patients infected with Pf in the trial, 28 isolates had either one of eight distinct SNPs or one of three insertions or deletions in the <i>Pfcarl</i> gene. None of the mutations detected were the same as the previously identified mutations associated with acquired resistance to KAF156 in the laboratory.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> There was no discernible difference between the clearance rates of infections or recrudescent parasites with the different <i>Pfcarl</i> genotypes, nor compared to isolates with the wild-type <i>Pfcarl</i> gene. Overall, KAF156 dosed three times in three consecutive days was effective in clearing both Pf and Pv in a small cohort of adults.</div><div class="NLM_p last">Presently, a phase IIb clinical trial (NCT03167242) of KAF156 has commenced<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> across multiple sites in Africa and South East Asia to determine the efficacy KAF156 in combination with a solid-dispersion formulation of lumefantrine to treat adults and children infected with uncomplicated Pf malaria (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). According to a 2018 report by the trial partner organization, MMV, “<i>Interim analysis on 261 patients is promising and shows no safety signal; more than 90% of subjects show no recrudescence at 45 days</i>”.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The complete outcome of the trial is expected around April 2020.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">DSM265</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Hit Identification</h3><div class="NLM_p">Dihydroorotate dehydrogenase (DHODH) is a flavin mononucleotide (FMN)-dependent enzyme that is responsible for the conversion of dihydroorotate (DHO) to orotate in de novo pyrimidine synthesis. The first step involves the transfer of two protons and two electrons to FMN to give the reduced form FMNH<sub>2</sub>. The cofactor is recycled back to the oxidized state (FMN) by the electron acceptor ubiquinone/coenzyme Q (CoQ). This step generates CoQH<sub>2</sub> and is subsequently oxidized by the cytochrome bc1 complex.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Malaria parasites lack the machinery to salvage pyrimidine bases or nucleotides, which makes DHODH essential to parasite survival.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p">A high-throughput screening campaign against PfDHODH led by Prof. Margaret Phillips at University of Texas Southwestern Medical Centre, identified DSM1 (Dallas–Seattle–Melbourne), compound <b>46</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), as a potent inhibitor of PfDHODH (IC<sub>50</sub> 0.047 μM) with >5000-fold selectivity compared to the human form of the enzyme (HsDHODH, IC<sub>50</sub> > 200 μM).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> It was noted that <b>46</b> was 5-fold less active against PbDHODH (IC<sub>50</sub> 0.23 μM) compared to PfDHODH. The decreased activity against PbDHODH was a trend throughout the development of DSM265 and would impact the evaluation of the series in Pb mouse models. Nevertheless, the PfDHODH activity of <b>46</b> robustly correlated with Pf 3D7 parasite activity (EC<sub>50</sub> 0.079 μM),<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and therefore throughout the development of the DSM series, promising candidates were evaluated in <i>P. falciparum</i> humanized mouse models.</div><figure id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Hit identified from HT screen against PfDHODH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Lead Identification and Optimization</h3><div class="NLM_p">Early structure–activity studies focused on variation of the <i>N</i><sup>7</sup>-(naphth-2-yl) substituent of <b>46</b> and preference for larger nonpolar aromatic rings, such as an anthracen-2-yl substituent (<b>47</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), was established (PfDHODH IC<sub>50</sub> 0.056 μM, 3D7 EC<sub>50</sub> 0.19 μM).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Activity against PfDHODH was decreased when an endocyclic nitrogen was substituted at any position of the naphthyl ring and indicated that the naphthyl ring was sensitive to modification.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The 5,6,7,8-tetrahydronaphth-2-yl analogue <b>48</b> had promising activity against Pf and PbDHODH (IC<sub>50</sub> 0.035 and 0.19 μM, respectively) and inhibited Pf parasite growth with an EC<sub>50</sub> of 0.16 μM.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> On the other hand, the 1,2,3,4-tetrahydronaphth-2-yl analogue <b>49</b> had markedly reduced PfDHODH inhibition (IC<sub>50</sub> 0.54 μM) and micromolar potency against the Pb orthologue and in parasites.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Interestingly, the aniline derived <b>50</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) showed no activity against the Pf enzyme or parasites (>100 μM).</div><figure id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of PfDHODH inhibitors in lead identification phase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig15" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of PfDHODH inhibitors in lead identification phase. * denotes the use of albumax supplemented media.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Early in the program it was established that additional substitution of the <i>exo</i>-cyclic amine<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> or C6 were not favorable for PfDHODH inhibition and efficacy. In general, replacing the 5-methyl substituent was detrimental for either PfDHODH or Pf3D7 activity, with only a single example of a 5-chloro group exhibiting favorable PfDHODH inhibition.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">Despite the promising inhibition of PbDHODH by the original hit compound <b>46</b> and <b>47</b>, these compounds demonstrated a lack of efficacy in the Pb mouse model.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> This was likely a result of poor exposure of both compounds based on data in parallel studies in healthy mice. Even though <b>47</b> displayed higher plasma concentrations that were maintained longer than for <b>46</b>, exposure was insufficient given the poor potency of <b>47</b> against PbDHODH (3.7 μM) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). After multiple days of dosing, the observed <i>C</i><sub>max</sub> values for <b>46</b> and <b>47</b> were lower than after a single day of treatment, which indicates that these compounds were likely metabolic inducers. In addition, <b>46</b> exhibited poor pharmacokinetics with high intrinsic clearance (CL<sub>int</sub> 96 μL/min/mg) in human liver microsome preparations and the estimated hepatic extraction ratio was high (<i>E</i><sub>h</sub> 0.84). Given the perceived liabilities of the naphthyl moiety,<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> phenyl substituted analogues were prepared with the aim of investigating electronic and steric requirements which could improve the activity of <b>50</b>.</div><div class="NLM_p">The structure–activity relationship of monosubstituted <i>N</i><sup>7</sup>-phenyl rings showed a clear pattern of activity associated with the substituent position. Substitution at the <i>ortho</i>-position (relative to the nitrogen) was not tolerated and in most cases resulted in no enzyme activity (IC<sub>50</sub> > 100 μM).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> In isolation, <i>meta</i>-substitution gave PfDHODH IC<sub>50</sub>s in the range of 1.4–14 μM, bis-<i>meta</i>-substitution was also largely inactive.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p">Analogues with <i>para</i>-substitution displayed good activity against Pf and Pb DHODH. Substituents such as bromine<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> and linear aliphatic groups up to five carbons in length (≤<i>n</i>-pentyl) produced submicromolar inhibitors of PfDHODH.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The 4-<i>tert</i>-butylphenyl derivative <b>51</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) was the most active in the aliphatic series with Pf and Pb DHODH inhibition of 0.08 and 0.40 μM, respectively, and modest efficacy against 3D7 parasites (EC<sub>50</sub> 0.32 μM).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Inclusion of polar functional groups such as ether or amine led to profound decreases in activity.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">The 4-(trifluoromethyl)aniline analogue <b>52</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) was identified in this series with activity against PfDHODH (IC<sub>50</sub> of 0.28 μM) and similar potency in the 3D7 growth inhibition assay with an EC<sub>50</sub> of 0.34 μM.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Importantly, <b>52</b> inhibition of PbDHODH (IC<sub>50</sub> 0.38 μM) was comparable to that for Pf, and studies in the Pb mouse model provided the first in vivo evidence that inhibition of plasmodial DHODH led to a reduction in parasitemia.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The <i>para</i>-trifluoromethyl compound <b>52</b> exhibited improved metabolic stability in the presence of human liver microsomes (CL<sub>int</sub> 7.5 μL/min/mg) compared with <b>46</b>.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Additionally, <b>52</b> had a log <i>D</i><sub>7.4</sub> of 2.5 and modest aqueous solubility (21–43 μM), while human plasma protein binding (hPPB) was relatively low as 86.9%.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">In general, combinations of 3,4-disubstitution on the aryl ring were less active against PfDHODH than the parent derivatives with an exception being the presence of 3-fluoro substituents adjacent to an activity-inducing <i>para</i>-substituent.<a onclick="showRef(event, 'ref26 ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref26 ref104 ref105">(26,104,105)</a> For example, the 3-fluoro-4-(trifluoromethyl)aniline derived analogue <b>53</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) demonstrated improved inhibition of PfDHODH (IC<sub>50</sub> 0.077 μM) compared to <b>52</b>. However, <b>53</b> had suboptimal 3D7 parasite activity (EC<sub>50</sub> of 1.3 μM).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> With two fluorine atoms adjacent to the trifluoromethyl moiety in <b>54</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>), Pf and PbDHODH inhibition (IC<sub>50</sub> 0.19 and 0.28 μM, respectively) and Pf parasite activity (EC<sub>50</sub> 1.1 μM) was modest.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The human protein binding of <b>54</b> was high (∼97%), and it was proposed that high serum binding in the in vitro assay negatively impacted parasite activity. When the whole cell parasite assay was conducted using albumax supplemented media (lower protein concentration), the potency of <b>54</b> against Pf 3D7 (EC<sub>50</sub> 0.22 μM) was reflective of PfDHODH inhibition.</div><div class="NLM_p">Species selectivity was adversely impacted by the inclusion of additional fluorine substituents which was a potential obstacle for future preclinical toxicological studies.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In the case of <b>54</b>, rat and mouse DHODH were inhibited with IC<sub>50</sub> values of 37 and >30 μM, respectively.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In contrast, <b>52</b>, was inactive against rat and mouse DHODH (IC<sub>50</sub> > 100 μM). A systematic investigation illustrated a trend between increasing fluorine substitution and off-species DHODH inhibition. In some instances, low micromolar inhibition of human DHODH was demonstrated and could be ascribed, in part, to close contacts between the fluorine atoms and hydrophobic side chains of HsDHODH.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><div class="NLM_p">The preference for hydrophobic moieties was further exploited with the inclusion of a 4-pentafluorosulfanyl group (<b>55</b>) (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> This analogue was the most active of the monosubstituted <i>N</i><sup>7</sup>-phenyl analogues with good activity against Pf and Pb DHODH (IC<sub>50</sub> 0.13 and 0.28 μM, respectively). Compound <b>55</b> also had high protein binding, and therefore the 3D7 growth inhibition (EC<sub>50</sub> 1.3 μM) did not correlate with enzyme inhibition unless serum was replaced with albumax supplemented media (EC<sub>50</sub> 0.18 μM).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The aqueous solubility at pH 6.5 of <b>55</b> was also improved (71–142 μM) in comparison to trifluoromethyl anilino-derived analogues. In mice, a single oral dose of 20 mg/kg of <b>55</b> resulted in high plasma exposure (<i>C</i><sub>max</sub> 12 μM) with plasma levels maintained above 1 μM for 19 h. This was similar in rats where a single oral dose (20 mg/kg) resulted in high plasma exposure (<i>C</i><sub>max</sub> 31 μM), a long half-life of 33 h, and excellent bioavailability (<i>F</i> 100%). In a Pb mouse model using ascending doses from 3 to 100 mg/kg once daily, <b>55</b> was efficacious with an ED<sub>50</sub> of 17 mg/kg.</div><div class="NLM_p">The C2 position on the triazolopyrimidine scaffolds of <b>52</b> and <b>55</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) were further explored with the aim to exploit further binding interactions with PfDHODH.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Aliphatic substituents which were less than three carbons (or atoms) in length were tolerated in the C2 position of the scaffold. Short alkoxy groups and methylsulfanyl substitution were well tolerated in the 2-position resulting in potent inhibitors of PfDHODH (IC<sub>50</sub> < 0.1 μM). Amine functionality was not tolerated in the C2-position.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p last">Short unbranched fluoroalkyl chains (CF<sub>3</sub>, CF<sub>2</sub>CH<sub>3</sub>, CF<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) were found to be the optimal substituent at C2 for PfDHODH inhibition, however, the trifluoromethyl group was later identified as a liability for inhibition of mammalian DHODH.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The inclusion of a CF<sub>2</sub>CH<sub>3</sub> group (DSM265) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), was optimal and led to a 23-fold improvement in potency against 3D7 parasites (EC<sub>50</sub> 0.0078 μM) and 4-fold against PfDHODH (IC<sub>50</sub> of 0.033 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) compared to <b>55</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The lipophilicity of DSM265 was still acceptable (log <i>D</i><sub>7.4</sub> 3.6) despite the presence of the SF<sub>5</sub> substituent and the addition of the difluoroethyl moiety. Relative to <b>52</b> and <b>54</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>), the kinetic solubility of DSM265 was improved at 30–60 μM, however, human PPB was higher (99.9%).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> DSM265 intrinsic clearance in mouse and human liver microsomes was low (CL<sub>int</sub> 8.1 μg/min/mg, and <5 μg/min/mg, respectively). The mouse PK of DSM265 was dose proportional over the range of 0.4–10 mg/kg after a single oral dose. At an oral dose of 50 mg/kg in rats, DSM265 exhibited a slow rate of absorption (<i>C</i><sub>max</sub> 6.4 μM, <i>T</i><sub>max</sub> > 8 h) with high plasma exposure (AUC<sub>0–inf</sub> 19305 μM·min), long half-life of >24 h, and good oral bioavailability (<i>F</i> 61%).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Mechanism of Action</h3><div class="NLM_p">The mechanism of action of DSM265 is based on direct inhibition of the <i>Plasmodium</i> DHODH enzyme and the resulting inhibition of de novo synthesis of essential pyrimidine nucleotides. Binding of DSM265 to PfDHODH has been directly demonstrated by X-ray crystallography (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>),<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and direct inhibition of PfDHODH enzyme activity has been demonstrated in vitro for a large number of DSM265 analogues, with a high correlation observed between the in vitro potency against the enzyme and the antiparasitic activity against Pf.<a onclick="showRef(event, 'ref26 ref102'); return false;" href="javascript:void(0);" class="ref ref26 ref102">(26,102)</a> Genetic confirmation of the role of DHODH in the mechanism of action of DSM265 was achieved by the use of a parasite line that overexpressed a yeast isoform of DHODH that was highly resistant to DSM265.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Unlike the plasmodium enzyme, the yeast DHODH (yDHODH) is not dependent on mitochondrially derived ubiquinone for regeneration of the FMN cofactor and therefore can also induce resistance to mitochondrial inhibitors such as atovaquone (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> However, parasites expressing yDHODH become sensitive to mitochondrial inhibitors (e.g., atovaquone) when tested in combination with proguanil (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), whereas these parasites remained resistant to DSM265 even in the presence of proguanil, indicating that DSM265 targets the DHODH enzyme itself rather than indirectly inhibiting the function of DHODH via a mitochondrial target.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="fig16" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Crystal structure of Pf dihydroorotate dehydrogenase bound to DSM265 (green), orotate, and FMN (magenta) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0">4RX0</a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> (A) Cartoon representation of PfDHODH showing mutations (orange) that confer resistance to DSM265 (G181C only)<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and structurally related analogues of DSM265.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The α helix 181–193 (center-front) is transparent for clarity. (B) Amino acids (blue) in the binding site of DSM265. Yellow dotted lines show hydrogen bonds between DSM265 and PfDHODH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vitro exposure of Pf to DSM265 readily generated resistant parasites that displayed gene amplification and/or point mutations in <i>Pfdhodh</i>. Phillips et al. reported copy number amplification along with a nonsynonymous polymorphism at G181C (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), which lies within the binding pocket for DSM265.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> A more recent study generated resistant clones associated with five different <i>Pfdhodh</i> mutations. Four of these mutations involved amino acids within the DSM265 binding pocket (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), whereas one resistance-conferring mutation, C276F, was located in the adjacent FMN-binding site.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> CRISPR-Cas9 gene editing confirmed that the C276F mutation was sufficient to induce resistance to DSM265, and X-ray structural analysis of this mutant enzyme revealed conformational changes that affected the DSM265 binding pocket.</div><div class="NLM_p">It is proposed that inhibition of DHODH would lead to depletion of pyrimidine nucleotides and subsequently prevent the formation of RNA and DNA that are necessary for cellular transcription and replication. Indeed, the activity of DSM265 within the asexual blood-stage parasite is greatest against early trophozoite and schizont stages when these processes are most active.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Functional confirmation of the role of pyrimidine synthesis in the mechanism of DSM265 action has been demonstrated by metabolic profiling of drug-treated Pf, whereby levels of the DHODH substrate, dihydroorotate, and its upstream precursor, <i>N</i>-carbamoyl <span class="smallcaps smallerCapital">l</span>-aspartate, are significantly elevated, along with decreases in the levels of downstream pyrimidine nucleotides.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Stable isotope labeling of parasites treated with DSM265 analogues confirmed the inhibition of metabolic flux through the de novo pyrimidine synthesis pathway at the point of DHODH, and untargeted metabolomics revealed that the impact on the cellular metabolome was highly specific to this pathway.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p last">The species-specific potency of DSM265 against Pb and Pv is not fully understood. It has been hypothesized that the weak activity against Pv and Pb may be due to the tropism of these parasites for immature red blood cells (reticulocytes) that may be able to supply the necessary pyrimidine nucleotides to the parasite in the absence of de novo pyrimidine synthesis.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> However, while reticulocytes have been shown to be rich in nutrients, including pyrimidines, genetic studies have shown that the enzymes of de novo pyrimidine synthesis appear to be essential in blood-stage Pb,<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> suggesting that these parasites would not be able to survive potent inhibition of DHODH. It has therefore been proposed that species-specific differences in drug–enzyme interactions contribute to the different antiparasitic potencies observed for different <i>Plasmodium</i> species. Indeed, the DSM265 IC<sub>50</sub> for enzyme inhibition of PbDHODH is about 300-fold higher than for the Pf enzyme, whereas inhibition of the Pv enzyme is only about 3-fold weaker than Pf.<a onclick="showRef(event, 'ref26 ref111'); return false;" href="javascript:void(0);" class="ref ref26 ref111">(26,111)</a> The 3-fold difference in enzyme IC<sub>50</sub> for DSM265 does not completely explain the 5-fold higher EC<sub>50</sub> for Pv compared to Pf in the whole parasite maturation assay.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> This raises the possibility that the physicochemical properties of the drug may play an additional role in determining potency in different parasite species.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Structural Biology</h3><div class="NLM_p">X-ray crystal structures of PfDHODH bound to DSM265 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0">4RX0</a>) reveal important information on the interactions present upon binding, justification for the observed SAR, and trends in species specificity.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> All DHODH structures with DSM ligands bound contain the FMN cofactor bound in the oxidized form with an adjacent molecule of orotate. An additional binding pocket, known as the species-selective inhibitor site, extends from the bound FMN cofactor to the N-terminal α-helix and is near or overlapping with the binding site for CoQ, which is required for the regeneration of FMN. Sequence homology across species is well conserved for the FMN and dihydroorotate binding sites, but sequence variability within the inhibitor binding site is responsible for species selective inhibition.</div><div class="NLM_p">In the bound state, DSM265 exists as a tautomeric form, resulting in a temporary dipole and electrostatic interactions with the protein. The Arg265 forms a hydrogen bonding interaction with N4 of the pyrimidine ring while the <i>exo</i>-cyclic N–H projects toward His185 making a hydrogen bond. The proximity of the histidine side chain to DSM265 occludes space for any further substitution of <i>N</i><sup>7</sup> and the replacement of N1, which is reflected in the SAR of early DSM analogues where the addition of <i>N</i><sup>7</sup>-methyl abolished PfDHODH inhibition.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Similarly, there is limited space in the binding pocket to accommodate substituents larger than a chloro or methyl substituent in the 5-position.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Inclusion of substituents at C6 was also detrimental to activity.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">The remainder of the DHODH inhibitor site is hydrophobic which is exploited by the inclusion of the C2-, <i>N</i><sup>7</sup>-substituents. A small tunnel extends from the species selective pocket and runs toward the FMN cofactor and is composed of Ile263, Ile272 the hydrophobic portion of the Arg265 side chain and of the hydroxyl and ring of Tyr528 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Small halogenated aliphatic moieties in the C2-position, such as the CF<sub>2</sub>CH<sub>3</sub> of DSM265, were found to be optimal in terms of enzyme inhibition and whole cell parasite activity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Small aliphatic and sulfanyl moieties were also accommodated by this tunnel, although extending the carbon chain beyond 2–3 carbons led to reduced potency.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In PbDHODH, Ser181 is present in the tunnel (Gly181 for PfDHODH) and restricts the size of the substituent that is tolerated. This structural difference in PbDHODH resulted in C2-substituted DSM analogues displaying weak activity against the murine parasite strain.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p last">The pocket which accommodates the <i>N</i><sup>7</sup>-is also completely hydrophobic in nature, which precludes polar or basic substituents (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The limited space near <i>N</i><sup>7</sup> and N1 also accounts for the poor activity observed for the <i>ortho</i>-substituted phenyl derivatives.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The structure also demonstrates that <i>para</i>-substituents extend outward from the pocket which is consistent with the presence of 4-CF<sub>3</sub> and 4-SF<sub>5</sub> in the highest potency analogues. There is space for <i>meta</i>-fluorine substituents in addition to <i>para</i>-moieties, and this pattern often resulted in greater potency at PfDHODH.<a onclick="showRef(event, 'ref103 ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref103 ref104 ref105">(103−105)</a> However, this can also lead to a loss of species selectivity as increasing the number of hydrophobic interactions restores activity in HsDHODH.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Antimalarial Activity</h3><div class="NLM_p">DSM265 has potent activity against asexual Pf strains (EC<sub>50</sub>s 7–16 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) that are resistant to known drugs, such as CQ and MQ (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> This indicates that DSM265 is unlikely to be susceptible to drug resistance mechanisms of known antimalarials. Several experiments show the killing kinetics of DSM265 to be similar to that for atovaquone (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which is consistent with their inherently related mechanism of action. The phenotypic and developmental response to treating blood-stage parasites with DSM265 at 10 × EC<sub>50</sub> was similar to atovaquone. Microscopy evaluation of parasites 48 h post-treatment with DSM265 showed that parasites were killed in the young trophozoite stage.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Determination of parasite kill rate at the EC<sub>50</sub> was shown to have a 96 h lag phase, while at ≥3 × EC<sub>50</sub>, the lag phase was 24–48 h before parasite killing (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), which is similar to that for atovaquone (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> This delayed phenotype was further exemplified with parasite clearance times of 85 and 82 h with treatment of 10- and 100-fold EC<sub>50</sub> concentrations of DSM265.</div><div class="NLM_p">DSM265 did not inhibit growth of the early and late gametocyte (NF54) forms (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> This is consistent with the observation that gametocyte levels were not affected by administration of DSM265 in humans.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Additionally, DSM265 displayed no activity in the dual gamete formation assay, suggesting DSM265 would not be effective in a therapy aimed at transmission blocking.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p">Liver cell invasion by sporozoites was not blocked by DSM265,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> however, EEF growth to schizonts was arrested with DSM265 with an EC<sub>50</sub> of 0.0057 μg/mL (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), which is 30-fold more potent than primaquine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Against <i>Plasmodium cynomolgi</i> in vitro, DSM265 was active against multinucleated large EEFs (EC<sub>50</sub> 0.13 μg/mL) but not against hypnozoites. The pre-erythrocytic activity combined with the long plasma half-life suggests DSM265 has potential as a single-exposure chemoprotectant. DSM265 displays potent activity against both asexual blood and liver schizont parasites and therefore would be suitable for use in TCP 1 and 4 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">As the program progressed, the humanized Pf SCID mouse became the gold standard preclinical efficacy model, virtually replacing the earlier Pb mouse model.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> DSM265 was tested for efficacy in this model to enable calculation of the minimum parasiticidal concentration (MPC). DSM265 (as a tosylate salt) was dosed once or twice daily in the SCID mouse model where the 90% effective dose (ED<sub>90</sub>) was 3 mg/kg (qd) and 1.5 mg/kg (b.i.d.).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The MPC was estimated to be 1–2 μg/mL (dose of 13 mg/kg per day or 6.4 mg/kg b.i.d.) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The detection of late trophozoites and early schizonts in the blood further supports a mechanism which interferes with parasite metabolism.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Synthesis</h3><div class="NLM_p">The GMP synthesis of DSM265 is a scale-up of the method developed for analogue generation in the medicinal chemistry campaign and the pathway is shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The 2,3-diamino-6-methyl-4(3<i>H</i>)-pyrimidinone (<b>56</b>) portion of the core was formed through the condensation of ethyl acetoacetate and aminoguanidine hydrochloride under basic conditions.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Treatment of <b>56</b> with ethyl 2,2-difluoropropanoate in the presence of base affords the C2-substituted-7-hydroxy pyrazolopyrimidine in high yield. Chlorination was achieved using POCl<sub>3</sub> in MeCN at elevated temperature to afford <b>58</b>. Displacement of the chloride by pentafluorosulfanyl aniline gave DSM265 in high yield.</div><figure id="sch4" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CH<sub>3</sub>CF<sub>2</sub>COOEt, NaOEt, EtOH, 78 °C, 3 h, 84%; (b) POCl<sub>3</sub>, MeCN, 80 °C, 5 h, 82%; (c) pentafluorosulfanyl aniline, EtOH, 60 °C, 3.5 h, 86%, 99.5% purity. Inset: byproduct <b>59</b> resulting from the synthesis of DSM265.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></p></figure><div class="NLM_p last">During GMP scale-up the 3-fluoro phenyl byproduct <b>59</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) was present at ∼0.6% in the GMP scale-up material which was due to a contaminant formed during the synthesis of the pentafluorosulfanyl aniline. The formation of <b>59</b> was synthetically unavoidable and could not be removed on purification of DSM265.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Compound <b>59</b> exhibited the same activity (IC<sub>50</sub> 0.010 μM) against PfDHODH as DSM265 but was 10-fold more potent against mammalian DHODH, including the human orthologue (IC<sub>50</sub> 3.7 μM). In contrast to the biochemical activity, <b>59</b> was 10-fold more potent against Pf in vitro (EC<sub>50</sub> 2 nM) than DSM265. Dosing DSM265 with 0.6% <b>59</b> present in the formulation was well tolerated in preclinical species but needs to be monitored closely in the human clinical trials because of potential human DHODH activity.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Preclinical Assessment</h3><div class="NLM_p">Evaluation of DSM265 in preclinical species were undertaken by Phillips et al.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> to ensure safety and to predict an effective dose for humans in clinical trials. The pharmacokinetic profile of DSM265 in dogs and monkeys was improved compared to that seen in rodents (discussed in an earlier section).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> In monkeys and dogs, DSM265 (both 1 mg/kg iv) displayed a long half-life ranging from 10 to 45 h, low plasma clearance (0.054–0.022 L/h/kg), and good exposure (AUC 16.7–46.9 μg·h/mL). The oral bioavailability of DSM265 was lower in dogs than in rats and monkeys, however, assessment of bioavailability in dogs was complicated by the presence of enterohepatic recirculation. A significant increase in plasma exposure of DSM265 was observed in the fed state compared to the fasted state in dogs, most likely resulting from poor aqueous dissolution of the freebase form of DSM265 in fasted versus fed state intestinal fluids. To improve solubility, a tosylate salt of DSM265 was produced, improving aqueous solubility somewhat and increasing exposure in mice compared to the free base form of DSM265, but a similar trend was not observed in rats or dogs. To improve the dissolution and absorption profile of DSM265, an amorphous spray dried dispersion (SDD) formulation was prepared. This formulation enhanced the simulated intestinal solubility approximately 10-fold (to 100 μg/mL) and increased plasma exposure levels approximately 8-fold under both fasted and fed conditions in dogs. Furthermore, the SDD formulation was stable for at least 9 months under temperate conditions. The pharmacokinetic studies undertaken in preclinical species enabled the estimation of human pharmacokinetic parameters using a physiologically based pharmacokinetic (PBPK) model.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Allometric scaling of the unbound clearance in preclinical species gave an estimated human clearance value of 0.25 L/h, and the PBPK model predicted a half-life of approximately 130 h, leading to an estimated human dose between 200 and 400 mg to achieve plasma concentrations above the plasma MPC (1–2 μg/mL) for at least 8 days.</div><div class="NLM_p">Metabolite profiling was performed to identify metabolites of DSM265 and their potential toxicity.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> One major metabolite and four minor metabolites were identified in in vivo samples from pharmacokinetic studies in animals. The structure of the major metabolite, <b>M60</b>, was confirmed by synthesis and mass spectra comparison. <b>M60</b> was produced from mono-oxidation of the 5-methyl group of the triazolo[1,5-<i>a</i>]pyrimidine core of DSM265. Other minor metabolites were formed by dehydrogenation (<b>M61</b>) and glucuronidation (<b>M62</b>) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). In preclinical species, <b>M60</b> was estimated to represent approximately 4–27% of the parent AUC. In vitro studies with each CYP450 isoform showed CYP2C8 and CYP2C19 were primarily associated with the oxidative biotransformation of DSM265. The metabolite <b>M60</b> is ∼3-fold less active against PfDHODH and 5-fold less active against PvDHODH in vitro compared to DSM265. Compound <b>M60</b> is inactive against human DHODH and was well tolerated in dose ranging experiments in preclinical species. Collectively, the data indicated that this metabolite was unlikely to pose a safety risk for DSM265 in the clinic.</div><figure id="fig17" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Proposed biotransformation pathway for the formation of metabolite <b>M60</b> and minor metabolites <b>M61</b> and <b>M62</b> from incubation of DSM265 in liver microsomes from preclinical species.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vitro toxicology was evaluated to identify potential safety issues with DSM265.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> DSM265 did not inhibit or induce any human CYP450 isoform, indicating a low likelihood of it impacting the metabolism of a coadministered partner agent. DSM265 displayed minimal inhibition (IC<sub>50</sub> > 4.2 mg/mL) of a panel of high-risk human receptors, ion channels, and a panel of kinases. DSM265 was shown to inhibit the hERG cardiac ion channel at elevated concentrations (IC<sub>50</sub> values of 2.9 and 0.66 μg/mL) using two patch clamp assays. However, DSM265 is unlikely to attain these concentrations in humans because of its low free fraction in plasma (unbound <i>C</i><sub>max</sub> < 0.01 μg/mL). Subsequently, DSM265 was shown not to affect QT prolongation or cardiac arrhythmia in a rabbit cardiac ventricular wedge assay or by electrocardiography when dosed in dogs, suggesting DSM265 was unlikely to cause an adverse cardiac event in clinical trials.</div><div class="NLM_p">G6PD deficiency is a common genetic disorder in malaria endemic regions.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> DSM265 was tested for hemolytic toxicity in immunodeficient mice engrafted with G6PD-deficient human erythrocytes but did not display hemolytic effects, indicating DSM265 could be safely dosed in humans with a G6PD deficiency. In further toxicology tests, DSM265 did not display genotoxicity in the Ames test or the bone marrow micronucleus test in mice, further demonstrating the robust safety profile of DSM265.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p last">Exploratory toxicology studies were undertaken to determine the maximum tolerated dose (MTD) of DSM265 in preclinical species.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> It was discovered that rats were overly sensitive to DSM265, and toxicity was attributed to the activity of DSM265 against the rat DHODH enzyme, combined with the lower plasma protein binding and higher unbound concentrations compared to other preclinical species. For this reason, mice and dogs were used for MTD studies. In these studies, DSM265 was well tolerated at all dose levels in mice (25–200 mg/kg per day once daily for 7 days) and dogs (30–480 mg/kg every other day for 10 days), and there was no accumulation of DSM265 or adverse events in either species. The MTD was therefore defined as exceeding 200 and 480 mg/kg in mice and dogs, respectively. The average plasma exposure levels of DSM265 at the highest dose tested was 10-fold higher in mice and 15-fold higher in dogs relative to the MPC from the humanized SCID mouse model. Collectively, these data suggested an adequate safety window between the MTD and predicted concentrations needed for parasite clearance.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Clinical Trial Progress</h3><div class="NLM_p">McCarthy et al. evaluated DSM265 in a phase Ia clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy volunteers (ACTRN12613000522718) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> DSM265 was administered orally as a single ascending dose (25–1200 mg) to cohorts of individuals. DSM265 was efficiently absorbed, reaching a <i>C</i><sub>max</sub> of 1310–34800 ng/mL between 1.5 and 4 h (<i>T</i><sub>max</sub>). Consistent with preclinical studies,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> DSM265 had a long half-life in humans of 86–118 h under fasted conditions. The plasma exposure of DSM265 increased in an approximately dose proportional manner with AUC<sub>0–∞</sub>, ranging from 107000–4720000 ng·h/mL over the dose range of 25 to 1200 mg. Under fed conditions, the pharmacokinetic profile of DSM265 was relatively unchanged. Compound <b>M60</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), the known hydroxylated metabolite of DSM265, reached a maximum concentration between 95 and 143 h post administration of DSM265 with plasma exposure (AUC<sub>0–∞</sub>) ranging from 167000 to 1170000 ng·h/mL (19–27% of the DSM265 exposure levels) and long half-life ranging from 98–164 h. The antimalarial activity of <b>M60</b> is significantly less potent than DSM265 against parasites (in vitro 3D7 EC<sub>50</sub> 1.8 vs 0.0078 μM) and is not expected to contribute to the antimalarial efficacy of DSM265. No treatment related serious adverse events were reported in the study, and no cardiac arrhythmias nor QT prolongation were observed. A higher incidence of mild adverse events in the DSM265 treated cohort versus the placebo was recorded, with the most common drug-related symptom being a headache. Overall, the trial demonstrated DSM265 was well tolerated and has a long half-life, suggesting it was suitable for a single dose treatment regimen. Additionally, PK/PD modeling of the trial data predicted a 340 mg dose of DSM265 would be curative in humans infected with Pf.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Overview of DSM265 Clinical Trials Completed or in Progress</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">phase/study</th><th class="colsep0 rowsep0" align="center">study population</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">end point and outcome</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, PK and tolerability</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">single dose of 5–1200 mg</td><td class="colsep0 rowsep0" align="left">primary measures: MTD, PK</td><td class="colsep0 rowsep0" align="center">ACTRN 12613000522718<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: half-life, 86–118 h; AUC<sub>0–480</sub>, 104000–4720000 ng·h/mL; <i>T</i><sub>max</sub>, 1.5–4 h; <i>C</i><sub>max</sub>, 1310–34800 ng/mL</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">no serious adverse events</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ib, efficacy</td><td class="colsep0 rowsep0" align="left">healthy adults infected with Pf asexual parasites</td><td class="colsep0 rowsep0" align="left">single 150 mg dose</td><td class="colsep0 rowsep0" align="left">primary measure: parasite clearance kinetics</td><td class="colsep0 rowsep0" align="center">ACTRN 12613000527763<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcome: parasite clearance half-life, 9.4 h</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MIC: 1040 ng/mL</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">predicted single efficacious dose: 340 mg</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ib, efficacy</td><td class="colsep0 rowsep0" align="left">healthy adults infected with Pf asexual parasites</td><td class="colsep0 rowsep0" align="left">single 400 mg dose</td><td class="colsep0 rowsep0" align="left">primary measures: tolerability, PK</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measure: asexual parasite and</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">gametocyte clearance</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PK and tolerability consistent with phase 1a</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100% asexual parasite clearance at day 12 (<i>n</i> = 7); no recrudescence at day 28</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">all patients became gametocytemic post treatment; gametocytes not cleared with second 400 mg dose of DSM265</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase IIa, efficacy</td><td class="colsep0 rowsep0" align="left">Pv or Pf monoinfected adults from Peru</td><td class="colsep0 rowsep0" align="left">Pf infected arm:</td><td class="colsep0 rowsep0" align="left">primary measures: parasitemia at day 14; PK</td><td class="colsep0 rowsep0" align="center">NCT02123290<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">250 or 400 mg single dose</td><td class="colsep0 rowsep0" align="left">secondary measures: parasite clearance kinetics; tolerability; gametocytemia up to day 28; parasitemia at day 28; PK/PD</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Pv infected arm: 400, 600, or 800 mg single dose</td><td class="colsep0 rowsep0" align="left">outcomes: % of patients cured from Pf infection at day 25 400 mg, 11%; 250 mg, 38%</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">percentage of patients cured from Pv infection at day 14:400 mg, 0%; 600 mg, 50%; 800 mg, 25%</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ib, efficacy with partner agent</td><td class="colsep0 rowsep0" align="left">healthy adults infected with Pf asexual parasites</td><td class="colsep0 rowsep0" align="left">arm 1: single dose of 200 mg of OZ439 and 100 mg of DSM265</td><td class="colsep0 rowsep0" align="left">primary measure: PK/PD</td><td class="colsep0 rowsep0" align="center">NCT02389348</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 2: single dose of 400 mg for DSM265 and 500 mg for OZ439</td><td class="colsep0 rowsep0" align="left">secondary measures: tolerability and safety; PK parameters</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcome expected: unknown</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">      </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ib, prophylactic efficacy</td><td class="colsep0 rowsep0" align="left">healthy adults infected with Pf sporozoites</td><td class="colsep0 rowsep0" align="left">400 mg at 3 time points pre- and post-Pf sporozoite infection.</td><td class="colsep0 rowsep0" align="left">primary measure: time from sporozoite infection to asexual parasitemia (blood smear)</td><td class="colsep0 rowsep0" align="center">NCT02450578<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measure: tolerability, PK, and PK/PD</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: DSM265 dosed 1 day preinfection: 100% protection (<i>n</i> = 5); DSM265 dosed 7 days preinfection: 50% protection (<i>n</i> = 6) at day 24</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ib, prophylactic efficacy</td><td class="colsep0 rowsep0" align="left">healthy adults infected with Pf sporozoites via mosquito bite</td><td class="colsep0 rowsep0" align="left">400 mg at 3 time points pre- and post-Pf infection</td><td class="colsep0 rowsep0" align="left">primary measures: percentage with parasitemia (qRT-PCR) at day 28 and time from infection to asexual parasitemia</td><td class="colsep0 rowsep0" align="center">NCT02562872<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: DSM265 dosed at 3 or 7 days preinfection; 33% protection (<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div><div class="NLM_p">The efficacy of DSM265, evidenced by its ability to clear blood-stage malaria, was next evaluated in a phase Ib trial (ACTRN12613000527763) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> In this trial, a single oral dose of DSM265 (150 mg) was administered to human volunteers 8 days after an induced infection with Pf, in a previously described induced blood-stage infection model.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> The parasite clearance half-life was 9.4 h, which was significantly longer than the control drug, MQ (10 mg/kg), with a parasite clearance half-life of 6.2 h. Post administration of DSM265, there was a 12 h lag phase until parasitemia levels started to decline. The delay in parasite reduction was consistent with the drug’s relatively slow onset of action as observed in in vitro PRR experiments which is associated with the mechanism by which DSM265 kills asexual blood-stage parasites. Recrudescence of parasitemia occurred in all volunteers between 10 and 22 days after treatment with DSM265, which allowed the estimation of the MIC (1040 ng/mL) and the curative dose (340 mg). There was no evidence of mutations in the DHODH gene detected in these parasites, implying resistance was not the cause of recrudescence. Gametocytemia was also detected 5 days after administration of DSM265, but gametocyte levels did not decline correlating with modest early stage and absence of late stage in vitro gametocyte activity of DSM265.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> In summary, the long half-life and slow PRR of DSM265 suggests it may be a useful as a single agent in a SERC therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) with a fast acting partner drug.</div><div class="NLM_p">An additional clinical trial was undertaken using a single 400 mg dose of DSM265 administered to individuals 8 days after inoculation with Pf (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> At the 400 mg dose, asexual stage parasitemia was cleared from all patients infected with Pf. However, all individuals became gametocytemic. A second 400 mg dose of DSM265 was administered 23 days after the initial infection to determine the effect on gametocytemia. Consistent with in vitro data,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> gametocytes were not cleared by DSM265. Nevertheless, the clinical trial established a likely efficacious dose of 400 mg DSM265 to treat symptomatic malaria.</div><div class="NLM_p">To further establish the potential of DSM265 in a curative SERC treatment (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), a phase IIa study (NCT02123290) was conducted in patients in Peru who had monoinfections with either Pf or Pv presenting with uncomplicated malaria (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Patients with Pf infection were treated with a single oral dose of either 250 or 400 mg of DSM265, while patients with Pv were treated with a single oral dose of either 400, 600, or 800 mg of DSM265. For the patients infected with Pf, parasitemia (assessed by blood smear) was cleared in 100% of cases within 72 h of treatment. By qPCR and blood smear, 100% of the 400 mg cohort and 88% of the 250 mg cohort achieved an adequate clinical and parasitological response (ACPR) at day 14. Kinetically, after the initial lag phase, DSM265 killed Pf parasites with a log PRR of 2.9 and 3.1 for the 400 mg and 250 mg dose groups, respectively. The median Pf clearance half-life was 5 h, significantly shorter than the 9 h previously reported.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The difference in clearance rate was attributed to the immune competency of the patients from a malaria endemic region in this trial compared to the immune naive volunteers in the phase Ib trial. One of the 11 patients in the 400 mg group and three of the eight patients in the 250 mg group were recrudescent by day 25. Approximately 60% of Pf infected patients were gametocyte positive at the end of the trial period, further showing that DSM265 is not effective at killing the sexual form of the parasite.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Of the Pf infected patients that were recrudescent at day 28, resistance mutations in the DHODH gene were identified in 2 of the 4 patients, while these mutations were not present at the time of infection, demonstrating resistance acquisition upon treatment with DSM265.</div><div class="NLM_p">In the phase IIa study (NCT02123290) in Pv-infected individuals, no patients treated with 400 mg, 50% dosed with 600 mg, and 25% dosed with 800 mg DSM265 were cured at day 14, a significantly poorer outcome than for Pf-infected patients (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The lag time for DSM265 for Pv ranged from 12 to 46 h, which was longer than for Pf, which ranged between 8.5 and 30 h. The log PRR value of 0.77 for Pv was also lower than the value of 1.54 for Pf. A possible reason for this difference is that DSM265 has significantly less potency against Pv compared to Pf clinical isolates from South East Asia (EC<sub>50</sub> 190 vs 918 nM) in a 48 h in vitro assay.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> These data are also consistent with in vitro activity on Pv isolates from South America (EC<sub>50</sub> 529 nM) by another group,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> although the difference in the biochemical potency of DSM265 against PfDHODH and PvDHODH (IC<sub>50</sub> 10 and 20 nM, respectively)<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> does not completely account for this loss in parasite activity.</div><div class="NLM_p">A suitable combination partner for a slow acting antimalarial such as DSM265 is a fast-acting drug such as ART or artefenomel (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Both artefenomel and DSM265 have a long pharmacokinetic half-life while having different modes of action, parasite stage killing profiles, and PRR. A phase Ib volunteer infection study (VIS) (NCT02389348) has been conducted to assess the efficacy of DSM265 in combination with artefenomel to treat Pf blood-stage infection in healthy volunteers (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The results are pending and may reveal one combination partner that is suitable for administration with DSM265 in a SERC therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">DSM265 is active against both the pre-erythrocytic and asexual erythrocytic stages of the malaria parasite lifecycle,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and combined with its long half-life in humans,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> DSM265 has the properties needed for inclusion as a potential single-exposure chemoprotection (SEC)<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> or prophylaxis therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). To assess the appropriateness of DSM265 as a prophylaxis agent, the Pf sporozoite challenge model<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121,122)</a> was implemented in two volunteer infection studies (VIS). Here, healthy individuals were administered DSM265 prior to inoculation with Pf sporozoites and then establishment of blood-stage infection was subsequently monitored.</div><div class="NLM_p">In the first trial (NCT02450578), Sulyok et al. administered a single 400 mg dose of DSM265 to healthy volunteers either 1 day or 7 days prior to intravenous administration of Pf sporozoites (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The different dosing regimens would offer insight into whether DSM265 was effective at clearing pre-erythrocytic in addition to asexual blood-stage parasitemia. The pharmacokinetic profile of DSM265 in this trial was consistent with previous data.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> When DSM265 was given 1 day prior to the sporozoite challenge, blood-stage parasitemia was not detected. When DSM265 was given 7 days prior to sporozoite infection, reduced efficacy was observed. Although patients were protected for a longer period of time than with the placebo, all patients developed blood-stage malaria with a mean prepatent period of 15 days and an average peak parasite time of 8.2 days post infection. The efficacy in this model appeared dependent on the concentration of DSM265 at the time of and during the initial establishment of infection. The data for the 1-day cohort suggest DSM265 likely clears liver stage parasites before the onset of blood-stage infection, and the concentration of DSM265 in the 7-day cohort was not sufficient to prevent induction or progression of blood-stage parasitemia.</div><div class="NLM_p last">In the second trial (NCT02562872), Murphy et al. administered a 400 mg dose of DSM265 either 3 days prior to intravenous inoculation of Pf sporozoites or 7 days prior to infection of Pf sporozoites intravenously or by bites from <i>Anopheles stephensi</i> mosquitoes (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In each instance, establishment and progression of blood-stage parasitemia was observed. There was a significant difference between the rate of increase in parasite burden between DSM265-treated compared to untreated cohorts. The median time to >250 parasites/mL in the placebo group was between 8 and 9 days compared to 15.3 for the 7-day cohort to 20.9 days for the 3-day treated cohort. Between individual treated cohorts, there was no significant difference in the median rate to achieve >250 parasites/mL. Of the 18 patients in the trial, two patients were protected, 1 each from 3- and 7-day treatment cohorts. In summary, although two patients were protected from infection, DSM265 overall displayed partial protection, suggesting it will require a fixed dose combination regimen for chemoprotection.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">MMV048 (MMV390048)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Hit Identification</h3><div class="NLM_p">A HTS campaign performed by Prof. Vicky Avery at the Griffith Research Institute for Drug Discovery (GRIDD), as part of a collaborative team led by Prof. Kelly Chibale at the University of Cape Town, used an image based screen<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> of the BioFocus DPI SoftFocus kinase library<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> to identify 3,5-diarylaminopyridines as in vitro antimalarial hit compounds.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The HTS was performed on 3D7 and Dd2 parasite strains with 36608 compounds tested. Of these, 442 demonstrated 50% inhibition at 1.82 μM against these strains and structural variation was seen between the 3- and 5-positions of the pyridine ring. Representative examples (<b>63</b>–<b>65</b>) of the initial hits are shown in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>.</div><figure id="fig18" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Initial hits of the 3,5-diarylaminopyridine class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Lead Identification and Optimization</h3><div class="NLM_p">Exploration of SAR started with the 5-(<i>p</i>-methylsulfonylphenyl)aminopyridine core and investigating the importance of the 3-position.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> These compounds featured various electron-donating and electron-withdrawing groups attached to either benzene or heteroaromatics such as pyridine and pyrazine. These compounds were examined for antimalarial activity against asexual NF54 Pf, and they had equivalent or greater activity than CQ. The most notable changes among this series were compounds featuring pyridine and/or electron-withdrawing groups, all of which exhibited EC<sub>50</sub> values <50 nM, and they had equipotent activity against the two strains. Highlighted compounds MMV048, <b>66</b>–<b>69</b> are depicted in <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>.</div><figure id="fig19" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Key aminopyridines and their antimalarial activity against NF54 asexual parasites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modifications to the core pyridine and the 2-amino group were made to enhance the antimalarial activity as well as improve solubility.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> With the 4-methoxypyridyl attachment fixed changes to the 2-amino group (<b>70</b>), including incorporation of iodo (<b>71</b>), trifluoromethyl (<b>72</b>), and hydroxyl (<b>73</b>) groups were investigated (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). These were formed from the amino compound via diazotization and iodination (<b>71</b>), subsequent trifluoromethylation with FSO<sub>2</sub>CF<sub>2</sub>CO<sub>2</sub>Me and CuI in DMF, and for the hydroxyl (<b>73</b>) analogue, reaction of the amino compound (<b>70</b>) with NaNO<sub>2</sub>, and TFA. These modifications were not tolerated and resulted in molecules with lower in vitro antimalarial activity. In addition, the <i>des</i>-amino (<b>74</b>) and substituted amino-containing compounds were likewise far less active.</div><figure id="fig20" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Changes to the 2-amino group and associated NF54 asexual parasite activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Replacement of the core pyridine was investigated with the synthesis of the phenyl (<b>75</b>), 3-aminopyridine (<b>76</b>), pyrazine (<b>77</b>), and pyridazine (<b>78</b>) compounds (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The marked difference in activity between the location of the nitrogen in the ring between <b>70</b> and <b>78</b> is striking (NF54 EC<sub>50</sub> 51 nM for <b>70</b> compared to >28000 nM for <b>76</b>). Only the pyrazine compound (<b>77</b>) showed good potency with an EC<sub>50</sub> value of 48 nM against Pf NF54.</div><figure id="fig21" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Changes to the scaffold core and associated NF54 asexual parasite activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pyrazine scaffold modification was further examined in combination with the <i>o</i>-trifluoromethylpyridine at the 3-position.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> This was further extended to improve aqueous solubility and potency by replacement of the <i>p</i>-methylsulfonylphenyl group with a number of varied substituents, with the piperazine amide (<b>79</b>) demonstrating the most attractive features.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The key lead compounds across this series are shown in <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>. Ultimately, <b>77</b> was not further pursued due to limited aqueous solubility at physiological pH and <b>79</b>, also known as UCT943<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> is a potential clinical substitute for MMV048 exhibiting greater aqueous solubility.</div><figure id="fig22" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Frontrunner compounds in the 3,5-diarylaminopyridine (pyrazine) series.<a onclick="showRef(event, 'ref50 ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref50 ref126 ref127">(50,126,127)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">MMV048 displays a log <i>D</i><sub>7.4</sub> of 2.6 and solubility of 6.3–12.5 μg/mL at pH 6.5.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Metabolism in human liver microsomes (HLM) demonstrated low clearance (CL<sub>int</sub> < 1.4 μL/min/mg) and low hepatic extraction ratio (<i>E</i><sub>H</sub> < 0.07). Pharmacokinetic studies of MMV048 dosed intravenously (5 mg/kg) and orally (5 or 20 mg/kg in an aqueous suspension) to male Sprague–Dawley rats revealed good oral bioavailability (<i>F</i> 51%), a long half-life (<i>T</i><sub>1/2</sub> 8.5 h), and good exposure (AUC<sub>0–inf</sub> 4,453 μM/min at an oral dose of 20 mg/kg). After iv dosing to rats, MMV048 had a moderate volume of distribution (<i>V</i><sub>ss</sub> 2.7 L/kg) and low plasma clearance (6.5 mL/min/kg).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Mechanism of Action</h3><div class="NLM_p">The mechanism of action of MMV048 is based on direct inhibition of the <i>Plasmodium</i> phosphatidylinositol 4-kinase (PI4K) enzyme, an essential enzyme responsible for phosphorylation of phosphatidylinositol lipids that are involved in membrane ingression during merozoite formation in Pf asexual blood-stage schizonts.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Identification of this target was achieved with a multifaceted approach involving genomic analysis of resistant mutants, chemoproteomic pull-down of the target protein, and direct analysis of the inhibition of recombinant PI4K enzyme.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> In vitro selection of resistant parasites under drug pressure (3–5 × EC<sub>50</sub>) was achieved relatively rapidly, consistent with a PI4K mutation rate of about 1 per 3 × 10<sup>6</sup> infected RBCs, raising some concerns about the potential for rapid development of MMV048 resistance in a clinical setting. Genomic sequencing of three resistant strains revealed consistent mutations in the <i>Pfpi4k</i> gene, involving A1319V or S743T mutations that suggest interaction of MMV048 with the ATP-binding pocket of PI4K (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> In addition, cross-resistance was observed in <i>Pfpi4k</i>–mutant parasite lines bearing mutations associated with resistance to structurally unique PI4K inhibitors from the imidazopyrazine (for example, KDU691, S1320L, and H1484Y) and quinoxaline classes (for example, BQR695, Y1356F).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><figure id="fig23" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Homology model of the Pf catalytic domain of PI4K built using the PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ENE">3ENE</a> as previously described by McNamara et al.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> MMV048 (green) was docked using CLC Drug Discovery workbench. (A) Resistance mutations for MMV048 are shown in orange.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Resistance mutations of the Pf PI4K inhibitors, KDU691or BQR695, are shown in magenta.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> MMV048 is cross resistant to clones that possess these mutations. (B) A surface representation of the ATP binding pocket and amino acids (blue) predicted to interact with MMV048.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Chemoproteomics studies utilized an amine-containing analogue, <b>80</b> (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>), the presence of the aliphatic amine allowed covalent attachment to sepharose beads for subsequent pull-down of the target protein from parasite lysates. Specificity for interaction of this immobilized MMV048 analogue with the target protein was achieved by competitive inhibition with free MMV048, and PI4K was the only protein consistently found to be enriched in a MMV048-dependent manner.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> A dose-dependent analysis of this interaction was conducted with a range of MMV048 analogues, and the IC<sub>50</sub> values for the dissociation of PI4K correlated well with the in vitro antiparasitic activity of these compounds. A related approach using nonspecific kinase ligands (“Kinobeads”) to pull-down parasite kinases also identified PI4K as the only enriched parasite kinase that was competitively displaced by free MMV048 in a dose-dependent manner.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><figure id="fig24" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structure of <b>80</b> used as a pull-down probe for immobilization to sepharose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">PI4K inhibition was further confirmed by analysis of kinase activity in recombinant PI4K from Pv.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> MMV048 demonstrated an IC<sub>50</sub> of 3.4 nM against PvPI4K.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Analysis of a range of MMV048 analogues also demonstrated a close relationship between the potency of inhibition of kinase activity and the in vitro antiparasitic activity against Pf.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Taken together, these complementary studies clearly demonstrate that MMV048 selectively inhibits PI4K in both of the common species of malaria parasites, Pf and Pv.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Antimalarial Activity</h3><div class="NLM_p">MMV048 has potent activity against NF54 asexual blood-stage parasites with an EC<sub>50</sub> of 28 nM and EC<sub>90</sub> of 40 nM<a onclick="showRef(event, 'ref50 ref130'); return false;" href="javascript:void(0);" class="ref ref50 ref130">(50,130)</a> and is most effective at the schizont stage of the asexual blood stage of the lifecycle. MMV048 has EC<sub>50</sub> values of 25, 17, and 9 nM against NF54,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> the CQ-resistant Dd2,<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> and the CQ-sensitive D10<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> parasite strains, respectively. The PRR was 2.7 at 10 × EC<sub>50</sub> of MMV048 with a lag-time of 24 h. In this way, MMV048 acts as a slow-onset antimalarial in vitro with a 4.8-fold higher EC<sub>50</sub> at 24 h compared to at 72 h (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">The liver stage effects of MMV048 were investigated in <i>P. cynomolgi</i>, a closely related simian orthologue of Pv.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Both schizonts and hypnozoites derived in a primary rhesus hepatocyte cell culture exhibited EC<sub>50</sub> values of 64 and 61 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). However, the effectiveness of MMV048 was reduced when administered to mature (>24 h) hypnozoites, with activity dropping from 61 nM at day 0 to >10 μM at day 5. This inability to eliminate mature hypnozoites was reconfirmed in vivo in <i>P. cynomolgus</i> infected macaques, suggesting that MMV048 will not have antirelapse (TCP3) potential (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">MMV048 inhibited both early stage (I, II, III) and late stage (IV, V) gametocytes in a luciferase reporter assay with EC<sub>50</sub>s of 214 and 140 nM, respectively.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> MMV048 also impacted gametogenesis exflagellation with an EC<sub>50</sub> of 90 nM (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). MMV048 was examined by direct SMFA (at the time of blood meal) or indirect SMFA (before mosquito feeding) by incubation with stage V Pf gametocytes at 24 h. In the SMFA MMV048 was able to inhibit the formation of oocysts in the midgut with activity of 111 nM. However, in the direct SMFA, MMV048 inhibited >25% oocyst formation at 1 μM. This difference infers a greater transmission-blocking ability against the stage V gametocytes in host blood rather than subsequent forms matured in the midgut of the mosquito. In summary, the multistage activity of MMV048 suggests it would be suitable for TCPs 1, 4, and 5 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">MMV048 administered to Pb-infected mice at five dose levels resulted in inhibition of between 98.0–99.5% parasitemia. When MMV048 was given as a single dose of 30 or 100 mg/kg all mice were cured. In this mouse model, CQ, ART, and MQ (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) do not result in a single dose cure. Efficacy in a Pf humanized SCID mouse model after a once daily dose of MMV048 over four consecutive days achieved an ED<sub>90</sub> of 0.57 mg/kg at day 7 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The mouse efficacy models support the use of MMV048 as a possible partner agent in a SERC therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Synthesis</h3><div class="NLM_p">The process used to generate analogues during the discovery phase was also used to synthesize MMV048.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The process was a relatively straightforward 3-step route beginning with iodination of 3-bromopyridin-2-amine (<b>81</b>) to give <b>82</b> in high yield. The aryl substituents were then successively installed in the 5- and then 3-positions using sequential Suzuki–Miyaura cross-coupling reactions in modest yields to generate MMV048 (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) I<sub>2</sub>, DMSO, 100 °C, 4 h, 79%; (b) <i>p</i>-MeSO<sub>2</sub>PhB(OH)<sub>2</sub>, 1,4-dioxane, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (5 mol %), 110 °C, 16 h, 58%; (c) 6-(trifluoromethyl)pyridin-3-yl)boronic acid, 1,4-dioxane, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (7 mol %), 110 °C, 16 h, 65%.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></p></figure></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Preclinical Assessment</h3><div class="NLM_p">Paquet et al. performed pharmacokinetic studies using preclinical species to assist in prediction of human pharmacokinetics and dose for MMV048.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> On intravenous administration of MMV048 to mice, rats, dogs, and monkeys, there were subtle differences in the pharmacokinetic profile between species. MMV048 possessed a low plasma clearance in dogs (CL 0.036 L/h/kg), and clearance was elevated in mice and rats (0.18 and 0.39 L/h/kg, respectively). The volume of distribution was moderate in all preclinical species (1.3–3.0 L/kg), while the half-life in dogs and monkeys (58 and 56 h) was longer than the half-life in mice and rats (5.6 and 9.2 h). On oral administration, the maximum concentrations of MMV048 attained in all species were dose-dependent. MMV048 on oral dosing was characterized by a long half-life in dogs and monkeys and an oral bioavailability between 45 and 74%. Using allometric scaling of data from preclinical species, it was predicted that in humans MMV048 would have a low clearance (0.02 L/h), a modest volume of distribution (2.8 L/kg), and long half-life of 90 h. At a dose of 80–100 mg in humans, MMV048 was predicted to maintain the desired plasma concentrations for 8 days, suggesting MMV048 has potential in a one-dose curative therapy. The long half-life of MMV048 combined with its liver stage activity imply MMV048 is also a suitable single agent for a chemoprotective or prophylaxis therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">In vitro safety data indicated that MMV048 is nontoxic to a panel of human cells at a therapeutically relevant concentration (CC<sub>50</sub> > 10 μM).<a onclick="showRef(event, 'ref128 ref130'); return false;" href="javascript:void(0);" class="ref ref128 ref130">(128,130)</a> MMV048 does not inhibit hERG or ion channels Na<sub>v</sub>1.5 and Ca<sub>v</sub>1.2 at concentrations >10 μM, suggesting MMV048 represents a low cardiac risk in the clinic.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> MMV048 was not active in the Ames or micronucleus test, suggesting it represents a low genotoxicity risk in humans.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> MMV048 did not decrease red blood cell levels or affect spleen weight in G6PD-deficient immunodeficient mice at 30 mg/kg daily for 4 days, indicating MMV048 is suitable for administration in patients with G6PD deficiency. At the time of writing this review, exploratory toxicology or MTD data in preclinical species has not been published, and therefore further safety aspects cannot be reported on, nonetheless, MMV048 has advanced into human clinical trials.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Clinical Trial Progress</h3><div class="NLM_p">MMV048 is currently in a phase II clinical trial. At time of writing this review, there were no literature reports regarding the efficacy outcome of MMV048 in human clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The phase I trial assessing the pharmacokinetic profile and tolerability of MMV048 (NCT02230579)<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> was the only clinical trial with results available at the NIH Clinical Trial Registry. In this trial, healthy fasted individuals were administered a single oral dose of MMV048 ranging from 5 to 120 mg. One cohort was fed and dosed 40 mg/kg orally to compare the effect of food on the pharmacokinetics. In the fasted arm, MMV048 was characterized by high plasma exposure (AUC<sub>0–∞</sub>) levels ranging between 2,136–156,036 h·ng/mL and a long half-life of between 163–252 h, correlating well with the half-life of MMV048 observed in preclinical species.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The plasma exposure levels of the fed versus fasted cohort (29004 and 21050 h·ng/mL for fed and fasted, respectively) indicated higher plasma exposure in the fasted group, while the half-life of MMV048 was not significantly affected (210 and 193 h for fed and fasted, respectively).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Overview of MMV048 Clinical Trials Completed or in Progress</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">phase/study</th><th class="colsep0 rowsep0" align="center">study population</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">end point and outcome</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, PK and tolerability</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">single dose of 5–120 mg</td><td class="colsep0 rowsep0" align="left">primary measures: tolerability, PK</td><td class="colsep0 rowsep0" align="center">NCT02230579</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measure: ex vivo efficacy up to 144 h</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcomes: half-life 163–210 h; AUC<sub>0–24</sub>: 2137–156,036 h·ng/mL; no serious adverse events; mild adverse events reported in 67–100% subjects</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ex vivo efficacy for 40 mg dose (IC<sub>50</sub>): 9.48 ng/mL</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, PK and tolerability</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">40 mg in two formulations</td><td class="colsep0 rowsep0" align="left">primary measure: PK</td><td class="colsep0 rowsep0" align="center">NCT02554799</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measure: tolerability</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcome expected: unknown</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ia, PK and tolerability</td><td class="colsep0 rowsep0" align="left">healthy adults</td><td class="colsep0 rowsep0" align="left">single dose of 40, 80, and 120 mg</td><td class="colsep0 rowsep0" align="left">primary measure: tolerability up to 28 days</td><td class="colsep0 rowsep0" align="center">NCT02783820</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">secondary measure: PK</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcome expected: unknown</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">      </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ib, efficacy</td><td class="colsep0 rowsep0" align="left">healthy adults infected with Pf asexual parasites</td><td class="colsep0 rowsep0" align="left">arm 1: single 20 mg</td><td class="colsep0 rowsep0" align="left">primary measure: parasitemia (qPCR) over 21 days</td><td class="colsep0 rowsep0" align="center">NCT02281344</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 2: single TBD</td><td class="colsep0 rowsep0" align="left">secondary measure: PK</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 3: single TBD</td><td class="colsep0 rowsep0" align="left">outcome expected: unknown</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase Ib, efficacy</td><td class="colsep0 rowsep0" align="left">healthy adults infected with Pf asexual parasites</td><td class="colsep0 rowsep0" align="left">arm 1: single 40 mg</td><td class="colsep0 rowsep0" align="left">primary measure: parasitemia (qPCR) over 28 days</td><td class="colsep0 rowsep0" align="center">NCT02783833</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arm 2: single TBD</td><td class="colsep0 rowsep0" align="left">secondary measure: PK; tolerability</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">outcome expected: unknown</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div><div class="NLM_p">A secondary outcome of the phase I trial (NCT02230579)<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> was to determine differences between the ex vivo EC<sub>50</sub> value of a serum sample taken 144 h post dosing 40 mg of MMV048 and a reference serum sample spiked with a known amount of MMV048 titrated into the Pf asexual assay. The sample taken from MMV048 treated volunteers at 144 h gave an EC<sub>50</sub> value of 24 nM, which correlated well with the reported EC<sub>50</sub> value of 28 nM.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> During the trial, a generalized myoclonic seizure was reported, but it is not known if this was a pre-existing condition or related to treatment with MMV048. Increased blood creatine kinase levels were noted at 40–80 mg doses of MMV048 but not at the lower doses of 5 and 30 mg. The cause of increased creatine kinase levels is not clear, as no other adverse drug-related events or cardiac aberrations were noted with increasing dose of MMV048. This trial gave a preliminary indication of the human pharmacokinetic profile of MMV048 and demonstrated that it was well tolerated.</div><div class="NLM_p last">Additional phase I trials (NCT02554799 and NCT02783820) investigated the effect of new formulations of MMV048 on the pharmacokinetic profile and safety in healthy individuals (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The trials have been completed, but to date the results have not been reported. Further phase Ib trials to investigate the efficacy of MMV048 in healthy individuals infected with Pf (NCT02281344 or NCT02783833) have also been completed (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The malaria research community awaits the results of these trials as phase II assessment of MMV048 continues.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the past l5 years, mass screening of academic and industry libraries against the <i>Plasmodium</i> parasite has produced a plethora of different chemotypes as starting points for development of antimalarials. The development of these scaffolds has been driven by collaborative efforts between multiple organizations from academia and industry with different infrastructure and skill sets. The highly collaborative programs, principally managed through the work of MMV and its partners, are underpinned by significant advancements in specialized in vitro and in vivo platforms to assess the antimalarial activity of compounds. These platforms have enabled thorough characterization of each antimalarial, informing decisions on developmental workflow, clinical trial design, and ultimately its suitability as a partner agent in an antimalarial therapy. Four of the most advanced of the antimalarials to emerge from the multidisciplinary collaborative initiatives, KAE609, KAF156, DSM265, and MMV048 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), are currently under assessment in phase II clinical trials and are the focus of this perspective.</div><div class="NLM_p">A cornerstone of modern antimalarials is their activity across multiple stages of the parasite lifecycle and alignment with treatment and elimination strategies outlined by leading malaria organizations; nevertheless, antimalarials with rapid action on asexual blood stages only and low propensity to generate resistance are also critically needed. All four focal antimalarials differentially target multiple stages of the malaria parasite life cycle (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Tables <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). In addition to targeting the asexual stage, KAF156, DSM265, and MMV048 kill liver stage schizonts. Combined with a long human plasma half-life, these three compounds could serve as chemoprotectants according to TPP2 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). KAF156 and MMV048 also show transmission blocking activity and combined with their long half-life could find potential use, ultimately, in campaigns focused on the control and elimination of malaria in endemic areas provided that the safety and tolerability is sufficient. KAE609 is very fast acting in vivo, displays transmission blocking activity, and has a moderate half-life. KAE609 will most likely find use in a combination therapy for treatment of uncomplicated malaria and could also be considered for severe malaria. Antimalarials KAF156, DSM265, and MMV048 could also serve as partner agents in a combination treatment therapy, but DSM265 is likely to need to be partnered with a fast-acting partner antimalarial because of its slower rate of parasite killing.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Summary of Antimalarial Activity for Each Clinical Candidates</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">KAE609</th><th class="colsep0 rowsep0" align="center">KAF156</th><th class="colsep0 rowsep0" align="center">DSM265</th><th class="colsep0 rowsep0" align="center">MMV048</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein target activity IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">12 (PfATP4 Na<sup>+</sup> homeostasis assay)</td><td class="colsep0 rowsep0" align="left">n/a</td><td class="colsep0 rowsep0" align="left">33 (PfDHODH)</td><td class="colsep0 rowsep0" align="left">3.4 (PvPI4K)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">asexual blood stage (72 h) EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">0.9 (NF54)</td><td class="colsep0 rowsep0" align="left">10 (3D7)</td><td class="colsep0 rowsep0" align="left">7.8 (3D7)</td><td class="colsep0 rowsep0" align="left">28 (NF54)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pf ABS PRR</td><td class="colsep0 rowsep0" align="left">kills early and late trophozoites and schizonts, moderate acting in vitro, very fast acting in vivo</td><td class="colsep0 rowsep0" align="left">fast acting</td><td class="colsep0 rowsep0" align="left">kills at early trophozoite stage, slow acting</td><td class="colsep0 rowsep0" align="left">moderate rate of kill</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gametocytes–early</td><td class="colsep0 rowsep0" align="left">EC<sub>99</sub> 50 nM</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> 214 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gametocytes–late</td><td class="colsep0 rowsep0" align="left">EC<sub>99</sub> 500 nM</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> 4 nM</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> 140 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dual gamete formation assay, male EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">no data</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dual gamete formation assay, female EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">no data</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMFA</td><td class="colsep0 rowsep0" align="left">EC<sub>99</sub> 500 nM</td><td class="colsep0 rowsep0" align="left">EC<sub>99</sub> 500 nM</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> 111 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver, schizont EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">10 (Pb)</td><td class="colsep0 rowsep0" align="left">5.7 (Pf)</td><td class="colsep0 rowsep0" align="left">64 (Pc)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver, hypnozoite EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pb mouse efficacy</td><td class="colsep0 rowsep0" align="left">ED<sub>99</sub> 5.3 mg/kg</td><td class="colsep0 rowsep0" align="left">ED<sub>99</sub> 2.2 mg/kg</td><td class="colsep0 rowsep0" align="left">no data</td><td class="colsep0 rowsep0" align="left">cure at a single 100 mg/kg oral dose</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pf mouse SCID efficacy</td><td class="colsep0 rowsep0" align="left">no data</td><td class="colsep0 rowsep0" align="left">no data</td><td class="colsep0 rowsep0" align="left">ED<sub>90</sub> 3 mg/kg (qd) and 1.5 mg/kg (b.i.d.)</td><td class="colsep0 rowsep0" align="left">ED<sub>90</sub> 1.1 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ref</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref38 ref49 ref61 ref69'); return false;" href="javascript:void(0);" class="ref ref38 ref49 ref61 ref69">(38,49,61,69)</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref84 ref87 ref90'); return false;" href="javascript:void(0);" class="ref ref84 ref87 ref90">(84,87,90)</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref26 ref106'); return false;" href="javascript:void(0);" class="ref ref26 ref106">(26,106)</a></td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref128 ref130'); return false;" href="javascript:void(0);" class="ref ref128 ref130">(128,130)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Overview of Each Antimalarial Clinical Candidate</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">KAE609</th><th class="colsep0 rowsep0" align="center">KAF156</th><th class="colsep0 rowsep0" align="center">DSM265</th><th class="colsep0 rowsep0" align="center">MMV048</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">chemotype</td><td class="colsep0 rowsep0" align="left">spiroindolone</td><td class="colsep0 rowsep0" align="left">imidazolopiperazine</td><td class="colsep0 rowsep0" align="left">triazolopyrimidine</td><td class="colsep0 rowsep0" align="left">amino pyridine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">identification strategy</td><td class="colsep0 rowsep0" align="left">phenotypic</td><td class="colsep0 rowsep0" align="left">phenotypic</td><td class="colsep0 rowsep0" align="left">target based</td><td class="colsep0 rowsep0" align="left">phenotypic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">target or resistance marker</td><td class="colsep0 rowsep0" align="left">PfATP4</td><td class="colsep0 rowsep0" align="left">PfCARL<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">PfDHODH</td><td class="colsep0 rowsep0" align="left">PfPI4K</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">parasite stage activity</td><td class="colsep0 rowsep0" align="left">asexual, gametocyte</td><td class="colsep0 rowsep0" align="left">asexual, liver, gametocyte</td><td class="colsep0 rowsep0" align="left">asexual, liver</td><td class="colsep0 rowsep0" align="left">asexual, liver, gametocyte</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pv mature hypnozoite</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td><td class="colsep0 rowsep0" align="left">not active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>Plasmodium</i> species<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Pf, Pv, Pk</td><td class="colsep0 rowsep0" align="left">Pf, Pv, Pk</td><td class="colsep0 rowsep0" align="left">Pf, Pv, Pk</td><td class="colsep0 rowsep0" align="left">Pf, Pv, Pk</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human half-life</td><td class="colsep0 rowsep0" align="left">24 h</td><td class="colsep0 rowsep0" align="left">2–3 days</td><td class="colsep0 rowsep0" align="left">3–4 days</td><td class="colsep0 rowsep0" align="left">6–8 days</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TCP</td><td class="colsep0 rowsep0" align="left">1 and 5</td><td class="colsep0 rowsep0" align="left">1, 4, and 5</td><td class="colsep0 rowsep0" align="left">1 and 4</td><td class="colsep0 rowsep0" align="left">1, 4, and 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">potential TPP</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1 or 2</td><td class="colsep0 rowsep0" align="left">1 or 2</td><td class="colsep0 rowsep0" align="left">1 or 2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Mechanism of resistance.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">no data on <i>P. ovale</i> or <i>P. malariae</i>.</p></div></div></div><div class="NLM_p">Laboratory models assist in determining the potential utility of an antimalarial agent, but ultimately clinical evidence is required. The clinical trial data currently available on the four focal antimalarials appears positive (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). In clinical trials, all four antimalarials were well tolerated as single agents. In preliminary efficacy studies, KAE609, KAF156, and DSM265 as single agents were able to significantly reduce or clear Pf and Pv infections in either healthy individuals or patients. DSM265 did not clear Pv as efficiently, and therefore its use for treating Pv infections may be limited unless combined with a suitable partner agent. The results for the efficacy of MMV048 in human clinical trials are yet to be reported. Of the four focal antimalarials, DSM265 as a single agent has been assessed for prophylactic inhibition of liver stage infection development under controlled sporozoite or mosquito fed challenge conditions. The liver schizont activity in the two trials suggest that the compound has potential for once weekly chemoprotection.</div><div class="NLM_p last">Overall clinical trials using KAE609, KAF156, and DSM265 as single agents for treating <i>Plasmodium</i> parasite infection in humans are positive, but further trials are necessary to determine their potential as partner agents for implementation in a SERC and/or SEC therapy (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Furthermore, the trials to date are on small demographic cohorts, and therefore more data are required to determine if the modern antimalarials demonstrate sufficient safety and tolerability and will be effective when implemented in a larger population with greater genetic diversity and more particularly for treating high risk groups such as infants and pregnant women.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00761" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darren J. Creek</span> - <span class="hlFld-Affiliation affiliation">Monash
Institute of Pharmaceutical Sciences, Monash
University, 381 Royal
Parade, Parkville, Victoria 3052, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7497-7082" title="Orcid link">http://orcid.org/0000-0001-7497-7082</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#debabfacacbbb0f0bdacbbbbb59eb3b1b0bfadb6f0bbbaab"><span class="__cf_email__" data-cfemail="1571746767707b3b766770707e55787a7b74667d3b707160">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brad E. Sleebs</span> - <span class="hlFld-Affiliation affiliation">The
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Medical Biology, The University of Melbourne, Parkville, Victoria 3052, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9117-1048" title="Orcid link">http://orcid.org/0000-0001-9117-1048</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#80f3ece5e5e2f3c0f7e5e8e9aee5e4f5aee1f5"><span class="__cf_email__" data-cfemail="dfacb3bababdac9fa8bab7b6f1babbaaf1beaa">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Trent D. Ashton</span> - <span class="hlFld-Affiliation affiliation">The
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Medical Biology, The University of Melbourne, Parkville, Victoria 3052, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shane M. Devine</span> - <span class="hlFld-Affiliation affiliation">Monash
Institute of Pharmaceutical Sciences, Monash
University, 381 Royal
Parade, Parkville, Victoria 3052, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8727-7392" title="Orcid link">http://orcid.org/0000-0001-8727-7392</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jörg J. Möhrle</span> - <span class="hlFld-Affiliation affiliation">Medicines
for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benoît Laleu</span> - <span class="hlFld-Affiliation affiliation">Medicines
for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy N. Burrows</span> - <span class="hlFld-Affiliation affiliation">Medicines
for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan A. Charman</span> - <span class="hlFld-Affiliation affiliation">Monash
Institute of Pharmaceutical Sciences, Monash
University, 381 Royal
Parade, Parkville, Victoria 3052, Australia</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Dr. Trent D. Ashton and Dr. Shane M. Devine contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74163" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74163" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Trent D. Ashton</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6454-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Trent D. Ashton</b> obtained his Ph.D. from the Monash Institute of Pharmaceutical Sciences in 2008. During postdoctoral positions at Boston University and Deakin University, he worked on multiple programs developing anti-infective agents and epigenetic modulators for the treatment of metabolic disorders. In 2018, he joined the Sleebs Laboratory at the Walter and Eliza Hall Institute where his current research focuses on the development of antimalarial compounds with novel modes of action.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Shane M. Devine</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6459-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Shane M. Devine</b> obtained his Ph.D. from La Trobe University in 2006 researching the synthesis of novel heterocyclic systems. He then joined Monash Institute of Pharmaceutical Sciences, where his research has included using fragment-based and structure guided drug design approaches in the design of G protein-coupled receptor ligands, novel anticancer agents, and more recently antimalarial compounds with novel mechanisms of action.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Jörg J. Möhrle</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6464-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jörg J. Möhrle</b> obtained his Ph.D. from Basel University researching protein kinases of <i>Plasmodium falciparum</i>. He then held several positions in clinical development in the pharmaceutical and biotech industry researching oncology, inflammatory diseases and neurology. He joined MMV in 2005 and was subsequently appointed Vice President, Head of Translational Medicine, Research and Development, for Medicines for Malaria Venture. Since 2017, he is also an Associate Professor for Infection Biology and Epidemiology at Basel University.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Benoît Laleu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6472-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Benoît Laleu</b> obtained a Ph.D. in Chemistry from the University of Geneva, Switzerland, in 2006. After completing postdoctoral studies at the University of Toronto, Canada, in 2007, he joined GenKyoTex, a Swiss biotechnology company, where he spent 7 years as a medicinal chemist. In 2015, Benoît joined Medicines for Malaria Venture where he is currently Associate Director of Drug Discovery and has responsibility for a portfolio of antimalarial drug discovery projects working with pharmaceutical companies and academic groups.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Jeremy N. Burrows</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6477-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jeremy N. Burrows</b> obtained a Ph.D. in organic chemistry at Oxford University in 1996. He then joined AstraZeneca in the UK and focused on infection, cardiovascular, and inflammation research. In 2005, he moved to AstraZeneca in Sweden to focus on Alzheimer’s disease. In 2010, he was appointed Head of Drug Discovery at the Medicines for Malaria Venture and manages a portfolio of enabling technology, screening, hit-to-lead, and lead optimization projects in malaria and neglected diseases.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Susan A. Charman</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6482-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Susan A. Charman</b> obtained a Ph.D. in pharmaceutical sciences from the University of Florida in 1987. She spent two years in the pharmaceutical industry in the US before assuming an academic position at the Monash Institute of Pharmaceutical Sciences. She is currently Professor and Director of the Centre for Drug Candidate Optimisation. She leads a team of 25 postdoctoral fellows and research assistants that provide expertise in physicochemical, ADME, and pharmacokinetic properties to enhance the discovery and development of novel drug candidates to treat tropical infectious diseases, cancer, metabolic, and CNS disorders.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Darren J. Creek</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6487-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Darren J. Creek</b> obtained a Ph.D. from the Monash Institute of Pharmaceutical Sciences in 2008. He has postdoctoral experience in antimalarial pharmacology, biochemical parasitology, and metabolomics from Makerere University—UCSF, Monash University, University of Glasgow, and University of Melbourne. Since 2014, he has led a laboratory focused on understanding mechanisms of antiparasitic drug action using metabolomics and proteomics. He is also the metabolomics director of the Monash Proteomics and Metabolomics Facility.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Brad E. Sleebs</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=BIO-d7e6492-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Brad E. Sleebs</b> obtained his Ph.D. from La Trobe University in 2005. He then joined The Walter and Eliza Hall Institute as a Research Officer and focused on the development of novel anxiolytics and agents that target the BH3 family of proteins for treating blood cancers. He was recently appointed Laboratory Head in the Chemical Biology Division at the Walter and Eliza Hall Institute. His current research focuses on designing small molecule probes to better understand biological processes that are critical to the survival of the malaria parasite and the progression of cancer malignancies, and in collaboration with industry partners the development of novel antimalarial and oncology therapies.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Health and Medical Research Council of Australia (development grant 1113712 to B.E.S.; fellowship 1148700 to D.J.C.; project grant 1163235 to D.J.C. and S.M.D.), Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. B.E.S. is a Corin Centenary Fellow.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACT</td><td class="NLM_def"><p class="first last">artemisinin combination therapy</p></td></tr><tr><td class="NLM_term">ACPR</td><td class="NLM_def"><p class="first last">adequate clinical and parasitological response</p></td></tr><tr><td class="NLM_term">ART</td><td class="NLM_def"><p class="first last">artemisinin</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CARL</td><td class="NLM_def"><p class="first last">cyclic amine resistance locus</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CRT</td><td class="NLM_def"><p class="first last">CQ resistance transporter</p></td></tr><tr><td class="NLM_term">DHODH</td><td class="NLM_def"><p class="first last">dihydroorotate dehydrogenase</p></td></tr><tr><td class="NLM_term">EEF</td><td class="NLM_def"><p class="first last">exoerythrocytic form</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>u</sub></td><td class="NLM_def"><p class="first last">fraction unbound in plasma</p></td></tr><tr><td class="NLM_term">G6PD</td><td class="NLM_def"><p class="first last">glucose-6-phosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">GMP</td><td class="NLM_def"><p class="first last">good manufacturing practice</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">ether-à-go-go-related gene</p></td></tr><tr><td class="NLM_term">Hs</td><td class="NLM_def"><p class="first last"><i>Homo sapiens</i></p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistant</p></td></tr><tr><td class="NLM_term">MQ</td><td class="NLM_def"><p class="first last">mefloquine</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimum inhibitory concentration</p></td></tr><tr><td class="NLM_term">MMV</td><td class="NLM_def"><p class="first last">Medicines for Malaria Venture</p></td></tr><tr><td class="NLM_term">MPC</td><td class="NLM_def"><p class="first last">minimal parasiticidal concentration</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">Pb</td><td class="NLM_def"><p class="first last"><i>Plasmodium berghei</i></p></td></tr><tr><td class="NLM_term">Pf</td><td class="NLM_def"><p class="first last"><i>Plasmodium falciparum</i></p></td></tr><tr><td class="NLM_term">Pv</td><td class="NLM_def"><p class="first last"><i>Plasmodium vivax</i></p></td></tr><tr><td class="NLM_term">PPQ</td><td class="NLM_def"><p class="first last">piperaquine</p></td></tr><tr><td class="NLM_term">PRR</td><td class="NLM_def"><p class="first last">parasite reduction ratio</p></td></tr><tr><td class="NLM_term">QT</td><td class="NLM_def"><p class="first last">interval between Q and T wave of cardiac rhythm</p></td></tr><tr><td class="NLM_term">RBC</td><td class="NLM_def"><p class="first last">red blood cell</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immunodeficiency</p></td></tr><tr><td class="NLM_term">SERC</td><td class="NLM_def"><p class="first last">single exposure radical cure</p></td></tr><tr><td class="NLM_term">SEC</td><td class="NLM_def"><p class="first last">single exposure chemoprotection</p></td></tr><tr><td class="NLM_term">SMFA</td><td class="NLM_def"><p class="first last">standard membrane feeding assay</p></td></tr><tr><td class="NLM_term">SNP</td><td class="NLM_def"><p class="first last">single-nucleotide polymorphism</p></td></tr><tr><td class="NLM_term">TCP</td><td class="NLM_def"><p class="first last">target candidate profile</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time to reach the maximum concentration</p></td></tr><tr><td class="NLM_term">TPP</td><td class="NLM_def"><p class="first last">target product profile</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 133 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>World Malaria Report 2018</i>; <span class="NLM_publisher-name">World Health
Organization</span>, <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="http://www.who.int/malaria/publications/world-malaria-report-2018/en/" class="extLink">www.who.int/malaria/publications/world-malaria-report-2018/en/</a> (accessed Dec 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World+Malaria+Report+2018%3B+World+Health%0AOrganization%2C+Geneva%2C+2018%3B+www.who.int%2Fmalaria%2Fpublications%2Fworld-malaria-report-2018%2Fen%2F+%28accessed+Dec+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Malaria%2520Report%25202018%26pub%3DWorld%2520Health%250AOrganization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. J.</span></span> <span> </span><span class="NLM_article-title">Persistent parasitism: The adaptive biology of <i>malariae</i> and <i>ovale</i> Malaria</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">808</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2016.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.pt.2016.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27480365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC2s3mvVSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=808-819&issue=10&author=C.+J.+Sutherland&title=Persistent+parasitism%3A+The+adaptive+biology+of+malariae+and+ovale+Malaria&doi=10.1016%2Fj.pt.2016.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent Parasitism: The Adaptive Biology of Malariae and Ovale Malaria</span></div><div class="casAuthors">Sutherland Colin J</div><div class="citationInfo"><span class="NLM_cas:title">Trends in parasitology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">808-819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Plasmodium malariae causes malaria in humans throughout the tropics and subtropics.  Plasmodium ovale curtisi and Plasmodium ovale wallikeri are sympatric sibling species common in sub-Saharan Africa and also found in Oceania and Asia.  Although rarely identified as the cause of malaria cases in endemic countries, PCR detection has confirmed all three parasite species to be more prevalent, and persistent, than previously thought.  Chronic, low-density, multispecies asymptomatic infection is a successful biological adaptation by these Plasmodium spp., a pattern also observed among malaria parasites of wild primates.  Current whole-genome analyses are illuminating the species barrier separating the ovale parasite species and reveal substantial expansion of subtelomeric gene families.  The evidence for and against a quiescent pre-erythrocytic form of P. malariae is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlWO-xSHQPne_Q9URG6Dx8fW6udTcc2ebrpKvocv2FgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3mvVSitg%253D%253D&md5=d6d2a844f63466c16e61c048b6a06442</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2016.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2016.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DC.%2BJ.%26atitle%3DPersistent%2520parasitism%253A%2520The%2520adaptive%2520biology%2520of%2520malariae%2520and%2520ovale%2520Malaria%26jtitle%3DTrends%2520Parasitol.%26date%3D2016%26volume%3D32%26issue%3D10%26spage%3D808%26epage%3D819%26doi%3D10.1016%2Fj.pt.2016.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span> <span> </span><span class="NLM_article-title">Can mixed parasite infections thwart targeted malaria elimination program in india?</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2017</i></span>,  <span class="NLM_fpage">2847548</span>, <span class="refDoi"> DOI: 10.1155/2017/2847548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1155%2F2017%2F2847548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28900620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1cbnsFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2017&publication_year=2017&pages=2847548&author=U.+S.+Singhauthor=N.+Siwalauthor=V.+Pandeauthor=A.+Das&title=Can+mixed+parasite+infections+thwart+targeted+malaria+elimination+program+in+india%3F&doi=10.1155%2F2017%2F2847548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Can Mixed Parasite Infections Thwart Targeted Malaria Elimination Program in India?</span></div><div class="casAuthors">Singh Upasana Shyamsunder; Siwal Nisha; Das Aparup; Pande Veena</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2847548</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">India is highly endemic to malaria with prevalence of all five species of human malaria parasites of Plasmodium genus.  India is set for malaria elimination by 2030.  Since cases of mixed Plasmodium species infections remain usually undetected but cause huge disease burden, in order to understand the distributional prevalence of both monospecies infections and mixed species infections in India, we collated published data on the differential infection incidences of the five different malaria parasites based on PCR diagnostic assay.  About 11% of total cases were due to mixed species infection.  Among several interesting observations on both single and mixed parasitic infections, incidences of Plasmodium falciparum monoinfection were found to be significantly higher than P. vivax monoinfection.  Also, P. malariae seems to be emerging as a potential malaria threat in India.  Putting all the facts together, it appears that the dream of achieving malaria elimination in India will not be completely successful without dealing with mixed species infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXc-UriKIvJJNiNltV31zlfW6udTcc2eYlqpt1TaBCWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbnsFOgug%253D%253D&md5=e8698bda04f357aeb44b7ada3d674fbd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1155%2F2017%2F2847548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2017%252F2847548%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DU.%2BS.%26aulast%3DSiwal%26aufirst%3DN.%26aulast%3DPande%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DCan%2520mixed%2520parasite%2520infections%2520thwart%2520targeted%2520malaria%2520elimination%2520program%2520in%2520india%253F%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2017%26volume%3D2017%26spage%3D2847548%26doi%3D10.1155%2F2017%2F2847548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamsul, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox-Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, D. J.</span></span> <span> </span><span class="NLM_article-title">A large focus of naturally acquired <i>Plasmodium knowlesi</i> infections in human beings</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)15836-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS0140-6736%2804%2915836-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=15051281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD2c7lvVamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2004&pages=1017-1024&author=B.+Singhauthor=L.+K.+Sungauthor=A.+Matusopauthor=A.+Radhakrishnanauthor=S.+S.+Shamsulauthor=J.+Cox-Singhauthor=A.+Thomasauthor=D.+J.+Conway&title=A+large+focus+of+naturally+acquired+Plasmodium+knowlesi+infections+in+human+beings&doi=10.1016%2FS0140-6736%2804%2915836-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A large focus of naturally acquired Plasmodium knowlesi infections in human beings</span></div><div class="casAuthors">Singh Balbir; Kim Sung Lee; Matusop Asmad; Radhakrishnan Anand; Shamsul Sunita S G; Cox-Singh Janet; Thomas Alan; Conway David J</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9414</span>),
    <span class="NLM_cas:pages">1017-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  About a fifth of malaria cases in 1999 for the Kapit division of Malaysian Borneo had routinely been identified by microscopy as Plasmodium malariae, although these infections appeared atypical and a nested PCR assay failed to identify P malariae DNA.  We aimed to investigate whether such infections could be attributable to a variant form of P malariae or a newly emergent Plasmodium species.  METHODS:  We took blood samples from 208 people with malaria in the Kapit division between March, 2000, and November, 2002.  The small subunit ribosomal RNA and the circumsporozoite protein genes were sequenced for eight isolates that had been microscopically identified as P malariae.  All blood samples were characterised with a genus-specific and species-specific nested PCR assay together with newly designed P knowlesi-specific primers.  FINDINGS:  All DNA sequences were phylogenetically indistinguishable from those of P knowlesi, a malaria parasite of long-tailed macaque monkeys, but were significantly different from other malaria parasite species.  By PCR assay, 120 (58%) of 208 people with malaria tested positive for P knowlesi, whereas none was positive for P malariae.  P knowlesi parasites in human erythrocytes were difficult to distinguish from P malariae by microscopy.  Most of the P knowlesi infections were in adults and we did not note any clustering of cases within communities.  P knowlesi infections were successfully treated with chloroquine and primaquine.  INTERPRETATION:  Naturally acquired P knowlesi infections, misdiagnosed by microscopy mainly as P malariae, accounted for over half of all malaria cases in our study.  Morphological similarities between P knowlesi and P malariae necessitate the use of molecular methods for correct identification.  Further work is needed to determine whether human P knowlesi infections in the Kapit division are acquired from macaque monkeys or whether a host switch to human beings has occurred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS63eAmJYZFM_xQvRxYU81tfW6udTcc2eYlqpt1TaBCWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7lvVamsQ%253D%253D&md5=b92dfd518397de50cdda216811f4946e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2915836-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252915836-4%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DSung%26aufirst%3DL.%2BK.%26aulast%3DMatusop%26aufirst%3DA.%26aulast%3DRadhakrishnan%26aufirst%3DA.%26aulast%3DShamsul%26aufirst%3DS.%2BS.%26aulast%3DCox-Singh%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DConway%26aufirst%3DD.%2BJ.%26atitle%3DA%2520large%2520focus%2520of%2520naturally%2520acquired%2520Plasmodium%2520knowlesi%2520infections%2520in%2520human%2520beings%26jtitle%3DLancet%26date%3D2004%26volume%3D363%26spage%3D1017%26epage%3D1024%26doi%3D10.1016%2FS0140-6736%2804%2915836-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutteridge, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaszubska, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">New developments in anti-malarial target candidate and product profiles</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12936-016-1675-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-016-1675-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28086874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=26&author=J.+N.+Burrowsauthor=S.+Duparcauthor=W.+E.+Gutteridgeauthor=R.+Hooft+van+Huijsduijnenauthor=W.+Kaszubskaauthor=F.+Macintyreauthor=S.+Mazzuriauthor=J.+J.+M%C3%B6hrleauthor=T.+N.+C.+Wells&title=New+developments+in+anti-malarial+target+candidate+and+product+profiles&doi=10.1186%2Fs12936-016-1675-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in anti-malarial target candidate and product profiles</span></div><div class="casAuthors">Burrows, Jeremy N.; Duparc, Stephan; Gutteridge, Winston E.; Hooft van Huijsduijnen, Rob; Kaszubska, Wiweka; MacIntyre, Fiona; Mazzuri, Sebastien; Mohrle, Jorg J.; Wells, Timothy N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26/1-26/29</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  A decade of discovery and development of new anti-malarial medicines has led to a renewed focus on malaria elimination and eradication.  Changes in the way new anti-malarial drugs are discovered and developed have led to a dramatic increase in the no. and diversity of new mols. presently in pre-clin. and early clin. development.  The twin challenges faced can be summarized by multi-drug resistant malaria from the Greater Mekong Subregion, and the need to provide simplified medicines.  This review lists changes in anti-malarial target candidate and target product profiles over the last 4 years.  As well as new medicines to treat disease and prevent transmission, there has been increased focus on the longer term goal of finding new medicines for chemoprotection, potentially with long-acting mols., or parenteral formulations.  Other gaps in the malaria armamentarium, such as drugs to treat severe malaria and endectocides (that kill mosquitoes which feed on people who have taken the drug), are defined here.  Ultimately the elimination of malaria requires medicines that are safe and well-tolerated to be used in vulnerable populations: in pregnancy, esp. the first trimester, and in those suffering from malnutrition or co-infection with other pathogens.  These updates reflect the maturing of an understanding of the key challenges in producing the next generation of medicines to control, eliminate and ultimately eradicate malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjgdhMYAylM7Vg90H21EOLACvtfcHk0liJnBaY73b1GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D&md5=17984994f7a29c9fb184faa5214d4d35</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs12936-016-1675-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-016-1675-x%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DGutteridge%26aufirst%3DW.%2BE.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DKaszubska%26aufirst%3DW.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DMazzuri%26aufirst%3DS.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DNew%2520developments%2520in%2520anti-malarial%2520target%2520candidate%2520and%2520product%2520profiles%26jtitle%3DMalar.%2520J.%26date%3D2017%26volume%3D16%26spage%3D26%26doi%3D10.1186%2Fs12936-016-1675-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manyando, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">Malaria</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">17050</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2017.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnrdp.2017.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28770814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=17050&author=M.+A.+Phillipsauthor=J.+N.+Burrowsauthor=C.+Manyandoauthor=R.+Hooft+van+Huijsduijnenauthor=W.+C.+Van+Voorhisauthor=T.+N.+C.+Wells&title=Malaria&doi=10.1038%2Fnrdp.2017.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria</span></div><div class="casAuthors">Phillips Margaret A; Burrows Jeremy N; van Huijsduijnen Rob Hooft; Wells Timothy N C; Manyando Christine; Van Voorhis Wesley C</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17050</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Malaria is caused in humans by five species of single-celled eukaryotic Plasmodium parasites (mainly Plasmodium falciparum and Plasmodium vivax) that are transmitted by the bite of Anopheles spp. mosquitoes.  Malaria remains one of the most serious infectious diseases; it threatens nearly half of the world's population and led to hundreds of thousands of deaths in 2015, predominantly among children in Africa.  Malaria is managed through a combination of vector control approaches (such as insecticide spraying and the use of insecticide-treated bed nets) and drugs for both treatment and prevention.  The widespread use of artemisinin-based combination therapies has contributed to substantial declines in the number of malaria-related deaths; however, the emergence of drug resistance threatens to reverse this progress.  Advances in our understanding of the underlying molecular basis of pathogenesis have fuelled the development of new diagnostics, drugs and insecticides.  Several new combination therapies are in clinical development that have efficacy against drug-resistant parasites and the potential to be used in single-dose regimens to improve compliance.  This ambitious programme to eliminate malaria also includes new approaches that could yield malaria vaccines or novel vector control strategies.  However, despite these achievements, a well-coordinated global effort on multiple fronts is needed if malaria elimination is to be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcfdgTdv0RVI2y4bB4mnvYfW6udTcc2eYTJKyv2kYxn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D&md5=ec450ab6baef0a6c2b6bd6bac030771a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2017.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2017.50%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DManyando%26aufirst%3DC.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DMalaria%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2017%26volume%3D3%26spage%3D17050%26doi%3D10.1038%2Fnrdp.2017.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisanzio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mappin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenger, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penny, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yukich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisele, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fergus, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindgren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cibulskis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gething, P. W.</span></span> <span> </span><span class="NLM_article-title">The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span> (<span class="NLM_issue">7572</span>),  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1038/nature15535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature15535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26375008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFersLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=207-211&issue=7572&author=S.+Bhattauthor=D.+J.+Weissauthor=E.+Cameronauthor=D.+Bisanzioauthor=B.+Mappinauthor=U.+Dalrympleauthor=K.+Battleauthor=C.+L.+Moyesauthor=A.+Henryauthor=P.+A.+Eckhoffauthor=E.+A.+Wengerauthor=O.+Brietauthor=M.+A.+Pennyauthor=T.+A.+Smithauthor=A.+Bennettauthor=J.+Yukichauthor=T.+P.+Eiseleauthor=J.+T.+Griffinauthor=C.+A.+Fergusauthor=M.+Lynchauthor=F.+Lindgrenauthor=J.+M.+Cohenauthor=C.+L.+J.+Murrayauthor=D.+L.+Smithauthor=S.+I.+Hayauthor=R.+E.+Cibulskisauthor=P.+W.+Gething&title=The+effect+of+malaria+control+on+Plasmodium+falciparum+in+Africa+between+2000+and+2015&doi=10.1038%2Fnature15535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015</span></div><div class="casAuthors">Bhatt, S.; Weiss, D. J.; Cameron, E.; Bisanzio, D.; Mappin, B.; Dalrymple, U.; Battle, K. E.; Moyes, C. L.; Henry, A.; Eckhoff, P. A.; Wenger, E. A.; Briet, O.; Penny, M. A.; Smith, T. A.; Bennett, A.; Yukich, J.; Eisele, T. P.; Griffin, J. T.; Fergus, C. A.; Lynch, M.; Lindgren, F.; Cohen, J. M.; Murray, C. L. J.; Smith, D. L.; Hay, S. I.; Cibulskis, R. E.; Gething, P. W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7572</span>),
    <span class="NLM_cas:pages">207-211</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the year 2000, a concerted campaign against malaria has led to unprecedented levels of intervention coverage across sub-Saharan Africa.  Understanding the effect of this control effort is vital to inform future control planning.  However, the effect of malaria interventions across the varied epidemiol. settings of Africa remains poorly understood owing to the absence of reliable surveillance data and the simplistic approaches underlying current disease ests.  Here we link a large database of malaria field surveys with detailed reconstructions of changing intervention coverage to directly evaluate trends from 2000 to 2015, and quantify the attributable effect of malaria disease control efforts.  We found that Plasmodium falciparum infection prevalence in endemic Africa halved and the incidence of clin. disease fell by 40% between 2000 and 2015.  We est. that interventions have averted 663 (542-753 credible interval) million clin. cases since 2000.  Insecticide-treated nets, the most widespread intervention, were by far the largest contributor (68% of cases averted).  Although still below target levels, current malaria interventions have substantially reduced malaria disease incidence across the continent.  Increasing access to these interventions, and maintaining their effectiveness in the face of insecticide and drug resistance, should form a cornerstone of post-2015 control strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwpE0BNY1LmrVg90H21EOLACvtfcHk0lh18te-SeUyKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFersLrN&md5=a6d38c412efb48432a0d1a4ec50c75fc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature15535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature15535%26sid%3Dliteratum%253Aachs%26aulast%3DBhatt%26aufirst%3DS.%26aulast%3DWeiss%26aufirst%3DD.%2BJ.%26aulast%3DCameron%26aufirst%3DE.%26aulast%3DBisanzio%26aufirst%3DD.%26aulast%3DMappin%26aufirst%3DB.%26aulast%3DDalrymple%26aufirst%3DU.%26aulast%3DBattle%26aufirst%3DK.%26aulast%3DMoyes%26aufirst%3DC.%2BL.%26aulast%3DHenry%26aufirst%3DA.%26aulast%3DEckhoff%26aufirst%3DP.%2BA.%26aulast%3DWenger%26aufirst%3DE.%2BA.%26aulast%3DBriet%26aufirst%3DO.%26aulast%3DPenny%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DT.%2BA.%26aulast%3DBennett%26aufirst%3DA.%26aulast%3DYukich%26aufirst%3DJ.%26aulast%3DEisele%26aufirst%3DT.%2BP.%26aulast%3DGriffin%26aufirst%3DJ.%2BT.%26aulast%3DFergus%26aufirst%3DC.%2BA.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLindgren%26aufirst%3DF.%26aulast%3DCohen%26aufirst%3DJ.%2BM.%26aulast%3DMurray%26aufirst%3DC.%2BL.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DHay%26aufirst%3DS.%2BI.%26aulast%3DCibulskis%26aufirst%3DR.%2BE.%26aulast%3DGething%26aufirst%3DP.%2BW.%26atitle%3DThe%2520effect%2520of%2520malaria%2520control%2520on%2520Plasmodium%2520falciparum%2520in%2520Africa%2520between%25202000%2520and%25202015%26jtitle%3DNature%26date%3D2015%26volume%3D526%26issue%3D7572%26spage%3D207%26epage%3D211%26doi%3D10.1038%2Fnature15535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">RTS,S
Clinical Trials Partnership</span> <span> </span><span class="NLM_article-title">Efficacy and safety of RTS,S/AS01 malaria vaccine with or without
a booster dose in infants and children in Africa: final results of
a phase 3, individually randomised, controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)60721-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS0140-6736%2815%2960721-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25913272" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=31-45&author=RTS%2CS%0AClinical+Trials+Partnership&title=Efficacy+and+safety+of+RTS%2CS%2FAS01+malaria+vaccine+with+or+without%0Aa+booster+dose+in+infants+and+children+in+Africa%3A+final+results+of%0Aa+phase+3%2C+individually+randomised%2C+controlled+trial&doi=10.1016%2FS0140-6736%2815%2960721-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960721-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960721-8%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520RTS%252CS%252FAS01%2520malaria%2520vaccine%2520with%2520or%2520without%250Aa%2520booster%2520dose%2520in%2520infants%2520and%2520children%2520in%2520Africa%253A%2520final%2520results%2520of%250Aa%2520phase%25203%252C%2520individually%2520randomised%252C%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D31%26epage%3D45%26doi%3D10.1016%2FS0140-6736%2815%2960721-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doritchamou, J. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, P. E.</span></span> <span> </span><span class="NLM_article-title">Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium</span>. <i>NPJ. Vaccines</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.1038/s41541-017-0035-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fs41541-017-0035-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29522056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsVWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=34&author=C.+H.+Coelhoauthor=J.+Y.+A.+Doritchamouauthor=I.+Zaidiauthor=P.+E.+Duffy&title=Advances+in+malaria+vaccine+development%3A+report+from+the+2017+malaria+vaccine+symposium&doi=10.1038%2Fs41541-017-0035-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium</span></div><div class="casAuthors">Coelho Camila Henriques; Doritchamou Justin Yai Alamou; Zaidi Irfan; Duffy Patrick E</div><div class="citationInfo"><span class="NLM_cas:title">NPJ vaccines</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Malaria Vaccine Symposium occurred at Johns Hopkins University in Baltimore, MD, USA on April 25th, 2017, coinciding with World Malaria Day and the WHO announcement that the RTS,S malaria vaccine would begin pilot implementation programs in Ghana, Kenya, and Malawi in 2018.  Scientists from several disciplines reported progress on an array of malaria vaccine concepts and product candidates, including pre-erythrocytic vaccines that prevent infection, blood-stage vaccines that limit infection and disease, and transmission-blocking vaccines that interrupt the spread of infection.  Other speakers highlighted the immunological and genetic considerations that must be addressed by vaccinologists to yield the most efficacious vaccines.  Here, we highlight the advances in malaria vaccinology that were reported at the symposium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSc4UpbiNekB0H3Rlp_k91zfW6udTcc2ea4UsQ3XJTzJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsVWqtg%253D%253D&md5=c8afcd09959bd0999276859d0a31dd5f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41541-017-0035-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41541-017-0035-3%26sid%3Dliteratum%253Aachs%26aulast%3DCoelho%26aufirst%3DC.%2BH.%26aulast%3DDoritchamou%26aufirst%3DJ.%2BY.%2BA.%26aulast%3DZaidi%26aufirst%3DI.%26aulast%3DDuffy%26aufirst%3DP.%2BE.%26atitle%3DAdvances%2520in%2520malaria%2520vaccine%2520development%253A%2520report%2520from%2520the%25202017%2520malaria%2520vaccine%2520symposium%26jtitle%3DNPJ.%2520Vaccines%26date%3D2017%26volume%3D2%26spage%3D34%26doi%3D10.1038%2Fs41541-017-0035-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, E.</span></span> <span> </span><span class="NLM_article-title">Prophylaxis of malaria</span>. <i>Mediterr. J. Hematol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e2012045</span>, <span class="refDoi"> DOI: 10.4084/mjhid.2012.45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.4084%2Fmjhid.2012.45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22811794" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=e2012045&issue=1&author=E.+Schwartz&title=Prophylaxis+of+malaria&doi=10.4084%2Fmjhid.2012.45"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4084%2Fmjhid.2012.45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4084%252Fmjhid.2012.45%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DE.%26atitle%3DProphylaxis%2520of%2520malaria%26jtitle%3DMediterr.%2520J.%2520Hematol.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D4%26issue%3D1%26spage%3De2012045%26doi%3D10.4084%2Fmjhid.2012.45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavogui, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zongo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghini-Fuhrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakite, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togo, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koumare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somé, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulibaly, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djimde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamadio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidibe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulibaly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhousseini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niangaly, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diarra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabore, M. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouattara, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargougou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diarra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soré, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougouma, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compaore, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylla, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiema, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doumbo, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouedraogo, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirima, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djimde, A. A.</span></span> <span> </span><span class="NLM_article-title">Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span> (<span class="NLM_issue">10128</span>),  <span class="NLM_fpage">1378</span>– <span class="NLM_lpage">1390</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30291-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS0140-6736%2818%2930291-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29606364" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=1378-1390&issue=10128&author=I.+Sagaraauthor=A.+H.+Beavoguiauthor=I.+Zongoauthor=I.+Soulamaauthor=I.+Borghini-Fuhrerauthor=B.+Fofanaauthor=A.+Traoreauthor=N.+Dialloauthor=H.+Diakiteauthor=A.+H.+Togoauthor=S.+Koumareauthor=M.+Keitaauthor=D.+Camaraauthor=A.+F.+Som%C3%A9author=A.+S.+Coulibalyauthor=O.+B.+Traoreauthor=S.+Damaauthor=S.+Goitaauthor=M.+Djimdeauthor=A.+Bamadioauthor=N.+Daraauthor=H.+Maigaauthor=B.+Sidibeauthor=F.+Daoauthor=M.+Coulibalyauthor=M.+L.+Alhousseiniauthor=H.+Niangalyauthor=B.+Sangareauthor=M.+Diarraauthor=S.+Coumareauthor=M.+J.+T.+Kaboreauthor=S.+M.+Ouattaraauthor=A.+Barryauthor=D.+Kargougouauthor=A.+Diarraauthor=N.+Henryauthor=H.+Sor%C3%A9author=E.+C.+Bougoumaauthor=I.+Theraauthor=Y.+D.+Compaoreauthor=C.+J.+Sutherlandauthor=M.+M.+Syllaauthor=F.+Nikiemaauthor=M.+S.+Dialloauthor=A.+Dickoauthor=S.+Picotauthor=S.+Borrmannauthor=S.+Duparcauthor=R.+M.+Millerauthor=O.+K.+Doumboauthor=J.+Shinauthor=J.+P.+Gilauthor=A.+Bj%C3%B6rkmanauthor=J.+B.+Ouedraogoauthor=S.+B.+Sirimaauthor=A.+A.+Djimde&title=Pyronaridine-artesunate+or+dihydroartemisinin-piperaquine+versus+current+first-line+therapies+for+repeated+treatment+of+uncomplicated+malaria%3A+a+randomised%2C+multicentre%2C+open-label%2C+longitudinal%2C+controlled%2C+phase+3b%2F4+trial&doi=10.1016%2FS0140-6736%2818%2930291-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930291-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930291-5%26sid%3Dliteratum%253Aachs%26aulast%3DSagara%26aufirst%3DI.%26aulast%3DBeavogui%26aufirst%3DA.%2BH.%26aulast%3DZongo%26aufirst%3DI.%26aulast%3DSoulama%26aufirst%3DI.%26aulast%3DBorghini-Fuhrer%26aufirst%3DI.%26aulast%3DFofana%26aufirst%3DB.%26aulast%3DTraore%26aufirst%3DA.%26aulast%3DDiallo%26aufirst%3DN.%26aulast%3DDiakite%26aufirst%3DH.%26aulast%3DTogo%26aufirst%3DA.%2BH.%26aulast%3DKoumare%26aufirst%3DS.%26aulast%3DKeita%26aufirst%3DM.%26aulast%3DCamara%26aufirst%3DD.%26aulast%3DSom%25C3%25A9%26aufirst%3DA.%2BF.%26aulast%3DCoulibaly%26aufirst%3DA.%2BS.%26aulast%3DTraore%26aufirst%3DO.%2BB.%26aulast%3DDama%26aufirst%3DS.%26aulast%3DGoita%26aufirst%3DS.%26aulast%3DDjimde%26aufirst%3DM.%26aulast%3DBamadio%26aufirst%3DA.%26aulast%3DDara%26aufirst%3DN.%26aulast%3DMaiga%26aufirst%3DH.%26aulast%3DSidibe%26aufirst%3DB.%26aulast%3DDao%26aufirst%3DF.%26aulast%3DCoulibaly%26aufirst%3DM.%26aulast%3DAlhousseini%26aufirst%3DM.%2BL.%26aulast%3DNiangaly%26aufirst%3DH.%26aulast%3DSangare%26aufirst%3DB.%26aulast%3DDiarra%26aufirst%3DM.%26aulast%3DCoumare%26aufirst%3DS.%26aulast%3DKabore%26aufirst%3DM.%2BJ.%2BT.%26aulast%3DOuattara%26aufirst%3DS.%2BM.%26aulast%3DBarry%26aufirst%3DA.%26aulast%3DKargougou%26aufirst%3DD.%26aulast%3DDiarra%26aufirst%3DA.%26aulast%3DHenry%26aufirst%3DN.%26aulast%3DSor%25C3%25A9%26aufirst%3DH.%26aulast%3DBougouma%26aufirst%3DE.%2BC.%26aulast%3DThera%26aufirst%3DI.%26aulast%3DCompaore%26aufirst%3DY.%2BD.%26aulast%3DSutherland%26aufirst%3DC.%2BJ.%26aulast%3DSylla%26aufirst%3DM.%2BM.%26aulast%3DNikiema%26aufirst%3DF.%26aulast%3DDiallo%26aufirst%3DM.%2BS.%26aulast%3DDicko%26aufirst%3DA.%26aulast%3DPicot%26aufirst%3DS.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DDoumbo%26aufirst%3DO.%2BK.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DGil%26aufirst%3DJ.%2BP.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DA.%26aulast%3DOuedraogo%26aufirst%3DJ.%2BB.%26aulast%3DSirima%26aufirst%3DS.%2BB.%26aulast%3DDjimde%26aufirst%3DA.%2BA.%26atitle%3DPyronaridine-artesunate%2520or%2520dihydroartemisinin-piperaquine%2520versus%2520current%2520first-line%2520therapies%2520for%2520repeated%2520treatment%2520of%2520uncomplicated%2520malaria%253A%2520a%2520randomised%252C%2520multicentre%252C%2520open-label%252C%2520longitudinal%252C%2520controlled%252C%2520phase%25203b%252F4%2520trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26issue%3D10128%26spage%3D1378%26epage%3D1390%26doi%3D10.1016%2FS0140-6736%2818%2930291-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lwin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanpithakpong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhasivanon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindegardh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socheat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Artemisinin resistance in <i>Plasmodium falciparum</i> malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0808859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa0808859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=19641202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=455-467&author=A.+M.+Dondorpauthor=F.+Nostenauthor=P.+Yiauthor=D.+Dasauthor=A.+P.+Phyoauthor=J.+Tarningauthor=K.+M.+Lwinauthor=F.+Arieyauthor=W.+Hanpithakpongauthor=S.+J.+Leeauthor=P.+Ringwaldauthor=K.+Silamutauthor=M.+Imwongauthor=K.+Chotivanichauthor=P.+Limauthor=T.+Herdmanauthor=S.+S.+Anauthor=S.+Yeungauthor=P.+Singhasivanonauthor=N.+P.+J.+Dayauthor=N.+Lindegardhauthor=D.+Socheatauthor=N.+J.+White&title=Artemisinin+resistance+in+Plasmodium+falciparum+malaria&doi=10.1056%2FNEJMoa0808859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Dondorp, Arjen M.; Nosten, Francois; Yi, Poravuth; Das, Debashish; Phyo, Aung Phae; Tarning, Joel; Lwin, Khin Maung; Ariey, Frederic; Hanpithakpong, Warunee; Lee, Sue J.; Ringwald, Pascal; Silamut, Kamolrat; Imwong, Mallika; Chotivanich, Kesinee; Lim, Pharath; Herdman, Trent; Sam An, Sen; Yeung, Shunmay; Singhasivanon, Pratap; Day, Nicholas P. J.; Lindegardh, Niklas; Socheat, Duong; White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Artemisinin-based combination therapies are the recommended first-line treatments of falciparum malaria in all countries with endemic disease.  There are recent concerns that the efficacy of such therapies has declined on the Thai-Cambodian border, historically a site of emerging antimalarial-drug resistance.  METHODS: In two open-label, randomized trials, we compared the efficacies of two treatments for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, northwestern Thailand: oral artesunate given at a dose of 2 mg per kg of body wt. per day, for 7 days, and artesunate given at a dose of 4 mg per kg per day, for 3 days, followed by mefloqine at two doses totaling 25 mg per kg.  We assessed in vitro and in vivo Plasmodium-falciparum susceptibility, artesunate pharmacokinetics, and mol. markers of resistance.  RESULTS: We studied 40 patients in each of the two locations.  The overall median parasite clearance times were 84 h (interquartile range, 60 to 96) in Pailin and 48 h (interquartile range, 36 to 66) in Wang Pha (P < 0.001).  Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate-mefloqine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), resp., in Wang Pha (P = 0.31).  These markedly different parasitol. responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative mol. correlates of P.falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco-endoplasmic reticulum calcium ATPase6 [PfSERCA]).  Adverse events were mild and did not differ significantly between the two treatment groups.  CONCLUSIONS: P.falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand.  Resistance is characterized by slow parasite clearance in vivo without corresponding redns. on conventional in vitro susceptibility testing.  Containment measures are urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVvi4ozTDSLVg90H21EOLACvtfcHk0lgMcFywGXnjJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D&md5=ae3098a15e9fb82c80fa0ddd05378220</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808859%26sid%3Dliteratum%253Aachs%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DLwin%26aufirst%3DK.%2BM.%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DHanpithakpong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DHerdman%26aufirst%3DT.%26aulast%3DAn%26aufirst%3DS.%2BS.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DSinghasivanon%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DN.%2BP.%2BJ.%26aulast%3DLindegardh%26aufirst%3DN.%26aulast%3DSocheat%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DArtemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D455%26epage%3D467%26doi%3D10.1056%2FNEJMoa0808859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nsanzabana, C.</span></span> <span> </span><span class="NLM_article-title">Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug!</span>. <i>Trop. Med. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.3390/tropicalmed4010026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.3390%2Ftropicalmed4010026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30717149" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=26&issue=1&author=C.+Nsanzabana&title=Resistance+to+artemisinin+combination+therapies+%28ACTs%29%3A+do+not+forget+the+partner+drug%21&doi=10.3390%2Ftropicalmed4010026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Ftropicalmed4010026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftropicalmed4010026%26sid%3Dliteratum%253Aachs%26aulast%3DNsanzabana%26aufirst%3DC.%26atitle%3DResistance%2520to%2520artemisinin%2520combination%2520therapies%2520%2528ACTs%2529%253A%2520do%2520not%2520forget%2520the%2520partner%2520drug%2521%26jtitle%3DTrop.%2520Med.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D4%26issue%3D1%26spage%3D26%26doi%3D10.3390%2Ftropicalmed4010026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovannaroth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchatsoonthorn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runcharoen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Htut, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aye, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokuolu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaosebikan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folaranmi, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayxay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanthavong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hongvanthong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyamboko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanello, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashraheil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacInnis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozdech, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeyapant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakulthaew, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intharabut, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihokhern, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunasol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flegg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowe, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Spread of Artemisinin resistance in <i>Plasmodium falciparum</i> Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1314981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1314981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25075834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=411-423&issue=5&author=E.+A.+Ashleyauthor=M.+Dhordaauthor=R.+M.+Fairhurstauthor=C.+Amaratungaauthor=P.+Limauthor=S.+Suonauthor=S.+Srengauthor=J.+M.+Andersonauthor=S.+Maoauthor=B.+Samauthor=C.+Sophaauthor=C.+M.+Chuorauthor=C.+Nguonauthor=S.+Sovannarothauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chotivanichauthor=K.+Chutasmitauthor=C.+Suchatsoonthornauthor=R.+Runcharoenauthor=T.+T.+Hienauthor=N.+T.+Thuy-Nhienauthor=N.+V.+Thanhauthor=N.+H.+Phuauthor=Y.+Htutauthor=K.+T.+Hanauthor=K.+H.+Ayeauthor=O.+A.+Mokuoluauthor=R.+R.+Olaosebikanauthor=O.+O.+Folaranmiauthor=M.+Mayxayauthor=M.+Khanthavongauthor=B.+Hongvanthongauthor=P.+N.+Newtonauthor=M.+A.+Onyambokoauthor=C.+I.+Fanelloauthor=A.+K.+Tshefuauthor=N.+Mishraauthor=N.+Valechaauthor=A.+P.+Phyoauthor=F.+Nostenauthor=P.+Yiauthor=R.+Tripuraauthor=S.+Borrmannauthor=M.+Bashraheilauthor=J.+Peshuauthor=M.+A.+Faizauthor=A.+Ghoseauthor=M.+A.+Hossainauthor=R.+Samadauthor=M.+R.+Rahmanauthor=M.+M.+Hasanauthor=A.+Islamauthor=O.+Miottoauthor=R.+Amatoauthor=B.+MacInnisauthor=J.+Stalkerauthor=D.+P.+Kwiatkowskiauthor=Z.+Bozdechauthor=A.+Jeeyapantauthor=P.+Y.+Cheahauthor=T.+Sakulthaewauthor=J.+Chalkauthor=B.+Intharabutauthor=K.+Silamutauthor=S.+J.+Leeauthor=B.+Vihokhernauthor=C.+Kunasolauthor=M.+Imwongauthor=J.+Tarningauthor=W.+J.+Taylorauthor=S.+Yeungauthor=C.+J.+Woodrowauthor=J.+A.+Fleggauthor=D.+Dasauthor=J.+Smithauthor=M.+Venkatesanauthor=C.+V.+Ploweauthor=K.+Stepniewskaauthor=P.+J.+Guerinauthor=A.+M.+Dondorpauthor=N.+P.+Dayauthor=N.+J.+White&title=Spread+of+Artemisinin+resistance+in+Plasmodium+falciparum+Malaria&doi=10.1056%2FNEJMoa1314981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Spread of artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Ashley, E. A.; Dhorda, M.; Fairhurst, R. M.; Amaratunga, C.; Lim, P.; Suon, S.; Sreng, S.; Anderson, J. M.; Mao, S.; Sam, B.; Sopha, C.; Chuor, C. M.; Nguon, C.; Sovannaroth, S.; Pukrittayakamee, S.; Jittamala, P.; Chotivanich, K.; Chutasmit, K.; Suchatsoonthorn, C.; Runcharoen, R.; Hien, T. T.; Thuy-Nhien, N. T.; Thanh, N. V.; Phu, N. H.; Htut, Y.; Han, K.-T.; Aye, K. H.; Mokuolu, O. A.; Olaosebikan, R. R.; Folaranmi, O. O.; Mayxay, M.; Khanthavong, M.; Hongvanthong, B.; Newton, P. N.; Onyamboko, M. A.; Fanello, C. I.; Tshefu, A. K.; Mishra, N.; Valecha, N.; Phyo, A. P.; Nosten, F.; Yi, P.; Tripura, R.; Borrmann, S.; Bashraheil, M.; Peshu, J.; Faiz, M. A.; Ghose, A.; Hossain, M. A.; Samad, R.; Rahman, M. R.; Hasan, M. M.; Islam, A.; Miotto, O.; Amato, R.; MacInnis, B.; Stalker, J.; Kwiatkowski, D. P.; Bozdech, Z.; Jeeyapant, A.; Cheah, P. Y.; Sakulthaew, T.; Chalk, J.; Intharabut, B.; Silamut, K.; Lee, S. J.; Vihokhern, B.; Kunasol, C.; Imwong, M.; Tarning, J.; Taylor, W. J.; Yeung, S.; Woodrow, C. J.; Flegg, J. A.; Das, D.; Smith, J.; Venkatesan, M.; Plowe, C. V.; Stepniewska, K.; Guerin, P. J.; Dondorp, A. M.; Day, N. P.; White, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-423, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria.  Mapping the geog. extent of resistance is essential for planning containment and elimination strategies.  Methods: Between May 2011 and Apr. 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa).  Patients received artesunate, administered orally at a daily dose of either 2 mg per kg of body wt. per day or 4 mg per kg, for 3 days, followed by a std. 3-day course of artemisinin-based combination therapy.  Parasite counts in peripheral-blood samples were measured every 6 h, and the parasite clearance half-lives were detd.  Results: The median parasite clearance half-lives ranged from 1.9 h in the Democratic Republic of Congo to 7.0 h at the Thailand-Cambodia border.  Slowly clearing infections (parasite clearance half-life >5 h), strongly assocd. with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from Southern Vietnam to central Myanmar.  The incidence of pre-treatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission.  In Western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was assocd. with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days.  Conclusions: Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is assocd. with mutations in kelch13.  Prolonged courses of artemisinin- based combination therapies are currently efficacious in areas where std. 3-day treatments are failing. (Funded by the U.K. Department of International Development and others).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7aJ4A3O4W8rVg90H21EOLACvtfcHk0lhr21VAKNXsZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF&md5=bb2f2a4d554ba6a1f4c605868be43f6e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1314981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1314981%26sid%3Dliteratum%253Aachs%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DSam%26aufirst%3DB.%26aulast%3DSopha%26aufirst%3DC.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DNguon%26aufirst%3DC.%26aulast%3DSovannaroth%26aufirst%3DS.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSuchatsoonthorn%26aufirst%3DC.%26aulast%3DRuncharoen%26aufirst%3DR.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DPhu%26aufirst%3DN.%2BH.%26aulast%3DHtut%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DK.%2BT.%26aulast%3DAye%26aufirst%3DK.%2BH.%26aulast%3DMokuolu%26aufirst%3DO.%2BA.%26aulast%3DOlaosebikan%26aufirst%3DR.%2BR.%26aulast%3DFolaranmi%26aufirst%3DO.%2BO.%26aulast%3DMayxay%26aufirst%3DM.%26aulast%3DKhanthavong%26aufirst%3DM.%26aulast%3DHongvanthong%26aufirst%3DB.%26aulast%3DNewton%26aufirst%3DP.%2BN.%26aulast%3DOnyamboko%26aufirst%3DM.%2BA.%26aulast%3DFanello%26aufirst%3DC.%2BI.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DMishra%26aufirst%3DN.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DBashraheil%26aufirst%3DM.%26aulast%3DPeshu%26aufirst%3DJ.%26aulast%3DFaiz%26aufirst%3DM.%2BA.%26aulast%3DGhose%26aufirst%3DA.%26aulast%3DHossain%26aufirst%3DM.%2BA.%26aulast%3DSamad%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DM.%2BR.%26aulast%3DHasan%26aufirst%3DM.%2BM.%26aulast%3DIslam%26aufirst%3DA.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DMacInnis%26aufirst%3DB.%26aulast%3DStalker%26aufirst%3DJ.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DBozdech%26aufirst%3DZ.%26aulast%3DJeeyapant%26aufirst%3DA.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DSakulthaew%26aufirst%3DT.%26aulast%3DChalk%26aufirst%3DJ.%26aulast%3DIntharabut%26aufirst%3DB.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DVihokhern%26aufirst%3DB.%26aulast%3DKunasol%26aufirst%3DC.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DW.%2BJ.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DWoodrow%26aufirst%3DC.%2BJ.%26aulast%3DFlegg%26aufirst%3DJ.%2BA.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DM.%26aulast%3DPlowe%26aufirst%3DC.%2BV.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DGuerin%26aufirst%3DP.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DSpread%2520of%2520Artemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D5%26spage%3D411%26epage%3D423%26doi%3D10.1056%2FNEJMoa1314981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, M. V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llanos-Cuentas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krudsood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista
Pereira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espino, F. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mia, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuquiyauri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Val, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casapía, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito, M. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M. R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buathong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noedl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wubie, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdissa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeynudin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abebe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellam, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousell, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardaker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clover, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugwuegbulam, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, G. C. K. W.</span></span> <span> </span><span class="NLM_article-title">Single-dose tafenoquine to prevent relapse of <i>Plasmodium vivax</i> malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1710775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1710775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30650322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=215-228&issue=3&author=M.+V.+G.+Lacerdaauthor=A.+Llanos-Cuentasauthor=S.+Krudsoodauthor=C.+Lonauthor=D.+L.+Saundersauthor=R.+Mohammedauthor=D.+Yilmaauthor=D.+Batista%0APereiraauthor=F.+E.+J.+Espinoauthor=R.+Z.+Miaauthor=R.+Chuquiyauriauthor=F.+Valauthor=M.+Casap%C3%ADaauthor=W.+M.+Monteiroauthor=M.+A.+M.+Britoauthor=M.+R.+F.+Costaauthor=N.+Buathongauthor=H.+Noedlauthor=E.+Diroauthor=S.+Getieauthor=K.+M.+Wubieauthor=A.+Abdissaauthor=A.+Zeynudinauthor=C.+Abebeauthor=M.+S.+Tadaauthor=F.+Brandauthor=H.-P.+Beckauthor=B.+Angusauthor=S.+Duparcauthor=J.-P.+Kleimauthor=L.+M.+Kellamauthor=V.+M.+Rousellauthor=S.+W.+Jonesauthor=E.+Hardakerauthor=K.+Mohamedauthor=D.+D.+Cloverauthor=K.+Fletcherauthor=J.+J.+Bretonauthor=C.+O.+Ugwuegbulamauthor=J.+A.+Greenauthor=G.+C.+K.+W.+Koh&title=Single-dose+tafenoquine+to+prevent+relapse+of+Plasmodium+vivax+malaria&doi=10.1056%2FNEJMoa1710775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria</span></div><div class="casAuthors">Lacerda, M. V. G.; Llanos-Cuentas, A.; Krudsood, S.; Lon, C.; Saunders, D. L.; Mohammed, R.; Yilma, D.; Pereira, D. Batista; Espino, F. E. J.; Mia, R. Z.; Chuquiyauri, R.; Val, F.; Casapia, M.; Monteiro, W. M.; Brito, M. A. M.; Costa, M. R. F.; Buathong, N.; Noedl, H.; Diro, E.; Getie, S.; Wubie, K. M.; Abdissa, A.; Zeynudin, A.; Abebe, C.; Tada, M. S.; Brand, F.; Beck, H.-P.; Angus, B.; Duparc, S.; Kleim, J.-P.; Kellam, L. M.; Rousell, V. M.; Jones, S. W.; Hardaker, E.; Mohamed, K.; Clover, D. D.; Fletcher, K.; Breton, J. J.; Ugwuegbulam, C. O.; Green, J. A.; Koh, G. C. K. W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-228</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical cure").  Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax.  Methods This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines.  We enrolled 522 patients with microscopically confirmed P. vivax infection (>100 to <100,000 parasites per μL) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value detd. at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial).  All patients received a 3-day course of chloroquine (total dose of 1500 mg).  In addn., patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients).  The primary outcome was the Kaplan-Meier estd. percentage of patients who were free from recurrence at 6 mo, defined as P. vivax clearance without recurrent parasitemia.  Results In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 mo was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1).  The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P<0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P<0.001).  Tafenoquine was assocd. with asymptomatic declines in Hb levels, which resolved without intervention.  Conclusions Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvrzXV4arPRbVg90H21EOLACvtfcHk0lj2mtu84DxO-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWgsrk%253D&md5=d6f2739d9be0b6f05fc718cc00665e71</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1710775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1710775%26sid%3Dliteratum%253Aachs%26aulast%3DLacerda%26aufirst%3DM.%2BV.%2BG.%26aulast%3DLlanos-Cuentas%26aufirst%3DA.%26aulast%3DKrudsood%26aufirst%3DS.%26aulast%3DLon%26aufirst%3DC.%26aulast%3DSaunders%26aufirst%3DD.%2BL.%26aulast%3DMohammed%26aufirst%3DR.%26aulast%3DYilma%26aufirst%3DD.%26aulast%3DBatista%2BPereira%26aufirst%3DD.%26aulast%3DEspino%26aufirst%3DF.%2BE.%2BJ.%26aulast%3DMia%26aufirst%3DR.%2BZ.%26aulast%3DChuquiyauri%26aufirst%3DR.%26aulast%3DVal%26aufirst%3DF.%26aulast%3DCasap%25C3%25ADa%26aufirst%3DM.%26aulast%3DMonteiro%26aufirst%3DW.%2BM.%26aulast%3DBrito%26aufirst%3DM.%2BA.%2BM.%26aulast%3DCosta%26aufirst%3DM.%2BR.%2BF.%26aulast%3DBuathong%26aufirst%3DN.%26aulast%3DNoedl%26aufirst%3DH.%26aulast%3DDiro%26aufirst%3DE.%26aulast%3DGetie%26aufirst%3DS.%26aulast%3DWubie%26aufirst%3DK.%2BM.%26aulast%3DAbdissa%26aufirst%3DA.%26aulast%3DZeynudin%26aufirst%3DA.%26aulast%3DAbebe%26aufirst%3DC.%26aulast%3DTada%26aufirst%3DM.%2BS.%26aulast%3DBrand%26aufirst%3DF.%26aulast%3DBeck%26aufirst%3DH.-P.%26aulast%3DAngus%26aufirst%3DB.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DKleim%26aufirst%3DJ.-P.%26aulast%3DKellam%26aufirst%3DL.%2BM.%26aulast%3DRousell%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DS.%2BW.%26aulast%3DHardaker%26aufirst%3DE.%26aulast%3DMohamed%26aufirst%3DK.%26aulast%3DClover%26aufirst%3DD.%2BD.%26aulast%3DFletcher%26aufirst%3DK.%26aulast%3DBreton%26aufirst%3DJ.%2BJ.%26aulast%3DUgwuegbulam%26aufirst%3DC.%2BO.%26aulast%3DGreen%26aufirst%3DJ.%2BA.%26aulast%3DKoh%26aufirst%3DG.%2BC.%2BK.%2BW.%26atitle%3DSingle-dose%2520tafenoquine%2520to%2520prevent%2520relapse%2520of%2520Plasmodium%2520vivax%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D3%26spage%3D215%26epage%3D228%26doi%3D10.1056%2FNEJMoa1710775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span> <span> </span><span class="NLM_article-title">Primaquine revisited six decades after its discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ejmech.2008.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18930565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVOmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=937-953&issue=3&author=N.+Valeauthor=R.+Moreiraauthor=P.+Gomes&title=Primaquine+revisited+six+decades+after+its+discovery&doi=10.1016%2Fj.ejmech.2008.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Primaquine revisited six decades after its discovery</span></div><div class="casAuthors">Vale, Nuno; Moreira, Rui; Gomes, Paula</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">937-953</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Primaquine was firstly synthesized in 1946 in the USA, and is the most representative member of the anti-malarial 8-aminoquinolines.  Six decades have passed and primaquine is still the only transmission-blocking anti-malarial clin. available, displaying a marked activity against gametocytes of all species of human malaria, including multi-resistant Plasmodium falciparum strains.  Primaquine is also effective against all exoerythrocytic forms of the parasite and is used in conjunction with other anti-malarials for the treatment of vivax and ovale malaria.  However, primaquine is often assocd. with serious adverse effects, in consequence of its toxic metabolites.  5-Hydroxyprimaquine or 6-methoxy-8-aminoquinoline has been considered to be directly responsible for complications such as hemolytic anemia.  Primaquine toxicity is aggravated in people deficient of 6-glucose phosphate dehydrogenase or glutathione synthetase.  Adverse effects are further amplified by the fact that primaquine must be repeatedly administered at high doses, due to its limited oral bioavailability.  Over the last two decades, Medicinal Chemists have battled against primaquine's disadvantages, while keeping or even improving its unequalled performance as an anti-malarial.  The present text revisits primaquine and its properties on the occasion of its 60th anniversary and aims to give a general overview of what has been the path towards the development of effective and safe primaquine-based anti-malarials.  Presently, aablaquine and tafenoquine the two most promising primaquine analogs are already in the final stages of clin. trials against Plasmodium vivax and P. falciparum.  Both compds. are a new hope against malaria and other primaquine-sensitive illnesses, such as Pneumocystis Pneumonia or the Chagas disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSnsLTnEOK1bVg90H21EOLACvtfcHk0liNsp61kdrSeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVOmtrc%253D&md5=9b864141a9603247e96fec5e3cec8211</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DVale%26aufirst%3DN.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DP.%26atitle%3DPrimaquine%2520revisited%2520six%2520decades%2520after%2520its%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26issue%3D3%26spage%3D937%26epage%3D953%26doi%3D10.1016%2Fj.ejmech.2008.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria: an open-label phase 2 trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)00320-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2815%2900320-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26448141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=61-69&issue=1&author=A.+P.+Phyoauthor=P.+Jittamalaauthor=F.+H.+Nostenauthor=S.+Pukrittayakameeauthor=M.+Imwongauthor=N.+J.+Whiteauthor=S.+Duparcauthor=F.+Macintyreauthor=M.+Bakerauthor=J.+J.+M%C3%B6hrle&title=Antimalarial+activity+of+artefenomel+%28OZ439%29%2C+a+novel+synthetic+antimalarial+endoperoxide%2C+in+patients+with+Plasmodium+falciparum+and+Plasmodium+vivax+malaria%3A+an+open-label+phase+2+trial&doi=10.1016%2FS1473-3099%2815%2900320-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial</span></div><div class="casAuthors">Phyo, Aung Pyae; Jittamala, Podjanee; Nosten, Francois H.; Pukrittayakamee, Sasithon; Imwong, Mallika; White, Nicholas J.; Duparc, Stephan; MacIntyre, Fiona; Baker, Mark; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared with other antimalarial drugs with the artemisinin pharmacophore.  Artefenomel has been generally well tolerated in volunteers at doses up to 1600 mg and is being developed as a partner drug in an antimalarial combination treatment.  We investigated the efficacy, tolerability, and pharmacokinetics of artefenomel at different doses in patients with Plasmodium falciparum or Plasmodium vivax malaria.  This phase 2a exploratory, open-label trial was done at the Hospital for Tropical Diseases, Bangkok, and the Shoklo Malaria Research Unit in Thailand.  Adult patients with acute, uncomplicated P falciparum or P vivax malaria received artefenomel in a single oral dose (200 mg, 400 mg, 800 mg, or 1200 mg).  The first cohort received 800 mg.  Testing of a new dose of artefenomel in a patient cohort was decided on after safety and efficacy assessment of the preceding cohort.  The primary endpoint was the natural log parasite redn. per 24 h.  Definitive oral treatment was given at 36 h.  This trial is registered with ClinicalTrials.gov, no. NCT01213966.  Between Oct 24, 2010, and May 25, 2012, 82 patients were enrolled (20 in each of the 200 mg, 400 mg, and 800 mg cohorts, and 21 in the 1200 mg cohort).  One patient withdrew consent (before the administration of artefenomel) but there were no further dropouts.  The parasite redn. rates per 24 h ranged from 0·90 to 1·88 for P falciparum, and 2·09 to 2·53 for P vivax.  All doses were equally effective in both P falciparum and P vivax malaria, with median parasite clearance half-lives of 4·1 h (range 1·3-6·7) to 5·6 h (2·0-8·5) for P falciparum and 2·3 h (1·2-3·9) to 3·2 h (0·9-15·0) for P vivax.  Maximum plasma concns., dose-proportional to 800 mg, occurred at 4 h (median).  The estd. elimination half-life was 46-62 h.  No serious drug-related adverse effects were reported; other adverse effects were generally mild and reversible, with the highest no. in the 1200 mg cohort (17 [81%] patients with at least one adverse event).  The most frequently reported adverse effect was an asymptomatic increase in plasma creatine phosphokinase concn. (200 mg, n=5; 400 mg, n=3; 800 mg, n=1; 1200 mg, n=3).  Artefenomel is a new synthetic antimalarial peroxide with a good safety profile that clears parasitemia rapidly in both P falciparum and P vivax malaria.  Its long half-life suggests a possible use in a single-dose treatment in combination with other drugs.  Bill & Melinda Gates Foundation, Wellcome Trust, and UK Department for International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_OEYJuv5VVrVg90H21EOLACvtfcHk0liNsp61kdrSeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP&md5=368550e5ec73242c603c8abdc6a66f12</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900320-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900320-5%26sid%3Dliteratum%253Aachs%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DNosten%26aufirst%3DF.%2BH.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26atitle%3DAntimalarial%2520activity%2520of%2520artefenomel%2520%2528OZ439%2529%252C%2520a%2520novel%2520synthetic%2520antimalarial%2520endoperoxide%252C%2520in%2520patients%2520with%2520Plasmodium%2520falciparum%2520and%2520Plasmodium%2520vivax%2520malaria%253A%2520an%2520open-label%2520phase%25202%2520trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26issue%3D1%26spage%3D61%26epage%3D69%26doi%3D10.1016%2FS1473-3099%2815%2900320-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toure, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwapasa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaye, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheshwar, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anvikar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span> <span> </span><span class="NLM_article-title">Assessment of efficacy and safety of arterolane maleate-piperaquine phosphate dispersible tablets in comparison with artemether-lumefantrine dispersible tablets in pediatric patients with acute uncomplicated <i>Plasmodium falciparum</i> malaria: a phase 3, randomized, multicenter trial in India and Africa</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1720</span>, <span class="refDoi"> DOI: 10.1093/cid/cix617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Fcid%2Fcix617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29020247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSrtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=1711-1720&issue=10&author=O.+A.+Toureauthor=V.+Mwapasaauthor=I.+Sagaraauthor=O.+Gayeauthor=R.+Thompsonauthor=A.+V.+Maheshwarauthor=P.+Mishraauthor=N.+Behraauthor=A.+K.+Tshefuauthor=R.+R.+Dasauthor=A.+R.+Anvikarauthor=P.+Sharmaauthor=A.+Royauthor=S.+K.+Sharmaauthor=A.+Nasaauthor=R.+K.+Jalaliauthor=N.+Valecha&title=Assessment+of+efficacy+and+safety+of+arterolane+maleate-piperaquine+phosphate+dispersible+tablets+in+comparison+with+artemether-lumefantrine+dispersible+tablets+in+pediatric+patients+with+acute+uncomplicated+Plasmodium+falciparum+malaria%3A+a+phase+3%2C+randomized%2C+multicenter+trial+in+India+and+Africa&doi=10.1093%2Fcid%2Fcix617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of efficacy and safety of arterolane maleate-piperaquine phosphate dispersible tablets in comparison with artemether-lumefantrine dispersible tablets in pediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase 3, randomized, multicenter trial in India and Africa</span></div><div class="casAuthors">Toure, Offianan Andre; Mwapasa, Victor; Sagara, Issaka; Gaye, Oumar; Thompson, Ricardo; Maheshwar, Aishwarya V.; Mishra, Pitabas; Behra, Narendra; Tshefu, Antoinette K.; Das, Rashmi R.; Anvikar, Anupkumar R.; Sharma, Pradeep; Roy, Arjun; Sharma, Sanjay K.; Nasa, Amit; Jalali, Rajinder K.; Valecha, Neena</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1711-1720</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.Administration of artemisinin-based combination therapy (ACT) to infant and young children can be challenging.  A formulation with accurate dose and ease of administration will improve adherence and compliance in children.  The fixed-dose combination dispersible tablet of arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg can make dosing convenient in children.  Methods.This multicenter (India and Africa), comparative, parallel-group trial enrolled 859 patients aged 6 mo to 12 years with Plasmodium falciparummalaria.  Patients were randomized in a ratio of 2:1 to AM-PQP (571 patients) once daily and artemether-lumefantrine (AL) (288 patients) twice daily for 3 days and followed for 42 days.  Results.The cure rate (ie, polymerase chain reaction-cor. adequate clin. and parasitol. response) in the per-protocol population at day 28 was 100.0% and 98.5% (difference, 1.48% [95% confidence interval {CI},.04%-2.91%]) in the AM-PQP and AL arms, resp., and 96.0% and 95.8% (difference, 0.14% [95% CI, -2.68% to 2.95%]) in the intention-to-treat (ITT) population.  The cure rate was comparable at day 42 in the ITT population (AM-PQP, 94.4% vs AL, 93.1%).  The median parasite clearance time was 24 h in both the arms.  The median fever clearance time was 6 h in AM-PQP and 12 h in the AL arm.  Both the treatments were found to be safe and well tolerated.  Overall, safety profile of both the treatments was similar.  Conclusions.The efficacy and safety of fixed-dose combination of AM and PQP was comparable to AL for the treatment of uncomplicated P. falciparum malaria in pediatric patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqegdwsrY2Uv7Vg90H21EOLACvtfcHk0liXAULm_5GTYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSrtbbN&md5=c2b86ff3bf500a5bbc6c7322628704ee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcix617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcix617%26sid%3Dliteratum%253Aachs%26aulast%3DToure%26aufirst%3DO.%2BA.%26aulast%3DMwapasa%26aufirst%3DV.%26aulast%3DSagara%26aufirst%3DI.%26aulast%3DGaye%26aufirst%3DO.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DMaheshwar%26aufirst%3DA.%2BV.%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DBehra%26aufirst%3DN.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DDas%26aufirst%3DR.%2BR.%26aulast%3DAnvikar%26aufirst%3DA.%2BR.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DNasa%26aufirst%3DA.%26aulast%3DJalali%26aufirst%3DR.%2BK.%26aulast%3DValecha%26aufirst%3DN.%26atitle%3DAssessment%2520of%2520efficacy%2520and%2520safety%2520of%2520arterolane%2520maleate-piperaquine%2520phosphate%2520dispersible%2520tablets%2520in%2520comparison%2520with%2520artemether-lumefantrine%2520dispersible%2520tablets%2520in%2520pediatric%2520patients%2520with%2520acute%2520uncomplicated%2520Plasmodium%2520falciparum%2520malaria%253A%2520a%2520phase%25203%252C%2520randomized%252C%2520multicenter%2520trial%2520in%2520India%2520and%2520Africa%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D65%26issue%3D10%26spage%3D1711%26epage%3D1720%26doi%3D10.1093%2Fcid%2Fcix617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toure, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krudsood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaye, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohanty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anvikar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwapasa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noedl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiacoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enosse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangpukdee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokolomami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndiaye, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yumva, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidibe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohanty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyirenda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starzengruber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swoboda, P.</span></span> <span> </span><span class="NLM_article-title">A phase 3, double-blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">964</span>– <span class="NLM_lpage">971</span>, <span class="refDoi"> DOI: 10.1093/cid/ciw029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Fcid%2Fciw029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26908796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2016&pages=964-971&author=O.+A.+Toureauthor=N.+Valechaauthor=A.+K.+Tshefuauthor=R.+Thompsonauthor=S.+Krudsoodauthor=O.+Gayeauthor=B.+H.+K.+Raoauthor=I.+Sagaraauthor=T.+K.+Boseauthor=S.+Mohantyauthor=B.+S.+Raoauthor=A.+R.+Anvikarauthor=V.+Mwapasaauthor=H.+Noedlauthor=S.+Aroraauthor=A.+Royauthor=S.+S.+Iyerauthor=P.+Sharmaauthor=N.+Sahaauthor=R.+K.+Jalaliauthor=L.+Tiacohauthor=S.+Enosseauthor=N.+Tangpukdeeauthor=J.+Kokolomamiauthor=J.+L.+Ndiayeauthor=D.+Raoauthor=N.+N.+Yumvaauthor=B.+Sidibeauthor=R.+Mohantyauthor=A.+C.+Jhaauthor=M.+Nyirendaauthor=P.+Starzengruberauthor=P.+Swoboda&title=A+phase+3%2C+double-blind%2C+randomized+study+of+arterolane+maleate-piperaquine+phosphate+vs+artemether-lumefantrine+for+falciparum+malaria+in+adolescent+and+adult+patients+in+Asia+and+Africa&doi=10.1093%2Fcid%2Fciw029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 3, double-blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa</span></div><div class="casAuthors">Toure, Offianan Andre; Valecha, Neena; Tshefu, Antoinette K.; Thompson, Ricardo; Krudsood, Srivicha; Gaye, Oumar; Rao, Bappanaidu Hoigegudde Krishnamurthy; Sagara, Issaka; Bose, Tarit Kumar; Mohanty, Sanjib; Rao, Ballamudi Srinivas; Anvikar, Anupkumar R.; Mwapasa, Victor; Noedl, Harald; Arora, Sudershan; Roy, Arjun; Iyer, Sunil S.; Sharma, Pradeep; Saha, Nilanjan; Jalali, Rajinder K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">964-971</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Artemisinins, which are derived from plants, are subject to risk of supply interruption due to climatic changes.  Consequently, an effort to identify a new synthetic antimalarial was initiated.  A fixed-dose combination of arterolane maleate (AM), a new synthetic trioxolane, with piperaquine phosphate (PQP), a long half-life bisquinoline, was evaluated in patients with uncomplicated Plasmodium falciparum malaria.  Methods: In this multicenter, randomized, double-blind, comparative, parallel-group trial, 1072 patients aged 12-65 years with P. falciparum monoinfection received either AM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients) twice daily for 3 days.  All patients were followed up until day 42.  Results: Of the 714 patients in the AM-PQP group, 638 (89.4%) completed the study; of the 358 patients in the A-L group, 301(84.1%) completed the study.  In both groups, the polymerase chain reaction cor. adequate clin. and parasitol. response (PCR-cor. ACPR) on day 28 in intent-to-treat (ITT) and per-protocol (PP) populations was 92.86% and 92.46% and 99.25% and 99.07%, resp.  The corresponding figures on day 42 in the ITT and PP populations were 90.48% and 91.34%, resp.  After adjusting for survival ITT, the PCR-cor. ACPR on day 42 was > 98% in both groups.  The overall incidence of adverse events was comparable.  Conclusions: AM-PQP showed comparable efficacy and safety to A-L in the treatment of uncomplicated P. falciparum malaria in adolescent and adult patients.  AM-PQP demonstrated high clin. and parasitol. response rates as well as rapid parasite clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfvidmlOCaMrVg90H21EOLACvtfcHk0liXAULm_5GTYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGrtbo%253D&md5=fde69cb1e4da2ef26ee13781a512c499</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciw029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciw029%26sid%3Dliteratum%253Aachs%26aulast%3DToure%26aufirst%3DO.%2BA.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DKrudsood%26aufirst%3DS.%26aulast%3DGaye%26aufirst%3DO.%26aulast%3DRao%26aufirst%3DB.%2BH.%2BK.%26aulast%3DSagara%26aufirst%3DI.%26aulast%3DBose%26aufirst%3DT.%2BK.%26aulast%3DMohanty%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DB.%2BS.%26aulast%3DAnvikar%26aufirst%3DA.%2BR.%26aulast%3DMwapasa%26aufirst%3DV.%26aulast%3DNoedl%26aufirst%3DH.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DIyer%26aufirst%3DS.%2BS.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DSaha%26aufirst%3DN.%26aulast%3DJalali%26aufirst%3DR.%2BK.%26aulast%3DTiacoh%26aufirst%3DL.%26aulast%3DEnosse%26aufirst%3DS.%26aulast%3DTangpukdee%26aufirst%3DN.%26aulast%3DKokolomami%26aufirst%3DJ.%26aulast%3DNdiaye%26aufirst%3DJ.%2BL.%26aulast%3DRao%26aufirst%3DD.%26aulast%3DYumva%26aufirst%3DN.%2BN.%26aulast%3DSidibe%26aufirst%3DB.%26aulast%3DMohanty%26aufirst%3DR.%26aulast%3DJha%26aufirst%3DA.%2BC.%26aulast%3DNyirenda%26aufirst%3DM.%26aulast%3DStarzengruber%26aufirst%3DP.%26aulast%3DSwoboda%26aufirst%3DP.%26atitle%3DA%2520phase%25203%252C%2520double-blind%252C%2520randomized%2520study%2520of%2520arterolane%2520maleate-piperaquine%2520phosphate%2520vs%2520artemether-lumefantrine%2520for%2520falciparum%2520malaria%2520in%2520adolescent%2520and%2520adult%2520patients%2520in%2520Asia%2520and%2520Africa%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D62%26spage%3D964%26epage%3D971%26doi%3D10.1093%2Fcid%2Fciw029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbe-Barnes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chollet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matile, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papastogiannidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriraghavan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stingelin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urwyler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vennerstrom, J. L.</span></span> <span> </span><span class="NLM_article-title">Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4400</span>– <span class="NLM_lpage">4405</span>, <span class="refDoi"> DOI: 10.1073/pnas.1015762108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.1015762108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21300861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvV2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=4400-4405&issue=11&author=S.+A.+Charmanauthor=S.+Arbe-Barnesauthor=I.+C.+Bathurstauthor=R.+Brunauthor=M.+Campbellauthor=W.+N.+Charmanauthor=F.+C.+K.+Chiuauthor=J.+Cholletauthor=J.+C.+Craftauthor=D.+J.+Creekauthor=Y.+Dongauthor=H.+Matileauthor=M.+Maurerauthor=J.+Morizziauthor=T.+Nguyenauthor=P.+Papastogiannidisauthor=C.+Scheurerauthor=D.+M.+Shacklefordauthor=K.+Sriraghavanauthor=L.+Stingelinauthor=Y.+Tangauthor=H.+Urwylerauthor=X.+Wangauthor=K.+L.+Whiteauthor=S.+Wittlinauthor=L.+Zhouauthor=J.+L.+Vennerstrom&title=Synthetic+ozonide+drug+candidate+OZ439+offers+new+hope+for+a+single-dose+cure+of+uncomplicated+malaria&doi=10.1073%2Fpnas.1015762108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria</span></div><div class="casAuthors">Charman, Susan A.; Arbe-Barnes, Sarah; Bathurst, Ian C.; Brun, Reto; Campbell, Michael; Charman, William N.; Chiu, Francis C. K.; Chollet, Jacques; Craft, J. Carl; Creek, Darren J.; Dong, Yuxiang; Matile, Hugues; Maurer, Melanie; Morizzi, Julia; Nguyen, Tien; Papastogiannidis, Petros; Scheurer, Christian; Shackleford, David M.; Sriraghavan, Kamaraj; Stingelin, Lukas; Tang, Yuanqing; Urwyler, Heinrich; Wang, Xiaofang; White, Karen L.; Wittlin, Sergio; Zhou, Lin; Vennerstrom, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4400-4405, S4400/1-S4400/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans.  OZ439 has successfully completed Phase I clin. trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase Ila trials in malaria patients.  Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clin. drug development candidate.  In vitro, OZ439 is fast-acting against all asexual erythrocytic Plasmodium falciparum stages with ICs0 values comparable to those for the clin. used artemisinin derivs.  Unlike all other synthetic peroxides and semisynthetic artemisinin derivs., OZ439 completely cures Plasmodium berghei-infected mice with a single oral dose of 20 mg/kg and exhibits prophylactic activity superior to that of the benchmark chemoprophylactic agent, mefloquine.  Compared with other peroxide-contg. antimalarial agents, such as the artemisinin derivs. and the first-generation ozonide OZ277, OZ439 exhibits a substantial increase in the pharmacokinetic half-life and blood concn. vs. time profile in three preclin. species.  The outstanding efficacy and prolonged blood concns. of OZ439 are the result of a design strategy that stabilizes the intrinsically unstable pharmacophoric peroxide bond, thereby reducing clearance yet maintaining the necessary Fe(II)-reactivity to elicit parasite death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQxoUteI8z2bVg90H21EOLACvtfcHk0lhe73UtTtt3pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvV2jtL4%253D&md5=5da13be1d57a8dd58b21246814f6c268</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1015762108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1015762108%26sid%3Dliteratum%253Aachs%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DArbe-Barnes%26aufirst%3DS.%26aulast%3DBathurst%26aufirst%3DI.%2BC.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DChiu%26aufirst%3DF.%2BC.%2BK.%26aulast%3DChollet%26aufirst%3DJ.%26aulast%3DCraft%26aufirst%3DJ.%2BC.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DMatile%26aufirst%3DH.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DPapastogiannidis%26aufirst%3DP.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DSriraghavan%26aufirst%3DK.%26aulast%3DStingelin%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DUrwyler%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DVennerstrom%26aufirst%3DJ.%2BL.%26atitle%3DSynthetic%2520ozonide%2520drug%2520candidate%2520OZ439%2520offers%2520new%2520hope%2520for%2520a%2520single-dose%2520cure%2520of%2520uncomplicated%2520malaria%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D11%26spage%3D4400%26epage%3D4405%26doi%3D10.1073%2Fpnas.1015762108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnädig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium falciparum</i> K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e00172-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.00172-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FmBio.00172-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28400526" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=e00172-17&issue=2&author=J.+Straimerauthor=N.+F.+Gn%C3%A4digauthor=B.+H.+Stokesauthor=M.+Ehrenbergerauthor=A.+A.+Craneauthor=D.+A.+Fidock&title=Plasmodium+falciparum+K13+mutations+differentially+impact+ozonide+susceptibility+and+parasite+fitness+in+vitro&doi=10.1128%2FmBio.00172-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FmBio.00172-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00172-17%26sid%3Dliteratum%253Aachs%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGn%25C3%25A4dig%26aufirst%3DN.%2BF.%26aulast%3DStokes%26aufirst%3DB.%2BH.%26aulast%3DEhrenberger%26aufirst%3DM.%26aulast%3DCrane%26aufirst%3DA.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DPlasmodium%2520falciparum%2520K13%2520mutations%2520differentially%2520impact%2520ozonide%2520susceptibility%2520and%2520parasite%2520fitness%2520in%2520vitro%26jtitle%3DmBio%26date%3D2017%26volume%3D8%26issue%3D2%26spage%3De00172-17%26doi%3D10.1128%2FmBio.00172-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumgärtner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1186/s12936-017-1696-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-017-1696-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28122617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1c7pt1Gnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=45&author=F.+Baumg%C3%A4rtnerauthor=J.+Jourdanauthor=C.+Scheurerauthor=B.+Blascoauthor=B.+Campoauthor=P.+M%C3%A4serauthor=S.+Wittlin&title=In+vitro+activity+of+anti-malarial+ozonides+against+an+artemisinin-resistant+isolate&doi=10.1186%2Fs12936-017-1696-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate</span></div><div class="casAuthors">Baumgartner Fabian; Jourdan Joelle; Scheurer Christian; Maser Pascal; Wittlin Sergio; Baumgartner Fabian; Jourdan Joelle; Scheurer Christian; Maser Pascal; Wittlin Sergio; Blasco Benjamin; Campo Brice</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recently published data suggest that artemisinin derivatives and synthetic peroxides, such as the ozonides OZ277 and OZ439, have a similar mode of action.  Here the cross-resistance of OZ277 and OZ439 and four additional next-generation ozonides was probed against the artemisinin-resistant clinical isolate Plasmodium falciparum Cam3.I, which carries the K13-propeller mutation R539T (Cam3.I(R539T)).  METHODS:  The previously described in vitro ring-stage survival assay (RSA0-3h) was employed and a simplified variation of the original protocol was developed.  RESULTS:  At the pharmacologically relevant concentration of 700 nM, all six ozonides were highly effective against the dihydroartemisinin-resistant P. falciparum Cam3.I(R539T) parasites, showing a per cent survival ranging from <0.01 to 1.83%.  A simplified version of the original RSA0-3h method was developed and gave similar results, thus providing a practical drug discovery tool for further optimization of next-generation anti-malarial peroxides.  CONCLUSION:  The absence of in vitro cross-resistance against the artemisinin-resistant clinical isolate Cam3.I(R539T) suggests that ozonides could be effective against artemisinin-resistant P. falciparum.  How this will translate to the human situation in clinical settings remains to be investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT81D1FD4aMH-kdrW1FkXG-fW6udTcc2eatc-G9Zd3MHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7pt1Gnsg%253D%253D&md5=3ef0b5011d7a16980762522cd3f65926</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2Fs12936-017-1696-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-017-1696-0%26sid%3Dliteratum%253Aachs%26aulast%3DBaumg%25C3%25A4rtner%26aufirst%3DF.%26aulast%3DJourdan%26aufirst%3DJ.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DM%25C3%25A4ser%26aufirst%3DP.%26aulast%3DWittlin%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520activity%2520of%2520anti-malarial%2520ozonides%2520against%2520an%2520artemisinin-resistant%2520isolate%26jtitle%3DMalar.%2520J.%26date%3D2017%26volume%3D16%26spage%3D45%26doi%3D10.1186%2Fs12936-017-1696-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannangelo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowkes, F. J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span> <span> </span><span class="NLM_article-title">Ozonide antimalarial activity in the context of artemisinin-resistant malaria</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2019.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.pt.2019.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=31176584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWks73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=529-543&issue=7&author=C.+Giannangeloauthor=F.+J.+I.+Fowkesauthor=J.+A.+Simpsonauthor=S.+A.+Charmanauthor=D.+J.+Creek&title=Ozonide+antimalarial+activity+in+the+context+of+artemisinin-resistant+malaria&doi=10.1016%2Fj.pt.2019.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria</span></div><div class="casAuthors">Giannangelo, Carlo; Fowkes, Freya J. I.; Simpson, Julie A.; Charman, Susan A.; Creek, Darren J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">529-543</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ozonides are one of the most advanced drug classes in the antimalarial development pipeline and were designed to improve on limitations assocd. with current front-line artemisinin-based therapies.  Like the artemisinins, the pharmacophoric peroxide bond of ozonides is essential for activity, and it appears that these antimalarials share a similar mode of action, raising the possibility of cross-resistance.  Resistance to artemisinins is assocd. with Plasmodium falciparum mutations that allow resistant parasites to escape short-term artemisinin-mediated damage (elimination half-life ∼1 h).  Importantly, some ozonides (e.g., OZ439) have a sustained in vivo drug exposure profile, providing a major pharmacokinetic advantage over the artemisinin derivs.  Here, it describe recent progress made towards understanding ozonide antimalarial activity and discuss ozonide utility within the context of artemisinin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhhxuyVZnSNbVg90H21EOLACvtfcHk0li2dlh8cxE3wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWks73L&md5=3937db84c408934ef27525ca79abde8d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2019.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2019.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGiannangelo%26aufirst%3DC.%26aulast%3DFowkes%26aufirst%3DF.%2BJ.%2BI.%26aulast%3DSimpson%26aufirst%3DJ.%2BA.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26atitle%3DOzonide%2520antimalarial%2520activity%2520in%2520the%2520context%2520of%2520artemisinin-resistant%2520malaria%26jtitle%3DTrends%2520Parasitol.%26date%3D2019%26volume%3D35%26issue%3D7%26spage%3D529%26epage%3D543%26doi%3D10.1016%2Fj.pt.2019.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puthukkuti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P.</span></span> <span> </span><span class="NLM_article-title">Screening and hit evaluation of a chemical library against blood-stage <i>Plasmodium falciparum</i></span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">190</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-13-190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2F1475-2875-13-190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24886460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=190&issue=1&author=V.+M.+Averyauthor=S.+Bashyamauthor=J.+N.+Burrowsauthor=S.+Duffyauthor=G.+Papadatosauthor=S.+Puthukkutiauthor=Y.+Sambandanauthor=S.+Singhauthor=T.+Spangenbergauthor=D.+Watersonauthor=P.+Willis&title=Screening+and+hit+evaluation+of+a+chemical+library+against+blood-stage+Plasmodium+falciparum&doi=10.1186%2F1475-2875-13-190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum</span></div><div class="casAuthors">Avery, Vicky M.; Bashyam, Sridevi; Burrows, Jeremy N.; Duffy, Sandra; Papadatos, George; Puthukkuti, Shyni; Sambandan, Yuvaraj; Singh, Shivendra; Spangenberg, Thomas; Waterson, David; Willis, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190/1-190/26, 26</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background In view of the need to continuously feed the pipeline with new anti-malarial agents adapted to differentiated and more stringent target product profiles (e g, new modes of action, transmission-blocking activity or long-duration chemo-protection), a chem. library consisting of more than 250,000 compds. has been evaluated in a blood-stage Plasmodium falciparum growth inhibition assay and further assessed for chem. diversity and novelty.  Methods The selection cascade used for the triaging of hits from the chem. library started with a robust three-step in vitro assay followed by an in silico anal. of the resulting confirmed hits.  Upon reaching the predefined requirements for selectivity and potency, the set of hits was subjected to computational anal. to assess chem. properties and diversity.  Furthermore, known marketed anti-malarial drugs were co-clustered acting as 'signposts' in the chem. space defined by the hits.  Then, in cerebro evaluation of the chem. structures was performed to identify scaffolds that currently are or have been the focus of anti-malarial medicinal chem. programs.  Next, prioritization according to relaxed physicochem. parameters took place, along with the search for structural analogs.  Ultimately, synthesis of novel chemotypes with desired properties was performed and the resulting compds. were subsequently retested in a P. falciparum growth inhibition assay.  Results This screening campaign led to a 1.25% primary hit rate, which decreased to 0.77% upon confirmatory repeat screening.  With the predefined potency (EC50 < 1 μM) and selectivity (SI > 10) criteria, 178 compds. progressed to the next steps where chem. diversity, physicochem. properties and novelty assessment were taken into account.  This resulted in the selection of 15 distinct chem. series.  Conclusion A selection cascade was applied to prioritize hits resulting from the screening of a medium-sized chem. library against blood-stage P. falciparum.  Emphasis was placed on chem. novelty whereby computational clustering, data mining of known anti-malarial chemotypes and the application of relaxed physicochem. filters, were key to the process.  This led to the selection of 15 chem. series from which ten confirmed their activity when newly synthesized sample were tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotiUY-7lEbpLVg90H21EOLACvtfcHk0lgvwOw5clSOBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gs7zK&md5=7649bdd8a2aa1c7ec76ad920ba72b949</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-13-190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-13-190%26sid%3Dliteratum%253Aachs%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DPapadatos%26aufirst%3DG.%26aulast%3DPuthukkuti%26aufirst%3DS.%26aulast%3DSambandan%26aufirst%3DY.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DSpangenberg%26aufirst%3DT.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWillis%26aufirst%3DP.%26atitle%3DScreening%2520and%2520hit%2520evaluation%2520of%2520a%2520chemical%2520library%2520against%2520blood-stage%2520Plasmodium%2520falciparum%26jtitle%3DMalar.%2520J.%26date%3D2014%26volume%3D13%26issue%3D1%26spage%3D190%26doi%3D10.1186%2F1475-2875-13-190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A clinical drug library screen identifies astemizole as an antimalarial agent</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1038/nchembio806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnchembio806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16816845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=415-416&issue=8&author=C.+R.+Chongauthor=X.+Chenauthor=L.+Shiauthor=J.+O.+Liuauthor=D.+J.+Sullivan&title=A+clinical+drug+library+screen+identifies+astemizole+as+an+antimalarial+agent&doi=10.1038%2Fnchembio806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical drug library screen identifies astemizole as an antimalarial agent</span></div><div class="casAuthors">Chong, Curtis R.; Chen, Xiaochun; Shi, Lirong; Liu, Jun O.; Sullivan, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">415-416</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The high cost and protracted time line of new drug discovery are major roadblocks to creating therapies for neglected diseases.  To accelerate drug discovery the authors created a library of 2687 existing drugs and screened for inhibitors of the human malaria parasite Plasmodium falciparum.  The antihistamine astemizole and its principal human metabolite are promising new inhibitors of chloroquine-sensitive and multidrug-resistant parasites, and they show efficacy in two mouse models of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7g4KV9AfkZrVg90H21EOLACvtfcHk0lgvwOw5clSOBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrs%253D&md5=85212419b5102292f830cc32f551f385</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnchembio806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio806%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DSullivan%26aufirst%3DD.%2BJ.%26atitle%3DA%2520clinical%2520drug%2520library%2520screen%2520identifies%2520astemizole%2520as%2520an%2520antimalarial%2520agent%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D8%26spage%3D415%26epage%3D416%26doi%3D10.1038%2Fnchembio806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coteron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors with clinical candidate potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5540</span>– <span class="NLM_lpage">5561</span>, <span class="refDoi"> DOI: 10.1021/jm200592f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200592f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5540-5561&issue=15&author=J.+M.+Coteronauthor=M.+Marcoauthor=J.+Esquiviasauthor=X.+Dengauthor=K.+L.+Whiteauthor=J.+Whiteauthor=M.+Koltunauthor=F.+El+Mazouniauthor=S.+Kokkondaauthor=K.+Katneniauthor=R.+Bhamidipatiauthor=D.+M.+Shacklefordauthor=I.+Angulo-Barturenauthor=S.+B.+Ferrerauthor=M.+B.+Jimenez-Diazauthor=F.+J.+Gamoauthor=E.+J.+Goldsmithauthor=W.+N.+Charmanauthor=I.+Bathurstauthor=D.+Floydauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=P.+K.+Rathodauthor=S.+A.+Charmanauthor=M.+A.+Phillips&title=Structure-guided+lead+optimization+of+triazolopyrimidine-ring+substituents+identifies+potent+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+with+clinical+candidate+potential&doi=10.1021%2Fjm200592f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential</span></div><div class="casAuthors">Coteron, Jose M.; Marco, Maria; Esquivias, Jorge; Deng, Xiaoyi; White, Karen L.; White, John; Koltun, Maria; El Mazouni, Farah; Kokkonda, Sreekanth; Katneni, Kasiram; Bhamidipati, Ravi; Shackleford, David M.; Angulo-Barturen, Inigo; Ferrer, Santiago B.; Jimenez-Diaz, Maria Belen; Gamo, Francisco-Javier; Goldsmith, Elizabeth J.; Charman, William N.; Bathurst, Ian; Floyd, David; Matthews, David; Burrows, Jeremy N.; Rathod, Pradipsinh K.; Charman, Susan A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5540-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance.  In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.  The X-ray structure of PfDHODH was used to inform the medicinal chem. program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite.  This compd. has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance.  These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compd. toward clin. candidate status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpPPR2Tcs9rVg90H21EOLACvtfcHk0ljPKujL2XXVxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D&md5=d92f71aeda04fbbbbcd8905a657df011</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm200592f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200592f%26sid%3Dliteratum%253Aachs%26aulast%3DCoteron%26aufirst%3DJ.%2BM.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKoltun%26aufirst%3DM.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DBhamidipati%26aufirst%3DR.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%2BB.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DFloyd%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DStructure-guided%2520lead%2520optimization%2520of%2520triazolopyrimidine-ring%2520substituents%2520identifies%2520potent%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520with%2520clinical%2520candidate%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D15%26spage%3D5540%26epage%3D5561%26doi%3D10.1021%2Fjm200592f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span> <span> </span><span class="NLM_article-title">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2012.11-0302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.4269%2Fajtmh.2012.11-0302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22232455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=84-92&issue=1&author=S.+Duffyauthor=V.+M.+Avery&title=Development+and+optimization+of+a+novel+384-well+anti-malarial+imaging+assay+validated+for+high-throughput+screening&doi=10.4269%2Fajtmh.2012.11-0302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span></div><div class="casAuthors">Duffy, Sandra; Avery, Vicky M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">With the increasing occurrence of drug resistance in the malaria parasite, Plasmodium falciparum, there is a great need for new and novel anti-malarial drugs.  We have developed a 384-well, high-throughput imaging assay for the detection of new anti-malarial compds., which was initially validated by screening a marine natural product library, and subsequently used to screen more than 3 million data points from a variety of compd. sources.  Founded on another fluorescence-based P. falciparum growth inhibition assay, the DNA-intercalating dye 4',6-diamidino-2-phenylindole, was used to monitor changes in parasite no.  Fluorescent images were acquired on the PerkinElmer Opera High Throughput confocal imaging system and analyzed with a spot detection algorithm using the Acapella data processing software.  Further optimization of this assay sought to increase throughput, assay stability, and compatibility with our high-throughput screening equipment platforms.  The assay typically yielded Z'-factor values of 0.5-0.6, with signal-to-noise ratios of 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9mpHAvJlL67Vg90H21EOLACvtfcHk0ljPKujL2XXVxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D&md5=60ae874f46758c03566acfdc948e1188</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2012.11-0302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2012.11-0302%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26atitle%3DDevelopment%2520and%2520optimization%2520of%2520a%2520novel%2520384-well%2520anti-malarial%2520imaging%2520assay%2520validated%2520for%2520high-throughput%2520screening%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2012%26volume%3D86%26issue%3D1%26spage%3D84%26epage%3D92%26doi%3D10.4269%2Fajtmh.2012.11-0302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cozar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peishoff, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span> <span> </span><span class="NLM_article-title">Thousands of chemical starting points for antimalarial lead identification</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">305</span>, <span class="refDoi"> DOI: 10.1038/nature09107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature09107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20485427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=305&author=F.-J.+Gamoauthor=L.+M.+Sanzauthor=J.+Vidalauthor=C.+de+Cozarauthor=E.+Alvarezauthor=J.-L.+Lavanderaauthor=D.+E.+Vanderwallauthor=D.+V.+S.+Greenauthor=V.+Kumarauthor=S.+Hasanauthor=J.+R.+Brownauthor=C.+E.+Peishoffauthor=L.+R.+Cardonauthor=J.+F.+Garcia-Bustos&title=Thousands+of+chemical+starting+points+for+antimalarial+lead+identification&doi=10.1038%2Fnature09107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Thousands of chemical starting points for antimalarial lead identification</span></div><div class="casAuthors">Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria is a devastating infection caused by protozoa of the genus Plasmodium.  Drug resistance is widespread, no new chem. class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs.  We screened nearly 2 million compds. in GlaxoSmithKline's chem. library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 μM concn.  More than 8,000 also showed potent activity against the multidrug resistant strain Dd2.  Most (82%) compds. originate from internal company projects and are new to the malaria community.  Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets.  Chem. structures and assocd. data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHijpWK_kBF7Vg90H21EOLACvtfcHk0liQZ3M4LdbsEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D&md5=a1fd8c0b89a5650ecba31f5456928b42</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature09107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09107%26sid%3Dliteratum%253Aachs%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DVidal%26aufirst%3DJ.%26aulast%3Dde%2BCozar%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DLavandera%26aufirst%3DJ.-L.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHasan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26atitle%3DThousands%2520of%2520chemical%2520starting%2520points%2520for%2520antimalarial%2520lead%2520identification%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D305%26doi%3D10.1038%2Fnature09107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guiguemde, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharlow, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowble, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forquer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinley, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derisi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riscoe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span> <span> </span><span class="NLM_article-title">Chemical genetics of Plasmodium falciparum</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nature09099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature09099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20485428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1OjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=311-315&author=W.+A.+Guiguemdeauthor=A.+A.+Shelatauthor=D.+Bouckauthor=S.+Duffyauthor=G.+J.+Crowtherauthor=P.+H.+Davisauthor=D.+C.+Smithsonauthor=M.+Connellyauthor=J.+Clarkauthor=F.+Zhuauthor=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=M.+S.+Martinezauthor=E.+B.+Wilsonauthor=A.+K.+Tripathiauthor=J.+Gutauthor=E.+R.+Sharlowauthor=I.+Bathurstauthor=F.+El+Mazouniauthor=J.+W.+Fowbleauthor=I.+Forquerauthor=P.+L.+McGinleyauthor=S.+Castroauthor=I.+Angulo-Barturenauthor=S.+Ferrerauthor=P.+J.+Rosenthalauthor=J.+L.+Derisiauthor=D.+J.+Sullivanauthor=J.+S.+Lazoauthor=D.+S.+Roosauthor=M.+K.+Riscoeauthor=M.+A.+Phillipsauthor=P.+K.+Rathodauthor=W.+C.+Van+Voorhisauthor=V.+M.+Averyauthor=R.+K.+Guy&title=Chemical+genetics+of+Plasmodium+falciparum&doi=10.1038%2Fnature09099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics of Plasmodium falciparum</span></div><div class="casAuthors">Guiguemde, W. Armand; Shelat, Anang A.; Bouck, David; Duffy, Sandra; Crowther, Gregory J.; Davis, Paul H.; Smithson, David C.; Connelly, Michele; Clark, Julie; Zhu, Fangyi; Jimenez-Diaz, Maria B.; Martinez, Maria S.; Wilson, Emily B.; Tripathi, Abhai K.; Gut, Jiri; Sharlow, Elizabeth R.; Bathurst, Ian; El Mazouni, Farah; Fowble, Joseph W.; Forquer, Isaac; McGinley, Paula L.; Castro, Steve; Angulo-Barturen, Inigo; Ferrer, Santiago; Rosenthal, Philip J.; De Risi, Joseph L.; Sullivan, David J., Jr.; Lazo, John S.; Roos, David S.; Riscoe, Michael K.; Phillips, Margaret A.; Rathod, Pradipsinh K.; Van Voorhis, Wesley C.; Avery, Vicky M.; Guy, R. Kiplin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">311-315</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000 deaths per yr worldwide.  Vaccine development has proved difficult and resistance has emerged for most antimalarial drugs.  To discover new antimalarial chemotypes, we have used a phenotypic forward chem. genetic approach to assay 309,474 chems.  Here we disclose structures and biol. activity of the entire library-many of which showed potent in vitro activity against drug-resistant P. falciparum strains-and detailed profiling of 172 representative candidates.  A reverse chem. genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins.  Phylochemogenetic profiling in several organisms revealed similarities between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum and related protozoans.  One exemplar compd. displayed efficacy in a murine model.  Our findings provide the scientific community with new starting points for malaria drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC5VVynAR2NLVg90H21EOLACvtfcHk0liQZ3M4LdbsEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1OjtL4%253D&md5=b1b838f5e43adeb4de019c3e41c33017</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature09099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09099%26sid%3Dliteratum%253Aachs%26aulast%3DGuiguemde%26aufirst%3DW.%2BA.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DBouck%26aufirst%3DD.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DDavis%26aufirst%3DP.%2BH.%26aulast%3DSmithson%26aufirst%3DD.%2BC.%26aulast%3DConnelly%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DWilson%26aufirst%3DE.%2BB.%26aulast%3DTripathi%26aufirst%3DA.%2BK.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DSharlow%26aufirst%3DE.%2BR.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DFowble%26aufirst%3DJ.%2BW.%26aulast%3DForquer%26aufirst%3DI.%26aulast%3DMcGinley%26aufirst%3DP.%2BL.%26aulast%3DCastro%26aufirst%3DS.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DDerisi%26aufirst%3DJ.%2BL.%26aulast%3DSullivan%26aufirst%3DD.%2BJ.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DRoos%26aufirst%3DD.%2BS.%26aulast%3DRiscoe%26aufirst%3DM.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3DChemical%2520genetics%2520of%2520Plasmodium%2520falciparum%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D311%26epage%3D315%26doi%3D10.1038%2Fnature09099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidebrecht, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulrooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandapani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekland, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcaurelle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span> <span> </span><span class="NLM_article-title">Diversity-oriented synthesis yields a novel lead for the treatment of malaria</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1021/ml200244k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200244k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=112-117&issue=2&author=R.+W.+Heidebrechtauthor=C.+Mulrooneyauthor=C.+P.+Austinauthor=R.+H.+Barkerauthor=J.+A.+Beaudoinauthor=K.+C.-C.+Chengauthor=E.+Comerauthor=S.+Dandapaniauthor=J.+Dickauthor=J.+R.+Duvallauthor=E.+H.+Eklandauthor=D.+A.+Fidockauthor=M.+E.+Fitzgeraldauthor=M.+Foleyauthor=R.+Guhaauthor=P.+Hinksonauthor=M.+Kramerauthor=A.+K.+Lukensauthor=D.+Masiauthor=L.+A.+Marcaurelleauthor=X.-Z.+Suauthor=C.+J.+Thomasauthor=M.+We%C3%AFwerauthor=R.+C.+Wiegandauthor=D.+Wirthauthor=M.+Xiaauthor=J.+Yuanauthor=J.+Zhaoauthor=M.+Palmerauthor=B.+Munozauthor=S.+Schreiber&title=Diversity-oriented+synthesis+yields+a+novel+lead+for+the+treatment+of+malaria&doi=10.1021%2Fml200244k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria</span></div><div class="casAuthors">Heidebrecht, Richard W., Jr.; Mulrooney, Carol; Austin, Christopher P.; Barker, Robert H., Jr.; Beaudoin, Jennifer A.; Cheng, Ken Chih-Chien; Comer, Eamon; Dandapani, Sivaraman; Dick, Justin; Duvall, Jeremy R.; Ekland, Eric H.; Fidock, David A.; Fitzgerald, Mark E.; Foley, Michael; Guha, Rajarshi; Hinkson, Paul; Kramer, Martin; Lukens, Amanda K.; Masi, Daniela; Marcaurelle, Lisa A.; Su, Xin-Zhuan; Thomas, Craig J.; Weiwer, Michel; Wiegand, Roger C.; Wirth, Dyann; Xia, Menghang; Yuan, Jing; Zhao, Jinghua; Palmer, Michelle; Munoz, Benito; Schreiber, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-117</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, the discovery of a novel antimalarial agent using phenotypic screening of Plasmodium falciparum asexual blood-stage parasites is described.  Screening a novel compd. collection created using diversity-oriented synthesis (DOS) led to the initial hit.  Structure-activity relationships guided the synthesis of compds. having improved potency and water soly., yielding a subnanomolar inhibitor of parasite asexual blood-stage growth.  Optimized compd. I has an excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable in human plasma.  This compd. is available via the mol. libraries probe prodn. centers network (MLPCN) and is designated ML238.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7VDOEDURT07Vg90H21EOLACvtfcHk0lhhZRm6cLVfww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLbP&md5=543bf89bfbc03ef58ef4379718f1b0e1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml200244k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200244k%26sid%3Dliteratum%253Aachs%26aulast%3DHeidebrecht%26aufirst%3DR.%2BW.%26aulast%3DMulrooney%26aufirst%3DC.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DBarker%26aufirst%3DR.%2BH.%26aulast%3DBeaudoin%26aufirst%3DJ.%2BA.%26aulast%3DCheng%26aufirst%3DK.%2BC.-C.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DDandapani%26aufirst%3DS.%26aulast%3DDick%26aufirst%3DJ.%26aulast%3DDuvall%26aufirst%3DJ.%2BR.%26aulast%3DEkland%26aufirst%3DE.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DFitzgerald%26aufirst%3DM.%2BE.%26aulast%3DFoley%26aufirst%3DM.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DHinkson%26aufirst%3DP.%26aulast%3DKramer%26aufirst%3DM.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DMasi%26aufirst%3DD.%26aulast%3DMarcaurelle%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DX.-Z.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DWiegand%26aufirst%3DR.%2BC.%26aulast%3DWirth%26aufirst%3DD.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DSchreiber%26aufirst%3DS.%26atitle%3DDiversity-oriented%2520synthesis%2520yields%2520a%2520novel%2520lead%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D2%26spage%3D112%26epage%3D117%26doi%3D10.1021%2Fml200244k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maetani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancucci, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derbyshire, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dornan, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoe, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibalan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitasev, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gessel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catteruccia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusovsky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neafsey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Diversity-oriented synthesis yields novel multistage antimalarial inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>538</i></span> (<span class="NLM_issue">7625</span>),  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1038/nature19804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature19804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27602946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=538&publication_year=2016&pages=344-349&issue=7625&author=N.+Katoauthor=E.+Comerauthor=T.+Sakata-Katoauthor=A.+Sharmaauthor=M.+Sharmaauthor=M.+Maetaniauthor=J.+Bastienauthor=N.+M.+Brancucciauthor=J.+A.+Bittkerauthor=V.+Coreyauthor=D.+Clarkeauthor=E.+R.+Derbyshireauthor=G.+L.+Dornanauthor=S.+Duffyauthor=S.+Eckleyauthor=M.+A.+Itoeauthor=K.+M.+Koolenauthor=T.+A.+Lewisauthor=P.+S.+Luiauthor=A.+K.+Lukensauthor=E.+Lundauthor=S.+Marchauthor=E.+Meibalanauthor=B.+C.+Meierauthor=J.+A.+McPhailauthor=B.+Mitasevauthor=E.+L.+Mossauthor=M.+Sayesauthor=Y.+Van+Gesselauthor=M.+J.+Wawerauthor=T.+Yoshinagaauthor=A.+M.+Zeemanauthor=V.+M.+Averyauthor=S.+N.+Bhatiaauthor=J.+E.+Burkeauthor=F.+Catterucciaauthor=J.+C.+Clardyauthor=P.+A.+Clemonsauthor=K.+J.+Decheringauthor=J.+R.+Duvallauthor=M.+A.+Foleyauthor=F.+Gusovskyauthor=C.+H.+Kockenauthor=M.+Martiauthor=M.+L.+Morningstarauthor=B.+Munozauthor=D.+E.+Neafseyauthor=A.+Sharmaauthor=E.+A.+Winzelerauthor=D.+F.+Wirthauthor=C.+A.+Schererauthor=S.+L.+Schreiber&title=Diversity-oriented+synthesis+yields+novel+multistage+antimalarial+inhibitors&doi=10.1038%2Fnature19804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-oriented synthesis yields novel multistage antimalarial inhibitors</span></div><div class="casAuthors">Kato, Nobutaka; Comer, Eamon; Sakata-Kato, Tomoyo; Sharma, Arvind; Sharma, Manmohan; Maetani, Micah; Bastien, Jessica; Brancucci, Nicolas M.; Bittker, Joshua A.; Corey, Victoria; Clarke, David; Derbyshire, Emily R.; Dornan, Gillian L.; Duffy, Sandra; Eckley, Sean; Itoe, Maurice A.; Koolen, Karin M. J.; Lewis, Timothy A.; Lui, Ping S.; Lukens, Amanda K.; Lund, Emily; March, Sandra; Meibalan, Elamaran; Meier, Bennett C.; McPhail, Jacob A.; Mitasev, Branko; Moss, Eli L.; Sayes, Morgane; Van Gessel, Yvonne; Wawer, Mathias J.; Yoshinaga, Takashi; Zeeman, Anne-Marie; Avery, Vicky M.; Bhatia, Sangeeta N.; Burke, John E.; Catteruccia, Flaminia; Clardy, Jon C.; Clemons, Paul A.; Dechering, Koen J.; Duvall, Jeremy R.; Foley, Michael A.; Gusovsky, Fabian; Kocken, Clemens H. M.; Marti, Matthias; Morningstar, Marshall L.; Munoz, Benito; Neafsey, Daniel E.; Sharma, Amit; Winzeler, Elizabeth A.; Wirth, Dyann F.; Scherer, Christina A.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">538</span>
        (<span class="NLM_cas:issue">7625</span>),
    <span class="NLM_cas:pages">344-349</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compds.  Here the authors investigate whether antimalarial agents with novel mechanisms of action could be discovered using a diverse collection of synthetic compds. that have three-dimensional features reminiscent of natural products and are underrepresented in typical screening collections.  The authors report the identification of such compds. with both previously reported and undescribed mechanisms of action, including a series of bicyclic azetidines that inhibit a new antimalarial target, phenylalanyl-tRNA synthetase.  These mols. are curative in mice at a single, low dose and show activity against all parasite life stages in multiple in vivo efficacy models.  The authors' findings identify bicyclic azetidines with the potential to both cure and prevent transmission of the disease as well as protect at-risk populations with a single oral dose, highlighting the strength of diversity-oriented synthesis in revealing promising therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9CdwKMqzmhLVg90H21EOLACvtfcHk0lgUcwbmNZevTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWhsLrI&md5=68e6e2018f2d49278d255ee02bfc8d16</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature19804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19804%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DN.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DMaetani%26aufirst%3DM.%26aulast%3DBastien%26aufirst%3DJ.%26aulast%3DBrancucci%26aufirst%3DN.%2BM.%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DD.%26aulast%3DDerbyshire%26aufirst%3DE.%2BR.%26aulast%3DDornan%26aufirst%3DG.%2BL.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DEckley%26aufirst%3DS.%26aulast%3DItoe%26aufirst%3DM.%2BA.%26aulast%3DKoolen%26aufirst%3DK.%2BM.%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DLui%26aufirst%3DP.%2BS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DLund%26aufirst%3DE.%26aulast%3DMarch%26aufirst%3DS.%26aulast%3DMeibalan%26aufirst%3DE.%26aulast%3DMeier%26aufirst%3DB.%2BC.%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DMitasev%26aufirst%3DB.%26aulast%3DMoss%26aufirst%3DE.%2BL.%26aulast%3DSayes%26aufirst%3DM.%26aulast%3DVan%2BGessel%26aufirst%3DY.%26aulast%3DWawer%26aufirst%3DM.%2BJ.%26aulast%3DYoshinaga%26aufirst%3DT.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DCatteruccia%26aufirst%3DF.%26aulast%3DClardy%26aufirst%3DJ.%2BC.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DDuvall%26aufirst%3DJ.%2BR.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DGusovsky%26aufirst%3DF.%26aulast%3DKocken%26aufirst%3DC.%2BH.%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMorningstar%26aufirst%3DM.%2BL.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DNeafsey%26aufirst%3DD.%2BE.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DScherer%26aufirst%3DC.%2BA.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DDiversity-oriented%2520synthesis%2520yields%2520novel%2520multistage%2520antimalarial%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D538%26issue%3D7625%26spage%3D344%26epage%3D349%26doi%3D10.1038%2Fnature19804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trager, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">9059</span>– <span class="NLM_lpage">9064</span>, <span class="refDoi"> DOI: 10.1073/pnas.0802982105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.0802982105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18579783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=9059-9064&issue=26&author=D.+Plouffeauthor=A.+Brinkerauthor=C.+McNamaraauthor=K.+Hensonauthor=N.+Katoauthor=K.+Kuhenauthor=A.+Nagleauthor=F.+Adrianauthor=J.+T.+Matzenauthor=P.+Andersonauthor=T.+G.+Namauthor=N.+S.+Grayauthor=A.+Chatterjeeauthor=J.+Janesauthor=S.+F.+Yanauthor=R.+Tragerauthor=J.+S.+Caldwellauthor=P.+G.+Schultzauthor=Y.+Zhouauthor=E.+A.+Winzeler&title=In+silico+activity+profiling+reveals+the+mechanism+of+action+of+antimalarials+discovered+in+a+high-throughput+screen&doi=10.1073%2Fpnas.0802982105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen</span></div><div class="casAuthors">Plouffe, David; Brinker, Achim; McNamara, Case; Henson, Kerstin; Kato, Nobutaka; Kuhen, Kelli; Nagle, Advait; Adrian, Francisco; Matzen, Jason T.; Anderson, Paul; Nam, Tae-gyu; Gray, Nathanael S.; Chatterjee, Arnab; Janes, Jeff; Yan, S. Frank; Trager, Richard; Caldwell, Jeremy S.; Schultz, Peter G.; Zhou, Yingyao; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9059-9064</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The growing resistance to current first-line antimalarial drugs represents a major health challenge.  To facilitate the discovery of new antimalarials, we have implemented an efficient and robust high-throughput cell-based screen (1,536-well format) based on proliferation of Plasmodium falciparum (Pf) in erythrocytes.  From a screen of ≈ 1.7 million compds., we identified a diverse collection of ≈ 6,000 small mols. comprised of > 530 distinct scaffolds, all of which show potent antimalarial activity (< 1.25 μM).  Most known antimalarials were identified in this screen, thus validating our approach.  In addn., we identified many novel chem. scaffolds, which likely act through both known and novel pathways.  We further show that in some cases the mechanism of action of these antimalarials can be detd. by in silico compd. activity profiling.  This method uses large datasets from unrelated cellular and biochem. screens and the guilt-by-assocn. principle to predict which cellular pathway and/or protein target is being inhibited by select compds.  In addn., the screening method has the potential to provide the malaria community with many new starting points for the development of biol. probes and drugs with novel antiparasitic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL9PFy0SUhdbVg90H21EOLACvtfcHk0livR-rIhrtXwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCiurw%253D&md5=bf14f093078c982e3604089588827166</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802982105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802982105%26sid%3Dliteratum%253Aachs%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DBrinker%26aufirst%3DA.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DHenson%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DAnderson%26aufirst%3DP.%26aulast%3DNam%26aufirst%3DT.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DTrager%26aufirst%3DR.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DIn%2520silico%2520activity%2520profiling%2520reveals%2520the%2520mechanism%2520of%2520action%2520of%2520antimalarials%2520discovered%2520in%2520a%2520high-throughput%2520screen%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D26%26spage%3D9059%26epage%3D9064%26doi%3D10.1073%2Fpnas.0802982105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiplin, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRisi, J. L.</span></span> <span> </span><span class="NLM_article-title">Searching for new antimalarial therapeutics amongst known drugs</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2006.00391.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1111%2Fj.1747-0285.2006.00391.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16882315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=409-416&author=J.+L.+Weismanauthor=A.+P.+Liouauthor=A.+A.+Shelatauthor=F.+E.+Cohenauthor=R.+G.+Kiplinauthor=J.+L.+DeRisi&title=Searching+for+new+antimalarial+therapeutics+amongst+known+drugs&doi=10.1111%2Fj.1747-0285.2006.00391.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Searching for new antimalarial therapeutics amongst known drugs</span></div><div class="casAuthors">Weisman, Jennifer L.; Liou, Ally P.; Shelat, Anang A.; Cohen, Fred E.; Guy, R. Kiplin; DeRisi, Joseph L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">409-416</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The need to discover and develop new antimalarial therapeutics is overwhelming.  The annual mortality attributed to malaria, currently approx. 2.5 million, is increasing due primarily to widespread resistance to currently used drugs.  One strategy to identify new treatment alternatives for malaria is to examine libraries of diverse compds. for the possible identification of novel scaffolds.  Beginning with libraries of drug or drug-like compds. is an ideal starting point because, in the case of approved drugs, substantial pharmacokinetic and toxicol. data should be available for each compd. series.  The authors have employed a highthroughput screen of the MicroSource Spectrum and Killer Collections, a library of known drugs, bioactive compds., and natural products.  Our screening assay identifies compds. that inhibit growth of Plasmodium falciparum cultured in human erythrocytes.  The authors have identified 36 novel inhibitors of P. falciparum, of which 19 are therapeutics, and five of these drugs exhibit effective 50% inhibitory concns. within similar ranges to therapeutic serum concns. for their recently indicated uses: propafenone, thioridazine, chlorprothixene, perhexiline, and azlocillin.  The findings the authors report here indicate that this is an effective strategy to identify novel scaffolds and therefore aid in antimalarial drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMk7-TJgPPKrVg90H21EOLACvtfcHk0lgM7gNTvSXDEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVKrtbg%253D&md5=594c50ba27e74542137496a542b1bba9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2006.00391.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2006.00391.x%26sid%3Dliteratum%253Aachs%26aulast%3DWeisman%26aufirst%3DJ.%2BL.%26aulast%3DLiou%26aufirst%3DA.%2BP.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DF.%2BE.%26aulast%3DKiplin%26aufirst%3DR.%2BG.%26aulast%3DDeRisi%26aufirst%3DJ.%2BL.%26atitle%3DSearching%2520for%2520new%2520antimalarial%2520therapeutics%2520amongst%2520known%2520drugs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D409%26epage%3D416%26doi%3D10.1111%2Fj.1747-0285.2006.00391.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaradilokrat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellems, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. Z.</span></span> <span> </span><span class="NLM_article-title">Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>333</i></span> (<span class="NLM_issue">6043</span>),  <span class="NLM_fpage">724</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1126/science.1205216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1205216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21817045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1SgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2011&pages=724-729&issue=6043&author=J.+Yuanauthor=K.+C.+Chengauthor=R.+L.+Johnsonauthor=R.+Huangauthor=S.+Pattaradilokratauthor=A.+Liuauthor=R.+Guhaauthor=D.+A.+Fidockauthor=J.+Ingleseauthor=T.+E.+Wellemsauthor=C.+P.+Austinauthor=X.+Z.+Su&title=Chemical+genomic+profiling+for+antimalarial+therapies%2C+response+signatures%2C+and+molecular+targets&doi=10.1126%2Fscience.1205216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets</span></div><div class="casAuthors">Yuan, Jing; Cheng, Ken Chih-Chien; Johnson, Ronald L.; Huang, Ruili; Pattaradilokrat, Sittiporn; Liu, Anna; Guha, Rajarshi; Fidock, David A.; Inglese, James; Wellems, Thomas E.; Austin, Christopher P.; Su, Xin-zhuan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">6043</span>),
    <span class="NLM_cas:pages">724-729</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Malaria remains a devastating disease largely because of widespread drug resistance.  New drugs and a better understanding of the mechanisms of drug action and resistance are essential for fulfilling the promise of eradicating malaria.  Using high-throughput chem. screening and genome-wide assocn. anal., we identified 32 highly active compds. and genetic loci assocd. with differential chem. phenotypes (DCPs), defined as greater than or equal to fivefold differences in half-max. inhibitor concn. (IC50) between parasite lines.  Chromosomal loci assocd. with 49 DCPs were confirmed by linkage anal. and tests of genetically modified parasites, including three genes that were linked to 96% of the DCPs.  Drugs whose responses mapped to wild-type or mutant pfcrt alleles were tested in combination in vitro and in vivo, which yielded promising new leads for antimalarial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6k7L-fLswrrVg90H21EOLACvtfcHk0lgM7gNTvSXDEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1SgtbY%253D&md5=e027070abade3470d3630b842a7c9331</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.1205216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1205216%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DJohnson%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DPattaradilokrat%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DWellems%26aufirst%3DT.%2BE.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DSu%26aufirst%3DX.%2BZ.%26atitle%3DChemical%2520genomic%2520profiling%2520for%2520antimalarial%2520therapies%252C%2520response%2520signatures%252C%2520and%2520molecular%2520targets%26jtitle%3DScience%26date%3D2011%26volume%3D333%26issue%3D6043%26spage%3D724%26epage%3D729%26doi%3D10.1126%2Fscience.1205216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luth, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jado, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaumeau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eribez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambachew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouillier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Open-source discovery of chemical leads for next-generation chemoprotective antimalarials</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span> (<span class="NLM_issue">6419</span>),  <span class="NLM_fpage">eaat9446</span>, <span class="refDoi"> DOI: 10.1126/science.aat9446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.aat9446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30523084" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&pages=eaat9446&issue=6419&author=Y.+Antonova-Kochauthor=S.+Meisterauthor=M.+Abrahamauthor=M.+R.+Luthauthor=S.+Ottilieauthor=A.+K.+Lukensauthor=T.+Sakata-Katoauthor=M.+Vanaerschotauthor=E.+Owenauthor=J.+C.+Jadoauthor=S.+P.+Maherauthor=J.+Callaauthor=D.+Plouffeauthor=Y.+Zhongauthor=K.+Chenauthor=V.+Chaumeauauthor=A.+J.+Conwayauthor=C.+W.+McNamaraauthor=M.+Ibanezauthor=K.+Gagaringauthor=F.+N.+Serranoauthor=K.+Eribezauthor=C.+M.+Taggardauthor=A.+L.+Cheungauthor=C.+Lincolnauthor=B.+Ambachewauthor=M.+Rouillierauthor=D.+Siegelauthor=F.+Nostenauthor=D.+E.+Kyleauthor=F.+J.+Gamoauthor=Y.+Zhouauthor=M.+Llinasauthor=D.+A.+Fidockauthor=D.+F.+Wirthauthor=J.+Burrowsauthor=B.+Campoauthor=E.+A.+Winzeler&title=Open-source+discovery+of+chemical+leads+for+next-generation+chemoprotective+antimalarials&doi=10.1126%2Fscience.aat9446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat9446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat9446%26sid%3Dliteratum%253Aachs%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLuth%26aufirst%3DM.%2BR.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DE.%26aulast%3DJado%26aufirst%3DJ.%2BC.%26aulast%3DMaher%26aufirst%3DS.%2BP.%26aulast%3DCalla%26aufirst%3DJ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChaumeau%26aufirst%3DV.%26aulast%3DConway%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DSerrano%26aufirst%3DF.%2BN.%26aulast%3DEribez%26aufirst%3DK.%26aulast%3DTaggard%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DA.%2BL.%26aulast%3DLincoln%26aufirst%3DC.%26aulast%3DAmbachew%26aufirst%3DB.%26aulast%3DRouillier%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DOpen-source%2520discovery%2520of%2520chemical%2520leads%2520for%2520next-generation%2520chemoprotective%2520antimalarials%26jtitle%3DScience%26date%3D2018%26volume%3D362%26issue%3D6419%26spage%3Deaat9446%26doi%3D10.1126%2Fscience.aat9446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Blanco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straschil, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueda-Zubiaurre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, J.</span></span> <span> </span><span class="NLM_article-title">A high throughput screen for next-generation leads targeting malaria parasite transmission</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3805</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05777-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fs41467-018-05777-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30228275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BB3czgtFSlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3805&author=M.+J.+Delvesauthor=C.+Miguel-Blancoauthor=H.+Matthewsauthor=I.+Molinaauthor=A.+Rueckerauthor=S.+Yahiyaauthor=U.+Straschilauthor=M.+Abrahamauthor=M.+L.+Le%C3%B3nauthor=O.+J.+Fischerauthor=A.+Rueda-Zubiaurreauthor=J.+R.+Brandtauthor=%C3%81.+Cort%C3%A9sauthor=A.+Barnardauthor=M.+J.+Fuchterauthor=F.+Calder%C3%B3nauthor=E.+A.+Winzelerauthor=R.+E.+Sindenauthor=E.+Herrerosauthor=F.+J.+Gamoauthor=J.+Baum&title=A+high+throughput+screen+for+next-generation+leads+targeting+malaria+parasite+transmission&doi=10.1038%2Fs41467-018-05777-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A high throughput screen for next-generation leads targeting malaria parasite transmission</span></div><div class="casAuthors">Delves Michael J; Miguel-Blanco Celia; Matthews Holly; Ruecker Andrea; Yahiya Sabrina; Straschil Ursula; Sinden Robert E; Baum Jake; Miguel-Blanco Celia; Molina Irene; Leon Maria Luisa; Cortes Alvaro; Calderon Felix; Herreros Esperanza; Gamo Francisco J; Abraham Matthew; Winzeler Elizabeth A; Fischer Oliver J; Rueda-Zubiaurre Ainoa; Brandt Jochen R; Barnard Anna; Fuchter Matthew J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3805</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spread of parasite resistance to artemisinin threatens current frontline antimalarial therapies, highlighting the need for new drugs with alternative modes of action.  Since only 0.2-1% of asexual parasites differentiate into sexual, transmission-competent forms, targeting this natural bottleneck provides a tangible route to interrupt disease transmission and mitigate resistance selection.  Here we present a high-throughput screen of gametogenesis against a ~70,000 compound diversity library, identifying seventeen drug-like molecules that target transmission.  Hit molecules possess varied activity profiles including male-specific, dual acting male-female and dual-asexual-sexual, with one promising N-((4-hydroxychroman-4-yl)methyl)-sulphonamide scaffold found to have sub-micromolar activity in vitro and in vivo efficacy.  Development of leads with modes of action focussed on the sexual stages of malaria parasite development provide a previously unexplored base from which future therapeutics can be developed, capable of preventing parasite transmission through the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRm0WpjOO-yVDUE-swuRqsHfW6udTcc2eYapRw4zMvyv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czgtFSlsg%253D%253D&md5=d62b545c247a6ef26d1521aea097d629</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05777-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05777-2%26sid%3Dliteratum%253Aachs%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DMiguel-Blanco%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DYahiya%26aufirst%3DS.%26aulast%3DStraschil%26aufirst%3DU.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLe%25C3%25B3n%26aufirst%3DM.%2BL.%26aulast%3DFischer%26aufirst%3DO.%2BJ.%26aulast%3DRueda-Zubiaurre%26aufirst%3DA.%26aulast%3DBrandt%26aufirst%3DJ.%2BR.%26aulast%3DCort%25C3%25A9s%26aufirst%3D%25C3%2581.%26aulast%3DBarnard%26aufirst%3DA.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DCalder%25C3%25B3n%26aufirst%3DF.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DSinden%26aufirst%3DR.%2BE.%26aulast%3DHerreros%26aufirst%3DE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DBaum%26aufirst%3DJ.%26atitle%3DA%2520high%2520throughput%2520screen%2520for%2520next-generation%2520leads%2520targeting%2520malaria%2520parasite%2520transmission%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3805%26doi%3D10.1038%2Fs41467-018-05777-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derbyshire, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Liver-stage malaria parasites vulnerable to diverse chemical scaffolds</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8511</span>– <span class="NLM_lpage">8516</span>, <span class="refDoi"> DOI: 10.1073/pnas.1118370109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.1118370109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22586124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=8511-8516&issue=22&author=E.+R.+Derbyshireauthor=M.+Prudencioauthor=M.+M.+Motaauthor=J.+Clardy&title=Liver-stage+malaria+parasites+vulnerable+to+diverse+chemical+scaffolds&doi=10.1073%2Fpnas.1118370109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Liver-stage malaria parasites vulnerable to diverse chemical scaffolds</span></div><div class="casAuthors">Derbyshire, Emily R.; Prudencio, Miguel; Mota, Maria M.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8511-8516, S8511/1-S8511/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human malaria infection begins with a one-time asymptomatic liver stage followed by a cyclic symptomatic blood stage.  All high-throughput malaria drug discovery efforts have focused on the cyclic blood stage, which has limited potential for the prophylaxis, transmission blocking, and eradication efforts that will be needed in the future.  To address these unmet needs, a high-throughput phenotypic liver-stage Plasmodium parasite screen was developed to systematically identify mols. with liver-stage efficacy.  The screen recapitulates liver-stage infection by isolating luciferase-expressing Plasmodium berghei parasites directly from the salivary glands of infected mosquitoes, adding them to confluent human liver cells in 384-well plates, and measuring luciferase activity after a suitable incubation period.  Screening 5,375 known bioactive compds. identified 37 liver-stage malaria inhibitors with diverse modes of action, as shown by inhibition time course expts.  Further anal. of the hits in the Food and Drug Administration-approved drug subset revealed compds. that seem to act specifically on the liver stage of infection, suggesting that this phase of the parasite's life cycle presents a promising area for new drug discovery.  Notably, many active compds. in this screen have mol. structures and putative targets distinctly different from those of known antimalarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKUwSlcR8EYbVg90H21EOLACvtfcHk0ljn3IRl_x4Y7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslKhtLY%253D&md5=0d0a920537afd794d6c98836c1ded5b4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1118370109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1118370109%26sid%3Dliteratum%253Aachs%26aulast%3DDerbyshire%26aufirst%3DE.%2BR.%26aulast%3DPrudencio%26aufirst%3DM.%26aulast%3DMota%26aufirst%3DM.%2BM.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DLiver-stage%2520malaria%2520parasites%2520vulnerable%2520to%2520diverse%2520chemical%2520scaffolds%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D22%26spage%3D8511%26epage%3D8516%26doi%3D10.1073%2Fpnas.1118370109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bopp, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, T.-g.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">6061</span>),  <span class="NLM_fpage">1372</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1126/science.1211936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1211936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22096101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=1372-1377&issue=6061&author=S.+Meisterauthor=D.+M.+Plouffeauthor=K.+L.+Kuhenauthor=G.+M.+C.+Bonamyauthor=T.+Wuauthor=S.+W.+Barnesauthor=S.+E.+Boppauthor=R.+Borboaauthor=A.+T.+Brightauthor=J.+Cheauthor=S.+Cohenauthor=N.+V.+Dhariaauthor=K.+Gagaringauthor=M.+Gettayacaminauthor=P.+Gordonauthor=T.+Groesslauthor=N.+Katoauthor=M.+C.+S.+Leeauthor=C.+W.+McNamaraauthor=D.+A.+Fidockauthor=A.+Nagleauthor=T.-g.+Namauthor=W.+Richmondauthor=J.+Rolandauthor=M.+Rottmannauthor=B.+Zhouauthor=P.+Froissardauthor=R.+J.+Glynneauthor=D.+Mazierauthor=J.+Sattabongkotauthor=P.+G.+Schultzauthor=T.+Tuntlandauthor=J.+R.+Walkerauthor=Y.+Zhouauthor=A.+Chatterjeeauthor=T.+T.+Diaganaauthor=E.+A.+Winzeler&title=Imaging+of+Plasmodium+liver+stages+to+drive+next-generation+antimalarial+drug+discovery&doi=10.1126%2Fscience.1211936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery</span></div><div class="casAuthors">Meister, Stephan; Plouffe, David M.; Kuhen, Kelli L.; Bonamy, Ghislain M. C.; Wu, Tao; Barnes, S. Whitney; Bopp, Selina E.; Borboa, Rachel; Bright, A. Taylor; Che, Jianwei; Cohen, Steve; Dharia, Neekesh V.; Gagaring, Kerstin; Gettayacamin, Montip; Gordon, Perry; Groessl, Todd; Kato, Nobutaka; Lee, Marcus C. S.; McNamara, Case W.; Fidock, David A.; Nagle, Advait; Nam, Tae-gyu; Richmond, Wendy; Roland, Jason; Rottmann, Matthias; Zhou, Bin; Froissard, Patrick; Glynne, Richard J.; Mazier, Dominique; Sattabongkot, Jetsumon; Schultz, Peter G.; Tuntland, Tove; Walker, John R.; Zhou, Yingyao; Chatterjee, Arnab; Diagana, Thierry T.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6061</span>),
    <span class="NLM_cas:pages">1372-1377</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Most malaria drug development focuses on parasite stages detected in red blood cells, even though, to achieve eradication, next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable.  We applied a multifactorial approach to a set of >4000 com. available compds. with previously demonstrated blood-stage activity (median inhibitory concn. < 1 micromolar) and identified chem. scaffolds with potent activity against both forms.  From this screen, we identified an imidazolopiperazine scaffold series that was highly enriched among compds. active against Plasmodium liver stages.  The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 mg/kg) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity.  The open-source chem. tools resulting from our effort provide starting points for future drug discovery programs, as well as opportunities for researchers to investigate the biol. of exo-erythrocytic forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyO41naZtcdrVg90H21EOLACvtfcHk0ljuaq4dB_N9Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN&md5=45b2993be36e36eabe1d9280c86c3db2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211936%26sid%3Dliteratum%253Aachs%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%2BC.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DBopp%26aufirst%3DS.%2BE.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBright%26aufirst%3DA.%2BT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DNam%26aufirst%3DT.-g.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DRoland%26aufirst%3DJ.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFroissard%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DMazier%26aufirst%3DD.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DImaging%2520of%2520Plasmodium%2520liver%2520stages%2520to%2520drive%2520next-generation%2520antimalarial%2520drug%2520discovery%26jtitle%3DScience%26date%3D2011%26volume%3D334%26issue%3D6061%26spage%3D1372%26epage%3D1377%26doi%3D10.1126%2Fscience.1211936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Blanco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardera, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de las Heras, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colmenarejo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Martínez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreros, E.</span></span> <span> </span><span class="NLM_article-title">Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15160</span>, <span class="refDoi"> DOI: 10.1038/ncomms15160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fncomms15160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28513586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15160&author=C.+Miguel-Blancoauthor=I.+Molinaauthor=A.+I.+Barderaauthor=B.+D%C3%ADazauthor=L.+de+las+Herasauthor=S.+Lozanoauthor=C.+Gonz%C3%A1lezauthor=J.+Rodriguesauthor=M.+J.+Delvesauthor=A.+Rueckerauthor=G.+Colmenarejoauthor=S.+Vieraauthor=M.+S.+Mart%C3%ADnez-Mart%C3%ADnezauthor=E.+Fern%C3%A1ndezauthor=J.+Baumauthor=R.+E.+Sindenauthor=E.+Herreros&title=Hundreds+of+dual-stage+antimalarial+molecules+discovered+by+a+functional+gametocyte+screen&doi=10.1038%2Fncomms15160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen</span></div><div class="casAuthors">Miguel-Blanco, Celia; Molina, Irene; Bardera, Ana I.; Diaz, Beatriz; de las Heras, Laura; Lozano, Sonia; Gonzalez, Carolina; Rodrigues, Janneth; Delves, Michael J.; Ruecker, Andrea; Colmenarejo, Gonzalo; Viera, Sara; Martinez-Martinez, Maria S.; Fernandez, Esther; Baum, Jake; Sinden, Robert E.; Herreros, Esperanza</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15160</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Plasmodium falciparum stage V gametocytes are responsible for parasite transmission, and drugs targeting this stage are needed to support malaria elimination.  We here screen the Tres Cantos Antimalarial Set (TCAMS) using the previously developed P. falciparum female gametocyte activation assay (Pf FGAA), which assesses stage V female gametocyte viability and functionality using Pfs25 expression.  We identify over 400 compds. with activities <2 μM, chem. classified into 57 clusters and 33 singletons.  Up to 68% of the hits are chemotypes described for the first time as late-stage gametocyte-targeting mols.  In addn., the biol. profile of 90 compds. representing the chem. diversity is assessed.  We confirm in vitro transmission-blocking activity of four of the six selected mols. belonging to three distinct scaffold clusters.  Overall, this TCAMS gametocyte screen provides 276 promising antimalarial mols. with dual asexual/sexual activity, representing starting points for target identification and candidate selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplYIJfzE0ttLVg90H21EOLACvtfcHk0ljuaq4dB_N9Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGlsrk%253D&md5=906ab6be730f22c19e27a926e3b2e075</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fncomms15160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15160%26sid%3Dliteratum%253Aachs%26aulast%3DMiguel-Blanco%26aufirst%3DC.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DBardera%26aufirst%3DA.%2BI.%26aulast%3DD%25C3%25ADaz%26aufirst%3DB.%26aulast%3Dde%2Blas%2BHeras%26aufirst%3DL.%26aulast%3DLozano%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DC.%26aulast%3DRodrigues%26aufirst%3DJ.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DColmenarejo%26aufirst%3DG.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DMart%25C3%25ADnez-Mart%25C3%25ADnez%26aufirst%3DM.%2BS.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DBaum%26aufirst%3DJ.%26aulast%3DSinden%26aufirst%3DR.%2BE.%26aulast%3DHerreros%26aufirst%3DE.%26atitle%3DHundreds%2520of%2520dual-stage%2520antimalarial%2520molecules%2520discovered%2520by%2520a%2520functional%2520gametocyte%2520screen%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15160%26doi%3D10.1038%2Fncomms15160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maetani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span> <span> </span><span class="NLM_article-title">High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.5b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.5b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=281-293&issue=4&author=J.+Swannauthor=V.+Coreyauthor=C.+A.+Schererauthor=N.+Katoauthor=E.+Comerauthor=M.+Maetaniauthor=Y.+Antonova-Kochauthor=C.+Reimerauthor=K.+Gagaringauthor=M.+Ibanezauthor=D.+Plouffeauthor=A.+M.+Zeemanauthor=C.+H.+Kockenauthor=C.+W.+McNamaraauthor=S.+L.+Schreiberauthor=B.+Campoauthor=E.+A.+Winzelerauthor=S.+Meister&title=High-throughput+luciferase-based+assay+for+the+discovery+of+therapeutics+that+prevent+malaria&doi=10.1021%2Facsinfecdis.5b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria</span></div><div class="casAuthors">Swann, Justine; Corey, Victoria; Scherer, Christina A.; Kato, Nobutaka; Comer, Eamon; Maetani, Micah; Antonova-Koch, Yevgeniya; Reimer, Christin; Gagaring, Kerstin; Ibanez, Maureen; Plouffe, David; Zeeman, Anne-Marie; Kocken, Clemens H. M.; McNamara, Case W.; Schreiber, Stuart L.; Campo, Brice; Winzeler, Elizabeth A.; Meister, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">281-293</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to identify the most attractive starting points for drugs that can be used to prevent malaria, a diverse chem. space comprising tens of thousands to millions of small mols. may need to be examd.  Achieving this throughput necessitates the development of efficient ultra-high-throughput screening methods.  Here, the authors report the development and evaluation of a luciferase-based phenotypic screen of malaria exoerythrocytic-stage parasites optimized for a 1536-well format.  This assay uses the exoerythrocytic stage of the rodent malaria parasite, Plasmodium berghei, and a human hepatoma cell line.  The authors use this assay to evaluate several biased and unbiased compd. libraries, including two small sets of mols. (400 and 89 compds., resp.) with known activity against malaria erythrocytic-stage parasites and a set of 9886 diversity-oriented synthesis (DOS)-derived compds.  Of the compds. screened, the authors obtain hit rates of 12-13 and 0.6% in preselected and naive libraries, resp., and identify 52 compds. with exoerythrocytic-stage activity less than 1 μM and having minimal host cell toxicity.  The data demonstrate the ability of this method to identify compds. known to have causal prophylactic activity in both human and animal models of malaria, as well as novel compds., including some exclusively active against parasite exoerythrocytic stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4sAMW8HfXO7Vg90H21EOLACvtfcHk0liLO47__IISxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit12nsr4%253D&md5=b9bd0256f0c8e80469a712f2492c6106</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.5b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.5b00143%26sid%3Dliteratum%253Aachs%26aulast%3DSwann%26aufirst%3DJ.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DScherer%26aufirst%3DC.%2BA.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DMaetani%26aufirst%3DM.%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%2BH.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DMeister%26aufirst%3DS.%26atitle%3DHigh-throughput%2520luciferase-based%2520assay%2520for%2520the%2520discovery%2520of%2520therapeutics%2520that%2520prevent%2520malaria%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26issue%3D4%26spage%3D281%26epage%3D293%26doi%3D10.1021%2Facsinfecdis.5b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michnoff, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening for potent and selective inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">21847</span>– <span class="NLM_lpage">21853</span>, <span class="refDoi"> DOI: 10.1074/jbc.M501100200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M501100200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=15795226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksl2hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=21847-21853&issue=23&author=J.+Baldwinauthor=C.+H.+Michnoffauthor=N.+A.+Malmquistauthor=J.+Whiteauthor=M.+G.+Rothauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=High-throughput+screening+for+potent+and+selective+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase&doi=10.1074%2Fjbc.M501100200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Baldwin, Jeffrey; Michnoff, Carolyn H.; Malmquist, Nicholas A.; White, John; Roth, Michael G.; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">21847-21853</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum is the causative agent of the most serious and fatal malarial infections, and it has developed resistance to commonly employed chemotherapeutics.  The de novo pyrimidine biosynthesis enzymes offer potential as targets for drug design, because, unlike the host, the parasite does not have pyrimidine salvage pathways.  Dihydroorotate dehydrogenase (DHODH) is a flavin-dependent mitochondrial enzyme that catalyzes the fourth reaction in this essential pathway.  Coenzyme Q (CoQ) is utilized as the oxidant.  Potent and species-selective inhibitors of malarial DHODH were identified by high-throughput screening of a chem. library, which contained 220,000 drug-like mols.  These novel inhibitors represent a diverse range of chem. scaffolds, including a series of halogenated Ph benzamide/naphthamides and urea-based compds. contg. naphthyl or quinolinyl substituents.  Inhibitors in these classes with IC50 values below 600 nM were purified by high pressure liq. chromatog., characterized by mass spectroscopy, and subjected to kinetic anal. against the parasite and human enzymes.  The most active compd. is a competitive inhibitor of CoQ with an IC50 against malarial DHODH of 16 nM, and it is 12,500-fold less active against the human enzyme.  Site-directed mutagenesis of residues in the CoQ-binding site significantly reduced inhibitor potency.  The structural basis for the species selective enzyme inhibition is explained by the variable amino acid sequence in this binding site, making DHODH a particularly strong candidate for the development of new anti-malarial compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPMFFguZbemrVg90H21EOLACvtfcHk0liLO47__IISxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksl2hsr8%253D&md5=0ff927280426ad1c9808de7412df1f1b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M501100200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M501100200%26sid%3Dliteratum%253Aachs%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DMichnoff%26aufirst%3DC.%2BH.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DM.%2BG.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DHigh-throughput%2520screening%2520for%2520potent%2520and%2520selective%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D23%26spage%3D21847%26epage%3D21853%26doi%3D10.1074%2Fjbc.M501100200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillesland, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyloun, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krahn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasari, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, A. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bakkouri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojo, K. K.</span></span> <span> </span><span class="NLM_article-title">Biochemical screening of five protein kinases from <i>Plasmodium falciparum</i> against 14,000 cell-active compounds</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e0149996</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0149996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.pone.0149996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26934697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFSjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0149996&issue=3&author=G.+J.+Crowtherauthor=H.+K.+Hilleslandauthor=K.+R.+Keylounauthor=M.+C.+Reidauthor=M.+J.+Lafuente-Monasterioauthor=S.+Ghidelli-Disseauthor=S.+E.+Leonardauthor=P.+Heauthor=J.+C.+Jonesauthor=M.+M.+Krahnauthor=J.+S.+Moauthor=K.+S.+Dasariauthor=A.+M.+W.+Foxauthor=M.+Boescheauthor=M.+El+Bakkouriauthor=K.+L.+Rivasauthor=D.+Leroyauthor=R.+Huiauthor=G.+Drewesauthor=D.+J.+Malyauthor=W.+C.+Van+Voorhisauthor=K.+K.+Ojo&title=Biochemical+screening+of+five+protein+kinases+from+Plasmodium+falciparum+against+14%2C000+cell-active+compounds&doi=10.1371%2Fjournal.pone.0149996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical screening of five protein kinases from Plasmodium falciparum against 14,000 cell-active compounds</span></div><div class="casAuthors">Crowther, Gregory J.; Hillesland, Heidi K.; Keyloun, Katelyn R.; Reid, Molly C.; Lafuente-Monasterio, Maria Jose; Ghidelli-Disse, Sonja; Leonard, Stephen E.; He, Panqing; Jones, Jackson C.; Krahn, Mallory M.; Mo, Jack S.; Dasari, Kartheek S.; Fox, Anna M. W.; Boesche, Markus; El Bakkouri, Majida; Rivas, Kasey L.; Leroy, Didier; Hui, Raymond; Drewes, Gerard; Maly, Dustin J.; Van Voorhis, Wesley C.; Ojo, Kayode K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0149996/1-e0149996/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In 2010 the identities of thousands of anti-Plasmodium compds. were released publicly to facilitate malaria drug development.  Understanding these compds. mechanisms of action, i.e., the specific mol. targets by which they kill the parasite, would further facilitate the drug development process.  Given that kinases are promising anti-malaria targets, the authors screened ∼14,000 cell-active compds. for activity against five different protein kinases.  Collections of cell-active compds. from GlaxoSmithKline (the ∼13,000-compd. Tres Cantos Antimalarial Set, or TCAMS), St. Jude Children's Research Hospital (260 compds.), and the Medicines for Malaria Venture (the 400-compd. Malaria Box) were screened in biochem. assays of Plasmodium falciparum calcium-dependent protein kinases 1 and 4 (CDPK1 and CDPK4), mitogen-assocd. protein kinase 2 (MAPK2/ MAP2), protein kinase 6 (PK6), and protein kinase 7 (PK7).  Novel potent inhibitors (IC50 < 1 μM) were discovered for three of the kinases: CDPK1, CDPK4, and PK6.  The PK6 inhibitors are the most potent yet discovered for this enzyme and deserve further scrutiny.  Addnl., kinome-wide competition assays revealed a compd. that inhibits CDPK4 with few effects on ∼150 human kinases, and several related compds. that inhibit CDPK1 and CDPK4 yet have limited cytotoxicity to human (HepG2) cells.  The authors' data suggest that inhibiting multiple Plasmodium kinase targets without harming human cells is challenging but feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQjOI-LR9zrVg90H21EOLACvtfcHk0lgvEgmMxt7jKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFSjurk%253D&md5=a55e4cf30328bbe04218100c69705ebc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0149996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0149996%26sid%3Dliteratum%253Aachs%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DHillesland%26aufirst%3DH.%2BK.%26aulast%3DKeyloun%26aufirst%3DK.%2BR.%26aulast%3DReid%26aufirst%3DM.%2BC.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DS.%2BE.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DJ.%2BC.%26aulast%3DKrahn%26aufirst%3DM.%2BM.%26aulast%3DMo%26aufirst%3DJ.%2BS.%26aulast%3DDasari%26aufirst%3DK.%2BS.%26aulast%3DFox%26aufirst%3DA.%2BM.%2BW.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DEl%2BBakkouri%26aufirst%3DM.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DOjo%26aufirst%3DK.%2BK.%26atitle%3DBiochemical%2520screening%2520of%2520five%2520protein%2520kinases%2520from%2520Plasmodium%2520falciparum%2520against%252014%252C000%2520cell-active%2520compounds%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D3%26spage%3De0149996%26doi%3D10.1371%2Fjournal.pone.0149996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napuli, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagostino, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockmyer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodenbough, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaneda, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engels, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantauzzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span> <span> </span><span class="NLM_article-title">Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds</span>. <i>Mol. Biochem. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.molbiopara.2010.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.molbiopara.2010.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20813141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2011&pages=21-29&issue=1&author=G.+J.+Crowtherauthor=A.+J.+Napuliauthor=J.+H.+Gilliganauthor=K.+Gagaringauthor=R.+Borboaauthor=C.+Francekauthor=Z.+Chenauthor=E.+F.+Dagostinoauthor=J.+B.+Stockmyerauthor=Y.+Wangauthor=P.+P.+Rodenboughauthor=L.+J.+Castanedaauthor=D.+J.+Leiblyauthor=J.+Bhandariauthor=M.+H.+Gelbauthor=A.+Brinkerauthor=I.+H.+Engelsauthor=J.+Taylorauthor=A.+K.+Chatterjeeauthor=P.+Fantauzziauthor=R.+J.+Glynneauthor=W.+C.+Van+Voorhisauthor=K.+L.+Kuhen&title=Identification+of+inhibitors+for+putative+malaria+drug+targets+among+novel+antimalarial+compounds&doi=10.1016%2Fj.molbiopara.2010.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds</span></div><div class="casAuthors">Crowther, Gregory J.; Napuli, Alberto J.; Gilligan, James H.; Gagaring, Kerstin; Borboa, Rachel; Francek, Carolyn; Chen, Zhong; Dagostino, Eleanor F.; Stockmyer, Justin B.; Wang, Yu; Rodenbough, Philip P.; Castaneda, Lisa J.; Leibly, David J.; Bhandari, Janhavi; Gelb, Michael H.; Brinker, Achim; Engels, Ingo H.; Taylor, Jennifer; Chatterjee, Arnab K.; Fantauzzi, Pascal; Glynne, Richard J.; Van Voorhis, Wesley C.; Kuhen, Kelli L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Biochemical Parasitology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-29</span>CODEN:
                <span class="NLM_cas:coden">MBIPDP</span>;
        ISSN:<span class="NLM_cas:issn">0166-6851</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">The efficacy of most marketed antimalarial drugs has been compromised by evolution of parasite resistance, underscoring an urgent need to find new drugs with new mechanisms of action.  We have taken a high-throughput approach toward identifying novel antimalarial chem. inhibitors of prioritized drug targets for Plasmodium falciparum, excluding targets which are inhibited by currently used drugs.  A screen of com. available libraries identified 5655 low mol. wt. compds. that inhibit growth of P. falciparum cultures with EC50 values below 1.25 μM.  These compds. were then tested in 384- or 1536-well biochem. assays for activity against nine Plasmodium enzymes: adenylosuccinate synthetase (AdSS), choline kinase (CK), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), glutamate dehydrogenase (GDH), guanylate kinase (GK), N-myristoyltransferase (NMT), orotidine 5'-monophosphate decarboxylase (OMPDC), farnesyl pyrophosphate synthase (FPPS) and S-adenosylhomocysteine hydrolase (SAHH).  These enzymes were selected using TDRtargets.org, and are believed to have excellent potential as drug targets based on criteria such as their likely essentiality, druggability, and amenability to high-throughput biochem. screening.  Six of these targets were inhibited by one or more of the antimalarial scaffolds and may have potential use in drug development, further target validation studies and exploration of P. falciparum biochem. and biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOMQ0tUYOGbLVg90H21EOLACvtfcHk0lhB38o0QHAD_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtbjJ&md5=68c7c2e9ee0bc40abc0a3b99187be9ff</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.molbiopara.2010.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molbiopara.2010.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DNapuli%26aufirst%3DA.%2BJ.%26aulast%3DGilligan%26aufirst%3DJ.%2BH.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDagostino%26aufirst%3DE.%2BF.%26aulast%3DStockmyer%26aufirst%3DJ.%2BB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRodenbough%26aufirst%3DP.%2BP.%26aulast%3DCastaneda%26aufirst%3DL.%2BJ.%26aulast%3DLeibly%26aufirst%3DD.%2BJ.%26aulast%3DBhandari%26aufirst%3DJ.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DBrinker%26aufirst%3DA.%26aulast%3DEngels%26aufirst%3DI.%2BH.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DFantauzzi%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26atitle%3DIdentification%2520of%2520inhibitors%2520for%2520putative%2520malaria%2520drug%2520targets%2520among%2520novel%2520antimalarial%2520compounds%26jtitle%3DMol.%2520Biochem.%2520Parasitol.%26date%3D2011%26volume%3D175%26issue%3D1%26spage%3D21%26epage%3D29%26doi%3D10.1016%2Fj.molbiopara.2010.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holder, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leatherbarrow, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3578</span>– <span class="NLM_lpage">3582</span>, <span class="refDoi"> DOI: 10.1021/jm300040p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300040p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVKgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3578-3582&issue=7&author=V.+Goncalvesauthor=J.+A.+Branniganauthor=D.+Whalleyauthor=K.+H.+Ansellauthor=B.+Saxtyauthor=A.+A.+Holderauthor=A.+J.+Wilkinsonauthor=E.+W.+Tateauthor=R.+J.+Leatherbarrow&title=Discovery+of+Plasmodium+vivax+N-myristoyltransferase+inhibitors%3A+screening%2C+synthesis%2C+and+structural+characterization+of+their+binding+mode&doi=10.1021%2Fjm300040p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Plasmodium vivax N-Myristoyltransferase Inhibitors: Screening, Synthesis, and Structural Characterization of their Binding Mode</span></div><div class="casAuthors">Goncalves, Victor; Brannigan, James A.; Whalley, David; Ansell, Keith H.; Saxty, Barbara; Holder, Anthony A.; Wilkinson, Anthony J.; Tate, Edward W.; Leatherbarrow, Robin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3578-3582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Myristoyltransferase (NMT) is a prospective drug target against parasitic protozoa.  Herein we report the successful discovery of a series of Plasmodium vivax NMT inhibitors by high-throughput screening.  A high-resoln. crystal structure of the hit compd. in complex with NMT was obtained, allowing understanding of its novel binding mode.  A set of analogs was designed and tested to define the chem. groups relevant for activity and selectivity.  Compd. 7 (I) was identified which exhibits micromolar activity against PvNMT, some selectivity over human NMT isoforms, and improved lead-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQffTqfTp5rLVg90H21EOLACvtfcHk0lhB38o0QHAD_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVKgtbc%253D&md5=0e42a947e40a044763db187bea7fb76e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm300040p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300040p%26sid%3Dliteratum%253Aachs%26aulast%3DGoncalves%26aufirst%3DV.%26aulast%3DBrannigan%26aufirst%3DJ.%2BA.%26aulast%3DWhalley%26aufirst%3DD.%26aulast%3DAnsell%26aufirst%3DK.%2BH.%26aulast%3DSaxty%26aufirst%3DB.%26aulast%3DHolder%26aufirst%3DA.%2BA.%26aulast%3DWilkinson%26aufirst%3DA.%2BJ.%26aulast%3DTate%26aufirst%3DE.%2BW.%26aulast%3DLeatherbarrow%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520Plasmodium%2520vivax%2520N-myristoyltransferase%2520inhibitors%253A%2520screening%252C%2520synthesis%252C%2520and%2520structural%2520characterization%2520of%2520their%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D7%26spage%3D3578%26epage%3D3582%26doi%3D10.1021%2Fjm300040p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celatka, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraisingh, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of small molecule inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">35078</span>– <span class="NLM_lpage">35085</span>, <span class="refDoi"> DOI: 10.1074/jbc.M804990200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M804990200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18842591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=35078-35085&issue=50&author=V.+Patelauthor=M.+Bookerauthor=M.+Kramerauthor=L.+Rossauthor=C.+A.+Celatkaauthor=L.+M.+Kennedyauthor=J.+D.+Dvorinauthor=M.+T.+Duraisinghauthor=P.+Slizauthor=D.+F.+Wirthauthor=J.+Clardy&title=Identification+and+characterization+of+small+molecule+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase&doi=10.1074%2Fjbc.M804990200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of Small Molecule Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Patel, Vishal; Booker, Michael; Kramer, Martin; Ross, Leila; Celatka, Cassandra A.; Kennedy, Leah M.; Dvorin, Jeffrey D.; Duraisingh, Manoj T.; Sliz, Piotr; Wirth, Dyann F.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35078-35085</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum causes the most deadly form of malaria and accounts for over one million deaths annually.  The malaria parasite is unable to salvage pyrimidines and relies on de novo biosynthesis for survival.  Dihydroorotate dehydrogenase (DHOD), a mitochondrially localized flavoenzyme, catalyzes the rate-limiting step of this pathway and is therefore an attractive antimalarial chemotherapeutic target.  Using a target-based high throughput screen, we have identified a series of potent, species-specific inhibitors of P. falciparum DHOD (pfDHOD) that are also efficacious against three cultured strains (3D7, HB3, and Dd2) of P. falciparum.  The primary antimalarial mechanism of action of these compds. was confirmed to be inhibition of pfDHOD through a secondary assay with transgenic malaria parasites, and the structural basis for enzyme inhibition was explored through in silico structure-based docking and site-directed mutagenesis.  Compd.-mediated cytotoxicity was not obsd. with human dermal fibroblasts or renal epithelial cells.  These data validate pfDHOD as an antimalarial drug target and provide chem. scaffolds with which to begin medicinal chem. efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy01Yc9ycCLVg90H21EOLACvtfcHk0ljNzt2Ma0kkPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt7%252FF&md5=beb67f818baaeb9e70637debb50047a3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M804990200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M804990200%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DBooker%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DCelatka%26aufirst%3DC.%2BA.%26aulast%3DKennedy%26aufirst%3DL.%2BM.%26aulast%3DDvorin%26aufirst%3DJ.%2BD.%26aulast%3DDuraisingh%26aufirst%3DM.%2BT.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520small%2520molecule%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D50%26spage%3D35078%26epage%3D35085%26doi%3D10.1074%2Fjbc.M804990200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Capua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams-Noonan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouwer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner-Adams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, W. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based screening of a natural product library against 62 potential malaria drug targets employing native mass spectrometry</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.7b00197</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.7b00197" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1ahs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=431-444&issue=4&author=H.+Vuauthor=L.+Pedroauthor=T.+Makauthor=B.+McCormickauthor=J.+Rowleyauthor=M.+Liuauthor=A.+Di+Capuaauthor=B.+Williams-Noonanauthor=N.+B.+Phamauthor=R.+Pouwerauthor=B.+Nguyenauthor=K.+T.+Andrewsauthor=T.+Skinner-Adamsauthor=J.+Kimauthor=W.+G.+J.+Holauthor=R.+Huiauthor=G.+J.+Crowtherauthor=W.+C.+Van+Voorhisauthor=R.+J.+Quinn&title=Fragment-based+screening+of+a+natural+product+library+against+62+potential+malaria+drug+targets+employing+native+mass+spectrometry&doi=10.1021%2Facsinfecdis.7b00197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry</span></div><div class="casAuthors">Vu, Hoan; Pedro, Liliana; Mak, Tin; McCormick, Brendan; Rowley, Jessica; Liu, Miaomiao; Di Capua, Angela; Williams-Noonan, Billy; Pham, Ngoc B.; Pouwer, Rebecca; Nguyen, Bao; Andrews, Katherine T.; Skinner-Adams, Tina; Kim, Jessica; Hol, Wim G. J.; Hui, Raymond; Crowther, Gregory J.; Van Voorhis, Wesley C.; Quinn, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-444</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Natural products are well known for their biol. relevance, high degree of three-dimensionality, and access to areas of largely unexplored chem. space.  To shape our understanding of the interaction between natural products and protein targets in the postgenomic era, we have used native mass spectrometry to investigate 62 potential protein targets for malaria using a natural-product-based fragment library.  We reveal here 96 low-mol.-wt. natural products identified as binding partners of 32 of the putative malarial targets.  Seventy-nine (79) fragments have direct growth inhibition on Plasmodium falciparum at concns. that are promising for the development of fragment hits against these protein targets.  This adds a fragment library to the published HTS active libraries in the public domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGrG7it9DQS7Vg90H21EOLACvtfcHk0ljNzt2Ma0kkPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1ahs7s%253D&md5=5e6ea1be111f64c97f08e272f2e83dae</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.7b00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.7b00197%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DH.%26aulast%3DPedro%26aufirst%3DL.%26aulast%3DMak%26aufirst%3DT.%26aulast%3DMcCormick%26aufirst%3DB.%26aulast%3DRowley%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DDi%2BCapua%26aufirst%3DA.%26aulast%3DWilliams-Noonan%26aufirst%3DB.%26aulast%3DPham%26aufirst%3DN.%2BB.%26aulast%3DPouwer%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DK.%2BT.%26aulast%3DSkinner-Adams%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHol%26aufirst%3DW.%2BG.%2BJ.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DFragment-based%2520screening%2520of%2520a%2520natural%2520product%2520library%2520against%252062%2520potential%2520malaria%2520drug%2520targets%2520employing%2520native%2520mass%2520spectrometry%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2018%26volume%3D4%26issue%3D4%26spage%3D431%26epage%3D444%26doi%3D10.1021%2Facsinfecdis.7b00197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roullier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campitelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenholme, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner-Adams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">Plasmodium gametocyte inhibition identified from a natural-product-based fragment library</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2654</span>– <span class="NLM_lpage">2659</span>, <span class="refDoi"> DOI: 10.1021/cb400582b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400582b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFeltrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2654-2659&issue=12&author=H.+Vuauthor=C.+Roullierauthor=M.+Campitelliauthor=K.+R.+Trenholmeauthor=D.+L.+Gardinerauthor=K.+T.+Andrewsauthor=T.+Skinner-Adamsauthor=G.+J.+Crowtherauthor=W.+C.+Van+Voorhisauthor=R.+J.+Quinn&title=Plasmodium+gametocyte+inhibition+identified+from+a+natural-product-based+fragment+library&doi=10.1021%2Fcb400582b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium gametocyte inhibition identified from a natural product-based fragment library</span></div><div class="casAuthors">Vu, Hoan; Roullier, Catherine; Campitelli, Marc; Trenholme, Katharine R.; Gardiner, Donald L.; Andrews, Katherine T.; Skinner-Adams, Tina; Crowther, Gregory J.; Van Voorhis, Wesley C.; Quinn, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2654-2659</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based screening is commonly used to identify compds. with relatively weak but efficient localized binding to protein surfaces.  The authors used mass spectrometry to study fragment-sized three-dimensional natural products.  They identified seven securinine-related compds. binding to Plasmodium falciparum 2'-deoxyuridine 5'-triphosphate nucleotidohydrolase (PfdUTPase).  Securinine bound allosterically to PfdUTPase, enhancing enzyme activity and inhibiting viability of both P. falciparum gametocyte (sexual) and blood (asexual) stage parasites.  The results provide a new insight into mechanisms that may be applicable to transmission-blocking agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1yoUh32TRcLVg90H21EOLACvtfcHk0liHzdrcvKEnGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFeltrzJ&md5=19d7db1596702529d16bd6a82e7cf4ab</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fcb400582b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400582b%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DH.%26aulast%3DRoullier%26aufirst%3DC.%26aulast%3DCampitelli%26aufirst%3DM.%26aulast%3DTrenholme%26aufirst%3DK.%2BR.%26aulast%3DGardiner%26aufirst%3DD.%2BL.%26aulast%3DAndrews%26aufirst%3DK.%2BT.%26aulast%3DSkinner-Adams%26aufirst%3DT.%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DPlasmodium%2520gametocyte%2520inhibition%2520identified%2520from%2520a%2520natural-product-based%2520fragment%2520library%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26issue%3D12%26spage%3D2654%26epage%3D2659%26doi%3D10.1021%2Fcb400582b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okombo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Recent updates in the discovery and development of novel antimalarial drug candidates</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1039/C7MD00637C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1039%2FC7MD00637C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30108934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFygs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=437-453&issue=3&author=J.+Okomboauthor=K.+Chibale&title=Recent+updates+in+the+discovery+and+development+of+novel+antimalarial+drug+candidates&doi=10.1039%2FC7MD00637C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates in the discovery and development of novel antimalarial drug candidates</span></div><div class="casAuthors">Okombo, John; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">437-453</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Though morbidity and mortality due to malaria have declined in the last 15 years, emerging resistance to first-line artemisinin-based antimalarials, absence of efficacious vaccines and limited chemotherapeutic alternatives imperil the consolidation of these gains.  As a blueprint to steer future designs of new medicines, malaria drug discovery recently adopted a descriptive proposal for the ideal candidate mols. and drugs likely to successfully progress into the final stages of clin. development.  As an audit of recent developments in the chemotherapy of malaria in the last five years, this review captures a landscape of diverse mols. at various stages of drug development and discusses their progress.  In brief, we also discuss how omics data on Plasmodium has been extensively leveraged to identify potential vaccine candidates and putative targets of mols. in development and clin. use as well as map loci implicit in their modes of resistance.  Future perspective on malaria drug development should involve a reconciliation of some of the challenges of the target candidate profiles (TCPs), specifically TCP3, with the promise of effective anti-hypnozoite medicines.  Similarly, with the recent development of a humanized mouse model that can evaluate the prophylactic potential of candidate drugs, we argue for increased effort at identifying more liver-stage mols., which are often only secondarily prioritized in conventional screening programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvmARzFwQAebVg90H21EOLACvtfcHk0liHzdrcvKEnGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFygs7Y%253D&md5=760def6cbcd82971f114de94132b27f7</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1039%2FC7MD00637C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00637C%26sid%3Dliteratum%253Aachs%26aulast%3DOkombo%26aufirst%3DJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DRecent%2520updates%2520in%2520the%2520discovery%2520and%2520development%2520of%2520novel%2520antimalarial%2520drug%2520candidates%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D437%26epage%3D453%26doi%3D10.1039%2FC7MD00637C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Paez, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Spiroindolones, a potent compound class for the treatment of malaria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span> (<span class="NLM_issue">5996</span>),  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1126/science.1193225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1193225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20813948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=1175-1180&issue=5996&author=M.+Rottmannauthor=C.+McNamaraauthor=B.+K.+Yeungauthor=M.+C.+Leeauthor=B.+Zouauthor=B.+Russellauthor=P.+Seitzauthor=D.+M.+Plouffeauthor=N.+V.+Dhariaauthor=J.+Tanauthor=S.+B.+Cohenauthor=K.+R.+Spencerauthor=G.+E.+Gonzalez-Paezauthor=S.+B.+Lakshminarayanaauthor=A.+Gohauthor=R.+Suwanaruskauthor=T.+Jeglaauthor=E.+K.+Schmittauthor=H.+P.+Beckauthor=R.+Brunauthor=F.+Nostenauthor=L.+Reniaauthor=V.+Dartoisauthor=T.+H.+Kellerauthor=D.+A.+Fidockauthor=E.+A.+Winzelerauthor=T.+T.+Diagana&title=Spiroindolones%2C+a+potent+compound+class+for+the+treatment+of+malaria&doi=10.1126%2Fscience.1193225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span></div><div class="casAuthors">Rottmann, Matthias; McNamara, Case; Yeung, Bryan K. S.; Lee, Marcus C. S.; Zou, Bin; Russell, Bruce; Seitz, Patrick; Plouffe, David M.; Dharia, Neekesh V.; Tan, Jocelyn; Cohen, Steven B.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Lakshminarayana, Suresh B.; Goh, Anne; Suwanarusk, Rossarin; Jegla, Timothy; Schmitt, Esther K.; Beck, Hans-Peter; Brun, Reto; Nosten, Francois; Renia, Laurent; Dartois, Veronique; Keller, Thomas H.; Fidock, David A.; Winzeler, Elizabeth A.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5996</span>),
    <span class="NLM_cas:pages">1175-1180</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Recent reports of increased tolerance to artemisinin derivs.-the most recently adopted class of antimalarials-have prompted a need for new treatments.  The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clin. isolates at low nanomolar concn.  Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4).  The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6O1WaX-1b7Vg90H21EOLACvtfcHk0lgj2i9mpGEWOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ&md5=239bc9babd5cb5f07e2be38741038e2c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscience.1193225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1193225%26sid%3Dliteratum%253Aachs%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DSpencer%26aufirst%3DK.%2BR.%26aulast%3DGonzalez-Paez%26aufirst%3DG.%2BE.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DJegla%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DBeck%26aufirst%3DH.%2BP.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DSpiroindolones%252C%2520a%2520potent%2520compound%2520class%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DScience%26date%3D2010%26volume%3D329%26issue%3D5996%26spage%3D1175%26epage%3D1180%26doi%3D10.1126%2Fscience.1193225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabiulla, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3487</span>, <span class="refDoi"> DOI: 10.1021/jm3001373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3001373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1SqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3479-3487&author=Y.+Younisauthor=F.+Douelleauthor=T.+S.+Fengauthor=D.+Gonzalez+Cabreraauthor=C.+Le+Manachauthor=A.+T.+Nchindaauthor=S.+Duffyauthor=K.+L.+Whiteauthor=D.+M.+Shacklefordauthor=J.+Morizziauthor=J.+Mannilaauthor=K.+Katneniauthor=R.+Bhamidipatiauthor=K.+M.+Zabiullaauthor=J.+T.+Josephauthor=S.+Bashyamauthor=D.+Watersonauthor=M.+J.+Wittyauthor=D.+Hardickauthor=S.+Wittlinauthor=V.+Averyauthor=S.+A.+Charmanauthor=K.+Chibale&title=3%2C5-Diaryl-2-aminopyridines+as+a+novel+class+of+orally+active+antimalarials+demonstrating+single+dose+cure+in+mice+and+clinical+candidate+potential&doi=10.1021%2Fjm3001373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">3,5-Diaryl-2-aminopyridines as a Novel Class of Orally Active Antimalarials Demonstrating Single Dose Cure in Mice and Clinical Candidate Potential</span></div><div class="casAuthors">Younis, Yassir; Douelle, Frederic; Feng, Tzu-Shean; Cabrera, Diego Gonzalez; Manach, Claire Le; Nchinda, Aloysius T.; Duffy, Sandra; White, Karen L.; Shackleford, David M.; Morizzi, Julia; Mannila, Janne; Katneni, Kasiram; Bhamidipati, Ravi; Zabiulla, K. Mohammed; Joseph, Jayan T.; Bashyam, Sridevi; Waterson, David; Witty, Michael J.; Hardick, David; Wittlin, Sergio; Avery, Vicky; Charman, Susan A.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3479-3487</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of orally active antimalarial 3,5-diaryl-2-aminopyridines has been identified from phenotypic whole cell high-throughput screening of a com. available SoftFocus kinase library.  The compds. were evaluated in vitro for their antiplasmodial activity against K1 (chloroquine and drug-resistant strain) and NF54 (chloroquine-susceptible strain) as well as for their cytotoxicity.  Synthesis and structure-activity studies identified a no. of promising compds. with selective antiplasmodial activity.  One of these front-runner compds., I, was equipotent across the two strains (K1 = 25.0 nM, NF54 = 28.0 nM) and superior to chloroquine in the K1 strain (chloroquine IC50 K1 = 194.0 nM).  Compd. I completely cured Plasmodium berghei-infected mice with a single oral dose of 30 mg/kg.  Dose-response studies generated ED50 and ED90 values of 0.83 and 1.74 mg/kg for 15 in the std. four-dose Peters test.  Pharmacokinetic studies in the rat indicated that I has good oral bioavailability (51% at 20 mg/kg) and a reasonable half-life (t1/2 ∼ 7-8 h).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSW6icCPhdOrVg90H21EOLACvtfcHk0lgj2i9mpGEWOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1SqtL4%253D&md5=6f8bd20049550b82b81b3c7c5b0b9aae</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm3001373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3001373%26sid%3Dliteratum%253Aachs%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DDouelle%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DT.%2BS.%26aulast%3DGonzalez%2BCabrera%26aufirst%3DD.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DMannila%26aufirst%3DJ.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DBhamidipati%26aufirst%3DR.%26aulast%3DZabiulla%26aufirst%3DK.%2BM.%26aulast%3DJoseph%26aufirst%3DJ.%2BT.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DHardick%26aufirst%3DD.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DAvery%26aufirst%3DV.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3D3%252C5-Diaryl-2-aminopyridines%2520as%2520a%2520novel%2520class%2520of%2520orally%2520active%2520antimalarials%2520demonstrating%2520single%2520dose%2520cure%2520in%2520mice%2520and%2520clinical%2520candidate%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3479%26epage%3D3487%26doi%3D10.1021%2Fjm3001373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite <i>Plasmodium falciparum</i></span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3649</span>– <span class="NLM_lpage">3653</span>, <span class="refDoi"> DOI: 10.1021/jm8001026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1Gisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3649-3653&issue=12&author=M.+A.+Phillipsauthor=R.+Gujjarauthor=N.+A.+Malmquistauthor=J.+Whiteauthor=F.+El+Mazouniauthor=J.+Baldwinauthor=P.+K.+Rathod&title=Triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitors+with+potent+and+selective+activity+against+the+malaria+parasite+Plasmodium+falciparum&doi=10.1021%2Fjm8001026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitors with Potent and Selective Activity against the Malaria Parasite Plasmodium falciparum</span></div><div class="casAuthors">Phillips, Margaret A.; Gujjar, Ramesh; Malmquist, Nicholas A.; White, John; El Mazouni, Farah; Baldwin, Jeffrey; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3649-3653</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor I that is potent (KI = 15 nM) and species-selective (>5000-fold over the human enzyme) was identified by high-throughput screening.  The substituted triazolopyrimidine and its structural analogs were produced by an inexpensive three-step synthesis, and the series showed good assocn. between PfDHODH inhibition and parasite toxicity.  This study has identified the first nanomolar PfDHODH inhibitor with potent antimalarial activity in whole cells (EC50 = 79 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklJJmj9EM77Vg90H21EOLACvtfcHk0lgnLqXoyBHP1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1Gisbs%253D&md5=7bdbdc57d346ef3290623adc4aed89ee</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm8001026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001026%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DTriazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520with%2520potent%2520and%2520selective%2520activity%2520against%2520the%2520malaria%2520parasite%2520Plasmodium%2520falciparum%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D12%26spage%3D3649%26epage%3D3653%26doi%3D10.1021%2Fjm8001026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller-Maerki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krastel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5155</span>– <span class="NLM_lpage">5164</span>, <span class="refDoi"> DOI: 10.1021/jm100410f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100410f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVKqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5155-5164&issue=14&author=B.+K.+Yeungauthor=B.+Zouauthor=M.+Rottmannauthor=S.+B.+Lakshminarayanaauthor=S.+H.+Angauthor=S.+Y.+Leongauthor=J.+Tanauthor=J.+Wongauthor=S.+Keller-Maerkiauthor=C.+Fischliauthor=A.+Gohauthor=E.+K.+Schmittauthor=P.+Krastelauthor=E.+Francotteauthor=K.+Kuhenauthor=D.+Plouffeauthor=K.+Hensonauthor=T.+Wagnerauthor=E.+A.+Winzelerauthor=F.+Petersenauthor=R.+Brunauthor=V.+Dartoisauthor=T.+T.+Diaganaauthor=T.+H.+Keller&title=Spirotetrahydro+beta-carbolines+%28spiroindolones%29%3A+a+new+class+of+potent+and+orally+efficacious+compounds+for+the+treatment+of+malaria&doi=10.1021%2Fjm100410f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria</span></div><div class="casAuthors">Yeung, Bryan K. S.; Zou, Bin; Rottmann, Matthias; Lakshminarayana, Suresh B.; Ang, Shi Hua; Leong, Seh Yong; Tan, Jocelyn; Wong, Josephine; Keller-Maerki, Sonja; Fischli, Christoph; Goh, Anne; Schmitt, Esther K.; Krastel, Philipp; Francotte, Eric; Kuhen, Kelli; Plouffe, David; Henson, Kerstin; Wagner, Trixie; Winzeler, Elizabeth A.; Petersen, Frank; Brun, Reto; Dartois, Veronique; Diagana, Thierry T.; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5155-5164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antiplasmodial activity of a series of spirotetrahydro β-carbolines is described.  Racemic spiroazepineindole (1) was identified from a phenotypic screen on wild type Plasmodium falciparum with an in vitro IC50 of 90 nM.  Structure-activity relationships for the optimization of 1 to compd. 20a (IC50 = 0.2 nM) including the identification of the active 1R,3S enantiomer and elimination of metabolic liabilities is presented.  Improvement of the pharmacokinetic profile of the series translated to exceptional oral efficacy in the P. berghei infected malaria mouse model where full cure was achieved in four of five mice with three daily doses of 30 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE8TIv2auzE7Vg90H21EOLACvtfcHk0lgOedJGVzWgLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVKqu78%253D&md5=1c00e45eb1625a9f9c2bef41fcf9d075</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm100410f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100410f%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DLeong%26aufirst%3DS.%2BY.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DKeller-Maerki%26aufirst%3DS.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DKrastel%26aufirst%3DP.%26aulast%3DFrancotte%26aufirst%3DE.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DHenson%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DPetersen%26aufirst%3DF.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DSpirotetrahydro%2520beta-carbolines%2520%2528spiroindolones%2529%253A%2520a%2520new%2520class%2520of%2520potent%2520and%2520orally%2520efficacious%2520compounds%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D14%26spage%3D5155%26epage%3D5164%26doi%3D10.1021%2Fjm100410f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeyasu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, J. M.</span></span> <span> </span><span class="NLM_article-title">Expression and functional characterization of a <i>Plasmodium falciparum</i> Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">10782</span>– <span class="NLM_lpage">10787</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010554200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M010554200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=11145964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFCqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=10782-10787&issue=14&author=S.+Krishnaauthor=C.+Woodrowauthor=R.+Webbauthor=J.+Pennyauthor=K.+Takeyasuauthor=M.+Kimuraauthor=J.+M.+East&title=Expression+and+functional+characterization+of+a+Plasmodium+falciparum+Ca2%2B-ATPase+%28PfATP4%29+belonging+to+a+subclass+unique+to+apicomplexan+organisms&doi=10.1074%2Fjbc.M010554200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms</span></div><div class="casAuthors">Krishna, Sanjeev; Woodrow, Charles; Webb, Richard; Penny, Jeff; Takeyasu, Kunio; Kimura, Masatsugu; East, J. Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">10782-10787</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We have obtained a full-length P type ATPase sequence (PfATP4) encoded by Plasmodium falciparum and expressed PfATP4 in Xenopus laevis oocytes to study its function.  Comparison of the hitherto incomplete open reading frame with other Ca2+-ATPase sequences reveals that PfATP4 differs significantly from previously defined categories.  The Ca2+-dependent ATPase activity of PfATP4 is stimulated by a much broader range of [Ca2+]free (3.2-320 μM) than are an avian SERCA1 pump or rabbit SERCA 1a (maximal activity < 10 μM).  The activity of PfATP4 is resistant to inhibition by ouabain (200 μM) or thapsigargin (0.8 μM) but is inhibited by vanadate (1 mM) or cyclopiazonic acid (1 μM).  We used a quant. polymerase chain reaction to assay expression of mRNA encoding PfATP4 relative to that for β-tubulin in synchronized asexual stages and found variable expression throughout the life cycle with a maximal 5-fold increase in meronts compared with ring stages.  This anal. suggests that PfATP4 defines a novel subclass of Ca2+-ATPases unique to apicomplexan organisms and therefore offers potential as a drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSjQHYI-oI0rVg90H21EOLACvtfcHk0lgOedJGVzWgLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFCqtb8%253D&md5=2283dd607f69f5ef414cc7af3b46f014</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010554200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010554200%26sid%3Dliteratum%253Aachs%26aulast%3DKrishna%26aufirst%3DS.%26aulast%3DWoodrow%26aufirst%3DC.%26aulast%3DWebb%26aufirst%3DR.%26aulast%3DPenny%26aufirst%3DJ.%26aulast%3DTakeyasu%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DM.%26aulast%3DEast%26aufirst%3DJ.%2BM.%26atitle%3DExpression%2520and%2520functional%2520characterization%2520of%2520a%2520Plasmodium%2520falciparum%2520Ca2%252B-ATPase%2520%2528PfATP4%2529%2520belonging%2520to%2520a%2520subclass%2520unique%2520to%2520apicomplexan%2520organisms%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D14%26spage%3D10782%26epage%3D10787%26doi%3D10.1074%2Fjbc.M010554200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">Na(+) regulation in the malaria parasite <i>Plasmodium falciparum</i> involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.chom.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=23414762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVOhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=227-237&issue=2&author=N.+J.+Spillmanauthor=R.+J.+Allenauthor=C.+W.+McNamaraauthor=B.+K.+Yeungauthor=E.+A.+Winzelerauthor=T.+T.+Diaganaauthor=K.+Kirk&title=Na%28%2B%29+regulation+in+the+malaria+parasite+Plasmodium+falciparum+involves+the+cation+ATPase+PfATP4+and+is+a+target+of+the+spiroindolone+antimalarials&doi=10.1016%2Fj.chom.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Na+ Regulation in the Malaria Parasite Plasmodium falciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone Antimalarials</span></div><div class="casAuthors">Spillman, Natalie J.; Allen, Richard J. W.; McNamara, Case W.; Yeung, Bryan K. S.; Winzeler, Elizabeth A.; Diagana, Thierry T.; Kirk, Kiaran</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">227-237</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The malaria parasite Plasmodium falciparum establishes in the host erythrocyte plasma membrane new permeability pathways that mediate nutrient uptake into the infected cell.  These pathways simultaneously allow Na+ influx, causing [Na+] in the infected erythrocyte cytosol to increase to high levels.  The intraerythrocytic parasite itself maintains a low cytosolic [Na+] via unknown mechanisms.  Here the authors present evidence that the intraerythrocytic parasite actively extrudes Na+ against an inward gradient via PfATP4, a parasite plasma membrane protein with sequence similarities to Na+-ATPases of lower eukaryotes.  Mutations in PfATP4 confer resistance to a potent class of antimalarials, the spiroindolones.  Consistent with this, the spiroindolones cause a profound disruption in parasite Na+ homeostasis, which is attenuated in parasites bearing resistance-conferring mutations in PfATP4.  The mutant parasites also show some impairment of Na+ regulation.  Taken together, the authors' results are consistent with PfATP4 being a Na+ efflux ATPase and a target of the spiroindolones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTK9LqgiWhDLVg90H21EOLACvtfcHk0liIsdASf9iV_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVOhtL4%253D&md5=415ec48b192ee6ea4681c97695b2b208</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DAllen%26aufirst%3DR.%2BJ.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DNa%2528%252B%2529%2520regulation%2520in%2520the%2520malaria%2520parasite%2520Plasmodium%2520falciparum%2520involves%2520the%2520cation%2520ATPase%2520PfATP4%2520and%2520is%2520a%2520target%2520of%2520the%2520spiroindolone%2520antimalarials%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2013%26volume%3D13%26issue%3D2%26spage%3D227%26epage%3D237%26doi%3D10.1016%2Fj.chom.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrand-Lapierre, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justino de Almeida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, A. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diep, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endsley, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedewa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiguemde, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Alejandre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRisi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span> <span> </span><span class="NLM_article-title">(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">E5455</span>– <span class="NLM_lpage">6462</span>, <span class="refDoi"> DOI: 10.1073/pnas.1414221111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.1414221111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25453091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSitb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E5455-6462&issue=50&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=D.+Ebertauthor=Y.+Salinasauthor=A.+Pradhanauthor=A.+M.+Lehaneauthor=M.-E.+Myrand-Lapierreauthor=K.+G.+O%E2%80%99Loughlinauthor=D.+M.+Shacklefordauthor=M.+Justino+de+Almeidaauthor=A.+K.+Carrilloauthor=J.+A.+Clarkauthor=A.+S.+M.+Dennisauthor=J.+Diepauthor=X.+Dengauthor=S.+Duffyauthor=A.+N.+Endsleyauthor=G.+Fedewaauthor=W.+A.+Guiguemdeauthor=M.+G.+G%C3%B3mezauthor=G.+Holbrookauthor=J.+Horstauthor=C.+C.+Kimauthor=J.+Liuauthor=M.+C.+S.+Leeauthor=A.+Mathenyauthor=M.+S.+Mart%C3%ADnezauthor=G.+Millerauthor=A.+Rodr%C3%ADguez-Alejandreauthor=L.+Sanzauthor=M.+Sigalauthor=N.+J.+Spillmanauthor=P.+D.+Steinauthor=Z.+Wangauthor=F.+Zhuauthor=D.+Watersonauthor=S.+Knappauthor=A.+Shelatauthor=V.+M.+Averyauthor=D.+A.+Fidockauthor=F.-J.+Gamoauthor=S.+A.+Charmanauthor=J.+C.+Mirsalisauthor=H.+Maauthor=S.+Ferrerauthor=K.+Kirkauthor=I.+Angulo-Barturenauthor=D.+E.+Kyleauthor=J.+L.+DeRisiauthor=D.+M.+Floydauthor=R.+K.+Guy&title=%28%2B%29-SJ733%2C+a+clinical+candidate+for+malaria+that+acts+through+ATP4+to+induce+rapid+host-mediated+clearance+of+Plasmodium&doi=10.1073%2Fpnas.1414221111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Ebert, Daniel; Salinas, Yandira; Pradhan, Anupam; Lehane, Adele M.; Myrand-Lapierre, Marie-Eve; O'Loughlin, Kathleen G.; Shackleford, David M.; Justino de Almeida, Mariana; Carrillo, Angela K.; Clark, Julie A.; Dennis, Adelaide S. M.; Diep, Jonathon; Deng, Xiaoyan; Duffy, Sandra; Endsley, Aaron N.; Fedewa, Greg; Guiguemde, W. Armand; Gomez, Maria G.; Holbrook, Gloria; Horst, Jeremy; Kim, Charles C.; Liu, Jian; Lee, Marcus C. S.; Matheny, Amy; Martinez, Maria Santos; Miller, Gregory; Rodriguez-Alejandre, Ane; Sanz, Laura; Sigal, Martina; Spillman, Natalie J.; Stein, Philip D.; Wang, Zheng; Zhu, Fangyi; Waterson, David; Knapp, Spencer; Shelat, Anang; Avery, Vicky M.; Fidock, David A.; Gamo, Francisco-Javier; Charman, Susan A.; Mirsalis, Jon C.; Ma, Hongshen; Ferrer, Santiago; Kirk, Kiaran; Angulo-Barturen, Inigo; Kyle, Dennis E.; DeRisi, Joseph L.; Floyd, David M.; Guy, R. Kiplin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">E5455-E5462</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compds. identified by phenotypic screening.  The process of developing these compds. as drug leads and studying the cellular responses they induce is revealing new targets that regulate key processes in the Plasmodium parasites that cause malaria.  We disclose herein that the clin. candidate (+)-SJ733 acts upon one of these targets, ATP4.  ATP4 is thought to be a cation-transporting ATPase responsible for maintaining low intracellular Na+ levels in the parasite.  Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na+ homeostasis in the parasite.  This perturbation was followed by profound phys. changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence.  These changes are proposed to underpin the rapid (+)-SJ733-induced clearance of parasites seen in vivo.  Plasmodium falciparum ATPase 4 (pfatp4) mutations that confer resistance to (+)-SJ733 carry a high fitness cost.  The speed with which (+)-SJ733 kills parasites and the high fitness cost assocd. with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo.  Together, our data suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNc7Cu9b336LVg90H21EOLACvtfcHk0liIsdASf9iV_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSitb3I&md5=45ff827f956702f2bd9761ae9bc8879a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1414221111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1414221111%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DEbert%26aufirst%3DD.%26aulast%3DSalinas%26aufirst%3DY.%26aulast%3DPradhan%26aufirst%3DA.%26aulast%3DLehane%26aufirst%3DA.%2BM.%26aulast%3DMyrand-Lapierre%26aufirst%3DM.-E.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%2BG.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DJustino%2Bde%2BAlmeida%26aufirst%3DM.%26aulast%3DCarrillo%26aufirst%3DA.%2BK.%26aulast%3DClark%26aufirst%3DJ.%2BA.%26aulast%3DDennis%26aufirst%3DA.%2BS.%2BM.%26aulast%3DDiep%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DEndsley%26aufirst%3DA.%2BN.%26aulast%3DFedewa%26aufirst%3DG.%26aulast%3DGuiguemde%26aufirst%3DW.%2BA.%26aulast%3DG%25C3%25B3mez%26aufirst%3DM.%2BG.%26aulast%3DHolbrook%26aufirst%3DG.%26aulast%3DHorst%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DC.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DMatheny%26aufirst%3DA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DM.%2BS.%26aulast%3DMiller%26aufirst%3DG.%26aulast%3DRodr%25C3%25ADguez-Alejandre%26aufirst%3DA.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DSigal%26aufirst%3DM.%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DStein%26aufirst%3DP.%2BD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DShelat%26aufirst%3DA.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMirsalis%26aufirst%3DJ.%2BC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DKirk%26aufirst%3DK.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DDeRisi%26aufirst%3DJ.%2BL.%26aulast%3DFloyd%26aufirst%3DD.%2BM.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3D%2528%252B%2529-SJ733%252C%2520a%2520clinical%2520candidate%2520for%2520malaria%2520that%2520acts%2520through%2520ATP4%2520to%2520induce%2520rapid%2520host-mediated%2520clearance%2520of%2520Plasmodium%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D50%26spage%3DE5455%26epage%3D6462%26doi%3D10.1073%2Fpnas.1414221111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manary, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinetz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1021/cb500616x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500616x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKktrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=413-420&issue=2&author=E.+L.+Flanneryauthor=C.+W.+McNamaraauthor=S.+W.+Kimauthor=T.+S.+Katoauthor=F.+Liauthor=C.+H.+Tengauthor=K.+Gagaringauthor=M.+J.+Manaryauthor=R.+Barboaauthor=S.+Meisterauthor=K.+Kuhenauthor=J.+M.+Vinetzauthor=A.+K.+Chatterjeeauthor=E.+A.+Winzeler&title=Mutations+in+the+P-type+cation-transporter+ATPase+4%2C+PfATP4%2C+mediate+resistance+to+both+aminopyrazole+and+spiroindolone+antimalarials&doi=10.1021%2Fcb500616x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials</span></div><div class="casAuthors">Flannery, Erika L.; McNamara, Case W.; Kim, Sang Wan; Kato, Tomoyo Sakata; Li, Fengwu; Teng, Christine H.; Gagaring, Kerstin; Manary, Micah J.; Barboa, Rachel; Meister, Stephan; Kuhen, Kelli; Vinetz, Joseph M.; Chatterjee, Arnab K.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-420</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aminopyrazoles are a new class of antimalarial compds. identified in a cellular antiparasitic screen with potent activity against Plasmodium falciparum asexual and sexual stage parasites.  To investigate their unknown mechanism of action and thus identify their target, we cultured parasites in the presence of a representative member of the aminopyrazole series, GNF-Pf4492, to select for resistance.  Whole genome sequencing of three resistant lines showed that each had acquired independent mutations in a P-type cation-transporter ATPase, PfATP4 (PF3D7_1211900), a protein implicated as the novel Plasmodium spp. target of another, structurally unrelated, class of antimalarials called the spiroindolones and characterized as an important sodium transporter of the cell.  Similarly to the spiroindolones, GNF-Pf4492 blocks parasite transmission to mosquitoes and disrupts intracellular sodium homeostasis.  Our data demonstrate that PfATP4 plays a crit. role in cellular processes, can be inhibited by two distinct antimalarial pharmacophores, and supports the recent observations that PfATP4 is a crit. antimalarial target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvVy0dxOiKa7Vg90H21EOLACvtfcHk0lgEc2kvQ6VGog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKktrnF&md5=c839292aa357bc027e0b4ff0f2b39e44</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fcb500616x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500616x%26sid%3Dliteratum%253Aachs%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKato%26aufirst%3DT.%2BS.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DTeng%26aufirst%3DC.%2BH.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DManary%26aufirst%3DM.%2BJ.%26aulast%3DBarboa%26aufirst%3DR.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DVinetz%26aufirst%3DJ.%2BM.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMutations%2520in%2520the%2520P-type%2520cation-transporter%2520ATPase%25204%252C%2520PfATP4%252C%2520mediate%2520resistance%2520to%2520both%2520aminopyrazole%2520and%2520spiroindolone%2520antimalarials%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3D413%26epage%3D420%26doi%3D10.1021%2Fcb500616x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyvratt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebayang, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasiak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belen Jimenez-Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, L. W.</span></span> <span> </span><span class="NLM_article-title">Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic <i>Plasmodium falciparum</i></span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5521</span>, <span class="refDoi"> DOI: 10.1038/ncomms6521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fncomms6521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25422853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFWqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5521&author=A.+B.+Vaidyaauthor=J.+M.+Morriseyauthor=Z.+Zhangauthor=S.+Dasauthor=T.+M.+Dalyauthor=T.+D.+Ottoauthor=N.+J.+Spillmanauthor=M.+Wyvrattauthor=P.+Sieglauthor=J.+Marfurtauthor=G.+Wirjanataauthor=B.+F.+Sebayangauthor=R.+N.+Priceauthor=A.+Chatterjeeauthor=A.+Nagleauthor=M.+Stasiakauthor=S.+A.+Charmanauthor=I.+Angulo-Barturenauthor=S.+Ferrerauthor=M.+Belen+Jimenez-Diazauthor=M.+S.+Martinezauthor=F.+J.+Gamoauthor=V.+M.+Averyauthor=A.+Rueckerauthor=M.+Delvesauthor=K.+Kirkauthor=M.+Berrimanauthor=S.+Kortagereauthor=J.+Burrowsauthor=E.+Fanauthor=L.+W.+Bergman&title=Pyrazoleamide+compounds+are+potent+antimalarials+that+target+Na%2B+homeostasis+in+intraerythrocytic+Plasmodium+falciparum&doi=10.1038%2Fncomms6521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum</span></div><div class="casAuthors">Vaidya, Akhil B.; Morrisey, Joanne M.; Zhang, Zhongsheng; Das, Sudipta; Daly, Thomas M.; Otto, Thomas D.; Spillman, Natalie J.; Wyvratt, Matthew; Siegl, Peter; Marfurt, Jutta; Wirjanata, Grennady; Sebayang, Boni F.; Price, Ric N.; Chatterjee, Arnab; Nagle, Advait; Stasiak, Marcin; Charman, Susan A.; Angulo-Barturen, Inigo; Ferrer, Santiago; Belen Jimenez-Diaz, Maria; Martinez, Maria Santos; Gamo, Francisco Javier; Avery, Vicky M.; Ruecker, Andrea; Delves, Michael; Kirk, Kiaran; Berriman, Matthew; Kortagere, Sandhya; Burrows, Jeremy; Fan, Erkang; Bergman, Lawrence W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5521</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The quest for new antimalarial drugs, esp. those with novel modes of action, is essential in the face of emerging drug-resistant parasites.  Here we describe a new chem. class of mols., pyrazoleamides, with potent activity against human malaria parasites and showing remarkably rapid parasite clearance in an in vivo model.  Investigations involving pyrazoleamide-resistant parasites, whole-genome sequencing and gene transfers reveal that mutations in two proteins, a calcium-dependent protein kinase (PfCDPK5) and a P-type cation-ATPase (PfATP4), are necessary to impart full resistance to these compds.  A pyrazoleamide compd. causes a rapid disruption of Na+ regulation in blood-stage Plasmodium falciparum parasites.  Similar effect on Na+ homeostasis was recently reported for spiroindolones, which are antimalarials of a chem. class quite distinct from pyrazoleamides.  Our results reveal that disruption of Na+ homeostasis in malaria parasites is a promising mode of antimalarial action mediated by at least two distinct chem. classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreHdwzsZqcX7Vg90H21EOLACvtfcHk0lh5J_yEAsAaGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFWqtrs%253D&md5=479ca0ae2654088f6399dc6a026567f1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fncomms6521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms6521%26sid%3Dliteratum%253Aachs%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DDaly%26aufirst%3DT.%2BM.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DWyvratt%26aufirst%3DM.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DSebayang%26aufirst%3DB.%2BF.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DStasiak%26aufirst%3DM.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DBelen%2BJimenez-Diaz%26aufirst%3DM.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DK.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DE.%26aulast%3DBergman%26aufirst%3DL.%2BW.%26atitle%3DPyrazoleamide%2520compounds%2520are%2520potent%2520antimalarials%2520that%2520target%2520Na%252B%2520homeostasis%2520in%2520intraerythrocytic%2520Plasmodium%2520falciparum%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D5521%26doi%3D10.1038%2Fncomms6521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs</span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ijpddr.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26401486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC283ltlWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=149-162&issue=3&author=N.+J.+Spillmanauthor=K.+Kirk&title=The+malaria+parasite+cation+ATPase+PfATP4+and+its+role+in+the+mechanism+of+action+of+a+new+arsenal+of+antimalarial+drugs&doi=10.1016%2Fj.ijpddr.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs</span></div><div class="casAuthors">Spillman Natalie Jane; Kirk Kiaran</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-62</span>
        ISSN:<span class="NLM_cas:issn">2211-3207</span>.
    </div><div class="casAbstract">The intraerythrocytic malaria parasite, Plasmodium falciparum, maintains a low cytosolic Na(+) concentration and the plasma membrane P-type cation translocating ATPase 'PfATP4' has been implicated as playing a key role in this process.  PfATP4 has been the subject of significant attention in recent years as mutations in this protein confer resistance to a growing number of new antimalarial compounds, including the spiroindolones, the pyrazoles, the dihydroisoquinolones, and a number of the antimalarial agents in the Medicines for Malaria Venture's 'Malaria Box'.  On exposure of parasites to these compounds there is a rapid disruption of cytosolic Na(+).  Whether, and if so how, such chemically distinct compounds interact with PfATP4, and how such interactions lead to parasite death, is not yet clear.  The fact that multiple different chemical classes have converged upon PfATP4 highlights its significance as a potential target for new generation antimalarial agents.  A spiroindolone (KAE609, now known as cipargamin) has progressed through Phase I and IIa clinical trials with favourable results.  In this review we consider the physiological role of PfATP4, summarise the current repertoire of antimalarial compounds for which PfATP4 is implicated in their mechanism of action, and provide an outlook on translation from target identification in the laboratory to patient treatment in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuXVN_00JXMBfKb6ELK8t0fW6udTcc2eaYR2EBVeIJ57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ltlWitw%253D%253D&md5=a56f7c306f3d3e7f9b0479c8650fb937</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DThe%2520malaria%2520parasite%2520cation%2520ATPase%2520PfATP4%2520and%2520its%2520role%2520in%2520the%2520mechanism%2520of%2520action%2520of%2520a%2520new%2520arsenal%2520of%2520antimalarial%2520drugs%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2015%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D162%26doi%3D10.1016%2Fj.ijpddr.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">Diverse chemotypes disrupt ion homeostasis in the Malaria parasite</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1111/mmi.12765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1111%2Fmmi.12765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25145582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSku7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=327-339&issue=2&author=A.+M.+Lehaneauthor=M.+C.+Ridgwayauthor=E.+Bakerauthor=K.+Kirk&title=Diverse+chemotypes+disrupt+ion+homeostasis+in+the+Malaria+parasite&doi=10.1111%2Fmmi.12765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse chemotypes disrupt ion homeostasis in the malaria parasite</span></div><div class="casAuthors">Lehane, Adele M.; Ridgway, Melanie C.; Baker, Eileen; Kirk, Kiaran</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-339</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The antimalarial spiroindolones disrupt Plasmodium falciparum Na+ regulation and induce an alkalinization of the parasite cytosol.  It has been proposed that they do so by inhibiting PfATP4, a parasite plasma membrane P-type ATPase postulated to export Na+ and import H+ equiv.  Here, we screened the 400 antiplasmodial compds. of the open access Malaria Box for their effects on parasite ion regulation.  Twenty eight compds. affected parasite Na+ and pH regulation in a manner consistent with PfATP4 inhibition.  Six of these, with chem. diverse structures, were selected for further anal.  All 6 showed reduced antiplasmodial activity against spiroindolone-resistant parasites carrying mutations in pfatp4.  We exposed parasites to incrementally increasing concns. of 2 of the 6 compds. and in both cases obtained resistant parasites with mutations in pfatp4.  The finding that diverse chemotypes have an apparently similar mechanism of action indicates that PfATP4 may be a significant Achilles' heel for the parasite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_hf1RONxDZLVg90H21EOLACvtfcHk0lil_WRfLdEKcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSku7nK&md5=f541327849168f5d6b0be80684370ab3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fmmi.12765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fmmi.12765%26sid%3Dliteratum%253Aachs%26aulast%3DLehane%26aufirst%3DA.%2BM.%26aulast%3DRidgway%26aufirst%3DM.%2BC.%26aulast%3DBaker%26aufirst%3DE.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DDiverse%2520chemotypes%2520disrupt%2520ion%2520homeostasis%2520in%2520the%2520Malaria%2520parasite%26jtitle%3DMol.%2520Microbiol.%26date%3D2014%26volume%3D94%26issue%3D2%26spage%3D327%26epage%3D339%26doi%3D10.1111%2Fmmi.12765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, A. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">Cell swelling induced by the antimalarial KAE609 (cipargamin) and other PfATP4-associated antimalarials</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e00087-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.00087-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.00087-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29555632" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00087-18&author=A.+S.+M.+Dennisauthor=A.+M.+Lehaneauthor=M.+C.+Ridgwayauthor=J.+P.+Holleranauthor=K.+Kirk&title=Cell+swelling+induced+by+the+antimalarial+KAE609+%28cipargamin%29+and+other+PfATP4-associated+antimalarials&doi=10.1128%2FAAC.00087-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1128%2FAAC.00087-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00087-18%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DA.%2BS.%2BM.%26aulast%3DLehane%26aufirst%3DA.%2BM.%26aulast%3DRidgway%26aufirst%3DM.%2BC.%26aulast%3DHolleran%26aufirst%3DJ.%2BP.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DCell%2520swelling%2520induced%2520by%2520the%2520antimalarial%2520KAE609%2520%2528cipargamin%2529%2520and%2520other%2520PfATP4-associated%2520antimalarials%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De00087-18%26doi%3D10.1128%2FAAC.00087-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosling, J. E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization and chemical inhibition of PfATP4-associated Na(+)-ATPase activity in <i>Plasmodium falciparum</i> membranes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">13327</span>– <span class="NLM_lpage">13337</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.003640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.RA118.003640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29986883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyjt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=13327-13337&issue=34&author=J.+E.+O.+Roslingauthor=M.+C.+Ridgwayauthor=R.+L.+Summersauthor=K.+Kirkauthor=A.+M.+Lehane&title=Biochemical+characterization+and+chemical+inhibition+of+PfATP4-associated+Na%28%2B%29-ATPase+activity+in+Plasmodium+falciparum+membranes&doi=10.1074%2Fjbc.RA118.003640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes</span></div><div class="casAuthors">Rosling, James E. O.; Ridgway, Melanie C.; Summers, Robert L.; Kirk, Kiaran; Lehane, Adele M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">13327-13337</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The antimalarial activity of chem. diverse compds., including the clin. candidate cipargamin, has been linked to the ATPase PfATP4 in the malaria-causing parasite Plasmodium falciparum.  The characterization of PfATP4 has been hampered by the inability thus far to achieve its functional expression in a heterologous system.  Here, we optimized a membrane ATPase assay to probe the function of PfATP4 and its chem. sensitivity.  We found that cipargamin inhibited the Na+-dependent ATPase activity present in P. falciparum membranes from WT parasites and that its potency was reduced in cipargamin-resistant PfATP4-mutant parasites.  The cipargamin-sensitive fraction of membrane ATPase activity was inhibited by all 28 of the compds. in the "Malaria Box" shown previously to disrupt ion regulation in P. falciparum in a cipargamin-like manner.  This is consistent with PfATP4 being the direct target of these compds.  Characterization of the cipargamin-sensitive ATPase activity yielded data consistent with PfATP4 being a Na+ transporter that is sensitive to physiol. relevant perturbations of pH, but not of [K+] or [Ca2+].  With an apparent Km for ATP of 0.2 mm and an apparent Km for Na+ of 16-17 mm, the protein is predicted to operate at below its half-maximal rate under normal physiol. conditions, allowing the rate of Na+ efflux to increase in response to an increase in cytosolic [Na+].  In membranes from a cipargamin-resistant PfATP4-mutant line, the apparent Km for Na+ is slightly elevated.  Our study provides new insights into the biochem. properties and chem. sensitivity of an important new antimalarial drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfYHxHytLJh7Vg90H21EOLACvtfcHk0lil_WRfLdEKcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyjt77L&md5=0f1c5b22f03f828b2d1a04f685dc563d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.003640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.003640%26sid%3Dliteratum%253Aachs%26aulast%3DRosling%26aufirst%3DJ.%2BE.%2BO.%26aulast%3DRidgway%26aufirst%3DM.%2BC.%26aulast%3DSummers%26aufirst%3DR.%2BL.%26aulast%3DKirk%26aufirst%3DK.%26aulast%3DLehane%26aufirst%3DA.%2BM.%26atitle%3DBiochemical%2520characterization%2520and%2520chemical%2520inhibition%2520of%2520PfATP4-associated%2520Na%2528%252B%2529-ATPase%2520activity%2520in%2520Plasmodium%2520falciparum%2520membranes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26issue%3D34%26spage%3D13327%26epage%3D13337%26doi%3D10.1074%2Fjbc.RA118.003640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A.-M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, T. L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Møller, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, P.</span></span> <span> </span><span class="NLM_article-title">Modulatory and catalytic modes of ATP binding by the calcium pump</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2305</span>– <span class="NLM_lpage">2314</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fsj.emboj.7601135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16710301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD28zktlaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=2305-2314&issue=11&author=A.-M.+L.+Jensenauthor=T.+L.-M.+S%C3%B8rensenauthor=C.+Olesenauthor=J.+V.+M%C3%B8llerauthor=P.+Nissen&title=Modulatory+and+catalytic+modes+of+ATP+binding+by+the+calcium+pump&doi=10.1038%2Fsj.emboj.7601135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Modulatory and catalytic modes of ATP binding by the calcium pump</span></div><div class="casAuthors">Jensen Anne-Marie Lund; Sorensen Thomas Lykke-Moller; Olesen Claus; Moller Jesper Vuust; Nissen Poul</div><div class="citationInfo"><span class="NLM_cas:title">The EMBO journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2305-14</span>
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    </div><div class="casAbstract">We present crystal structures of the calcium-free E2 state of the sarcoplasmic reticulum Ca2+ -ATPase, stabilized by the inhibitor thapsigargin and the ATP analog AMPPCP.  The structures allow us to describe the ATP binding site in a modulatory mode uncoupled from the Asp351 phosphorylation site.  The Glu439 side chain interacts with AMPPCP via an Mg2+ ion in accordance with previous Fe2+ -cleavage studies implicating this residue in the ATPase cycle and in magnesium binding.  Functional data on Ca2+ mediated activation indicate that the crystallized state represents an initial stage of ATP modulated deprotonation of E2, preceding the binding of Ca2+ ions in the membrane from the cytoplasmic side.  We propose a mechanism of Ca2+ activation of phosphorylation leading directly from the compact E2-ATP form to the Ca2E1-ATP state.  In addition, a role of Glu439 in ATP modulation of other steps of the functional cycle is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQH72L5PQJlJwaK-_ZudimnfW6udTcc2eb_T_4FdJILd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zktlaqtQ%253D%253D&md5=1db5b38b24405c5b1d40852c941eaadf</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601135%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.-M.%2BL.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DT.%2BL.-M.%26aulast%3DOlesen%26aufirst%3DC.%26aulast%3DM%25C3%25B8ller%26aufirst%3DJ.%2BV.%26aulast%3DNissen%26aufirst%3DP.%26atitle%3DModulatory%2520and%2520catalytic%2520modes%2520of%2520ATP%2520binding%2520by%2520the%2520calcium%2520pump%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26issue%3D11%26spage%3D2305%26epage%3D2314%26doi%3D10.1038%2Fsj.emboj.7601135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldgof, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostylev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manary, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanhope, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayman, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaro, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27806</span>, <span class="refDoi"> DOI: 10.1038/srep27806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fsrep27806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27291296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSlu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=27806&author=G.+M.+Goldgofauthor=J.+D.+Durrantauthor=S.+Ottilieauthor=E.+Vigilauthor=K.+E.+Allenauthor=F.+Gunawanauthor=M.+Kostylevauthor=K.+A.+Hendersonauthor=J.+Yangauthor=J.+Schenkenauthor=G.+M.+LaMonteauthor=M.+J.+Manaryauthor=A.+Muraoauthor=M.+Nachonauthor=R.+Stanhopeauthor=M.+Prescottauthor=C.+W.+McNamaraauthor=C.+W.+Slaymanauthor=R.+E.+Amaroauthor=Y.+Suzukiauthor=E.+A.+Winzeler&title=Comparative+chemical+genomics+reveal+that+the+spiroindolone+antimalarial+KAE609+%28Cipargamin%29+is+a+P-type+ATPase+inhibitor&doi=10.1038%2Fsrep27806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor</span></div><div class="casAuthors">Goldgof, Gregory M.; Durrant, Jacob D.; Ottilie, Sabine; Vigil, Edgar; Allen, Kenneth E.; Gunawan, Felicia; Kostylev, Maxim; Henderson, Kiersten A.; Yang, Jennifer; Schenken, Jake; LaMonte, Gregory M.; Manary, Micah J.; Murao, Ayako; Nachon, Marie; Stanhope, Rebecca; Prescott, Maximo; McNamara, Case W.; Slayman, Carolyn W.; Amaro, Rommie E.; Suzuki, Yo; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27806</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The spiroindolones, a new class of antimalarial medicines discovered in a cellular screen, are rendered less active by mutations in a parasite P-type ATPase, PfATP4.  We show here that Saccharomyces cerevisiae also acquires mutations in a gene encoding a P-type ATPase (ScPMA1) after exposure to spiroindolones and that these mutations are sufficient for resistance.  KAE609 resistance mutations in ScPMA1 do not confer resistance to unrelated antimicrobials, but do confer cross sensitivity to the alkyl-lysophospholipid edelfosine, which is known to displace ScPma1p from the plasma membrane.  Using an in vitro cell-free assay, we demonstrate that KAE609 directly inhibits ScPma1p ATPase activity.  KAE609 also increases cytoplasmic hydrogen ion concns. in yeast cells.  Computer docking into a ScPma1p homol. model identifies a binding mode that supports genetic resistance determinants and in vitro exptl. structure-activity relationships in both P. falciparum and S. cerevisiae.  This model also suggests a shared binding site with the dihydroisoquinolones antimalarials.  Our data support a model in which KAE609 exerts its antimalarial activity by directly interfering with P-type ATPase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe1clRbyKPb7Vg90H21EOLACvtfcHk0lgRB-BfJ4XF9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSlu7%252FK&md5=b6c042fd4d15ed7c3339ba297d860266</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fsrep27806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27806%26sid%3Dliteratum%253Aachs%26aulast%3DGoldgof%26aufirst%3DG.%2BM.%26aulast%3DDurrant%26aufirst%3DJ.%2BD.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DVigil%26aufirst%3DE.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DGunawan%26aufirst%3DF.%26aulast%3DKostylev%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DK.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSchenken%26aufirst%3DJ.%26aulast%3DLaMonte%26aufirst%3DG.%2BM.%26aulast%3DManary%26aufirst%3DM.%2BJ.%26aulast%3DMurao%26aufirst%3DA.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DStanhope%26aufirst%3DR.%26aulast%3DPrescott%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DSlayman%26aufirst%3DC.%2BW.%26aulast%3DAmaro%26aufirst%3DR.%2BE.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DComparative%2520chemical%2520genomics%2520reveal%2520that%2520the%2520spiroindolone%2520antimalarial%2520KAE609%2520%2528Cipargamin%2529%2520is%2520a%2520P-type%2520ATPase%2520inhibitor%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D27806%26doi%3D10.1038%2Fsrep27806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasquilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span> <span> </span><span class="NLM_article-title">Metabolomic profiling of the Malaria Box reveals antimalarial target pathways</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6635</span>– <span class="NLM_lpage">6649</span>, <span class="refDoi"> DOI: 10.1128/AAC.01224-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01224-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27572391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitV2gsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6635-6649&issue=11&author=E.+L.+Allmanauthor=H.+J.+Painterauthor=J.+Samraauthor=M.+Carrasquillaauthor=M.+Llinas&title=Metabolomic+profiling+of+the+Malaria+Box+reveals+antimalarial+target+pathways&doi=10.1128%2FAAC.01224-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomic profiling of the malaria box reveals antimalarial target pathways</span></div><div class="casAuthors">Allman, Erik L.; Painter, Heather J.; Samra, Jasmeet; Carrasquilla, Manuela; Llinas, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6635-6649</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The threat of widespread drug resistance to frontline antimalarials has renewed the urgency for identifying inexpensive chemotherapeutic compds. that are effective against Plasmodium falciparum, the parasite species responsible for the greatest no. of malaria-related deaths worldwide.  To aid in the fight against malaria, a recent extensive screening campaign has generated thousands of lead compds. with low micromolar activity against blood stage parasites.  A subset of these leads has been compiled by the Medicines for Malaria Venture (MMV) into a collection of structurally diverse compds. known as the MMV Malaria Box.  Currently, little is known regarding the activity of these Malaria Box compds. on parasite metab. during intraerythrocytic development, and a majority of the targets for these drugs have yet to be defined.  Here we interrogated the in vitro metabolic effects of 189 drugs (including 169 of the drug-like compds. from the Malaria Box) using ultra-high-performance liq. chromatog.-mass spectrometry (UHPLC-MS).  The resulting metabolic fingerprints provide information on the parasite biochem. pathways affected by pharmacol. intervention and offer a crit. blueprint for selecting and advancing lead compds. as next-generation antimalarial drugs.  Our results reveal several major classes of metabolic disruption, which allow us to predict the mode of action (MoA) for many of the Malaria Box compds.  We anticipate that future combination therapies will be greatly informed by these results, allowing for the selection of appropriate drug combinations that simultaneously target multiple metabolic pathways, with the aim of eliminating malaria and forestalling the expansion of drug-resistant parasites in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzNnR2JibEGrVg90H21EOLACvtfcHk0lgP_O8KkOl7zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitV2gsbY%253D&md5=d0e52536f10b6faebd13fe20ae3861f3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FAAC.01224-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01224-16%26sid%3Dliteratum%253Aachs%26aulast%3DAllman%26aufirst%3DE.%2BL.%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DSamra%26aufirst%3DJ.%26aulast%3DCarrasquilla%26aufirst%3DM.%26aulast%3DLlinas%26aufirst%3DM.%26atitle%3DMetabolomic%2520profiling%2520of%2520the%2520Malaria%2520Box%2520reveals%2520antimalarial%2520target%2520pathways%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26issue%3D11%26spage%3D6635%26epage%3D6649%26doi%3D10.1128%2FAAC.01224-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobbold, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijagal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacRae, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerman, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConville, M. J.</span></span> <span> </span><span class="NLM_article-title">Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6650</span>– <span class="NLM_lpage">6663</span>, <span class="refDoi"> DOI: 10.1128/AAC.01226-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01226-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27572396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitV2gtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6650-6663&issue=11&author=D.+J.+Creekauthor=H.+H.+Chuaauthor=S.+A.+Cobboldauthor=B.+Nijagalauthor=J.+I.+MacRaeauthor=B.+K.+Dickermanauthor=P.+R.+Gilsonauthor=S.+A.+Ralphauthor=M.+J.+McConville&title=Metabolomics-based+screening+of+the+Malaria+Box+reveals+both+novel+and+established+mechanisms+of+action&doi=10.1128%2FAAC.01226-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action</span></div><div class="casAuthors">Creek, Darren J.; Chua, Hwa H.; Cobbold, Simon A.; Nijagal, Brunda; MacRae, James I.; Dickerman, Benjamin K.; Gilson, Paul R.; Ralph, Stuart A.; McConville, Malcolm J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6650-6663</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">High-throughput phenotypic screening of chem. libraries has resulted in the identification of thousands of compds. with potent antimalarial activity, although in most cases, the mechanism(s) of action of these compds. remains unknown.  Here we have investigated the mode of action of 90 antimalarial compds. derived from the Malaria Box collection using high-coverage, untargeted metabolomics anal.  Approx. half of the tested compds. induced significant metabolic perturbations in in vitro cultures of Plasmodium falciparum.  In most cases, the metabolic profiles were highly correlated with known antimalarials, in particular artemisinin, the 4-aminoquinolines, or atovaquone.  Select Malaria Box compds. also induced changes in intermediates in essential metabolic pathways, such as isoprenoid biosynthesis (i.e., 2-C-methyl-d-erythritol 2,4-cyclodiphosphate) and linolenic acid metab. (i.e., traumatic acid).  This study provides a comprehensive database of the metabolic perturbations induced by chem. diverse inhibitors and highlights the utility of metabolomics for triaging new lead compds. and defining specific modes of action, which will assist with the development and optimization of new antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofzXMyCItAxLVg90H21EOLACvtfcHk0lgP_O8KkOl7zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitV2gtL0%253D&md5=9c5d2d434d0ba847358b8dee2fbc2e41</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1128%2FAAC.01226-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01226-16%26sid%3Dliteratum%253Aachs%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DChua%26aufirst%3DH.%2BH.%26aulast%3DCobbold%26aufirst%3DS.%2BA.%26aulast%3DNijagal%26aufirst%3DB.%26aulast%3DMacRae%26aufirst%3DJ.%2BI.%26aulast%3DDickerman%26aufirst%3DB.%2BK.%26aulast%3DGilson%26aufirst%3DP.%2BR.%26aulast%3DRalph%26aufirst%3DS.%2BA.%26aulast%3DMcConville%26aufirst%3DM.%2BJ.%26atitle%3DMetabolomics-based%2520screening%2520of%2520the%2520Malaria%2520Box%2520reveals%2520both%2520novel%2520and%2520established%2520mechanisms%2520of%2520action%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26issue%3D11%26spage%3D6650%26epage%3D6663%26doi%3D10.1128%2FAAC.01226-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatanagar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, J. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppens, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Na+ Influx Induced by new antimalarials causes rapid alterations in the cholesterol content and morphology of <i>Plasmodium falciparum</i></span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e1005647</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.ppat.1005647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27227970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOju77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1005647&issue=5&author=S.+Dasauthor=S.+Bhatanagarauthor=J.+M.+Morriseyauthor=T.+M.+Dalyauthor=J.+M.+Burnsauthor=I.+Coppensauthor=A.+B.+Vaidya&title=Na%2B+Influx+Induced+by+new+antimalarials+causes+rapid+alterations+in+the+cholesterol+content+and+morphology+of+Plasmodium+falciparum&doi=10.1371%2Fjournal.ppat.1005647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Na+ influx induced by new antimalarials causes rapid alterations in the cholesterol content and morphology of Plasmodium falciparum</span></div><div class="casAuthors">Das, Sudipta; Bhatanagar, Suyash; Morrisey, Joanne M.; Daly, Thomas M.; Burns, James M., Jr.; Coppens, Isabelle; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e1005647/1-e1005647/25</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Among the several new antimalarials discovered over the past decade are ≥3 clin. candidate drugs, each with a distinct chem. structure, that disrupt Na+ homeostasis resulting in a rapid increase in intracellular Na+ concn. ([Na+]i) within the erythrocytic stages of Plasmodium falciparum.  At present, events triggered by Na+ influx that result in parasite demise are not well-understood.  Here we report effects of 2 such drugs, a pyrazoleamide and a spiroindolone, on intraerythrocytic P. falciparum.  Within minutes following the exposure to these drugs, the trophozoite stage parasite, which normally contains little cholesterol, was made permeant by cholesterol-dependent detergents, suggesting it acquired a substantial amt. of the lipid.  Consistently, the merozoite surface protein 1 and 2 (MSP1 and MSP2), glycosylphosphotidylinositol (GPI)-anchored proteins normally uniformly distributed in the parasite plasma membrane, coalesced into clusters.  These alterations were not obsd. following drug treatment of P. falciparum parasites adapted to grow in a low [Na+] growth medium.  Both cholesterol acquisition and MSP1 coalescence were reversible upon the removal of the drugs, implicating an active process of cholesterol exclusion from trophozoites that we hypothesize is inhibited by high [Na+]i.  Electron microscopy of drug-treated trophozoites revealed substantial morphol. changes normally seen at the later schizont stage including the appearance of partial inner membrane complexes, dense organelles that resemble rhoptries and apparent nuclear division.  Together these results suggest that [Na+]i disruptor drugs by altering levels of cholesterol in the parasite, dysregulate trophozoite to schizont development and cause parasite demise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvaNdWVrmWPLVg90H21EOLACvtfcHk0lhPdE1quqk3mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOju77N&md5=f42d036aafc701beab3a1386774c5527</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005647%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBhatanagar%26aufirst%3DS.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DDaly%26aufirst%3DT.%2BM.%26aulast%3DBurns%26aufirst%3DJ.%2BM.%26aulast%3DCoppens%26aufirst%3DI.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DNa%252B%2520Influx%2520Induced%2520by%2520new%2520antimalarials%2520causes%2520rapid%2520alterations%2520in%2520the%2520cholesterol%2520content%2520and%2520morphology%2520of%2520Plasmodium%2520falciparum%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26issue%3D5%26spage%3De1005647%26doi%3D10.1371%2Fjournal.ppat.1005647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span> <span> </span><span class="NLM_article-title">A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>213</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiv358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Finfdis%2Fjiv358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26136472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFequ7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2016&pages=100-104&issue=1&author=R.+Zhangauthor=R.+Suwanaruskauthor=B.+Malleretauthor=B.+M.+Cookeauthor=F.+Nostenauthor=Y.+L.+Lauauthor=M.+Daoauthor=C.+T.+Limauthor=L.+Reniaauthor=K.+S.+Tanauthor=B.+Russell&title=A+basis+for+rapid+clearance+of+circulating+ring-stage+malaria+parasites+by+the+spiroindolone+KAE609&doi=10.1093%2Finfdis%2Fjiv358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609</span></div><div class="casAuthors">Zhang, Rou; Suwanarusk, Rossarin; Malleret, Benoit; Cooke, Brian M.; Nosten, Francois; Lau, Yee-Ling; Dao, Ming; Lim, Chwee Teck; Renia, Laurent; Tan, Kevin Shyong Wei; Russell, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-104</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Recent clin. trials revealed a surprisingly rapid clearance of red blood cells (RBCs) infected with malaria parasites by the spiroindolone KAE609.  Here, we show that ring-stage parasite-infected RBCs exposed to KAE609 become spherical and rigid, probably through osmotic dysregulation consequent to the disruption of the parasite's sodium efflux pump (ATP 4).  We also show that this peculiar drug effect is likely to cause accelerated splenic clearance of the rheol. impaired Plasmodium vivax- and Plasmodium falciparum-infected RBCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvIUy7xhSEObVg90H21EOLACvtfcHk0lhPdE1quqk3mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFequ7s%253D&md5=27f3145a76b04cb8f18d1747591e9b85</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiv358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiv358%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DMalleret%26aufirst%3DB.%26aulast%3DCooke%26aufirst%3DB.%2BM.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DLau%26aufirst%3DY.%2BL.%26aulast%3DDao%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DC.%2BT.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DK.%2BS.%26aulast%3DRussell%26aufirst%3DB.%26atitle%3DA%2520basis%2520for%2520rapid%2520clearance%2520of%2520circulating%2520ring-stage%2520malaria%2520parasites%2520by%2520the%2520spiroindolone%2520KAE609%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D213%26issue%3D1%26spage%3D100%26epage%3D104%26doi%3D10.1093%2Finfdis%2Fjiv358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Schalkwyk, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davina Nunez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, J. W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. J.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium knowlesi</i> exhibits distinct in vitro drug susceptibility profiles from those of <i>Plasmodium falciparum</i></span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2019.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ijpddr.2019.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30831468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtFygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=93-99&author=D.+A.+van%0ASchalkwykauthor=B.+Blascoauthor=R.+Davina+Nunezauthor=J.+W.+K.+Liewauthor=A.+Amirauthor=Y.+L.+Lauauthor=D.+Leroyauthor=R.+W.+Moonauthor=C.+J.+Sutherland&title=Plasmodium+knowlesi+exhibits+distinct+in+vitro+drug+susceptibility+profiles+from+those+of+Plasmodium+falciparum&doi=10.1016%2Fj.ijpddr.2019.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum</span></div><div class="casAuthors">van Schalkwyk Donelly A; Blasco Benjamin; Davina Nunez Rocio; Leroy Didier; Liew Jonathan W K; Amir Amirah; Lau Yee L; Moon Robert W; Sutherland Colin J</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">New antimalarial agents are identified and developed after extensive testing on Plasmodium falciparum parasites that can be grown in vitro.  These susceptibility studies are important to inform lead optimisation and support further drug development.  Until recently, little was known about the susceptibility of non-falciparum species as these had not been adapted to in vitro culture.  The recent culture adaptation of P. knowlesi has therefore offered an opportunity to routinely define the drug susceptibility of this species, which is phylogenetically closer to all other human malarias than is P. falciparum.  We compared the in vitro susceptibility of P. knowlesi and P. falciparum to a range of established and novel antimalarial agents under identical assay conditions.  We demonstrated that P. knowlesi is significantly less susceptible than P. falciparum to six of the compounds tested; and notably these include three ATP4 inhibitors currently under development as novel antimalarial agents, and one investigational antimalarial, AN13762, which is 67 fold less effective against P. knowlesi.  For the other compounds there was a less than two-fold difference in susceptibility between species.  We then compared the susceptibility of a recent P. knowlesi isolate, UM01, to that of the well-established, older A1-H.1 clone.  This recent isolate showed similar in vitro drug susceptibility to the A1-H.1 clone, supporting the ongoing use of the better characterised clone to further study drug susceptibility.  Lastly, we used isobologram analysis to explore the interaction of a selection of drug combinations and showed similar drug interactions across species.  The species differences in drug susceptibility reported by us here and previously, support adding in vitro drug screens against P. knowlesi to those using P. falciparum strains to inform new drug discovery and lead optimisation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaiwizgFCh9yjiVMCqkKxVfW6udTcc2eYh5GNeNPv86bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtFygsg%253D%253D&md5=5fa1213f71f2c9aeba488850ec22235e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2019.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2019.02.004%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BSchalkwyk%26aufirst%3DD.%2BA.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DDavina%2BNunez%26aufirst%3DR.%26aulast%3DLiew%26aufirst%3DJ.%2BW.%2BK.%26aulast%3DAmir%26aufirst%3DA.%26aulast%3DLau%26aufirst%3DY.%2BL.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DMoon%26aufirst%3DR.%2BW.%26aulast%3DSutherland%26aufirst%3DC.%2BJ.%26atitle%3DPlasmodium%2520knowlesi%2520exhibits%2520distinct%2520in%2520vitro%2520drug%2520susceptibility%2520profiles%2520from%2520those%2520of%2520Plasmodium%2520falciparum%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2019%26volume%3D9%26spage%3D93%26epage%3D99%26doi%3D10.1016%2Fj.ijpddr.2019.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Pelt-Koops, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pett, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graumans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Vegte-Bolmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gemert, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span> <span> </span><span class="NLM_article-title">The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks <i>Plasmodium falciparum</i> transmission to anopheles mosquito vector</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3544</span>– <span class="NLM_lpage">3548</span>, <span class="refDoi"> DOI: 10.1128/AAC.06377-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.06377-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22508309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsV2ju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3544-3548&issue=7&author=J.+C.+van%0APelt-Koopsauthor=H.+E.+Pettauthor=W.+Graumansauthor=M.+van+der%0AVegte-Bolmerauthor=G.+J.+van+Gemertauthor=M.+Rottmannauthor=B.+K.+Yeungauthor=T.+T.+Diaganaauthor=R.+W.+Sauerwein&title=The+spiroindolone+drug+candidate+NITD609+potently+inhibits+gametocytogenesis+and+blocks+Plasmodium+falciparum+transmission+to+anopheles+mosquito+vector&doi=10.1128%2FAAC.06377-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to Anopheles mosquito vector</span></div><div class="casAuthors">van Pelt-Koops, J. C.; Pett, H. E.; Graumans, W.; van der Vegte-Bolmer, M.; van Gemert, G. J.; Rottmann, M.; Yeung, B. K. S.; Diagana, T. T.; Sauerwein, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3544-3548</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The global malaria agenda has undergone a reorientation from control of clin. cases to entirely eradicating malaria.  For that purpose, a key objective is blocking transmission of malaria parasites from humans to mosquito vectors.  The new antimalarial drug candidate NITD609 was evaluated for its transmission-reducing potential and compared to a few established antimalarials (lumefantrine, artemether, primaquine), using a suite of in vitro assays.  By the use of a microscopic readout, NITD609 was found to inhibit the early and late development of Plasmodium falciparum gametocytes in vitro in a dose-dependent fashion over a range of 5 to 500 nM.  In addn., using the std. membrane feeding assay, NITD609 was also found to be a very effective drug in reducing transmission to the Anopheles stephensi mosquito vector.  Collectively, our data suggest a strong transmission-reducing effect of NITD609 acting against different P. falciparum transmission stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqE-wBC9ABY7Vg90H21EOLACvtfcHk0lh711meqNBR4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsV2ju7g%253D&md5=6568eacc3ad85bcefbad6893335e5636</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2FAAC.06377-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06377-11%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BPelt-Koops%26aufirst%3DJ.%2BC.%26aulast%3DPett%26aufirst%3DH.%2BE.%26aulast%3DGraumans%26aufirst%3DW.%26aulast%3Dvan%2Bder%2BVegte-Bolmer%26aufirst%3DM.%26aulast%3Dvan%2BGemert%26aufirst%3DG.%2BJ.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26atitle%3DThe%2520spiroindolone%2520drug%2520candidate%2520NITD609%2520potently%2520inhibits%2520gametocytogenesis%2520and%2520blocks%2520Plasmodium%2520falciparum%2520transmission%2520to%2520anopheles%2520mosquito%2520vector%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26issue%3D7%26spage%3D3544%26epage%3D3548%26doi%3D10.1128%2FAAC.06377-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazor, J.</span>; <span class="NLM_string-name">Smith, D.</span>; <span class="NLM_string-name">Crowe, M.</span>; <span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Collier, S. J.</span></span> WO Patent. <span> </span><span class="NLM_article-title">Biocatalysts and Methods for Synthesizing Derivatives of Tryptamine and Tryptamine Analogs</span>. <span class="NLM_patent">WO2009132921</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Nazor&author=D.+Smith&author=M.+Crowe&author=S.+Song&author=S.+J.+Collier&title=Biocatalysts+and+Methods+for+Synthesizing+Derivatives+of+Tryptamine+and+Tryptamine+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazor%26aufirst%3DJ.%26atitle%3DBiocatalysts%2520and%2520Methods%2520for%2520Synthesizing%2520Derivatives%2520of%2520Tryptamine%2520and%2520Tryptamine%2520Analogs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span>; <span class="NLM_string-name">Franese, G.</span>; <span class="NLM_string-name">Kuesters, E.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Lin, C.</span>; <span class="NLM_string-name">Nazor, J.</span>; <span class="NLM_string-name">Smith, D. A.</span>; <span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Teng, S.</span></span> <span> </span><span class="NLM_article-title">Chemical Process for Preparing Spiroindolones and Intermediates Thereof</span>. WO Patent. <span class="NLM_patent">WO/2013/139987</span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Crowe&author=G.+Franese&author=E.+Kuesters&author=Y.+Li&author=C.+Lin&author=J.+Nazor&author=D.+A.+Smith&author=S.+Song&author=S.+Teng&title=Chemical+Process+for+Preparing+Spiroindolones+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrowe%26aufirst%3DM.%26atitle%3DChemical%2520Process%2520for%2520Preparing%2520Spiroindolones%2520and%2520Intermediates%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazor, J.</span>; <span class="NLM_string-name">Smith, D.</span>; <span class="NLM_string-name">Crowe, M.</span>; <span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Collier, S. J.</span></span> <span> </span><span class="NLM_article-title">Biocatalysts and Methods for Synthesizing Derivatives of Tryptamine and Tryptamine Analogs</span>. WO Patent <span class="NLM_patent">WO 2013/142770</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Nazor&author=D.+Smith&author=M.+Crowe&author=S.+Song&author=S.+J.+Collier&title=Biocatalysts+and+Methods+for+Synthesizing+Derivatives+of+Tryptamine+and+Tryptamine+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazor%26aufirst%3DJ.%26atitle%3DBiocatalysts%2520and%2520Methods%2520for%2520Synthesizing%2520Derivatives%2520of%2520Tryptamine%2520and%2520Tryptamine%2520Analogs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggimann, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kittelmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luneau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J. B.</span></span> <span> </span><span class="NLM_article-title">Identification of three novel ring expansion metabolites of KAE609, a new spiroindolone agent for the treatment of malaria, in rats, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.069112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1124%2Fdmd.115.069112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26921386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGmu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=653-664&issue=5&author=S.+E.+Huskeyauthor=C.+Q.+Zhuauthor=M.+M.+Linauthor=R.+R.+Forsethauthor=H.+Guauthor=O.+Simonauthor=F.+K.+Eggimannauthor=M.+Kittelmannauthor=A.+Luneauauthor=A.+Vargasauthor=H.+Liauthor=L.+Wangauthor=H.+J.+Einolfauthor=J.+Zhangauthor=S.+Favaraauthor=H.+Heauthor=J.+B.+Mangold&title=Identification+of+three+novel+ring+expansion+metabolites+of+KAE609%2C+a+new+spiroindolone+agent+for+the+treatment+of+malaria%2C+in+rats%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.115.069112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of three novel ring expansion metabolites of KAE609, a new spiroindolone agent for the treatment of malaria, in rats, dogs, and humans</span></div><div class="casAuthors">Huskey, Su-Er W.; Zhu, Chun-qi; Lin, Melissa M.; Forseth, Ry R.; Gu, Helen; Simon, Oliver; Eggimann, Fabian K.; Kittelmann, Matthias; Luneau, Alexandre; Vargas, Alexandra; Li, Hongmei; Wang, Lai; Einolf, Heidi J.; Zhang, Jin; Favara, Sarah; He, Handan; Mangold, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">KAE609 [(1'R,3'S)-5,7'-dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[indoline-3,1'-pyridol[3,4-b]indol]-2-one] is a potent, fast-acting, schizonticidal agent being developed for the treatment of malaria.  After oral dosing of KAE609 to rats and dogs, the major radioactive component in plasma was KAE609.  An oxidative metabolite, M18, was the prominent metabolite in rat and dog plasma.  KAE609 was well absorbed and extensively metabolized such that low levels of parent compd. (≤11% of the dose) were detected in feces.  The elimination of KAE609 and metabolites was primarily mediated via biliary pathways (≥93% of the dose) in the feces of rats and dogs.  M37 and M23 were the major metabolites in rat and dog feces, resp.  Among the prominent metabolites of KAE609, the isobaric chem. species, M37, was obsd., suggesting the involvement of an isomerization or rearrangement during biotransformation.  Subsequent structural elucidation of M37 revealed that KAE609, a spiroindolone, undergoes an unusual C-C bond cleavage, followed by a 1,2-acyl shift to form a ring expansion metabolite M37.  The in vitro metab. of KAE609 in hepatocytes was investigated to understand this novel biotransformation.  The metab. of KAE609 was qual. similar across the species studied; thus, further investigation was conducted using human recombinant cytochrome P 450 enzymes.  The ring expansion reaction was found to be primarily catalyzed by cytochrome P 450 (CYP) 3A4 yielding M37.  M37 was subsequently oxidized to M18 by CYP3A4 and hydroxylated to M23 primarily by CYP1A2.  Interestingly, M37 was colorless, whereas M18 and M23 showed orange yellow color.  The source of the color of M18 and M23 was attributed to their extended conjugated system of double bonds in the structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZTtqLs5iqe7Vg90H21EOLACvtfcHk0ljmmdF7QrrGEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGmu73J&md5=cff56a60f7e40f40fb85645f9efd5ed2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.069112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.069112%26sid%3Dliteratum%253Aachs%26aulast%3DHuskey%26aufirst%3DS.%2BE.%26aulast%3DZhu%26aufirst%3DC.%2BQ.%26aulast%3DLin%26aufirst%3DM.%2BM.%26aulast%3DForseth%26aufirst%3DR.%2BR.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DSimon%26aufirst%3DO.%26aulast%3DEggimann%26aufirst%3DF.%2BK.%26aulast%3DKittelmann%26aufirst%3DM.%26aulast%3DLuneau%26aufirst%3DA.%26aulast%3DVargas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFavara%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DMangold%26aufirst%3DJ.%2BB.%26atitle%3DIdentification%2520of%2520three%2520novel%2520ring%2520expansion%2520metabolites%2520of%2520KAE609%252C%2520a%2520new%2520spiroindolone%2520agent%2520for%2520the%2520treatment%2520of%2520malaria%252C%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D5%26spage%3D653%26epage%3D664%26doi%3D10.1124%2Fdmd.115.069112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredenhagen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhnol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luneau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunkara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. S.</span></span> <span> </span><span class="NLM_article-title">KAE609 (cipargamin), a new spiroindolone agent for the treatment of malaria: evaluation of the absorption, distribution, metabolism, and excretion of a single oral 300-mg dose of [14C]KAE609 in healthy male subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.069187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1124%2Fdmd.115.069187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26921387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFelurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=672-682&issue=5&author=S.+E.+Huskeyauthor=C.+Q.+Zhuauthor=A.+Fredenhagenauthor=J.+Kuhnolauthor=A.+Luneauauthor=Z.+Jianauthor=Z.+Yangauthor=Z.+Miaoauthor=F.+Yangauthor=J.+P.+Jainauthor=G.+Sunkaraauthor=J.+B.+Mangoldauthor=D.+S.+Stein&title=KAE609+%28cipargamin%29%2C+a+new+spiroindolone+agent+for+the+treatment+of+malaria%3A+evaluation+of+the+absorption%2C+distribution%2C+metabolism%2C+and+excretion+of+a+single+oral+300-mg+dose+of+%5B14C%5DKAE609+in+healthy+male+subjects&doi=10.1124%2Fdmd.115.069187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">KAE609 (cipargamin), a new spiroindolone agent for the treatment of malaria: evaluation of the absorption, distribution, metabolism, and excretion of a single oral 300-mg dose of [14C]KAE609 in healthy male subjects</span></div><div class="casAuthors">Huskey, Su-Er W.; Zhu, Chun-qi; Fredenhagen, Andreas; Kuhnol, Jurgen; Luneau, Alexandre; Jian, Zhigang; Yang, Ziping; Miao, Zhuang; Yang, Fan; Jain, Jay P.; Sunkara, Gangadhar; Mangold, James B.; Stein, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">672-682</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">KAE609 [(1' R,3' S)-5,7'-dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[ indoline-3,1'-pyridol[3,4-b]indol]-2-one] is a potent, fast-acting, schizonticidal agent in clin. development for the treatment of malaria.  This study investigated the absorption, distribution, metab., and excretion of KAE609 after oral administration of [14C]KAE609 in healthy subjects.  After oral administration to human subjects, KAE609 was the major radioactive component (approx. 76% of the total radioactivity in plasma); M23 was the major circulating oxidative metabolite (approx. 12% of the total radioactivity in plasma).  Several minor oxidative metabolites (M14, M16, M18, and M23.5B) were also identified, each accounting for approx. 3%-8% of the total radioactivity in plasma.  KAE609 was well absorbed and extensively metabolized, such that KAE609 accounted for approx. 32% of the dose in feces.  The elimination of KAE609 and metabolites was primarily mediated via biliary pathways.  M23 was the major metabolite in feces.  Subjects reported semen discoloration after dosing in prior studies; therefore, semen samples were collected once from each subject to further evaluate this clin. observation.  Radioactivity excreted in semen was negligible, but the major component in semen was M23, supporting the rationale that this yellow-colored metabolite was the main source of semen discoloration.  In this study, a new metabolite,M16, was identified in all biol. matrixes albeit at low levels.  All 19 recombinant human cytochrome P 450 enzymes were capable of catalyzing the hydroxylation of M23 to form M16 even though the extent of turnover was very low.  Thus, electrochem. was used to generate a sufficient quantity of M16 for structural elucidation.  Metabolic pathways of KAE609 in humans are summarized herein and M23 is the major metabolite in plasma and excreta.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAsHpw7CEIRrVg90H21EOLACvtfcHk0lgBFFJ30itwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFelurnP&md5=b4312de9c877c142fa82085db2e72377</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.069187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.069187%26sid%3Dliteratum%253Aachs%26aulast%3DHuskey%26aufirst%3DS.%2BE.%26aulast%3DZhu%26aufirst%3DC.%2BQ.%26aulast%3DFredenhagen%26aufirst%3DA.%26aulast%3DKuhnol%26aufirst%3DJ.%26aulast%3DLuneau%26aufirst%3DA.%26aulast%3DJian%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DSunkara%26aufirst%3DG.%26aulast%3DMangold%26aufirst%3DJ.%2BB.%26aulast%3DStein%26aufirst%3DD.%2BS.%26atitle%3DKAE609%2520%2528cipargamin%2529%252C%2520a%2520new%2520spiroindolone%2520agent%2520for%2520the%2520treatment%2520of%2520malaria%253A%2520evaluation%2520of%2520the%2520absorption%252C%2520distribution%252C%2520metabolism%252C%2520and%2520excretion%2520of%2520a%2520single%2520oral%2520300-mg%2520dose%2520of%2520%255B14C%255DKAE609%2520in%2520healthy%2520male%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D5%26spage%3D672%26epage%3D682%26doi%3D10.1124%2Fdmd.115.069187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">6209</span>– <span class="NLM_lpage">6214</span>, <span class="refDoi"> DOI: 10.1128/AAC.03393-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.03393-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25114127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSit7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=6209-6214&issue=10&author=F.+J.+Leongauthor=R.+Liauthor=J.+P.+Jainauthor=G.+Lefevreauthor=B.+Magnussonauthor=T.+T.+Diaganaauthor=P.+Pertel&title=A+first-in-human+randomized%2C+double-blind%2C+placebo-controlled%2C+single-+and+multiple-ascending+oral+dose+study+of+novel+antimalarial+Spiroindolone+KAE609+%28Cipargamin%29+to+assess+its+safety%2C+tolerability%2C+and+pharmacokinetics+in+healthy+adult+volunteers&doi=10.1128%2FAAC.03393-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone KAE609 (cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span></div><div class="casAuthors">Leong, F. Joel; Li, Ruobing; Jain, Jay Prakash; Lefevre, Gilbert; Magnusson, Baldur; Diagana, Thierry T.; Pertel, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6209-6214, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This first-in-human randomized, double-blind, placebo-controlled, ascending-single and -multiple oral dose study was designed to evaluate the safety, tolerability, and pharmacokinetics in healthy volunteers of KAE609 (cipargamin; formerly NITD609), a spiroindolone now in trials for malaria treatment.  It was studied in single-dose cohorts (1 to 300 mg, including one 30-mg food effect cohort) with 4 to 10 subjects in each cohort and in multiple-dose cohorts (10 to 150 mg once daily for 3 days) with 8 subjects in each cohort.  The follow-up period was 6 to 8 days post-last dose.  Safety and pharmacokinetics were assessed at scheduled time points during the study.  Systemic exposure in terms of the area under the concn.-time curve from 0h extrapolated to infinity (AUC0-inf) increased in a dose-proportional manner over the dose range of 1 to 300 mg.  The AUC from time zero to the time of the last quantifiable concn. (AUClast) and the max. concn. of drug in plasma (Cmax) also increased in an approx. dose-proportional manner.  When administered daily for 3 days, the accumulation ratio on day 3 (the AUC from time zero to 24 h postdosing [AUC0-24] on day 3/AUC0-24 on day 1) was in the range of 1.5 to 2 in the studied dose range (10 to 150 mg) and was consistent with an elimination half-life of around 24 h.  Urine anal. for unchanged KAE609 revealed negligible amts. (≤0.01%) were excreted renally.  The high fat food intake did not affect the extent of KAE609 absorption (AUC); however, the Cmax was reduced by around 27%.  KAE609 was tolerated in this study, with transient gastrointestinal and genitourinary adverse events of mild to moderate intensity (semen discoloration, diarrhea, nausea and abdominal discomfort, dizziness and headache, catheter site hematoma).  Gastrointestinal and genitourinary adverse events increased with rising doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RN4uvEbCA7Vg90H21EOLACvtfcHk0lgBFFJ30itwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSit7vM&md5=ed3f8398fedfb5a3d1f752adb3a4b38f</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.03393-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03393-14%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DLefevre%26aufirst%3DG.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26atitle%3DA%2520first-in-human%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520single-%2520and%2520multiple-ascending%2520oral%2520dose%2520study%2520of%2520novel%2520antimalarial%2520Spiroindolone%2520KAE609%2520%2528Cipargamin%2529%2520to%2520assess%2520its%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D10%26spage%3D6209%26epage%3D6214%26doi%3D10.1128%2FAAC.03393-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Cardiotoxicity of antimalarial drugs</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(07)70187-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2807%2970187-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=17646028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsF2rsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=549-558&issue=8&author=N.+J.+White&title=Cardiotoxicity+of+antimalarial+drugs&doi=10.1016%2FS1473-3099%2807%2970187-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of antimalarial drugs</span></div><div class="casAuthors">White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">549-558</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  There are consistent differences in cardiovascular state between acute illness in malaria and recovery that prolong the electrocardiog. QT interval and have been misinterpreted as resulting from antimalarial cardiotoxicity.  Of the different classes of antimalarial drugs, only the quinolines, and structurally related antimalarial drugs, have clin. significant cardiovascular effects.  Drugs in this class can exacerbate malaria-assocd. orthostatic hypotension and several have been shown to delay ventricular depolarization slightly (class 1c effect), resulting in widening of the QRS complex, but only quinidine and halofantrine have clin. significant effects on ventricular repolarization (class 3 effect).  Both drugs cause potentially dangerous QT prolongation, and halofantrine has been assocd. with sudden death.  The parenteral quinoline formulations (chloroquine, quinine, and quinidine) are predictably hypotensive when injected rapidly, and cardiovascular collapse can occur with self-poisoning.  Transiently hypotensive plasma concns. of chloroquine can occur when doses of 5 mg base/kg or more are given by i.m. or s.c. injection.  At currently recommended doses, other antimalarial drugs do not have clin. significant cardiac effects.  More information on amodiaquine, primaquine, and the newer structurally related compds. is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHUfXc7qSBrVg90H21EOLACvtfcHk0lgL-Goq2HTMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsF2rsLc%253D&md5=5a3ea7424802a3c9a899b1e545f55773</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2807%2970187-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252807%252970187-1%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DCardiotoxicity%2520of%2520antimalarial%2520drugs%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2007%26volume%3D7%26issue%3D8%26spage%3D549%26epage%3D558%26doi%3D10.1016%2FS1473-3099%2807%2970187-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Se, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somethy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phann, S.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriwichai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buathong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntawunginn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitprasat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siripokasupkul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teja-Isavadharm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmermans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanteri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewkungwal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auayporn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chour, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantilena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D.</span></span> <span> </span><span class="NLM_article-title">Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6067</span>, <span class="refDoi"> DOI: 10.1128/AAC.02667-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.02667-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25092702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslShsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=6056-6067&issue=10&author=J.+Manningauthor=P.+Vanachayangkulauthor=C.+Lonauthor=M.+Springauthor=M.+Soauthor=D.+Seaauthor=Y.+Seauthor=S.+Somethyauthor=S.-T.+Phannauthor=S.+Channauthor=S.+Sriwichaiauthor=N.+Buathongauthor=W.+Kuntawunginnauthor=M.+Mitprasatauthor=R.+Siripokasupkulauthor=P.+Teja-Isavadharmauthor=E.+Sohauthor=A.+Timmermansauthor=C.+Lanteriauthor=J.+Kaewkungwalauthor=M.+Auaypornauthor=D.+Tangauthor=C.+M.+Chourauthor=S.+Promauthor=M.+Haigneyauthor=L.+Cantilenaauthor=D.+Saunders&title=Randomized%2C+double-blind%2C+placebo-controlled+clinical+trial+of+a+two-day+regimen+of+dihydroartemisinin-piperaquine+for+malaria+prevention+halted+for+concern+over+prolonged+corrected+QT+interval&doi=10.1128%2FAAC.02667-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval</span></div><div class="casAuthors">Manning, Jessica; Vanachayangkul, Pattaraporn; Lon, Chanthap; Spring, Michele; So, Mary; Sea, Darapiseth; Se, Youry; Somethy, Sok; Phann, Sut-Thang; Chann, Soklyda; Sriwichai, Sabaithip; Buathong, Nillawan; Kuntawunginn, Worachet; Mitprasat, Mashamon; Siripokasupkul, Raveewan; Teja-Isavadharm, Paktiya; Soh, Eugene; Timmermans, Ans; Lanteri, Charlotte; Kaewkungwal, Jaranit; Auayporn, Montida; Tang, Douglas; Chour, Char Meng; Prom, Satharath; Haigney, Mark; Cantilena, Louis; Saunders, David</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6056-6067, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen.  We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces.  The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation.  Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg piperaquine within 30 min to 3 h of a meal once per mo for a planned 4-mo period with periodic electrocardiog. and pharmacokinetic assessment.  The study was halted after only 6 wk (69 of 231 projected volunteers enrolled) when four volunteers met a prespecified cardiac safety endpoint of QTcF (Fridericia's formula for correct QT interval) prolongation of >500 ms.  The pharmacodynamic effect on the surface ECG (ECG) peaked approx. 4 h after piperaquine dosing and lasted 4 to 8 h.  Unblinded review by the data safety monitoring board revealed mean QTcF prolongation of 46 ms over placebo at the max. concn. of drug in serum (Cmax) on day 2.  Given that dihydroartemisinin-piperaquine is one of the few remaining effective antimalarial agents in Cambodia, compressed 2-day treatment courses of dihydroartemisinin-piperaquine are best avoided until the clin. significance of these findings are more thoroughly evaluated.  Because ECG monitoring is often unavailable in areas where malaria is endemic, repolarization risk could be mitigated by using conventional 3-day regimens, fasting, and avoidance of repeated dosing or coadministration with other QT-prolonging medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo70UliZKVFc7Vg90H21EOLACvtfcHk0lgL-Goq2HTMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslShsrrI&md5=a762034b2cb8ec20bd13b85ed622dffb</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1128%2FAAC.02667-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02667-14%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DJ.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DLon%26aufirst%3DC.%26aulast%3DSpring%26aufirst%3DM.%26aulast%3DSo%26aufirst%3DM.%26aulast%3DSea%26aufirst%3DD.%26aulast%3DSe%26aufirst%3DY.%26aulast%3DSomethy%26aufirst%3DS.%26aulast%3DPhann%26aufirst%3DS.-T.%26aulast%3DChann%26aufirst%3DS.%26aulast%3DSriwichai%26aufirst%3DS.%26aulast%3DBuathong%26aufirst%3DN.%26aulast%3DKuntawunginn%26aufirst%3DW.%26aulast%3DMitprasat%26aufirst%3DM.%26aulast%3DSiripokasupkul%26aufirst%3DR.%26aulast%3DTeja-Isavadharm%26aufirst%3DP.%26aulast%3DSoh%26aufirst%3DE.%26aulast%3DTimmermans%26aufirst%3DA.%26aulast%3DLanteri%26aufirst%3DC.%26aulast%3DKaewkungwal%26aufirst%3DJ.%26aulast%3DAuayporn%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DD.%26aulast%3DChour%26aufirst%3DC.%2BM.%26aulast%3DProm%26aufirst%3DS.%26aulast%3DHaigney%26aufirst%3DM.%26aulast%3DCantilena%26aufirst%3DL.%26aulast%3DSaunders%26aufirst%3DD.%26atitle%3DRandomized%252C%2520double-blind%252C%2520placebo-controlled%2520clinical%2520trial%2520of%2520a%2520two-day%2520regimen%2520of%2520dihydroartemisinin-piperaquine%2520for%2520malaria%2520prevention%2520halted%2520for%2520concern%2520over%2520prolonged%2520corrected%2520QT%2520interval%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D10%26spage%3D6056%26epage%3D6067%26doi%3D10.1128%2FAAC.02667-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kangas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lickliter, J.</span></span> <span> </span><span class="NLM_article-title">Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3500</span>, <span class="refDoi"> DOI: 10.1128/AAC.00340-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.00340-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25845867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFGisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3493-3500&issue=6&author=D.+S.+Steinauthor=J.+P.+Jainauthor=M.+Kangasauthor=G.+Lefevreauthor=S.+Machineniauthor=P.+Griffinauthor=J.+Lickliter&title=Open-label%2C+single-dose%2C+parallel-group+study+in+healthy+volunteers+to+determine+the+drug-drug+interaction+potential+between+KAE609+%28cipargamin%29+and+piperaquine&doi=10.1128%2FAAC.00340-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine</span></div><div class="casAuthors">Stein, Daniel S.; Jain, Jay Prakash; Kangas, Michael; Lefevre, Gilbert; Machineni, Surendra; Griffin, Paul; Lickliter, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3493-3500</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">KAE609 represents a new class of potent, fast-acting, schizonticidal antimalarials.  This study investigated the safety and pharmacokinetics of KAE609 in combination with the long-acting antimalarial piperaquine (PPQ) in healthy volunteers.  A two-way pharmacokinetic interaction was hypothesized for KAE609 and PPQ, as both drugs are CYP3A4 substrates and inhibitors.  The potential for both agents to affect the QT interval was also assessed.  This was an open-label, parallel-group, single-dose study with healthy volunteers.  Subjects were randomized to four parallel dosing arms with five cohorts (2:2:2:2:1), receiving 75 mg KAE609 plus 320 mg PPQ, 25 mg KAE609 plus 1,280 mg PPQ, 25 mg KAE609 alone, 320 mg PPQ alone, or 1,280 mg PPQ alone.  Triplicate electrocardiograms were performed over the first 24 h after dosing, with single electrocardiograms at other time points.  Routine safety (up to 89 days) and pharmacokinetic (up to 61 days) assessments were performed.  Of the 110 subjects recruited, 99 completed the study.  Coadministration of PPQ had no overall effect on exposure to KAE609, although 1,280 mg PPQ decreased the KAE609 max. concn. (Cmax) by 17%.  The group that received 25 mg KAE609 plus 1,280 mg PPQ showed a 32% increase in the PPQ area under the concn.-time curve from 0 to infinity (AUCinf), while the group that received 75 mg KAE609 plus 320 mg PPQ showed a 14% redn.  Mean changes from baseline in the QT interval cor. by Fridericia's method (QTcF) and the QT interval cor. by Bazett's method (QTcB) with PPQ were consistent with its known effects.  PPQ but not KAE609 exposure correlated with cor. QT interval (QTc) increases, and KAE609 did not affect the PPQ exposure-QTc relationship.  The QTcF effect for PPQ (least-squares est. of the difference in mean maximal changes from baseline of 7.47 ms [90% confidence interval, 3.55 to 11.4 ms]) was consistent with the criteria for a pos. thorough QT study.  No subject had QTcF or QTcB values of >500 ms.  Both drugs given alone or in combination were well tolerated, with no deaths, serious adverse events (AEs), or severe AEs reported.  Most AEs were mild; upper respiratory tract infections, headache, diarrhea, and oropharyngeal pain were most common.  PPQ and KAE609 coadministration had no relevant effect on exposure to either agent, and KAE609 did not affect or potentiate the known effects of PPQ on cardiac conduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOxcJwuhFJJLVg90H21EOLACvtfcHk0lj02BiTMrbMAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFGisb8%253D&md5=d697e51100b0a149663658bc78b5fe31</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FAAC.00340-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00340-15%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DD.%2BS.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DKangas%26aufirst%3DM.%26aulast%3DLefevre%26aufirst%3DG.%26aulast%3DMachineni%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DLickliter%26aufirst%3DJ.%26atitle%3DOpen-label%252C%2520single-dose%252C%2520parallel-group%2520study%2520in%2520healthy%2520volunteers%2520to%2520determine%2520the%2520drug-drug%2520interaction%2520potential%2520between%2520KAE609%2520%2528cipargamin%2529%2520and%2520piperaquine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D6%26spage%3D3493%26epage%3D3500%26doi%3D10.1128%2FAAC.00340-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span> </span><span class="NLM_article-title">A Study to Assess Efficacy, Safety of KAE609
in Adult Patients With
Acute Malaria Mono-Infection</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2015</span>;  <span class="NLM_fpage">NCT01860989</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT01860989?term=NCT01860989&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01860989?term=NCT01860989&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+to+Assess+Efficacy%2C+Safety+of+KAE609%0Ain+Adult+Patients+With%0AAcute+Malaria+Mono-Infection.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%2C+2015%3B+NCT01860989%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01860989%3Fterm%3DNCT01860989%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520to%2520Assess%2520Efficacy%252C%2520Safety%2520of%2520KAE609%250Ain%2520Adult%2520Patients%2520With%250AAcute%2520Malaria%2520Mono-Infection%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015%26spage%3DNCT01860989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoa, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamed, K.</span></span> <span> </span><span class="NLM_article-title">Estimation of the in vivo MIC of cipargamin in uncomplicated <i>Plasmodium falciparum</i> malaria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e01940-16</span>, <span class="refDoi"> DOI: 10.1128/AAC.01940-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01940-16" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=e01940-16&issue=2&author=T.+T.+Hienauthor=N.+J.+Whiteauthor=N.+T.+Thuy-Nhienauthor=N.+T.+Hoaauthor=P.+D.+Thuanauthor=J.+Tarningauthor=F.+Nostenauthor=B.+Magnussonauthor=J.+P.+Jainauthor=K.+Hamed&title=Estimation+of+the+in+vivo+MIC+of+cipargamin+in+uncomplicated+Plasmodium+falciparum+malaria&doi=10.1128%2FAAC.01940-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1128%2FAAC.01940-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01940-16%26sid%3Dliteratum%253Aachs%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DHoa%26aufirst%3DN.%2BT.%26aulast%3DThuan%26aufirst%3DP.%2BD.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DHamed%26aufirst%3DK.%26atitle%3DEstimation%2520of%2520the%2520in%2520vivo%2520MIC%2520of%2520cipargamin%2520in%2520uncomplicated%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D61%26issue%3D2%26spage%3De01940-16%26doi%3D10.1128%2FAAC.01940-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueangweerayut, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeyapant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Spiroindolone KAE609 for falciparum and vivax malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1315860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1315860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25075833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=403-410&issue=5&author=N.+J.+Whiteauthor=S.+Pukrittayakameeauthor=A.+P.+Phyoauthor=R.+Rueangweerayutauthor=F.+Nostenauthor=P.+Jittamalaauthor=A.+Jeeyapantauthor=J.+P.+Jainauthor=G.+Lefevreauthor=R.+Liauthor=B.+Magnussonauthor=T.+T.+Diaganaauthor=F.+J.+Leong&title=Spiroindolone+KAE609+for+falciparum+and+vivax+malaria&doi=10.1056%2FNEJMoa1315860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolone KAE609 for falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Pukrittayakamee, Sasithon; Phyo, Aung Pyae; Rueangweerayut, Ronnatrai; Nosten, Francois; Jittamala, Podjanee; Jeeyapant, Atthanee; Jain, Jay Prakash; Lefevre, Gilbert; Li, Ruobing; Magnusson, Baldur; Diagana, Thierry T.; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">403-410, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synthetic antimalarial spiroindolone analog with potent, dose-dependent antimalarial activity against asexual and sexual stages of Plasmodium falciparum.  Methods: We conducted a phase 2, open-label study at three centers in Thailand to assess the antimalarial efficacy, safety, and adverse-event profile of KAE609, at a dose of 30 mg per day for 3 days, in two sequential cohorts of adults with uncomplicated P. vivax malaria (10 patients) or P. falciparum malaria.  The primary end point was the parasite clearance time.  Results: The median parasite clearance time was 12 h in each cohort (interquartile range, 8 to 16 h in patients with P. vivax malaria and 10 to 16 h in those with P. falciparum malaria).  The median half-lives for parasite clearance were 0.95 h (range, 0.68 to 2.01; interquartile range, 0.85 to 1.14) in the patients with P. vivax malaria and 0.90 h (range, 0.68 to 1.64; interquartile range, 0.78 to 1.07) in those with P. falciparum malaria.  By comparison, only 19 of 5076 patients with P. falciparum malaria (<1%) who were treated with oral artesunate in Southeast Asia had a parasite clearance half-life of less than 1 h.  Adverse events were reported in 14 patients (67%), with nausea being the most common.  The adverse events were generally mild and did not lead to any discontinuations of the drug.  The mean terminal half-life for the elimination of KAE609 was 20.8 h (range, 11.3 to 37.6), supporting a once-daily oral dosing regimen.  Conclusions: KAE609, at dose of 30 mg daily for 3 days, cleared parasitemia rapidly in adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkg77w-ALxg7Vg90H21EOLACvtfcHk0lgFFNtItC641Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7vF&md5=a760f4182037c5e2c1834fddfaf21db9</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315860%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DRueangweerayut%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DJeeyapant%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DLefevre%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DSpiroindolone%2520KAE609%2520for%2520falciparum%2520and%2520vivax%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D5%26spage%3D403%26epage%3D410%26doi%3D10.1056%2FNEJMoa1315860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flegg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span> <span> </span><span class="NLM_article-title">Standardizing the measurement of parasite clearance in <i>falciparum</i> malaria: the parasite clearance estimator</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-10-339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2F1475-2875-10-339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22074219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FmsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=339&author=J.+A.+Fleggauthor=P.+J.+Guerinauthor=N.+J.+Whiteauthor=K.+Stepniewska&title=Standardizing+the+measurement+of+parasite+clearance+in+falciparum+malaria%3A+the+parasite+clearance+estimator&doi=10.1186%2F1475-2875-10-339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator</span></div><div class="casAuthors">Flegg Jennifer A; Guerin Philippe J; White Nicholas J; Stepniewska Kasia</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A significant reduction in parasite clearance rates following artesunate treatment of falciparum malaria, and increased failure rates following artemisinin combination treatments (ACT), signaled emergent artemisinin resistance in Western Cambodia.  Accurate measurement of parasite clearance is therefore essential to assess the spread of artemisinin resistance in Plasmodium falciparum.  The slope of the log-parasitaemia versus time relationship is considered to be the most robust measure of anti-malarial effect.  However, an initial lag phase of numerical instability often precedes a steady exponential decline in the parasite count after the start of anti-malarial treatment.  This lag complicates the clearance estimation, introduces observer subjectivity, and may influence the accuracy and consistency of reported results.  METHODS:  To address this problem, a new approach to modelling clearance of malaria parasites from parasitaemia-time profiles has been explored and validated.  The methodology detects when a lag phase is present, selects the most appropriate model (linear, quadratic or cubic) to fit log-transformed parasite data, and calculates estimates of parasite clearance adjusted for this lag phase.  Departing from previous approaches, parasite counts below the level of detection are accounted for and not excluded from the calculation.  RESULTS:  Data from large clinical studies with frequent parasite counts were examined.  The effect of a lag phase on parasite clearance rate estimates is discussed, using individual patient data examples.  As part of the World Wide Antimalarial Resistance Network's (WWARN) efforts to make innovative approaches available to the malaria community, an automated informatics tool: the parasite clearance estimator has been developed.  CONCLUSIONS:  The parasite clearance estimator provides a consistent, reliable and accurate method to estimate the lag phase and malaria parasite clearance rate.  It could be used to detect early signs of emerging resistance to artemisinin derivatives and other compounds which affect ring-stage clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSXdhEejvf5WgRQsDqrjW_fW6udTcc2eaZ3jssOuNW57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FmsVKgtQ%253D%253D&md5=4b11cba2c31cd4b7ea4abf0776b2689a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-10-339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-10-339%26sid%3Dliteratum%253Aachs%26aulast%3DFlegg%26aufirst%3DJ.%2BA.%26aulast%3DGuerin%26aufirst%3DP.%2BJ.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DStepniewska%26aufirst%3DK.%26atitle%3DStandardizing%2520the%2520measurement%2520of%2520parasite%2520clearance%2520in%2520falciparum%2520malaria%253A%2520the%2520parasite%2520clearance%2520estimator%26jtitle%3DMalar.%2520J.%26date%3D2011%26volume%3D10%26spage%3D339%26doi%3D10.1186%2F1475-2875-10-339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span> </span><span class="NLM_article-title">Safety of KAE609 in Adults With Uncomplicated <i>Plasmodium
falciparum</i> Malaria</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>. <span class="NLM_year" style="font-weight: bold;">2017</span>;  <span class="NLM_fpage">NCT03334747</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03334747?term=NCT03334747&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03334747?term=NCT03334747&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety+of+KAE609+in+Adults+With+Uncomplicated+Plasmodium%0Afalciparum+Malaria.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health.+2017%3B+NCT03334747%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03334747%3Fterm%3DNCT03334747%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DSafety%2520of%2520KAE609%2520in%2520Adults%2520With%2520Uncomplicated%2520Plasmodium%250Afalciparum%2520Malaria%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03334747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span> <span> </span><span class="NLM_article-title">Imidazolopiperazines: hit to lead optimization of new antimalarial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5116</span>– <span class="NLM_lpage">5130</span>, <span class="refDoi"> DOI: 10.1021/jm2003359</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003359" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5116-5130&issue=14&author=T.+Wuauthor=A.+Nagleauthor=K.+Kuhenauthor=K.+Gagaringauthor=R.+Borboaauthor=C.+Francekauthor=Z.+Chenauthor=D.+Plouffeauthor=A.+Gohauthor=S.+B.+Lakshminarayanaauthor=J.+Wuauthor=H.+Q.+Angauthor=P.+Zengauthor=M.+L.+Kangauthor=W.+Tanauthor=M.+Tanauthor=N.+Yeauthor=X.+Linauthor=C.+Caldwellauthor=J.+Ekauthor=S.+Skolnikauthor=F.+Liuauthor=J.+Wangauthor=J.+Changauthor=C.+Liauthor=T.+Hollenbeckauthor=T.+Tuntlandauthor=J.+Isbellauthor=C.+Fischliauthor=R.+Brunauthor=M.+Rottmannauthor=V.+Dartoisauthor=T.+Kellerauthor=T.+Diaganaauthor=E.+Winzelerauthor=R.+Glynneauthor=D.+C.+Tullyauthor=A.+K.+Chatterjee&title=Imidazolopiperazines%3A+hit+to+lead+optimization+of+new+antimalarial+agents&doi=10.1021%2Fjm2003359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents</span></div><div class="casAuthors">Wu, Tao; Nagle, Advait; Kuhen, Kelli; Gagaring, Kerstin; Borboa, Rachel; Francek, Caroline; Chen, Zhong; Plouffe, David; Goh, Anne; Lakshminarayana, Suresh B.; Wu, Jeanette; Ang, Hui Qing; Zeng, Peiting; Kang, Min Low; Tan, William; Tan, Maria; Ye, Nicole; Lin, Xuena; Caldwell, Christopher; Ek, Jared; Skolnik, Suzanne; Liu, Fenghua; Wang, Jianling; Chang, Jonathan; Li, Chun; Hollenbeck, Thomas; Tuntland, Tove; Isbell, John; Fischli, Christoph; Brun, Reto; Rottmann, Matthias; Dartois, Veronique; Keller, Thomas; Diagana, Thierry; Winzeler, Elizabeth; Glynne, Richard; Tully, David C.; Chatterjee, Arnab K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5116-5130</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from a hit series from a GNF compd. library collection and based on a cell-based proliferation assay of Plasmodium falciparum, a novel imidazolopiperazine scaffold was optimized.  SAR for this series of compds. is discussed, focusing on optimization of cellular potency against wild-type and drug resistant parasites and improvement of physiochem. and pharmacokinetic properties.  The lead compds. in this series showed good potencies in vitro and decent oral exposure levels in vivo.  In a Plasmodium berghei mouse infection model, one lead compd. lowered the parasitemia level by 99.4% after administration of 100 mg/kg single oral dose and prolonged mice survival by an av. of 17.0 days.  The lead compds. were also well-tolerated in the preliminary in vitro toxicity studies and represents an interesting lead for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaD1QipkA-QLVg90H21EOLACvtfcHk0lidS6i06v8uvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFags7s%253D&md5=eab02c18fda60302ffbcc581256cf149</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm2003359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003359%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DAng%26aufirst%3DH.%2BQ.%26aulast%3DZeng%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DM.%2BL.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DEk%26aufirst%3DJ.%26aulast%3DSkolnik%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DHollenbeck%26aufirst%3DT.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DDiagana%26aufirst%3DT.%26aulast%3DWinzeler%26aufirst%3DE.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DTully%26aufirst%3DD.%2BC.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26atitle%3DImidazolopiperazines%253A%2520hit%2520to%2520lead%2520optimization%2520of%2520new%2520antimalarial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D14%26spage%3D5116%26epage%3D5130%26doi%3D10.1021%2Fjm2003359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span> <span> </span><span class="NLM_article-title">Snapshot PK: a rapid rodent in vivo preclinical screening approach</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2007.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.drudis.2007.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18405850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD1c3kslSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=360-367&author=B.+Liuauthor=J.+Changauthor=W.+P.+Gordonauthor=J.+Isbellauthor=Y.+Zhouauthor=T.+Tuntland&title=Snapshot+PK%3A+a+rapid+rodent+in+vivo+preclinical+screening+approach&doi=10.1016%2Fj.drudis.2007.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Snapshot PK: a rapid rodent in vivo preclinical screening approach</span></div><div class="casAuthors">Liu Bo; Chang Jonathan; Gordon William P; Isbell John; Zhou Yingyao; Tuntland Tove</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">360-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Described in this article are strategies implemented to increase the throughput of in vivo rodent pharmacokinetic (PK) studies using the snapshot PK study design and automated methods for compound submission, sample processing, data analysis and reporting.  Applying snapshot PK studies to categorize the oral exposure of >1300 discovery compounds as low, moderate or high resulted in an attrition rate of 86%.  The follow up full PK studies on the remaining compounds found that 98% of the compounds were predicted in the correct (69%) or adjacent (29%) oral exposure category by the snapshot PK studies.  These results demonstrate that the snapshot PK screen in rodents can serve as an effective and efficient in vivo tool in the compound selection process in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7lxjN22Wtb4xhnOQkIHOxfW6udTcc2ebqyZPyM7pCybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3kslSkuw%253D%253D&md5=2f0ca34fc2b06e13fc85fb28be221ffe</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2007.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2007.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26atitle%3DSnapshot%2520PK%253A%2520a%2520rapid%2520rodent%2520in%2520vivo%2520preclinical%2520screening%2520approach%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D360%26epage%3D367%26doi%3D10.1016%2Fj.drudis.2007.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alper, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span> <span> </span><span class="NLM_article-title">Imidazolopiperazines: lead optimization of the second-generation antimalarial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4244</span>– <span class="NLM_lpage">4273</span>, <span class="refDoi"> DOI: 10.1021/jm300041e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300041e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2kt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4244-4273&issue=9&author=A.+Nagleauthor=T.+Wuauthor=K.+Kuhenauthor=K.+Gagaringauthor=R.+Borboaauthor=C.+Francekauthor=Z.+Chenauthor=D.+Plouffeauthor=X.+Linauthor=C.+Caldwellauthor=J.+Ekauthor=S.+Skolnikauthor=F.+Liuauthor=J.+Wangauthor=J.+Changauthor=C.+Liauthor=B.+Liuauthor=T.+Hollenbeckauthor=T.+Tuntlandauthor=J.+Isbellauthor=T.+Chuanauthor=P.+B.+Alperauthor=C.+Fischliauthor=R.+Brunauthor=S.+B.+Lakshminarayanaauthor=M.+Rottmannauthor=T.+T.+Diaganaauthor=E.+A.+Winzelerauthor=R.+Glynneauthor=D.+C.+Tullyauthor=A.+K.+Chatterjee&title=Imidazolopiperazines%3A+lead+optimization+of+the+second-generation+antimalarial+agents&doi=10.1021%2Fjm300041e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazolopiperazines: Lead optimization of the second-generation antimalarial agents</span></div><div class="casAuthors">Nagle, Advait; Wu, Tao; Kuhen, Kelli; Gagaring, Kerstin; Borboa, Rachel; Francek, Caroline; Chen, Zhong; Plouffe, David; Lin, Xuena; Caldwell, Christopher; Ek, Jared; Skolnik, Suzanne; Liu, Fenghua; Wang, Jianling; Chang, Jonathan; Li, Chun; Liu, Bo; Hollenbeck, Thomas; Tuntland, Tove; Isbell, John; Chuan, Tiffany; Alper, Philip B.; Fischli, Christoph; Brun, Reto; Lakshminarayana, Suresh B.; Rottmann, Matthias; Diagana, Thierry T.; Winzeler, Elizabeth A.; Glynne, Richard; Tully, David C.; Chatterjee, Arnab K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4244-4273</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compds. involving changes in the core piperazine ring was synthesized to improve antimalarial properties.  These changes were carried out to further improve the potency and metabolic stability of the compds. by leveraging the outcome of a set of in vitro metabolic identification studies.  The optimized 8,8-di-Me imidazolopiperazine analogs I(R = 4-F, 4-Me, 3,4-F2) and II(R = 4-Me, 3-Cl-4-F) III(R = Me, F) exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice.  The optimized compds. were found to be more efficacious than the current antimalarials in a malaria mouse model.  They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonl3aXJKMqObVg90H21EOLACvtfcHk0lhI521k8MBYgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2kt7k%253D&md5=6c46f2f5ca76ae5a5089b542ec15e2ac</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm300041e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300041e%26sid%3Dliteratum%253Aachs%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DEk%26aufirst%3DJ.%26aulast%3DSkolnik%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHollenbeck%26aufirst%3DT.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DChuan%26aufirst%3DT.%26aulast%3DAlper%26aufirst%3DP.%2BB.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DTully%26aufirst%3DD.%2BC.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26atitle%3DImidazolopiperazines%253A%2520lead%2520optimization%2520of%2520the%2520second-generation%2520antimalarial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D9%26spage%3D4244%26epage%3D4273%26doi%3D10.1021%2Fjm300041e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenviaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graumans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vegte-Bolmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gemert, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebayang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patra, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinetz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">5060</span>– <span class="NLM_lpage">5067</span>, <span class="refDoi"> DOI: 10.1128/AAC.02727-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.02727-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24913172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5060-5067&issue=9&author=K.+L.+Kuhenauthor=A.+K.+Chatterjeeauthor=M.+Rottmannauthor=K.+Gagaringauthor=R.+Borboaauthor=J.+Buenviajeauthor=Z.+Chenauthor=C.+Francekauthor=T.+Wuauthor=A.+Nagleauthor=S.+W.+Barnesauthor=D.+Plouffeauthor=M.+C.+Leeauthor=D.+A.+Fidockauthor=W.+Graumansauthor=M.+van+de+Vegte-Bolmerauthor=G.+J.+van+Gemertauthor=G.+Wirjanataauthor=B.+Sebayangauthor=J.+Marfurtauthor=B.+Russellauthor=R.+Suwanaruskauthor=R.+N.+Priceauthor=F.+Nostenauthor=A.+Tungtaengauthor=M.+Gettayacaminauthor=J.+Sattabongkotauthor=J.+Taylorauthor=J.+R.+Walkerauthor=D.+Tullyauthor=K.+P.+Patraauthor=E.+L.+Flanneryauthor=J.+M.+Vinetzauthor=L.+Reniaauthor=R.+W.+Sauerweinauthor=E.+A.+Winzelerauthor=R.+J.+Glynneauthor=T.+T.+Diagana&title=KAF156+is+an+antimalarial+clinical+candidate+with+potential+for+use+in+prophylaxis%2C+treatment%2C+and+prevention+of+disease+transmission&doi=10.1128%2FAAC.02727-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">KAf156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span></div><div class="casAuthors">Kuhen, Kelli L.; Chatterjee, Arnab K.; Rottmann, Matthias; Gagaring, Kerstin; Borboa, Rachel; Buenviaje, Jennifer; Chen, Zhong; Francek, Carolyn; Wu, Tao; Nagle, Advait; Barnes, S. Whitney; Plouffe, David; Lee, Marcus C. S.; Fidock, David A.; Graumans, Wouter; van de Vegte-Bolmer, Marga; van Gemert, Geert J.; Wirjanata, Grennady; Sebayang, Boni; Marfurt, Jutta; Russell, Bruce; Suwanarusk, Rossarin; Price, Ric N.; Nosten, Francois; Tungtaeng, Anchalee; Gettayacamin, Montip; Sattabongkot, Jetsumon; Taylor, Jennifer; Walker, John R.; Tully, David; Patra, Kailash P.; Flannery, Erika L.; Vinetz, Joseph M.; Renia, Laurent; Sauerwein, Robert W.; Winzeler, Elizabeth A.; Glynne, Richard J.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5060-5067, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle.  We have previously reported the discovery of a novel class of antimalarial compds. in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria.  Consistent with the previously reported activity profile of this series, the clin. candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concns. of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99 % EDs of 0.6, 0.9, and 1.4 mg/kg, resp.  When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg.  Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo.  Collectively, our data suggest that KAF156, currently under evaluation in clin. trials, has the potential to treat, prevent, and block the transmission of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QluxrWtdq7Vg90H21EOLACvtfcHk0lgfsiz2k_lSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK&md5=c97e07e4832e871885546880084be5ca</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2FAAC.02727-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02727-13%26sid%3Dliteratum%253Aachs%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBuenviaje%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DGraumans%26aufirst%3DW.%26aulast%3Dvan%2Bde%2BVegte-Bolmer%26aufirst%3DM.%26aulast%3Dvan%2BGemert%26aufirst%3DG.%2BJ.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DSebayang%26aufirst%3DB.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTully%26aufirst%3DD.%26aulast%3DPatra%26aufirst%3DK.%2BP.%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DVinetz%26aufirst%3DJ.%2BM.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DKAF156%2520is%2520an%2520antimalarial%2520clinical%2520candidate%2520with%2520potential%2520for%2520use%2520in%2520prophylaxis%252C%2520treatment%252C%2520and%2520prevention%2520of%2520disease%2520transmission%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D9%26spage%3D5060%26epage%3D5067%26doi%3D10.1128%2FAAC.02727-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bopp, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">6061</span>),  <span class="NLM_fpage">1372</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1126/science.1211936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1211936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22096101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=1372-1377&issue=6061&author=S.+Meisterauthor=D.+M.+Plouffeauthor=K.+L.+Kuhenauthor=G.+M.+Bonamyauthor=T.+Wuauthor=S.+W.+Barnesauthor=S.+E.+Boppauthor=R.+Borboaauthor=A.+T.+Brightauthor=J.+Cheauthor=S.+Cohenauthor=N.+V.+Dhariaauthor=K.+Gagaringauthor=M.+Gettayacaminauthor=P.+Gordonauthor=T.+Groesslauthor=N.+Katoauthor=M.+C.+Leeauthor=C.+W.+McNamaraauthor=D.+A.+Fidockauthor=A.+Nagleauthor=T.+G.+Namauthor=W.+Richmondauthor=J.+Rolandauthor=M.+Rottmannauthor=B.+Zhouauthor=P.+Froissardauthor=R.+J.+Glynneauthor=D.+Mazierauthor=J.+Sattabongkotauthor=P.+G.+Schultzauthor=T.+Tuntlandauthor=J.+R.+Walkerauthor=Y.+Zhouauthor=A.+Chatterjeeauthor=T.+T.+Diaganaauthor=E.+A.+Winzeler&title=Imaging+of+Plasmodium+liver+stages+to+drive+next-generation+antimalarial+drug+discovery&doi=10.1126%2Fscience.1211936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery</span></div><div class="casAuthors">Meister, Stephan; Plouffe, David M.; Kuhen, Kelli L.; Bonamy, Ghislain M. C.; Wu, Tao; Barnes, S. Whitney; Bopp, Selina E.; Borboa, Rachel; Bright, A. Taylor; Che, Jianwei; Cohen, Steve; Dharia, Neekesh V.; Gagaring, Kerstin; Gettayacamin, Montip; Gordon, Perry; Groessl, Todd; Kato, Nobutaka; Lee, Marcus C. S.; McNamara, Case W.; Fidock, David A.; Nagle, Advait; Nam, Tae-gyu; Richmond, Wendy; Roland, Jason; Rottmann, Matthias; Zhou, Bin; Froissard, Patrick; Glynne, Richard J.; Mazier, Dominique; Sattabongkot, Jetsumon; Schultz, Peter G.; Tuntland, Tove; Walker, John R.; Zhou, Yingyao; Chatterjee, Arnab; Diagana, Thierry T.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6061</span>),
    <span class="NLM_cas:pages">1372-1377</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Most malaria drug development focuses on parasite stages detected in red blood cells, even though, to achieve eradication, next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable.  We applied a multifactorial approach to a set of >4000 com. available compds. with previously demonstrated blood-stage activity (median inhibitory concn. < 1 micromolar) and identified chem. scaffolds with potent activity against both forms.  From this screen, we identified an imidazolopiperazine scaffold series that was highly enriched among compds. active against Plasmodium liver stages.  The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 mg/kg) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity.  The open-source chem. tools resulting from our effort provide starting points for future drug discovery programs, as well as opportunities for researchers to investigate the biol. of exo-erythrocytic forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyO41naZtcdrVg90H21EOLACvtfcHk0lgfsiz2k_lSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN&md5=45b2993be36e36eabe1d9280c86c3db2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211936%26sid%3Dliteratum%253Aachs%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DBopp%26aufirst%3DS.%2BE.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBright%26aufirst%3DA.%2BT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DNam%26aufirst%3DT.%2BG.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DRoland%26aufirst%3DJ.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFroissard%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DMazier%26aufirst%3DD.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DImaging%2520of%2520Plasmodium%2520liver%2520stages%2520to%2520drive%2520next-generation%2520antimalarial%2520drug%2520discovery%26jtitle%3DScience%26date%3D2011%26volume%3D334%26issue%3D6061%26spage%3D1372%26epage%3D1377%26doi%3D10.1126%2Fscience.1211936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the <i>Plasmodium falciparum</i> cyclic amine resistance locus (PfCARL) confer multidrug resistance</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e00696-16</span>, <span class="refDoi"> DOI: 10.1128/mBio.00696-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FmBio.00696-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27381290" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=e00696-16&author=G.+LaMonteauthor=M.+Y.+Limauthor=M.+Wreeauthor=C.+Reimerauthor=M.+Nachonauthor=V.+Coreyauthor=P.+Gedeckauthor=D.+Plouffeauthor=A.+Duauthor=N.+Figueroaauthor=B.+Yeungauthor=P.+Bifaniauthor=E.+A.+Winzeler&title=Mutations+in+the+Plasmodium+falciparum+cyclic+amine+resistance+locus+%28PfCARL%29+confer+multidrug+resistance&doi=10.1128%2FmBio.00696-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1128%2FmBio.00696-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00696-16%26sid%3Dliteratum%253Aachs%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DWree%26aufirst%3DM.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DA.%26aulast%3DFigueroa%26aufirst%3DN.%26aulast%3DYeung%26aufirst%3DB.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMutations%2520in%2520the%2520Plasmodium%2520falciparum%2520cyclic%2520amine%2520resistance%2520locus%2520%2528PfCARL%2529%2520confer%2520multidrug%2520resistance%26jtitle%3DmBio%26date%3D2016%26volume%3D7%26spage%3De00696-16%26doi%3D10.1128%2FmBio.00696-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magistrado, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium falciparum</i> cyclic amine resistance locus (PfCARL), a resistance mechanism for two distinct compound classes</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=816-826&issue=11&author=P.+A.+Magistradoauthor=V.+C.+Coreyauthor=A.+K.+Lukensauthor=G.+LaMonteauthor=E.+Sasakiauthor=S.+Meisterauthor=M.+Wreeauthor=E.+Winzelerauthor=D.+F.+Wirth&title=Plasmodium+falciparum+cyclic+amine+resistance+locus+%28PfCARL%29%2C+a+resistance+mechanism+for+two+distinct+compound+classes&doi=10.1021%2Facsinfecdis.6b00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes</span></div><div class="casAuthors">Magistrado, Pamela A.; Corey, Victoria C.; Lukens, Amanda K.; LaMonte, Greg; Sasaki, Erika; Meister, Stephan; Wree, Melanie; Winzeler, Elizabeth; Wirth, Dyann F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">816-826</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MMV007564 is a novel antimalarial benzimidazolyl piperidine chemotype identified in cellular screens.  To identify the genetic determinant of MMV007564 resistance, parasites were cultured in the presence of the compd. to generate resistant lines.  Whole genome sequencing revealed distinct mutations in the gene named Plasmodium falciparum cyclic amine resistance locus (pfcarl), encoding a conserved protein of unknown function.  Mutations in pfcarl are strongly assocd. with resistance to a structurally unrelated class of compds., the imidazolopiperazines, including KAF156, currently in clin. trials.  Our data demonstrate that pfcarl mutations confer resistance to two distinct compd. classes, benzimidazolyl piperidines and imidazolopiperazines.  However, MMV007564 and the imidazolopiperazines, KAF156 and GNF179, have different timings of action in the asexual blood stage and different potencies against the liver and sexual blood stages.  These data suggest that pfcarl is a multidrug-resistance gene rather than a common target for benzimidazolyl piperidines and imidazolopiperazines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO2hqloBBVgbVg90H21EOLACvtfcHk0lggUNIRfeDPgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCrsLo%253D&md5=099493350b8b85ee6363c844f9f325cf</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00025%26sid%3Dliteratum%253Aachs%26aulast%3DMagistrado%26aufirst%3DP.%2BA.%26aulast%3DCorey%26aufirst%3DV.%2BC.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DSasaki%26aufirst%3DE.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DWree%26aufirst%3DM.%26aulast%3DWinzeler%26aufirst%3DE.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DPlasmodium%2520falciparum%2520cyclic%2520amine%2520resistance%2520locus%2520%2528PfCARL%2529%252C%2520a%2520resistance%2520mechanism%2520for%2520two%2520distinct%2520compound%2520classes%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26issue%3D11%26spage%3D816%26epage%3D826%26doi%3D10.1021%2Facsinfecdis.6b00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjahjadi, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span> <span> </span><span class="NLM_article-title">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16166</span>, <span class="refDoi"> DOI: 10.1038/nmicrobiol.2016.166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnmicrobiol.2016.166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27642791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16166&author=M.+Y.+Limauthor=G.+LaMonteauthor=M.+C.+Leeauthor=C.+Reimerauthor=B.+H.+Tanauthor=V.+Coreyauthor=B.+F.+Tjahjadiauthor=A.+Chuaauthor=M.+Nachonauthor=R.+Wintjensauthor=P.+Gedeckauthor=B.+Malleretauthor=L.+Reniaauthor=G.+M.+Bonamyauthor=P.+C.+Hoauthor=B.+K.+Yeungauthor=E.+D.+Chowauthor=L.+Limauthor=D.+A.+Fidockauthor=T.+T.+Diaganaauthor=E.+A.+Winzelerauthor=P.+Bifani&title=UDP-galactose+and+acetyl-CoA+transporters+as+Plasmodium+multidrug+resistance+genes&doi=10.1038%2Fnmicrobiol.2016.166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span></div><div class="casAuthors">Lim, Michelle Yi-Xiu; La Monte, Gregory; Lee, Marcus C. S.; Reimer, Christin; Tan, Bee Huat; Corey, Victoria; Tjahjadi, Bianca F.; Chua, Adeline; Nachon, Marie; Wintjens, Rene; Gedeck, Peter; Malleret, Benoit; Renia, Laurent; Bonamy, Ghislain M. C.; Ho, Paul Chi-Lui; Yeung, Bryan K. S.; Chow, Eric D.; Lim, Liting; Fidock, David A.; Diagana, Thierry T.; Winzeler, Elizabeth A.; Bifani, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">16166</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A mol. understanding of drug resistance mechanisms enables surveillance of the effectiveness of new antimicrobial therapies during development and deployment in the field.  We used conventional drug resistance selection as well as a regime of limiting diln. at early stages of drug treatment to probe 2 antimalarial imidazolopiperazines, KAF156 and GNF179.  The latter approach permits the isolation of low-fitness mutants that might otherwise be out-competed during selection.  Whole-genome sequencing of 24 independently derived resistant Plasmodium falciparum clones revealed 4 parasites with mutations in the known cyclic amine resistance locus (pfcarl) and a further 20 with mutations in 2 previously unreported P. falciparum drug resistance genes, an acetyl-CoA transporter (pfact) and a UDP-galactose transporter (pfugt).  Mutations were validated both in vitro by CRISPR editing in P. falciparum and in vivo by evolution of resistant Plasmodium berghei mutants.  Both PfACT and PfUGT were localized to the endoplasmic reticulum by fluorescence microscopy.  As mutations in pfact and pfugt conveyed resistance against addnl. unrelated chem. scaffolds, these genes are probably involved in broad mechanisms of antimalarial drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWucZl9WjFw7Vg90H21EOLACvtfcHk0lionMV6dKnveQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D&md5=c87d57996e20bb94d7d44c556553daf4</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnmicrobiol.2016.166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmicrobiol.2016.166%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DTjahjadi%26aufirst%3DB.%2BF.%26aulast%3DChua%26aufirst%3DA.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DMalleret%26aufirst%3DB.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%26aulast%3DHo%26aufirst%3DP.%2BC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DChow%26aufirst%3DE.%2BD.%26aulast%3DLim%26aufirst%3DL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DBifani%26aufirst%3DP.%26atitle%3DUDP-galactose%2520and%2520acetyl-CoA%2520transporters%2520as%2520Plasmodium%2520multidrug%2520resistance%2520genes%26jtitle%3DNat.%2520Microbiol.%26date%3D2016%26volume%3D1%26spage%3D16166%26doi%3D10.1038%2Fnmicrobiol.2016.166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catoire, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flarakos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J. B.</span></span> <span> </span><span class="NLM_article-title">Utilization of stable isotope labeling to facilitate the identification of polar metabolites of KAF156, an antimalarial agent</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.072108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1124%2Fdmd.116.072108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27486238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyls77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1697-1708&issue=10&author=S.+E.+Huskeyauthor=R.+R.+Forsethauthor=H.+Liauthor=Z.+Jianauthor=A.+Catoireauthor=J.+Zhangauthor=T.+Rayauthor=H.+Heauthor=J.+Flarakosauthor=J.+B.+Mangold&title=Utilization+of+stable+isotope+labeling+to+facilitate+the+identification+of+polar+metabolites+of+KAF156%2C+an+antimalarial+agent&doi=10.1124%2Fdmd.116.072108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Utilization of stable isotope labeling to facilitate the identification of polar metabolites of KAF156, an antimalarial agent</span></div><div class="casAuthors">Huskey, Su-Er W.; Forseth, Ry R.; Li, Hongmei; Jian, Zhigang; Catoire, Alexandre; Zhang, Jin; Ray, Tapan; He, Handan; Flarakos, Jimmy; Mangold, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1697-1708</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Identification of polar metabolites of drug candidates during development is often challenging.  Several prominent polar metabolites of 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone ([14C]KAF156), an antimalarial agent, were detected in rat urine from an absorption, distribution, metab., and excretion study but could not be characterized by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) because of low ionization efficiency.  In such instances, a strategy often chosen by investigators is to use a radiolabeled compd. with high specific activity, having an isotopic mass ratio (i.e., [12C]/[14C]) and mass difference that serve as the basis for a mass filter using accurate mass spectrometry.  Unfortunately, [14C]KAF156-1 was uniformly labeled (n = 1-6) with the mass ratio of ∼0.1.  This ratio was insufficient to be useful as a mass filter despite the high specific activity (120 μCi/mg).  At this stage in development, stable isotope labeled [13C6]KAF156-1 was available as the internal std. for the quantification of KAF156.  We were thus able to design an oral dose as a mixt. of [14C]KAF156-1 (specific activity 3.65 μCi/mg) and [13C6]KAF156-1 with a mass ratio of [12C]/[13C6] as 0.9 and the mass difference as 6.0202.  By using this mass filter strategy, four polar metabolites were successfully identified in rat urine.  Subsequently, using a similar dual labeling approach, [14C]KAF156-2 and [13C2]KAF156-2 were synthesized to allow the detection of any putative polar metabolites that may have lost labeling during biotransformations using the previous [14C]KAF156-1.  Three polar metabolites were thereby identified and M43, a less polar metabolite, was proposed as the key intermediate metabolite leading to the formation of a total of seven polar metabolites.  Overall this dual labeling approach proved practical and valuable for the identification of polar metabolites by LC-MS/MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGG9TzGB-u_bVg90H21EOLACvtfcHk0lionMV6dKnveQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyls77I&md5=7035911a24a04a39ac4251e70bc9b3c2</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072108%26sid%3Dliteratum%253Aachs%26aulast%3DHuskey%26aufirst%3DS.%2BE.%26aulast%3DForseth%26aufirst%3DR.%2BR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DJian%26aufirst%3DZ.%26aulast%3DCatoire%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DRay%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DFlarakos%26aufirst%3DJ.%26aulast%3DMangold%26aufirst%3DJ.%2BB.%26atitle%3DUtilization%2520of%2520stable%2520isotope%2520labeling%2520to%2520facilitate%2520the%2520identification%2520of%2520polar%2520metabolites%2520of%2520KAF156%252C%2520an%2520antimalarial%2520agent%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D10%26spage%3D1697%26epage%3D1708%26doi%3D10.1124%2Fdmd.116.072108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6437</span>– <span class="NLM_lpage">6443</span>, <span class="refDoi"> DOI: 10.1128/AAC.03478-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.03478-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25136017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=6437-6443&issue=11&author=F.+J.+Leongauthor=R.+Zhaoauthor=S.+Zengauthor=B.+Magnussonauthor=T.+T.+Diaganaauthor=P.+Pertel&title=A+first-in-human+randomized%2C+double-blind%2C+placebo-controlled%2C+single-+and+multiple-ascending+oral+dose+study+of+novel+Imidazolopiperazine+KAF156+to+assess+its+safety%2C+tolerability%2C+and+pharmacokinetics+in+healthy+adult+volunteers&doi=10.1128%2FAAC.03478-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span></div><div class="casAuthors">Leong, F. Joel; Zhao, Rong; Zeng, Shuqi; Magnusson, Baldur; Diagana, Thierry T.; Pertel, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6437-6443, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">KAF156 belongs to a new class of antimalarial, the imidazolopiperazines, and is currently in clin. development for the treatment of uncomplicated malaria.  This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers detd. the max. oral dose of KAF156 tolerated by healthy adults and derived pharmacokinetic data including preliminary food effect to enable dose calcns. for malaria patients.  KAF156 was studied in single-dose cohorts 10 to 1,200 mg, including one 400-mg food effect cohort 4 to 10 subjects/cohort, and in multiple-dose cohorts 60 to 600 mg once daily for 3 days; 8 subjects/cohort.  The follow-up period was 6 to 14 days after the last dose.  KAF156 was tolerated, with self-limited mild to moderate gastrointestinal and neurol. adverse events.  In treated subjects after single doses, headache n = 4; 11.1%, diarrhea n = 3; 8.3%, dizziness n = 3; 8.3%, and abdominal pain n = 2; 5.6% were the most common adverse events.  Headache n = 4; 16.7%, nausea n = 3; 12.5%, upper respiratory tract infection n = 3; 12.5%, and dizziness n = 2; 8.3% were the most common adverse events following multiple doses.  KAF156 time to max. concn. (Tmax) was between 1.0 and 6.0 h.  Both the area under the concn.-time curve (AUC) and max. concn. (Cmax) increased more than dose-proportionally in both single- and multiple-ascending-dose cohorts terminal half-life, 42.5 to 70.7 h.  There was no significant accumulation over 3-day repeated administration.  The extent of absorption was not significantly affected by food at a single dose of 400 mg, while mean Cmax decreased from 778 ng/mL to 627 ng/mL and Tmax was delayed from a median of 3.0 h under fasting conditions to 6.0 h under fed conditions.  Renal elimination is a minor route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHd497-XrpVbVg90H21EOLACvtfcHk0liA_tv5FOyT3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjE&md5=e533daf63d5a0f60db93f12e592a1a0a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1128%2FAAC.03478-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03478-14%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26atitle%3DA%2520first-in-human%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520single-%2520and%2520multiple-ascending%2520oral%2520dose%2520study%2520of%2520novel%2520Imidazolopiperazine%2520KAF156%2520to%2520assess%2520its%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D11%26spage%3D6437%26epage%3D6443%26doi%3D10.1128%2FAAC.03478-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. S.</span></span> <span> </span><span class="NLM_article-title">A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/s12936-017-2162-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-017-2162-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29304859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Ogsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=7&author=F.+J.+Leongauthor=J.+P.+Jainauthor=Y.+Fengauthor=B.+Goswamiauthor=D.+S.+Stein&title=A+phase+1+evaluation+of+the+pharmacokinetic%2Fpharmacodynamic+interaction+of+the+anti-malarial+agents+KAF156+and+piperaquine&doi=10.1186%2Fs12936-017-2162-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine</span></div><div class="casAuthors">Leong, F. Joel; Jain, Jay Prakash; Feng, Yiyan; Goswami, Budhaditya; Stein, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7/1-7/11</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages.  Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are CYP3A4 substrates and inhibitors.  Potential combination effects on the QT interval were also assessed.  Methods: This was an open-label, parallel-group, single-dose study in healthy volunteers randomized to three parallel arms (1:1:1) of 800 mg KAF156 + 1280 mg PPQ, 800 mg KAF156 alone and 1280 mg PPQ alone.  Triplicate ECGs were done up to 48 h post-dose.  Routine safety and pharmacokinetic assessments were carried out up to 61 days.  Results: Of the 72 healthy male subjects recruited, 68 completed the study.  Co-administration of PPQ and KAF156 had no overall effect on AUC of either compd., but the Cmax values of both KAF156 (∼ 23%) and piperaquine (∼ 70%) increased.  Both drugs given alone or in combination were well tolerated with no deaths or serious adverse events (SAEs).  AEs were obsd. at the frequency of 87.5, 79.2 and 58.3% resp. for KAF156 + PPQ, PPQ and KAF156 arms.  The most common AEs were nausea and headache.  There were no Grade 3 or 4 events.  There were no ECG related AEs, no QTcF interval > 480 ms and no QTcF interval increase from baseline > 60 ms.  There was a pos. ΔQTcF trend in the KAF156 + PPQ arm when either KAF156 or piperaquine concn. increases, but there was no significant difference between the combination arm and other arms in max. ΔQTcF.  Conclusions: No safety/cardiac risk or drug interaction was identified which would preclude use of a KAF156 and PPQ combination in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx6g-lwFLSVLVg90H21EOLACvtfcHk0liA_tv5FOyT3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Ogsb4%253D&md5=0f95442418a2b9571498dac188486bba</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1186%2Fs12936-017-2162-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-017-2162-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DGoswami%26aufirst%3DB.%26aulast%3DStein%26aufirst%3DD.%2BS.%26atitle%3DA%2520phase%25201%2520evaluation%2520of%2520the%2520pharmacokinetic%252Fpharmacodynamic%2520interaction%2520of%2520the%2520anti-malarial%2520agents%2520KAF156%2520and%2520piperaquine%26jtitle%3DMalar.%2520J.%26date%3D2018%26volume%3D17%26spage%3D7%26doi%3D10.1186%2Fs12936-017-2162-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthaisin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuthasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of KAF156 in falciparum and vivax malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1602250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27653565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1152-1160&issue=12&author=N.+J.+Whiteauthor=T.+T.+Duongauthor=C.+Uthaisinauthor=F.+Nostenauthor=A.+P.+Phyoauthor=B.+Hanboonkunupakarnauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chuthasmitauthor=M.+S.+Cheungauthor=Y.+Fengauthor=R.+Liauthor=B.+Magnussonauthor=M.+Sultanauthor=D.+Wieserauthor=X.+Xunauthor=R.+Zhaoauthor=T.+T.+Diaganaauthor=P.+Pertelauthor=F.+J.+Leong&title=Antimalarial+activity+of+KAF156+in+falciparum+and+vivax+malaria&doi=10.1056%2FNEJMoa1602250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of KAF156 in falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Duong, Tran T.; Uthaisin, Chirapong; Nosten, Francois; Phyo, Aung P.; Hanboonkunupakarn, Borimas; Pukrittayakamee, Sasithon; Jittamala, Podjanee; Chuthasmit, Kittiphum; Cheung, Ming S.; Feng, Yiyan; Li, Ruobing; Magnusson, Baldur; Sultan, Marc; Wieser, Daniela; Xun, Xiaolei; Zhao, Rong; Diagana, Thierry T.; Pertel, Peter; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1152-1160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.  METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria.  Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a sep. cohort of patients with falciparum malaria who received a single dose (800 mg).  RESULTS: Median parasite clearance times were 45 h (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 h (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 h (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.  Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84).  The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 h.  There were no serious adverse events in this small study.  The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia.  Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose.  More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts.  CONCLUSIONS: KAF156 showed antimalarial activity without evident safety concerns in a small no. of adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHzWNldN2RLbVg90H21EOLACvtfcHk0lgkgjidw0cbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN&md5=24d0943da6d583f8c0fe4fe9f380ec99</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602250%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DUthaisin%26aufirst%3DC.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChuthasmit%26aufirst%3DK.%26aulast%3DCheung%26aufirst%3DM.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DSultan%26aufirst%3DM.%26aulast%3DWieser%26aufirst%3DD.%26aulast%3DXun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DAntimalarial%2520activity%2520of%2520KAF156%2520in%2520falciparum%2520and%2520vivax%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D12%26spage%3D1152%26epage%3D1160%26doi%3D10.1056%2FNEJMoa1602250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bout, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, W. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandeur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Bras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barale, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span> <span> </span><span class="NLM_article-title">A molecular marker of artemisinin-resistant <i>Plasmodium falciparum</i> malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>505</i></span> (<span class="NLM_issue">7481</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/nature12876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature12876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24352242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2014&pages=50-55&issue=7481&author=F.+Arieyauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=J.+Beghainauthor=A.+C.+Langloisauthor=N.+Khimauthor=S.+Kimauthor=V.+Duruauthor=C.+Bouchierauthor=L.+Maauthor=P.+Limauthor=R.+Leangauthor=S.+Duongauthor=S.+Srengauthor=S.+Suonauthor=C.+M.+Chuorauthor=D.+M.+Boutauthor=S.+Menardauthor=W.+O.+Rogersauthor=B.+Gentonauthor=T.+Fandeurauthor=O.+Miottoauthor=P.+Ringwaldauthor=J.+Le+Brasauthor=A.+Berryauthor=J.+C.+Baraleauthor=R.+M.+Fairhurstauthor=F.+Benoit-Vicalauthor=O.+Mercereau-Puijalonauthor=D.+Menard&title=A+molecular+marker+of+artemisinin-resistant+Plasmodium+falciparum+malaria&doi=10.1038%2Fnature12876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular marker of artemisinin-resistant Plasmodium falciparum malaria</span></div><div class="casAuthors">Ariey Frederic; Beghain Johann; Barale Jean-Christophe; Witkowski Benoit; Khim Nimol; Kim Saorin; Duru Valentine; Amaratunga Chanaki; Langlois Anne-Claire; Bouchier Christiane; Ma Laurence; Lim Pharath; Leang Rithea; Duong Socheat; Sreng Sokunthea; Suon Seila; Chuor Char Meng; Bout Denis Mey; Menard Sandie; Berry Antoine; Rogers William O; Genton Blaise; Fandeur Thierry; Miotto Olivo; Ringwald Pascal; Le Bras Jacques; Fairhurst Rick M; Benoit-Vical Francoise; Mercereau-Puijalon Odile; Menard Didier</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">7481</span>),
    <span class="NLM_cas:pages">50-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide.  To monitor the spread of artemisinin resistance, a molecular marker is urgently needed.  Here, using whole-genome sequencing of an artemisinin-resistant parasite line from Africa and clinical parasite isolates from Cambodia, we associate mutations in the PF3D7_1343700 kelch propeller domain ('K13-propeller') with artemisinin resistance in vitro and in vivo.  Mutant K13-propeller alleles cluster in Cambodian provinces where resistance is prevalent, and the increasing frequency of a dominant mutant K13-propeller allele correlates with the recent spread of resistance in western Cambodia.  Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance.  K13-propeller polymorphism constitutes a useful molecular marker for large-scale surveillance efforts to contain artemisinin resistance in the Greater Mekong Subregion and prevent its global spread.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTg24yBOxa0oSjiVMCqkKxVfW6udTcc2eb7aa_NLQdnMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D&md5=e25f4dcc9ccc361de4c35e650391b7ca</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fnature12876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12876%26sid%3Dliteratum%253Aachs%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DBeghain%26aufirst%3DJ.%26aulast%3DLanglois%26aufirst%3DA.%2BC.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DBouchier%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DLeang%26aufirst%3DR.%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DBout%26aufirst%3DD.%2BM.%26aulast%3DMenard%26aufirst%3DS.%26aulast%3DRogers%26aufirst%3DW.%2BO.%26aulast%3DGenton%26aufirst%3DB.%26aulast%3DFandeur%26aufirst%3DT.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DLe%2BBras%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DA.%26aulast%3DBarale%26aufirst%3DJ.%2BC.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DMenard%26aufirst%3DD.%26atitle%3DA%2520molecular%2520marker%2520of%2520artemisinin-resistant%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DNature%26date%3D2014%26volume%3D505%26issue%3D7481%26spage%3D50%26epage%3D55%26doi%3D10.1038%2Fnature12876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadani, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urnov, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Drug resistance. K13-propeller mutations confer artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span> (<span class="NLM_issue">6220</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1126/science.1260867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1260867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25502314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=428-431&issue=6220&author=J.+Straimerauthor=N.+F.+Gnadigauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=V.+Duruauthor=A.+P.+Ramadaniauthor=M.+Dacheuxauthor=N.+Khimauthor=L.+Zhangauthor=S.+Lamauthor=P.+D.+Gregoryauthor=F.+D.+Urnovauthor=O.+Mercereau-Puijalonauthor=F.+Benoit-Vicalauthor=R.+M.+Fairhurstauthor=D.+Menardauthor=D.+A.+Fidock&title=Drug+resistance.+K13-propeller+mutations+confer+artemisinin+resistance+in+Plasmodium+falciparum+clinical+isolates&doi=10.1126%2Fscience.1260867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates</span></div><div class="casAuthors">Straimer, Judith; Gnaedig, Nina F.; Witkowski, Benoit; Amaratunga, Chanaki; Duru, Valentine; Ramadani, Arba Pramundita; Dacheux, Melanie; Khim, Nimol; Zhang, Lei; Lam, Stephen; Gregory, Philip D.; Urnov, Fyodor D.; Mercereau-Puijalon, Odile; Benoit-Vical, Francoise; Fairhurst, Rick M.; Menard, Didier; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6220</span>),
    <span class="NLM_cas:pages">428-431</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The emergence of artemisinin resistance in Southeast Asia imperils efforts to reduce the global malaria burden.  We genetically modified the Plasmodium falciparum K13 locus using zinc-finger nucleases and measured ring-stage survival rates after drug exposure in vitro; these rates correlate with parasite clearance half-lives in artemisinin-treated patients.  With isolates from Cambodia, where resistance first emerged, survival rates decreased from 13 to 49% to 0.3 to 2.4% after the removal of K13 mutations.  Conversely, survival rates in wild-type parasites increased from ≤0.6% to 2 to 29% after the insertion of K13 mutations.  These mutations conferred elevated resistance to recent Cambodian isolates compared with that of ref. lines, suggesting a contemporary contribution of addnl. genetic factors.  Our data provide a conclusive rationale for worldwide K13-propeller sequencing to identify and eliminate artemisinin-resistant parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Ml-eUMKETLVg90H21EOLACvtfcHk0litkY6SIOm-Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D&md5=5776238fb78428d16bcaed8d16fa73af</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1126%2Fscience.1260867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1260867%26sid%3Dliteratum%253Aachs%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DRamadani%26aufirst%3DA.%2BP.%26aulast%3DDacheux%26aufirst%3DM.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26aulast%3DUrnov%26aufirst%3DF.%2BD.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DDrug%2520resistance.%2520K13-propeller%2520mutations%2520confer%2520artemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520clinical%2520isolates%26jtitle%3DScience%26date%3D2015%26volume%3D347%26issue%3D6220%26spage%3D428%26epage%3D431%26doi%3D10.1126%2Fscience.1260867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roepe, P. D.</span></span> <span> </span><span class="NLM_article-title">Functional comparison of 45 naturally occurring isoforms of the <i>Plasmodium falciparum</i> chloroquine resistance transporter (PfCRT)</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">5083</span>– <span class="NLM_lpage">5094</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1agsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=5083-5094&issue=32&author=P.+S.+Callaghanauthor=M.+R.+Hassettauthor=P.+D.+Roepe&title=Functional+comparison+of+45+naturally+occurring+isoforms+of+the+Plasmodium+falciparum+chloroquine+resistance+transporter+%28PfCRT%29&doi=10.1021%2Facs.biochem.5b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Comparison of 45 Naturally Occurring Isoforms of the Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT)</span></div><div class="casAuthors">Callaghan, Paul S.; Hassett, Matthew R.; Roepe, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5083-5094</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">At least 53 distinct isoforms of Plasmodium falciparum chloroquine resistance transporter (PfCRT) protein are expressed in strains or isolates of P. falciparum malarial parasites from around the globe.  These parasites exhibit a range of sensitivities to chloroquine (CQ) and other drugs.  Mutant PfCRT is believed to confer cytostatic CQ resistance (CQRCS) by transporting CQ away from its DV target (free heme released upon Hb digestion).  One theory is that variable CQ transport catalyzed by these different PfCRT isoforms is responsible for the range of CQ sensitivities now found for P. falciparum.  Alternatively, addnl. mutations in drug-selected parasites, or addnl. functions of PfCRT, might complement PfCRT-mediated CQ transport in conferring the range of obsd. resistance phenotypes.  To distinguish between these possibilities, we recently optimized a convenient method for measuring PfCRT-mediated CQ transport, involving heterologous expression in Saccharomyces cerevisiae.  Here, we use this method to quantify drug transport activity for 45 of 53 of the naturally occurring PfCRT isoforms.  Data show that variable levels of CQR likely depend upon either addnl. PfCRT functions or addnl. genetic events, including perhaps changes that influence DV membrane potential.  The data also suggest that the common K76T PfCRT mutation that is often used to distinguish a P. falciparum CQR phenotype is not, in and of itself, a fully reliable indicator of CQR status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoP3eVuSL3frVg90H21EOLACvtfcHk0lhwEMTVS0-6KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1agsrjE&md5=ea0a066cfcbab062341ed57f9addd188</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00412%26sid%3Dliteratum%253Aachs%26aulast%3DCallaghan%26aufirst%3DP.%2BS.%26aulast%3DHassett%26aufirst%3DM.%2BR.%26aulast%3DRoepe%26aufirst%3DP.%2BD.%26atitle%3DFunctional%2520comparison%2520of%252045%2520naturally%2520occurring%2520isoforms%2520of%2520the%2520Plasmodium%2520falciparum%2520chloroquine%2520resistance%2520transporter%2520%2528PfCRT%2529%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26issue%3D32%26spage%3D5083%26epage%3D5094%26doi%3D10.1021%2Facs.biochem.5b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlemann, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valderramos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valderramos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Decreasing pfmdr1 copy number in <i>Plasmodium falciparum</i> malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>194</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1086/507115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1086%2F507115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16845638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD28vit1alug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2006&pages=528-535&issue=4&author=A.+B.+Sidhuauthor=A.+C.+Uhlemannauthor=S.+G.+Valderramosauthor=J.+C.+Valderramosauthor=S.+Krishnaauthor=D.+A.+Fidock&title=Decreasing+pfmdr1+copy+number+in+Plasmodium+falciparum+malaria+heightens+susceptibility+to+mefloquine%2C+lumefantrine%2C+halofantrine%2C+quinine%2C+and+artemisinin&doi=10.1086%2F507115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin</span></div><div class="casAuthors">Sidhu Amar Bir Singh; Uhlemann Anne-Catrin; Valderramos Stephanie G; Valderramos Juan-Carlos; Krishna Sanjeev; Fidock David A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">528-35</span>
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    </div><div class="casAbstract">The global dissemination of drug-resistant Plasmodium falciparum is spurring intense efforts to implement artemisinin (ART)-based combination therapies for malaria, including mefloquine (MFQ)-artesunate and lumefantrine (LUM)-artemether.  Clinical studies have identified an association between an increased risk of MFQ, MFQ-artesunate, and LUM-artemether treatment failures and pfmdr1 gene amplification.  To directly address the contribution that pfmdr1 copy number makes to drug resistance, we genetically disrupted 1 of the 2 pfmdr1 copies in the drug-resistant FCB line, which resulted in reduced pfmdr1 mRNA and protein expression.  These knockdown clones manifested a 3-fold decrease in MFQ IC(50) values, compared with that for the FCB line, verifying the role played by pfmdr1 expression levels in mediating resistance to MFQ.  These clones also showed increased susceptibility to LUM, halofantrine, quinine, and ART.  No change was observed for chloroquine.  These results highlight the importance of pfmdr1 copy number in determining P. falciparum susceptibility to multiple agents currently being used to combat malaria caused by multidrug-resistant parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1o6ybd2Dyzo2y4bB4mnvYfW6udTcc2ebm9_BLT9H_Fbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vit1alug%253D%253D&md5=630ecb75857529bfcbf4e6db1fa3d779</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1086%2F507115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F507115%26sid%3Dliteratum%253Aachs%26aulast%3DSidhu%26aufirst%3DA.%2BB.%26aulast%3DUhlemann%26aufirst%3DA.%2BC.%26aulast%3DValderramos%26aufirst%3DS.%2BG.%26aulast%3DValderramos%26aufirst%3DJ.%2BC.%26aulast%3DKrishna%26aufirst%3DS.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DDecreasing%2520pfmdr1%2520copy%2520number%2520in%2520Plasmodium%2520falciparum%2520malaria%2520heightens%2520susceptibility%2520to%2520mefloquine%252C%2520lumefantrine%252C%2520halofantrine%252C%2520quinine%252C%2520and%2520artemisinin%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2006%26volume%3D194%26issue%3D4%26spage%3D528%26epage%3D535%26doi%3D10.1086%2F507115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span> </span><span class="NLM_article-title">Efficacy and Safety of KAF156 in Combination
With LUM-SDF in Adults
and Children With Uncomplicated <i>Plasmodium falciparum</i> Malaria</span>.  <i>ClinicalTrials.gov</i>: <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2019</span>;  <span class="NLM_fpage">NCT03167242</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03167242?term=NCT03167242&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03167242?term=NCT03167242&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy+and+Safety+of+KAF156+in+Combination%0AWith+LUM-SDF+in+Adults%0Aand+Children+With+Uncomplicated+Plasmodium+falciparum+Malaria.+ClinicalTrials.gov%3A+U.S.+National+Institutes+of+Health%2C+2019%3B+NCT03167242%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03167242%3Fterm%3DNCT03167242%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520KAF156%2520in%2520Combination%250AWith%2520LUM-SDF%2520in%2520Adults%250Aand%2520Children%2520With%2520Uncomplicated%2520Plasmodium%2520falciparum%2520Malaria%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2019%26spage%3DNCT03167242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span> <i>2018—A Triumph of Partnerships</i>; <span class="NLM_publisher-name">Medicines
for Malaria Venture</span>, 19 Dec <span class="NLM_year">2018</span>; <a href="http://www.mmv.org/newsroom/news/2018-triumph-partnerships" class="extLink">www.mmv.org/newsroom/news/2018-triumph-partnerships</a> (accessed
Jul. 10 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2018%E2%80%94A+Triumph+of+Partnerships%3B+Medicines%0Afor+Malaria+Venture%2C+19+Dec+2018%3B+www.mmv.org%2Fnewsroom%2Fnews%2F2018-triumph-partnerships+%28accessed%0AJul.+10+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2018%25E2%2580%2594A%2520Triumph%2520of%2520Partnerships%26pub%3DMedicines%250Afor%2520Malaria%2520Venture%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy</span>. <i>Infect. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.2174/187152610791163336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.2174%2F187152610791163336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20334617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1egtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=226-239&author=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Plasmodium+dihydroorotate+dehydrogenase%3A+a+promising+target+for+novel+anti-malarial+chemotherapy&doi=10.2174%2F187152610791163336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy</span></div><div class="casAuthors">Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">226-239</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Malaria remains a globally prevalent infectious disease that leads to significant morbidity and mortality.  While there are a no. of drugs approved for its treatment, drug resistance has compromised most of them, making the development of new drugs for the treatment and prevention of malaria essential.  The completion of the Plasmodium falciparum genome and a growing understanding of parasite biol. are fueling the search for novel drug targets.  Despite this, few targets have been chem. validated in vivo.  The pyrimidine biosynthetic pathway illustrates one of the best examples of successful identification of anti-malarial drug targets.  This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum. dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery.  Several chem. scaffolds have been identified by high throughput screening as potent inhibitors of PfDHODH and these show strong selectivity for the material enzyme over that from the human host.  Potent activity against parasites in whole cell models with good correlation between activity on the enzyme and the parasite have also been obsd. for a no. of the identified series.  Lead optimization of a triazolopyrimidine-based series has identified an analog with prolonged plasma exposure, that is orally bioavailable, and which shows good efficacy against the in vivo mouse model of the disease.  These data provide strong evidence that PfDHODH is a validated target for the identification of new antimalarial chemotherapy.  The challenge remains to identify compds. with the necessary combination of potency and metabolic stability to allow identification of a clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-GwvHVLyauLVg90H21EOLACvtfcHk0lgOWRNHspmfZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1egtLw%253D&md5=71abaa02fc1f5ccc9d44a138f5ce357b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.2174%2F187152610791163336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152610791163336%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DPlasmodium%2520dihydroorotate%2520dehydrogenase%253A%2520a%2520promising%2520target%2520for%2520novel%2520anti-malarial%2520chemotherapy%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2010%26volume%3D10%26spage%3D226%26epage%3D239%26doi%3D10.2174%2F187152610791163336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase with antimalarial activity in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3935</span>– <span class="NLM_lpage">3949</span>, <span class="refDoi"> DOI: 10.1021/jm200265b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200265b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3935-3949&issue=11&author=R.+Gujjarauthor=F.+El+Mazouniauthor=K.+L.+Whiteauthor=J.+Whiteauthor=S.+Creasonauthor=D.+M.+Shacklefordauthor=X.+Dengauthor=W.+N.+Charmanauthor=I.+Bathurstauthor=J.+Burrowsauthor=D.+M.+Floydauthor=D.+Matthewsauthor=F.+S.+Bucknerauthor=S.+A.+Charmanauthor=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Lead+optimization+of+aryl+and+aralkyl+amine-based+triazolopyrimidine+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+with+antimalarial+activity+in+mice&doi=10.1021%2Fjm200265b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice</span></div><div class="casAuthors">Gujjar, Ramesh; El Mazouni, Farah; White, Karen L.; White, John; Creason, Sharon; Shackleford, David M.; Deng, Xiaoyi; Charman, William N.; Bathurst, Ian; Burrows, Jeremy; Floyd, David M.; Matthews, David; Buckner, Frederick S.; Charman, Susan A.; Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3935-3949</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.  We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development.  Active compds. from the series contained a triazolopyrimidine ring attached to an arom. group through a bridging nitrogen atom.  Herein, we describe systematic efforts to optimize the arom. functionality with the goal of improving potency and in vivo properties of compds. from the series.  These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4-CF3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compds. from the series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh3es6zVLa3bVg90H21EOLACvtfcHk0lgOWRNHspmfZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWmsbw%253D&md5=a04f0a93af71a83c7c8b4cd6932abb87</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm200265b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200265b%26sid%3Dliteratum%253Aachs%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DCreason%26aufirst%3DS.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DFloyd%26aufirst%3DD.%2BM.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DLead%2520optimization%2520of%2520aryl%2520and%2520aralkyl%2520amine-based%2520triazolopyrimidine%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520with%2520antimalarial%2520activity%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D11%26spage%3D3935%26epage%3D3949%26doi%3D10.1021%2Fjm200265b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1864</span>– <span class="NLM_lpage">1872</span>, <span class="refDoi"> DOI: 10.1021/jm801343r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801343r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlenuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1864-1872&issue=7&author=R.+Gujjarauthor=A.+Marwahaauthor=F.+El+Mazouniauthor=J.+Whiteauthor=K.+L.+Whiteauthor=S.+Creasonauthor=D.+M.+Shacklefordauthor=J.+Baldwinauthor=W.+N.+Charmanauthor=F.+S.+Bucknerauthor=S.+Charmanauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Identification+of+a+metabolically+stable+triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitor+with+antimalarial+activity+in+mice&doi=10.1021%2Fjm801343r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Metabolically Stable Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Antimalarial Activity in Mice</span></div><div class="casAuthors">Gujjar, Ramesh; Marwaha, Alka; El Mazouni, Farah; White, John; White, Karen L.; Creason, Sharon; Shackleford, David M.; Baldwin, Jeffrey; Charman, William N.; Buckner, Frederick S.; Charman, Susan; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1864-1872</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Plasmodium falciparum causes 1-2 million deaths annually.  Yet current drug therapies are compromised by resistance.  We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo.  Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH.  For compds. contg. naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing.  Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metab. in human liver microsomes and which showed prolonged exposure in mice.  Compd. 21 (DSM74), contg. p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration.  This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKZ374sKZfCrVg90H21EOLACvtfcHk0lh3Z90zie6RiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlenuro%253D&md5=773ca17ea78a4f833c092c211c90c199</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fjm801343r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801343r%26sid%3Dliteratum%253Aachs%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DMarwaha%26aufirst%3DA.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCreason%26aufirst%3DS.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DCharman%26aufirst%3DS.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520of%2520a%2520metabolically%2520stable%2520triazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520with%2520antimalarial%2520activity%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D7%26spage%3D1864%26epage%3D1872%26doi%3D10.1021%2Fjm801343r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine modulates species selectivity in the triazolopyrimidine class of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5381</span>– <span class="NLM_lpage">5394</span>, <span class="refDoi"> DOI: 10.1021/jm500481t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500481t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5381-5394&issue=12&author=X.+Dengauthor=S.+Kokkondaauthor=F.+El+Mazouniauthor=J.+Whiteauthor=J.+N.+Burrowsauthor=W.+Kaminskyauthor=S.+A.+Charmanauthor=D.+Matthewsauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Fluorine+modulates+species+selectivity+in+the+triazolopyrimidine+class+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors&doi=10.1021%2Fjm500481t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors</span></div><div class="casAuthors">Deng, Xiaoyi; Kokkonda, Sreekanth; El Mazouni, Farah; White, John; Burrows, Jeremy N.; Kaminsky, Werner; Charman, Susan A.; Matthews, David; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5381-5394</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most serious global infectious diseases.  The pyrimidine biosynthetic enzyme Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) is an important target for antimalarial chemotherapy.  The authors describe a detailed anal. of protein-ligand interactions between DHODH and a triazolopyrimidine-based inhibitor series to explore the effects of fluorine on affinity and species selectivity.  The authors show that increasing fluorination dramatically increases binding to mammalian DHODHs, leading to a loss of species selectivity.  Triazolopyrimidines bind Plasmodium and mammalian DHODHs in overlapping but distinct binding sites.  Key hydrogen-bond and stacking interactions underlying strong binding to PfDHODH are absent in the mammalian enzymes.  Increasing fluorine substitution leads to an increase in the entropic contribution to binding, suggesting that strong binding to mammalian DHODH is a consequence of an enhanced hydrophobic effect upon binding to an apolar pocket.  The authors conclude that hydrophobic interactions between fluorine and hydrocarbons provide significant binding energy to protein-ligand interactions.  The authors' studies define the requirements for species-selective binding to PfDHODH and show that the triazolopyrimidine scaffold can alternatively be tuned to inhibit human DHODH, an important target for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFg5a-YaPFpLVg90H21EOLACvtfcHk0lh3Z90zie6RiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D&md5=abfc8df6c8510665049e65338732acf0</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjm500481t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500481t%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DFluorine%2520modulates%2520species%2520selectivity%2520in%2520the%2520triazolopyrimidine%2520class%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D12%26spage%3D5381%26epage%3D5394%26doi%3D10.1021%2Fjm500481t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselden, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louttit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickham, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gahagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathhurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">296</span>),  <span class="NLM_fpage">296ra111</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa6645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscitranslmed.aaa6645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26180101" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=296ra111&issue=296&author=M.+A.+Phillipsauthor=J.+Lothariusauthor=K.+Marshauthor=J.+Whiteauthor=A.+Dayanauthor=K.+L.+Whiteauthor=J.+W.+Njorogeauthor=F.+El+Mazouniauthor=Y.+Laoauthor=S.+Kokkondaauthor=D.+R.+Tomchickauthor=X.+Dengauthor=T.+Lairdauthor=S.+N.+Bhatiaauthor=S.+Marchauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=S.+Wittlinauthor=M.+Lafuente-Monasterioauthor=F.+J.+Benitoauthor=L.+M.+Alonsoauthor=M.+S.+Martinezauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=J.+N.+Haseldenauthor=J.+Louttitauthor=Y.+Cuiauthor=A.+Sridharauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=R.+Sauerweinauthor=K.+Decheringauthor=V.+M.+Averyauthor=S.+Duffyauthor=M.+Delvesauthor=R.+Sindenauthor=A.+Rueckerauthor=K.+S.+Wickhamauthor=R.+Rochfordauthor=J.+Gahagenauthor=L.+Iyerauthor=E.+Riccioauthor=J.+Mirsalisauthor=I.+Bathhurstauthor=T.+Rueckleauthor=X.+Dingauthor=B.+Campoauthor=D.+Leroyauthor=M.+J.+Rogersauthor=P.+K.+Rathodauthor=J.+N.+Burrowsauthor=S.+A.+Charman&title=A+long-duration+dihydroorotate+dehydrogenase+inhibitor+%28DSM265%29+for+prevention+and+treatment+of+malaria&doi=10.1126%2Fscitranslmed.aaa6645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa6645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa6645%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDayan%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DNjoroge%26aufirst%3DJ.%2BW.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLao%26aufirst%3DY.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLaird%26aufirst%3DT.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DMarch%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DBenito%26aufirst%3DF.%2BJ.%26aulast%3DAlonso%26aufirst%3DL.%2BM.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DHaselden%26aufirst%3DJ.%2BN.%26aulast%3DLouttit%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DSauerwein%26aufirst%3DR.%26aulast%3DDechering%26aufirst%3DK.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DSinden%26aufirst%3DR.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DWickham%26aufirst%3DK.%2BS.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DGahagen%26aufirst%3DJ.%26aulast%3DIyer%26aufirst%3DL.%26aulast%3DRiccio%26aufirst%3DE.%26aulast%3DMirsalis%26aufirst%3DJ.%26aulast%3DBathhurst%26aufirst%3DI.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520long-duration%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520%2528DSM265%2529%2520for%2520prevention%2520and%2520treatment%2520of%2520malaria%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D296%26spage%3D296ra111%26doi%3D10.1126%2Fscitranslmed.aaa6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span> </span><span class="NLM_article-title">Efficacy, Safety, Tolerability and Pharmacokinetics
of KAF156 in
Adult Patients With Acute, Uncomplicated <i>Plasmodium falciparum</i> or <i>vivax</i> Malaria Mono-infection</span>.  <i>Clinical trials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2015</span>;  <span class="NLM_fpage">NCT01753323</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT01753323?term=NCT01753323&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01753323?term=NCT01753323&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy%2C+Safety%2C+Tolerability+and+Pharmacokinetics%0Aof+KAF156+in%0AAdult+Patients+With+Acute%2C+Uncomplicated+Plasmodium+falciparum+or+vivax+Malaria+Mono-infection.+Clinical+trials.gov%3B+U.S.+National%0AInstitutes+of+Health%2C+2015%3B+NCT01753323%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01753323%3Fterm%3DNCT01753323%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%252C%2520Safety%252C%2520Tolerability%2520and%2520Pharmacokinetics%250Aof%2520KAF156%2520in%250AAdult%2520Patients%2520With%2520Acute%252C%2520Uncomplicated%2520Plasmodium%2520falciparum%2520or%2520vivax%2520Malaria%2520Mono-infection%26jtitle%3DClinical%2520trials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2015%26spage%3DNCT01753323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title">In vitro resistance selections for <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">17980</span>– <span class="NLM_lpage">17995</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.558353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M114.558353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24782313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=17980-17995&issue=26&author=L.+S.+Rossauthor=F.+J.+Gamoauthor=M.+J.+Lafuente-Monasterioauthor=O.+M.+Singhauthor=P.+Rowlandauthor=R.+C.+Wiegandauthor=D.+F.+Wirth&title=In+vitro+resistance+selections+for+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+give+mutants+with+multiple+point+mutations+in+the+drug-binding+site+and+altered+growth&doi=10.1074%2Fjbc.M114.558353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Resistance Selections for Plasmodium Falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered Growth</span></div><div class="casAuthors">Ross, Leila S.; Gamo, Francisco Javier; Lafuente-Monasterio, Maria Jose; Singh, Onkar M. P.; Rowland, Paul; Wiegand, Roger C.; Wirth, Dyann F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">17980-17995</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Malaria is a preventable and treatable disease; yet half of the world's population lives at risk of infection, and an estd. 660,000 people die of malaria-related causes every year.  Rising drug resistance threatens to make malaria untreatable, necessitating both the discovery of new antimalarial agents and the development of strategies to identify and suppress the emergence and spread of drug resistance.  We focused on in-development dihydroorotate dehydrogenase (DHODH) inhibitors.  Characterizing resistance pathways for antimalarial agents not yet in clin. use will increase our understanding of the potential for resistance.  We identified resistance mechanisms of Plasmodium falciparum (Pf) DHODH inhibitors via in vitro resistance selections.  We found 11 point mutations in the PfDHODH target.  Target gene amplification and unknown mechanisms also contributed to resistance, albeit to a lesser extent.  These mutant parasites were often hypersensitive to other PfDHODH inhibitors, which immediately suggested a novel combination therapy approach to preventing resistance.  Indeed, a combination of wild-type and mutant-type selective inhibitors led to resistance far less often than either drug alone.  The effects of point mutations in PfDHODH were corroborated with purified recombinant wild-type and mutant-type PfDHODH proteins, which showed the same trends in drug response as the cognate cell lines.  Comparative growth assays demonstrated that two mutant parasites grew less robustly than their wild-type parent, and the purified protein of those mutants showed a decrease in catalytic efficiency, thereby suggesting a reason for the diminished growth rate.  Co-crystallog. of PfDHODH with three inhibitors suggested that hydrophobic interactions are important for drug binding and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro56dX8r--uLVg90H21EOLACvtfcHk0li4mxZcLHgNAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO&md5=35ea613c4223241c76a7bc0436cf9adb</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.558353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.558353%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DL.%2BS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DO.%2BM.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DWiegand%26aufirst%3DR.%2BC.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DIn%2520vitro%2520resistance%2520selections%2520for%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520give%2520mutants%2520with%2520multiple%2520point%2520mutations%2520in%2520the%2520drug-binding%2520site%2520and%2520altered%2520growth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D26%26spage%3D17980%26epage%3D17995%26doi%3D10.1074%2Fjbc.M114.558353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhingra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afanador, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in <i>Plasmodium falciparum</i> that confer in vitro resistance to the clinical candidate DSM265</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00211</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00211" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=90-101&issue=1&author=J.+Whiteauthor=S.+K.+Dhingraauthor=X.+Dengauthor=F.+El+Mazouniauthor=M.+C.+S.+Leeauthor=G.+A.+Afanadorauthor=A.+Lawongauthor=D.+R.+Tomchickauthor=C.+L.+Ngauthor=J.+Bathauthor=P.+K.+Rathodauthor=D.+A.+Fidockauthor=M.+A.+Phillips&title=Identification+and+mechanistic+understanding+of+dihydroorotate+dehydrogenase+point+mutations+in+Plasmodium+falciparum+that+confer+in+vitro+resistance+to+the+clinical+candidate+DSM265&doi=10.1021%2Facsinfecdis.8b00211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265</span></div><div class="casAuthors">White, John; Dhingra, Satish K.; Deng, Xiaoyi; El Mazouni, Farah; Lee, Marcus C. S.; Afanador, Gustavo A.; Lawong, Aloysus; Tomchick, Diana R.; Ng, Caroline L.; Bath, Jade; Rathod, Pradipsinh K.; Fidock, David A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-101</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most challenging human infectious diseases, and both prevention and control have been hindered by the development of Plasmodium falciparum resistance to existing therapies.  Several new compds. with novel mechanisms are in clin. development for the treatment of malaria, including DSM265, an inhibitor of Plasmodium dihydroorotate dehydrogenase.  To explore the mechanisms by which resistance might develop to DSM265 in the field, we selected for DSM265-resistant P. falciparum parasites in vitro.  Any of five different amino acid changes led to reduced efficacy on the parasite and to decreased DSM265 binding to P. falciparum DHODH.  The DSM265-resistant parasites retained full sensitivity to atovaquone.  All but one of the obsd. mutations were in the DSM265 binding site, and the remaining C276F was in the adjacent flavin cofactor site.  The C276F mutation was previously identified in a recrudescent parasite during a Phase IIa clin. study.  We confirmed that this mutation (and the related C276Y) accounted for the full level of obsd. DSM265 resistance by regenerating the mutation using CRISPR/Cas9 genome editing.  X-ray structure anal. of the C276F mutant enzyme showed that conformational changes of nearby residues were required to accommodate the larger F276 residue, which in turn led to a restriction in the size of the DSM265 binding pocket.  These findings underscore the importance of developing DSM265 as part of a combination therapy with other agents for successful use against malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQMMzkCwd_zrVg90H21EOLACvtfcHk0ljN9KYj92PC5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN&md5=6b9001020d2332016c7f189a6dbe9380</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00211%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDhingra%26aufirst%3DS.%2BK.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DAfanador%26aufirst%3DG.%2BA.%26aulast%3DLawong%26aufirst%3DA.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520and%2520mechanistic%2520understanding%2520of%2520dihydroorotate%2520dehydrogenase%2520point%2520mutations%2520in%2520Plasmodium%2520falciparum%2520that%2520confer%2520in%2520vitro%2520resistance%2520to%2520the%2520clinical%2520candidate%2520DSM265%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26issue%3D1%26spage%3D90%26epage%3D101%26doi%3D10.1021%2Facsinfecdis.8b00211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacRae, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, A. P.</span></span> <span> </span><span class="NLM_article-title">Stage-specific changes in Plasmodium metabolism required for differentiation and adaptation to different host and vector environments</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e1006094</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1006094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.ppat.1006094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28027318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVyisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1006094&issue=12&author=A.+Srivastavaauthor=N.+Philipauthor=K.+R.+Hughesauthor=K.+Georgiouauthor=J.+I.+MacRaeauthor=M.+P.+Barrettauthor=D.+J.+Creekauthor=M.+J.+McConvilleauthor=A.+P.+Waters&title=Stage-specific+changes+in+Plasmodium+metabolism+required+for+differentiation+and+adaptation+to+different+host+and+vector+environments&doi=10.1371%2Fjournal.ppat.1006094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Stage-specific changes in Plasmodium metabolism required for differentiation and adaptation to different host and vector environments</span></div><div class="casAuthors">Srivastava, Anubhav; Philip, Nisha; Hughes, Katie R.; Georgiou, Konstantina; MacRae, James I.; Barrett, Michael P.; Creek, Darren J.; McConville, Malcolm J.; Waters, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1006094/1-e1006094/30</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Malaria parasites (Plasmodium spp.) encounter markedly different (nutritional) environments during their complex life cycles in the mosquito and human hosts.  Adaptation to these different host niches is assocd. with a dramatic rewiring of metab., from a highly glycolytic metab. in the asexual blood stages to increased dependence on tricarboxylic acid (TCA) metab. in mosquito stages.  Here we have used stable isotope labeling, targeted metabolomics and reverse genetics to map stage-specific changes in Plasmodium berghei carbon metab. and det. the functional significance of these changes on parasite survival in the blood and mosquito stages.  We show that glutamine serves as the predominant input into TCA metab. in both asexual and sexual blood stages and is important for complete male gametogenesis.  Glutamine catabolism, as well as key reactions in intermediary metab. and CoA synthesis are also essential for ookinete to oocyst transition in the mosquito.  These data extend our knowledge of Plasmodium metab. and point towards possible targets for transmission-blocking intervention strategies.  Furthermore, they highlight significant metabolic differences between Plasmodium species which are not easily anticipated based on genomics or transcriptomics studies and underline the importance of integration of metabolomics data with other platforms in order to better inform drug discovery and design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2vX-n_xTKWrVg90H21EOLACvtfcHk0lgMIDJ64PXi2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVyisLk%253D&md5=1a8476606b4e89170d4521992546d123</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006094%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DPhilip%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DK.%2BR.%26aulast%3DGeorgiou%26aufirst%3DK.%26aulast%3DMacRae%26aufirst%3DJ.%2BI.%26aulast%3DBarrett%26aufirst%3DM.%2BP.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DMcConville%26aufirst%3DM.%2BJ.%26aulast%3DWaters%26aufirst%3DA.%2BP.%26atitle%3DStage-specific%2520changes%2520in%2520Plasmodium%2520metabolism%2520required%2520for%2520differentiation%2520and%2520adaptation%2520to%2520different%2520host%2520and%2520vector%2520environments%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26issue%3D12%26spage%3De1006094%26doi%3D10.1371%2Fjournal.ppat.1006094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjalanagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossignol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=945-957&issue=12&author=M.+A.+Phillipsauthor=K.+L.+Whiteauthor=S.+Kokkondaauthor=X.+Dengauthor=J.+Whiteauthor=F.+El+Mazouniauthor=K.+Marshauthor=D.+R.+Tomchickauthor=K.+Manjalanagaraauthor=K.+R.+Rudraauthor=G.+Wirjanataauthor=R.+Noviyantiauthor=R.+N.+Priceauthor=J.+Marfurtauthor=D.+M.+Shacklefordauthor=F.+C.+Chiuauthor=M.+Campbellauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=M.+Lafuente-Monasterioauthor=W.+Kaminskyauthor=K.+Silueauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=D.+Leroyauthor=B.+Blascoauthor=E.+Rossignolauthor=T.+Rueckleauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=D.+Watersonauthor=M.+J.+Palmerauthor=P.+K.+Rathodauthor=S.+A.+Charman&title=A+triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitor+with+improved+drug-like+properties+for+treatment+and+prevention+of+malaria&doi=10.1021%2Facsinfecdis.6b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria</span></div><div class="casAuthors">Phillips, Margaret A.; White, Karen L.; Kokkonda, Sreekanth; Deng, Xiaoyi; White, John; El Mazouni, Farah; Marsh, Kennan; Tomchick, Diana R.; Manjalanagara, Krishne; Rudra, Kakali Rani; Wirjanata, Grennady; Noviyanti, Rintis; Price, Ric N.; Marfurt, Jutta; Shackleford, David M.; Chiu, Francis C. K.; Campbell, Michael; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Inigo; Martinez, Maria Santos; Lafuente-Monasterio, Maria; Kaminsky, Werner; Silue, Kigbafori; Zeeman, Anne-Marie; Kocken, Clemens; Leroy, Didier; Blasco, Benjamin; Rossignol, Emilie; Rueckle, Thomas; Matthews, Dave; Burrows, Jeremy N.; Waterson, David; Palmer, Michael J.; Rathod, Pradipsinh K.; Charman, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">945-957</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistant malaria parasites continues to hamper efforts to control this lethal disease.  Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria and a selective inhibitor I of the Plasmodium enzyme is currently in clin. development.  With the goal of identifying a backup compd. to I, the authors explored replacement of the SF5-aniline moiety of I with a series of CF3-pyridinyls, while maintaining the core triazolopyrimidine scaffold.  This effort led to the identification of II, which has improved soly., lower intrinsic clearance and increased plasma exposure after oral dosing compared to I, while maintaining a long predicted human half-life.  Its improved phys. and chem. properties will allow it to be formulated more readily than I.  II showed excellent efficacy in the SCID mouse model of P. falciparum malaria that supports the prediction of a low human dose (<200 mg).  Importantly II showed equal activity against both P. falciparum and P. vivax field isolates, while I was more active on P. falciparum.  II has the potential to be developed as a single dose cure or once-weekly chemopreventative for both P. falciparum and P. vivax malaria leading to its advancement as a preclin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE-Pm5_CT2LrVg90H21EOLACvtfcHk0lgMIDJ64PXi2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ&md5=df58b9d21b75ad84d6181d42a2341e60</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00144%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DManjalanagara%26aufirst%3DK.%26aulast%3DRudra%26aufirst%3DK.%2BR.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DChiu%26aufirst%3DF.%2BC.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DSilue%26aufirst%3DK.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DRossignol%26aufirst%3DE.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520triazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520with%2520improved%2520drug-like%2520properties%2520for%2520treatment%2520and%2520prevention%2520of%2520malaria%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26issue%3D12%26spage%3D945%26epage%3D957%26doi%3D10.1021%2Facsinfecdis.6b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span> <span> </span><span class="NLM_article-title">DSM265 400 mg clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with <i>Plasmodium falciparum</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e01837-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.01837-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01837-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30858218" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e01837-18&author=K.+A.+Collinsauthor=T.+Ruckleauthor=S.+Elliottauthor=L.+Marquartauthor=E.+Ballardauthor=S.+Chalonauthor=P.+Griffinauthor=J.+J.+Mohrleauthor=J.+S.+McCarthy&title=DSM265+400+mg+clears+asexual+stage+parasites+but+not+mature+gametocytes+from+the+blood+of+healthy+subjects+experimentally+infected+with+Plasmodium+falciparum&doi=10.1128%2FAAC.01837-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1128%2FAAC.01837-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01837-18%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DK.%2BA.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DBallard%26aufirst%3DE.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26atitle%3DDSM265%2520400%2520mg%2520clears%2520asexual%2520stage%2520parasites%2520but%2520not%2520mature%2520gametocytes%2520from%2520the%2520blood%2520of%2520healthy%2520subjects%2520experimentally%2520infected%2520with%2520Plasmodium%2520falciparum%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De01837-18%26doi%3D10.1128%2FAAC.01837-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibáñez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Doval, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo-Viola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Improved murine model of malaria using <i>Plasmodium falciparum</i> competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4533</span>– <span class="NLM_lpage">4536</span>, <span class="refDoi"> DOI: 10.1128/AAC.00519-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.00519-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=19596869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=4533-4536&issue=10&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=T.+Muletauthor=S.+Vieraauthor=V.+G%C3%B3mezauthor=H.+Garutiauthor=J.+Ib%C3%A1%C3%B1ezauthor=A.+Alvarez-Dovalauthor=L.+D.+Shultzauthor=A.+Mart%C3%ADnezauthor=D.+Gargallo-Violaauthor=I.+Angulo-Barturen&title=Improved+murine+model+of+malaria+using+Plasmodium+falciparum+competent+strains+and+non-myelodepleted+NOD-scid+IL2Rgammanull+mice+engrafted+with+human+erythrocytes&doi=10.1128%2FAAC.00519-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Mulet, Teresa; Viera, Sara; Gomez, Vanessa; Garuti, Helen; Ibanez, Javier; Alvarez-Doval, Angela; Shultz, Leonard D.; Martinez, Antonio; Gargallo-Viola, Domingo; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4533-4536</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Plasmodium falciparum malaria may become crucial tools in drug discovery.  Here we show that non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes support an infectious burden up to tenfold higher than that supported by engrafted NOD-scid β2microglobulinnull mice.  The new model was validated for drug discovery and was used to assess the therapeutic efficacy of 4-pyridones, selective inhibitors of P. falciparum cytochrome bc1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoGw5NKfthdbVg90H21EOLACvtfcHk0liZ8PrXQLJDjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO&md5=df25f5f7382b0b422a9e9b2137a66093</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1128%2FAAC.00519-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00519-09%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DG%25C3%25B3mez%26aufirst%3DV.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DJ.%26aulast%3DAlvarez-Doval%26aufirst%3DA.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DGargallo-Viola%26aufirst%3DD.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DImproved%2520murine%2520model%2520of%2520malaria%2520using%2520Plasmodium%2520falciparum%2520competent%2520strains%2520and%2520non-myelodepleted%2520NOD-scid%2520IL2Rgammanull%2520mice%2520engrafted%2520with%2520human%2520erythrocytes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26issue%3D10%26spage%3D4533%26epage%3D4536%26doi%3D10.1128%2FAAC.00519-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haworth, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. J.</span></span> <span> </span><span class="NLM_article-title">Physiologically based pharmacokinetic modeling in lead optimization. 1. Evaluation and adaptation of GastroPlus to predict bioavailability of Medchem series</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00972</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00972" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=821-830&issue=3&author=P.+R.+Dagaauthor=M.+B.+Bolgerauthor=I.+S.+Haworthauthor=R.+D.+Clarkauthor=E.+J.+Martin&title=Physiologically+based+pharmacokinetic+modeling+in+lead+optimization.+1.+Evaluation+and+adaptation+of+GastroPlus+to+predict+bioavailability+of+Medchem+series&doi=10.1021%2Facs.molpharmaceut.7b00972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series</span></div><div class="casAuthors">Daga, Pankaj R.; Bolger, Michael B.; Haworth, Ian S.; Clark, Robert D.; Martin, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">821-830</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">When medicinal chemists need to improve bioavailability (%F) within a chem. series during lead optimization, they synthesize new series members with systematically modified properties mainly by following experience and general rules of thumb.  More quant. models that predict %F of proposed compds. from chem. structure alone have proven elusive.  Global empirical %F quant. structure-property (QSPR) models perform poorly, and projects have too little data to train local %F QSPR models.  Mechanistic oral absorption and physiol. based pharmacokinetic (PBPK) models simulate the dissoln., absorption, systemic distribution, and clearance of a drug in preclin. species and humans.  Attempts to build global PBPK models based purely on calcd. inputs have not achieved the <2-fold av. error needed to guide lead optimization.  In this work, local GastroPlus PBPK models are instead customized for individual medchem series.  The key innovation was building a local QSPR for a numerically fitted effective intrinsic clearance (CLloc).  All inputs are subsequently computed from structure alone, so the models can be applied in advance of synthesis.  Training CLloc on the first 15-18 rat %F measurements gave adequate predictions, with clear improvements up to about 30 measurements, and incremental improvements beyond that.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTTUNr32xw1bVg90H21EOLACvtfcHk0lixy8Espo0mQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsw%253D%253D&md5=c7b89c1733fcb755e16a67ef3843a596</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00972%26sid%3Dliteratum%253Aachs%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DBolger%26aufirst%3DM.%2BB.%26aulast%3DHaworth%26aufirst%3DI.%2BS.%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DMartin%26aufirst%3DE.%2BJ.%26atitle%3DPhysiologically%2520based%2520pharmacokinetic%2520modeling%2520in%2520lead%2520optimization.%25201.%2520Evaluation%2520and%2520adaptation%2520of%2520GastroPlus%2520to%2520predict%2520bioavailability%2520of%2520Medchem%2520series%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26issue%3D3%26spage%3D821%26epage%3D830%26doi%3D10.1021%2Facs.molpharmaceut.7b00972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruwende, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allsopp, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newbold, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. V. S.</span></span> <span> </span><span class="NLM_article-title">Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">6537</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1038/376246a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2F376246a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=7617034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADyaK2MXntFSmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=246-249&issue=6537&author=C.+Ruwendeauthor=S.+C.+Khooauthor=R.+W.+Snowauthor=S.+N.+Yatesauthor=D.+Kwiatkowskiauthor=S.+Guptaauthor=P.+Warnauthor=C.+E.+Allsoppauthor=S.+C.+Gilbertauthor=N.+Peschuauthor=C.+I.+Newboldauthor=B.+M.+Greenwoodauthor=K.+Marshauthor=A.+V.+S.+Hill&title=Natural+selection+of+hemi-+and+heterozygotes+for+G6PD+deficiency+in+Africa+by+resistance+to+severe+malaria&doi=10.1038%2F376246a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria</span></div><div class="casAuthors">Ruwende, C.; Khoo, S. C.; Snow, R. W.; Yates, S. N. R.; Kwiatkowski, D.; Gupta, S.; Warn, P.; Allsopp, C. E. M.; Gilbert, S. C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6537</span>),
    <span class="NLM_cas:pages">246-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common enzymopathy of humans, affects over 400 million people.  The geog. correlation of its distribution with the historical endemicity of malaria suggests that this disorder has risen in frequency through natural selection by malaria.  However, attempts to confirm that G6PD deficiency is protective in case-control studies of malaria have yielded conflicting results.  Hence, for this X-linked disorder, it is unclear whether both male hemizygotes and female heterozygotes are protected or, as frequently suggested, only females.  Furthermore, how much protection may be afforded is unknown.  Here the authors report that, in two large case-control studies of over 2,000 African children, the common African form of G6PD deficiency (G6PD A-) is assocd. with a 46-58% redn. in risk of severe malaria for both female heterozygotes and male hemizygotes.  A math. model incorporating the measured selective advantage against malaria suggests that a counterbalancing selective disadvantage, assocd. with this enzyme deficiency, has retarded its rise in frequency in malaria-endemic regions.  Although G6PD deficiency is now regarded as a generally benign disorder, in earlier environmental conditions it could have been significantly disadvantageous.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEDjI_LQJXE7Vg90H21EOLACvtfcHk0lixy8Espo0mQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntFSmu74%253D&md5=489a3ff9129219acd7010536069b1553</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2F376246a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376246a0%26sid%3Dliteratum%253Aachs%26aulast%3DRuwende%26aufirst%3DC.%26aulast%3DKhoo%26aufirst%3DS.%2BC.%26aulast%3DSnow%26aufirst%3DR.%2BW.%26aulast%3DYates%26aufirst%3DS.%2BN.%26aulast%3DKwiatkowski%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DWarn%26aufirst%3DP.%26aulast%3DAllsopp%26aufirst%3DC.%2BE.%26aulast%3DGilbert%26aufirst%3DS.%2BC.%26aulast%3DPeschu%26aufirst%3DN.%26aulast%3DNewbold%26aufirst%3DC.%2BI.%26aulast%3DGreenwood%26aufirst%3DB.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DA.%2BV.%2BS.%26atitle%3DNatural%2520selection%2520of%2520hemi-%2520and%2520heterozygotes%2520for%2520G6PD%2520deficiency%2520in%2520Africa%2520by%2520resistance%2520to%2520severe%2520malaria%26jtitle%3DNature%26date%3D1995%26volume%3D376%26issue%3D6537%26spage%3D246%26epage%3D249%26doi%3D10.1038%2F376246a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekuloski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebrevska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30171-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2817%2930171-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28363636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=626-635&issue=6&author=J.+S.+McCarthyauthor=J.+Lothariusauthor=T.+Ruckleauthor=S.+Chalonauthor=M.+A.+Phillipsauthor=S.+Elliottauthor=S.+Sekuloskiauthor=P.+Griffinauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=L.+Marquartauthor=N.+S.+Williamsauthor=N.+Gobeauauthor=L.+Bebrevskaauthor=M.+Rosarioauthor=K.+Marshauthor=J.+J.+Mohrle&title=Safety%2C+tolerability%2C+pharmacokinetics%2C+and+activity+of+the+novel+long-acting+antimalarial+DSM265%3A+a+two-part+first-in-human+phase+1a%2F1b+randomised+study&doi=10.1016%2FS1473-3099%2817%2930171-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span></div><div class="casAuthors">McCarthy, James S.; Lotharius, Julie; Ruckle, Thomas; Chalon, Stephan; Phillips, Margaret A.; Elliott, Suzanne; Sekuloski, Silvana; Griffin, Paul; Ng, Caroline L.; Fidock, David A.; Marquart, Louise; Williams, Noelle S.; Gobeau, Nathalie; Bebrevska, Lidiya; Rosario, Maria; Marsh, Kennan; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis.  We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity.  Healthy participants aged 18-55 years were enrolled in a two-part study: part 1, a single ascending dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised, active-comparator controlled study, in which participants were inoculated with Plasmodium falciparum induced blood-stage malaria (IBSM) and treated with DSM265 (150 mg) or mefloquine (10 mg/kg).  Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics.  Randomisation lists were created using a validated, automated system.  Both parts were registered with the Australian New Zealand Clin. Trials Registry, no. ACTRN12613000522718 (part 1) and no. ACTRN12613000527763 (part 2).  In part 1, 73 participants were enrolled between Apr. 12, 2013, and July 14, 2015 (DSM265, n = 55; placebo, n = 18).  In part 2, nine participants were enrolled between Sept 30 and Nov 25, 2013 (150 mg DSM265, n = 7; 10 mg/kg mefloquine, n = 2).  In part 1, 117 adverse events were reported; no drug-related serious or severe events were reported.  The most common drug-related adverse event was headache.  The mean DSM265 peak plasma concn. (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1.5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.  In part 2, the log10 parasite redn. ratio at 48 h in the DSM265 (150 mg) group was 1.55 (95% CI 1.42-1.67) and in the mefloquine (10 mg/kg) group was 2.34 (2.17-2.52), corresponding to a parasite clearance half-life of 9.4 h (8.7-10.2) and 6.2 h (5.7-6.7), resp.  The median min. inhibitory concn. of DSM265 in blood was estd. as 1040 ng/mL (range 552-1500), resulting in a predicted single efficacious dose of 340 mg.  Parasite clearance was significantly faster in participants who received mefloquine than in participants who received DSM265 (p<0.0001).  The good safety profile, long elimination half-life, and antimalarial effect of DSM265 supports its development as a partner drug in a single-dose antimalarial combination treatment.  Wellcome Trust, UK Department for International Development, Global Health Innovative Technol. Fund, Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc6SKwiEAKqbVg90H21EOLACvtfcHk0lj4bqvaYC8Unw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D&md5=144cece3cf70a64af921f7f37df7c72d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930171-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930171-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DSekuloski%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DN.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DBebrevska%26aufirst%3DL.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520activity%2520of%2520the%2520novel%2520long-acting%2520antimalarial%2520DSM265%253A%2520a%2520two-part%2520first-in-human%2520phase%25201a%252F1b%2520randomised%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26issue%3D6%26spage%3D626%26epage%3D635%26doi%3D10.1016%2FS1473-3099%2817%2930171-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekuloski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peatey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenholme, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humberstone, A. J.</span></span> <span> </span><span class="NLM_article-title">A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e21914</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0021914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.pone.0021914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21887214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFyrs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21914&issue=8&author=J.+S.+McCarthyauthor=S.+Sekuloskiauthor=P.+M.+Griffinauthor=S.+Elliottauthor=N.+Douglasauthor=C.+Peateyauthor=R.+Rockettauthor=P.+O%E2%80%99Rourkeauthor=L.+Marquartauthor=C.+Hermsenauthor=S.+Duparcauthor=J.+Mohrleauthor=K.+R.+Trenholmeauthor=A.+J.+Humberstone&title=A+pilot+randomised+trial+of+induced+blood-stage+Plasmodium+falciparum+infections+in+healthy+volunteers+for+testing+efficacy+of+new+antimalarial+drugs&doi=10.1371%2Fjournal.pone.0021914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs</span></div><div class="casAuthors">McCarthy, James S.; Sekuloski, Silvana; Griffin, Paul M.; Elliott, Suzanne; Douglas, Nanette; Peatey, Chris; Rockett, Rebecca; O'Rourke, Peter; Marquart, Louise; Hermsen, Cornelius; Duparc, Stephan; Mohrle, Jorg; Trenholme, Katharine R.; Humberstone, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e21914</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Crit. to the development of new drugs for treatment of malaria is the capacity to safely evaluate their activity in human subjects.  The approach that has been most commonly used is testing in subjects with natural malaria infection, a methodol. that may expose symptomatic subjects to the risk of ineffective treatment.  Here we describe the development and pilot testing of a system to undertake exptl. infection using blood stage Plasmodium falciparum parasites (BSP).  The objectives of the study were to assess the feasibility and safety of induced BSP infection as a method for assessment of efficacy of new drug candidates for the treatment of P. falciparum infection.  Methods and Findings: A prospective, unblinded, Phase IIa trial was undertaken in 19 healthy, malaria-naive, male adult volunteers who were infected with BSP and followed with careful clin. and lab. observation, including a sensitive, quant. malaria PCR assay.  Volunteers were randomly allocated to treatment with either of two licensed antimalarial drug combinations, artemether-lumefantrine (A/L) or atovaquone-proguanil (A/P).  In the first cohort (n = 6) where volunteers received ∼360 BSP, none reached the target parasitemia of 1,000 before the day designated for antimalarial treatment (day 6).  In the second and third cohorts, 13 volunteers received 1,800 BSP, with all reaching the target parasitemia before receiving treatment (A/L, n = 6; A/P, n = 7).  The study demonstrated safety in the 19 volunteers tested, and a significant difference in the clearance kinetics of parasitemia between the drugs in the 13 evaluable subjects, with mean parasite redn. ratios of 759 for A/L and 17 for A/P (95% CI 120-4786 and 7-40 resp.; p<0.01).  Conclusions: This system offers a flexible and safe approach to testing the in vivo activity of novel antimalarials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpydB01EN7H4bVg90H21EOLACvtfcHk0lj4bqvaYC8Unw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFyrs73I&md5=7673c39450a9daadb2ab7781fa94295e</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021914%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26aulast%3DSekuloski%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%2BM.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DDouglas%26aufirst%3DN.%26aulast%3DPeatey%26aufirst%3DC.%26aulast%3DRockett%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DP.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DHermsen%26aufirst%3DC.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMohrle%26aufirst%3DJ.%26aulast%3DTrenholme%26aufirst%3DK.%2BR.%26aulast%3DHumberstone%26aufirst%3DA.%2BJ.%26atitle%3DA%2520pilot%2520randomised%2520trial%2520of%2520induced%2520blood-stage%2520Plasmodium%2520falciparum%2520infections%2520in%2520healthy%2520volunteers%2520for%2520testing%2520efficacy%2520of%2520new%2520antimalarial%2520drugs%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D8%26spage%3De21914%26doi%3D10.1371%2Fjournal.pone.0021914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llanos-Cuentas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casapia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuquiyauri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinojosa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toovey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arch, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenberg, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft
van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araeipour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated <i>Plasmodium falciparum</i> or <i>Plasmodium vivax</i> malaria infection: a proof-of-concept, open-label, phase 2a study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30309-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2818%2930309-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29909069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=874-883&issue=8&author=A.+Llanos-Cuentasauthor=M.+Casapiaauthor=R.+Chuquiyauriauthor=J.+C.+Hinojosaauthor=N.+Kerrauthor=M.+Rosarioauthor=S.+Tooveyauthor=R.+H.+Archauthor=M.+A.+Phillipsauthor=F.+D.+Rozenbergauthor=J.+Bathauthor=C.+L.+Ngauthor=A.+N.+Cowellauthor=E.+A.+Winzelerauthor=D.+A.+Fidockauthor=M.+Bakerauthor=J.+J.+Mohrleauthor=R.+Hooft%0Avan+Huijsduijnenauthor=N.+Gobeauauthor=N.+Araeipourauthor=N.+Andenmattenauthor=T.+Ruckleauthor=S.+Duparc&title=Antimalarial+activity+of+single-dose+DSM265%2C+a+novel+plasmodium+dihydroorotate+dehydrogenase+inhibitor%2C+in+patients+with+uncomplicated+Plasmodium+falciparum+or+Plasmodium+vivax+malaria+infection%3A+a+proof-of-concept%2C+open-label%2C+phase+2a+study&doi=10.1016%2FS1473-3099%2818%2930309-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study</span></div><div class="casAuthors">Llanos-Cuentas, Alejandro; Casapia, Martin; Chuquiyauri, Raul; Hinojosa, Juan-Carlos; Kerr, Nicola; Rosario, Maria; Toovey, Stephen; Arch, Robert H.; Phillips, Margaret A.; Rozenberg, Felix D.; Bath, Jade; Ng, Caroline L.; Cowell, Annie N.; Winzeler, Elizabeth A.; Fidock, David A.; Baker, Mark; Mohrle, Jorg J.; Hooft van Huijsduijnen, Rob; Gobeau, Nathalie; Araeipour, Nada; Andenmatten, Nicole; Ruckle, Thomas; Duparc, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">874-883</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum.  This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection.  This proof-of-concept, open-label, phase 2a study was conducted at the Asociacio´n Civil Selva Amazo´nica in Iquitos, Peru.  Patients aged 18-70 years, weighing 45-90 kg, who had clin. malaria (P falciparum or P vivax monoinfection) and fever within the previous 24 h were eligible.  Exclusion criteria were clin. or lab. signs of severe malaria, inability to take oral medicine, and use of other antimalarial treatment in the preceding 14 days.  Patients were divided into cohorts of those with P falciparum (cohort a) or P vivax (cohort b) infection.  Two initial cohorts received single oral doses of 400 mg DSM265.  Patients were followed up for efficacy for 28 days and safety for 35 days.  Further cohorts received escalated or de-escalated doses of DSM265, after safety and efficacy assessment of the initial dose.  The primary endpoints were the proportion of patients achieving PCR-adjusted adequate clin. and parasitol. response (ACPR) by day 14 for patients infected with P falciparum and the proportion of patients achieving a crude cure by day 14 for those infected with P vivax.  Cohort success, the criteria for dose escalation, was defined as ACPR (P falciparum) or crude cure (P vivax) in at least 80% of patients in the cohort.  The primary anal. was done in the intention-to-treat population (ITT) and the per-protocol population, and safety analyses were done in all patients who received the study drug.  This study is registered at ClinicalTrials.gov (NCT02123290).  Between Jan 12, 2015, and Dec 2, 2015, 45 Peruvian patients (24 with P falciparum [cohort a] and 21 with P vivax [cohort b] infection) were sequentially enrolled.  For patients with P falciparum malaria in the per-protocol population, all 11 (100%) in the 400 mg group and eight (80%) of ten in the 250 mg group achieved ACPR on day 14.  In the ITT anal., 11 (85%) of 13 in the 400 mg group and eight (73%) of 11 in the 250 mg group achieved ACPR at day 14.  For the patients with P vivax malaria, the primary endpoint was not met.  In the per-protocol anal., none of four patients who had 400 mg, three (50%) of six who had 600 mg, and one (25%) of four who had 800 mg DSM265 achieved crude cure at day 14.  In the ITT anal., none of five in the 400 mg group, three (33%) of nine in the 600 mg group, and one (14%) of seven in the 800 mg group achieved crude cure at day 14.  During the 28-day extended observation of P falciparum patients, a resistance-assocd. mutation in the gene encoding the DSM265 target DHODH was obsd. in two of four recurring patients.  DSM265 was well tolerated.  The most common adverse events were pyrexia (20 [44%] of 45) and headache (18 [40%] of 45), which are both common symptoms of malaria, and no patients had any treatment-related serious adverse events or adverse events leading to study discontinuation.  After a single dose of DSM265, P falciparum parasitemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics.  Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies.  The Global Health Innovative Technol. Fund, the Bill & Melinda Gates Foundation, the National Institutes of Health (R01 AI103058), the Wellcome Trust, and the UK Department of International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgJbUWoNq8m7Vg90H21EOLACvtfcHk0lgL1ApOKTwSVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI&md5=05eacd75b07eee65fca20ec28ea3c1c4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930309-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930309-8%26sid%3Dliteratum%253Aachs%26aulast%3DLlanos-Cuentas%26aufirst%3DA.%26aulast%3DCasapia%26aufirst%3DM.%26aulast%3DChuquiyauri%26aufirst%3DR.%26aulast%3DHinojosa%26aufirst%3DJ.%2BC.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DToovey%26aufirst%3DS.%26aulast%3DArch%26aufirst%3DR.%2BH.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRozenberg%26aufirst%3DF.%2BD.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DCowell%26aufirst%3DA.%2BN.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DAraeipour%26aufirst%3DN.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DDuparc%26aufirst%3DS.%26atitle%3DAntimalarial%2520activity%2520of%2520single-dose%2520DSM265%252C%2520a%2520novel%2520plasmodium%2520dihydroorotate%2520dehydrogenase%2520inhibitor%252C%2520in%2520patients%2520with%2520uncomplicated%2520Plasmodium%2520falciparum%2520or%2520Plasmodium%2520vivax%2520malaria%2520infection%253A%2520a%2520proof-of-concept%252C%2520open-label%252C%2520phase%25202a%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26issue%3D8%26spage%3D874%26epage%3D883%26doi%3D10.1016%2FS1473-3099%2818%2930309-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span> </span><span class="NLM_article-title">DSM265
Phase IIa Investigation Treating <i>Plasmodium falciparum</i> or <i>vivax</i></span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2014</span>;  <span class="NLM_fpage">NCT02123290</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02123290?term=NCT02123290&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02123290?term=NCT02123290&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DSM265%0APhase+IIa+Investigation+Treating+Plasmodium+falciparum+or+vivax.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%2C+2014%3B+NCT02123290%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02123290%3Fterm%3DNCT02123290%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DDSM265%250APhase%2520IIa%2520Investigation%2520Treating%2520Plasmodium%2520falciparum%2520or%2520vivax%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2014%26spage%3DNCT02123290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rangel, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanjee, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw-Saliba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chery, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraisingh, M. T.</span></span> <span> </span><span class="NLM_article-title">Enhanced ex vivo <i>Plasmodium vivax</i> intraerythrocytic enrichment and maturation for rapid and sensitive parasite growth assays</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e02519-17</span>, <span class="refDoi"> DOI: 10.1128/AAC.02519-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.02519-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29378713" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e02519-17&author=G.+W.+Rangelauthor=M.+A.+Clarkauthor=U.+Kanjeeauthor=C.+Limauthor=K.+Shaw-Salibaauthor=M.+J.+Menezesauthor=A.+Mascarenhasauthor=L.+Cheryauthor=E.+Gomesauthor=P.+K.+Rathodauthor=M.+U.+Ferreiraauthor=M.+T.+Duraisingh&title=Enhanced+ex+vivo+Plasmodium+vivax+intraerythrocytic+enrichment+and+maturation+for+rapid+and+sensitive+parasite+growth+assays&doi=10.1128%2FAAC.02519-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1128%2FAAC.02519-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02519-17%26sid%3Dliteratum%253Aachs%26aulast%3DRangel%26aufirst%3DG.%2BW.%26aulast%3DClark%26aufirst%3DM.%2BA.%26aulast%3DKanjee%26aufirst%3DU.%26aulast%3DLim%26aufirst%3DC.%26aulast%3DShaw-Saliba%26aufirst%3DK.%26aulast%3DMenezes%26aufirst%3DM.%2BJ.%26aulast%3DMascarenhas%26aufirst%3DA.%26aulast%3DChery%26aufirst%3DL.%26aulast%3DGomes%26aufirst%3DE.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DFerreira%26aufirst%3DM.%2BU.%26aulast%3DDuraisingh%26aufirst%3DM.%2BT.%26atitle%3DEnhanced%2520ex%2520vivo%2520Plasmodium%2520vivax%2520intraerythrocytic%2520enrichment%2520and%2520maturation%2520for%2520rapid%2520and%2520sensitive%2520parasite%2520growth%2520assays%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De02519-17%26doi%3D10.1128%2FAAC.02519-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Perez, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legarda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballester, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moncunill, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cistero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zita, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhamuave, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Basteiro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunasekera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aponte, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinovart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonijoan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, P. L.</span></span> <span> </span><span class="NLM_article-title">Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved <i>Plasmodium falciparum</i> sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">306</span>, <span class="refDoi"> DOI: 10.1186/s12936-015-0817-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-015-0817-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26245196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC287gtFGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=306&author=G.+P.+Gomez-Perezauthor=A.+Legardaauthor=J.+Munozauthor=B.+K.+Simauthor=M.+R.+Ballesterauthor=C.+Dobanoauthor=G.+Moncunillauthor=J.+J.+Campoauthor=P.+Cisteroauthor=A.+Jimenezauthor=D.+Barriosauthor=B.+Mordmullerauthor=J.+Pardosauthor=M.+Navarroauthor=C.+J.+Zitaauthor=C.+A.+Nhamuaveauthor=A.+L.+Garcia-Basteiroauthor=A.+Sanzauthor=M.+Aldeaauthor=A.+Manojauthor=A.+Gunasekeraauthor=P.+F.+Billingsleyauthor=J.+J.+Aponteauthor=E.+R.+Jamesauthor=C.+Guinovartauthor=R.+M.+Antonijoanauthor=P.+G.+Kremsnerauthor=S.+L.+Hoffmanauthor=P.+L.+Alonso&title=Controlled+human+malaria+infection+by+intramuscular+and+direct+venous+inoculation+of+cryopreserved+Plasmodium+falciparum+sporozoites+in+malaria-naive+volunteers%3A+effect+of+injection+volume+and+dose+on+infectivity+rates&doi=10.1186%2Fs12936-015-0817-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates</span></div><div class="casAuthors">Gomez-Perez Gloria P; Legarda Almudena; Munoz Jose; Dobano Carlota; Moncunill Gemma; Campo Joseph J; Cistero Pau; Jimenez Alfons; Barrios Diana; Pardos Josefina; Navarro Mireia; Garcia-Basteiro Alberto L; Sanz Ariadna; Aldea Marta; Aponte John J; Guinovart Caterina; Alonso Pedro L; Gomez-Perez Gloria P; Sim B Kim Lee; Manoj Anita; Gunasekera Anusha; Billingsley Peter F; James Eric R; Hoffman Stephen L; Ballester Maria Rosa; Antonijoan Rosa M; Ballester Maria Rosa; Antonijoan Rosa M; Campo Joseph J; Mordmuller Benjamin; Kremsner Peter G; Zita Cecilia Justino; Nhamuave Carlos Arlindo; Garcia-Basteiro Alberto L; Aldea Marta; Alonso Pedro L</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">306</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Controlled human malaria infection (CHMI) by mosquito bite is a powerful tool for evaluation of vaccines and drugs against Plasmodium falciparum malaria.  However, only a small number of research centres have the facilities required to perform such studies.  CHMI by needle and syringe could help to accelerate the development of anti-malaria interventions by enabling centres worldwide to employ CHMI.  METHODS:  An open-label CHMI study was performed with aseptic, purified, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) in 36 malaria naive volunteers.  In part A, the effect of the inoculation volume was assessed: 18 participants were injected intramuscularly (IM) with a dose of 2,500 PfSPZ divided into two injections of 10 μL (n = 6), 50 μL (n = 6) or 250 μL (n = 6), respectively.  In part B, the injection volume that resulted in highest infectivity rates in part A (10 μL) was used to formulate IM doses of 25,000 PfSPZ (n = 6) and 75,000 PfSPZ (n = 6) divided into two 10-μL injections.  Results from a parallel trial led to the decision to add a positive control group (n = 6), each volunteer receiving 3,200 PfSPZ in a single 500-μL injection by direct venous inoculation (DVI).  RESULTS:  Four/six participants in the 10-μL group, 1/6 in the 50-μL group and 2/6 in the 250-μL group developed parasitaemia.  Geometric mean (GM) pre-patent periods were 13.9, 14.0 and 15.0 days, respectively.  Six/six (100%) participants developed parasitaemia in the 25,000 and 75,000 PfSPZ IM and 3,200 PfSPZ DVI groups.  GM pre-patent periods were 12.2, 11.4 and 11.4 days, respectively.  Injection of PfSPZ Challenge was well tolerated and safe in all groups.  CONCLUSIONS:  IM injection of 75,000 PfSPZ and DVI injection of 3,200 PfSPZ resulted in infection rates and pre-patent periods comparable to the bite of five PfSPZ-infected mosquitoes.  Remarkably, it required 23.4-fold more PfSPZ administered IM than DVI to achieve the same parasite kinetics.  These results allow for translation of CHMI from research to routine use, and inoculation of PfSPZ by IM and DVI regimens.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT01771848.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwVVux3zYjKRdUSIfHIn4FfW6udTcc2eYTTr7NLtPkBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287gtFGmtA%253D%253D&md5=b1cdda3548bcf9921a59681bbe3d4c96</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1186%2Fs12936-015-0817-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-015-0817-x%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Perez%26aufirst%3DG.%2BP.%26aulast%3DLegarda%26aufirst%3DA.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DB.%2BK.%26aulast%3DBallester%26aufirst%3DM.%2BR.%26aulast%3DDobano%26aufirst%3DC.%26aulast%3DMoncunill%26aufirst%3DG.%26aulast%3DCampo%26aufirst%3DJ.%2BJ.%26aulast%3DCistero%26aufirst%3DP.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DBarrios%26aufirst%3DD.%26aulast%3DMordmuller%26aufirst%3DB.%26aulast%3DPardos%26aufirst%3DJ.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DZita%26aufirst%3DC.%2BJ.%26aulast%3DNhamuave%26aufirst%3DC.%2BA.%26aulast%3DGarcia-Basteiro%26aufirst%3DA.%2BL.%26aulast%3DSanz%26aufirst%3DA.%26aulast%3DAldea%26aufirst%3DM.%26aulast%3DManoj%26aufirst%3DA.%26aulast%3DGunasekera%26aufirst%3DA.%26aulast%3DBillingsley%26aufirst%3DP.%2BF.%26aulast%3DAponte%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DE.%2BR.%26aulast%3DGuinovart%26aufirst%3DC.%26aulast%3DAntonijoan%26aufirst%3DR.%2BM.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DAlonso%26aufirst%3DP.%2BL.%26atitle%3DControlled%2520human%2520malaria%2520infection%2520by%2520intramuscular%2520and%2520direct%2520venous%2520inoculation%2520of%2520cryopreserved%2520Plasmodium%2520falciparum%2520sporozoites%2520in%2520malaria-naive%2520volunteers%253A%2520effect%2520of%2520injection%2520volume%2520and%2520dose%2520on%2520infectivity%2520rates%26jtitle%3DMalar.%2520J.%26date%3D2015%26volume%3D14%26spage%3D306%26doi%3D10.1186%2Fs12936-015-0817-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Perez, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ospina Salazar, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joanny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamsfus Calle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohr, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalremruata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunasekera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legarda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonijoan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballester, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span> <span> </span><span class="NLM_article-title">Direct venous inoculation of <i>Plasmodium falciparum</i> sporozoites for controlled human malaria infection: a dose-finding trial in two centres</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">117</span>, <span class="refDoi"> DOI: 10.1186/s12936-015-0628-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-015-0628-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25889522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC2MjlvVSlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=117&author=B.+Mordmullerauthor=C.+Supanauthor=K.+L.+Simauthor=G.+P.+Gomez-Perezauthor=C.+L.+Ospina+Salazarauthor=J.+Heldauthor=S.+Bolteauthor=M.+Esenauthor=S.+Tschanauthor=F.+Joannyauthor=C.+Lamsfus+Calleauthor=S.+J.+Lohrauthor=A.+Lalremruataauthor=A.+Gunasekeraauthor=E.+R.+Jamesauthor=P.+F.+Billingsleyauthor=A.+Richmanauthor=S.+Chakravartyauthor=A.+Legardaauthor=J.+Munozauthor=R.+M.+Antonijoanauthor=M.+R.+Ballesterauthor=S.+L.+Hoffmanauthor=P.+L.+Alonsoauthor=P.+G.+Kremsner&title=Direct+venous+inoculation+of+Plasmodium+falciparum+sporozoites+for+controlled+human+malaria+infection%3A+a+dose-finding+trial+in+two+centres&doi=10.1186%2Fs12936-015-0628-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres</span></div><div class="casAuthors">Mordmuller Benjamin; Supan Christian; Ospina Salazar Carmen Lucelly; Held Jana; Bolte Stefanie; Esen Meral; Tschan Serena; Joanny Fanny; Lamsfus Calle Carlos; Lohr Sascha J Z; Lalremruata Albert; Kremsner Peter G; Sim Kim Lee; Gunasekera Anusha; James Eric R; Billingsley Peter F; Richman Adam; Chakravarty Sumana; Hoffman Stephen L; Gomez-Perez Gloria P; Legarda Almudena; Munoz Jose; Alonso Pedro L; Antonijoan Rosa M; Ballester Maria Rosa; Antonijoan Rosa M; Ballester Maria Rosa</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Controlled human malaria infection (CHMI) accelerates development of anti-malarial interventions.  So far, CHMI is done by exposure of volunteers to bites of five mosquitoes carrying Plasmodium falciparum sporozoites (PfSPZ), a technique available in only a few centres worldwide.  Mosquito-mediated CHMI is logistically complex, exact PfSPZ dosage is impossible and live mosquito-based interventions are not suitable for further clinical development.  METHODS:  An open-labelled, randomized, dose-finding study in 18-45 year old, healthy, malaria-naive volunteers was performed to assess if intravenous (IV) injection of 50 to 3,200 aseptic, purified, cryopreserved PfSPZ is safe and achieves infection kinetics comparable to published data of mosquito-mediated CHMI.  An independent study site verified the fully infectious dose using direct venous inoculation of PfSPZ.  Parasite kinetics were assessed by thick blood smear microscopy and quantitative real time PCR.  RESULTS:  IV inoculation with 50, 200, 800, or 3,200 PfSPZ led to parasitaemia in 1/3, 1/3, 7/9, and 9/9 volunteers, respectively.  The geometric mean pre-patent period (GMPPP) was 11.2 days (range 10.5-12.5) in the 3,200 PfSPZ IV group.  Subsequently, six volunteers received 3,200 PfSPZ by direct venous inoculation at an independent investigational site.  All six developed parasitaemia (GMPPP: 11.4 days, range: 10.4-12.3).  Inoculation of PfSPZ was safe.  Infection rate and pre-patent period depended on dose, and injection of 3,200 PfSPZ led to a GMPPP similar to CHMI with five PfSPZ-infected mosquitoes.  The infectious dose of PfSPZ predicted dosage of radiation-attenuated PfSPZ required for successful vaccination.  CONCLUSIONS:  IV inoculation of PfSPZ is safe, well tolerated and highly reproducible.  It shall further accelerate development of anti-malarial interventions through standardization and facilitation of CHMI.  Beyond this, rational dose selection for whole PfSPZ-based immunization and complex study designs are now possible.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT01624961 and NCT01771848 .</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNVDU3Wimq3LHHuJhbyicZfW6udTcc2eZJg-qg4aXdwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjlvVSlug%253D%253D&md5=cb2d519863b13b859152e2a9b696e13c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2Fs12936-015-0628-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-015-0628-0%26sid%3Dliteratum%253Aachs%26aulast%3DMordmuller%26aufirst%3DB.%26aulast%3DSupan%26aufirst%3DC.%26aulast%3DSim%26aufirst%3DK.%2BL.%26aulast%3DGomez-Perez%26aufirst%3DG.%2BP.%26aulast%3DOspina%2BSalazar%26aufirst%3DC.%2BL.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DBolte%26aufirst%3DS.%26aulast%3DEsen%26aufirst%3DM.%26aulast%3DTschan%26aufirst%3DS.%26aulast%3DJoanny%26aufirst%3DF.%26aulast%3DLamsfus%2BCalle%26aufirst%3DC.%26aulast%3DLohr%26aufirst%3DS.%2BJ.%26aulast%3DLalremruata%26aufirst%3DA.%26aulast%3DGunasekera%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DE.%2BR.%26aulast%3DBillingsley%26aufirst%3DP.%2BF.%26aulast%3DRichman%26aufirst%3DA.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DLegarda%26aufirst%3DA.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DAntonijoan%26aufirst%3DR.%2BM.%26aulast%3DBallester%26aufirst%3DM.%2BR.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DAlonso%26aufirst%3DP.%2BL.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26atitle%3DDirect%2520venous%2520inoculation%2520of%2520Plasmodium%2520falciparum%2520sporozoites%2520for%2520controlled%2520human%2520malaria%2520infection%253A%2520a%2520dose-finding%2520trial%2520in%2520two%2520centres%26jtitle%3DMalar.%2520J.%26date%3D2015%26volume%3D14%26spage%3D117%26doi%3D10.1186%2Fs12936-015-0628-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murbeth, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samec, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calle, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granados, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguetse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalremruata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, B. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">DSM265 for <i>Plasmodium falciparum</i> chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30139-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2817%2930139-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28363637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=636-644&issue=6&author=M.+Sulyokauthor=T.+Ruckleauthor=A.+Rothauthor=R.+E.+Murbethauthor=S.+Chalonauthor=N.+Kerrauthor=S.+S.+Samecauthor=N.+Gobeauauthor=C.+L.+Calleauthor=J.+Ibanezauthor=Z.+Sulyokauthor=J.+Heldauthor=T.+Gebruauthor=P.+Granadosauthor=S.+Brucknerauthor=C.+Nguetseauthor=J.+Mengueauthor=A.+Lalremruataauthor=B.+K.+L.+Simauthor=S.+L.+Hoffmanauthor=J.+J.+Mohrleauthor=P.+G.+Kremsnerauthor=B.+Mordmuller&title=DSM265+for+Plasmodium+falciparum+chemoprophylaxis%3A+a+randomised%2C+double+blinded%2C+phase+1+trial+with+controlled+human+malaria+infection&doi=10.1016%2FS1473-3099%2817%2930139-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span></div><div class="casAuthors">Sulyok, Mihaly; Rueckle, Thomas; Roth, Alexandra; Muerbeth, Raymund E.; Chalon, Stephan; Kerr, Nicola; Samec, Sonia Schnieper; Gobeau, Nathalie; Calle, Carlos Lamsfus; Ibanez, Javier; Sulyok, Zita; Held, Jana; Gebru, Tamirat; Granados, Patricia; Brueckner, Sina; Nguetse, Christian; Mengue, Juliana; Lalremruata, Albert; Sim, Kim Lee; Hoffman, Stephen L.; Moehrle, Joerg J.; Kremsner, Peter G.; Mordmueller, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-644</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substantially advance malaria control.  DSM265 is an exptl. antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase.  DSM265 shows in vitro activity against liver and blood stages of P falciparum.  We assessed the prophylactic activity of DSM265 against controlled human malaria infection (CHMI).  At the Institute of Tropical Medicine, Eberhard Karls University (Tubingen, Germany), healthy, malaria-naive adults were allocated to receive 400 mg DSM265 or placebo either 1 day (cohort 1A) or 7 days (cohort 2) before CHMI by direct venous inoculation (DVI) of 3200 aseptic, purified, cryopreserved P falciparum sporozoites (PfSPZ Challenge; Sanaria Inc, Rockville, MD, USA).  An addnl. group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1 day before CHMI (cohort 1B).  Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an interactive web response system.  Allocation to cohort 1A and 1B was open-label, within cohorts 1A and 2, allocation to DSM265 and placebo was double-blinded.  All treatments were given orally.  Volunteers were treated with an antimalarial on day 28, or when parasitemic, as detected by thick blood smear (TBS) microscopy.  The primary efficacy endpoint was time-to-parasitemia, assessed by TBS.  All participants receiving at least one dose of chemoprophylaxis or placebo were considered for safety, those receiving PfSPZ Challenge for efficacy analyzes.  Log-rank test was used to compare time-to-parasitemia between interventions.  The trial was registered with ClinicalTrials.gov, no. NCT02450578.22 participants were enrolled between Oct 23, 2015, and Jan 18, 2016.  Five participants received 400 mg DSM265 and two participants received placebo 1 day before CHMI (cohort 1A), six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and six participants received 400 mg DSM265 and two participants received placebo 7 days before CHMI (cohort 2).  Five of five participants receiving DSM265 1 day before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas placebo recipients (two of two) developed malaria on days 11 and 14.  When given 7 days before CHMI, three of six volunteers receiving DSM265 became TBS pos. on days 11, 13, and 24.  The remaining three DSM265-treated, TBS-neg. participants of cohort 2 developed transient submicroscopic parasitemia.  Both participants receiving placebo 7 days before CHMI became TBS pos. on day 11.  The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin in one participant.  A single dose of 400 mg DSM265 was well tolerated and had causal prophylactic activity when given 1 day before CHMI.  Future trials are needed to investigate further the use of DSM265 for the prophylaxis of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Qz_g361v_rVg90H21EOLACvtfcHk0liGyazIbKFGfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D&md5=17e414f86bbefda108b858930ae28bfc</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930139-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930139-1%26sid%3Dliteratum%253Aachs%26aulast%3DSulyok%26aufirst%3DM.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%26aulast%3DMurbeth%26aufirst%3DR.%2BE.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DSamec%26aufirst%3DS.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DCalle%26aufirst%3DC.%2BL.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DSulyok%26aufirst%3DZ.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DGebru%26aufirst%3DT.%26aulast%3DGranados%26aufirst%3DP.%26aulast%3DBruckner%26aufirst%3DS.%26aulast%3DNguetse%26aufirst%3DC.%26aulast%3DMengue%26aufirst%3DJ.%26aulast%3DLalremruata%26aufirst%3DA.%26aulast%3DSim%26aufirst%3DB.%2BK.%2BL.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DDSM265%2520for%2520Plasmodium%2520falciparum%2520chemoprophylaxis%253A%2520a%2520randomised%252C%2520double%2520blinded%252C%2520phase%25201%2520trial%2520with%2520controlled%2520human%2520malaria%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26issue%3D6%26spage%3D636%26epage%3D644%26doi%3D10.1016%2FS1473-3099%2817%2930139-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seilie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbaugher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VonGoedert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappe, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcsisin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kublin, J. G.</span></span> <span> </span><span class="NLM_article-title">A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic <i>Plasmodium falciparum</i> infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Finfdis%2Fjix613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29216395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2018&pages=693-702&issue=5&author=S.+C.+Murphyauthor=E.+R.+Dukeauthor=K.+J.+Shipmanauthor=R.+L.+Jensenauthor=Y.+Fongauthor=S.+Fergusonauthor=H.+E.+Janesauthor=K.+Gillespieauthor=A.+M.+Seilieauthor=A.+E.+Hanronauthor=L.+Rinnauthor=M.+Fishbaugherauthor=T.+VonGoedertauthor=E.+Fritzenauthor=S.+H.+Kappeauthor=M.+Changauthor=J.+C.+Sousaauthor=S.+R.+Marcsisinauthor=S.+Chalonauthor=S.+Duparcauthor=N.+Kerrauthor=J.+J.+Mohrleauthor=N.+Andenmattenauthor=T.+Rueckleauthor=J.+G.+Kublin&title=A+randomized+trial+evaluating+the+prophylactic+activity+of+DSM265+against+preerythrocytic+Plasmodium+falciparum+infection+during+controlled+human+malarial+infection+by+mosquito+bites+and+direct+venous+inoculation&doi=10.1093%2Finfdis%2Fjix613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span></div><div class="casAuthors">Murphy, Sean C.; Duke, Elizabeth R.; Shipman, Kelly J.; Jensen, Ryan L.; Fong, Youyi; Ferguson, Sue; Janes, Holly E.; Gillespie, Kevin; Seilie, Annette M.; Hanron, Amelia E.; Rinn, Laurie; Fishbaugher, Matthew; VonGoedert, Tracie; Fritzen, Emma; Kappe, Stefan H.; Chang, Ming; Sousa, Jason C.; Marcsisin, Sean R.; Chalon, Stephan; Duparc, Stephan; Kerr, Nicola; Mohrle, Jorg J.; Andenmatten, Nicole; Rueckle, Thomas; Kublin, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">693-702</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  DSM265 is a selective inhibitor of Plasmodium dihydroorotate dehydrogenase that fully protected against controlled human malarial infection (CHMI) by direct venous inoculation of Plasmodium falciparum sporozoites when administered 1 day before challenge and provided partial protection when administered 7 days before challenge.  Methods.  A double-blinded, randomized, placebo-controlled trial was performed to assess safety, tolerability, pharmacokinetics, and efficacy of 1 oral dose of 400 mg of DSM265 before CHMI.  Three cohorts were studied, with DSM265 administered 3 or 7 days before direct venous inoculation of sporozoites or 7 days before 5 bites from infected mosquitoes.  Results.  DSM265-related adverse events consisted of mild-to-moderate headache and gastrointestinal symptoms.  DSM265 concns. were consistent with pharmacokinetic models (mean area under the curve extrapolated to infinity, 1707 μg*h/mL).  Placebo-treated participants became pos. by quant. reverse transcription-polymerase chain reaction (qRT-PCR) and were treated 7-10 days after CHMI.  Among DSM265-treated subjects, 2 of 6 in each cohort were sterilely protected.  DSM265-treated recipients had longer times to development of parasitemia than placebo-treated participants (P < .004).  Conclusions.  This was the first CHMI study of a novel antimalarial compd. to compare direct venous inoculation of sporozoites and mosquito bites.  Times to qRT-PCR positivity and treatment were comparable for both routes.  DSM265 given 3 or 7 days before CHMI was safe and well tolerated but sterilely protected only one third of participants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMZHT578xgCrVg90H21EOLACvtfcHk0lhZRd4yUgKLew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D&md5=09ad9e8ac99393967ca57e475f2f52bb</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix613%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DS.%2BC.%26aulast%3DDuke%26aufirst%3DE.%2BR.%26aulast%3DShipman%26aufirst%3DK.%2BJ.%26aulast%3DJensen%26aufirst%3DR.%2BL.%26aulast%3DFong%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DS.%26aulast%3DJanes%26aufirst%3DH.%2BE.%26aulast%3DGillespie%26aufirst%3DK.%26aulast%3DSeilie%26aufirst%3DA.%2BM.%26aulast%3DHanron%26aufirst%3DA.%2BE.%26aulast%3DRinn%26aufirst%3DL.%26aulast%3DFishbaugher%26aufirst%3DM.%26aulast%3DVonGoedert%26aufirst%3DT.%26aulast%3DFritzen%26aufirst%3DE.%26aulast%3DKappe%26aufirst%3DS.%2BH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DSousa%26aufirst%3DJ.%2BC.%26aulast%3DMarcsisin%26aufirst%3DS.%2BR.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DKublin%26aufirst%3DJ.%2BG.%26atitle%3DA%2520randomized%2520trial%2520evaluating%2520the%2520prophylactic%2520activity%2520of%2520DSM265%2520against%2520preerythrocytic%2520Plasmodium%2520falciparum%2520infection%2520during%2520controlled%2520human%2520malarial%2520infection%2520by%2520mosquito%2520bites%2520and%2520direct%2520venous%2520inoculation%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D217%26issue%3D5%26spage%3D693%26epage%3D702%26doi%3D10.1093%2Finfdis%2Fjix613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P. F.</span></span> <span> </span><span class="NLM_article-title">The design and application of target-focused compound libraries</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.2174/138620711795767802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.2174%2F138620711795767802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21521154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=521-531&author=C.+J.+Harrisauthor=R.+D.+Hillauthor=D.+W.+Sheppardauthor=M.+J.+Slaterauthor=P.+F.+Stouten&title=The+design+and+application+of+target-focused+compound+libraries&doi=10.2174%2F138620711795767802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The design and application of target-focused compound libraries</span></div><div class="casAuthors">Harris, C. John; Hill, Richard D.; Sheppard, David W.; Slater, Martin J.; Stouten, Pieter F. W.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">521-531</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Target-focused compd. libraries are collections of compds. which are designed to interact with an individual protein target or, frequently, a family of related targets (such as kinases, voltage-gated ion channels, serine/cysteine proteases).  They are used for screening against therapeutic targets in order to find hit compds. that might be further developed into drugs.  The design of such libraries generally utilizes structural information about the target or family of interest.  In the absence of such structural information, a chemogenomic model that incorporates sequence and mutagenesis data to predict the properties of the binding site can be employed.  A third option, usually pursued when no structural data are available, utilizes knowledge of the ligands of the target from' which focused libraries can be developed via scaffold hopping.  Consequently, the methods used for the design of target-focused libraries vary according to the quantity and quality of structural or ligand data that is available for each target family.  This article describes examples of each of these design approaches and illustrates them with case studies, which highlight some of the issues and successes obsd. when screening target-focused libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKS2t0qb2xBbVg90H21EOLACvtfcHk0lhkG5l6fpnnxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVSmu70%253D&md5=9070e45f5b842fccfee38c15e6cb6127</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.2174%2F138620711795767802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620711795767802%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DHill%26aufirst%3DR.%2BD.%26aulast%3DSheppard%26aufirst%3DD.%2BW.%26aulast%3DSlater%26aufirst%3DM.%2BJ.%26aulast%3DStouten%26aufirst%3DP.%2BF.%26atitle%3DThe%2520design%2520and%2520application%2520of%2520target-focused%2520compound%2520libraries%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2011%26volume%3D14%26spage%3D521%26epage%3D531%26doi%3D10.2174%2F138620711795767802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez
Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabiulla, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">8860</span>– <span class="NLM_lpage">8871</span>, <span class="refDoi"> DOI: 10.1021/jm401278d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401278d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFygurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8860-8871&issue=21&author=Y.+Younisauthor=F.+Douelleauthor=D.+Gonzalez%0ACabreraauthor=C.+Le+Manachauthor=A.+T.+Nchindaauthor=T.+Paquetauthor=L.+J.+Streetauthor=K.+L.+Whiteauthor=K.+M.+Zabiullaauthor=J.+T.+Josephauthor=S.+Bashyamauthor=D.+Watersonauthor=M.+J.+Wittyauthor=S.+Wittlinauthor=S.+A.+Charmanauthor=K.+Chibale&title=Structure-activity-relationship+studies+around+the+2-amino+group+and+pyridine+core+of+antimalarial+3%2C5-diarylaminopyridines+lead+to+a+novel+series+of+pyrazine+analogues+with+oral+in+vivo+activity&doi=10.1021%2Fjm401278d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity-Relationship Studies around the 2 Amino Group and Pyridine Core of Antimalarial 3,5-Diarylaminopyridines Lead to a Novel Series of Pyrazine Analogues with Oral in Vivo Activity</span></div><div class="casAuthors">Younis, Yassir; Douelle, Frederic; Gonzalez Cabrera, Diego; Le Manach, Claire; Nchinda, Aloysius T.; Paquet, Tanya; Street, Leslie J.; White, Karen L.; Zabiulla, K. Mohammed; Joseph, Jayan T.; Bashyam, Sridevi; Waterson, David; Witty, Michael J.; Wittlin, Sergio; Charman, Susan A.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8860-8871</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Replacement of the pyridine core of antimalarial 3,5-diaryl-2-aminopyridines led to the identification of a novel series of pyrazine analogs with potent oral antimalarial activity.  However, other changes to the pyridine core and replacement or substitution of the 2-amino group led to loss of antimalarial activity.  The 3,5-diaryl-2-aminopyrazine series showed impressive in vitro antiplasmodial activity against the K1 (multidrug resistant) and NF54 (sensitive) strains of Plasmodium falciparum in the nanomolar IC50 range of 6-94 nM while also demonstrating good in vitro metabolic stability in human liver microsomes.  In the Plasmodium berghei mouse model, this series generally exhibited good efficacy at low oral doses.  One of the frontrunner compds., (I), displayed potent in vitro antiplasmodial activity with IC50 values of 8.4 and 10 nM against the K1 and NF54 strains, resp.  When evaluated in P. berghei-infected mice, compd. I was completely curative at an oral dose of 4×10 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVhf8mhQH0rVg90H21EOLACvtfcHk0lhkG5l6fpnnxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFygurbF&md5=5ad6dd7f13247c70182bed236dbedaa3</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm401278d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401278d%26sid%3Dliteratum%253Aachs%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DDouelle%26aufirst%3DF.%26aulast%3DGonzalez%2BCabrera%26aufirst%3DD.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DZabiulla%26aufirst%3DK.%2BM.%26aulast%3DJoseph%26aufirst%3DJ.%2BT.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DStructure-activity-relationship%2520studies%2520around%2520the%25202-amino%2520group%2520and%2520pyridine%2520core%2520of%2520antimalarial%25203%252C5-diarylaminopyridines%2520lead%2520to%2520a%2520novel%2520series%2520of%2520pyrazine%2520analogues%2520with%2520oral%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D21%26spage%3D8860%26epage%3D8871%26doi%3D10.1021%2Fjm401278d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez
Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabiulla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botha, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nondaba, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9890</span>– <span class="NLM_lpage">9905</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01265</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01265" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ylurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9890-9905&issue=21&author=C.+Le+Manachauthor=A.+T.+Nchindaauthor=T.+Paquetauthor=D.+Gonzalez%0ACabreraauthor=Y.+Younisauthor=Z.+Hanauthor=S.+Bashyamauthor=M.+Zabiullaauthor=D.+Taylorauthor=N.+Lawrenceauthor=K.+L.+Whiteauthor=S.+A.+Charmanauthor=D.+Watersonauthor=M.+J.+Wittyauthor=S.+Wittlinauthor=M.+E.+Bothaauthor=S.+H.+Nondabaauthor=J.+Readerauthor=L.+M.+Birkholtzauthor=M.+B.+Jimenez-Diazauthor=M.+S.+Martinezauthor=S.+Ferrerauthor=I.+Angulo-Barturenauthor=S.+Meisterauthor=Y.+Antonova-Kochauthor=E.+A.+Winzelerauthor=L.+J.+Streetauthor=K.+Chibale&title=Identification+of+a+potential+antimalarial+drug+candidate+from+a+series+of+2-aminopyrazines+by+optimization+of+aqueous+solubility+and+potency+across+the+parasite+life+cycle&doi=10.1021%2Facs.jmedchem.6b01265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle</span></div><div class="casAuthors">Le Manach, Claire; Nchinda, Aloysius T.; Paquet, Tanya; Gonzalez Cabrera, Diego; Younis, Yassir; Han, Ze; Bashyam, Sridevi; Zabiulla, Mohammed; Taylor, Dale; Lawrence, Nina; White, Karen L.; Charman, Susan A.; Waterson, David; Witty, Michael J.; Wittlin, Sergio; Botha, Mariette E.; Nondaba, Sindisiswe H.; Reader, Janette; Birkholtz, Lyn-Marie; Jimenez-Diaz, Maria Belen; Martinez, Maria Santos; Ferrer, Santiago; Angulo-Barturen, Inigo; Meister, Stephan; Antonova-Koch, Yevgeniya; Winzeler, Elizabeth A.; Street, Leslie J.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9890-9905</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Introduction of water-solubilizing groups on the 5-Ph ring of a 2-aminopyrazine series led to the identification of highly potent compds. against the blood life-cycle stage of the human malaria parasite Plasmodium falciparum.  Several compds. displayed high in vivo efficacy in two different mouse models for malaria, P. berghei-infected mice and P. falciparum-infected NOD-scid IL-2Rγnull mice.  One of the front runners, compd. I, was identified to also have good pharmacokinetics, and addnl., very potent activity against the liver and gametocyte parasite life-cycle stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlhtTctb-IjbVg90H21EOLACvtfcHk0ljaGrd1plMAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ylurzK&md5=8841bac4d21b51a9b88c0fe844ca8ba0</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01265%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DGonzalez%2BCabrera%26aufirst%3DD.%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DZabiulla%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DBotha%26aufirst%3DM.%2BE.%26aulast%3DNondaba%26aufirst%3DS.%2BH.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520a%2520potential%2520antimalarial%2520drug%2520candidate%2520from%2520a%2520series%2520of%25202-aminopyrazines%2520by%2520optimization%2520of%2520aqueous%2520solubility%2520and%2520potency%2520across%2520the%2520parasite%2520life%2520cycle%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9890%26epage%3D9905%26doi%3D10.1021%2Facs.jmedchem.6b01265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzer, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Watt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silue, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">UCT943, a next-generation <i>Plasmodium falciparum</i> PI4K inhibitor preclinical candidate for the treatment of malaria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e00012-18</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1128/AAC.01941-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01941-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29941635" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00012-18-18&issue=9&author=C.+Brunschwigauthor=N.+Lawrenceauthor=D.+Taylorauthor=E.+Abayauthor=M.+Njorogeauthor=G.+S.+Basarabauthor=C.+Le+Manachauthor=T.+Paquetauthor=D.+Gonzalez-Cabreraauthor=A.+T.+Nchindaauthor=C.+de+Kockauthor=L.+Wiesnerauthor=P.+Dentiauthor=D.+Watersonauthor=B.+Blascoauthor=D.+Leroyauthor=M.+J.+Wittyauthor=C.+Doniniauthor=J.+Duffyauthor=S.+Wittlinauthor=K.+L.+Whiteauthor=S.+A.+Charmanauthor=M.+B.+Jimenez-Diazauthor=I.+Angulo-Barturenauthor=E.+Herrerosauthor=F.+J.+Gamoauthor=R.+Rochfordauthor=D.+Mancamaauthor=T.+L.+Coetzerauthor=M.+E.+van+der+Wattauthor=J.+Readerauthor=L.+M.+Birkholtzauthor=K.+C.+Marshauthor=S.+M.+Solapureauthor=J.+E.+Burkeauthor=J.+A.+McPhailauthor=M.+Vanaerschotauthor=D.+A.+Fidockauthor=P.+V.+Fishauthor=P.+Sieglauthor=D.+A.+Smithauthor=G.+Wirjanataauthor=R.+Noviyantiauthor=R.+N.+Priceauthor=J.+Marfurtauthor=K.+D.+Silueauthor=L.+J.+Streetauthor=K.+Chibale&title=UCT943%2C+a+next-generation+Plasmodium+falciparum+PI4K+inhibitor+preclinical+candidate+for+the+treatment+of+malaria&doi=10.1128%2FAAC.01941-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1128%2FAAC.01941-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01941-18%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschwig%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DAbay%26aufirst%3DE.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DGonzalez-Cabrera%26aufirst%3DD.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DWiesner%26aufirst%3DL.%26aulast%3DDenti%26aufirst%3DP.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DDonini%26aufirst%3DC.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DHerreros%26aufirst%3DE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DMancama%26aufirst%3DD.%26aulast%3DCoetzer%26aufirst%3DT.%2BL.%26aulast%3Dvan%2Bder%2BWatt%26aufirst%3DM.%2BE.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DSolapure%26aufirst%3DS.%2BM.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DSilue%26aufirst%3DK.%2BD.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DUCT943%252C%2520a%2520next-generation%2520Plasmodium%2520falciparum%2520PI4K%2520inhibitor%2520preclinical%2520candidate%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26issue%3D9%26spage%3De00012-18%26epage%3D18%26doi%3D10.1128%2FAAC.01941-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manary, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haasen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenreider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Plasmodium PI(4)K to eliminate malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span> (<span class="NLM_issue">7479</span>),  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/nature12782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature12782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24284631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFaqsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=248-253&issue=7479&author=C.+W.+McNamaraauthor=M.+C.+Leeauthor=C.+S.+Limauthor=S.+H.+Limauthor=J.+Rolandauthor=O.+Simonauthor=B.+K.+Yeungauthor=A.+K.+Chatterjeeauthor=S.+L.+McCormackauthor=M.+J.+Manaryauthor=A.+M.+Zeemanauthor=K.+J.+Decheringauthor=T.+S.+Kumarauthor=P.+P.+Henrichauthor=K.+Gagaringauthor=M.+Ibanezauthor=N.+Katoauthor=K.+L.+Kuhenauthor=C.+Fischliauthor=A.+Nagleauthor=M.+Rottmannauthor=D.+M.+Plouffeauthor=B.+Bursulayaauthor=S.+Meisterauthor=L.+Ramehauthor=J.+Trappeauthor=D.+Haasenauthor=M.+Timmermanauthor=R.+W.+Sauerweinauthor=R.+Suwanaruskauthor=B.+Russellauthor=L.+Reniaauthor=F.+Nostenauthor=D.+C.+Tullyauthor=C.+H.+Kockenauthor=R.+J.+Glynneauthor=C.+Bodenreiderauthor=D.+A.+Fidockauthor=T.+T.+Diaganaauthor=E.+A.+Winzeler&title=Targeting+Plasmodium+PI%284%29K+to+eliminate+malaria&doi=10.1038%2Fnature12782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Plasmodium PI(4)K to eliminate malaria</span></div><div class="casAuthors">McNamara, Case W.; Lee, Marcus C. S.; Lim, Chek Shik; Lim, Siau Hoi; Roland, Jason; Nagle, Advait; Simon, Oliver; Yeung, Bryan K. S.; Chatterjee, Arnab K.; McCormack, Susan L.; Manary, Micah J.; Zeeman, Anne-Marie; Dechering, Koen J.; Kumar, T. R. Santha; Henrich, Philipp P.; Gagaring, Kerstin; Ibanez, Maureen; Kato, Nobutaka; Kuhen, Kelli L.; Fischli, Christoph; Rottmann, Matthias; Plouffe, David M.; Bursulaya, Badry; Meister, Stephan; Rameh, Lucia; Trappe, Joerg; Haasen, Dorothea; Timmerman, Martijn; Sauerwein, Robert W.; Suwanarusk, Rossarin; Russell, Bruce; Renia, Laurent; Nosten, Francois; Tully, David C.; Kocken, Clemens H. M.; Glynne, Richard J.; Bodenreider, Christophe; Fidock, David A.; Diagana, Thierry T.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">7479</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Achieving the goal of malaria elimination will depend on targeting Plasmodium pathways essential across all life stages.  Here the authors identify a lipid kinase, phosphatidylinositol-4-OH kinase (PI(4)K), as the target of imidazopyrazines, a new antimalarial compd. class that inhibits the intracellular development of multiple Plasmodium species at each stage of infection in the vertebrate host.  Imidazopyrazines demonstrate potent preventive, therapeutic, and transmission-blocking activity in rodent malaria models, are active against blood-stage field isolates of the major human pathogens P. falciparum and P. vivax, and inhibit liver-stage hypnozoites in the simian parasite P. cynomolgi.  The authors show that imidazopyrazines exert their effect through inhibitory interaction with the ATP-binding pocket of PI(4)K, altering the intracellular distribution of phosphatidylinositol-4-phosphate.  Collectively, the authors' data define PI(4)K as a key Plasmodium vulnerability, opening up new avenues of target-based discovery to identify drugs with an ideal activity profile for the prevention, treatment and elimination of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTOmMeWluIubVg90H21EOLACvtfcHk0lhcuMVz0EZfuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFaqsLzP&md5=9ed8f3e41d257bb4535b4c813abd54cf</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnature12782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12782%26sid%3Dliteratum%253Aachs%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DLim%26aufirst%3DC.%2BS.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DRoland%26aufirst%3DJ.%26aulast%3DSimon%26aufirst%3DO.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DMcCormack%26aufirst%3DS.%2BL.%26aulast%3DManary%26aufirst%3DM.%2BJ.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DKumar%26aufirst%3DT.%2BS.%26aulast%3DHenrich%26aufirst%3DP.%2BP.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DHaasen%26aufirst%3DD.%26aulast%3DTimmerman%26aufirst%3DM.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DTully%26aufirst%3DD.%2BC.%26aulast%3DKocken%26aufirst%3DC.%2BH.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DBodenreider%26aufirst%3DC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DTargeting%2520Plasmodium%2520PI%25284%2529K%2520to%2520eliminate%2520malaria%26jtitle%3DNature%26date%3D2013%26volume%3D504%26issue%3D7479%26spage%3D248%26epage%3D253%26doi%3D10.1038%2Fnature12782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagborough, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakutansky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenreider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">387</span>),  <span class="NLM_fpage">eaad9735</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscitranslmed.aad9735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28446690" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaad9735&issue=387&author=T.+Paquetauthor=C.+Le+Manachauthor=D.+G.+Cabreraauthor=Y.+Younisauthor=P.+P.+Henrichauthor=T.+S.+Abrahamauthor=M.+C.+S.+Leeauthor=R.+Basakauthor=S.+Ghidelli-Disseauthor=M.+J.+Lafuente-Monasterioauthor=M.+Bantscheffauthor=A.+Rueckerauthor=A.+M.+Blagboroughauthor=S.+E.+Zakutanskyauthor=A.+M.+Zeemanauthor=K.+L.+Whiteauthor=D.+M.+Shacklefordauthor=J.+Mannilaauthor=J.+Morizziauthor=C.+Scheurerauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=S.+Ferrerauthor=L.+M.+Sanzauthor=F.+J.+Gamoauthor=J.+Readerauthor=M.+Bothaauthor=K.+J.+Decheringauthor=R.+W.+Sauerweinauthor=A.+Tungtaengauthor=P.+Vanachayangkulauthor=C.+S.+Limauthor=J.+Burrowsauthor=M.+J.+Wittyauthor=K.+C.+Marshauthor=C.+Bodenreiderauthor=R.+Rochfordauthor=S.+M.+Solapureauthor=M.+B.+Jimenez-Diazauthor=S.+Wittlinauthor=S.+A.+Charmanauthor=C.+Doniniauthor=B.+Campoauthor=L.+M.+Birkholtzauthor=K.+K.+Hansonauthor=G.+Drewesauthor=C.+H.+M.+Kockenauthor=M.+J.+Delvesauthor=D.+Leroyauthor=D.+A.+Fidockauthor=D.+Watersonauthor=L.+J.+Streetauthor=K.+Chibale&title=Antimalarial+efficacy+of+MMV390048%2C+an+inhibitor+of+Plasmodium+phosphatidylinositol+4-kinase&doi=10.1126%2Fscitranslmed.aad9735"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9735%26sid%3Dliteratum%253Aachs%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DCabrera%26aufirst%3DD.%2BG.%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DHenrich%26aufirst%3DP.%2BP.%26aulast%3DAbraham%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DBasak%26aufirst%3DR.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DBlagborough%26aufirst%3DA.%2BM.%26aulast%3DZakutansky%26aufirst%3DS.%2BE.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMannila%26aufirst%3DJ.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBotha%26aufirst%3DM.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DC.%2BS.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DBodenreider%26aufirst%3DC.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DSolapure%26aufirst%3DS.%2BM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonini%26aufirst%3DC.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DHanson%26aufirst%3DK.%2BK.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DKocken%26aufirst%3DC.%2BH.%2BM.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DAntimalarial%2520efficacy%2520of%2520MMV390048%252C%2520an%2520inhibitor%2520of%2520Plasmodium%2520phosphatidylinositol%25204-kinase%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26issue%3D387%26spage%3Deaad9735%26doi%3D10.1126%2Fscitranslmed.aad9735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ejmech.2013.05.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=23811093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SkurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=314-323&author=K.+Singhauthor=H.+Kaurauthor=K.+Chibaleauthor=J.+Balzarini&title=Synthesis+of+4-aminoquinoline-pyrimidine+hybrids+as+potent+antimalarials+and+their+mode+of+action+studies&doi=10.1016%2Fj.ejmech.2013.05.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies</span></div><div class="casAuthors">Singh, Kamaljit; Kaur, Hardeep; Chibale, Kelly; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">314-323</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">One of the most viable options to tackle the growing resistance to the antimalarial drugs such as artemisinin is to resort to synthetic drugs.  The multi-target strategy involving the use of hybrid drugs has shown promise.  In line with this, new hybrids of quinoline with pyrimidine I were synthesized and evaluated for their antiplasmodial activity against both CQS and CQR strains of Plasmodium falciparum.  These depicted activity in nanomolar range and were found to bind to heme and AT rich pUC18 DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OBIjVzVXubVg90H21EOLACvtfcHk0ljpgh1-rhw8Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SkurvK&md5=0dd9abed47c0494cf6f29eb76ef47ad9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.046%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DKaur%26aufirst%3DH.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%25204-aminoquinoline-pyrimidine%2520hybrids%2520as%2520potent%2520antimalarials%2520and%2520their%2520mode%2520of%2520action%2520studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D314%26epage%3D323%26doi%3D10.1016%2Fj.ejmech.2013.05.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Quinoline–pyrimidine hybrids: Synthesis, antiplasmodial activity, SAR, and mode of action studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1021/jm4014778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4014778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=435-448&issue=2&author=K.+Singhauthor=H.+Kaurauthor=P.+Smithauthor=C.+de+Kockauthor=K.+Chibaleauthor=J.+Balzarini&title=Quinoline%E2%80%93pyrimidine+hybrids%3A+Synthesis%2C+antiplasmodial+activity%2C+SAR%2C+and+mode+of+action+studies&doi=10.1021%2Fjm4014778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Quinoline-Pyrimidine Hybrids: Synthesis, Antiplasmodial Activity, SAR, and Mode of Action Studies</span></div><div class="casAuthors">Singh, Kamaljit; Kaur, Hardeep; Smith, Peter; de Kock, Carmen; Chibale, Kelly; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">For the treatment of malaria which affects nearly 200 million people each year and the continued exacerbation by the emergence of drug resistance to most of the available antimalarials, the "covalent bitherapy" suggests hybrid mols. to be the next-generation antimalarial drugs.  In this investigation, new hybrids of 4-aminoquinoline and pyrimidine moieties, e.g., I [A = (CH2)3, "X" = O; X-rays single crystal structure shown], that show antiplasmodial activity in the nM range against chloroquine-resistant as well as chloroquine-sensitive strains of Plasmodium falciparum have been prepd.  Compd. I [A = (CH2)3, "X" = CH2] was found to be the most potent.  Cytotoxicity evaluation and mode of action of most potent hybrid mol. have been conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbZNA9D1VDZ7Vg90H21EOLACvtfcHk0ljpgh1-rhw8Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKqtLzL&md5=b233c8922f87a3bc2aa0bd679552660b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fjm4014778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4014778%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DKaur%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DQuinoline%25E2%2580%2593pyrimidine%2520hybrids%253A%2520Synthesis%252C%2520antiplasmodial%2520activity%252C%2520SAR%252C%2520and%2520mode%2520of%2520action%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D2%26spage%3D435%26epage%3D448%26doi%3D10.1021%2Fjm4014778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span> </span><span class="NLM_article-title">Phase I Study of Ascending Doses of MMV390048
in Healthy Adult Volunteers</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2014</span>;  <span class="NLM_fpage">NCT02230579</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02230579?term=NCT02230579&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02230579?term=NCT02230579&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+I+Study+of+Ascending+Doses+of+MMV390048%0Ain+Healthy+Adult+Volunteers.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%2C+2014%3B+NCT02230579%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02230579%3Fterm%3DNCT02230579%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%2520I%2520Study%2520of%2520Ascending%2520Doses%2520of%2520MMV390048%250Ain%2520Healthy%2520Adult%2520Volunteers%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2014%26spage%3DNCT02230579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Michael J. Palmer, Xiaoyi Deng, Shawn Watts, Goran Krilov, Aleksey Gerasyuto, Sreekanth Kokkonda, Farah El Mazouni, John White, Karen L. White, Josefine Striepen, Jade Bath, Kyra A. Schindler, Tomas Yeo, David M. Shackleford, Sachel Mok, Ioanna Deni, Aloysus Lawong, Ann Huang, Gong Chen, Wen Wang, Jaya Jayaseelan, Kasiram Katneni, Rahul Patil, Jessica Saunders, Shatrughan P. Shahi, Rajesh Chittimalla, Iñigo Angulo-Barturen, María Belén Jiménez-Díaz, Sergio Wittlin, Patrick K. Tumwebaze, Philip J. Rosenthal, Roland A. Cooper, Anna Caroline Campos Aguiar, Rafael V. C. Guido, Dhelio B. Pereira, Nimisha Mittal, Elizabeth A. Winzeler, Diana R. Tomchick, Benoît Laleu, Jeremy N. Burrows, Pradipsinh K. Rathod, David A. Fidock, Susan A. Charman, <span class="NLM_string-name hlFld-ContribAuthor">Margaret A. Phillips</span>. </span><span class="cited-content_cbyCitation_article-title">Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 6085-6136. <a href="https://doi.org/10.1021/acs.jmedchem.1c00173" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00173%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252BAntimalarials%252Bwith%252BDevelopment%252BPotential%252BIdentified%252Bby%252BStructure-Guided%252BComputational%252BOptimization%252Bof%252Ba%252BPyrrole-Based%252BDihydroorotate%252BDehydrogenase%252BInhibitor%252BSeries%26aulast%3DPalmer%26aufirst%3DMichael%2BJ.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30012021%26date%3D20042021%26volume%3D64%26issue%3D9%26spage%3D6085%26epage%3D6136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniel L. Priebbenow, Mitch Mathiew, Da-Hua Shi, Jitendra R. Harjani, Julia G. Beveridge, Marina Chavchich, Michael D. Edstein, Sandra Duffy, Vicky M. Avery, Robert T. Jacobs, Stephen Brand, David M. Shackleford, Wen Wang, Longjin Zhong, Given Lee, Erin Tay, Helena Barker, Elly Crighton, Karen L. White, Susan A. Charman, Amanda De Paoli, Darren J. Creek, <span class="NLM_string-name hlFld-ContribAuthor">Jonathan B. Baell</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 4150-4162. <a href="https://doi.org/10.1021/acs.jmedchem.1c00044" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BFast-Acting%252BAntimalarial%252BBis-1%25252C2%25252C4-triazines%26aulast%3DPriebbenow%26aufirst%3DDaniel%2BL.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D11012021%26date%3D24032021%26volume%3D64%26issue%3D7%26spage%3D4150%26epage%3D4162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Woo Cheol Jang, Myeongjin Jung, <span class="NLM_string-name hlFld-ContribAuthor">Haye Min Ko</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Six-Membered Spiro Azacyclic Oxindole Derivatives via a One-Pot Process of Umpolung Allylation/Aza-Prins Cyclization. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (4)
                                     , 1510-1515. <a href="https://doi.org/10.1021/acs.orglett.1c00292" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c00292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c00292%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BSix-Membered%252BSpiro%252BAzacyclic%252BOxindole%252BDerivatives%252Bvia%252Ba%252BOne-Pot%252BProcess%252Bof%252BUmpolung%252BAllylation%25252FAza-Prins%252BCyclization%26aulast%3DJang%26aufirst%3DWoo%2BCheol%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D26012021%26date%3D09022021%26volume%3D23%26issue%3D4%26spage%3D1510%26epage%3D1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Scott Eagon, Jared T. Hammill, Martina Sigal, Kevin J. Ahn, Julia E. Tryhorn, Grant Koch, Briana Belanger, Cory A. Chaplan, Lauren Loop, Anna S. Kashtanova, Kenya Yniguez, Horacio Lazaro, Steven P. Wilkinson, Amy L. Rice, Mofolusho O. Falade, Rei Takahashi, Katie Kim, Ashley Cheung, Celine DiBernardo, Joshua J. Kimball, Elizabeth A. Winzeler, Korina Eribez, Nimisha Mittal, Francisco-Javier Gamo, Benigno Crespo, Alisje Churchyard, Irene García-Barbazán, Jake Baum, Marc O. Anderson, Benoît Laleu, <span class="NLM_string-name hlFld-ContribAuthor">R. Kiplin Guy</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Structure–Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-b]pyridines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11902-11919. <a href="https://doi.org/10.1021/acs.jmedchem.0c01152" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01152%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252Bof%252BDual-Stage%252BAntimalarial%252BPyrazolo%25255B3%25252C4-b%25255Dpyridines%26aulast%3DEagon%26aufirst%3DScott%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03072020%26date%3D01102020%26date%3D18092020%26volume%3D63%26issue%3D20%26spage%3D11902%26epage%3D11919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Papireddy Kancharla, Rozalia A. Dodean, Yuexin Li, Sovitj Pou, Brandon Pybus, Victor Melendez, Lisa Read, Charles E. Bane, Brian Vesely, Mara Kreishman-Deitrick, Chad Black, Qigui Li, Richard J. Sciotti, Raul Olmeda, Thu-Lan Luong, Heather Gaona, Brittney Potter, Jason Sousa, Sean Marcsisin, Diana Caridha, Lisa Xie, Chau Vuong, Qiang Zeng, Jing Zhang, Ping Zhang, Hsiuling Lin, Kirk Butler, Norma Roncal, Lacy Gaynor-Ohnstad, Susan E. Leed, Christina Nolan, Frida G. Ceja, Stephanie A. Rasmussen, Patrick K. Tumwebaze, Philip J. Rosenthal, Jianbing Mu, Brett R. Bayles, Roland A. Cooper, Kevin A. Reynolds, Martin J. Smilkstein, Michael K. Riscoe, <span class="NLM_string-name hlFld-ContribAuthor">Jane X. Kelly</span>. </span><span class="cited-content_cbyCitation_article-title">Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 6179-6202. <a href="https://doi.org/10.1021/acs.jmedchem.0c00539" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00539</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00539%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLead%252BOptimization%252Bof%252BSecond-Generation%252BAcridones%252Bas%252BBroad-Spectrum%252BAntimalarials%26aulast%3DKancharla%26aufirst%3DPapireddy%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D02042020%26date%3D26052020%26date%3D11052020%26volume%3D63%26issue%3D11%26spage%3D6179%26epage%3D6202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi-Huan Lai, Run-Shi Wu, Jie Huang, Jun-Yu Huang, <span class="NLM_string-name hlFld-ContribAuthor">Da-Zhen Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Iron-Catalyzed Oxidative Coupling of Indoline-2-ones with Aminobenzamides via Dual C–H Functionalization. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (10)
                                     , 3825-3829. <a href="https://doi.org/10.1021/acs.orglett.0c01066" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01066%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DIron-Catalyzed%252BOxidative%252BCoupling%252Bof%252BIndoline-2-ones%252Bwith%252BAminobenzamides%252Bvia%252BDual%252BC%2525E2%252580%252593H%252BFunctionalization%26aulast%3DLai%26aufirst%3DYi-Huan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24032020%26date%3D07052020%26volume%3D22%26issue%3D10%26spage%3D3825%26epage%3D3829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shane M.  Devine</span>, <span class="hlFld-ContribAuthor ">Matthew P.  Challis</span>, <span class="hlFld-ContribAuthor ">Jomo K.  Kigotho</span>, <span class="hlFld-ContribAuthor ">Ghizal  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Amanda  De Paoli</span>, <span class="hlFld-ContribAuthor ">Christopher A.  MacRaild</span>, <span class="hlFld-ContribAuthor ">Vicky M.  Avery</span>, <span class="hlFld-ContribAuthor ">Darren J.  Creek</span>, <span class="hlFld-ContribAuthor ">Raymond S.  Norton</span>, <span class="hlFld-ContribAuthor ">Peter J.  Scammells</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and development of 2-aminobenzimidazoles as potent antimalarials. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113518. <a href="https://doi.org/10.1016/j.ejmech.2021.113518" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113518%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bdevelopment%252Bof%252B2-aminobenzimidazoles%252Bas%252Bpotent%252Bantimalarials%26aulast%3DDevine%26aufirst%3DShane%2BM.%26date%3D2021%26volume%3D221%26spage%3D113518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott  Eagon</span>, <span class="hlFld-ContribAuthor ">Jared T.  Hammill</span>, <span class="hlFld-ContribAuthor ">Kasey  Fitzsimmons</span>, <span class="hlFld-ContribAuthor ">Natalie  Sienko</span>, <span class="hlFld-ContribAuthor ">Brandon  Nguyen</span>, <span class="hlFld-ContribAuthor ">Jarvis  Law</span>, <span class="hlFld-ContribAuthor ">Aashrita  Manjunath</span>, <span class="hlFld-ContribAuthor ">Steven P.  Wilkinson</span>, <span class="hlFld-ContribAuthor ">Kara  Thompson</span>, <span class="hlFld-ContribAuthor ">Julia Elizabeth  Glidden</span>, <span class="hlFld-ContribAuthor ">Amy L.  Rice</span>, <span class="hlFld-ContribAuthor ">Mofolusho O.  Falade</span>, <span class="hlFld-ContribAuthor ">Joshua J.  Kimball</span>, <span class="hlFld-ContribAuthor ">Celine  DiBernardo</span>, <span class="hlFld-ContribAuthor ">R. Kiplin  Guy</span>. </span><span class="cited-content_cbyCitation_article-title">Antimalarial activity of 2,6-dibenzylidenecyclohexanone derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128216. <a href="https://doi.org/10.1016/j.bmcl.2021.128216" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128216%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAntimalarial%252Bactivity%252Bof%252B2%25252C6-dibenzylidenecyclohexanone%252Bderivatives%26aulast%3DEagon%26aufirst%3DScott%26date%3D2021%26volume%3D47%26spage%3D128216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Sneha  Ray</span>, <span class="hlFld-ContribAuthor ">Leah  Imlay</span>, <span class="hlFld-ContribAuthor ">Lauren T.  Callaghan</span>, <span class="hlFld-ContribAuthor ">Hanspeter  Niederstrasser</span>, <span class="hlFld-ContribAuthor ">Prema Latha  Mallipeddi</span>, <span class="hlFld-ContribAuthor ">Bruce A.  Posner</span>, <span class="hlFld-ContribAuthor ">Dawn M.  Wetzel</span>, <span class="hlFld-ContribAuthor ">Margaret A.  Phillips</span>, <span class="hlFld-ContribAuthor ">Myles W.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Total synthesis of (+)-spiroindimicin A and congeners unveils their antiparasitic activity. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (30)
                                     , 10388-10394. <a href="https://doi.org/10.1039/D1SC02838C" title="DOI URL">https://doi.org/10.1039/D1SC02838C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC02838C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC02838C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DTotal%252Bsynthesis%252Bof%252B%252528%25252B%252529-spiroindimicin%252BA%252Band%252Bcongeners%252Bunveils%252Btheir%252Bantiparasitic%252Bactivity%26aulast%3DZhang%26aufirst%3DZhen%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D30%26spage%3D10388%26epage%3D10394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vivek K.  Vyas</span>, <span class="hlFld-ContribAuthor ">Sapna  Bhati</span>, <span class="hlFld-ContribAuthor ">Shivani  Patel</span>, <span class="hlFld-ContribAuthor ">Manjunath  Ghate</span>. </span><span class="cited-content_cbyCitation_article-title">Structure- and ligand-based drug design methods for the modeling of antimalarial agents: a review of updates from 2012 onwards. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>18 </em>, 1-26. <a href="https://doi.org/10.1080/07391102.2021.1932598" title="DOI URL">https://doi.org/10.1080/07391102.2021.1932598</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1932598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1932598%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DStructure-%252Band%252Bligand-based%252Bdrug%252Bdesign%252Bmethods%252Bfor%252Bthe%252Bmodeling%252Bof%252Bantimalarial%252Bagents%25253A%252Ba%252Breview%252Bof%252Bupdates%252Bfrom%252B2012%252Bonwards%26aulast%3DVyas%26aufirst%3DVivek%2BK.%26date%3D2021%26date%3D2021%26volume%3D18%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fenghai  Zhao</span>, <span class="hlFld-ContribAuthor ">Thishana  Singh</span>, <span class="hlFld-ContribAuthor ">Yumei  Xiao</span>, <span class="hlFld-ContribAuthor ">Wangcang  Su</span>, <span class="hlFld-ContribAuthor ">Dongyan  Yang</span>, <span class="hlFld-ContribAuthor ">Changqing  Jia</span>, <span class="hlFld-ContribAuthor ">Jia-Qi  Li</span>, <span class="hlFld-ContribAuthor ">Zhaohai  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent Synthesis of Substituted Amino-1,2,4-triazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Synthesis</span><span> <strong>2021,</strong> <em>53 </em>
                                    (11)
                                     , 1901-1910. <a href="https://doi.org/10.1055/a-1477-4630" title="DOI URL">https://doi.org/10.1055/a-1477-4630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1477-4630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1477-4630%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%26atitle%3DDivergent%252BSynthesis%252Bof%252BSubstituted%252BAmino-1%25252C2%25252C4-triazole%252BDerivatives%26aulast%3DZhao%26aufirst%3DFenghai%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D11%26spage%3D1901%26epage%3D1910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mustafa  Bilici</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of a Novel Molecularly Imprinted Polymer for the Sensitive and Selective Determination of Artemisinin in Urine Samples Based on Solid-Phase Extraction (SPE) and Determination with High-Performance Liquid Chromatography (HPLC). </span><span class="cited-content_cbyCitation_journal-name">Analytical Letters</span><span> <strong>2021,</strong> <em>54 </em>
                                    (7)
                                     , 1145-1161. <a href="https://doi.org/10.1080/00032719.2020.1795187" title="DOI URL">https://doi.org/10.1080/00032719.2020.1795187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00032719.2020.1795187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00032719.2020.1795187%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Letters%26atitle%3DSynthesis%252Bof%252Ba%252BNovel%252BMolecularly%252BImprinted%252BPolymer%252Bfor%252Bthe%252BSensitive%252Band%252BSelective%252BDetermination%252Bof%252BArtemisinin%252Bin%252BUrine%252BSamples%252BBased%252Bon%252BSolid-Phase%252BExtraction%252B%252528SPE%252529%252Band%252BDetermination%252Bwith%252BHigh-Performance%252BLiquid%252BChromatography%252B%252528HPLC%252529%26aulast%3DBilici%26aufirst%3DMustafa%26date%3D2021%26date%3D2020%26volume%3D54%26issue%3D7%26spage%3D1145%26epage%3D1161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander J.  Boddy</span>, <span class="hlFld-ContribAuthor ">James A.  Bull</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective synthesis and applications of spirocyclic oxindoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (5)
                                     , 1026-1084. <a href="https://doi.org/10.1039/D0QO01085E" title="DOI URL">https://doi.org/10.1039/D0QO01085E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01085E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01085E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DStereoselective%252Bsynthesis%252Band%252Bapplications%252Bof%252Bspirocyclic%252Boxindoles%26aulast%3DBoddy%26aufirst%3DAlexander%2BJ.%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D5%26spage%3D1026%26epage%3D1084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikalet  Everson</span>, <span class="hlFld-ContribAuthor ">Jordan  Bach</span>, <span class="hlFld-ContribAuthor ">Jared T.  Hammill</span>, <span class="hlFld-ContribAuthor ">Mofolusho O.  Falade</span>, <span class="hlFld-ContribAuthor ">Amy L.  Rice</span>, <span class="hlFld-ContribAuthor ">R. Kiplin  Guy</span>, <span class="hlFld-ContribAuthor ">Scott  Eagon</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Plasmodium falciparum heat shock 90 inhibitors via molecular docking. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>35 </em>, 127818. <a href="https://doi.org/10.1016/j.bmcl.2021.127818" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127818</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127818%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252BPlasmodium%252Bfalciparum%252Bheat%252Bshock%252B90%252Binhibitors%252Bvia%252Bmolecular%252Bdocking%26aulast%3DEverson%26aufirst%3DNikalet%26date%3D2021%26volume%3D35%26spage%3D127818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  Nguyen</span>, <span class="hlFld-ContribAuthor ">Madeline G.  Dans</span>, <span class="hlFld-ContribAuthor ">Anna  Ngo</span>, <span class="hlFld-ContribAuthor ">Maria R.  Gancheva</span>, <span class="hlFld-ContribAuthor ">Ornella  Romeo</span>, <span class="hlFld-ContribAuthor ">Sandra  Duffy</span>, <span class="hlFld-ContribAuthor ">Tania F.  de Koning-Ward</span>, <span class="hlFld-ContribAuthor ">Kym N.  Lowes</span>, <span class="hlFld-ContribAuthor ">Helene Jousset  Sabroux</span>, <span class="hlFld-ContribAuthor ">Vicky M.  Avery</span>, <span class="hlFld-ContribAuthor ">Danny W.  Wilson</span>, <span class="hlFld-ContribAuthor ">Paul R.  Gilson</span>, <span class="hlFld-ContribAuthor ">Brad E.  Sleebs</span>. </span><span class="cited-content_cbyCitation_article-title">Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113253. <a href="https://doi.org/10.1016/j.ejmech.2021.113253" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113253%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252Bactivity%252Brefinement%252Bof%252Bphenylsulfonyl%252Bpiperazines%252Bas%252Bantimalarials%252Bthat%252Bblock%252Berythrocytic%252Binvasion%26aulast%3DNguyen%26aufirst%3DWilliam%26date%3D2021%26volume%3D214%26spage%3D113253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Flávia F.  Silveira</span>, <span class="hlFld-ContribAuthor ">Juliana O.  de Souza</span>, <span class="hlFld-ContribAuthor ">Lucas V.B.  Hoelz</span>, <span class="hlFld-ContribAuthor ">Vinícius R.  Campos</span>, <span class="hlFld-ContribAuthor ">Valquíria A.P.  Jabor</span>, <span class="hlFld-ContribAuthor ">Anna C.C.  Aguiar</span>, <span class="hlFld-ContribAuthor ">M. Cristina  Nonato</span>, <span class="hlFld-ContribAuthor ">Magaly G.  Albuquerque</span>, <span class="hlFld-ContribAuthor ">Rafael V.C.  Guido</span>, <span class="hlFld-ContribAuthor ">Nubia  Boechat</span>, <span class="hlFld-ContribAuthor ">Luiz C.S.  Pinheiro</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112941. <a href="https://doi.org/10.1016/j.ejmech.2020.112941" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112941</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112941%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComparative%252Bstudy%252Bbetween%252Bthe%252Banti-P.%2525C2%2525A0falciparum%252Bactivity%252Bof%252Btriazolopyrimidine%25252C%252Bpyrazolopyrimidine%252Band%252Bquinoline%252Bderivatives%252Band%252Bthe%252Bidentification%252Bof%252Bnew%252BPfDHODH%252Binhibitors%26aulast%3DSilveira%26aufirst%3DFl%25C3%25A1via%2BF.%26date%3D2021%26volume%3D209%26spage%3D112941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brad E.  Sleebs</span>, <span class="hlFld-ContribAuthor ">Kate E.  Jarman</span>, <span class="hlFld-ContribAuthor ">Sonja  Frolich</span>, <span class="hlFld-ContribAuthor ">Wilson  Wong</span>, <span class="hlFld-ContribAuthor ">Julie  Healer</span>, <span class="hlFld-ContribAuthor ">Weiwen  Dai</span>, <span class="hlFld-ContribAuthor ">Isabelle S.  Lucet</span>, <span class="hlFld-ContribAuthor ">Danny W.  Wilson</span>, <span class="hlFld-ContribAuthor ">Alan F.  Cowman</span>. </span><span class="cited-content_cbyCitation_article-title">Development and application of a high-throughput screening assay for identification of small molecule inhibitors of the P. falciparum reticulocyte binding-like homologue 5 protein. </span><span class="cited-content_cbyCitation_journal-name">International Journal for Parasitology: Drugs and Drug Resistance</span><span> <strong>2020,</strong> <em>14 </em>, 188-200. <a href="https://doi.org/10.1016/j.ijpddr.2020.10.008" title="DOI URL">https://doi.org/10.1016/j.ijpddr.2020.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpddr.2020.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpddr.2020.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520for%2520Parasitology%253A%2520Drugs%2520and%2520Drug%2520Resistance%26atitle%3DDevelopment%252Band%252Bapplication%252Bof%252Ba%252Bhigh-throughput%252Bscreening%252Bassay%252Bfor%252Bidentification%252Bof%252Bsmall%252Bmolecule%252Binhibitors%252Bof%252Bthe%252BP.%252Bfalciparum%252Breticulocyte%252Bbinding-like%252Bhomologue%252B5%252Bprotein%26aulast%3DSleebs%26aufirst%3DBrad%2BE.%26date%3D2020%26volume%3D14%26spage%3D188%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amy L.  Burns</span>, <span class="hlFld-ContribAuthor ">Brad E.  Sleebs</span>, <span class="hlFld-ContribAuthor ">Ghizal  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Amanda E.  De Paoli</span>, <span class="hlFld-ContribAuthor ">Dovile  Anderson</span>, <span class="hlFld-ContribAuthor ">Benjamin  Liffner</span>, <span class="hlFld-ContribAuthor ">Richard  Harvey</span>, <span class="hlFld-ContribAuthor ">James G.  Beeson</span>, <span class="hlFld-ContribAuthor ">Darren J.  Creek</span>, <span class="hlFld-ContribAuthor ">Christopher D.  Goodman</span>, <span class="hlFld-ContribAuthor ">Geoffrey I.  McFadden</span>, <span class="hlFld-ContribAuthor ">Danny W.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Retargeting azithromycin analogues to have dual-modality antimalarial activity. </span><span class="cited-content_cbyCitation_journal-name">BMC Biology</span><span> <strong>2020,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12915-020-00859-4" title="DOI URL">https://doi.org/10.1186/s12915-020-00859-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12915-020-00859-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12915-020-00859-4%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Biology%26atitle%3DRetargeting%252Bazithromycin%252Banalogues%252Bto%252Bhave%252Bdual-modality%252Bantimalarial%252Bactivity%26aulast%3DBurns%26aufirst%3DAmy%2BL.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romain  Mustière</span>, <span class="hlFld-ContribAuthor ">Patrice  Vanelle</span>, <span class="hlFld-ContribAuthor ">Nicolas  Primas</span>. </span><span class="cited-content_cbyCitation_article-title">Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (24)
                                     , 5949. <a href="https://doi.org/10.3390/molecules25245949" title="DOI URL">https://doi.org/10.3390/molecules25245949</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25245949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25245949%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPlasmodial%252BKinase%252BInhibitors%252BTargeting%252BMalaria%25253A%252BRecent%252BDevelopments%26aulast%3DMusti%25C3%25A8re%26aufirst%3DRomain%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D24%26spage%3D5949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Petar P. S.  Calic</span>, <span class="hlFld-ContribAuthor ">Mahta  Mansouri</span>, <span class="hlFld-ContribAuthor ">Peter J.  Scammells</span>, <span class="hlFld-ContribAuthor ">Sheena  McGowan</span>. </span><span class="cited-content_cbyCitation_article-title">Driving antimalarial design through understanding of target mechanism. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2020,</strong> <em>48 </em>
                                    (5)
                                     , 2067-2078. <a href="https://doi.org/10.1042/BST20200224" title="DOI URL">https://doi.org/10.1042/BST20200224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20200224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20200224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DDriving%252Bantimalarial%252Bdesign%252Bthrough%252Bunderstanding%252Bof%252Btarget%252Bmechanism%26aulast%3DCalic%26aufirst%3DPetar%2BP.%2BS.%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D5%26spage%3D2067%26epage%3D2078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Santosh Kumar  Sahu</span>, <span class="hlFld-ContribAuthor ">Pradyota Kumar  Behera</span>, <span class="hlFld-ContribAuthor ">Prabhupada  Choudhury</span>, <span class="hlFld-ContribAuthor ">Subhalaxmi  Panda</span>, <span class="hlFld-ContribAuthor ">Laxmidhar  Rout</span>. </span><span class="cited-content_cbyCitation_article-title">Strategy and Problems for Synthesis of Antimalaria Artemisinin (Qinghaosu). </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (40)
                                     , 12333-12344. <a href="https://doi.org/10.1002/slct.202002885" title="DOI URL">https://doi.org/10.1002/slct.202002885</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202002885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202002885%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DStrategy%252Band%252BProblems%252Bfor%252BSynthesis%252Bof%252BAntimalaria%252BArtemisinin%252B%252528Qinghaosu%252529%26aulast%3DSahu%26aufirst%3DSantosh%2BKumar%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D40%26spage%3D12333%26epage%3D12344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariana L.  Garcia</span>, <span class="hlFld-ContribAuthor ">Andrew A.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Renata V.  Bueno</span>, <span class="hlFld-ContribAuthor ">Victor H. R.  Nogueira</span>, <span class="hlFld-ContribAuthor ">Guilherme E.  Souza</span>, <span class="hlFld-ContribAuthor ">Rafael V. C.  Guido</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR studies on benzothiophene derivatives as
              
                Plasmodium falciparum
              
              N‐myristoyltransferase inhibitors: Molecular insights into affinity and selectivity. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2020,</strong> <em>61 </em><a href="https://doi.org/10.1002/ddr.21646" title="DOI URL">https://doi.org/10.1002/ddr.21646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21646%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DQSAR%252Bstudies%252Bon%252Bbenzothiophene%252Bderivatives%252Bas%252BPlasmodium%252Bfalciparum%252BN%2525E2%252580%252590myristoyltransferase%252Binhibitors%25253A%252BMolecular%252Binsights%252Binto%252Baffinity%252Band%252Bselectivity%26aulast%3DGarcia%26aufirst%3DMariana%2BL.%26date%3D2020%26date%3D2020%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of currently used antimalarials and the ozonides, arterolane and artefenomel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of antimalarial clinical candidates that are the focus of this Perspective.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hit compound and resynthesized and resolved isomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of spiroindoles in lead identification phase including clinical candidate KAE609.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. homology model of PfATP4. Cartoon representation of PfATP4 showing mutations (magenta) that confer resistance to KAE609,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and mutations, orange, that confer resistance to KAE678, a structurally related analogue of KAE609. Spiroindolones are cross resistant to parasites that possess these mutations.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The previously described homology model of PfATP4 was recreated with SWISS-MODEL based on the crystal structure of the rabbit SERCA pump (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2C88">2C88</a><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The predicted transmembrane region of PfATP4 is shown by the dotted line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Et<sub>2</sub>NH (10 mol %), K<sub>2</sub>CO<sub>3</sub> (10 mol %), acetone, 56 °C, 2 h, 84%; (b) (EtO)<sub>3</sub>CH, <i>p</i>-TsOH·H<sub>2</sub>O, ethylene glycol, 40–50 °C, 2 h, 95%; (c) (i) Red-Al, THF, 3 h, (ii) 20% HCl, 20 min, 75% (over two steps); (d) EtNO<sub>2</sub>, NH<sub>4</sub>OAc, 100 °C, 4 h, 97%; (e) (i) 5% Pt/C, H<sub>2</sub>, EtOAc, 21 °C, (ii) NaHSO<sub>3</sub>, H<sub>2</sub>O, EtOH, 80 °C, 60% (over two steps).<a onclick="showRef(event, 'ref52 ref71'); return false;" href="javascript:void(0);" class="ref ref52 ref71">(52,71)</a></p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) <i>i</i>-PrNH<sub>2</sub>·HCl, ATA256, P5P, PEG-200, triethanolamine buffer pH 7, NaOH<sub>(aq)</sub>, 50 °C, 24 h, (ii) (+)-CSA, <i>i</i>-PrOAc, 89 °C then cooled to 0 °C, 84% (over two steps); (b) (i) Et<sub>3</sub>N, 5-chloroisatin, <i>i</i>-PrOH, 83 °C, 24 h, (ii) (+)-CSA, (iii) solvent exchange to EtOH/EtOAc (1:14), 77 °C then cooled to 0 °C for 24 h, 86%; (c) (i) Na<sub>2</sub>CO<sub>3</sub>, EtOH/H<sub>2</sub>O (3/1), 58 °C, (ii) recrystallization, 91%.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></p></p></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Proposed mechanism for the formation of metabolite <b>M17</b> and the metabolic pathway of major metabolites detected in humans and preclinical species after oral dosing of <sup>14</sup>C-labeled KAE609.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Hit compounds in the imidazolopiperazine class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Modifications to optimize the imidazolopiperazine core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Key SAR for the first-generation imidazolopiperazine series with activity against NF54 parasites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Major metabolites resulted from chemical instability and C8-oxidation of <b>M29</b>, leading to inactive compounds.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effect of methyl substitution on the imidazolopiperazine series.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 4 h, 84%; (b) NH<sub>4</sub>OAc, toluene, 111 °C, 3 h, 88%; (c) (i) ethyl 2-bromoacetate, K<sub>2</sub>CO<sub>3</sub>, DMF, 25 °C, 2.5 h, 83%, (ii) H<sub>2</sub>, Pd/C, EtOH, 25 °C, 3 d, 91%; (d) (i) BH<sub>3</sub>–THF, THF, 66 °C, 16 h, 95%, (ii) 2-(<i>tert</i>-butoxycarbonylamino)acetic acid, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 8 h, 70%; (e) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 30 min, 100%; (f) (i) 4-fluoroaniline, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 25 °C, 15 min, then 120 °C, 8 h, 89%, (ii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 2 h, 52%.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></p></p></figure><figure data-id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Proposed mechanism for the formation of metabolite <b>M40</b> and the metabolic pathway of major metabolites detected in rats after oral and intravenous dosing of <sup>14</sup>C-labeled KAF156.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Hit identified from HT screen against PfDHODH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of PfDHODH inhibitors in lead identification phase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of PfDHODH inhibitors in lead identification phase. * denotes the use of albumax supplemented media.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Crystal structure of Pf dihydroorotate dehydrogenase bound to DSM265 (green), orotate, and FMN (magenta) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0">4RX0</a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> (A) Cartoon representation of PfDHODH showing mutations (orange) that confer resistance to DSM265 (G181C only)<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and structurally related analogues of DSM265.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The α helix 181–193 (center-front) is transparent for clarity. (B) Amino acids (blue) in the binding site of DSM265. Yellow dotted lines show hydrogen bonds between DSM265 and PfDHODH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CH<sub>3</sub>CF<sub>2</sub>COOEt, NaOEt, EtOH, 78 °C, 3 h, 84%; (b) POCl<sub>3</sub>, MeCN, 80 °C, 5 h, 82%; (c) pentafluorosulfanyl aniline, EtOH, 60 °C, 3.5 h, 86%, 99.5% purity. Inset: byproduct <b>59</b> resulting from the synthesis of DSM265.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></p></figure><figure data-id="fig17" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Proposed biotransformation pathway for the formation of metabolite <b>M60</b> and minor metabolites <b>M61</b> and <b>M62</b> from incubation of DSM265 in liver microsomes from preclinical species.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Initial hits of the 3,5-diarylaminopyridine class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Key aminopyridines and their antimalarial activity against NF54 asexual parasites.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Changes to the 2-amino group and associated NF54 asexual parasite activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Changes to the scaffold core and associated NF54 asexual parasite activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Frontrunner compounds in the 3,5-diarylaminopyridine (pyrazine) series.<a onclick="showRef(event, 'ref50 ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref50 ref126 ref127">(50,126,127)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Homology model of the Pf catalytic domain of PI4K built using the PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ENE">3ENE</a> as previously described by McNamara et al.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> MMV048 (green) was docked using CLC Drug Discovery workbench. (A) Resistance mutations for MMV048 are shown in orange.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Resistance mutations of the Pf PI4K inhibitors, KDU691or BQR695, are shown in magenta.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> MMV048 is cross resistant to clones that possess these mutations. (B) A surface representation of the ATP binding pocket and amino acids (blue) predicted to interact with MMV048.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structure of <b>80</b> used as a pull-down probe for immobilization to sepharose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/medium/jm9b00761_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00761/20191205/images/large/jm9b00761_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00761&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) I<sub>2</sub>, DMSO, 100 °C, 4 h, 79%; (b) <i>p</i>-MeSO<sub>2</sub>PhB(OH)<sub>2</sub>, 1,4-dioxane, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (5 mol %), 110 °C, 16 h, 58%; (c) 6-(trifluoromethyl)pyridin-3-yl)boronic acid, 1,4-dioxane, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (7 mol %), 110 °C, 16 h, 65%.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71181" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71181" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 133 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>World Malaria Report 2018</i>; <span class="NLM_publisher-name">World Health
Organization</span>, <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="http://www.who.int/malaria/publications/world-malaria-report-2018/en/" class="extLink">www.who.int/malaria/publications/world-malaria-report-2018/en/</a> (accessed Dec 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World+Malaria+Report+2018%3B+World+Health%0AOrganization%2C+Geneva%2C+2018%3B+www.who.int%2Fmalaria%2Fpublications%2Fworld-malaria-report-2018%2Fen%2F+%28accessed+Dec+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Malaria%2520Report%25202018%26pub%3DWorld%2520Health%250AOrganization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. J.</span></span> <span> </span><span class="NLM_article-title">Persistent parasitism: The adaptive biology of <i>malariae</i> and <i>ovale</i> Malaria</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">808</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2016.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.pt.2016.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27480365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC2s3mvVSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=808-819&issue=10&author=C.+J.+Sutherland&title=Persistent+parasitism%3A+The+adaptive+biology+of+malariae+and+ovale+Malaria&doi=10.1016%2Fj.pt.2016.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent Parasitism: The Adaptive Biology of Malariae and Ovale Malaria</span></div><div class="casAuthors">Sutherland Colin J</div><div class="citationInfo"><span class="NLM_cas:title">Trends in parasitology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">808-819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Plasmodium malariae causes malaria in humans throughout the tropics and subtropics.  Plasmodium ovale curtisi and Plasmodium ovale wallikeri are sympatric sibling species common in sub-Saharan Africa and also found in Oceania and Asia.  Although rarely identified as the cause of malaria cases in endemic countries, PCR detection has confirmed all three parasite species to be more prevalent, and persistent, than previously thought.  Chronic, low-density, multispecies asymptomatic infection is a successful biological adaptation by these Plasmodium spp., a pattern also observed among malaria parasites of wild primates.  Current whole-genome analyses are illuminating the species barrier separating the ovale parasite species and reveal substantial expansion of subtelomeric gene families.  The evidence for and against a quiescent pre-erythrocytic form of P. malariae is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlWO-xSHQPne_Q9URG6Dx8fW6udTcc2ea_b6xaAiojRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3mvVSitg%253D%253D&md5=d6d2a844f63466c16e61c048b6a06442</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2016.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2016.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DC.%2BJ.%26atitle%3DPersistent%2520parasitism%253A%2520The%2520adaptive%2520biology%2520of%2520malariae%2520and%2520ovale%2520Malaria%26jtitle%3DTrends%2520Parasitol.%26date%3D2016%26volume%3D32%26issue%3D10%26spage%3D808%26epage%3D819%26doi%3D10.1016%2Fj.pt.2016.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span> <span> </span><span class="NLM_article-title">Can mixed parasite infections thwart targeted malaria elimination program in india?</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2017</i></span>,  <span class="NLM_fpage">2847548</span>, <span class="refDoi"> DOI: 10.1155/2017/2847548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1155%2F2017%2F2847548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28900620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1cbnsFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2017&publication_year=2017&pages=2847548&author=U.+S.+Singhauthor=N.+Siwalauthor=V.+Pandeauthor=A.+Das&title=Can+mixed+parasite+infections+thwart+targeted+malaria+elimination+program+in+india%3F&doi=10.1155%2F2017%2F2847548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Can Mixed Parasite Infections Thwart Targeted Malaria Elimination Program in India?</span></div><div class="casAuthors">Singh Upasana Shyamsunder; Siwal Nisha; Das Aparup; Pande Veena</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2847548</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">India is highly endemic to malaria with prevalence of all five species of human malaria parasites of Plasmodium genus.  India is set for malaria elimination by 2030.  Since cases of mixed Plasmodium species infections remain usually undetected but cause huge disease burden, in order to understand the distributional prevalence of both monospecies infections and mixed species infections in India, we collated published data on the differential infection incidences of the five different malaria parasites based on PCR diagnostic assay.  About 11% of total cases were due to mixed species infection.  Among several interesting observations on both single and mixed parasitic infections, incidences of Plasmodium falciparum monoinfection were found to be significantly higher than P. vivax monoinfection.  Also, P. malariae seems to be emerging as a potential malaria threat in India.  Putting all the facts together, it appears that the dream of achieving malaria elimination in India will not be completely successful without dealing with mixed species infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXc-UriKIvJJNiNltV31zlfW6udTcc2ea2lOICIFSZk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbnsFOgug%253D%253D&md5=e8698bda04f357aeb44b7ada3d674fbd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1155%2F2017%2F2847548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2017%252F2847548%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DU.%2BS.%26aulast%3DSiwal%26aufirst%3DN.%26aulast%3DPande%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DA.%26atitle%3DCan%2520mixed%2520parasite%2520infections%2520thwart%2520targeted%2520malaria%2520elimination%2520program%2520in%2520india%253F%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2017%26volume%3D2017%26spage%3D2847548%26doi%3D10.1155%2F2017%2F2847548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matusop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamsul, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox-Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, D. J.</span></span> <span> </span><span class="NLM_article-title">A large focus of naturally acquired <i>Plasmodium knowlesi</i> infections in human beings</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)15836-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS0140-6736%2804%2915836-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=15051281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD2c7lvVamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2004&pages=1017-1024&author=B.+Singhauthor=L.+K.+Sungauthor=A.+Matusopauthor=A.+Radhakrishnanauthor=S.+S.+Shamsulauthor=J.+Cox-Singhauthor=A.+Thomasauthor=D.+J.+Conway&title=A+large+focus+of+naturally+acquired+Plasmodium+knowlesi+infections+in+human+beings&doi=10.1016%2FS0140-6736%2804%2915836-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A large focus of naturally acquired Plasmodium knowlesi infections in human beings</span></div><div class="casAuthors">Singh Balbir; Kim Sung Lee; Matusop Asmad; Radhakrishnan Anand; Shamsul Sunita S G; Cox-Singh Janet; Thomas Alan; Conway David J</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9414</span>),
    <span class="NLM_cas:pages">1017-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  About a fifth of malaria cases in 1999 for the Kapit division of Malaysian Borneo had routinely been identified by microscopy as Plasmodium malariae, although these infections appeared atypical and a nested PCR assay failed to identify P malariae DNA.  We aimed to investigate whether such infections could be attributable to a variant form of P malariae or a newly emergent Plasmodium species.  METHODS:  We took blood samples from 208 people with malaria in the Kapit division between March, 2000, and November, 2002.  The small subunit ribosomal RNA and the circumsporozoite protein genes were sequenced for eight isolates that had been microscopically identified as P malariae.  All blood samples were characterised with a genus-specific and species-specific nested PCR assay together with newly designed P knowlesi-specific primers.  FINDINGS:  All DNA sequences were phylogenetically indistinguishable from those of P knowlesi, a malaria parasite of long-tailed macaque monkeys, but were significantly different from other malaria parasite species.  By PCR assay, 120 (58%) of 208 people with malaria tested positive for P knowlesi, whereas none was positive for P malariae.  P knowlesi parasites in human erythrocytes were difficult to distinguish from P malariae by microscopy.  Most of the P knowlesi infections were in adults and we did not note any clustering of cases within communities.  P knowlesi infections were successfully treated with chloroquine and primaquine.  INTERPRETATION:  Naturally acquired P knowlesi infections, misdiagnosed by microscopy mainly as P malariae, accounted for over half of all malaria cases in our study.  Morphological similarities between P knowlesi and P malariae necessitate the use of molecular methods for correct identification.  Further work is needed to determine whether human P knowlesi infections in the Kapit division are acquired from macaque monkeys or whether a host switch to human beings has occurred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS63eAmJYZFM_xQvRxYU81tfW6udTcc2ea2lOICIFSZk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7lvVamsQ%253D%253D&md5=b92dfd518397de50cdda216811f4946e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2915836-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252915836-4%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DSung%26aufirst%3DL.%2BK.%26aulast%3DMatusop%26aufirst%3DA.%26aulast%3DRadhakrishnan%26aufirst%3DA.%26aulast%3DShamsul%26aufirst%3DS.%2BS.%26aulast%3DCox-Singh%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DConway%26aufirst%3DD.%2BJ.%26atitle%3DA%2520large%2520focus%2520of%2520naturally%2520acquired%2520Plasmodium%2520knowlesi%2520infections%2520in%2520human%2520beings%26jtitle%3DLancet%26date%3D2004%26volume%3D363%26spage%3D1017%26epage%3D1024%26doi%3D10.1016%2FS0140-6736%2804%2915836-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutteridge, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaszubska, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">New developments in anti-malarial target candidate and product profiles</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12936-016-1675-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-016-1675-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28086874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=26&author=J.+N.+Burrowsauthor=S.+Duparcauthor=W.+E.+Gutteridgeauthor=R.+Hooft+van+Huijsduijnenauthor=W.+Kaszubskaauthor=F.+Macintyreauthor=S.+Mazzuriauthor=J.+J.+M%C3%B6hrleauthor=T.+N.+C.+Wells&title=New+developments+in+anti-malarial+target+candidate+and+product+profiles&doi=10.1186%2Fs12936-016-1675-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New developments in anti-malarial target candidate and product profiles</span></div><div class="casAuthors">Burrows, Jeremy N.; Duparc, Stephan; Gutteridge, Winston E.; Hooft van Huijsduijnen, Rob; Kaszubska, Wiweka; MacIntyre, Fiona; Mazzuri, Sebastien; Mohrle, Jorg J.; Wells, Timothy N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26/1-26/29</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  A decade of discovery and development of new anti-malarial medicines has led to a renewed focus on malaria elimination and eradication.  Changes in the way new anti-malarial drugs are discovered and developed have led to a dramatic increase in the no. and diversity of new mols. presently in pre-clin. and early clin. development.  The twin challenges faced can be summarized by multi-drug resistant malaria from the Greater Mekong Subregion, and the need to provide simplified medicines.  This review lists changes in anti-malarial target candidate and target product profiles over the last 4 years.  As well as new medicines to treat disease and prevent transmission, there has been increased focus on the longer term goal of finding new medicines for chemoprotection, potentially with long-acting mols., or parenteral formulations.  Other gaps in the malaria armamentarium, such as drugs to treat severe malaria and endectocides (that kill mosquitoes which feed on people who have taken the drug), are defined here.  Ultimately the elimination of malaria requires medicines that are safe and well-tolerated to be used in vulnerable populations: in pregnancy, esp. the first trimester, and in those suffering from malnutrition or co-infection with other pathogens.  These updates reflect the maturing of an understanding of the key challenges in producing the next generation of medicines to control, eliminate and ultimately eradicate malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjgdhMYAylM7Vg90H21EOLACvtfcHk0ljvMF_c6_emCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCqu7g%253D&md5=17984994f7a29c9fb184faa5214d4d35</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs12936-016-1675-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-016-1675-x%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DGutteridge%26aufirst%3DW.%2BE.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DKaszubska%26aufirst%3DW.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DMazzuri%26aufirst%3DS.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DNew%2520developments%2520in%2520anti-malarial%2520target%2520candidate%2520and%2520product%2520profiles%26jtitle%3DMalar.%2520J.%26date%3D2017%26volume%3D16%26spage%3D26%26doi%3D10.1186%2Fs12936-016-1675-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manyando, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N. C.</span></span> <span> </span><span class="NLM_article-title">Malaria</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">17050</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2017.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnrdp.2017.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28770814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=17050&author=M.+A.+Phillipsauthor=J.+N.+Burrowsauthor=C.+Manyandoauthor=R.+Hooft+van+Huijsduijnenauthor=W.+C.+Van+Voorhisauthor=T.+N.+C.+Wells&title=Malaria&doi=10.1038%2Fnrdp.2017.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria</span></div><div class="casAuthors">Phillips Margaret A; Burrows Jeremy N; van Huijsduijnen Rob Hooft; Wells Timothy N C; Manyando Christine; Van Voorhis Wesley C</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17050</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Malaria is caused in humans by five species of single-celled eukaryotic Plasmodium parasites (mainly Plasmodium falciparum and Plasmodium vivax) that are transmitted by the bite of Anopheles spp. mosquitoes.  Malaria remains one of the most serious infectious diseases; it threatens nearly half of the world's population and led to hundreds of thousands of deaths in 2015, predominantly among children in Africa.  Malaria is managed through a combination of vector control approaches (such as insecticide spraying and the use of insecticide-treated bed nets) and drugs for both treatment and prevention.  The widespread use of artemisinin-based combination therapies has contributed to substantial declines in the number of malaria-related deaths; however, the emergence of drug resistance threatens to reverse this progress.  Advances in our understanding of the underlying molecular basis of pathogenesis have fuelled the development of new diagnostics, drugs and insecticides.  Several new combination therapies are in clinical development that have efficacy against drug-resistant parasites and the potential to be used in single-dose regimens to improve compliance.  This ambitious programme to eliminate malaria also includes new approaches that could yield malaria vaccines or novel vector control strategies.  However, despite these achievements, a well-coordinated global effort on multiple fronts is needed if malaria elimination is to be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcfdgTdv0RVI2y4bB4mnvYfW6udTcc2eZTAhqM1fH_ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfjvVGhtg%253D%253D&md5=ec450ab6baef0a6c2b6bd6bac030771a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2017.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2017.50%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DManyando%26aufirst%3DC.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DWells%26aufirst%3DT.%2BN.%2BC.%26atitle%3DMalaria%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2017%26volume%3D3%26spage%3D17050%26doi%3D10.1038%2Fnrdp.2017.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisanzio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mappin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenger, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penny, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yukich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisele, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fergus, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindgren, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cibulskis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gething, P. W.</span></span> <span> </span><span class="NLM_article-title">The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span> (<span class="NLM_issue">7572</span>),  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1038/nature15535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature15535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26375008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFersLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=207-211&issue=7572&author=S.+Bhattauthor=D.+J.+Weissauthor=E.+Cameronauthor=D.+Bisanzioauthor=B.+Mappinauthor=U.+Dalrympleauthor=K.+Battleauthor=C.+L.+Moyesauthor=A.+Henryauthor=P.+A.+Eckhoffauthor=E.+A.+Wengerauthor=O.+Brietauthor=M.+A.+Pennyauthor=T.+A.+Smithauthor=A.+Bennettauthor=J.+Yukichauthor=T.+P.+Eiseleauthor=J.+T.+Griffinauthor=C.+A.+Fergusauthor=M.+Lynchauthor=F.+Lindgrenauthor=J.+M.+Cohenauthor=C.+L.+J.+Murrayauthor=D.+L.+Smithauthor=S.+I.+Hayauthor=R.+E.+Cibulskisauthor=P.+W.+Gething&title=The+effect+of+malaria+control+on+Plasmodium+falciparum+in+Africa+between+2000+and+2015&doi=10.1038%2Fnature15535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015</span></div><div class="casAuthors">Bhatt, S.; Weiss, D. J.; Cameron, E.; Bisanzio, D.; Mappin, B.; Dalrymple, U.; Battle, K. E.; Moyes, C. L.; Henry, A.; Eckhoff, P. A.; Wenger, E. A.; Briet, O.; Penny, M. A.; Smith, T. A.; Bennett, A.; Yukich, J.; Eisele, T. P.; Griffin, J. T.; Fergus, C. A.; Lynch, M.; Lindgren, F.; Cohen, J. M.; Murray, C. L. J.; Smith, D. L.; Hay, S. I.; Cibulskis, R. E.; Gething, P. W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7572</span>),
    <span class="NLM_cas:pages">207-211</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the year 2000, a concerted campaign against malaria has led to unprecedented levels of intervention coverage across sub-Saharan Africa.  Understanding the effect of this control effort is vital to inform future control planning.  However, the effect of malaria interventions across the varied epidemiol. settings of Africa remains poorly understood owing to the absence of reliable surveillance data and the simplistic approaches underlying current disease ests.  Here we link a large database of malaria field surveys with detailed reconstructions of changing intervention coverage to directly evaluate trends from 2000 to 2015, and quantify the attributable effect of malaria disease control efforts.  We found that Plasmodium falciparum infection prevalence in endemic Africa halved and the incidence of clin. disease fell by 40% between 2000 and 2015.  We est. that interventions have averted 663 (542-753 credible interval) million clin. cases since 2000.  Insecticide-treated nets, the most widespread intervention, were by far the largest contributor (68% of cases averted).  Although still below target levels, current malaria interventions have substantially reduced malaria disease incidence across the continent.  Increasing access to these interventions, and maintaining their effectiveness in the face of insecticide and drug resistance, should form a cornerstone of post-2015 control strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwpE0BNY1LmrVg90H21EOLACvtfcHk0lj4zqdGv-deMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFersLrN&md5=a6d38c412efb48432a0d1a4ec50c75fc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature15535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature15535%26sid%3Dliteratum%253Aachs%26aulast%3DBhatt%26aufirst%3DS.%26aulast%3DWeiss%26aufirst%3DD.%2BJ.%26aulast%3DCameron%26aufirst%3DE.%26aulast%3DBisanzio%26aufirst%3DD.%26aulast%3DMappin%26aufirst%3DB.%26aulast%3DDalrymple%26aufirst%3DU.%26aulast%3DBattle%26aufirst%3DK.%26aulast%3DMoyes%26aufirst%3DC.%2BL.%26aulast%3DHenry%26aufirst%3DA.%26aulast%3DEckhoff%26aufirst%3DP.%2BA.%26aulast%3DWenger%26aufirst%3DE.%2BA.%26aulast%3DBriet%26aufirst%3DO.%26aulast%3DPenny%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DT.%2BA.%26aulast%3DBennett%26aufirst%3DA.%26aulast%3DYukich%26aufirst%3DJ.%26aulast%3DEisele%26aufirst%3DT.%2BP.%26aulast%3DGriffin%26aufirst%3DJ.%2BT.%26aulast%3DFergus%26aufirst%3DC.%2BA.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLindgren%26aufirst%3DF.%26aulast%3DCohen%26aufirst%3DJ.%2BM.%26aulast%3DMurray%26aufirst%3DC.%2BL.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DHay%26aufirst%3DS.%2BI.%26aulast%3DCibulskis%26aufirst%3DR.%2BE.%26aulast%3DGething%26aufirst%3DP.%2BW.%26atitle%3DThe%2520effect%2520of%2520malaria%2520control%2520on%2520Plasmodium%2520falciparum%2520in%2520Africa%2520between%25202000%2520and%25202015%26jtitle%3DNature%26date%3D2015%26volume%3D526%26issue%3D7572%26spage%3D207%26epage%3D211%26doi%3D10.1038%2Fnature15535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">RTS,S
Clinical Trials Partnership</span> <span> </span><span class="NLM_article-title">Efficacy and safety of RTS,S/AS01 malaria vaccine with or without
a booster dose in infants and children in Africa: final results of
a phase 3, individually randomised, controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)60721-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS0140-6736%2815%2960721-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25913272" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=31-45&author=RTS%2CS%0AClinical+Trials+Partnership&title=Efficacy+and+safety+of+RTS%2CS%2FAS01+malaria+vaccine+with+or+without%0Aa+booster+dose+in+infants+and+children+in+Africa%3A+final+results+of%0Aa+phase+3%2C+individually+randomised%2C+controlled+trial&doi=10.1016%2FS0140-6736%2815%2960721-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960721-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960721-8%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520RTS%252CS%252FAS01%2520malaria%2520vaccine%2520with%2520or%2520without%250Aa%2520booster%2520dose%2520in%2520infants%2520and%2520children%2520in%2520Africa%253A%2520final%2520results%2520of%250Aa%2520phase%25203%252C%2520individually%2520randomised%252C%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D31%26epage%3D45%26doi%3D10.1016%2FS0140-6736%2815%2960721-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doritchamou, J. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, P. E.</span></span> <span> </span><span class="NLM_article-title">Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium</span>. <i>NPJ. Vaccines</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.1038/s41541-017-0035-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fs41541-017-0035-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29522056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1MrpsVWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=34&author=C.+H.+Coelhoauthor=J.+Y.+A.+Doritchamouauthor=I.+Zaidiauthor=P.+E.+Duffy&title=Advances+in+malaria+vaccine+development%3A+report+from+the+2017+malaria+vaccine+symposium&doi=10.1038%2Fs41541-017-0035-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium</span></div><div class="casAuthors">Coelho Camila Henriques; Doritchamou Justin Yai Alamou; Zaidi Irfan; Duffy Patrick E</div><div class="citationInfo"><span class="NLM_cas:title">NPJ vaccines</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Malaria Vaccine Symposium occurred at Johns Hopkins University in Baltimore, MD, USA on April 25th, 2017, coinciding with World Malaria Day and the WHO announcement that the RTS,S malaria vaccine would begin pilot implementation programs in Ghana, Kenya, and Malawi in 2018.  Scientists from several disciplines reported progress on an array of malaria vaccine concepts and product candidates, including pre-erythrocytic vaccines that prevent infection, blood-stage vaccines that limit infection and disease, and transmission-blocking vaccines that interrupt the spread of infection.  Other speakers highlighted the immunological and genetic considerations that must be addressed by vaccinologists to yield the most efficacious vaccines.  Here, we highlight the advances in malaria vaccinology that were reported at the symposium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSc4UpbiNekB0H3Rlp_k91zfW6udTcc2eZkFIOzzX07hrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrpsVWqtg%253D%253D&md5=c8afcd09959bd0999276859d0a31dd5f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41541-017-0035-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41541-017-0035-3%26sid%3Dliteratum%253Aachs%26aulast%3DCoelho%26aufirst%3DC.%2BH.%26aulast%3DDoritchamou%26aufirst%3DJ.%2BY.%2BA.%26aulast%3DZaidi%26aufirst%3DI.%26aulast%3DDuffy%26aufirst%3DP.%2BE.%26atitle%3DAdvances%2520in%2520malaria%2520vaccine%2520development%253A%2520report%2520from%2520the%25202017%2520malaria%2520vaccine%2520symposium%26jtitle%3DNPJ.%2520Vaccines%26date%3D2017%26volume%3D2%26spage%3D34%26doi%3D10.1038%2Fs41541-017-0035-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, E.</span></span> <span> </span><span class="NLM_article-title">Prophylaxis of malaria</span>. <i>Mediterr. J. Hematol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e2012045</span>, <span class="refDoi"> DOI: 10.4084/mjhid.2012.45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.4084%2Fmjhid.2012.45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22811794" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=e2012045&issue=1&author=E.+Schwartz&title=Prophylaxis+of+malaria&doi=10.4084%2Fmjhid.2012.45"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4084%2Fmjhid.2012.45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4084%252Fmjhid.2012.45%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DE.%26atitle%3DProphylaxis%2520of%2520malaria%26jtitle%3DMediterr.%2520J.%2520Hematol.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D4%26issue%3D1%26spage%3De2012045%26doi%3D10.4084%2Fmjhid.2012.45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavogui, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zongo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghini-Fuhrer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diakite, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togo, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koumare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somé, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulibaly, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djimde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamadio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidibe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulibaly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhousseini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niangaly, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diarra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabore, M. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouattara, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargougou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diarra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soré, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougouma, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compaore, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylla, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiema, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doumbo, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouedraogo, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirima, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djimde, A. A.</span></span> <span> </span><span class="NLM_article-title">Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span> (<span class="NLM_issue">10128</span>),  <span class="NLM_fpage">1378</span>– <span class="NLM_lpage">1390</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30291-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS0140-6736%2818%2930291-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29606364" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=1378-1390&issue=10128&author=I.+Sagaraauthor=A.+H.+Beavoguiauthor=I.+Zongoauthor=I.+Soulamaauthor=I.+Borghini-Fuhrerauthor=B.+Fofanaauthor=A.+Traoreauthor=N.+Dialloauthor=H.+Diakiteauthor=A.+H.+Togoauthor=S.+Koumareauthor=M.+Keitaauthor=D.+Camaraauthor=A.+F.+Som%C3%A9author=A.+S.+Coulibalyauthor=O.+B.+Traoreauthor=S.+Damaauthor=S.+Goitaauthor=M.+Djimdeauthor=A.+Bamadioauthor=N.+Daraauthor=H.+Maigaauthor=B.+Sidibeauthor=F.+Daoauthor=M.+Coulibalyauthor=M.+L.+Alhousseiniauthor=H.+Niangalyauthor=B.+Sangareauthor=M.+Diarraauthor=S.+Coumareauthor=M.+J.+T.+Kaboreauthor=S.+M.+Ouattaraauthor=A.+Barryauthor=D.+Kargougouauthor=A.+Diarraauthor=N.+Henryauthor=H.+Sor%C3%A9author=E.+C.+Bougoumaauthor=I.+Theraauthor=Y.+D.+Compaoreauthor=C.+J.+Sutherlandauthor=M.+M.+Syllaauthor=F.+Nikiemaauthor=M.+S.+Dialloauthor=A.+Dickoauthor=S.+Picotauthor=S.+Borrmannauthor=S.+Duparcauthor=R.+M.+Millerauthor=O.+K.+Doumboauthor=J.+Shinauthor=J.+P.+Gilauthor=A.+Bj%C3%B6rkmanauthor=J.+B.+Ouedraogoauthor=S.+B.+Sirimaauthor=A.+A.+Djimde&title=Pyronaridine-artesunate+or+dihydroartemisinin-piperaquine+versus+current+first-line+therapies+for+repeated+treatment+of+uncomplicated+malaria%3A+a+randomised%2C+multicentre%2C+open-label%2C+longitudinal%2C+controlled%2C+phase+3b%2F4+trial&doi=10.1016%2FS0140-6736%2818%2930291-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930291-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930291-5%26sid%3Dliteratum%253Aachs%26aulast%3DSagara%26aufirst%3DI.%26aulast%3DBeavogui%26aufirst%3DA.%2BH.%26aulast%3DZongo%26aufirst%3DI.%26aulast%3DSoulama%26aufirst%3DI.%26aulast%3DBorghini-Fuhrer%26aufirst%3DI.%26aulast%3DFofana%26aufirst%3DB.%26aulast%3DTraore%26aufirst%3DA.%26aulast%3DDiallo%26aufirst%3DN.%26aulast%3DDiakite%26aufirst%3DH.%26aulast%3DTogo%26aufirst%3DA.%2BH.%26aulast%3DKoumare%26aufirst%3DS.%26aulast%3DKeita%26aufirst%3DM.%26aulast%3DCamara%26aufirst%3DD.%26aulast%3DSom%25C3%25A9%26aufirst%3DA.%2BF.%26aulast%3DCoulibaly%26aufirst%3DA.%2BS.%26aulast%3DTraore%26aufirst%3DO.%2BB.%26aulast%3DDama%26aufirst%3DS.%26aulast%3DGoita%26aufirst%3DS.%26aulast%3DDjimde%26aufirst%3DM.%26aulast%3DBamadio%26aufirst%3DA.%26aulast%3DDara%26aufirst%3DN.%26aulast%3DMaiga%26aufirst%3DH.%26aulast%3DSidibe%26aufirst%3DB.%26aulast%3DDao%26aufirst%3DF.%26aulast%3DCoulibaly%26aufirst%3DM.%26aulast%3DAlhousseini%26aufirst%3DM.%2BL.%26aulast%3DNiangaly%26aufirst%3DH.%26aulast%3DSangare%26aufirst%3DB.%26aulast%3DDiarra%26aufirst%3DM.%26aulast%3DCoumare%26aufirst%3DS.%26aulast%3DKabore%26aufirst%3DM.%2BJ.%2BT.%26aulast%3DOuattara%26aufirst%3DS.%2BM.%26aulast%3DBarry%26aufirst%3DA.%26aulast%3DKargougou%26aufirst%3DD.%26aulast%3DDiarra%26aufirst%3DA.%26aulast%3DHenry%26aufirst%3DN.%26aulast%3DSor%25C3%25A9%26aufirst%3DH.%26aulast%3DBougouma%26aufirst%3DE.%2BC.%26aulast%3DThera%26aufirst%3DI.%26aulast%3DCompaore%26aufirst%3DY.%2BD.%26aulast%3DSutherland%26aufirst%3DC.%2BJ.%26aulast%3DSylla%26aufirst%3DM.%2BM.%26aulast%3DNikiema%26aufirst%3DF.%26aulast%3DDiallo%26aufirst%3DM.%2BS.%26aulast%3DDicko%26aufirst%3DA.%26aulast%3DPicot%26aufirst%3DS.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DDoumbo%26aufirst%3DO.%2BK.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DGil%26aufirst%3DJ.%2BP.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DA.%26aulast%3DOuedraogo%26aufirst%3DJ.%2BB.%26aulast%3DSirima%26aufirst%3DS.%2BB.%26aulast%3DDjimde%26aufirst%3DA.%2BA.%26atitle%3DPyronaridine-artesunate%2520or%2520dihydroartemisinin-piperaquine%2520versus%2520current%2520first-line%2520therapies%2520for%2520repeated%2520treatment%2520of%2520uncomplicated%2520malaria%253A%2520a%2520randomised%252C%2520multicentre%252C%2520open-label%252C%2520longitudinal%252C%2520controlled%252C%2520phase%25203b%252F4%2520trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26issue%3D10128%26spage%3D1378%26epage%3D1390%26doi%3D10.1016%2FS0140-6736%2818%2930291-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lwin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanpithakpong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhasivanon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindegardh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socheat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Artemisinin resistance in <i>Plasmodium falciparum</i> malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0808859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa0808859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=19641202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=455-467&author=A.+M.+Dondorpauthor=F.+Nostenauthor=P.+Yiauthor=D.+Dasauthor=A.+P.+Phyoauthor=J.+Tarningauthor=K.+M.+Lwinauthor=F.+Arieyauthor=W.+Hanpithakpongauthor=S.+J.+Leeauthor=P.+Ringwaldauthor=K.+Silamutauthor=M.+Imwongauthor=K.+Chotivanichauthor=P.+Limauthor=T.+Herdmanauthor=S.+S.+Anauthor=S.+Yeungauthor=P.+Singhasivanonauthor=N.+P.+J.+Dayauthor=N.+Lindegardhauthor=D.+Socheatauthor=N.+J.+White&title=Artemisinin+resistance+in+Plasmodium+falciparum+malaria&doi=10.1056%2FNEJMoa0808859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Dondorp, Arjen M.; Nosten, Francois; Yi, Poravuth; Das, Debashish; Phyo, Aung Phae; Tarning, Joel; Lwin, Khin Maung; Ariey, Frederic; Hanpithakpong, Warunee; Lee, Sue J.; Ringwald, Pascal; Silamut, Kamolrat; Imwong, Mallika; Chotivanich, Kesinee; Lim, Pharath; Herdman, Trent; Sam An, Sen; Yeung, Shunmay; Singhasivanon, Pratap; Day, Nicholas P. J.; Lindegardh, Niklas; Socheat, Duong; White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Artemisinin-based combination therapies are the recommended first-line treatments of falciparum malaria in all countries with endemic disease.  There are recent concerns that the efficacy of such therapies has declined on the Thai-Cambodian border, historically a site of emerging antimalarial-drug resistance.  METHODS: In two open-label, randomized trials, we compared the efficacies of two treatments for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, northwestern Thailand: oral artesunate given at a dose of 2 mg per kg of body wt. per day, for 7 days, and artesunate given at a dose of 4 mg per kg per day, for 3 days, followed by mefloqine at two doses totaling 25 mg per kg.  We assessed in vitro and in vivo Plasmodium-falciparum susceptibility, artesunate pharmacokinetics, and mol. markers of resistance.  RESULTS: We studied 40 patients in each of the two locations.  The overall median parasite clearance times were 84 h (interquartile range, 60 to 96) in Pailin and 48 h (interquartile range, 36 to 66) in Wang Pha (P < 0.001).  Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate-mefloqine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), resp., in Wang Pha (P = 0.31).  These markedly different parasitol. responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative mol. correlates of P.falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco-endoplasmic reticulum calcium ATPase6 [PfSERCA]).  Adverse events were mild and did not differ significantly between the two treatment groups.  CONCLUSIONS: P.falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand.  Resistance is characterized by slow parasite clearance in vivo without corresponding redns. on conventional in vitro susceptibility testing.  Containment measures are urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVvi4ozTDSLVg90H21EOLACvtfcHk0lgPk_oEc6cgsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D&md5=ae3098a15e9fb82c80fa0ddd05378220</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808859%26sid%3Dliteratum%253Aachs%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DLwin%26aufirst%3DK.%2BM.%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DHanpithakpong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DHerdman%26aufirst%3DT.%26aulast%3DAn%26aufirst%3DS.%2BS.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DSinghasivanon%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DN.%2BP.%2BJ.%26aulast%3DLindegardh%26aufirst%3DN.%26aulast%3DSocheat%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DArtemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D455%26epage%3D467%26doi%3D10.1056%2FNEJMoa0808859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nsanzabana, C.</span></span> <span> </span><span class="NLM_article-title">Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug!</span>. <i>Trop. Med. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.3390/tropicalmed4010026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.3390%2Ftropicalmed4010026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30717149" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=26&issue=1&author=C.+Nsanzabana&title=Resistance+to+artemisinin+combination+therapies+%28ACTs%29%3A+do+not+forget+the+partner+drug%21&doi=10.3390%2Ftropicalmed4010026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Ftropicalmed4010026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftropicalmed4010026%26sid%3Dliteratum%253Aachs%26aulast%3DNsanzabana%26aufirst%3DC.%26atitle%3DResistance%2520to%2520artemisinin%2520combination%2520therapies%2520%2528ACTs%2529%253A%2520do%2520not%2520forget%2520the%2520partner%2520drug%2521%26jtitle%3DTrop.%2520Med.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D4%26issue%3D1%26spage%3D26%26doi%3D10.3390%2Ftropicalmed4010026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovannaroth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchatsoonthorn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runcharoen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Htut, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aye, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokuolu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaosebikan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folaranmi, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayxay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanthavong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hongvanthong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyamboko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanello, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashraheil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacInnis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozdech, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeyapant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakulthaew, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intharabut, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihokhern, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunasol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flegg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowe, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Spread of Artemisinin resistance in <i>Plasmodium falciparum</i> Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1314981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1314981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25075834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=411-423&issue=5&author=E.+A.+Ashleyauthor=M.+Dhordaauthor=R.+M.+Fairhurstauthor=C.+Amaratungaauthor=P.+Limauthor=S.+Suonauthor=S.+Srengauthor=J.+M.+Andersonauthor=S.+Maoauthor=B.+Samauthor=C.+Sophaauthor=C.+M.+Chuorauthor=C.+Nguonauthor=S.+Sovannarothauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chotivanichauthor=K.+Chutasmitauthor=C.+Suchatsoonthornauthor=R.+Runcharoenauthor=T.+T.+Hienauthor=N.+T.+Thuy-Nhienauthor=N.+V.+Thanhauthor=N.+H.+Phuauthor=Y.+Htutauthor=K.+T.+Hanauthor=K.+H.+Ayeauthor=O.+A.+Mokuoluauthor=R.+R.+Olaosebikanauthor=O.+O.+Folaranmiauthor=M.+Mayxayauthor=M.+Khanthavongauthor=B.+Hongvanthongauthor=P.+N.+Newtonauthor=M.+A.+Onyambokoauthor=C.+I.+Fanelloauthor=A.+K.+Tshefuauthor=N.+Mishraauthor=N.+Valechaauthor=A.+P.+Phyoauthor=F.+Nostenauthor=P.+Yiauthor=R.+Tripuraauthor=S.+Borrmannauthor=M.+Bashraheilauthor=J.+Peshuauthor=M.+A.+Faizauthor=A.+Ghoseauthor=M.+A.+Hossainauthor=R.+Samadauthor=M.+R.+Rahmanauthor=M.+M.+Hasanauthor=A.+Islamauthor=O.+Miottoauthor=R.+Amatoauthor=B.+MacInnisauthor=J.+Stalkerauthor=D.+P.+Kwiatkowskiauthor=Z.+Bozdechauthor=A.+Jeeyapantauthor=P.+Y.+Cheahauthor=T.+Sakulthaewauthor=J.+Chalkauthor=B.+Intharabutauthor=K.+Silamutauthor=S.+J.+Leeauthor=B.+Vihokhernauthor=C.+Kunasolauthor=M.+Imwongauthor=J.+Tarningauthor=W.+J.+Taylorauthor=S.+Yeungauthor=C.+J.+Woodrowauthor=J.+A.+Fleggauthor=D.+Dasauthor=J.+Smithauthor=M.+Venkatesanauthor=C.+V.+Ploweauthor=K.+Stepniewskaauthor=P.+J.+Guerinauthor=A.+M.+Dondorpauthor=N.+P.+Dayauthor=N.+J.+White&title=Spread+of+Artemisinin+resistance+in+Plasmodium+falciparum+Malaria&doi=10.1056%2FNEJMoa1314981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Spread of artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Ashley, E. A.; Dhorda, M.; Fairhurst, R. M.; Amaratunga, C.; Lim, P.; Suon, S.; Sreng, S.; Anderson, J. M.; Mao, S.; Sam, B.; Sopha, C.; Chuor, C. M.; Nguon, C.; Sovannaroth, S.; Pukrittayakamee, S.; Jittamala, P.; Chotivanich, K.; Chutasmit, K.; Suchatsoonthorn, C.; Runcharoen, R.; Hien, T. T.; Thuy-Nhien, N. T.; Thanh, N. V.; Phu, N. H.; Htut, Y.; Han, K.-T.; Aye, K. H.; Mokuolu, O. A.; Olaosebikan, R. R.; Folaranmi, O. O.; Mayxay, M.; Khanthavong, M.; Hongvanthong, B.; Newton, P. N.; Onyamboko, M. A.; Fanello, C. I.; Tshefu, A. K.; Mishra, N.; Valecha, N.; Phyo, A. P.; Nosten, F.; Yi, P.; Tripura, R.; Borrmann, S.; Bashraheil, M.; Peshu, J.; Faiz, M. A.; Ghose, A.; Hossain, M. A.; Samad, R.; Rahman, M. R.; Hasan, M. M.; Islam, A.; Miotto, O.; Amato, R.; MacInnis, B.; Stalker, J.; Kwiatkowski, D. P.; Bozdech, Z.; Jeeyapant, A.; Cheah, P. Y.; Sakulthaew, T.; Chalk, J.; Intharabut, B.; Silamut, K.; Lee, S. J.; Vihokhern, B.; Kunasol, C.; Imwong, M.; Tarning, J.; Taylor, W. J.; Yeung, S.; Woodrow, C. J.; Flegg, J. A.; Das, D.; Smith, J.; Venkatesan, M.; Plowe, C. V.; Stepniewska, K.; Guerin, P. J.; Dondorp, A. M.; Day, N. P.; White, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-423, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria.  Mapping the geog. extent of resistance is essential for planning containment and elimination strategies.  Methods: Between May 2011 and Apr. 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa).  Patients received artesunate, administered orally at a daily dose of either 2 mg per kg of body wt. per day or 4 mg per kg, for 3 days, followed by a std. 3-day course of artemisinin-based combination therapy.  Parasite counts in peripheral-blood samples were measured every 6 h, and the parasite clearance half-lives were detd.  Results: The median parasite clearance half-lives ranged from 1.9 h in the Democratic Republic of Congo to 7.0 h at the Thailand-Cambodia border.  Slowly clearing infections (parasite clearance half-life >5 h), strongly assocd. with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from Southern Vietnam to central Myanmar.  The incidence of pre-treatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission.  In Western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was assocd. with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days.  Conclusions: Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is assocd. with mutations in kelch13.  Prolonged courses of artemisinin- based combination therapies are currently efficacious in areas where std. 3-day treatments are failing. (Funded by the U.K. Department of International Development and others).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7aJ4A3O4W8rVg90H21EOLACvtfcHk0lgPk_oEc6cgsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF&md5=bb2f2a4d554ba6a1f4c605868be43f6e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1314981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1314981%26sid%3Dliteratum%253Aachs%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DSam%26aufirst%3DB.%26aulast%3DSopha%26aufirst%3DC.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DNguon%26aufirst%3DC.%26aulast%3DSovannaroth%26aufirst%3DS.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSuchatsoonthorn%26aufirst%3DC.%26aulast%3DRuncharoen%26aufirst%3DR.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DPhu%26aufirst%3DN.%2BH.%26aulast%3DHtut%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DK.%2BT.%26aulast%3DAye%26aufirst%3DK.%2BH.%26aulast%3DMokuolu%26aufirst%3DO.%2BA.%26aulast%3DOlaosebikan%26aufirst%3DR.%2BR.%26aulast%3DFolaranmi%26aufirst%3DO.%2BO.%26aulast%3DMayxay%26aufirst%3DM.%26aulast%3DKhanthavong%26aufirst%3DM.%26aulast%3DHongvanthong%26aufirst%3DB.%26aulast%3DNewton%26aufirst%3DP.%2BN.%26aulast%3DOnyamboko%26aufirst%3DM.%2BA.%26aulast%3DFanello%26aufirst%3DC.%2BI.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DMishra%26aufirst%3DN.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DBashraheil%26aufirst%3DM.%26aulast%3DPeshu%26aufirst%3DJ.%26aulast%3DFaiz%26aufirst%3DM.%2BA.%26aulast%3DGhose%26aufirst%3DA.%26aulast%3DHossain%26aufirst%3DM.%2BA.%26aulast%3DSamad%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DM.%2BR.%26aulast%3DHasan%26aufirst%3DM.%2BM.%26aulast%3DIslam%26aufirst%3DA.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DMacInnis%26aufirst%3DB.%26aulast%3DStalker%26aufirst%3DJ.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DBozdech%26aufirst%3DZ.%26aulast%3DJeeyapant%26aufirst%3DA.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DSakulthaew%26aufirst%3DT.%26aulast%3DChalk%26aufirst%3DJ.%26aulast%3DIntharabut%26aufirst%3DB.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DVihokhern%26aufirst%3DB.%26aulast%3DKunasol%26aufirst%3DC.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DW.%2BJ.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DWoodrow%26aufirst%3DC.%2BJ.%26aulast%3DFlegg%26aufirst%3DJ.%2BA.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DM.%26aulast%3DPlowe%26aufirst%3DC.%2BV.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DGuerin%26aufirst%3DP.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DSpread%2520of%2520Artemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D5%26spage%3D411%26epage%3D423%26doi%3D10.1056%2FNEJMoa1314981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, M. V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llanos-Cuentas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krudsood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista
Pereira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espino, F. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mia, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuquiyauri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Val, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casapía, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito, M. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M. R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buathong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noedl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wubie, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdissa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeynudin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abebe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellam, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousell, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardaker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clover, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugwuegbulam, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, G. C. K. W.</span></span> <span> </span><span class="NLM_article-title">Single-dose tafenoquine to prevent relapse of <i>Plasmodium vivax</i> malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1710775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1710775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30650322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=215-228&issue=3&author=M.+V.+G.+Lacerdaauthor=A.+Llanos-Cuentasauthor=S.+Krudsoodauthor=C.+Lonauthor=D.+L.+Saundersauthor=R.+Mohammedauthor=D.+Yilmaauthor=D.+Batista%0APereiraauthor=F.+E.+J.+Espinoauthor=R.+Z.+Miaauthor=R.+Chuquiyauriauthor=F.+Valauthor=M.+Casap%C3%ADaauthor=W.+M.+Monteiroauthor=M.+A.+M.+Britoauthor=M.+R.+F.+Costaauthor=N.+Buathongauthor=H.+Noedlauthor=E.+Diroauthor=S.+Getieauthor=K.+M.+Wubieauthor=A.+Abdissaauthor=A.+Zeynudinauthor=C.+Abebeauthor=M.+S.+Tadaauthor=F.+Brandauthor=H.-P.+Beckauthor=B.+Angusauthor=S.+Duparcauthor=J.-P.+Kleimauthor=L.+M.+Kellamauthor=V.+M.+Rousellauthor=S.+W.+Jonesauthor=E.+Hardakerauthor=K.+Mohamedauthor=D.+D.+Cloverauthor=K.+Fletcherauthor=J.+J.+Bretonauthor=C.+O.+Ugwuegbulamauthor=J.+A.+Greenauthor=G.+C.+K.+W.+Koh&title=Single-dose+tafenoquine+to+prevent+relapse+of+Plasmodium+vivax+malaria&doi=10.1056%2FNEJMoa1710775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria</span></div><div class="casAuthors">Lacerda, M. V. G.; Llanos-Cuentas, A.; Krudsood, S.; Lon, C.; Saunders, D. L.; Mohammed, R.; Yilma, D.; Pereira, D. Batista; Espino, F. E. J.; Mia, R. Z.; Chuquiyauri, R.; Val, F.; Casapia, M.; Monteiro, W. M.; Brito, M. A. M.; Costa, M. R. F.; Buathong, N.; Noedl, H.; Diro, E.; Getie, S.; Wubie, K. M.; Abdissa, A.; Zeynudin, A.; Abebe, C.; Tada, M. S.; Brand, F.; Beck, H.-P.; Angus, B.; Duparc, S.; Kleim, J.-P.; Kellam, L. M.; Rousell, V. M.; Jones, S. W.; Hardaker, E.; Mohamed, K.; Clover, D. D.; Fletcher, K.; Breton, J. J.; Ugwuegbulam, C. O.; Green, J. A.; Koh, G. C. K. W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-228</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical cure").  Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax.  Methods This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines.  We enrolled 522 patients with microscopically confirmed P. vivax infection (>100 to <100,000 parasites per μL) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value detd. at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial).  All patients received a 3-day course of chloroquine (total dose of 1500 mg).  In addn., patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients).  The primary outcome was the Kaplan-Meier estd. percentage of patients who were free from recurrence at 6 mo, defined as P. vivax clearance without recurrent parasitemia.  Results In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 mo was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1).  The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P<0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P<0.001).  Tafenoquine was assocd. with asymptomatic declines in Hb levels, which resolved without intervention.  Conclusions Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvrzXV4arPRbVg90H21EOLACvtfcHk0lgA35AvdOtCvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWgsrk%253D&md5=d6f2739d9be0b6f05fc718cc00665e71</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1710775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1710775%26sid%3Dliteratum%253Aachs%26aulast%3DLacerda%26aufirst%3DM.%2BV.%2BG.%26aulast%3DLlanos-Cuentas%26aufirst%3DA.%26aulast%3DKrudsood%26aufirst%3DS.%26aulast%3DLon%26aufirst%3DC.%26aulast%3DSaunders%26aufirst%3DD.%2BL.%26aulast%3DMohammed%26aufirst%3DR.%26aulast%3DYilma%26aufirst%3DD.%26aulast%3DBatista%2BPereira%26aufirst%3DD.%26aulast%3DEspino%26aufirst%3DF.%2BE.%2BJ.%26aulast%3DMia%26aufirst%3DR.%2BZ.%26aulast%3DChuquiyauri%26aufirst%3DR.%26aulast%3DVal%26aufirst%3DF.%26aulast%3DCasap%25C3%25ADa%26aufirst%3DM.%26aulast%3DMonteiro%26aufirst%3DW.%2BM.%26aulast%3DBrito%26aufirst%3DM.%2BA.%2BM.%26aulast%3DCosta%26aufirst%3DM.%2BR.%2BF.%26aulast%3DBuathong%26aufirst%3DN.%26aulast%3DNoedl%26aufirst%3DH.%26aulast%3DDiro%26aufirst%3DE.%26aulast%3DGetie%26aufirst%3DS.%26aulast%3DWubie%26aufirst%3DK.%2BM.%26aulast%3DAbdissa%26aufirst%3DA.%26aulast%3DZeynudin%26aufirst%3DA.%26aulast%3DAbebe%26aufirst%3DC.%26aulast%3DTada%26aufirst%3DM.%2BS.%26aulast%3DBrand%26aufirst%3DF.%26aulast%3DBeck%26aufirst%3DH.-P.%26aulast%3DAngus%26aufirst%3DB.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DKleim%26aufirst%3DJ.-P.%26aulast%3DKellam%26aufirst%3DL.%2BM.%26aulast%3DRousell%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DS.%2BW.%26aulast%3DHardaker%26aufirst%3DE.%26aulast%3DMohamed%26aufirst%3DK.%26aulast%3DClover%26aufirst%3DD.%2BD.%26aulast%3DFletcher%26aufirst%3DK.%26aulast%3DBreton%26aufirst%3DJ.%2BJ.%26aulast%3DUgwuegbulam%26aufirst%3DC.%2BO.%26aulast%3DGreen%26aufirst%3DJ.%2BA.%26aulast%3DKoh%26aufirst%3DG.%2BC.%2BK.%2BW.%26atitle%3DSingle-dose%2520tafenoquine%2520to%2520prevent%2520relapse%2520of%2520Plasmodium%2520vivax%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D3%26spage%3D215%26epage%3D228%26doi%3D10.1056%2FNEJMoa1710775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span> <span> </span><span class="NLM_article-title">Primaquine revisited six decades after its discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ejmech.2008.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18930565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVOmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=937-953&issue=3&author=N.+Valeauthor=R.+Moreiraauthor=P.+Gomes&title=Primaquine+revisited+six+decades+after+its+discovery&doi=10.1016%2Fj.ejmech.2008.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Primaquine revisited six decades after its discovery</span></div><div class="casAuthors">Vale, Nuno; Moreira, Rui; Gomes, Paula</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">937-953</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Primaquine was firstly synthesized in 1946 in the USA, and is the most representative member of the anti-malarial 8-aminoquinolines.  Six decades have passed and primaquine is still the only transmission-blocking anti-malarial clin. available, displaying a marked activity against gametocytes of all species of human malaria, including multi-resistant Plasmodium falciparum strains.  Primaquine is also effective against all exoerythrocytic forms of the parasite and is used in conjunction with other anti-malarials for the treatment of vivax and ovale malaria.  However, primaquine is often assocd. with serious adverse effects, in consequence of its toxic metabolites.  5-Hydroxyprimaquine or 6-methoxy-8-aminoquinoline has been considered to be directly responsible for complications such as hemolytic anemia.  Primaquine toxicity is aggravated in people deficient of 6-glucose phosphate dehydrogenase or glutathione synthetase.  Adverse effects are further amplified by the fact that primaquine must be repeatedly administered at high doses, due to its limited oral bioavailability.  Over the last two decades, Medicinal Chemists have battled against primaquine's disadvantages, while keeping or even improving its unequalled performance as an anti-malarial.  The present text revisits primaquine and its properties on the occasion of its 60th anniversary and aims to give a general overview of what has been the path towards the development of effective and safe primaquine-based anti-malarials.  Presently, aablaquine and tafenoquine the two most promising primaquine analogs are already in the final stages of clin. trials against Plasmodium vivax and P. falciparum.  Both compds. are a new hope against malaria and other primaquine-sensitive illnesses, such as Pneumocystis Pneumonia or the Chagas disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSnsLTnEOK1bVg90H21EOLACvtfcHk0li3FOrCLMC_sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVOmtrc%253D&md5=9b864141a9603247e96fec5e3cec8211</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DVale%26aufirst%3DN.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DP.%26atitle%3DPrimaquine%2520revisited%2520six%2520decades%2520after%2520its%2520discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26issue%3D3%26spage%3D937%26epage%3D953%26doi%3D10.1016%2Fj.ejmech.2008.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria: an open-label phase 2 trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)00320-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2815%2900320-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26448141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=61-69&issue=1&author=A.+P.+Phyoauthor=P.+Jittamalaauthor=F.+H.+Nostenauthor=S.+Pukrittayakameeauthor=M.+Imwongauthor=N.+J.+Whiteauthor=S.+Duparcauthor=F.+Macintyreauthor=M.+Bakerauthor=J.+J.+M%C3%B6hrle&title=Antimalarial+activity+of+artefenomel+%28OZ439%29%2C+a+novel+synthetic+antimalarial+endoperoxide%2C+in+patients+with+Plasmodium+falciparum+and+Plasmodium+vivax+malaria%3A+an+open-label+phase+2+trial&doi=10.1016%2FS1473-3099%2815%2900320-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial</span></div><div class="casAuthors">Phyo, Aung Pyae; Jittamala, Podjanee; Nosten, Francois H.; Pukrittayakamee, Sasithon; Imwong, Mallika; White, Nicholas J.; Duparc, Stephan; MacIntyre, Fiona; Baker, Mark; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared with other antimalarial drugs with the artemisinin pharmacophore.  Artefenomel has been generally well tolerated in volunteers at doses up to 1600 mg and is being developed as a partner drug in an antimalarial combination treatment.  We investigated the efficacy, tolerability, and pharmacokinetics of artefenomel at different doses in patients with Plasmodium falciparum or Plasmodium vivax malaria.  This phase 2a exploratory, open-label trial was done at the Hospital for Tropical Diseases, Bangkok, and the Shoklo Malaria Research Unit in Thailand.  Adult patients with acute, uncomplicated P falciparum or P vivax malaria received artefenomel in a single oral dose (200 mg, 400 mg, 800 mg, or 1200 mg).  The first cohort received 800 mg.  Testing of a new dose of artefenomel in a patient cohort was decided on after safety and efficacy assessment of the preceding cohort.  The primary endpoint was the natural log parasite redn. per 24 h.  Definitive oral treatment was given at 36 h.  This trial is registered with ClinicalTrials.gov, no. NCT01213966.  Between Oct 24, 2010, and May 25, 2012, 82 patients were enrolled (20 in each of the 200 mg, 400 mg, and 800 mg cohorts, and 21 in the 1200 mg cohort).  One patient withdrew consent (before the administration of artefenomel) but there were no further dropouts.  The parasite redn. rates per 24 h ranged from 0·90 to 1·88 for P falciparum, and 2·09 to 2·53 for P vivax.  All doses were equally effective in both P falciparum and P vivax malaria, with median parasite clearance half-lives of 4·1 h (range 1·3-6·7) to 5·6 h (2·0-8·5) for P falciparum and 2·3 h (1·2-3·9) to 3·2 h (0·9-15·0) for P vivax.  Maximum plasma concns., dose-proportional to 800 mg, occurred at 4 h (median).  The estd. elimination half-life was 46-62 h.  No serious drug-related adverse effects were reported; other adverse effects were generally mild and reversible, with the highest no. in the 1200 mg cohort (17 [81%] patients with at least one adverse event).  The most frequently reported adverse effect was an asymptomatic increase in plasma creatine phosphokinase concn. (200 mg, n=5; 400 mg, n=3; 800 mg, n=1; 1200 mg, n=3).  Artefenomel is a new synthetic antimalarial peroxide with a good safety profile that clears parasitemia rapidly in both P falciparum and P vivax malaria.  Its long half-life suggests a possible use in a single-dose treatment in combination with other drugs.  Bill & Melinda Gates Foundation, Wellcome Trust, and UK Department for International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_OEYJuv5VVrVg90H21EOLACvtfcHk0li3FOrCLMC_sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP&md5=368550e5ec73242c603c8abdc6a66f12</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900320-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900320-5%26sid%3Dliteratum%253Aachs%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DNosten%26aufirst%3DF.%2BH.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26atitle%3DAntimalarial%2520activity%2520of%2520artefenomel%2520%2528OZ439%2529%252C%2520a%2520novel%2520synthetic%2520antimalarial%2520endoperoxide%252C%2520in%2520patients%2520with%2520Plasmodium%2520falciparum%2520and%2520Plasmodium%2520vivax%2520malaria%253A%2520an%2520open-label%2520phase%25202%2520trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26issue%3D1%26spage%3D61%26epage%3D69%26doi%3D10.1016%2FS1473-3099%2815%2900320-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toure, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwapasa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaye, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheshwar, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anvikar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span> <span> </span><span class="NLM_article-title">Assessment of efficacy and safety of arterolane maleate-piperaquine phosphate dispersible tablets in comparison with artemether-lumefantrine dispersible tablets in pediatric patients with acute uncomplicated <i>Plasmodium falciparum</i> malaria: a phase 3, randomized, multicenter trial in India and Africa</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1720</span>, <span class="refDoi"> DOI: 10.1093/cid/cix617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Fcid%2Fcix617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29020247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSrtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=1711-1720&issue=10&author=O.+A.+Toureauthor=V.+Mwapasaauthor=I.+Sagaraauthor=O.+Gayeauthor=R.+Thompsonauthor=A.+V.+Maheshwarauthor=P.+Mishraauthor=N.+Behraauthor=A.+K.+Tshefuauthor=R.+R.+Dasauthor=A.+R.+Anvikarauthor=P.+Sharmaauthor=A.+Royauthor=S.+K.+Sharmaauthor=A.+Nasaauthor=R.+K.+Jalaliauthor=N.+Valecha&title=Assessment+of+efficacy+and+safety+of+arterolane+maleate-piperaquine+phosphate+dispersible+tablets+in+comparison+with+artemether-lumefantrine+dispersible+tablets+in+pediatric+patients+with+acute+uncomplicated+Plasmodium+falciparum+malaria%3A+a+phase+3%2C+randomized%2C+multicenter+trial+in+India+and+Africa&doi=10.1093%2Fcid%2Fcix617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of efficacy and safety of arterolane maleate-piperaquine phosphate dispersible tablets in comparison with artemether-lumefantrine dispersible tablets in pediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase 3, randomized, multicenter trial in India and Africa</span></div><div class="casAuthors">Toure, Offianan Andre; Mwapasa, Victor; Sagara, Issaka; Gaye, Oumar; Thompson, Ricardo; Maheshwar, Aishwarya V.; Mishra, Pitabas; Behra, Narendra; Tshefu, Antoinette K.; Das, Rashmi R.; Anvikar, Anupkumar R.; Sharma, Pradeep; Roy, Arjun; Sharma, Sanjay K.; Nasa, Amit; Jalali, Rajinder K.; Valecha, Neena</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1711-1720</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.Administration of artemisinin-based combination therapy (ACT) to infant and young children can be challenging.  A formulation with accurate dose and ease of administration will improve adherence and compliance in children.  The fixed-dose combination dispersible tablet of arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg can make dosing convenient in children.  Methods.This multicenter (India and Africa), comparative, parallel-group trial enrolled 859 patients aged 6 mo to 12 years with Plasmodium falciparummalaria.  Patients were randomized in a ratio of 2:1 to AM-PQP (571 patients) once daily and artemether-lumefantrine (AL) (288 patients) twice daily for 3 days and followed for 42 days.  Results.The cure rate (ie, polymerase chain reaction-cor. adequate clin. and parasitol. response) in the per-protocol population at day 28 was 100.0% and 98.5% (difference, 1.48% [95% confidence interval {CI},.04%-2.91%]) in the AM-PQP and AL arms, resp., and 96.0% and 95.8% (difference, 0.14% [95% CI, -2.68% to 2.95%]) in the intention-to-treat (ITT) population.  The cure rate was comparable at day 42 in the ITT population (AM-PQP, 94.4% vs AL, 93.1%).  The median parasite clearance time was 24 h in both the arms.  The median fever clearance time was 6 h in AM-PQP and 12 h in the AL arm.  Both the treatments were found to be safe and well tolerated.  Overall, safety profile of both the treatments was similar.  Conclusions.The efficacy and safety of fixed-dose combination of AM and PQP was comparable to AL for the treatment of uncomplicated P. falciparum malaria in pediatric patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqegdwsrY2Uv7Vg90H21EOLACvtfcHk0li3FOrCLMC_sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSrtbbN&md5=c2b86ff3bf500a5bbc6c7322628704ee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcix617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcix617%26sid%3Dliteratum%253Aachs%26aulast%3DToure%26aufirst%3DO.%2BA.%26aulast%3DMwapasa%26aufirst%3DV.%26aulast%3DSagara%26aufirst%3DI.%26aulast%3DGaye%26aufirst%3DO.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DMaheshwar%26aufirst%3DA.%2BV.%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DBehra%26aufirst%3DN.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DDas%26aufirst%3DR.%2BR.%26aulast%3DAnvikar%26aufirst%3DA.%2BR.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DNasa%26aufirst%3DA.%26aulast%3DJalali%26aufirst%3DR.%2BK.%26aulast%3DValecha%26aufirst%3DN.%26atitle%3DAssessment%2520of%2520efficacy%2520and%2520safety%2520of%2520arterolane%2520maleate-piperaquine%2520phosphate%2520dispersible%2520tablets%2520in%2520comparison%2520with%2520artemether-lumefantrine%2520dispersible%2520tablets%2520in%2520pediatric%2520patients%2520with%2520acute%2520uncomplicated%2520Plasmodium%2520falciparum%2520malaria%253A%2520a%2520phase%25203%252C%2520randomized%252C%2520multicenter%2520trial%2520in%2520India%2520and%2520Africa%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D65%26issue%3D10%26spage%3D1711%26epage%3D1720%26doi%3D10.1093%2Fcid%2Fcix617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toure, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krudsood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaye, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohanty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anvikar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwapasa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noedl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiacoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enosse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangpukdee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokolomami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndiaye, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yumva, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidibe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohanty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyirenda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starzengruber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swoboda, P.</span></span> <span> </span><span class="NLM_article-title">A phase 3, double-blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">964</span>– <span class="NLM_lpage">971</span>, <span class="refDoi"> DOI: 10.1093/cid/ciw029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Fcid%2Fciw029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26908796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2016&pages=964-971&author=O.+A.+Toureauthor=N.+Valechaauthor=A.+K.+Tshefuauthor=R.+Thompsonauthor=S.+Krudsoodauthor=O.+Gayeauthor=B.+H.+K.+Raoauthor=I.+Sagaraauthor=T.+K.+Boseauthor=S.+Mohantyauthor=B.+S.+Raoauthor=A.+R.+Anvikarauthor=V.+Mwapasaauthor=H.+Noedlauthor=S.+Aroraauthor=A.+Royauthor=S.+S.+Iyerauthor=P.+Sharmaauthor=N.+Sahaauthor=R.+K.+Jalaliauthor=L.+Tiacohauthor=S.+Enosseauthor=N.+Tangpukdeeauthor=J.+Kokolomamiauthor=J.+L.+Ndiayeauthor=D.+Raoauthor=N.+N.+Yumvaauthor=B.+Sidibeauthor=R.+Mohantyauthor=A.+C.+Jhaauthor=M.+Nyirendaauthor=P.+Starzengruberauthor=P.+Swoboda&title=A+phase+3%2C+double-blind%2C+randomized+study+of+arterolane+maleate-piperaquine+phosphate+vs+artemether-lumefantrine+for+falciparum+malaria+in+adolescent+and+adult+patients+in+Asia+and+Africa&doi=10.1093%2Fcid%2Fciw029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 3, double-blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa</span></div><div class="casAuthors">Toure, Offianan Andre; Valecha, Neena; Tshefu, Antoinette K.; Thompson, Ricardo; Krudsood, Srivicha; Gaye, Oumar; Rao, Bappanaidu Hoigegudde Krishnamurthy; Sagara, Issaka; Bose, Tarit Kumar; Mohanty, Sanjib; Rao, Ballamudi Srinivas; Anvikar, Anupkumar R.; Mwapasa, Victor; Noedl, Harald; Arora, Sudershan; Roy, Arjun; Iyer, Sunil S.; Sharma, Pradeep; Saha, Nilanjan; Jalali, Rajinder K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">964-971</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Artemisinins, which are derived from plants, are subject to risk of supply interruption due to climatic changes.  Consequently, an effort to identify a new synthetic antimalarial was initiated.  A fixed-dose combination of arterolane maleate (AM), a new synthetic trioxolane, with piperaquine phosphate (PQP), a long half-life bisquinoline, was evaluated in patients with uncomplicated Plasmodium falciparum malaria.  Methods: In this multicenter, randomized, double-blind, comparative, parallel-group trial, 1072 patients aged 12-65 years with P. falciparum monoinfection received either AM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients) twice daily for 3 days.  All patients were followed up until day 42.  Results: Of the 714 patients in the AM-PQP group, 638 (89.4%) completed the study; of the 358 patients in the A-L group, 301(84.1%) completed the study.  In both groups, the polymerase chain reaction cor. adequate clin. and parasitol. response (PCR-cor. ACPR) on day 28 in intent-to-treat (ITT) and per-protocol (PP) populations was 92.86% and 92.46% and 99.25% and 99.07%, resp.  The corresponding figures on day 42 in the ITT and PP populations were 90.48% and 91.34%, resp.  After adjusting for survival ITT, the PCR-cor. ACPR on day 42 was > 98% in both groups.  The overall incidence of adverse events was comparable.  Conclusions: AM-PQP showed comparable efficacy and safety to A-L in the treatment of uncomplicated P. falciparum malaria in adolescent and adult patients.  AM-PQP demonstrated high clin. and parasitol. response rates as well as rapid parasite clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfvidmlOCaMrVg90H21EOLACvtfcHk0lj3u9EjiXJbYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGrtbo%253D&md5=fde69cb1e4da2ef26ee13781a512c499</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciw029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciw029%26sid%3Dliteratum%253Aachs%26aulast%3DToure%26aufirst%3DO.%2BA.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DKrudsood%26aufirst%3DS.%26aulast%3DGaye%26aufirst%3DO.%26aulast%3DRao%26aufirst%3DB.%2BH.%2BK.%26aulast%3DSagara%26aufirst%3DI.%26aulast%3DBose%26aufirst%3DT.%2BK.%26aulast%3DMohanty%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DB.%2BS.%26aulast%3DAnvikar%26aufirst%3DA.%2BR.%26aulast%3DMwapasa%26aufirst%3DV.%26aulast%3DNoedl%26aufirst%3DH.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DIyer%26aufirst%3DS.%2BS.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DSaha%26aufirst%3DN.%26aulast%3DJalali%26aufirst%3DR.%2BK.%26aulast%3DTiacoh%26aufirst%3DL.%26aulast%3DEnosse%26aufirst%3DS.%26aulast%3DTangpukdee%26aufirst%3DN.%26aulast%3DKokolomami%26aufirst%3DJ.%26aulast%3DNdiaye%26aufirst%3DJ.%2BL.%26aulast%3DRao%26aufirst%3DD.%26aulast%3DYumva%26aufirst%3DN.%2BN.%26aulast%3DSidibe%26aufirst%3DB.%26aulast%3DMohanty%26aufirst%3DR.%26aulast%3DJha%26aufirst%3DA.%2BC.%26aulast%3DNyirenda%26aufirst%3DM.%26aulast%3DStarzengruber%26aufirst%3DP.%26aulast%3DSwoboda%26aufirst%3DP.%26atitle%3DA%2520phase%25203%252C%2520double-blind%252C%2520randomized%2520study%2520of%2520arterolane%2520maleate-piperaquine%2520phosphate%2520vs%2520artemether-lumefantrine%2520for%2520falciparum%2520malaria%2520in%2520adolescent%2520and%2520adult%2520patients%2520in%2520Asia%2520and%2520Africa%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D62%26spage%3D964%26epage%3D971%26doi%3D10.1093%2Fcid%2Fciw029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbe-Barnes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chollet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matile, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papastogiannidis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriraghavan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stingelin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urwyler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vennerstrom, J. L.</span></span> <span> </span><span class="NLM_article-title">Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4400</span>– <span class="NLM_lpage">4405</span>, <span class="refDoi"> DOI: 10.1073/pnas.1015762108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.1015762108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21300861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvV2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=4400-4405&issue=11&author=S.+A.+Charmanauthor=S.+Arbe-Barnesauthor=I.+C.+Bathurstauthor=R.+Brunauthor=M.+Campbellauthor=W.+N.+Charmanauthor=F.+C.+K.+Chiuauthor=J.+Cholletauthor=J.+C.+Craftauthor=D.+J.+Creekauthor=Y.+Dongauthor=H.+Matileauthor=M.+Maurerauthor=J.+Morizziauthor=T.+Nguyenauthor=P.+Papastogiannidisauthor=C.+Scheurerauthor=D.+M.+Shacklefordauthor=K.+Sriraghavanauthor=L.+Stingelinauthor=Y.+Tangauthor=H.+Urwylerauthor=X.+Wangauthor=K.+L.+Whiteauthor=S.+Wittlinauthor=L.+Zhouauthor=J.+L.+Vennerstrom&title=Synthetic+ozonide+drug+candidate+OZ439+offers+new+hope+for+a+single-dose+cure+of+uncomplicated+malaria&doi=10.1073%2Fpnas.1015762108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria</span></div><div class="casAuthors">Charman, Susan A.; Arbe-Barnes, Sarah; Bathurst, Ian C.; Brun, Reto; Campbell, Michael; Charman, William N.; Chiu, Francis C. K.; Chollet, Jacques; Craft, J. Carl; Creek, Darren J.; Dong, Yuxiang; Matile, Hugues; Maurer, Melanie; Morizzi, Julia; Nguyen, Tien; Papastogiannidis, Petros; Scheurer, Christian; Shackleford, David M.; Sriraghavan, Kamaraj; Stingelin, Lukas; Tang, Yuanqing; Urwyler, Heinrich; Wang, Xiaofang; White, Karen L.; Wittlin, Sergio; Zhou, Lin; Vennerstrom, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4400-4405, S4400/1-S4400/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans.  OZ439 has successfully completed Phase I clin. trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase Ila trials in malaria patients.  Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clin. drug development candidate.  In vitro, OZ439 is fast-acting against all asexual erythrocytic Plasmodium falciparum stages with ICs0 values comparable to those for the clin. used artemisinin derivs.  Unlike all other synthetic peroxides and semisynthetic artemisinin derivs., OZ439 completely cures Plasmodium berghei-infected mice with a single oral dose of 20 mg/kg and exhibits prophylactic activity superior to that of the benchmark chemoprophylactic agent, mefloquine.  Compared with other peroxide-contg. antimalarial agents, such as the artemisinin derivs. and the first-generation ozonide OZ277, OZ439 exhibits a substantial increase in the pharmacokinetic half-life and blood concn. vs. time profile in three preclin. species.  The outstanding efficacy and prolonged blood concns. of OZ439 are the result of a design strategy that stabilizes the intrinsically unstable pharmacophoric peroxide bond, thereby reducing clearance yet maintaining the necessary Fe(II)-reactivity to elicit parasite death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQxoUteI8z2bVg90H21EOLACvtfcHk0ljOZMh2rPa7cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvV2jtL4%253D&md5=5da13be1d57a8dd58b21246814f6c268</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1015762108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1015762108%26sid%3Dliteratum%253Aachs%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DArbe-Barnes%26aufirst%3DS.%26aulast%3DBathurst%26aufirst%3DI.%2BC.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DChiu%26aufirst%3DF.%2BC.%2BK.%26aulast%3DChollet%26aufirst%3DJ.%26aulast%3DCraft%26aufirst%3DJ.%2BC.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DMatile%26aufirst%3DH.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DPapastogiannidis%26aufirst%3DP.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DSriraghavan%26aufirst%3DK.%26aulast%3DStingelin%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DUrwyler%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DVennerstrom%26aufirst%3DJ.%2BL.%26atitle%3DSynthetic%2520ozonide%2520drug%2520candidate%2520OZ439%2520offers%2520new%2520hope%2520for%2520a%2520single-dose%2520cure%2520of%2520uncomplicated%2520malaria%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D11%26spage%3D4400%26epage%3D4405%26doi%3D10.1073%2Fpnas.1015762108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnädig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium falciparum</i> K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e00172-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.00172-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FmBio.00172-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28400526" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=e00172-17&issue=2&author=J.+Straimerauthor=N.+F.+Gn%C3%A4digauthor=B.+H.+Stokesauthor=M.+Ehrenbergerauthor=A.+A.+Craneauthor=D.+A.+Fidock&title=Plasmodium+falciparum+K13+mutations+differentially+impact+ozonide+susceptibility+and+parasite+fitness+in+vitro&doi=10.1128%2FmBio.00172-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FmBio.00172-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00172-17%26sid%3Dliteratum%253Aachs%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGn%25C3%25A4dig%26aufirst%3DN.%2BF.%26aulast%3DStokes%26aufirst%3DB.%2BH.%26aulast%3DEhrenberger%26aufirst%3DM.%26aulast%3DCrane%26aufirst%3DA.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DPlasmodium%2520falciparum%2520K13%2520mutations%2520differentially%2520impact%2520ozonide%2520susceptibility%2520and%2520parasite%2520fitness%2520in%2520vitro%26jtitle%3DmBio%26date%3D2017%26volume%3D8%26issue%3D2%26spage%3De00172-17%26doi%3D10.1128%2FmBio.00172-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumgärtner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1186/s12936-017-1696-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-017-1696-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28122617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC1c7pt1Gnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=45&author=F.+Baumg%C3%A4rtnerauthor=J.+Jourdanauthor=C.+Scheurerauthor=B.+Blascoauthor=B.+Campoauthor=P.+M%C3%A4serauthor=S.+Wittlin&title=In+vitro+activity+of+anti-malarial+ozonides+against+an+artemisinin-resistant+isolate&doi=10.1186%2Fs12936-017-1696-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate</span></div><div class="casAuthors">Baumgartner Fabian; Jourdan Joelle; Scheurer Christian; Maser Pascal; Wittlin Sergio; Baumgartner Fabian; Jourdan Joelle; Scheurer Christian; Maser Pascal; Wittlin Sergio; Blasco Benjamin; Campo Brice</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recently published data suggest that artemisinin derivatives and synthetic peroxides, such as the ozonides OZ277 and OZ439, have a similar mode of action.  Here the cross-resistance of OZ277 and OZ439 and four additional next-generation ozonides was probed against the artemisinin-resistant clinical isolate Plasmodium falciparum Cam3.I, which carries the K13-propeller mutation R539T (Cam3.I(R539T)).  METHODS:  The previously described in vitro ring-stage survival assay (RSA0-3h) was employed and a simplified variation of the original protocol was developed.  RESULTS:  At the pharmacologically relevant concentration of 700 nM, all six ozonides were highly effective against the dihydroartemisinin-resistant P. falciparum Cam3.I(R539T) parasites, showing a per cent survival ranging from <0.01 to 1.83%.  A simplified version of the original RSA0-3h method was developed and gave similar results, thus providing a practical drug discovery tool for further optimization of next-generation anti-malarial peroxides.  CONCLUSION:  The absence of in vitro cross-resistance against the artemisinin-resistant clinical isolate Cam3.I(R539T) suggests that ozonides could be effective against artemisinin-resistant P. falciparum.  How this will translate to the human situation in clinical settings remains to be investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT81D1FD4aMH-kdrW1FkXG-fW6udTcc2ea5NZF0qhnHA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7pt1Gnsg%253D%253D&md5=3ef0b5011d7a16980762522cd3f65926</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1186%2Fs12936-017-1696-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-017-1696-0%26sid%3Dliteratum%253Aachs%26aulast%3DBaumg%25C3%25A4rtner%26aufirst%3DF.%26aulast%3DJourdan%26aufirst%3DJ.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DM%25C3%25A4ser%26aufirst%3DP.%26aulast%3DWittlin%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520activity%2520of%2520anti-malarial%2520ozonides%2520against%2520an%2520artemisinin-resistant%2520isolate%26jtitle%3DMalar.%2520J.%26date%3D2017%26volume%3D16%26spage%3D45%26doi%3D10.1186%2Fs12936-017-1696-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannangelo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowkes, F. J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span> <span> </span><span class="NLM_article-title">Ozonide antimalarial activity in the context of artemisinin-resistant malaria</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2019.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.pt.2019.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=31176584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWks73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=529-543&issue=7&author=C.+Giannangeloauthor=F.+J.+I.+Fowkesauthor=J.+A.+Simpsonauthor=S.+A.+Charmanauthor=D.+J.+Creek&title=Ozonide+antimalarial+activity+in+the+context+of+artemisinin-resistant+malaria&doi=10.1016%2Fj.pt.2019.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Ozonide Antimalarial Activity in the Context of Artemisinin-Resistant Malaria</span></div><div class="casAuthors">Giannangelo, Carlo; Fowkes, Freya J. I.; Simpson, Julie A.; Charman, Susan A.; Creek, Darren J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">529-543</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ozonides are one of the most advanced drug classes in the antimalarial development pipeline and were designed to improve on limitations assocd. with current front-line artemisinin-based therapies.  Like the artemisinins, the pharmacophoric peroxide bond of ozonides is essential for activity, and it appears that these antimalarials share a similar mode of action, raising the possibility of cross-resistance.  Resistance to artemisinins is assocd. with Plasmodium falciparum mutations that allow resistant parasites to escape short-term artemisinin-mediated damage (elimination half-life ∼1 h).  Importantly, some ozonides (e.g., OZ439) have a sustained in vivo drug exposure profile, providing a major pharmacokinetic advantage over the artemisinin derivs.  Here, it describe recent progress made towards understanding ozonide antimalarial activity and discuss ozonide utility within the context of artemisinin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhhxuyVZnSNbVg90H21EOLACvtfcHk0ljOZMh2rPa7cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWks73L&md5=3937db84c408934ef27525ca79abde8d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2019.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2019.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGiannangelo%26aufirst%3DC.%26aulast%3DFowkes%26aufirst%3DF.%2BJ.%2BI.%26aulast%3DSimpson%26aufirst%3DJ.%2BA.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26atitle%3DOzonide%2520antimalarial%2520activity%2520in%2520the%2520context%2520of%2520artemisinin-resistant%2520malaria%26jtitle%3DTrends%2520Parasitol.%26date%3D2019%26volume%3D35%26issue%3D7%26spage%3D529%26epage%3D543%26doi%3D10.1016%2Fj.pt.2019.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadatos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puthukkuti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P.</span></span> <span> </span><span class="NLM_article-title">Screening and hit evaluation of a chemical library against blood-stage <i>Plasmodium falciparum</i></span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">190</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-13-190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2F1475-2875-13-190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24886460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=190&issue=1&author=V.+M.+Averyauthor=S.+Bashyamauthor=J.+N.+Burrowsauthor=S.+Duffyauthor=G.+Papadatosauthor=S.+Puthukkutiauthor=Y.+Sambandanauthor=S.+Singhauthor=T.+Spangenbergauthor=D.+Watersonauthor=P.+Willis&title=Screening+and+hit+evaluation+of+a+chemical+library+against+blood-stage+Plasmodium+falciparum&doi=10.1186%2F1475-2875-13-190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum</span></div><div class="casAuthors">Avery, Vicky M.; Bashyam, Sridevi; Burrows, Jeremy N.; Duffy, Sandra; Papadatos, George; Puthukkuti, Shyni; Sambandan, Yuvaraj; Singh, Shivendra; Spangenberg, Thomas; Waterson, David; Willis, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190/1-190/26, 26</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background In view of the need to continuously feed the pipeline with new anti-malarial agents adapted to differentiated and more stringent target product profiles (e g, new modes of action, transmission-blocking activity or long-duration chemo-protection), a chem. library consisting of more than 250,000 compds. has been evaluated in a blood-stage Plasmodium falciparum growth inhibition assay and further assessed for chem. diversity and novelty.  Methods The selection cascade used for the triaging of hits from the chem. library started with a robust three-step in vitro assay followed by an in silico anal. of the resulting confirmed hits.  Upon reaching the predefined requirements for selectivity and potency, the set of hits was subjected to computational anal. to assess chem. properties and diversity.  Furthermore, known marketed anti-malarial drugs were co-clustered acting as 'signposts' in the chem. space defined by the hits.  Then, in cerebro evaluation of the chem. structures was performed to identify scaffolds that currently are or have been the focus of anti-malarial medicinal chem. programs.  Next, prioritization according to relaxed physicochem. parameters took place, along with the search for structural analogs.  Ultimately, synthesis of novel chemotypes with desired properties was performed and the resulting compds. were subsequently retested in a P. falciparum growth inhibition assay.  Results This screening campaign led to a 1.25% primary hit rate, which decreased to 0.77% upon confirmatory repeat screening.  With the predefined potency (EC50 < 1 μM) and selectivity (SI > 10) criteria, 178 compds. progressed to the next steps where chem. diversity, physicochem. properties and novelty assessment were taken into account.  This resulted in the selection of 15 distinct chem. series.  Conclusion A selection cascade was applied to prioritize hits resulting from the screening of a medium-sized chem. library against blood-stage P. falciparum.  Emphasis was placed on chem. novelty whereby computational clustering, data mining of known anti-malarial chemotypes and the application of relaxed physicochem. filters, were key to the process.  This led to the selection of 15 chem. series from which ten confirmed their activity when newly synthesized sample were tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotiUY-7lEbpLVg90H21EOLACvtfcHk0ljiYZQmRfFFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gs7zK&md5=7649bdd8a2aa1c7ec76ad920ba72b949</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-13-190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-13-190%26sid%3Dliteratum%253Aachs%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DPapadatos%26aufirst%3DG.%26aulast%3DPuthukkuti%26aufirst%3DS.%26aulast%3DSambandan%26aufirst%3DY.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DSpangenberg%26aufirst%3DT.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWillis%26aufirst%3DP.%26atitle%3DScreening%2520and%2520hit%2520evaluation%2520of%2520a%2520chemical%2520library%2520against%2520blood-stage%2520Plasmodium%2520falciparum%26jtitle%3DMalar.%2520J.%26date%3D2014%26volume%3D13%26issue%3D1%26spage%3D190%26doi%3D10.1186%2F1475-2875-13-190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A clinical drug library screen identifies astemizole as an antimalarial agent</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1038/nchembio806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnchembio806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16816845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=415-416&issue=8&author=C.+R.+Chongauthor=X.+Chenauthor=L.+Shiauthor=J.+O.+Liuauthor=D.+J.+Sullivan&title=A+clinical+drug+library+screen+identifies+astemizole+as+an+antimalarial+agent&doi=10.1038%2Fnchembio806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical drug library screen identifies astemizole as an antimalarial agent</span></div><div class="casAuthors">Chong, Curtis R.; Chen, Xiaochun; Shi, Lirong; Liu, Jun O.; Sullivan, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">415-416</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The high cost and protracted time line of new drug discovery are major roadblocks to creating therapies for neglected diseases.  To accelerate drug discovery the authors created a library of 2687 existing drugs and screened for inhibitors of the human malaria parasite Plasmodium falciparum.  The antihistamine astemizole and its principal human metabolite are promising new inhibitors of chloroquine-sensitive and multidrug-resistant parasites, and they show efficacy in two mouse models of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7g4KV9AfkZrVg90H21EOLACvtfcHk0ljiYZQmRfFFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFyqsrs%253D&md5=85212419b5102292f830cc32f551f385</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnchembio806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio806%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DSullivan%26aufirst%3DD.%2BJ.%26atitle%3DA%2520clinical%2520drug%2520library%2520screen%2520identifies%2520astemizole%2520as%2520an%2520antimalarial%2520agent%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D8%26spage%3D415%26epage%3D416%26doi%3D10.1038%2Fnchembio806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coteron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors with clinical candidate potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5540</span>– <span class="NLM_lpage">5561</span>, <span class="refDoi"> DOI: 10.1021/jm200592f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200592f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5540-5561&issue=15&author=J.+M.+Coteronauthor=M.+Marcoauthor=J.+Esquiviasauthor=X.+Dengauthor=K.+L.+Whiteauthor=J.+Whiteauthor=M.+Koltunauthor=F.+El+Mazouniauthor=S.+Kokkondaauthor=K.+Katneniauthor=R.+Bhamidipatiauthor=D.+M.+Shacklefordauthor=I.+Angulo-Barturenauthor=S.+B.+Ferrerauthor=M.+B.+Jimenez-Diazauthor=F.+J.+Gamoauthor=E.+J.+Goldsmithauthor=W.+N.+Charmanauthor=I.+Bathurstauthor=D.+Floydauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=P.+K.+Rathodauthor=S.+A.+Charmanauthor=M.+A.+Phillips&title=Structure-guided+lead+optimization+of+triazolopyrimidine-ring+substituents+identifies+potent+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+with+clinical+candidate+potential&doi=10.1021%2Fjm200592f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential</span></div><div class="casAuthors">Coteron, Jose M.; Marco, Maria; Esquivias, Jorge; Deng, Xiaoyi; White, Karen L.; White, John; Koltun, Maria; El Mazouni, Farah; Kokkonda, Sreekanth; Katneni, Kasiram; Bhamidipati, Ravi; Shackleford, David M.; Angulo-Barturen, Inigo; Ferrer, Santiago B.; Jimenez-Diaz, Maria Belen; Gamo, Francisco-Javier; Goldsmith, Elizabeth J.; Charman, William N.; Bathurst, Ian; Floyd, David; Matthews, David; Burrows, Jeremy N.; Rathod, Pradipsinh K.; Charman, Susan A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5540-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance.  In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.  The X-ray structure of PfDHODH was used to inform the medicinal chem. program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite.  This compd. has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance.  These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compd. toward clin. candidate status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpPPR2Tcs9rVg90H21EOLACvtfcHk0lhDD_PJu-ALBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVehsbg%253D&md5=d92f71aeda04fbbbbcd8905a657df011</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm200592f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200592f%26sid%3Dliteratum%253Aachs%26aulast%3DCoteron%26aufirst%3DJ.%2BM.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKoltun%26aufirst%3DM.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DBhamidipati%26aufirst%3DR.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%2BB.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DE.%2BJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DFloyd%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DStructure-guided%2520lead%2520optimization%2520of%2520triazolopyrimidine-ring%2520substituents%2520identifies%2520potent%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520with%2520clinical%2520candidate%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D15%26spage%3D5540%26epage%3D5561%26doi%3D10.1021%2Fjm200592f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span> <span> </span><span class="NLM_article-title">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2012.11-0302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.4269%2Fajtmh.2012.11-0302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22232455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=84-92&issue=1&author=S.+Duffyauthor=V.+M.+Avery&title=Development+and+optimization+of+a+novel+384-well+anti-malarial+imaging+assay+validated+for+high-throughput+screening&doi=10.4269%2Fajtmh.2012.11-0302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span></div><div class="casAuthors">Duffy, Sandra; Avery, Vicky M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">With the increasing occurrence of drug resistance in the malaria parasite, Plasmodium falciparum, there is a great need for new and novel anti-malarial drugs.  We have developed a 384-well, high-throughput imaging assay for the detection of new anti-malarial compds., which was initially validated by screening a marine natural product library, and subsequently used to screen more than 3 million data points from a variety of compd. sources.  Founded on another fluorescence-based P. falciparum growth inhibition assay, the DNA-intercalating dye 4',6-diamidino-2-phenylindole, was used to monitor changes in parasite no.  Fluorescent images were acquired on the PerkinElmer Opera High Throughput confocal imaging system and analyzed with a spot detection algorithm using the Acapella data processing software.  Further optimization of this assay sought to increase throughput, assay stability, and compatibility with our high-throughput screening equipment platforms.  The assay typically yielded Z'-factor values of 0.5-0.6, with signal-to-noise ratios of 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9mpHAvJlL67Vg90H21EOLACvtfcHk0lhDD_PJu-ALBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D&md5=60ae874f46758c03566acfdc948e1188</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2012.11-0302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2012.11-0302%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26atitle%3DDevelopment%2520and%2520optimization%2520of%2520a%2520novel%2520384-well%2520anti-malarial%2520imaging%2520assay%2520validated%2520for%2520high-throughput%2520screening%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2012%26volume%3D86%26issue%3D1%26spage%3D84%26epage%3D92%26doi%3D10.4269%2Fajtmh.2012.11-0302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cozar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peishoff, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span> <span> </span><span class="NLM_article-title">Thousands of chemical starting points for antimalarial lead identification</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">305</span>, <span class="refDoi"> DOI: 10.1038/nature09107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature09107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20485427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=305&author=F.-J.+Gamoauthor=L.+M.+Sanzauthor=J.+Vidalauthor=C.+de+Cozarauthor=E.+Alvarezauthor=J.-L.+Lavanderaauthor=D.+E.+Vanderwallauthor=D.+V.+S.+Greenauthor=V.+Kumarauthor=S.+Hasanauthor=J.+R.+Brownauthor=C.+E.+Peishoffauthor=L.+R.+Cardonauthor=J.+F.+Garcia-Bustos&title=Thousands+of+chemical+starting+points+for+antimalarial+lead+identification&doi=10.1038%2Fnature09107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Thousands of chemical starting points for antimalarial lead identification</span></div><div class="casAuthors">Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria is a devastating infection caused by protozoa of the genus Plasmodium.  Drug resistance is widespread, no new chem. class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs.  We screened nearly 2 million compds. in GlaxoSmithKline's chem. library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 μM concn.  More than 8,000 also showed potent activity against the multidrug resistant strain Dd2.  Most (82%) compds. originate from internal company projects and are new to the malaria community.  Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets.  Chem. structures and assocd. data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHijpWK_kBF7Vg90H21EOLACvtfcHk0lhDD_PJu-ALBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D&md5=a1fd8c0b89a5650ecba31f5456928b42</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature09107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09107%26sid%3Dliteratum%253Aachs%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DVidal%26aufirst%3DJ.%26aulast%3Dde%2BCozar%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DLavandera%26aufirst%3DJ.-L.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHasan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26atitle%3DThousands%2520of%2520chemical%2520starting%2520points%2520for%2520antimalarial%2520lead%2520identification%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D305%26doi%3D10.1038%2Fnature09107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guiguemde, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharlow, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowble, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forquer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinley, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derisi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riscoe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span> <span> </span><span class="NLM_article-title">Chemical genetics of Plasmodium falciparum</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nature09099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature09099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20485428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1OjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=311-315&author=W.+A.+Guiguemdeauthor=A.+A.+Shelatauthor=D.+Bouckauthor=S.+Duffyauthor=G.+J.+Crowtherauthor=P.+H.+Davisauthor=D.+C.+Smithsonauthor=M.+Connellyauthor=J.+Clarkauthor=F.+Zhuauthor=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=M.+S.+Martinezauthor=E.+B.+Wilsonauthor=A.+K.+Tripathiauthor=J.+Gutauthor=E.+R.+Sharlowauthor=I.+Bathurstauthor=F.+El+Mazouniauthor=J.+W.+Fowbleauthor=I.+Forquerauthor=P.+L.+McGinleyauthor=S.+Castroauthor=I.+Angulo-Barturenauthor=S.+Ferrerauthor=P.+J.+Rosenthalauthor=J.+L.+Derisiauthor=D.+J.+Sullivanauthor=J.+S.+Lazoauthor=D.+S.+Roosauthor=M.+K.+Riscoeauthor=M.+A.+Phillipsauthor=P.+K.+Rathodauthor=W.+C.+Van+Voorhisauthor=V.+M.+Averyauthor=R.+K.+Guy&title=Chemical+genetics+of+Plasmodium+falciparum&doi=10.1038%2Fnature09099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics of Plasmodium falciparum</span></div><div class="casAuthors">Guiguemde, W. Armand; Shelat, Anang A.; Bouck, David; Duffy, Sandra; Crowther, Gregory J.; Davis, Paul H.; Smithson, David C.; Connelly, Michele; Clark, Julie; Zhu, Fangyi; Jimenez-Diaz, Maria B.; Martinez, Maria S.; Wilson, Emily B.; Tripathi, Abhai K.; Gut, Jiri; Sharlow, Elizabeth R.; Bathurst, Ian; El Mazouni, Farah; Fowble, Joseph W.; Forquer, Isaac; McGinley, Paula L.; Castro, Steve; Angulo-Barturen, Inigo; Ferrer, Santiago; Rosenthal, Philip J.; De Risi, Joseph L.; Sullivan, David J., Jr.; Lazo, John S.; Roos, David S.; Riscoe, Michael K.; Phillips, Margaret A.; Rathod, Pradipsinh K.; Van Voorhis, Wesley C.; Avery, Vicky M.; Guy, R. Kiplin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">311-315</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000 deaths per yr worldwide.  Vaccine development has proved difficult and resistance has emerged for most antimalarial drugs.  To discover new antimalarial chemotypes, we have used a phenotypic forward chem. genetic approach to assay 309,474 chems.  Here we disclose structures and biol. activity of the entire library-many of which showed potent in vitro activity against drug-resistant P. falciparum strains-and detailed profiling of 172 representative candidates.  A reverse chem. genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins.  Phylochemogenetic profiling in several organisms revealed similarities between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum and related protozoans.  One exemplar compd. displayed efficacy in a murine model.  Our findings provide the scientific community with new starting points for malaria drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC5VVynAR2NLVg90H21EOLACvtfcHk0lj84PkkzSSF8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1OjtL4%253D&md5=b1b838f5e43adeb4de019c3e41c33017</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature09099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09099%26sid%3Dliteratum%253Aachs%26aulast%3DGuiguemde%26aufirst%3DW.%2BA.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DBouck%26aufirst%3DD.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DDavis%26aufirst%3DP.%2BH.%26aulast%3DSmithson%26aufirst%3DD.%2BC.%26aulast%3DConnelly%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DWilson%26aufirst%3DE.%2BB.%26aulast%3DTripathi%26aufirst%3DA.%2BK.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DSharlow%26aufirst%3DE.%2BR.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DFowble%26aufirst%3DJ.%2BW.%26aulast%3DForquer%26aufirst%3DI.%26aulast%3DMcGinley%26aufirst%3DP.%2BL.%26aulast%3DCastro%26aufirst%3DS.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DDerisi%26aufirst%3DJ.%2BL.%26aulast%3DSullivan%26aufirst%3DD.%2BJ.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DRoos%26aufirst%3DD.%2BS.%26aulast%3DRiscoe%26aufirst%3DM.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3DChemical%2520genetics%2520of%2520Plasmodium%2520falciparum%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D311%26epage%3D315%26doi%3D10.1038%2Fnature09099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidebrecht, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulrooney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandapani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekland, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcaurelle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span> <span> </span><span class="NLM_article-title">Diversity-oriented synthesis yields a novel lead for the treatment of malaria</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1021/ml200244k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200244k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=112-117&issue=2&author=R.+W.+Heidebrechtauthor=C.+Mulrooneyauthor=C.+P.+Austinauthor=R.+H.+Barkerauthor=J.+A.+Beaudoinauthor=K.+C.-C.+Chengauthor=E.+Comerauthor=S.+Dandapaniauthor=J.+Dickauthor=J.+R.+Duvallauthor=E.+H.+Eklandauthor=D.+A.+Fidockauthor=M.+E.+Fitzgeraldauthor=M.+Foleyauthor=R.+Guhaauthor=P.+Hinksonauthor=M.+Kramerauthor=A.+K.+Lukensauthor=D.+Masiauthor=L.+A.+Marcaurelleauthor=X.-Z.+Suauthor=C.+J.+Thomasauthor=M.+We%C3%AFwerauthor=R.+C.+Wiegandauthor=D.+Wirthauthor=M.+Xiaauthor=J.+Yuanauthor=J.+Zhaoauthor=M.+Palmerauthor=B.+Munozauthor=S.+Schreiber&title=Diversity-oriented+synthesis+yields+a+novel+lead+for+the+treatment+of+malaria&doi=10.1021%2Fml200244k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria</span></div><div class="casAuthors">Heidebrecht, Richard W., Jr.; Mulrooney, Carol; Austin, Christopher P.; Barker, Robert H., Jr.; Beaudoin, Jennifer A.; Cheng, Ken Chih-Chien; Comer, Eamon; Dandapani, Sivaraman; Dick, Justin; Duvall, Jeremy R.; Ekland, Eric H.; Fidock, David A.; Fitzgerald, Mark E.; Foley, Michael; Guha, Rajarshi; Hinkson, Paul; Kramer, Martin; Lukens, Amanda K.; Masi, Daniela; Marcaurelle, Lisa A.; Su, Xin-Zhuan; Thomas, Craig J.; Weiwer, Michel; Wiegand, Roger C.; Wirth, Dyann; Xia, Menghang; Yuan, Jing; Zhao, Jinghua; Palmer, Michelle; Munoz, Benito; Schreiber, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-117</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, the discovery of a novel antimalarial agent using phenotypic screening of Plasmodium falciparum asexual blood-stage parasites is described.  Screening a novel compd. collection created using diversity-oriented synthesis (DOS) led to the initial hit.  Structure-activity relationships guided the synthesis of compds. having improved potency and water soly., yielding a subnanomolar inhibitor of parasite asexual blood-stage growth.  Optimized compd. I has an excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable in human plasma.  This compd. is available via the mol. libraries probe prodn. centers network (MLPCN) and is designated ML238.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7VDOEDURT07Vg90H21EOLACvtfcHk0lj84PkkzSSF8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLbP&md5=543bf89bfbc03ef58ef4379718f1b0e1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml200244k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200244k%26sid%3Dliteratum%253Aachs%26aulast%3DHeidebrecht%26aufirst%3DR.%2BW.%26aulast%3DMulrooney%26aufirst%3DC.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DBarker%26aufirst%3DR.%2BH.%26aulast%3DBeaudoin%26aufirst%3DJ.%2BA.%26aulast%3DCheng%26aufirst%3DK.%2BC.-C.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DDandapani%26aufirst%3DS.%26aulast%3DDick%26aufirst%3DJ.%26aulast%3DDuvall%26aufirst%3DJ.%2BR.%26aulast%3DEkland%26aufirst%3DE.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DFitzgerald%26aufirst%3DM.%2BE.%26aulast%3DFoley%26aufirst%3DM.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DHinkson%26aufirst%3DP.%26aulast%3DKramer%26aufirst%3DM.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DMasi%26aufirst%3DD.%26aulast%3DMarcaurelle%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DX.-Z.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DWiegand%26aufirst%3DR.%2BC.%26aulast%3DWirth%26aufirst%3DD.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DSchreiber%26aufirst%3DS.%26atitle%3DDiversity-oriented%2520synthesis%2520yields%2520a%2520novel%2520lead%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D2%26spage%3D112%26epage%3D117%26doi%3D10.1021%2Fml200244k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maetani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancucci, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derbyshire, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dornan, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoe, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibalan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitasev, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gessel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catteruccia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusovsky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neafsey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Diversity-oriented synthesis yields novel multistage antimalarial inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>538</i></span> (<span class="NLM_issue">7625</span>),  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1038/nature19804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature19804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27602946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=538&publication_year=2016&pages=344-349&issue=7625&author=N.+Katoauthor=E.+Comerauthor=T.+Sakata-Katoauthor=A.+Sharmaauthor=M.+Sharmaauthor=M.+Maetaniauthor=J.+Bastienauthor=N.+M.+Brancucciauthor=J.+A.+Bittkerauthor=V.+Coreyauthor=D.+Clarkeauthor=E.+R.+Derbyshireauthor=G.+L.+Dornanauthor=S.+Duffyauthor=S.+Eckleyauthor=M.+A.+Itoeauthor=K.+M.+Koolenauthor=T.+A.+Lewisauthor=P.+S.+Luiauthor=A.+K.+Lukensauthor=E.+Lundauthor=S.+Marchauthor=E.+Meibalanauthor=B.+C.+Meierauthor=J.+A.+McPhailauthor=B.+Mitasevauthor=E.+L.+Mossauthor=M.+Sayesauthor=Y.+Van+Gesselauthor=M.+J.+Wawerauthor=T.+Yoshinagaauthor=A.+M.+Zeemanauthor=V.+M.+Averyauthor=S.+N.+Bhatiaauthor=J.+E.+Burkeauthor=F.+Catterucciaauthor=J.+C.+Clardyauthor=P.+A.+Clemonsauthor=K.+J.+Decheringauthor=J.+R.+Duvallauthor=M.+A.+Foleyauthor=F.+Gusovskyauthor=C.+H.+Kockenauthor=M.+Martiauthor=M.+L.+Morningstarauthor=B.+Munozauthor=D.+E.+Neafseyauthor=A.+Sharmaauthor=E.+A.+Winzelerauthor=D.+F.+Wirthauthor=C.+A.+Schererauthor=S.+L.+Schreiber&title=Diversity-oriented+synthesis+yields+novel+multistage+antimalarial+inhibitors&doi=10.1038%2Fnature19804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-oriented synthesis yields novel multistage antimalarial inhibitors</span></div><div class="casAuthors">Kato, Nobutaka; Comer, Eamon; Sakata-Kato, Tomoyo; Sharma, Arvind; Sharma, Manmohan; Maetani, Micah; Bastien, Jessica; Brancucci, Nicolas M.; Bittker, Joshua A.; Corey, Victoria; Clarke, David; Derbyshire, Emily R.; Dornan, Gillian L.; Duffy, Sandra; Eckley, Sean; Itoe, Maurice A.; Koolen, Karin M. J.; Lewis, Timothy A.; Lui, Ping S.; Lukens, Amanda K.; Lund, Emily; March, Sandra; Meibalan, Elamaran; Meier, Bennett C.; McPhail, Jacob A.; Mitasev, Branko; Moss, Eli L.; Sayes, Morgane; Van Gessel, Yvonne; Wawer, Mathias J.; Yoshinaga, Takashi; Zeeman, Anne-Marie; Avery, Vicky M.; Bhatia, Sangeeta N.; Burke, John E.; Catteruccia, Flaminia; Clardy, Jon C.; Clemons, Paul A.; Dechering, Koen J.; Duvall, Jeremy R.; Foley, Michael A.; Gusovsky, Fabian; Kocken, Clemens H. M.; Marti, Matthias; Morningstar, Marshall L.; Munoz, Benito; Neafsey, Daniel E.; Sharma, Amit; Winzeler, Elizabeth A.; Wirth, Dyann F.; Scherer, Christina A.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">538</span>
        (<span class="NLM_cas:issue">7625</span>),
    <span class="NLM_cas:pages">344-349</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compds.  Here the authors investigate whether antimalarial agents with novel mechanisms of action could be discovered using a diverse collection of synthetic compds. that have three-dimensional features reminiscent of natural products and are underrepresented in typical screening collections.  The authors report the identification of such compds. with both previously reported and undescribed mechanisms of action, including a series of bicyclic azetidines that inhibit a new antimalarial target, phenylalanyl-tRNA synthetase.  These mols. are curative in mice at a single, low dose and show activity against all parasite life stages in multiple in vivo efficacy models.  The authors' findings identify bicyclic azetidines with the potential to both cure and prevent transmission of the disease as well as protect at-risk populations with a single oral dose, highlighting the strength of diversity-oriented synthesis in revealing promising therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9CdwKMqzmhLVg90H21EOLACvtfcHk0lintjlnkaKeGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWhsLrI&md5=68e6e2018f2d49278d255ee02bfc8d16</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature19804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19804%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DN.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DMaetani%26aufirst%3DM.%26aulast%3DBastien%26aufirst%3DJ.%26aulast%3DBrancucci%26aufirst%3DN.%2BM.%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DD.%26aulast%3DDerbyshire%26aufirst%3DE.%2BR.%26aulast%3DDornan%26aufirst%3DG.%2BL.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DEckley%26aufirst%3DS.%26aulast%3DItoe%26aufirst%3DM.%2BA.%26aulast%3DKoolen%26aufirst%3DK.%2BM.%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DLui%26aufirst%3DP.%2BS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DLund%26aufirst%3DE.%26aulast%3DMarch%26aufirst%3DS.%26aulast%3DMeibalan%26aufirst%3DE.%26aulast%3DMeier%26aufirst%3DB.%2BC.%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DMitasev%26aufirst%3DB.%26aulast%3DMoss%26aufirst%3DE.%2BL.%26aulast%3DSayes%26aufirst%3DM.%26aulast%3DVan%2BGessel%26aufirst%3DY.%26aulast%3DWawer%26aufirst%3DM.%2BJ.%26aulast%3DYoshinaga%26aufirst%3DT.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DCatteruccia%26aufirst%3DF.%26aulast%3DClardy%26aufirst%3DJ.%2BC.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DDuvall%26aufirst%3DJ.%2BR.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DGusovsky%26aufirst%3DF.%26aulast%3DKocken%26aufirst%3DC.%2BH.%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMorningstar%26aufirst%3DM.%2BL.%26aulast%3DMunoz%26aufirst%3DB.%26aulast%3DNeafsey%26aufirst%3DD.%2BE.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DScherer%26aufirst%3DC.%2BA.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DDiversity-oriented%2520synthesis%2520yields%2520novel%2520multistage%2520antimalarial%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D538%26issue%3D7625%26spage%3D344%26epage%3D349%26doi%3D10.1038%2Fnature19804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trager, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">9059</span>– <span class="NLM_lpage">9064</span>, <span class="refDoi"> DOI: 10.1073/pnas.0802982105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.0802982105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18579783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=9059-9064&issue=26&author=D.+Plouffeauthor=A.+Brinkerauthor=C.+McNamaraauthor=K.+Hensonauthor=N.+Katoauthor=K.+Kuhenauthor=A.+Nagleauthor=F.+Adrianauthor=J.+T.+Matzenauthor=P.+Andersonauthor=T.+G.+Namauthor=N.+S.+Grayauthor=A.+Chatterjeeauthor=J.+Janesauthor=S.+F.+Yanauthor=R.+Tragerauthor=J.+S.+Caldwellauthor=P.+G.+Schultzauthor=Y.+Zhouauthor=E.+A.+Winzeler&title=In+silico+activity+profiling+reveals+the+mechanism+of+action+of+antimalarials+discovered+in+a+high-throughput+screen&doi=10.1073%2Fpnas.0802982105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen</span></div><div class="casAuthors">Plouffe, David; Brinker, Achim; McNamara, Case; Henson, Kerstin; Kato, Nobutaka; Kuhen, Kelli; Nagle, Advait; Adrian, Francisco; Matzen, Jason T.; Anderson, Paul; Nam, Tae-gyu; Gray, Nathanael S.; Chatterjee, Arnab; Janes, Jeff; Yan, S. Frank; Trager, Richard; Caldwell, Jeremy S.; Schultz, Peter G.; Zhou, Yingyao; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9059-9064</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The growing resistance to current first-line antimalarial drugs represents a major health challenge.  To facilitate the discovery of new antimalarials, we have implemented an efficient and robust high-throughput cell-based screen (1,536-well format) based on proliferation of Plasmodium falciparum (Pf) in erythrocytes.  From a screen of ≈ 1.7 million compds., we identified a diverse collection of ≈ 6,000 small mols. comprised of > 530 distinct scaffolds, all of which show potent antimalarial activity (< 1.25 μM).  Most known antimalarials were identified in this screen, thus validating our approach.  In addn., we identified many novel chem. scaffolds, which likely act through both known and novel pathways.  We further show that in some cases the mechanism of action of these antimalarials can be detd. by in silico compd. activity profiling.  This method uses large datasets from unrelated cellular and biochem. screens and the guilt-by-assocn. principle to predict which cellular pathway and/or protein target is being inhibited by select compds.  In addn., the screening method has the potential to provide the malaria community with many new starting points for the development of biol. probes and drugs with novel antiparasitic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL9PFy0SUhdbVg90H21EOLACvtfcHk0lintjlnkaKeGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCiurw%253D&md5=bf14f093078c982e3604089588827166</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802982105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802982105%26sid%3Dliteratum%253Aachs%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DBrinker%26aufirst%3DA.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DHenson%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DAnderson%26aufirst%3DP.%26aulast%3DNam%26aufirst%3DT.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DTrager%26aufirst%3DR.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DIn%2520silico%2520activity%2520profiling%2520reveals%2520the%2520mechanism%2520of%2520action%2520of%2520antimalarials%2520discovered%2520in%2520a%2520high-throughput%2520screen%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D26%26spage%3D9059%26epage%3D9064%26doi%3D10.1073%2Fpnas.0802982105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiplin, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRisi, J. L.</span></span> <span> </span><span class="NLM_article-title">Searching for new antimalarial therapeutics amongst known drugs</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2006.00391.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1111%2Fj.1747-0285.2006.00391.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16882315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=409-416&author=J.+L.+Weismanauthor=A.+P.+Liouauthor=A.+A.+Shelatauthor=F.+E.+Cohenauthor=R.+G.+Kiplinauthor=J.+L.+DeRisi&title=Searching+for+new+antimalarial+therapeutics+amongst+known+drugs&doi=10.1111%2Fj.1747-0285.2006.00391.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Searching for new antimalarial therapeutics amongst known drugs</span></div><div class="casAuthors">Weisman, Jennifer L.; Liou, Ally P.; Shelat, Anang A.; Cohen, Fred E.; Guy, R. Kiplin; DeRisi, Joseph L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">409-416</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The need to discover and develop new antimalarial therapeutics is overwhelming.  The annual mortality attributed to malaria, currently approx. 2.5 million, is increasing due primarily to widespread resistance to currently used drugs.  One strategy to identify new treatment alternatives for malaria is to examine libraries of diverse compds. for the possible identification of novel scaffolds.  Beginning with libraries of drug or drug-like compds. is an ideal starting point because, in the case of approved drugs, substantial pharmacokinetic and toxicol. data should be available for each compd. series.  The authors have employed a highthroughput screen of the MicroSource Spectrum and Killer Collections, a library of known drugs, bioactive compds., and natural products.  Our screening assay identifies compds. that inhibit growth of Plasmodium falciparum cultured in human erythrocytes.  The authors have identified 36 novel inhibitors of P. falciparum, of which 19 are therapeutics, and five of these drugs exhibit effective 50% inhibitory concns. within similar ranges to therapeutic serum concns. for their recently indicated uses: propafenone, thioridazine, chlorprothixene, perhexiline, and azlocillin.  The findings the authors report here indicate that this is an effective strategy to identify novel scaffolds and therefore aid in antimalarial drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMk7-TJgPPKrVg90H21EOLACvtfcHk0ljaeF8cHmYJmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVKrtbg%253D&md5=594c50ba27e74542137496a542b1bba9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2006.00391.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2006.00391.x%26sid%3Dliteratum%253Aachs%26aulast%3DWeisman%26aufirst%3DJ.%2BL.%26aulast%3DLiou%26aufirst%3DA.%2BP.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DF.%2BE.%26aulast%3DKiplin%26aufirst%3DR.%2BG.%26aulast%3DDeRisi%26aufirst%3DJ.%2BL.%26atitle%3DSearching%2520for%2520new%2520antimalarial%2520therapeutics%2520amongst%2520known%2520drugs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D409%26epage%3D416%26doi%3D10.1111%2Fj.1747-0285.2006.00391.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaradilokrat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellems, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. Z.</span></span> <span> </span><span class="NLM_article-title">Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>333</i></span> (<span class="NLM_issue">6043</span>),  <span class="NLM_fpage">724</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1126/science.1205216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1205216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21817045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1SgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2011&pages=724-729&issue=6043&author=J.+Yuanauthor=K.+C.+Chengauthor=R.+L.+Johnsonauthor=R.+Huangauthor=S.+Pattaradilokratauthor=A.+Liuauthor=R.+Guhaauthor=D.+A.+Fidockauthor=J.+Ingleseauthor=T.+E.+Wellemsauthor=C.+P.+Austinauthor=X.+Z.+Su&title=Chemical+genomic+profiling+for+antimalarial+therapies%2C+response+signatures%2C+and+molecular+targets&doi=10.1126%2Fscience.1205216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets</span></div><div class="casAuthors">Yuan, Jing; Cheng, Ken Chih-Chien; Johnson, Ronald L.; Huang, Ruili; Pattaradilokrat, Sittiporn; Liu, Anna; Guha, Rajarshi; Fidock, David A.; Inglese, James; Wellems, Thomas E.; Austin, Christopher P.; Su, Xin-zhuan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">6043</span>),
    <span class="NLM_cas:pages">724-729</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Malaria remains a devastating disease largely because of widespread drug resistance.  New drugs and a better understanding of the mechanisms of drug action and resistance are essential for fulfilling the promise of eradicating malaria.  Using high-throughput chem. screening and genome-wide assocn. anal., we identified 32 highly active compds. and genetic loci assocd. with differential chem. phenotypes (DCPs), defined as greater than or equal to fivefold differences in half-max. inhibitor concn. (IC50) between parasite lines.  Chromosomal loci assocd. with 49 DCPs were confirmed by linkage anal. and tests of genetically modified parasites, including three genes that were linked to 96% of the DCPs.  Drugs whose responses mapped to wild-type or mutant pfcrt alleles were tested in combination in vitro and in vivo, which yielded promising new leads for antimalarial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6k7L-fLswrrVg90H21EOLACvtfcHk0ljaeF8cHmYJmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1SgtbY%253D&md5=e027070abade3470d3630b842a7c9331</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.1205216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1205216%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DJohnson%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DPattaradilokrat%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DWellems%26aufirst%3DT.%2BE.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DSu%26aufirst%3DX.%2BZ.%26atitle%3DChemical%2520genomic%2520profiling%2520for%2520antimalarial%2520therapies%252C%2520response%2520signatures%252C%2520and%2520molecular%2520targets%26jtitle%3DScience%26date%3D2011%26volume%3D333%26issue%3D6043%26spage%3D724%26epage%3D729%26doi%3D10.1126%2Fscience.1205216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luth, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jado, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaumeau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eribez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambachew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouillier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Open-source discovery of chemical leads for next-generation chemoprotective antimalarials</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span> (<span class="NLM_issue">6419</span>),  <span class="NLM_fpage">eaat9446</span>, <span class="refDoi"> DOI: 10.1126/science.aat9446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.aat9446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30523084" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&pages=eaat9446&issue=6419&author=Y.+Antonova-Kochauthor=S.+Meisterauthor=M.+Abrahamauthor=M.+R.+Luthauthor=S.+Ottilieauthor=A.+K.+Lukensauthor=T.+Sakata-Katoauthor=M.+Vanaerschotauthor=E.+Owenauthor=J.+C.+Jadoauthor=S.+P.+Maherauthor=J.+Callaauthor=D.+Plouffeauthor=Y.+Zhongauthor=K.+Chenauthor=V.+Chaumeauauthor=A.+J.+Conwayauthor=C.+W.+McNamaraauthor=M.+Ibanezauthor=K.+Gagaringauthor=F.+N.+Serranoauthor=K.+Eribezauthor=C.+M.+Taggardauthor=A.+L.+Cheungauthor=C.+Lincolnauthor=B.+Ambachewauthor=M.+Rouillierauthor=D.+Siegelauthor=F.+Nostenauthor=D.+E.+Kyleauthor=F.+J.+Gamoauthor=Y.+Zhouauthor=M.+Llinasauthor=D.+A.+Fidockauthor=D.+F.+Wirthauthor=J.+Burrowsauthor=B.+Campoauthor=E.+A.+Winzeler&title=Open-source+discovery+of+chemical+leads+for+next-generation+chemoprotective+antimalarials&doi=10.1126%2Fscience.aat9446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat9446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat9446%26sid%3Dliteratum%253Aachs%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLuth%26aufirst%3DM.%2BR.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DE.%26aulast%3DJado%26aufirst%3DJ.%2BC.%26aulast%3DMaher%26aufirst%3DS.%2BP.%26aulast%3DCalla%26aufirst%3DJ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChaumeau%26aufirst%3DV.%26aulast%3DConway%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DSerrano%26aufirst%3DF.%2BN.%26aulast%3DEribez%26aufirst%3DK.%26aulast%3DTaggard%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DA.%2BL.%26aulast%3DLincoln%26aufirst%3DC.%26aulast%3DAmbachew%26aufirst%3DB.%26aulast%3DRouillier%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DOpen-source%2520discovery%2520of%2520chemical%2520leads%2520for%2520next-generation%2520chemoprotective%2520antimalarials%26jtitle%3DScience%26date%3D2018%26volume%3D362%26issue%3D6419%26spage%3Deaat9446%26doi%3D10.1126%2Fscience.aat9446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Blanco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straschil, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueda-Zubiaurre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, J.</span></span> <span> </span><span class="NLM_article-title">A high throughput screen for next-generation leads targeting malaria parasite transmission</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3805</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-05777-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fs41467-018-05777-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30228275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BB3czgtFSlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3805&author=M.+J.+Delvesauthor=C.+Miguel-Blancoauthor=H.+Matthewsauthor=I.+Molinaauthor=A.+Rueckerauthor=S.+Yahiyaauthor=U.+Straschilauthor=M.+Abrahamauthor=M.+L.+Le%C3%B3nauthor=O.+J.+Fischerauthor=A.+Rueda-Zubiaurreauthor=J.+R.+Brandtauthor=%C3%81.+Cort%C3%A9sauthor=A.+Barnardauthor=M.+J.+Fuchterauthor=F.+Calder%C3%B3nauthor=E.+A.+Winzelerauthor=R.+E.+Sindenauthor=E.+Herrerosauthor=F.+J.+Gamoauthor=J.+Baum&title=A+high+throughput+screen+for+next-generation+leads+targeting+malaria+parasite+transmission&doi=10.1038%2Fs41467-018-05777-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A high throughput screen for next-generation leads targeting malaria parasite transmission</span></div><div class="casAuthors">Delves Michael J; Miguel-Blanco Celia; Matthews Holly; Ruecker Andrea; Yahiya Sabrina; Straschil Ursula; Sinden Robert E; Baum Jake; Miguel-Blanco Celia; Molina Irene; Leon Maria Luisa; Cortes Alvaro; Calderon Felix; Herreros Esperanza; Gamo Francisco J; Abraham Matthew; Winzeler Elizabeth A; Fischer Oliver J; Rueda-Zubiaurre Ainoa; Brandt Jochen R; Barnard Anna; Fuchter Matthew J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3805</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spread of parasite resistance to artemisinin threatens current frontline antimalarial therapies, highlighting the need for new drugs with alternative modes of action.  Since only 0.2-1% of asexual parasites differentiate into sexual, transmission-competent forms, targeting this natural bottleneck provides a tangible route to interrupt disease transmission and mitigate resistance selection.  Here we present a high-throughput screen of gametogenesis against a ~70,000 compound diversity library, identifying seventeen drug-like molecules that target transmission.  Hit molecules possess varied activity profiles including male-specific, dual acting male-female and dual-asexual-sexual, with one promising N-((4-hydroxychroman-4-yl)methyl)-sulphonamide scaffold found to have sub-micromolar activity in vitro and in vivo efficacy.  Development of leads with modes of action focussed on the sexual stages of malaria parasite development provide a previously unexplored base from which future therapeutics can be developed, capable of preventing parasite transmission through the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRm0WpjOO-yVDUE-swuRqsHfW6udTcc2ebGH3fcgXYY8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czgtFSlsg%253D%253D&md5=d62b545c247a6ef26d1521aea097d629</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05777-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05777-2%26sid%3Dliteratum%253Aachs%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DMiguel-Blanco%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DH.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DYahiya%26aufirst%3DS.%26aulast%3DStraschil%26aufirst%3DU.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLe%25C3%25B3n%26aufirst%3DM.%2BL.%26aulast%3DFischer%26aufirst%3DO.%2BJ.%26aulast%3DRueda-Zubiaurre%26aufirst%3DA.%26aulast%3DBrandt%26aufirst%3DJ.%2BR.%26aulast%3DCort%25C3%25A9s%26aufirst%3D%25C3%2581.%26aulast%3DBarnard%26aufirst%3DA.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DCalder%25C3%25B3n%26aufirst%3DF.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DSinden%26aufirst%3DR.%2BE.%26aulast%3DHerreros%26aufirst%3DE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DBaum%26aufirst%3DJ.%26atitle%3DA%2520high%2520throughput%2520screen%2520for%2520next-generation%2520leads%2520targeting%2520malaria%2520parasite%2520transmission%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3805%26doi%3D10.1038%2Fs41467-018-05777-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derbyshire, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Liver-stage malaria parasites vulnerable to diverse chemical scaffolds</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8511</span>– <span class="NLM_lpage">8516</span>, <span class="refDoi"> DOI: 10.1073/pnas.1118370109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.1118370109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22586124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=8511-8516&issue=22&author=E.+R.+Derbyshireauthor=M.+Prudencioauthor=M.+M.+Motaauthor=J.+Clardy&title=Liver-stage+malaria+parasites+vulnerable+to+diverse+chemical+scaffolds&doi=10.1073%2Fpnas.1118370109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Liver-stage malaria parasites vulnerable to diverse chemical scaffolds</span></div><div class="casAuthors">Derbyshire, Emily R.; Prudencio, Miguel; Mota, Maria M.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8511-8516, S8511/1-S8511/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human malaria infection begins with a one-time asymptomatic liver stage followed by a cyclic symptomatic blood stage.  All high-throughput malaria drug discovery efforts have focused on the cyclic blood stage, which has limited potential for the prophylaxis, transmission blocking, and eradication efforts that will be needed in the future.  To address these unmet needs, a high-throughput phenotypic liver-stage Plasmodium parasite screen was developed to systematically identify mols. with liver-stage efficacy.  The screen recapitulates liver-stage infection by isolating luciferase-expressing Plasmodium berghei parasites directly from the salivary glands of infected mosquitoes, adding them to confluent human liver cells in 384-well plates, and measuring luciferase activity after a suitable incubation period.  Screening 5,375 known bioactive compds. identified 37 liver-stage malaria inhibitors with diverse modes of action, as shown by inhibition time course expts.  Further anal. of the hits in the Food and Drug Administration-approved drug subset revealed compds. that seem to act specifically on the liver stage of infection, suggesting that this phase of the parasite's life cycle presents a promising area for new drug discovery.  Notably, many active compds. in this screen have mol. structures and putative targets distinctly different from those of known antimalarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKUwSlcR8EYbVg90H21EOLACvtfcHk0ljVR56j0ZX7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslKhtLY%253D&md5=0d0a920537afd794d6c98836c1ded5b4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1118370109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1118370109%26sid%3Dliteratum%253Aachs%26aulast%3DDerbyshire%26aufirst%3DE.%2BR.%26aulast%3DPrudencio%26aufirst%3DM.%26aulast%3DMota%26aufirst%3DM.%2BM.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DLiver-stage%2520malaria%2520parasites%2520vulnerable%2520to%2520diverse%2520chemical%2520scaffolds%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D22%26spage%3D8511%26epage%3D8516%26doi%3D10.1073%2Fpnas.1118370109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bopp, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, T.-g.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">6061</span>),  <span class="NLM_fpage">1372</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1126/science.1211936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1211936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22096101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=1372-1377&issue=6061&author=S.+Meisterauthor=D.+M.+Plouffeauthor=K.+L.+Kuhenauthor=G.+M.+C.+Bonamyauthor=T.+Wuauthor=S.+W.+Barnesauthor=S.+E.+Boppauthor=R.+Borboaauthor=A.+T.+Brightauthor=J.+Cheauthor=S.+Cohenauthor=N.+V.+Dhariaauthor=K.+Gagaringauthor=M.+Gettayacaminauthor=P.+Gordonauthor=T.+Groesslauthor=N.+Katoauthor=M.+C.+S.+Leeauthor=C.+W.+McNamaraauthor=D.+A.+Fidockauthor=A.+Nagleauthor=T.-g.+Namauthor=W.+Richmondauthor=J.+Rolandauthor=M.+Rottmannauthor=B.+Zhouauthor=P.+Froissardauthor=R.+J.+Glynneauthor=D.+Mazierauthor=J.+Sattabongkotauthor=P.+G.+Schultzauthor=T.+Tuntlandauthor=J.+R.+Walkerauthor=Y.+Zhouauthor=A.+Chatterjeeauthor=T.+T.+Diaganaauthor=E.+A.+Winzeler&title=Imaging+of+Plasmodium+liver+stages+to+drive+next-generation+antimalarial+drug+discovery&doi=10.1126%2Fscience.1211936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery</span></div><div class="casAuthors">Meister, Stephan; Plouffe, David M.; Kuhen, Kelli L.; Bonamy, Ghislain M. C.; Wu, Tao; Barnes, S. Whitney; Bopp, Selina E.; Borboa, Rachel; Bright, A. Taylor; Che, Jianwei; Cohen, Steve; Dharia, Neekesh V.; Gagaring, Kerstin; Gettayacamin, Montip; Gordon, Perry; Groessl, Todd; Kato, Nobutaka; Lee, Marcus C. S.; McNamara, Case W.; Fidock, David A.; Nagle, Advait; Nam, Tae-gyu; Richmond, Wendy; Roland, Jason; Rottmann, Matthias; Zhou, Bin; Froissard, Patrick; Glynne, Richard J.; Mazier, Dominique; Sattabongkot, Jetsumon; Schultz, Peter G.; Tuntland, Tove; Walker, John R.; Zhou, Yingyao; Chatterjee, Arnab; Diagana, Thierry T.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6061</span>),
    <span class="NLM_cas:pages">1372-1377</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Most malaria drug development focuses on parasite stages detected in red blood cells, even though, to achieve eradication, next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable.  We applied a multifactorial approach to a set of >4000 com. available compds. with previously demonstrated blood-stage activity (median inhibitory concn. < 1 micromolar) and identified chem. scaffolds with potent activity against both forms.  From this screen, we identified an imidazolopiperazine scaffold series that was highly enriched among compds. active against Plasmodium liver stages.  The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 mg/kg) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity.  The open-source chem. tools resulting from our effort provide starting points for future drug discovery programs, as well as opportunities for researchers to investigate the biol. of exo-erythrocytic forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyO41naZtcdrVg90H21EOLACvtfcHk0ljVR56j0ZX7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN&md5=45b2993be36e36eabe1d9280c86c3db2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211936%26sid%3Dliteratum%253Aachs%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%2BC.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DBopp%26aufirst%3DS.%2BE.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBright%26aufirst%3DA.%2BT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DNam%26aufirst%3DT.-g.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DRoland%26aufirst%3DJ.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFroissard%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DMazier%26aufirst%3DD.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DImaging%2520of%2520Plasmodium%2520liver%2520stages%2520to%2520drive%2520next-generation%2520antimalarial%2520drug%2520discovery%26jtitle%3DScience%26date%3D2011%26volume%3D334%26issue%3D6061%26spage%3D1372%26epage%3D1377%26doi%3D10.1126%2Fscience.1211936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Blanco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardera, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de las Heras, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colmenarejo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Martínez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreros, E.</span></span> <span> </span><span class="NLM_article-title">Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15160</span>, <span class="refDoi"> DOI: 10.1038/ncomms15160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fncomms15160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28513586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15160&author=C.+Miguel-Blancoauthor=I.+Molinaauthor=A.+I.+Barderaauthor=B.+D%C3%ADazauthor=L.+de+las+Herasauthor=S.+Lozanoauthor=C.+Gonz%C3%A1lezauthor=J.+Rodriguesauthor=M.+J.+Delvesauthor=A.+Rueckerauthor=G.+Colmenarejoauthor=S.+Vieraauthor=M.+S.+Mart%C3%ADnez-Mart%C3%ADnezauthor=E.+Fern%C3%A1ndezauthor=J.+Baumauthor=R.+E.+Sindenauthor=E.+Herreros&title=Hundreds+of+dual-stage+antimalarial+molecules+discovered+by+a+functional+gametocyte+screen&doi=10.1038%2Fncomms15160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen</span></div><div class="casAuthors">Miguel-Blanco, Celia; Molina, Irene; Bardera, Ana I.; Diaz, Beatriz; de las Heras, Laura; Lozano, Sonia; Gonzalez, Carolina; Rodrigues, Janneth; Delves, Michael J.; Ruecker, Andrea; Colmenarejo, Gonzalo; Viera, Sara; Martinez-Martinez, Maria S.; Fernandez, Esther; Baum, Jake; Sinden, Robert E.; Herreros, Esperanza</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15160</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Plasmodium falciparum stage V gametocytes are responsible for parasite transmission, and drugs targeting this stage are needed to support malaria elimination.  We here screen the Tres Cantos Antimalarial Set (TCAMS) using the previously developed P. falciparum female gametocyte activation assay (Pf FGAA), which assesses stage V female gametocyte viability and functionality using Pfs25 expression.  We identify over 400 compds. with activities <2 μM, chem. classified into 57 clusters and 33 singletons.  Up to 68% of the hits are chemotypes described for the first time as late-stage gametocyte-targeting mols.  In addn., the biol. profile of 90 compds. representing the chem. diversity is assessed.  We confirm in vitro transmission-blocking activity of four of the six selected mols. belonging to three distinct scaffold clusters.  Overall, this TCAMS gametocyte screen provides 276 promising antimalarial mols. with dual asexual/sexual activity, representing starting points for target identification and candidate selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplYIJfzE0ttLVg90H21EOLACvtfcHk0ljvTLhcV5aUdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGlsrk%253D&md5=906ab6be730f22c19e27a926e3b2e075</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fncomms15160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15160%26sid%3Dliteratum%253Aachs%26aulast%3DMiguel-Blanco%26aufirst%3DC.%26aulast%3DMolina%26aufirst%3DI.%26aulast%3DBardera%26aufirst%3DA.%2BI.%26aulast%3DD%25C3%25ADaz%26aufirst%3DB.%26aulast%3Dde%2Blas%2BHeras%26aufirst%3DL.%26aulast%3DLozano%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DC.%26aulast%3DRodrigues%26aufirst%3DJ.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DColmenarejo%26aufirst%3DG.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DMart%25C3%25ADnez-Mart%25C3%25ADnez%26aufirst%3DM.%2BS.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DBaum%26aufirst%3DJ.%26aulast%3DSinden%26aufirst%3DR.%2BE.%26aulast%3DHerreros%26aufirst%3DE.%26atitle%3DHundreds%2520of%2520dual-stage%2520antimalarial%2520molecules%2520discovered%2520by%2520a%2520functional%2520gametocyte%2520screen%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15160%26doi%3D10.1038%2Fncomms15160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maetani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span> <span> </span><span class="NLM_article-title">High-throughput luciferase-based assay for the discovery of therapeutics that prevent malaria</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.5b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.5b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=281-293&issue=4&author=J.+Swannauthor=V.+Coreyauthor=C.+A.+Schererauthor=N.+Katoauthor=E.+Comerauthor=M.+Maetaniauthor=Y.+Antonova-Kochauthor=C.+Reimerauthor=K.+Gagaringauthor=M.+Ibanezauthor=D.+Plouffeauthor=A.+M.+Zeemanauthor=C.+H.+Kockenauthor=C.+W.+McNamaraauthor=S.+L.+Schreiberauthor=B.+Campoauthor=E.+A.+Winzelerauthor=S.+Meister&title=High-throughput+luciferase-based+assay+for+the+discovery+of+therapeutics+that+prevent+malaria&doi=10.1021%2Facsinfecdis.5b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria</span></div><div class="casAuthors">Swann, Justine; Corey, Victoria; Scherer, Christina A.; Kato, Nobutaka; Comer, Eamon; Maetani, Micah; Antonova-Koch, Yevgeniya; Reimer, Christin; Gagaring, Kerstin; Ibanez, Maureen; Plouffe, David; Zeeman, Anne-Marie; Kocken, Clemens H. M.; McNamara, Case W.; Schreiber, Stuart L.; Campo, Brice; Winzeler, Elizabeth A.; Meister, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">281-293</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to identify the most attractive starting points for drugs that can be used to prevent malaria, a diverse chem. space comprising tens of thousands to millions of small mols. may need to be examd.  Achieving this throughput necessitates the development of efficient ultra-high-throughput screening methods.  Here, the authors report the development and evaluation of a luciferase-based phenotypic screen of malaria exoerythrocytic-stage parasites optimized for a 1536-well format.  This assay uses the exoerythrocytic stage of the rodent malaria parasite, Plasmodium berghei, and a human hepatoma cell line.  The authors use this assay to evaluate several biased and unbiased compd. libraries, including two small sets of mols. (400 and 89 compds., resp.) with known activity against malaria erythrocytic-stage parasites and a set of 9886 diversity-oriented synthesis (DOS)-derived compds.  Of the compds. screened, the authors obtain hit rates of 12-13 and 0.6% in preselected and naive libraries, resp., and identify 52 compds. with exoerythrocytic-stage activity less than 1 μM and having minimal host cell toxicity.  The data demonstrate the ability of this method to identify compds. known to have causal prophylactic activity in both human and animal models of malaria, as well as novel compds., including some exclusively active against parasite exoerythrocytic stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4sAMW8HfXO7Vg90H21EOLACvtfcHk0ljvTLhcV5aUdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit12nsr4%253D&md5=b9bd0256f0c8e80469a712f2492c6106</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.5b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.5b00143%26sid%3Dliteratum%253Aachs%26aulast%3DSwann%26aufirst%3DJ.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DScherer%26aufirst%3DC.%2BA.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DMaetani%26aufirst%3DM.%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%2BH.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DMeister%26aufirst%3DS.%26atitle%3DHigh-throughput%2520luciferase-based%2520assay%2520for%2520the%2520discovery%2520of%2520therapeutics%2520that%2520prevent%2520malaria%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26issue%3D4%26spage%3D281%26epage%3D293%26doi%3D10.1021%2Facsinfecdis.5b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michnoff, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening for potent and selective inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">21847</span>– <span class="NLM_lpage">21853</span>, <span class="refDoi"> DOI: 10.1074/jbc.M501100200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M501100200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=15795226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksl2hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=21847-21853&issue=23&author=J.+Baldwinauthor=C.+H.+Michnoffauthor=N.+A.+Malmquistauthor=J.+Whiteauthor=M.+G.+Rothauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=High-throughput+screening+for+potent+and+selective+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase&doi=10.1074%2Fjbc.M501100200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Baldwin, Jeffrey; Michnoff, Carolyn H.; Malmquist, Nicholas A.; White, John; Roth, Michael G.; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">21847-21853</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum is the causative agent of the most serious and fatal malarial infections, and it has developed resistance to commonly employed chemotherapeutics.  The de novo pyrimidine biosynthesis enzymes offer potential as targets for drug design, because, unlike the host, the parasite does not have pyrimidine salvage pathways.  Dihydroorotate dehydrogenase (DHODH) is a flavin-dependent mitochondrial enzyme that catalyzes the fourth reaction in this essential pathway.  Coenzyme Q (CoQ) is utilized as the oxidant.  Potent and species-selective inhibitors of malarial DHODH were identified by high-throughput screening of a chem. library, which contained 220,000 drug-like mols.  These novel inhibitors represent a diverse range of chem. scaffolds, including a series of halogenated Ph benzamide/naphthamides and urea-based compds. contg. naphthyl or quinolinyl substituents.  Inhibitors in these classes with IC50 values below 600 nM were purified by high pressure liq. chromatog., characterized by mass spectroscopy, and subjected to kinetic anal. against the parasite and human enzymes.  The most active compd. is a competitive inhibitor of CoQ with an IC50 against malarial DHODH of 16 nM, and it is 12,500-fold less active against the human enzyme.  Site-directed mutagenesis of residues in the CoQ-binding site significantly reduced inhibitor potency.  The structural basis for the species selective enzyme inhibition is explained by the variable amino acid sequence in this binding site, making DHODH a particularly strong candidate for the development of new anti-malarial compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPMFFguZbemrVg90H21EOLACvtfcHk0lhVA8WpSFZdSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksl2hsr8%253D&md5=0ff927280426ad1c9808de7412df1f1b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M501100200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M501100200%26sid%3Dliteratum%253Aachs%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DMichnoff%26aufirst%3DC.%2BH.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DM.%2BG.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DHigh-throughput%2520screening%2520for%2520potent%2520and%2520selective%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26issue%3D23%26spage%3D21847%26epage%3D21853%26doi%3D10.1074%2Fjbc.M501100200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillesland, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyloun, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krahn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasari, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, A. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bakkouri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojo, K. K.</span></span> <span> </span><span class="NLM_article-title">Biochemical screening of five protein kinases from <i>Plasmodium falciparum</i> against 14,000 cell-active compounds</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e0149996</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0149996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.pone.0149996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26934697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsFSjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0149996&issue=3&author=G.+J.+Crowtherauthor=H.+K.+Hilleslandauthor=K.+R.+Keylounauthor=M.+C.+Reidauthor=M.+J.+Lafuente-Monasterioauthor=S.+Ghidelli-Disseauthor=S.+E.+Leonardauthor=P.+Heauthor=J.+C.+Jonesauthor=M.+M.+Krahnauthor=J.+S.+Moauthor=K.+S.+Dasariauthor=A.+M.+W.+Foxauthor=M.+Boescheauthor=M.+El+Bakkouriauthor=K.+L.+Rivasauthor=D.+Leroyauthor=R.+Huiauthor=G.+Drewesauthor=D.+J.+Malyauthor=W.+C.+Van+Voorhisauthor=K.+K.+Ojo&title=Biochemical+screening+of+five+protein+kinases+from+Plasmodium+falciparum+against+14%2C000+cell-active+compounds&doi=10.1371%2Fjournal.pone.0149996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical screening of five protein kinases from Plasmodium falciparum against 14,000 cell-active compounds</span></div><div class="casAuthors">Crowther, Gregory J.; Hillesland, Heidi K.; Keyloun, Katelyn R.; Reid, Molly C.; Lafuente-Monasterio, Maria Jose; Ghidelli-Disse, Sonja; Leonard, Stephen E.; He, Panqing; Jones, Jackson C.; Krahn, Mallory M.; Mo, Jack S.; Dasari, Kartheek S.; Fox, Anna M. W.; Boesche, Markus; El Bakkouri, Majida; Rivas, Kasey L.; Leroy, Didier; Hui, Raymond; Drewes, Gerard; Maly, Dustin J.; Van Voorhis, Wesley C.; Ojo, Kayode K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0149996/1-e0149996/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In 2010 the identities of thousands of anti-Plasmodium compds. were released publicly to facilitate malaria drug development.  Understanding these compds. mechanisms of action, i.e., the specific mol. targets by which they kill the parasite, would further facilitate the drug development process.  Given that kinases are promising anti-malaria targets, the authors screened ∼14,000 cell-active compds. for activity against five different protein kinases.  Collections of cell-active compds. from GlaxoSmithKline (the ∼13,000-compd. Tres Cantos Antimalarial Set, or TCAMS), St. Jude Children's Research Hospital (260 compds.), and the Medicines for Malaria Venture (the 400-compd. Malaria Box) were screened in biochem. assays of Plasmodium falciparum calcium-dependent protein kinases 1 and 4 (CDPK1 and CDPK4), mitogen-assocd. protein kinase 2 (MAPK2/ MAP2), protein kinase 6 (PK6), and protein kinase 7 (PK7).  Novel potent inhibitors (IC50 < 1 μM) were discovered for three of the kinases: CDPK1, CDPK4, and PK6.  The PK6 inhibitors are the most potent yet discovered for this enzyme and deserve further scrutiny.  Addnl., kinome-wide competition assays revealed a compd. that inhibits CDPK4 with few effects on ∼150 human kinases, and several related compds. that inhibit CDPK1 and CDPK4 yet have limited cytotoxicity to human (HepG2) cells.  The authors' data suggest that inhibiting multiple Plasmodium kinase targets without harming human cells is challenging but feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQjOI-LR9zrVg90H21EOLACvtfcHk0lhVA8WpSFZdSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsFSjurk%253D&md5=a55e4cf30328bbe04218100c69705ebc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0149996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0149996%26sid%3Dliteratum%253Aachs%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DHillesland%26aufirst%3DH.%2BK.%26aulast%3DKeyloun%26aufirst%3DK.%2BR.%26aulast%3DReid%26aufirst%3DM.%2BC.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DLeonard%26aufirst%3DS.%2BE.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DJ.%2BC.%26aulast%3DKrahn%26aufirst%3DM.%2BM.%26aulast%3DMo%26aufirst%3DJ.%2BS.%26aulast%3DDasari%26aufirst%3DK.%2BS.%26aulast%3DFox%26aufirst%3DA.%2BM.%2BW.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DEl%2BBakkouri%26aufirst%3DM.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DOjo%26aufirst%3DK.%2BK.%26atitle%3DBiochemical%2520screening%2520of%2520five%2520protein%2520kinases%2520from%2520Plasmodium%2520falciparum%2520against%252014%252C000%2520cell-active%2520compounds%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D3%26spage%3De0149996%26doi%3D10.1371%2Fjournal.pone.0149996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napuli, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagostino, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockmyer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodenbough, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaneda, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engels, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantauzzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span> <span> </span><span class="NLM_article-title">Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds</span>. <i>Mol. Biochem. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.molbiopara.2010.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.molbiopara.2010.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20813141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2011&pages=21-29&issue=1&author=G.+J.+Crowtherauthor=A.+J.+Napuliauthor=J.+H.+Gilliganauthor=K.+Gagaringauthor=R.+Borboaauthor=C.+Francekauthor=Z.+Chenauthor=E.+F.+Dagostinoauthor=J.+B.+Stockmyerauthor=Y.+Wangauthor=P.+P.+Rodenboughauthor=L.+J.+Castanedaauthor=D.+J.+Leiblyauthor=J.+Bhandariauthor=M.+H.+Gelbauthor=A.+Brinkerauthor=I.+H.+Engelsauthor=J.+Taylorauthor=A.+K.+Chatterjeeauthor=P.+Fantauzziauthor=R.+J.+Glynneauthor=W.+C.+Van+Voorhisauthor=K.+L.+Kuhen&title=Identification+of+inhibitors+for+putative+malaria+drug+targets+among+novel+antimalarial+compounds&doi=10.1016%2Fj.molbiopara.2010.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds</span></div><div class="casAuthors">Crowther, Gregory J.; Napuli, Alberto J.; Gilligan, James H.; Gagaring, Kerstin; Borboa, Rachel; Francek, Carolyn; Chen, Zhong; Dagostino, Eleanor F.; Stockmyer, Justin B.; Wang, Yu; Rodenbough, Philip P.; Castaneda, Lisa J.; Leibly, David J.; Bhandari, Janhavi; Gelb, Michael H.; Brinker, Achim; Engels, Ingo H.; Taylor, Jennifer; Chatterjee, Arnab K.; Fantauzzi, Pascal; Glynne, Richard J.; Van Voorhis, Wesley C.; Kuhen, Kelli L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Biochemical Parasitology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-29</span>CODEN:
                <span class="NLM_cas:coden">MBIPDP</span>;
        ISSN:<span class="NLM_cas:issn">0166-6851</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">The efficacy of most marketed antimalarial drugs has been compromised by evolution of parasite resistance, underscoring an urgent need to find new drugs with new mechanisms of action.  We have taken a high-throughput approach toward identifying novel antimalarial chem. inhibitors of prioritized drug targets for Plasmodium falciparum, excluding targets which are inhibited by currently used drugs.  A screen of com. available libraries identified 5655 low mol. wt. compds. that inhibit growth of P. falciparum cultures with EC50 values below 1.25 μM.  These compds. were then tested in 384- or 1536-well biochem. assays for activity against nine Plasmodium enzymes: adenylosuccinate synthetase (AdSS), choline kinase (CK), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), glutamate dehydrogenase (GDH), guanylate kinase (GK), N-myristoyltransferase (NMT), orotidine 5'-monophosphate decarboxylase (OMPDC), farnesyl pyrophosphate synthase (FPPS) and S-adenosylhomocysteine hydrolase (SAHH).  These enzymes were selected using TDRtargets.org, and are believed to have excellent potential as drug targets based on criteria such as their likely essentiality, druggability, and amenability to high-throughput biochem. screening.  Six of these targets were inhibited by one or more of the antimalarial scaffolds and may have potential use in drug development, further target validation studies and exploration of P. falciparum biochem. and biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOMQ0tUYOGbLVg90H21EOLACvtfcHk0lior4qSY7A3lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtbjJ&md5=68c7c2e9ee0bc40abc0a3b99187be9ff</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.molbiopara.2010.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molbiopara.2010.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DNapuli%26aufirst%3DA.%2BJ.%26aulast%3DGilligan%26aufirst%3DJ.%2BH.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDagostino%26aufirst%3DE.%2BF.%26aulast%3DStockmyer%26aufirst%3DJ.%2BB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRodenbough%26aufirst%3DP.%2BP.%26aulast%3DCastaneda%26aufirst%3DL.%2BJ.%26aulast%3DLeibly%26aufirst%3DD.%2BJ.%26aulast%3DBhandari%26aufirst%3DJ.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DBrinker%26aufirst%3DA.%26aulast%3DEngels%26aufirst%3DI.%2BH.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DFantauzzi%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26atitle%3DIdentification%2520of%2520inhibitors%2520for%2520putative%2520malaria%2520drug%2520targets%2520among%2520novel%2520antimalarial%2520compounds%26jtitle%3DMol.%2520Biochem.%2520Parasitol.%26date%3D2011%26volume%3D175%26issue%3D1%26spage%3D21%26epage%3D29%26doi%3D10.1016%2Fj.molbiopara.2010.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holder, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leatherbarrow, R. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3578</span>– <span class="NLM_lpage">3582</span>, <span class="refDoi"> DOI: 10.1021/jm300040p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300040p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVKgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3578-3582&issue=7&author=V.+Goncalvesauthor=J.+A.+Branniganauthor=D.+Whalleyauthor=K.+H.+Ansellauthor=B.+Saxtyauthor=A.+A.+Holderauthor=A.+J.+Wilkinsonauthor=E.+W.+Tateauthor=R.+J.+Leatherbarrow&title=Discovery+of+Plasmodium+vivax+N-myristoyltransferase+inhibitors%3A+screening%2C+synthesis%2C+and+structural+characterization+of+their+binding+mode&doi=10.1021%2Fjm300040p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Plasmodium vivax N-Myristoyltransferase Inhibitors: Screening, Synthesis, and Structural Characterization of their Binding Mode</span></div><div class="casAuthors">Goncalves, Victor; Brannigan, James A.; Whalley, David; Ansell, Keith H.; Saxty, Barbara; Holder, Anthony A.; Wilkinson, Anthony J.; Tate, Edward W.; Leatherbarrow, Robin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3578-3582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Myristoyltransferase (NMT) is a prospective drug target against parasitic protozoa.  Herein we report the successful discovery of a series of Plasmodium vivax NMT inhibitors by high-throughput screening.  A high-resoln. crystal structure of the hit compd. in complex with NMT was obtained, allowing understanding of its novel binding mode.  A set of analogs was designed and tested to define the chem. groups relevant for activity and selectivity.  Compd. 7 (I) was identified which exhibits micromolar activity against PvNMT, some selectivity over human NMT isoforms, and improved lead-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQffTqfTp5rLVg90H21EOLACvtfcHk0lior4qSY7A3lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVKgtbc%253D&md5=0e42a947e40a044763db187bea7fb76e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm300040p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300040p%26sid%3Dliteratum%253Aachs%26aulast%3DGoncalves%26aufirst%3DV.%26aulast%3DBrannigan%26aufirst%3DJ.%2BA.%26aulast%3DWhalley%26aufirst%3DD.%26aulast%3DAnsell%26aufirst%3DK.%2BH.%26aulast%3DSaxty%26aufirst%3DB.%26aulast%3DHolder%26aufirst%3DA.%2BA.%26aulast%3DWilkinson%26aufirst%3DA.%2BJ.%26aulast%3DTate%26aufirst%3DE.%2BW.%26aulast%3DLeatherbarrow%26aufirst%3DR.%2BJ.%26atitle%3DDiscovery%2520of%2520Plasmodium%2520vivax%2520N-myristoyltransferase%2520inhibitors%253A%2520screening%252C%2520synthesis%252C%2520and%2520structural%2520characterization%2520of%2520their%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D7%26spage%3D3578%26epage%3D3582%26doi%3D10.1021%2Fjm300040p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celatka, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraisingh, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of small molecule inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">35078</span>– <span class="NLM_lpage">35085</span>, <span class="refDoi"> DOI: 10.1074/jbc.M804990200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M804990200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18842591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=35078-35085&issue=50&author=V.+Patelauthor=M.+Bookerauthor=M.+Kramerauthor=L.+Rossauthor=C.+A.+Celatkaauthor=L.+M.+Kennedyauthor=J.+D.+Dvorinauthor=M.+T.+Duraisinghauthor=P.+Slizauthor=D.+F.+Wirthauthor=J.+Clardy&title=Identification+and+characterization+of+small+molecule+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase&doi=10.1074%2Fjbc.M804990200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of Small Molecule Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase</span></div><div class="casAuthors">Patel, Vishal; Booker, Michael; Kramer, Martin; Ross, Leila; Celatka, Cassandra A.; Kennedy, Leah M.; Dvorin, Jeffrey D.; Duraisingh, Manoj T.; Sliz, Piotr; Wirth, Dyann F.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35078-35085</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Plasmodium falciparum causes the most deadly form of malaria and accounts for over one million deaths annually.  The malaria parasite is unable to salvage pyrimidines and relies on de novo biosynthesis for survival.  Dihydroorotate dehydrogenase (DHOD), a mitochondrially localized flavoenzyme, catalyzes the rate-limiting step of this pathway and is therefore an attractive antimalarial chemotherapeutic target.  Using a target-based high throughput screen, we have identified a series of potent, species-specific inhibitors of P. falciparum DHOD (pfDHOD) that are also efficacious against three cultured strains (3D7, HB3, and Dd2) of P. falciparum.  The primary antimalarial mechanism of action of these compds. was confirmed to be inhibition of pfDHOD through a secondary assay with transgenic malaria parasites, and the structural basis for enzyme inhibition was explored through in silico structure-based docking and site-directed mutagenesis.  Compd.-mediated cytotoxicity was not obsd. with human dermal fibroblasts or renal epithelial cells.  These data validate pfDHOD as an antimalarial drug target and provide chem. scaffolds with which to begin medicinal chem. efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy01Yc9ycCLVg90H21EOLACvtfcHk0lior4qSY7A3lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGqt7%252FF&md5=beb67f818baaeb9e70637debb50047a3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M804990200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M804990200%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DBooker%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DCelatka%26aufirst%3DC.%2BA.%26aulast%3DKennedy%26aufirst%3DL.%2BM.%26aulast%3DDvorin%26aufirst%3DJ.%2BD.%26aulast%3DDuraisingh%26aufirst%3DM.%2BT.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520small%2520molecule%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D50%26spage%3D35078%26epage%3D35085%26doi%3D10.1074%2Fjbc.M804990200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Capua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams-Noonan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouwer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner-Adams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, W. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based screening of a natural product library against 62 potential malaria drug targets employing native mass spectrometry</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.7b00197</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.7b00197" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1ahs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=431-444&issue=4&author=H.+Vuauthor=L.+Pedroauthor=T.+Makauthor=B.+McCormickauthor=J.+Rowleyauthor=M.+Liuauthor=A.+Di+Capuaauthor=B.+Williams-Noonanauthor=N.+B.+Phamauthor=R.+Pouwerauthor=B.+Nguyenauthor=K.+T.+Andrewsauthor=T.+Skinner-Adamsauthor=J.+Kimauthor=W.+G.+J.+Holauthor=R.+Huiauthor=G.+J.+Crowtherauthor=W.+C.+Van+Voorhisauthor=R.+J.+Quinn&title=Fragment-based+screening+of+a+natural+product+library+against+62+potential+malaria+drug+targets+employing+native+mass+spectrometry&doi=10.1021%2Facsinfecdis.7b00197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry</span></div><div class="casAuthors">Vu, Hoan; Pedro, Liliana; Mak, Tin; McCormick, Brendan; Rowley, Jessica; Liu, Miaomiao; Di Capua, Angela; Williams-Noonan, Billy; Pham, Ngoc B.; Pouwer, Rebecca; Nguyen, Bao; Andrews, Katherine T.; Skinner-Adams, Tina; Kim, Jessica; Hol, Wim G. J.; Hui, Raymond; Crowther, Gregory J.; Van Voorhis, Wesley C.; Quinn, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-444</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Natural products are well known for their biol. relevance, high degree of three-dimensionality, and access to areas of largely unexplored chem. space.  To shape our understanding of the interaction between natural products and protein targets in the postgenomic era, we have used native mass spectrometry to investigate 62 potential protein targets for malaria using a natural-product-based fragment library.  We reveal here 96 low-mol.-wt. natural products identified as binding partners of 32 of the putative malarial targets.  Seventy-nine (79) fragments have direct growth inhibition on Plasmodium falciparum at concns. that are promising for the development of fragment hits against these protein targets.  This adds a fragment library to the published HTS active libraries in the public domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGrG7it9DQS7Vg90H21EOLACvtfcHk0liwIGIHYx5LBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1ahs7s%253D&md5=5e6ea1be111f64c97f08e272f2e83dae</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.7b00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.7b00197%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DH.%26aulast%3DPedro%26aufirst%3DL.%26aulast%3DMak%26aufirst%3DT.%26aulast%3DMcCormick%26aufirst%3DB.%26aulast%3DRowley%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DDi%2BCapua%26aufirst%3DA.%26aulast%3DWilliams-Noonan%26aufirst%3DB.%26aulast%3DPham%26aufirst%3DN.%2BB.%26aulast%3DPouwer%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DK.%2BT.%26aulast%3DSkinner-Adams%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHol%26aufirst%3DW.%2BG.%2BJ.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DFragment-based%2520screening%2520of%2520a%2520natural%2520product%2520library%2520against%252062%2520potential%2520malaria%2520drug%2520targets%2520employing%2520native%2520mass%2520spectrometry%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2018%26volume%3D4%26issue%3D4%26spage%3D431%26epage%3D444%26doi%3D10.1021%2Facsinfecdis.7b00197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roullier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campitelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenholme, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner-Adams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowther, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">Plasmodium gametocyte inhibition identified from a natural-product-based fragment library</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2654</span>– <span class="NLM_lpage">2659</span>, <span class="refDoi"> DOI: 10.1021/cb400582b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400582b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFeltrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2654-2659&issue=12&author=H.+Vuauthor=C.+Roullierauthor=M.+Campitelliauthor=K.+R.+Trenholmeauthor=D.+L.+Gardinerauthor=K.+T.+Andrewsauthor=T.+Skinner-Adamsauthor=G.+J.+Crowtherauthor=W.+C.+Van+Voorhisauthor=R.+J.+Quinn&title=Plasmodium+gametocyte+inhibition+identified+from+a+natural-product-based+fragment+library&doi=10.1021%2Fcb400582b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium gametocyte inhibition identified from a natural product-based fragment library</span></div><div class="casAuthors">Vu, Hoan; Roullier, Catherine; Campitelli, Marc; Trenholme, Katharine R.; Gardiner, Donald L.; Andrews, Katherine T.; Skinner-Adams, Tina; Crowther, Gregory J.; Van Voorhis, Wesley C.; Quinn, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2654-2659</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based screening is commonly used to identify compds. with relatively weak but efficient localized binding to protein surfaces.  The authors used mass spectrometry to study fragment-sized three-dimensional natural products.  They identified seven securinine-related compds. binding to Plasmodium falciparum 2'-deoxyuridine 5'-triphosphate nucleotidohydrolase (PfdUTPase).  Securinine bound allosterically to PfdUTPase, enhancing enzyme activity and inhibiting viability of both P. falciparum gametocyte (sexual) and blood (asexual) stage parasites.  The results provide a new insight into mechanisms that may be applicable to transmission-blocking agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1yoUh32TRcLVg90H21EOLACvtfcHk0liwIGIHYx5LBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFeltrzJ&md5=19d7db1596702529d16bd6a82e7cf4ab</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fcb400582b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400582b%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DH.%26aulast%3DRoullier%26aufirst%3DC.%26aulast%3DCampitelli%26aufirst%3DM.%26aulast%3DTrenholme%26aufirst%3DK.%2BR.%26aulast%3DGardiner%26aufirst%3DD.%2BL.%26aulast%3DAndrews%26aufirst%3DK.%2BT.%26aulast%3DSkinner-Adams%26aufirst%3DT.%26aulast%3DCrowther%26aufirst%3DG.%2BJ.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DPlasmodium%2520gametocyte%2520inhibition%2520identified%2520from%2520a%2520natural-product-based%2520fragment%2520library%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26issue%3D12%26spage%3D2654%26epage%3D2659%26doi%3D10.1021%2Fcb400582b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okombo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Recent updates in the discovery and development of novel antimalarial drug candidates</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1039/C7MD00637C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1039%2FC7MD00637C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30108934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFygs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=437-453&issue=3&author=J.+Okomboauthor=K.+Chibale&title=Recent+updates+in+the+discovery+and+development+of+novel+antimalarial+drug+candidates&doi=10.1039%2FC7MD00637C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates in the discovery and development of novel antimalarial drug candidates</span></div><div class="casAuthors">Okombo, John; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">437-453</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Though morbidity and mortality due to malaria have declined in the last 15 years, emerging resistance to first-line artemisinin-based antimalarials, absence of efficacious vaccines and limited chemotherapeutic alternatives imperil the consolidation of these gains.  As a blueprint to steer future designs of new medicines, malaria drug discovery recently adopted a descriptive proposal for the ideal candidate mols. and drugs likely to successfully progress into the final stages of clin. development.  As an audit of recent developments in the chemotherapy of malaria in the last five years, this review captures a landscape of diverse mols. at various stages of drug development and discusses their progress.  In brief, we also discuss how omics data on Plasmodium has been extensively leveraged to identify potential vaccine candidates and putative targets of mols. in development and clin. use as well as map loci implicit in their modes of resistance.  Future perspective on malaria drug development should involve a reconciliation of some of the challenges of the target candidate profiles (TCPs), specifically TCP3, with the promise of effective anti-hypnozoite medicines.  Similarly, with the recent development of a humanized mouse model that can evaluate the prophylactic potential of candidate drugs, we argue for increased effort at identifying more liver-stage mols., which are often only secondarily prioritized in conventional screening programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvmARzFwQAebVg90H21EOLACvtfcHk0liwIGIHYx5LBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFygs7Y%253D&md5=760def6cbcd82971f114de94132b27f7</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1039%2FC7MD00637C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00637C%26sid%3Dliteratum%253Aachs%26aulast%3DOkombo%26aufirst%3DJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DRecent%2520updates%2520in%2520the%2520discovery%2520and%2520development%2520of%2520novel%2520antimalarial%2520drug%2520candidates%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D437%26epage%3D453%26doi%3D10.1039%2FC7MD00637C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Paez, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Spiroindolones, a potent compound class for the treatment of malaria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span> (<span class="NLM_issue">5996</span>),  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1126/science.1193225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1193225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20813948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=1175-1180&issue=5996&author=M.+Rottmannauthor=C.+McNamaraauthor=B.+K.+Yeungauthor=M.+C.+Leeauthor=B.+Zouauthor=B.+Russellauthor=P.+Seitzauthor=D.+M.+Plouffeauthor=N.+V.+Dhariaauthor=J.+Tanauthor=S.+B.+Cohenauthor=K.+R.+Spencerauthor=G.+E.+Gonzalez-Paezauthor=S.+B.+Lakshminarayanaauthor=A.+Gohauthor=R.+Suwanaruskauthor=T.+Jeglaauthor=E.+K.+Schmittauthor=H.+P.+Beckauthor=R.+Brunauthor=F.+Nostenauthor=L.+Reniaauthor=V.+Dartoisauthor=T.+H.+Kellerauthor=D.+A.+Fidockauthor=E.+A.+Winzelerauthor=T.+T.+Diagana&title=Spiroindolones%2C+a+potent+compound+class+for+the+treatment+of+malaria&doi=10.1126%2Fscience.1193225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span></div><div class="casAuthors">Rottmann, Matthias; McNamara, Case; Yeung, Bryan K. S.; Lee, Marcus C. S.; Zou, Bin; Russell, Bruce; Seitz, Patrick; Plouffe, David M.; Dharia, Neekesh V.; Tan, Jocelyn; Cohen, Steven B.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Lakshminarayana, Suresh B.; Goh, Anne; Suwanarusk, Rossarin; Jegla, Timothy; Schmitt, Esther K.; Beck, Hans-Peter; Brun, Reto; Nosten, Francois; Renia, Laurent; Dartois, Veronique; Keller, Thomas H.; Fidock, David A.; Winzeler, Elizabeth A.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5996</span>),
    <span class="NLM_cas:pages">1175-1180</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Recent reports of increased tolerance to artemisinin derivs.-the most recently adopted class of antimalarials-have prompted a need for new treatments.  The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clin. isolates at low nanomolar concn.  Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4).  The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6O1WaX-1b7Vg90H21EOLACvtfcHk0licJlpj2sL1ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ&md5=239bc9babd5cb5f07e2be38741038e2c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscience.1193225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1193225%26sid%3Dliteratum%253Aachs%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DSpencer%26aufirst%3DK.%2BR.%26aulast%3DGonzalez-Paez%26aufirst%3DG.%2BE.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DJegla%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DBeck%26aufirst%3DH.%2BP.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DSpiroindolones%252C%2520a%2520potent%2520compound%2520class%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DScience%26date%3D2010%26volume%3D329%26issue%3D5996%26spage%3D1175%26epage%3D1180%26doi%3D10.1126%2Fscience.1193225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katneni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabiulla, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3487</span>, <span class="refDoi"> DOI: 10.1021/jm3001373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3001373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1SqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3479-3487&author=Y.+Younisauthor=F.+Douelleauthor=T.+S.+Fengauthor=D.+Gonzalez+Cabreraauthor=C.+Le+Manachauthor=A.+T.+Nchindaauthor=S.+Duffyauthor=K.+L.+Whiteauthor=D.+M.+Shacklefordauthor=J.+Morizziauthor=J.+Mannilaauthor=K.+Katneniauthor=R.+Bhamidipatiauthor=K.+M.+Zabiullaauthor=J.+T.+Josephauthor=S.+Bashyamauthor=D.+Watersonauthor=M.+J.+Wittyauthor=D.+Hardickauthor=S.+Wittlinauthor=V.+Averyauthor=S.+A.+Charmanauthor=K.+Chibale&title=3%2C5-Diaryl-2-aminopyridines+as+a+novel+class+of+orally+active+antimalarials+demonstrating+single+dose+cure+in+mice+and+clinical+candidate+potential&doi=10.1021%2Fjm3001373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">3,5-Diaryl-2-aminopyridines as a Novel Class of Orally Active Antimalarials Demonstrating Single Dose Cure in Mice and Clinical Candidate Potential</span></div><div class="casAuthors">Younis, Yassir; Douelle, Frederic; Feng, Tzu-Shean; Cabrera, Diego Gonzalez; Manach, Claire Le; Nchinda, Aloysius T.; Duffy, Sandra; White, Karen L.; Shackleford, David M.; Morizzi, Julia; Mannila, Janne; Katneni, Kasiram; Bhamidipati, Ravi; Zabiulla, K. Mohammed; Joseph, Jayan T.; Bashyam, Sridevi; Waterson, David; Witty, Michael J.; Hardick, David; Wittlin, Sergio; Avery, Vicky; Charman, Susan A.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3479-3487</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of orally active antimalarial 3,5-diaryl-2-aminopyridines has been identified from phenotypic whole cell high-throughput screening of a com. available SoftFocus kinase library.  The compds. were evaluated in vitro for their antiplasmodial activity against K1 (chloroquine and drug-resistant strain) and NF54 (chloroquine-susceptible strain) as well as for their cytotoxicity.  Synthesis and structure-activity studies identified a no. of promising compds. with selective antiplasmodial activity.  One of these front-runner compds., I, was equipotent across the two strains (K1 = 25.0 nM, NF54 = 28.0 nM) and superior to chloroquine in the K1 strain (chloroquine IC50 K1 = 194.0 nM).  Compd. I completely cured Plasmodium berghei-infected mice with a single oral dose of 30 mg/kg.  Dose-response studies generated ED50 and ED90 values of 0.83 and 1.74 mg/kg for 15 in the std. four-dose Peters test.  Pharmacokinetic studies in the rat indicated that I has good oral bioavailability (51% at 20 mg/kg) and a reasonable half-life (t1/2 ∼ 7-8 h).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSW6icCPhdOrVg90H21EOLACvtfcHk0licJlpj2sL1ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1SqtL4%253D&md5=6f8bd20049550b82b81b3c7c5b0b9aae</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm3001373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3001373%26sid%3Dliteratum%253Aachs%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DDouelle%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DT.%2BS.%26aulast%3DGonzalez%2BCabrera%26aufirst%3DD.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DMannila%26aufirst%3DJ.%26aulast%3DKatneni%26aufirst%3DK.%26aulast%3DBhamidipati%26aufirst%3DR.%26aulast%3DZabiulla%26aufirst%3DK.%2BM.%26aulast%3DJoseph%26aufirst%3DJ.%2BT.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DHardick%26aufirst%3DD.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DAvery%26aufirst%3DV.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3D3%252C5-Diaryl-2-aminopyridines%2520as%2520a%2520novel%2520class%2520of%2520orally%2520active%2520antimalarials%2520demonstrating%2520single%2520dose%2520cure%2520in%2520mice%2520and%2520clinical%2520candidate%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3479%26epage%3D3487%26doi%3D10.1021%2Fjm3001373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmquist, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite <i>Plasmodium falciparum</i></span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3649</span>– <span class="NLM_lpage">3653</span>, <span class="refDoi"> DOI: 10.1021/jm8001026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1Gisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3649-3653&issue=12&author=M.+A.+Phillipsauthor=R.+Gujjarauthor=N.+A.+Malmquistauthor=J.+Whiteauthor=F.+El+Mazouniauthor=J.+Baldwinauthor=P.+K.+Rathod&title=Triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitors+with+potent+and+selective+activity+against+the+malaria+parasite+Plasmodium+falciparum&doi=10.1021%2Fjm8001026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitors with Potent and Selective Activity against the Malaria Parasite Plasmodium falciparum</span></div><div class="casAuthors">Phillips, Margaret A.; Gujjar, Ramesh; Malmquist, Nicholas A.; White, John; El Mazouni, Farah; Baldwin, Jeffrey; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3649-3653</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor I that is potent (KI = 15 nM) and species-selective (>5000-fold over the human enzyme) was identified by high-throughput screening.  The substituted triazolopyrimidine and its structural analogs were produced by an inexpensive three-step synthesis, and the series showed good assocn. between PfDHODH inhibition and parasite toxicity.  This study has identified the first nanomolar PfDHODH inhibitor with potent antimalarial activity in whole cells (EC50 = 79 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpklJJmj9EM77Vg90H21EOLACvtfcHk0li5NxZQAUlI9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1Gisbs%253D&md5=7bdbdc57d346ef3290623adc4aed89ee</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm8001026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001026%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DMalmquist%26aufirst%3DN.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DTriazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520with%2520potent%2520and%2520selective%2520activity%2520against%2520the%2520malaria%2520parasite%2520Plasmodium%2520falciparum%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D12%26spage%3D3649%26epage%3D3653%26doi%3D10.1021%2Fjm8001026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller-Maerki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krastel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5155</span>– <span class="NLM_lpage">5164</span>, <span class="refDoi"> DOI: 10.1021/jm100410f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100410f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVKqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5155-5164&issue=14&author=B.+K.+Yeungauthor=B.+Zouauthor=M.+Rottmannauthor=S.+B.+Lakshminarayanaauthor=S.+H.+Angauthor=S.+Y.+Leongauthor=J.+Tanauthor=J.+Wongauthor=S.+Keller-Maerkiauthor=C.+Fischliauthor=A.+Gohauthor=E.+K.+Schmittauthor=P.+Krastelauthor=E.+Francotteauthor=K.+Kuhenauthor=D.+Plouffeauthor=K.+Hensonauthor=T.+Wagnerauthor=E.+A.+Winzelerauthor=F.+Petersenauthor=R.+Brunauthor=V.+Dartoisauthor=T.+T.+Diaganaauthor=T.+H.+Keller&title=Spirotetrahydro+beta-carbolines+%28spiroindolones%29%3A+a+new+class+of+potent+and+orally+efficacious+compounds+for+the+treatment+of+malaria&doi=10.1021%2Fjm100410f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria</span></div><div class="casAuthors">Yeung, Bryan K. S.; Zou, Bin; Rottmann, Matthias; Lakshminarayana, Suresh B.; Ang, Shi Hua; Leong, Seh Yong; Tan, Jocelyn; Wong, Josephine; Keller-Maerki, Sonja; Fischli, Christoph; Goh, Anne; Schmitt, Esther K.; Krastel, Philipp; Francotte, Eric; Kuhen, Kelli; Plouffe, David; Henson, Kerstin; Wagner, Trixie; Winzeler, Elizabeth A.; Petersen, Frank; Brun, Reto; Dartois, Veronique; Diagana, Thierry T.; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5155-5164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antiplasmodial activity of a series of spirotetrahydro β-carbolines is described.  Racemic spiroazepineindole (1) was identified from a phenotypic screen on wild type Plasmodium falciparum with an in vitro IC50 of 90 nM.  Structure-activity relationships for the optimization of 1 to compd. 20a (IC50 = 0.2 nM) including the identification of the active 1R,3S enantiomer and elimination of metabolic liabilities is presented.  Improvement of the pharmacokinetic profile of the series translated to exceptional oral efficacy in the P. berghei infected malaria mouse model where full cure was achieved in four of five mice with three daily doses of 30 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE8TIv2auzE7Vg90H21EOLACvtfcHk0li5NxZQAUlI9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVKqu78%253D&md5=1c00e45eb1625a9f9c2bef41fcf9d075</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm100410f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100410f%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DLeong%26aufirst%3DS.%2BY.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DKeller-Maerki%26aufirst%3DS.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DKrastel%26aufirst%3DP.%26aulast%3DFrancotte%26aufirst%3DE.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DHenson%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DPetersen%26aufirst%3DF.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DSpirotetrahydro%2520beta-carbolines%2520%2528spiroindolones%2529%253A%2520a%2520new%2520class%2520of%2520potent%2520and%2520orally%2520efficacious%2520compounds%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D14%26spage%3D5155%26epage%3D5164%26doi%3D10.1021%2Fjm100410f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeyasu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, J. M.</span></span> <span> </span><span class="NLM_article-title">Expression and functional characterization of a <i>Plasmodium falciparum</i> Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">10782</span>– <span class="NLM_lpage">10787</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010554200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M010554200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=11145964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFCqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=10782-10787&issue=14&author=S.+Krishnaauthor=C.+Woodrowauthor=R.+Webbauthor=J.+Pennyauthor=K.+Takeyasuauthor=M.+Kimuraauthor=J.+M.+East&title=Expression+and+functional+characterization+of+a+Plasmodium+falciparum+Ca2%2B-ATPase+%28PfATP4%29+belonging+to+a+subclass+unique+to+apicomplexan+organisms&doi=10.1074%2Fjbc.M010554200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms</span></div><div class="casAuthors">Krishna, Sanjeev; Woodrow, Charles; Webb, Richard; Penny, Jeff; Takeyasu, Kunio; Kimura, Masatsugu; East, J. Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">10782-10787</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We have obtained a full-length P type ATPase sequence (PfATP4) encoded by Plasmodium falciparum and expressed PfATP4 in Xenopus laevis oocytes to study its function.  Comparison of the hitherto incomplete open reading frame with other Ca2+-ATPase sequences reveals that PfATP4 differs significantly from previously defined categories.  The Ca2+-dependent ATPase activity of PfATP4 is stimulated by a much broader range of [Ca2+]free (3.2-320 μM) than are an avian SERCA1 pump or rabbit SERCA 1a (maximal activity < 10 μM).  The activity of PfATP4 is resistant to inhibition by ouabain (200 μM) or thapsigargin (0.8 μM) but is inhibited by vanadate (1 mM) or cyclopiazonic acid (1 μM).  We used a quant. polymerase chain reaction to assay expression of mRNA encoding PfATP4 relative to that for β-tubulin in synchronized asexual stages and found variable expression throughout the life cycle with a maximal 5-fold increase in meronts compared with ring stages.  This anal. suggests that PfATP4 defines a novel subclass of Ca2+-ATPases unique to apicomplexan organisms and therefore offers potential as a drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSjQHYI-oI0rVg90H21EOLACvtfcHk0lhlYQ92nAjBlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFCqtb8%253D&md5=2283dd607f69f5ef414cc7af3b46f014</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010554200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010554200%26sid%3Dliteratum%253Aachs%26aulast%3DKrishna%26aufirst%3DS.%26aulast%3DWoodrow%26aufirst%3DC.%26aulast%3DWebb%26aufirst%3DR.%26aulast%3DPenny%26aufirst%3DJ.%26aulast%3DTakeyasu%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DM.%26aulast%3DEast%26aufirst%3DJ.%2BM.%26atitle%3DExpression%2520and%2520functional%2520characterization%2520of%2520a%2520Plasmodium%2520falciparum%2520Ca2%252B-ATPase%2520%2528PfATP4%2529%2520belonging%2520to%2520a%2520subclass%2520unique%2520to%2520apicomplexan%2520organisms%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D14%26spage%3D10782%26epage%3D10787%26doi%3D10.1074%2Fjbc.M010554200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">Na(+) regulation in the malaria parasite <i>Plasmodium falciparum</i> involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.chom.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=23414762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVOhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=227-237&issue=2&author=N.+J.+Spillmanauthor=R.+J.+Allenauthor=C.+W.+McNamaraauthor=B.+K.+Yeungauthor=E.+A.+Winzelerauthor=T.+T.+Diaganaauthor=K.+Kirk&title=Na%28%2B%29+regulation+in+the+malaria+parasite+Plasmodium+falciparum+involves+the+cation+ATPase+PfATP4+and+is+a+target+of+the+spiroindolone+antimalarials&doi=10.1016%2Fj.chom.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Na+ Regulation in the Malaria Parasite Plasmodium falciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone Antimalarials</span></div><div class="casAuthors">Spillman, Natalie J.; Allen, Richard J. W.; McNamara, Case W.; Yeung, Bryan K. S.; Winzeler, Elizabeth A.; Diagana, Thierry T.; Kirk, Kiaran</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">227-237</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The malaria parasite Plasmodium falciparum establishes in the host erythrocyte plasma membrane new permeability pathways that mediate nutrient uptake into the infected cell.  These pathways simultaneously allow Na+ influx, causing [Na+] in the infected erythrocyte cytosol to increase to high levels.  The intraerythrocytic parasite itself maintains a low cytosolic [Na+] via unknown mechanisms.  Here the authors present evidence that the intraerythrocytic parasite actively extrudes Na+ against an inward gradient via PfATP4, a parasite plasma membrane protein with sequence similarities to Na+-ATPases of lower eukaryotes.  Mutations in PfATP4 confer resistance to a potent class of antimalarials, the spiroindolones.  Consistent with this, the spiroindolones cause a profound disruption in parasite Na+ homeostasis, which is attenuated in parasites bearing resistance-conferring mutations in PfATP4.  The mutant parasites also show some impairment of Na+ regulation.  Taken together, the authors' results are consistent with PfATP4 being a Na+ efflux ATPase and a target of the spiroindolones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTK9LqgiWhDLVg90H21EOLACvtfcHk0lhlYQ92nAjBlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVOhtL4%253D&md5=415ec48b192ee6ea4681c97695b2b208</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DAllen%26aufirst%3DR.%2BJ.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DNa%2528%252B%2529%2520regulation%2520in%2520the%2520malaria%2520parasite%2520Plasmodium%2520falciparum%2520involves%2520the%2520cation%2520ATPase%2520PfATP4%2520and%2520is%2520a%2520target%2520of%2520the%2520spiroindolone%2520antimalarials%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2013%26volume%3D13%26issue%3D2%26spage%3D227%26epage%3D237%26doi%3D10.1016%2Fj.chom.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrand-Lapierre, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justino de Almeida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, A. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diep, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endsley, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedewa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiguemde, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Alejandre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRisi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span> <span> </span><span class="NLM_article-title">(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">E5455</span>– <span class="NLM_lpage">6462</span>, <span class="refDoi"> DOI: 10.1073/pnas.1414221111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1073%2Fpnas.1414221111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25453091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSitb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E5455-6462&issue=50&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=D.+Ebertauthor=Y.+Salinasauthor=A.+Pradhanauthor=A.+M.+Lehaneauthor=M.-E.+Myrand-Lapierreauthor=K.+G.+O%E2%80%99Loughlinauthor=D.+M.+Shacklefordauthor=M.+Justino+de+Almeidaauthor=A.+K.+Carrilloauthor=J.+A.+Clarkauthor=A.+S.+M.+Dennisauthor=J.+Diepauthor=X.+Dengauthor=S.+Duffyauthor=A.+N.+Endsleyauthor=G.+Fedewaauthor=W.+A.+Guiguemdeauthor=M.+G.+G%C3%B3mezauthor=G.+Holbrookauthor=J.+Horstauthor=C.+C.+Kimauthor=J.+Liuauthor=M.+C.+S.+Leeauthor=A.+Mathenyauthor=M.+S.+Mart%C3%ADnezauthor=G.+Millerauthor=A.+Rodr%C3%ADguez-Alejandreauthor=L.+Sanzauthor=M.+Sigalauthor=N.+J.+Spillmanauthor=P.+D.+Steinauthor=Z.+Wangauthor=F.+Zhuauthor=D.+Watersonauthor=S.+Knappauthor=A.+Shelatauthor=V.+M.+Averyauthor=D.+A.+Fidockauthor=F.-J.+Gamoauthor=S.+A.+Charmanauthor=J.+C.+Mirsalisauthor=H.+Maauthor=S.+Ferrerauthor=K.+Kirkauthor=I.+Angulo-Barturenauthor=D.+E.+Kyleauthor=J.+L.+DeRisiauthor=D.+M.+Floydauthor=R.+K.+Guy&title=%28%2B%29-SJ733%2C+a+clinical+candidate+for+malaria+that+acts+through+ATP4+to+induce+rapid+host-mediated+clearance+of+Plasmodium&doi=10.1073%2Fpnas.1414221111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Ebert, Daniel; Salinas, Yandira; Pradhan, Anupam; Lehane, Adele M.; Myrand-Lapierre, Marie-Eve; O'Loughlin, Kathleen G.; Shackleford, David M.; Justino de Almeida, Mariana; Carrillo, Angela K.; Clark, Julie A.; Dennis, Adelaide S. M.; Diep, Jonathon; Deng, Xiaoyan; Duffy, Sandra; Endsley, Aaron N.; Fedewa, Greg; Guiguemde, W. Armand; Gomez, Maria G.; Holbrook, Gloria; Horst, Jeremy; Kim, Charles C.; Liu, Jian; Lee, Marcus C. S.; Matheny, Amy; Martinez, Maria Santos; Miller, Gregory; Rodriguez-Alejandre, Ane; Sanz, Laura; Sigal, Martina; Spillman, Natalie J.; Stein, Philip D.; Wang, Zheng; Zhu, Fangyi; Waterson, David; Knapp, Spencer; Shelat, Anang; Avery, Vicky M.; Fidock, David A.; Gamo, Francisco-Javier; Charman, Susan A.; Mirsalis, Jon C.; Ma, Hongshen; Ferrer, Santiago; Kirk, Kiaran; Angulo-Barturen, Inigo; Kyle, Dennis E.; DeRisi, Joseph L.; Floyd, David M.; Guy, R. Kiplin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">E5455-E5462</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drug discovery for malaria has been transformed in the last 5 years by the discovery of many new lead compds. identified by phenotypic screening.  The process of developing these compds. as drug leads and studying the cellular responses they induce is revealing new targets that regulate key processes in the Plasmodium parasites that cause malaria.  We disclose herein that the clin. candidate (+)-SJ733 acts upon one of these targets, ATP4.  ATP4 is thought to be a cation-transporting ATPase responsible for maintaining low intracellular Na+ levels in the parasite.  Treatment of parasitized erythrocytes with (+)-SJ733 in vitro caused a rapid perturbation of Na+ homeostasis in the parasite.  This perturbation was followed by profound phys. changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence.  These changes are proposed to underpin the rapid (+)-SJ733-induced clearance of parasites seen in vivo.  Plasmodium falciparum ATPase 4 (pfatp4) mutations that confer resistance to (+)-SJ733 carry a high fitness cost.  The speed with which (+)-SJ733 kills parasites and the high fitness cost assocd. with resistance-conferring mutations appear to slow and suppress the selection of highly drug-resistant mutants in vivo.  Together, our data suggest that inhibitors of PfATP4 have highly attractive features for fast-acting antimalarials to be used in the global eradication campaign.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNc7Cu9b336LVg90H21EOLACvtfcHk0lj0WQPgubRVDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSitb3I&md5=45ff827f956702f2bd9761ae9bc8879a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1414221111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1414221111%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DEbert%26aufirst%3DD.%26aulast%3DSalinas%26aufirst%3DY.%26aulast%3DPradhan%26aufirst%3DA.%26aulast%3DLehane%26aufirst%3DA.%2BM.%26aulast%3DMyrand-Lapierre%26aufirst%3DM.-E.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%2BG.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DJustino%2Bde%2BAlmeida%26aufirst%3DM.%26aulast%3DCarrillo%26aufirst%3DA.%2BK.%26aulast%3DClark%26aufirst%3DJ.%2BA.%26aulast%3DDennis%26aufirst%3DA.%2BS.%2BM.%26aulast%3DDiep%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DEndsley%26aufirst%3DA.%2BN.%26aulast%3DFedewa%26aufirst%3DG.%26aulast%3DGuiguemde%26aufirst%3DW.%2BA.%26aulast%3DG%25C3%25B3mez%26aufirst%3DM.%2BG.%26aulast%3DHolbrook%26aufirst%3DG.%26aulast%3DHorst%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DC.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DMatheny%26aufirst%3DA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DM.%2BS.%26aulast%3DMiller%26aufirst%3DG.%26aulast%3DRodr%25C3%25ADguez-Alejandre%26aufirst%3DA.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DSigal%26aufirst%3DM.%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DStein%26aufirst%3DP.%2BD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DShelat%26aufirst%3DA.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMirsalis%26aufirst%3DJ.%2BC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DKirk%26aufirst%3DK.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DDeRisi%26aufirst%3DJ.%2BL.%26aulast%3DFloyd%26aufirst%3DD.%2BM.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3D%2528%252B%2529-SJ733%252C%2520a%2520clinical%2520candidate%2520for%2520malaria%2520that%2520acts%2520through%2520ATP4%2520to%2520induce%2520rapid%2520host-mediated%2520clearance%2520of%2520Plasmodium%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D50%26spage%3DE5455%26epage%3D6462%26doi%3D10.1073%2Fpnas.1414221111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manary, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinetz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1021/cb500616x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500616x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKktrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=413-420&issue=2&author=E.+L.+Flanneryauthor=C.+W.+McNamaraauthor=S.+W.+Kimauthor=T.+S.+Katoauthor=F.+Liauthor=C.+H.+Tengauthor=K.+Gagaringauthor=M.+J.+Manaryauthor=R.+Barboaauthor=S.+Meisterauthor=K.+Kuhenauthor=J.+M.+Vinetzauthor=A.+K.+Chatterjeeauthor=E.+A.+Winzeler&title=Mutations+in+the+P-type+cation-transporter+ATPase+4%2C+PfATP4%2C+mediate+resistance+to+both+aminopyrazole+and+spiroindolone+antimalarials&doi=10.1021%2Fcb500616x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials</span></div><div class="casAuthors">Flannery, Erika L.; McNamara, Case W.; Kim, Sang Wan; Kato, Tomoyo Sakata; Li, Fengwu; Teng, Christine H.; Gagaring, Kerstin; Manary, Micah J.; Barboa, Rachel; Meister, Stephan; Kuhen, Kelli; Vinetz, Joseph M.; Chatterjee, Arnab K.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-420</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aminopyrazoles are a new class of antimalarial compds. identified in a cellular antiparasitic screen with potent activity against Plasmodium falciparum asexual and sexual stage parasites.  To investigate their unknown mechanism of action and thus identify their target, we cultured parasites in the presence of a representative member of the aminopyrazole series, GNF-Pf4492, to select for resistance.  Whole genome sequencing of three resistant lines showed that each had acquired independent mutations in a P-type cation-transporter ATPase, PfATP4 (PF3D7_1211900), a protein implicated as the novel Plasmodium spp. target of another, structurally unrelated, class of antimalarials called the spiroindolones and characterized as an important sodium transporter of the cell.  Similarly to the spiroindolones, GNF-Pf4492 blocks parasite transmission to mosquitoes and disrupts intracellular sodium homeostasis.  Our data demonstrate that PfATP4 plays a crit. role in cellular processes, can be inhibited by two distinct antimalarial pharmacophores, and supports the recent observations that PfATP4 is a crit. antimalarial target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvVy0dxOiKa7Vg90H21EOLACvtfcHk0lhWXz0L2H0V4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKktrnF&md5=c839292aa357bc027e0b4ff0f2b39e44</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fcb500616x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500616x%26sid%3Dliteratum%253Aachs%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKato%26aufirst%3DT.%2BS.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DTeng%26aufirst%3DC.%2BH.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DManary%26aufirst%3DM.%2BJ.%26aulast%3DBarboa%26aufirst%3DR.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DVinetz%26aufirst%3DJ.%2BM.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMutations%2520in%2520the%2520P-type%2520cation-transporter%2520ATPase%25204%252C%2520PfATP4%252C%2520mediate%2520resistance%2520to%2520both%2520aminopyrazole%2520and%2520spiroindolone%2520antimalarials%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D2%26spage%3D413%26epage%3D420%26doi%3D10.1021%2Fcb500616x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyvratt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebayang, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasiak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belen Jimenez-Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortagere, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, L. W.</span></span> <span> </span><span class="NLM_article-title">Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic <i>Plasmodium falciparum</i></span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5521</span>, <span class="refDoi"> DOI: 10.1038/ncomms6521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fncomms6521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25422853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFWqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5521&author=A.+B.+Vaidyaauthor=J.+M.+Morriseyauthor=Z.+Zhangauthor=S.+Dasauthor=T.+M.+Dalyauthor=T.+D.+Ottoauthor=N.+J.+Spillmanauthor=M.+Wyvrattauthor=P.+Sieglauthor=J.+Marfurtauthor=G.+Wirjanataauthor=B.+F.+Sebayangauthor=R.+N.+Priceauthor=A.+Chatterjeeauthor=A.+Nagleauthor=M.+Stasiakauthor=S.+A.+Charmanauthor=I.+Angulo-Barturenauthor=S.+Ferrerauthor=M.+Belen+Jimenez-Diazauthor=M.+S.+Martinezauthor=F.+J.+Gamoauthor=V.+M.+Averyauthor=A.+Rueckerauthor=M.+Delvesauthor=K.+Kirkauthor=M.+Berrimanauthor=S.+Kortagereauthor=J.+Burrowsauthor=E.+Fanauthor=L.+W.+Bergman&title=Pyrazoleamide+compounds+are+potent+antimalarials+that+target+Na%2B+homeostasis+in+intraerythrocytic+Plasmodium+falciparum&doi=10.1038%2Fncomms6521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum</span></div><div class="casAuthors">Vaidya, Akhil B.; Morrisey, Joanne M.; Zhang, Zhongsheng; Das, Sudipta; Daly, Thomas M.; Otto, Thomas D.; Spillman, Natalie J.; Wyvratt, Matthew; Siegl, Peter; Marfurt, Jutta; Wirjanata, Grennady; Sebayang, Boni F.; Price, Ric N.; Chatterjee, Arnab; Nagle, Advait; Stasiak, Marcin; Charman, Susan A.; Angulo-Barturen, Inigo; Ferrer, Santiago; Belen Jimenez-Diaz, Maria; Martinez, Maria Santos; Gamo, Francisco Javier; Avery, Vicky M.; Ruecker, Andrea; Delves, Michael; Kirk, Kiaran; Berriman, Matthew; Kortagere, Sandhya; Burrows, Jeremy; Fan, Erkang; Bergman, Lawrence W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5521</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The quest for new antimalarial drugs, esp. those with novel modes of action, is essential in the face of emerging drug-resistant parasites.  Here we describe a new chem. class of mols., pyrazoleamides, with potent activity against human malaria parasites and showing remarkably rapid parasite clearance in an in vivo model.  Investigations involving pyrazoleamide-resistant parasites, whole-genome sequencing and gene transfers reveal that mutations in two proteins, a calcium-dependent protein kinase (PfCDPK5) and a P-type cation-ATPase (PfATP4), are necessary to impart full resistance to these compds.  A pyrazoleamide compd. causes a rapid disruption of Na+ regulation in blood-stage Plasmodium falciparum parasites.  Similar effect on Na+ homeostasis was recently reported for spiroindolones, which are antimalarials of a chem. class quite distinct from pyrazoleamides.  Our results reveal that disruption of Na+ homeostasis in malaria parasites is a promising mode of antimalarial action mediated by at least two distinct chem. classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreHdwzsZqcX7Vg90H21EOLACvtfcHk0lhWXz0L2H0V4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFWqtrs%253D&md5=479ca0ae2654088f6399dc6a026567f1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fncomms6521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms6521%26sid%3Dliteratum%253Aachs%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DDaly%26aufirst%3DT.%2BM.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DWyvratt%26aufirst%3DM.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DSebayang%26aufirst%3DB.%2BF.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DStasiak%26aufirst%3DM.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DBelen%2BJimenez-Diaz%26aufirst%3DM.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DK.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DKortagere%26aufirst%3DS.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DE.%26aulast%3DBergman%26aufirst%3DL.%2BW.%26atitle%3DPyrazoleamide%2520compounds%2520are%2520potent%2520antimalarials%2520that%2520target%2520Na%252B%2520homeostasis%2520in%2520intraerythrocytic%2520Plasmodium%2520falciparum%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D5521%26doi%3D10.1038%2Fncomms6521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spillman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs</span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ijpddr.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26401486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC283ltlWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=149-162&issue=3&author=N.+J.+Spillmanauthor=K.+Kirk&title=The+malaria+parasite+cation+ATPase+PfATP4+and+its+role+in+the+mechanism+of+action+of+a+new+arsenal+of+antimalarial+drugs&doi=10.1016%2Fj.ijpddr.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs</span></div><div class="casAuthors">Spillman Natalie Jane; Kirk Kiaran</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-62</span>
        ISSN:<span class="NLM_cas:issn">2211-3207</span>.
    </div><div class="casAbstract">The intraerythrocytic malaria parasite, Plasmodium falciparum, maintains a low cytosolic Na(+) concentration and the plasma membrane P-type cation translocating ATPase 'PfATP4' has been implicated as playing a key role in this process.  PfATP4 has been the subject of significant attention in recent years as mutations in this protein confer resistance to a growing number of new antimalarial compounds, including the spiroindolones, the pyrazoles, the dihydroisoquinolones, and a number of the antimalarial agents in the Medicines for Malaria Venture's 'Malaria Box'.  On exposure of parasites to these compounds there is a rapid disruption of cytosolic Na(+).  Whether, and if so how, such chemically distinct compounds interact with PfATP4, and how such interactions lead to parasite death, is not yet clear.  The fact that multiple different chemical classes have converged upon PfATP4 highlights its significance as a potential target for new generation antimalarial agents.  A spiroindolone (KAE609, now known as cipargamin) has progressed through Phase I and IIa clinical trials with favourable results.  In this review we consider the physiological role of PfATP4, summarise the current repertoire of antimalarial compounds for which PfATP4 is implicated in their mechanism of action, and provide an outlook on translation from target identification in the laboratory to patient treatment in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuXVN_00JXMBfKb6ELK8t0fW6udTcc2eYAsDBWJKn_0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ltlWitw%253D%253D&md5=a56f7c306f3d3e7f9b0479c8650fb937</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DSpillman%26aufirst%3DN.%2BJ.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DThe%2520malaria%2520parasite%2520cation%2520ATPase%2520PfATP4%2520and%2520its%2520role%2520in%2520the%2520mechanism%2520of%2520action%2520of%2520a%2520new%2520arsenal%2520of%2520antimalarial%2520drugs%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2015%26volume%3D5%26issue%3D3%26spage%3D149%26epage%3D162%26doi%3D10.1016%2Fj.ijpddr.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">Diverse chemotypes disrupt ion homeostasis in the Malaria parasite</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1111/mmi.12765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1111%2Fmmi.12765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25145582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSku7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=327-339&issue=2&author=A.+M.+Lehaneauthor=M.+C.+Ridgwayauthor=E.+Bakerauthor=K.+Kirk&title=Diverse+chemotypes+disrupt+ion+homeostasis+in+the+Malaria+parasite&doi=10.1111%2Fmmi.12765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse chemotypes disrupt ion homeostasis in the malaria parasite</span></div><div class="casAuthors">Lehane, Adele M.; Ridgway, Melanie C.; Baker, Eileen; Kirk, Kiaran</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-339</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The antimalarial spiroindolones disrupt Plasmodium falciparum Na+ regulation and induce an alkalinization of the parasite cytosol.  It has been proposed that they do so by inhibiting PfATP4, a parasite plasma membrane P-type ATPase postulated to export Na+ and import H+ equiv.  Here, we screened the 400 antiplasmodial compds. of the open access Malaria Box for their effects on parasite ion regulation.  Twenty eight compds. affected parasite Na+ and pH regulation in a manner consistent with PfATP4 inhibition.  Six of these, with chem. diverse structures, were selected for further anal.  All 6 showed reduced antiplasmodial activity against spiroindolone-resistant parasites carrying mutations in pfatp4.  We exposed parasites to incrementally increasing concns. of 2 of the 6 compds. and in both cases obtained resistant parasites with mutations in pfatp4.  The finding that diverse chemotypes have an apparently similar mechanism of action indicates that PfATP4 may be a significant Achilles' heel for the parasite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_hf1RONxDZLVg90H21EOLACvtfcHk0ljn0KIQZ9VEkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSku7nK&md5=f541327849168f5d6b0be80684370ab3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fmmi.12765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fmmi.12765%26sid%3Dliteratum%253Aachs%26aulast%3DLehane%26aufirst%3DA.%2BM.%26aulast%3DRidgway%26aufirst%3DM.%2BC.%26aulast%3DBaker%26aufirst%3DE.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DDiverse%2520chemotypes%2520disrupt%2520ion%2520homeostasis%2520in%2520the%2520Malaria%2520parasite%26jtitle%3DMol.%2520Microbiol.%26date%3D2014%26volume%3D94%26issue%3D2%26spage%3D327%26epage%3D339%26doi%3D10.1111%2Fmmi.12765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, A. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span> <span> </span><span class="NLM_article-title">Cell swelling induced by the antimalarial KAE609 (cipargamin) and other PfATP4-associated antimalarials</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e00087-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.00087-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.00087-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29555632" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00087-18&author=A.+S.+M.+Dennisauthor=A.+M.+Lehaneauthor=M.+C.+Ridgwayauthor=J.+P.+Holleranauthor=K.+Kirk&title=Cell+swelling+induced+by+the+antimalarial+KAE609+%28cipargamin%29+and+other+PfATP4-associated+antimalarials&doi=10.1128%2FAAC.00087-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1128%2FAAC.00087-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00087-18%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DA.%2BS.%2BM.%26aulast%3DLehane%26aufirst%3DA.%2BM.%26aulast%3DRidgway%26aufirst%3DM.%2BC.%26aulast%3DHolleran%26aufirst%3DJ.%2BP.%26aulast%3DKirk%26aufirst%3DK.%26atitle%3DCell%2520swelling%2520induced%2520by%2520the%2520antimalarial%2520KAE609%2520%2528cipargamin%2529%2520and%2520other%2520PfATP4-associated%2520antimalarials%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De00087-18%26doi%3D10.1128%2FAAC.00087-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosling, J. E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehane, A. M.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization and chemical inhibition of PfATP4-associated Na(+)-ATPase activity in <i>Plasmodium falciparum</i> membranes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">13327</span>– <span class="NLM_lpage">13337</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.003640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.RA118.003640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29986883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyjt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=13327-13337&issue=34&author=J.+E.+O.+Roslingauthor=M.+C.+Ridgwayauthor=R.+L.+Summersauthor=K.+Kirkauthor=A.+M.+Lehane&title=Biochemical+characterization+and+chemical+inhibition+of+PfATP4-associated+Na%28%2B%29-ATPase+activity+in+Plasmodium+falciparum+membranes&doi=10.1074%2Fjbc.RA118.003640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes</span></div><div class="casAuthors">Rosling, James E. O.; Ridgway, Melanie C.; Summers, Robert L.; Kirk, Kiaran; Lehane, Adele M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">13327-13337</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The antimalarial activity of chem. diverse compds., including the clin. candidate cipargamin, has been linked to the ATPase PfATP4 in the malaria-causing parasite Plasmodium falciparum.  The characterization of PfATP4 has been hampered by the inability thus far to achieve its functional expression in a heterologous system.  Here, we optimized a membrane ATPase assay to probe the function of PfATP4 and its chem. sensitivity.  We found that cipargamin inhibited the Na+-dependent ATPase activity present in P. falciparum membranes from WT parasites and that its potency was reduced in cipargamin-resistant PfATP4-mutant parasites.  The cipargamin-sensitive fraction of membrane ATPase activity was inhibited by all 28 of the compds. in the "Malaria Box" shown previously to disrupt ion regulation in P. falciparum in a cipargamin-like manner.  This is consistent with PfATP4 being the direct target of these compds.  Characterization of the cipargamin-sensitive ATPase activity yielded data consistent with PfATP4 being a Na+ transporter that is sensitive to physiol. relevant perturbations of pH, but not of [K+] or [Ca2+].  With an apparent Km for ATP of 0.2 mm and an apparent Km for Na+ of 16-17 mm, the protein is predicted to operate at below its half-maximal rate under normal physiol. conditions, allowing the rate of Na+ efflux to increase in response to an increase in cytosolic [Na+].  In membranes from a cipargamin-resistant PfATP4-mutant line, the apparent Km for Na+ is slightly elevated.  Our study provides new insights into the biochem. properties and chem. sensitivity of an important new antimalarial drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfYHxHytLJh7Vg90H21EOLACvtfcHk0ljn0KIQZ9VEkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyjt77L&md5=0f1c5b22f03f828b2d1a04f685dc563d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.003640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.003640%26sid%3Dliteratum%253Aachs%26aulast%3DRosling%26aufirst%3DJ.%2BE.%2BO.%26aulast%3DRidgway%26aufirst%3DM.%2BC.%26aulast%3DSummers%26aufirst%3DR.%2BL.%26aulast%3DKirk%26aufirst%3DK.%26aulast%3DLehane%26aufirst%3DA.%2BM.%26atitle%3DBiochemical%2520characterization%2520and%2520chemical%2520inhibition%2520of%2520PfATP4-associated%2520Na%2528%252B%2529-ATPase%2520activity%2520in%2520Plasmodium%2520falciparum%2520membranes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26issue%3D34%26spage%3D13327%26epage%3D13337%26doi%3D10.1074%2Fjbc.RA118.003640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A.-M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, T. L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Møller, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, P.</span></span> <span> </span><span class="NLM_article-title">Modulatory and catalytic modes of ATP binding by the calcium pump</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2305</span>– <span class="NLM_lpage">2314</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fsj.emboj.7601135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16710301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD28zktlaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=2305-2314&issue=11&author=A.-M.+L.+Jensenauthor=T.+L.-M.+S%C3%B8rensenauthor=C.+Olesenauthor=J.+V.+M%C3%B8llerauthor=P.+Nissen&title=Modulatory+and+catalytic+modes+of+ATP+binding+by+the+calcium+pump&doi=10.1038%2Fsj.emboj.7601135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Modulatory and catalytic modes of ATP binding by the calcium pump</span></div><div class="casAuthors">Jensen Anne-Marie Lund; Sorensen Thomas Lykke-Moller; Olesen Claus; Moller Jesper Vuust; Nissen Poul</div><div class="citationInfo"><span class="NLM_cas:title">The EMBO journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2305-14</span>
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    </div><div class="casAbstract">We present crystal structures of the calcium-free E2 state of the sarcoplasmic reticulum Ca2+ -ATPase, stabilized by the inhibitor thapsigargin and the ATP analog AMPPCP.  The structures allow us to describe the ATP binding site in a modulatory mode uncoupled from the Asp351 phosphorylation site.  The Glu439 side chain interacts with AMPPCP via an Mg2+ ion in accordance with previous Fe2+ -cleavage studies implicating this residue in the ATPase cycle and in magnesium binding.  Functional data on Ca2+ mediated activation indicate that the crystallized state represents an initial stage of ATP modulated deprotonation of E2, preceding the binding of Ca2+ ions in the membrane from the cytoplasmic side.  We propose a mechanism of Ca2+ activation of phosphorylation leading directly from the compact E2-ATP form to the Ca2E1-ATP state.  In addition, a role of Glu439 in ATP modulation of other steps of the functional cycle is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQH72L5PQJlJwaK-_ZudimnfW6udTcc2eaX0O9eUlmq77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zktlaqtQ%253D%253D&md5=1db5b38b24405c5b1d40852c941eaadf</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601135%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.-M.%2BL.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DT.%2BL.-M.%26aulast%3DOlesen%26aufirst%3DC.%26aulast%3DM%25C3%25B8ller%26aufirst%3DJ.%2BV.%26aulast%3DNissen%26aufirst%3DP.%26atitle%3DModulatory%2520and%2520catalytic%2520modes%2520of%2520ATP%2520binding%2520by%2520the%2520calcium%2520pump%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26issue%3D11%26spage%3D2305%26epage%3D2314%26doi%3D10.1038%2Fsj.emboj.7601135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldgof, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostylev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manary, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanhope, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slayman, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaro, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">27806</span>, <span class="refDoi"> DOI: 10.1038/srep27806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fsrep27806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27291296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSlu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=27806&author=G.+M.+Goldgofauthor=J.+D.+Durrantauthor=S.+Ottilieauthor=E.+Vigilauthor=K.+E.+Allenauthor=F.+Gunawanauthor=M.+Kostylevauthor=K.+A.+Hendersonauthor=J.+Yangauthor=J.+Schenkenauthor=G.+M.+LaMonteauthor=M.+J.+Manaryauthor=A.+Muraoauthor=M.+Nachonauthor=R.+Stanhopeauthor=M.+Prescottauthor=C.+W.+McNamaraauthor=C.+W.+Slaymanauthor=R.+E.+Amaroauthor=Y.+Suzukiauthor=E.+A.+Winzeler&title=Comparative+chemical+genomics+reveal+that+the+spiroindolone+antimalarial+KAE609+%28Cipargamin%29+is+a+P-type+ATPase+inhibitor&doi=10.1038%2Fsrep27806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor</span></div><div class="casAuthors">Goldgof, Gregory M.; Durrant, Jacob D.; Ottilie, Sabine; Vigil, Edgar; Allen, Kenneth E.; Gunawan, Felicia; Kostylev, Maxim; Henderson, Kiersten A.; Yang, Jennifer; Schenken, Jake; LaMonte, Gregory M.; Manary, Micah J.; Murao, Ayako; Nachon, Marie; Stanhope, Rebecca; Prescott, Maximo; McNamara, Case W.; Slayman, Carolyn W.; Amaro, Rommie E.; Suzuki, Yo; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27806</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The spiroindolones, a new class of antimalarial medicines discovered in a cellular screen, are rendered less active by mutations in a parasite P-type ATPase, PfATP4.  We show here that Saccharomyces cerevisiae also acquires mutations in a gene encoding a P-type ATPase (ScPMA1) after exposure to spiroindolones and that these mutations are sufficient for resistance.  KAE609 resistance mutations in ScPMA1 do not confer resistance to unrelated antimicrobials, but do confer cross sensitivity to the alkyl-lysophospholipid edelfosine, which is known to displace ScPma1p from the plasma membrane.  Using an in vitro cell-free assay, we demonstrate that KAE609 directly inhibits ScPma1p ATPase activity.  KAE609 also increases cytoplasmic hydrogen ion concns. in yeast cells.  Computer docking into a ScPma1p homol. model identifies a binding mode that supports genetic resistance determinants and in vitro exptl. structure-activity relationships in both P. falciparum and S. cerevisiae.  This model also suggests a shared binding site with the dihydroisoquinolones antimalarials.  Our data support a model in which KAE609 exerts its antimalarial activity by directly interfering with P-type ATPase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe1clRbyKPb7Vg90H21EOLACvtfcHk0lg4ZtMBigeBKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSlu7%252FK&md5=b6c042fd4d15ed7c3339ba297d860266</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fsrep27806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep27806%26sid%3Dliteratum%253Aachs%26aulast%3DGoldgof%26aufirst%3DG.%2BM.%26aulast%3DDurrant%26aufirst%3DJ.%2BD.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DVigil%26aufirst%3DE.%26aulast%3DAllen%26aufirst%3DK.%2BE.%26aulast%3DGunawan%26aufirst%3DF.%26aulast%3DKostylev%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DK.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSchenken%26aufirst%3DJ.%26aulast%3DLaMonte%26aufirst%3DG.%2BM.%26aulast%3DManary%26aufirst%3DM.%2BJ.%26aulast%3DMurao%26aufirst%3DA.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DStanhope%26aufirst%3DR.%26aulast%3DPrescott%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DSlayman%26aufirst%3DC.%2BW.%26aulast%3DAmaro%26aufirst%3DR.%2BE.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DComparative%2520chemical%2520genomics%2520reveal%2520that%2520the%2520spiroindolone%2520antimalarial%2520KAE609%2520%2528Cipargamin%2529%2520is%2520a%2520P-type%2520ATPase%2520inhibitor%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D27806%26doi%3D10.1038%2Fsrep27806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasquilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span> <span> </span><span class="NLM_article-title">Metabolomic profiling of the Malaria Box reveals antimalarial target pathways</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6635</span>– <span class="NLM_lpage">6649</span>, <span class="refDoi"> DOI: 10.1128/AAC.01224-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01224-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27572391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitV2gsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6635-6649&issue=11&author=E.+L.+Allmanauthor=H.+J.+Painterauthor=J.+Samraauthor=M.+Carrasquillaauthor=M.+Llinas&title=Metabolomic+profiling+of+the+Malaria+Box+reveals+antimalarial+target+pathways&doi=10.1128%2FAAC.01224-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomic profiling of the malaria box reveals antimalarial target pathways</span></div><div class="casAuthors">Allman, Erik L.; Painter, Heather J.; Samra, Jasmeet; Carrasquilla, Manuela; Llinas, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6635-6649</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The threat of widespread drug resistance to frontline antimalarials has renewed the urgency for identifying inexpensive chemotherapeutic compds. that are effective against Plasmodium falciparum, the parasite species responsible for the greatest no. of malaria-related deaths worldwide.  To aid in the fight against malaria, a recent extensive screening campaign has generated thousands of lead compds. with low micromolar activity against blood stage parasites.  A subset of these leads has been compiled by the Medicines for Malaria Venture (MMV) into a collection of structurally diverse compds. known as the MMV Malaria Box.  Currently, little is known regarding the activity of these Malaria Box compds. on parasite metab. during intraerythrocytic development, and a majority of the targets for these drugs have yet to be defined.  Here we interrogated the in vitro metabolic effects of 189 drugs (including 169 of the drug-like compds. from the Malaria Box) using ultra-high-performance liq. chromatog.-mass spectrometry (UHPLC-MS).  The resulting metabolic fingerprints provide information on the parasite biochem. pathways affected by pharmacol. intervention and offer a crit. blueprint for selecting and advancing lead compds. as next-generation antimalarial drugs.  Our results reveal several major classes of metabolic disruption, which allow us to predict the mode of action (MoA) for many of the Malaria Box compds.  We anticipate that future combination therapies will be greatly informed by these results, allowing for the selection of appropriate drug combinations that simultaneously target multiple metabolic pathways, with the aim of eliminating malaria and forestalling the expansion of drug-resistant parasites in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzNnR2JibEGrVg90H21EOLACvtfcHk0lg4ZtMBigeBKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitV2gsbY%253D&md5=d0e52536f10b6faebd13fe20ae3861f3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FAAC.01224-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01224-16%26sid%3Dliteratum%253Aachs%26aulast%3DAllman%26aufirst%3DE.%2BL.%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DSamra%26aufirst%3DJ.%26aulast%3DCarrasquilla%26aufirst%3DM.%26aulast%3DLlinas%26aufirst%3DM.%26atitle%3DMetabolomic%2520profiling%2520of%2520the%2520Malaria%2520Box%2520reveals%2520antimalarial%2520target%2520pathways%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26issue%3D11%26spage%3D6635%26epage%3D6649%26doi%3D10.1128%2FAAC.01224-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobbold, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijagal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacRae, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerman, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralph, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConville, M. J.</span></span> <span> </span><span class="NLM_article-title">Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6650</span>– <span class="NLM_lpage">6663</span>, <span class="refDoi"> DOI: 10.1128/AAC.01226-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01226-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27572396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitV2gtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6650-6663&issue=11&author=D.+J.+Creekauthor=H.+H.+Chuaauthor=S.+A.+Cobboldauthor=B.+Nijagalauthor=J.+I.+MacRaeauthor=B.+K.+Dickermanauthor=P.+R.+Gilsonauthor=S.+A.+Ralphauthor=M.+J.+McConville&title=Metabolomics-based+screening+of+the+Malaria+Box+reveals+both+novel+and+established+mechanisms+of+action&doi=10.1128%2FAAC.01226-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action</span></div><div class="casAuthors">Creek, Darren J.; Chua, Hwa H.; Cobbold, Simon A.; Nijagal, Brunda; MacRae, James I.; Dickerman, Benjamin K.; Gilson, Paul R.; Ralph, Stuart A.; McConville, Malcolm J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6650-6663</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">High-throughput phenotypic screening of chem. libraries has resulted in the identification of thousands of compds. with potent antimalarial activity, although in most cases, the mechanism(s) of action of these compds. remains unknown.  Here we have investigated the mode of action of 90 antimalarial compds. derived from the Malaria Box collection using high-coverage, untargeted metabolomics anal.  Approx. half of the tested compds. induced significant metabolic perturbations in in vitro cultures of Plasmodium falciparum.  In most cases, the metabolic profiles were highly correlated with known antimalarials, in particular artemisinin, the 4-aminoquinolines, or atovaquone.  Select Malaria Box compds. also induced changes in intermediates in essential metabolic pathways, such as isoprenoid biosynthesis (i.e., 2-C-methyl-d-erythritol 2,4-cyclodiphosphate) and linolenic acid metab. (i.e., traumatic acid).  This study provides a comprehensive database of the metabolic perturbations induced by chem. diverse inhibitors and highlights the utility of metabolomics for triaging new lead compds. and defining specific modes of action, which will assist with the development and optimization of new antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofzXMyCItAxLVg90H21EOLACvtfcHk0lg4ZtMBigeBKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitV2gtL0%253D&md5=9c5d2d434d0ba847358b8dee2fbc2e41</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1128%2FAAC.01226-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01226-16%26sid%3Dliteratum%253Aachs%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DChua%26aufirst%3DH.%2BH.%26aulast%3DCobbold%26aufirst%3DS.%2BA.%26aulast%3DNijagal%26aufirst%3DB.%26aulast%3DMacRae%26aufirst%3DJ.%2BI.%26aulast%3DDickerman%26aufirst%3DB.%2BK.%26aulast%3DGilson%26aufirst%3DP.%2BR.%26aulast%3DRalph%26aufirst%3DS.%2BA.%26aulast%3DMcConville%26aufirst%3DM.%2BJ.%26atitle%3DMetabolomics-based%2520screening%2520of%2520the%2520Malaria%2520Box%2520reveals%2520both%2520novel%2520and%2520established%2520mechanisms%2520of%2520action%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26issue%3D11%26spage%3D6650%26epage%3D6663%26doi%3D10.1128%2FAAC.01226-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatanagar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrisey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, J. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppens, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Na+ Influx Induced by new antimalarials causes rapid alterations in the cholesterol content and morphology of <i>Plasmodium falciparum</i></span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e1005647</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.ppat.1005647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27227970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOju77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1005647&issue=5&author=S.+Dasauthor=S.+Bhatanagarauthor=J.+M.+Morriseyauthor=T.+M.+Dalyauthor=J.+M.+Burnsauthor=I.+Coppensauthor=A.+B.+Vaidya&title=Na%2B+Influx+Induced+by+new+antimalarials+causes+rapid+alterations+in+the+cholesterol+content+and+morphology+of+Plasmodium+falciparum&doi=10.1371%2Fjournal.ppat.1005647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Na+ influx induced by new antimalarials causes rapid alterations in the cholesterol content and morphology of Plasmodium falciparum</span></div><div class="casAuthors">Das, Sudipta; Bhatanagar, Suyash; Morrisey, Joanne M.; Daly, Thomas M.; Burns, James M., Jr.; Coppens, Isabelle; Vaidya, Akhil B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e1005647/1-e1005647/25</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Among the several new antimalarials discovered over the past decade are ≥3 clin. candidate drugs, each with a distinct chem. structure, that disrupt Na+ homeostasis resulting in a rapid increase in intracellular Na+ concn. ([Na+]i) within the erythrocytic stages of Plasmodium falciparum.  At present, events triggered by Na+ influx that result in parasite demise are not well-understood.  Here we report effects of 2 such drugs, a pyrazoleamide and a spiroindolone, on intraerythrocytic P. falciparum.  Within minutes following the exposure to these drugs, the trophozoite stage parasite, which normally contains little cholesterol, was made permeant by cholesterol-dependent detergents, suggesting it acquired a substantial amt. of the lipid.  Consistently, the merozoite surface protein 1 and 2 (MSP1 and MSP2), glycosylphosphotidylinositol (GPI)-anchored proteins normally uniformly distributed in the parasite plasma membrane, coalesced into clusters.  These alterations were not obsd. following drug treatment of P. falciparum parasites adapted to grow in a low [Na+] growth medium.  Both cholesterol acquisition and MSP1 coalescence were reversible upon the removal of the drugs, implicating an active process of cholesterol exclusion from trophozoites that we hypothesize is inhibited by high [Na+]i.  Electron microscopy of drug-treated trophozoites revealed substantial morphol. changes normally seen at the later schizont stage including the appearance of partial inner membrane complexes, dense organelles that resemble rhoptries and apparent nuclear division.  Together these results suggest that [Na+]i disruptor drugs by altering levels of cholesterol in the parasite, dysregulate trophozoite to schizont development and cause parasite demise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvaNdWVrmWPLVg90H21EOLACvtfcHk0liM4TK_IA-QUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOju77N&md5=f42d036aafc701beab3a1386774c5527</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005647%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DS.%26aulast%3DBhatanagar%26aufirst%3DS.%26aulast%3DMorrisey%26aufirst%3DJ.%2BM.%26aulast%3DDaly%26aufirst%3DT.%2BM.%26aulast%3DBurns%26aufirst%3DJ.%2BM.%26aulast%3DCoppens%26aufirst%3DI.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DNa%252B%2520Influx%2520Induced%2520by%2520new%2520antimalarials%2520causes%2520rapid%2520alterations%2520in%2520the%2520cholesterol%2520content%2520and%2520morphology%2520of%2520Plasmodium%2520falciparum%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26issue%3D5%26spage%3De1005647%26doi%3D10.1371%2Fjournal.ppat.1005647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span> <span> </span><span class="NLM_article-title">A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>213</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiv358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Finfdis%2Fjiv358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26136472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFequ7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2016&pages=100-104&issue=1&author=R.+Zhangauthor=R.+Suwanaruskauthor=B.+Malleretauthor=B.+M.+Cookeauthor=F.+Nostenauthor=Y.+L.+Lauauthor=M.+Daoauthor=C.+T.+Limauthor=L.+Reniaauthor=K.+S.+Tanauthor=B.+Russell&title=A+basis+for+rapid+clearance+of+circulating+ring-stage+malaria+parasites+by+the+spiroindolone+KAE609&doi=10.1093%2Finfdis%2Fjiv358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609</span></div><div class="casAuthors">Zhang, Rou; Suwanarusk, Rossarin; Malleret, Benoit; Cooke, Brian M.; Nosten, Francois; Lau, Yee-Ling; Dao, Ming; Lim, Chwee Teck; Renia, Laurent; Tan, Kevin Shyong Wei; Russell, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-104</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Recent clin. trials revealed a surprisingly rapid clearance of red blood cells (RBCs) infected with malaria parasites by the spiroindolone KAE609.  Here, we show that ring-stage parasite-infected RBCs exposed to KAE609 become spherical and rigid, probably through osmotic dysregulation consequent to the disruption of the parasite's sodium efflux pump (ATP 4).  We also show that this peculiar drug effect is likely to cause accelerated splenic clearance of the rheol. impaired Plasmodium vivax- and Plasmodium falciparum-infected RBCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvIUy7xhSEObVg90H21EOLACvtfcHk0liM4TK_IA-QUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFequ7s%253D&md5=27f3145a76b04cb8f18d1747591e9b85</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiv358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiv358%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DMalleret%26aufirst%3DB.%26aulast%3DCooke%26aufirst%3DB.%2BM.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DLau%26aufirst%3DY.%2BL.%26aulast%3DDao%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DC.%2BT.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DK.%2BS.%26aulast%3DRussell%26aufirst%3DB.%26atitle%3DA%2520basis%2520for%2520rapid%2520clearance%2520of%2520circulating%2520ring-stage%2520malaria%2520parasites%2520by%2520the%2520spiroindolone%2520KAE609%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2016%26volume%3D213%26issue%3D1%26spage%3D100%26epage%3D104%26doi%3D10.1093%2Finfdis%2Fjiv358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Schalkwyk, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davina Nunez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, J. W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. J.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium knowlesi</i> exhibits distinct in vitro drug susceptibility profiles from those of <i>Plasmodium falciparum</i></span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2019.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ijpddr.2019.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30831468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtFygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=93-99&author=D.+A.+van%0ASchalkwykauthor=B.+Blascoauthor=R.+Davina+Nunezauthor=J.+W.+K.+Liewauthor=A.+Amirauthor=Y.+L.+Lauauthor=D.+Leroyauthor=R.+W.+Moonauthor=C.+J.+Sutherland&title=Plasmodium+knowlesi+exhibits+distinct+in+vitro+drug+susceptibility+profiles+from+those+of+Plasmodium+falciparum&doi=10.1016%2Fj.ijpddr.2019.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum</span></div><div class="casAuthors">van Schalkwyk Donelly A; Blasco Benjamin; Davina Nunez Rocio; Leroy Didier; Liew Jonathan W K; Amir Amirah; Lau Yee L; Moon Robert W; Sutherland Colin J</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">New antimalarial agents are identified and developed after extensive testing on Plasmodium falciparum parasites that can be grown in vitro.  These susceptibility studies are important to inform lead optimisation and support further drug development.  Until recently, little was known about the susceptibility of non-falciparum species as these had not been adapted to in vitro culture.  The recent culture adaptation of P. knowlesi has therefore offered an opportunity to routinely define the drug susceptibility of this species, which is phylogenetically closer to all other human malarias than is P. falciparum.  We compared the in vitro susceptibility of P. knowlesi and P. falciparum to a range of established and novel antimalarial agents under identical assay conditions.  We demonstrated that P. knowlesi is significantly less susceptible than P. falciparum to six of the compounds tested; and notably these include three ATP4 inhibitors currently under development as novel antimalarial agents, and one investigational antimalarial, AN13762, which is 67 fold less effective against P. knowlesi.  For the other compounds there was a less than two-fold difference in susceptibility between species.  We then compared the susceptibility of a recent P. knowlesi isolate, UM01, to that of the well-established, older A1-H.1 clone.  This recent isolate showed similar in vitro drug susceptibility to the A1-H.1 clone, supporting the ongoing use of the better characterised clone to further study drug susceptibility.  Lastly, we used isobologram analysis to explore the interaction of a selection of drug combinations and showed similar drug interactions across species.  The species differences in drug susceptibility reported by us here and previously, support adding in vitro drug screens against P. knowlesi to those using P. falciparum strains to inform new drug discovery and lead optimisation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaiwizgFCh9yjiVMCqkKxVfW6udTcc2ebdIqO5cgDHibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtFygsg%253D%253D&md5=5fa1213f71f2c9aeba488850ec22235e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2019.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2019.02.004%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BSchalkwyk%26aufirst%3DD.%2BA.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DDavina%2BNunez%26aufirst%3DR.%26aulast%3DLiew%26aufirst%3DJ.%2BW.%2BK.%26aulast%3DAmir%26aufirst%3DA.%26aulast%3DLau%26aufirst%3DY.%2BL.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DMoon%26aufirst%3DR.%2BW.%26aulast%3DSutherland%26aufirst%3DC.%2BJ.%26atitle%3DPlasmodium%2520knowlesi%2520exhibits%2520distinct%2520in%2520vitro%2520drug%2520susceptibility%2520profiles%2520from%2520those%2520of%2520Plasmodium%2520falciparum%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2019%26volume%3D9%26spage%3D93%26epage%3D99%26doi%3D10.1016%2Fj.ijpddr.2019.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Pelt-Koops, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pett, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graumans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Vegte-Bolmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gemert, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span> <span> </span><span class="NLM_article-title">The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks <i>Plasmodium falciparum</i> transmission to anopheles mosquito vector</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3544</span>– <span class="NLM_lpage">3548</span>, <span class="refDoi"> DOI: 10.1128/AAC.06377-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.06377-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22508309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsV2ju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=3544-3548&issue=7&author=J.+C.+van%0APelt-Koopsauthor=H.+E.+Pettauthor=W.+Graumansauthor=M.+van+der%0AVegte-Bolmerauthor=G.+J.+van+Gemertauthor=M.+Rottmannauthor=B.+K.+Yeungauthor=T.+T.+Diaganaauthor=R.+W.+Sauerwein&title=The+spiroindolone+drug+candidate+NITD609+potently+inhibits+gametocytogenesis+and+blocks+Plasmodium+falciparum+transmission+to+anopheles+mosquito+vector&doi=10.1128%2FAAC.06377-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to Anopheles mosquito vector</span></div><div class="casAuthors">van Pelt-Koops, J. C.; Pett, H. E.; Graumans, W.; van der Vegte-Bolmer, M.; van Gemert, G. J.; Rottmann, M.; Yeung, B. K. S.; Diagana, T. T.; Sauerwein, R. W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3544-3548</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The global malaria agenda has undergone a reorientation from control of clin. cases to entirely eradicating malaria.  For that purpose, a key objective is blocking transmission of malaria parasites from humans to mosquito vectors.  The new antimalarial drug candidate NITD609 was evaluated for its transmission-reducing potential and compared to a few established antimalarials (lumefantrine, artemether, primaquine), using a suite of in vitro assays.  By the use of a microscopic readout, NITD609 was found to inhibit the early and late development of Plasmodium falciparum gametocytes in vitro in a dose-dependent fashion over a range of 5 to 500 nM.  In addn., using the std. membrane feeding assay, NITD609 was also found to be a very effective drug in reducing transmission to the Anopheles stephensi mosquito vector.  Collectively, our data suggest a strong transmission-reducing effect of NITD609 acting against different P. falciparum transmission stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqE-wBC9ABY7Vg90H21EOLACvtfcHk0lijw4T3YmAF_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsV2ju7g%253D&md5=6568eacc3ad85bcefbad6893335e5636</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2FAAC.06377-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.06377-11%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BPelt-Koops%26aufirst%3DJ.%2BC.%26aulast%3DPett%26aufirst%3DH.%2BE.%26aulast%3DGraumans%26aufirst%3DW.%26aulast%3Dvan%2Bder%2BVegte-Bolmer%26aufirst%3DM.%26aulast%3Dvan%2BGemert%26aufirst%3DG.%2BJ.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26atitle%3DThe%2520spiroindolone%2520drug%2520candidate%2520NITD609%2520potently%2520inhibits%2520gametocytogenesis%2520and%2520blocks%2520Plasmodium%2520falciparum%2520transmission%2520to%2520anopheles%2520mosquito%2520vector%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26issue%3D7%26spage%3D3544%26epage%3D3548%26doi%3D10.1128%2FAAC.06377-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazor, J.</span>; <span class="NLM_string-name">Smith, D.</span>; <span class="NLM_string-name">Crowe, M.</span>; <span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Collier, S. J.</span></span> WO Patent. <span> </span><span class="NLM_article-title">Biocatalysts and Methods for Synthesizing Derivatives of Tryptamine and Tryptamine Analogs</span>. <span class="NLM_patent">WO2009132921</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Nazor&author=D.+Smith&author=M.+Crowe&author=S.+Song&author=S.+J.+Collier&title=Biocatalysts+and+Methods+for+Synthesizing+Derivatives+of+Tryptamine+and+Tryptamine+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazor%26aufirst%3DJ.%26atitle%3DBiocatalysts%2520and%2520Methods%2520for%2520Synthesizing%2520Derivatives%2520of%2520Tryptamine%2520and%2520Tryptamine%2520Analogs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span>; <span class="NLM_string-name">Franese, G.</span>; <span class="NLM_string-name">Kuesters, E.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Lin, C.</span>; <span class="NLM_string-name">Nazor, J.</span>; <span class="NLM_string-name">Smith, D. A.</span>; <span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Teng, S.</span></span> <span> </span><span class="NLM_article-title">Chemical Process for Preparing Spiroindolones and Intermediates Thereof</span>. WO Patent. <span class="NLM_patent">WO/2013/139987</span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Crowe&author=G.+Franese&author=E.+Kuesters&author=Y.+Li&author=C.+Lin&author=J.+Nazor&author=D.+A.+Smith&author=S.+Song&author=S.+Teng&title=Chemical+Process+for+Preparing+Spiroindolones+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrowe%26aufirst%3DM.%26atitle%3DChemical%2520Process%2520for%2520Preparing%2520Spiroindolones%2520and%2520Intermediates%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nazor, J.</span>; <span class="NLM_string-name">Smith, D.</span>; <span class="NLM_string-name">Crowe, M.</span>; <span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Collier, S. J.</span></span> <span> </span><span class="NLM_article-title">Biocatalysts and Methods for Synthesizing Derivatives of Tryptamine and Tryptamine Analogs</span>. WO Patent <span class="NLM_patent">WO 2013/142770</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Nazor&author=D.+Smith&author=M.+Crowe&author=S.+Song&author=S.+J.+Collier&title=Biocatalysts+and+Methods+for+Synthesizing+Derivatives+of+Tryptamine+and+Tryptamine+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNazor%26aufirst%3DJ.%26atitle%3DBiocatalysts%2520and%2520Methods%2520for%2520Synthesizing%2520Derivatives%2520of%2520Tryptamine%2520and%2520Tryptamine%2520Analogs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggimann, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kittelmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luneau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einolf, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J. B.</span></span> <span> </span><span class="NLM_article-title">Identification of three novel ring expansion metabolites of KAE609, a new spiroindolone agent for the treatment of malaria, in rats, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.069112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1124%2Fdmd.115.069112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26921386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGmu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=653-664&issue=5&author=S.+E.+Huskeyauthor=C.+Q.+Zhuauthor=M.+M.+Linauthor=R.+R.+Forsethauthor=H.+Guauthor=O.+Simonauthor=F.+K.+Eggimannauthor=M.+Kittelmannauthor=A.+Luneauauthor=A.+Vargasauthor=H.+Liauthor=L.+Wangauthor=H.+J.+Einolfauthor=J.+Zhangauthor=S.+Favaraauthor=H.+Heauthor=J.+B.+Mangold&title=Identification+of+three+novel+ring+expansion+metabolites+of+KAE609%2C+a+new+spiroindolone+agent+for+the+treatment+of+malaria%2C+in+rats%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.115.069112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of three novel ring expansion metabolites of KAE609, a new spiroindolone agent for the treatment of malaria, in rats, dogs, and humans</span></div><div class="casAuthors">Huskey, Su-Er W.; Zhu, Chun-qi; Lin, Melissa M.; Forseth, Ry R.; Gu, Helen; Simon, Oliver; Eggimann, Fabian K.; Kittelmann, Matthias; Luneau, Alexandre; Vargas, Alexandra; Li, Hongmei; Wang, Lai; Einolf, Heidi J.; Zhang, Jin; Favara, Sarah; He, Handan; Mangold, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">KAE609 [(1'R,3'S)-5,7'-dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[indoline-3,1'-pyridol[3,4-b]indol]-2-one] is a potent, fast-acting, schizonticidal agent being developed for the treatment of malaria.  After oral dosing of KAE609 to rats and dogs, the major radioactive component in plasma was KAE609.  An oxidative metabolite, M18, was the prominent metabolite in rat and dog plasma.  KAE609 was well absorbed and extensively metabolized such that low levels of parent compd. (≤11% of the dose) were detected in feces.  The elimination of KAE609 and metabolites was primarily mediated via biliary pathways (≥93% of the dose) in the feces of rats and dogs.  M37 and M23 were the major metabolites in rat and dog feces, resp.  Among the prominent metabolites of KAE609, the isobaric chem. species, M37, was obsd., suggesting the involvement of an isomerization or rearrangement during biotransformation.  Subsequent structural elucidation of M37 revealed that KAE609, a spiroindolone, undergoes an unusual C-C bond cleavage, followed by a 1,2-acyl shift to form a ring expansion metabolite M37.  The in vitro metab. of KAE609 in hepatocytes was investigated to understand this novel biotransformation.  The metab. of KAE609 was qual. similar across the species studied; thus, further investigation was conducted using human recombinant cytochrome P 450 enzymes.  The ring expansion reaction was found to be primarily catalyzed by cytochrome P 450 (CYP) 3A4 yielding M37.  M37 was subsequently oxidized to M18 by CYP3A4 and hydroxylated to M23 primarily by CYP1A2.  Interestingly, M37 was colorless, whereas M18 and M23 showed orange yellow color.  The source of the color of M18 and M23 was attributed to their extended conjugated system of double bonds in the structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZTtqLs5iqe7Vg90H21EOLACvtfcHk0lijw4T3YmAF_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGmu73J&md5=cff56a60f7e40f40fb85645f9efd5ed2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.069112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.069112%26sid%3Dliteratum%253Aachs%26aulast%3DHuskey%26aufirst%3DS.%2BE.%26aulast%3DZhu%26aufirst%3DC.%2BQ.%26aulast%3DLin%26aufirst%3DM.%2BM.%26aulast%3DForseth%26aufirst%3DR.%2BR.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DSimon%26aufirst%3DO.%26aulast%3DEggimann%26aufirst%3DF.%2BK.%26aulast%3DKittelmann%26aufirst%3DM.%26aulast%3DLuneau%26aufirst%3DA.%26aulast%3DVargas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFavara%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DMangold%26aufirst%3DJ.%2BB.%26atitle%3DIdentification%2520of%2520three%2520novel%2520ring%2520expansion%2520metabolites%2520of%2520KAE609%252C%2520a%2520new%2520spiroindolone%2520agent%2520for%2520the%2520treatment%2520of%2520malaria%252C%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D5%26spage%3D653%26epage%3D664%26doi%3D10.1124%2Fdmd.115.069112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredenhagen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhnol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luneau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunkara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. S.</span></span> <span> </span><span class="NLM_article-title">KAE609 (cipargamin), a new spiroindolone agent for the treatment of malaria: evaluation of the absorption, distribution, metabolism, and excretion of a single oral 300-mg dose of [14C]KAE609 in healthy male subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.069187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1124%2Fdmd.115.069187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26921387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFelurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=672-682&issue=5&author=S.+E.+Huskeyauthor=C.+Q.+Zhuauthor=A.+Fredenhagenauthor=J.+Kuhnolauthor=A.+Luneauauthor=Z.+Jianauthor=Z.+Yangauthor=Z.+Miaoauthor=F.+Yangauthor=J.+P.+Jainauthor=G.+Sunkaraauthor=J.+B.+Mangoldauthor=D.+S.+Stein&title=KAE609+%28cipargamin%29%2C+a+new+spiroindolone+agent+for+the+treatment+of+malaria%3A+evaluation+of+the+absorption%2C+distribution%2C+metabolism%2C+and+excretion+of+a+single+oral+300-mg+dose+of+%5B14C%5DKAE609+in+healthy+male+subjects&doi=10.1124%2Fdmd.115.069187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">KAE609 (cipargamin), a new spiroindolone agent for the treatment of malaria: evaluation of the absorption, distribution, metabolism, and excretion of a single oral 300-mg dose of [14C]KAE609 in healthy male subjects</span></div><div class="casAuthors">Huskey, Su-Er W.; Zhu, Chun-qi; Fredenhagen, Andreas; Kuhnol, Jurgen; Luneau, Alexandre; Jian, Zhigang; Yang, Ziping; Miao, Zhuang; Yang, Fan; Jain, Jay P.; Sunkara, Gangadhar; Mangold, James B.; Stein, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">672-682</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">KAE609 [(1' R,3' S)-5,7'-dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[ indoline-3,1'-pyridol[3,4-b]indol]-2-one] is a potent, fast-acting, schizonticidal agent in clin. development for the treatment of malaria.  This study investigated the absorption, distribution, metab., and excretion of KAE609 after oral administration of [14C]KAE609 in healthy subjects.  After oral administration to human subjects, KAE609 was the major radioactive component (approx. 76% of the total radioactivity in plasma); M23 was the major circulating oxidative metabolite (approx. 12% of the total radioactivity in plasma).  Several minor oxidative metabolites (M14, M16, M18, and M23.5B) were also identified, each accounting for approx. 3%-8% of the total radioactivity in plasma.  KAE609 was well absorbed and extensively metabolized, such that KAE609 accounted for approx. 32% of the dose in feces.  The elimination of KAE609 and metabolites was primarily mediated via biliary pathways.  M23 was the major metabolite in feces.  Subjects reported semen discoloration after dosing in prior studies; therefore, semen samples were collected once from each subject to further evaluate this clin. observation.  Radioactivity excreted in semen was negligible, but the major component in semen was M23, supporting the rationale that this yellow-colored metabolite was the main source of semen discoloration.  In this study, a new metabolite,M16, was identified in all biol. matrixes albeit at low levels.  All 19 recombinant human cytochrome P 450 enzymes were capable of catalyzing the hydroxylation of M23 to form M16 even though the extent of turnover was very low.  Thus, electrochem. was used to generate a sufficient quantity of M16 for structural elucidation.  Metabolic pathways of KAE609 in humans are summarized herein and M23 is the major metabolite in plasma and excreta.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAsHpw7CEIRrVg90H21EOLACvtfcHk0ljy1Zbgqt_iRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFelurnP&md5=b4312de9c877c142fa82085db2e72377</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.069187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.069187%26sid%3Dliteratum%253Aachs%26aulast%3DHuskey%26aufirst%3DS.%2BE.%26aulast%3DZhu%26aufirst%3DC.%2BQ.%26aulast%3DFredenhagen%26aufirst%3DA.%26aulast%3DKuhnol%26aufirst%3DJ.%26aulast%3DLuneau%26aufirst%3DA.%26aulast%3DJian%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DSunkara%26aufirst%3DG.%26aulast%3DMangold%26aufirst%3DJ.%2BB.%26aulast%3DStein%26aufirst%3DD.%2BS.%26atitle%3DKAE609%2520%2528cipargamin%2529%252C%2520a%2520new%2520spiroindolone%2520agent%2520for%2520the%2520treatment%2520of%2520malaria%253A%2520evaluation%2520of%2520the%2520absorption%252C%2520distribution%252C%2520metabolism%252C%2520and%2520excretion%2520of%2520a%2520single%2520oral%2520300-mg%2520dose%2520of%2520%255B14C%255DKAE609%2520in%2520healthy%2520male%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D5%26spage%3D672%26epage%3D682%26doi%3D10.1124%2Fdmd.115.069187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">6209</span>– <span class="NLM_lpage">6214</span>, <span class="refDoi"> DOI: 10.1128/AAC.03393-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.03393-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25114127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSit7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=6209-6214&issue=10&author=F.+J.+Leongauthor=R.+Liauthor=J.+P.+Jainauthor=G.+Lefevreauthor=B.+Magnussonauthor=T.+T.+Diaganaauthor=P.+Pertel&title=A+first-in-human+randomized%2C+double-blind%2C+placebo-controlled%2C+single-+and+multiple-ascending+oral+dose+study+of+novel+antimalarial+Spiroindolone+KAE609+%28Cipargamin%29+to+assess+its+safety%2C+tolerability%2C+and+pharmacokinetics+in+healthy+adult+volunteers&doi=10.1128%2FAAC.03393-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone KAE609 (cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span></div><div class="casAuthors">Leong, F. Joel; Li, Ruobing; Jain, Jay Prakash; Lefevre, Gilbert; Magnusson, Baldur; Diagana, Thierry T.; Pertel, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6209-6214, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This first-in-human randomized, double-blind, placebo-controlled, ascending-single and -multiple oral dose study was designed to evaluate the safety, tolerability, and pharmacokinetics in healthy volunteers of KAE609 (cipargamin; formerly NITD609), a spiroindolone now in trials for malaria treatment.  It was studied in single-dose cohorts (1 to 300 mg, including one 30-mg food effect cohort) with 4 to 10 subjects in each cohort and in multiple-dose cohorts (10 to 150 mg once daily for 3 days) with 8 subjects in each cohort.  The follow-up period was 6 to 8 days post-last dose.  Safety and pharmacokinetics were assessed at scheduled time points during the study.  Systemic exposure in terms of the area under the concn.-time curve from 0h extrapolated to infinity (AUC0-inf) increased in a dose-proportional manner over the dose range of 1 to 300 mg.  The AUC from time zero to the time of the last quantifiable concn. (AUClast) and the max. concn. of drug in plasma (Cmax) also increased in an approx. dose-proportional manner.  When administered daily for 3 days, the accumulation ratio on day 3 (the AUC from time zero to 24 h postdosing [AUC0-24] on day 3/AUC0-24 on day 1) was in the range of 1.5 to 2 in the studied dose range (10 to 150 mg) and was consistent with an elimination half-life of around 24 h.  Urine anal. for unchanged KAE609 revealed negligible amts. (≤0.01%) were excreted renally.  The high fat food intake did not affect the extent of KAE609 absorption (AUC); however, the Cmax was reduced by around 27%.  KAE609 was tolerated in this study, with transient gastrointestinal and genitourinary adverse events of mild to moderate intensity (semen discoloration, diarrhea, nausea and abdominal discomfort, dizziness and headache, catheter site hematoma).  Gastrointestinal and genitourinary adverse events increased with rising doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RN4uvEbCA7Vg90H21EOLACvtfcHk0ljy1Zbgqt_iRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSit7vM&md5=ed3f8398fedfb5a3d1f752adb3a4b38f</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.03393-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03393-14%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DLefevre%26aufirst%3DG.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26atitle%3DA%2520first-in-human%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520single-%2520and%2520multiple-ascending%2520oral%2520dose%2520study%2520of%2520novel%2520antimalarial%2520Spiroindolone%2520KAE609%2520%2528Cipargamin%2529%2520to%2520assess%2520its%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D10%26spage%3D6209%26epage%3D6214%26doi%3D10.1128%2FAAC.03393-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Cardiotoxicity of antimalarial drugs</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(07)70187-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2807%2970187-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=17646028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsF2rsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=549-558&issue=8&author=N.+J.+White&title=Cardiotoxicity+of+antimalarial+drugs&doi=10.1016%2FS1473-3099%2807%2970187-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of antimalarial drugs</span></div><div class="casAuthors">White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">549-558</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  There are consistent differences in cardiovascular state between acute illness in malaria and recovery that prolong the electrocardiog. QT interval and have been misinterpreted as resulting from antimalarial cardiotoxicity.  Of the different classes of antimalarial drugs, only the quinolines, and structurally related antimalarial drugs, have clin. significant cardiovascular effects.  Drugs in this class can exacerbate malaria-assocd. orthostatic hypotension and several have been shown to delay ventricular depolarization slightly (class 1c effect), resulting in widening of the QRS complex, but only quinidine and halofantrine have clin. significant effects on ventricular repolarization (class 3 effect).  Both drugs cause potentially dangerous QT prolongation, and halofantrine has been assocd. with sudden death.  The parenteral quinoline formulations (chloroquine, quinine, and quinidine) are predictably hypotensive when injected rapidly, and cardiovascular collapse can occur with self-poisoning.  Transiently hypotensive plasma concns. of chloroquine can occur when doses of 5 mg base/kg or more are given by i.m. or s.c. injection.  At currently recommended doses, other antimalarial drugs do not have clin. significant cardiac effects.  More information on amodiaquine, primaquine, and the newer structurally related compds. is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHUfXc7qSBrVg90H21EOLACvtfcHk0ljy1Zbgqt_iRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsF2rsLc%253D&md5=5a3ea7424802a3c9a899b1e545f55773</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2807%2970187-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252807%252970187-1%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DCardiotoxicity%2520of%2520antimalarial%2520drugs%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2007%26volume%3D7%26issue%3D8%26spage%3D549%26epage%3D558%26doi%3D10.1016%2FS1473-3099%2807%2970187-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Se, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somethy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phann, S.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriwichai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buathong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntawunginn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitprasat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siripokasupkul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teja-Isavadharm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmermans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanteri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewkungwal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auayporn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chour, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantilena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D.</span></span> <span> </span><span class="NLM_article-title">Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6067</span>, <span class="refDoi"> DOI: 10.1128/AAC.02667-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.02667-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25092702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslShsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=6056-6067&issue=10&author=J.+Manningauthor=P.+Vanachayangkulauthor=C.+Lonauthor=M.+Springauthor=M.+Soauthor=D.+Seaauthor=Y.+Seauthor=S.+Somethyauthor=S.-T.+Phannauthor=S.+Channauthor=S.+Sriwichaiauthor=N.+Buathongauthor=W.+Kuntawunginnauthor=M.+Mitprasatauthor=R.+Siripokasupkulauthor=P.+Teja-Isavadharmauthor=E.+Sohauthor=A.+Timmermansauthor=C.+Lanteriauthor=J.+Kaewkungwalauthor=M.+Auaypornauthor=D.+Tangauthor=C.+M.+Chourauthor=S.+Promauthor=M.+Haigneyauthor=L.+Cantilenaauthor=D.+Saunders&title=Randomized%2C+double-blind%2C+placebo-controlled+clinical+trial+of+a+two-day+regimen+of+dihydroartemisinin-piperaquine+for+malaria+prevention+halted+for+concern+over+prolonged+corrected+QT+interval&doi=10.1128%2FAAC.02667-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval</span></div><div class="casAuthors">Manning, Jessica; Vanachayangkul, Pattaraporn; Lon, Chanthap; Spring, Michele; So, Mary; Sea, Darapiseth; Se, Youry; Somethy, Sok; Phann, Sut-Thang; Chann, Soklyda; Sriwichai, Sabaithip; Buathong, Nillawan; Kuntawunginn, Worachet; Mitprasat, Mashamon; Siripokasupkul, Raveewan; Teja-Isavadharm, Paktiya; Soh, Eugene; Timmermans, Ans; Lanteri, Charlotte; Kaewkungwal, Jaranit; Auayporn, Montida; Tang, Douglas; Chour, Char Meng; Prom, Satharath; Haigney, Mark; Cantilena, Louis; Saunders, David</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6056-6067, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen.  We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces.  The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation.  Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg piperaquine within 30 min to 3 h of a meal once per mo for a planned 4-mo period with periodic electrocardiog. and pharmacokinetic assessment.  The study was halted after only 6 wk (69 of 231 projected volunteers enrolled) when four volunteers met a prespecified cardiac safety endpoint of QTcF (Fridericia's formula for correct QT interval) prolongation of >500 ms.  The pharmacodynamic effect on the surface ECG (ECG) peaked approx. 4 h after piperaquine dosing and lasted 4 to 8 h.  Unblinded review by the data safety monitoring board revealed mean QTcF prolongation of 46 ms over placebo at the max. concn. of drug in serum (Cmax) on day 2.  Given that dihydroartemisinin-piperaquine is one of the few remaining effective antimalarial agents in Cambodia, compressed 2-day treatment courses of dihydroartemisinin-piperaquine are best avoided until the clin. significance of these findings are more thoroughly evaluated.  Because ECG monitoring is often unavailable in areas where malaria is endemic, repolarization risk could be mitigated by using conventional 3-day regimens, fasting, and avoidance of repeated dosing or coadministration with other QT-prolonging medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo70UliZKVFc7Vg90H21EOLACvtfcHk0lgAPLu1W5wPQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslShsrrI&md5=a762034b2cb8ec20bd13b85ed622dffb</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1128%2FAAC.02667-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02667-14%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DJ.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DLon%26aufirst%3DC.%26aulast%3DSpring%26aufirst%3DM.%26aulast%3DSo%26aufirst%3DM.%26aulast%3DSea%26aufirst%3DD.%26aulast%3DSe%26aufirst%3DY.%26aulast%3DSomethy%26aufirst%3DS.%26aulast%3DPhann%26aufirst%3DS.-T.%26aulast%3DChann%26aufirst%3DS.%26aulast%3DSriwichai%26aufirst%3DS.%26aulast%3DBuathong%26aufirst%3DN.%26aulast%3DKuntawunginn%26aufirst%3DW.%26aulast%3DMitprasat%26aufirst%3DM.%26aulast%3DSiripokasupkul%26aufirst%3DR.%26aulast%3DTeja-Isavadharm%26aufirst%3DP.%26aulast%3DSoh%26aufirst%3DE.%26aulast%3DTimmermans%26aufirst%3DA.%26aulast%3DLanteri%26aufirst%3DC.%26aulast%3DKaewkungwal%26aufirst%3DJ.%26aulast%3DAuayporn%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DD.%26aulast%3DChour%26aufirst%3DC.%2BM.%26aulast%3DProm%26aufirst%3DS.%26aulast%3DHaigney%26aufirst%3DM.%26aulast%3DCantilena%26aufirst%3DL.%26aulast%3DSaunders%26aufirst%3DD.%26atitle%3DRandomized%252C%2520double-blind%252C%2520placebo-controlled%2520clinical%2520trial%2520of%2520a%2520two-day%2520regimen%2520of%2520dihydroartemisinin-piperaquine%2520for%2520malaria%2520prevention%2520halted%2520for%2520concern%2520over%2520prolonged%2520corrected%2520QT%2520interval%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D10%26spage%3D6056%26epage%3D6067%26doi%3D10.1128%2FAAC.02667-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kangas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lickliter, J.</span></span> <span> </span><span class="NLM_article-title">Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3500</span>, <span class="refDoi"> DOI: 10.1128/AAC.00340-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.00340-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25845867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFGisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3493-3500&issue=6&author=D.+S.+Steinauthor=J.+P.+Jainauthor=M.+Kangasauthor=G.+Lefevreauthor=S.+Machineniauthor=P.+Griffinauthor=J.+Lickliter&title=Open-label%2C+single-dose%2C+parallel-group+study+in+healthy+volunteers+to+determine+the+drug-drug+interaction+potential+between+KAE609+%28cipargamin%29+and+piperaquine&doi=10.1128%2FAAC.00340-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine</span></div><div class="casAuthors">Stein, Daniel S.; Jain, Jay Prakash; Kangas, Michael; Lefevre, Gilbert; Machineni, Surendra; Griffin, Paul; Lickliter, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3493-3500</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">KAE609 represents a new class of potent, fast-acting, schizonticidal antimalarials.  This study investigated the safety and pharmacokinetics of KAE609 in combination with the long-acting antimalarial piperaquine (PPQ) in healthy volunteers.  A two-way pharmacokinetic interaction was hypothesized for KAE609 and PPQ, as both drugs are CYP3A4 substrates and inhibitors.  The potential for both agents to affect the QT interval was also assessed.  This was an open-label, parallel-group, single-dose study with healthy volunteers.  Subjects were randomized to four parallel dosing arms with five cohorts (2:2:2:2:1), receiving 75 mg KAE609 plus 320 mg PPQ, 25 mg KAE609 plus 1,280 mg PPQ, 25 mg KAE609 alone, 320 mg PPQ alone, or 1,280 mg PPQ alone.  Triplicate electrocardiograms were performed over the first 24 h after dosing, with single electrocardiograms at other time points.  Routine safety (up to 89 days) and pharmacokinetic (up to 61 days) assessments were performed.  Of the 110 subjects recruited, 99 completed the study.  Coadministration of PPQ had no overall effect on exposure to KAE609, although 1,280 mg PPQ decreased the KAE609 max. concn. (Cmax) by 17%.  The group that received 25 mg KAE609 plus 1,280 mg PPQ showed a 32% increase in the PPQ area under the concn.-time curve from 0 to infinity (AUCinf), while the group that received 75 mg KAE609 plus 320 mg PPQ showed a 14% redn.  Mean changes from baseline in the QT interval cor. by Fridericia's method (QTcF) and the QT interval cor. by Bazett's method (QTcB) with PPQ were consistent with its known effects.  PPQ but not KAE609 exposure correlated with cor. QT interval (QTc) increases, and KAE609 did not affect the PPQ exposure-QTc relationship.  The QTcF effect for PPQ (least-squares est. of the difference in mean maximal changes from baseline of 7.47 ms [90% confidence interval, 3.55 to 11.4 ms]) was consistent with the criteria for a pos. thorough QT study.  No subject had QTcF or QTcB values of >500 ms.  Both drugs given alone or in combination were well tolerated, with no deaths, serious adverse events (AEs), or severe AEs reported.  Most AEs were mild; upper respiratory tract infections, headache, diarrhea, and oropharyngeal pain were most common.  PPQ and KAE609 coadministration had no relevant effect on exposure to either agent, and KAE609 did not affect or potentiate the known effects of PPQ on cardiac conduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOxcJwuhFJJLVg90H21EOLACvtfcHk0lgAPLu1W5wPQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFGisb8%253D&md5=d697e51100b0a149663658bc78b5fe31</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FAAC.00340-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00340-15%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DD.%2BS.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DKangas%26aufirst%3DM.%26aulast%3DLefevre%26aufirst%3DG.%26aulast%3DMachineni%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DLickliter%26aufirst%3DJ.%26atitle%3DOpen-label%252C%2520single-dose%252C%2520parallel-group%2520study%2520in%2520healthy%2520volunteers%2520to%2520determine%2520the%2520drug-drug%2520interaction%2520potential%2520between%2520KAE609%2520%2528cipargamin%2529%2520and%2520piperaquine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D6%26spage%3D3493%26epage%3D3500%26doi%3D10.1128%2FAAC.00340-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span> </span><span class="NLM_article-title">A Study to Assess Efficacy, Safety of KAE609
in Adult Patients With
Acute Malaria Mono-Infection</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2015</span>;  <span class="NLM_fpage">NCT01860989</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT01860989?term=NCT01860989&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01860989?term=NCT01860989&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+to+Assess+Efficacy%2C+Safety+of+KAE609%0Ain+Adult+Patients+With%0AAcute+Malaria+Mono-Infection.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%2C+2015%3B+NCT01860989%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01860989%3Fterm%3DNCT01860989%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520to%2520Assess%2520Efficacy%252C%2520Safety%2520of%2520KAE609%250Ain%2520Adult%2520Patients%2520With%250AAcute%2520Malaria%2520Mono-Infection%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015%26spage%3DNCT01860989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoa, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamed, K.</span></span> <span> </span><span class="NLM_article-title">Estimation of the in vivo MIC of cipargamin in uncomplicated <i>Plasmodium falciparum</i> malaria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e01940-16</span>, <span class="refDoi"> DOI: 10.1128/AAC.01940-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01940-16" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=e01940-16&issue=2&author=T.+T.+Hienauthor=N.+J.+Whiteauthor=N.+T.+Thuy-Nhienauthor=N.+T.+Hoaauthor=P.+D.+Thuanauthor=J.+Tarningauthor=F.+Nostenauthor=B.+Magnussonauthor=J.+P.+Jainauthor=K.+Hamed&title=Estimation+of+the+in+vivo+MIC+of+cipargamin+in+uncomplicated+Plasmodium+falciparum+malaria&doi=10.1128%2FAAC.01940-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1128%2FAAC.01940-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01940-16%26sid%3Dliteratum%253Aachs%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DHoa%26aufirst%3DN.%2BT.%26aulast%3DThuan%26aufirst%3DP.%2BD.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DHamed%26aufirst%3DK.%26atitle%3DEstimation%2520of%2520the%2520in%2520vivo%2520MIC%2520of%2520cipargamin%2520in%2520uncomplicated%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D61%26issue%3D2%26spage%3De01940-16%26doi%3D10.1128%2FAAC.01940-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueangweerayut, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeyapant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefevre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Spiroindolone KAE609 for falciparum and vivax malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1315860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1315860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25075833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=403-410&issue=5&author=N.+J.+Whiteauthor=S.+Pukrittayakameeauthor=A.+P.+Phyoauthor=R.+Rueangweerayutauthor=F.+Nostenauthor=P.+Jittamalaauthor=A.+Jeeyapantauthor=J.+P.+Jainauthor=G.+Lefevreauthor=R.+Liauthor=B.+Magnussonauthor=T.+T.+Diaganaauthor=F.+J.+Leong&title=Spiroindolone+KAE609+for+falciparum+and+vivax+malaria&doi=10.1056%2FNEJMoa1315860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolone KAE609 for falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Pukrittayakamee, Sasithon; Phyo, Aung Pyae; Rueangweerayut, Ronnatrai; Nosten, Francois; Jittamala, Podjanee; Jeeyapant, Atthanee; Jain, Jay Prakash; Lefevre, Gilbert; Li, Ruobing; Magnusson, Baldur; Diagana, Thierry T.; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">403-410, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synthetic antimalarial spiroindolone analog with potent, dose-dependent antimalarial activity against asexual and sexual stages of Plasmodium falciparum.  Methods: We conducted a phase 2, open-label study at three centers in Thailand to assess the antimalarial efficacy, safety, and adverse-event profile of KAE609, at a dose of 30 mg per day for 3 days, in two sequential cohorts of adults with uncomplicated P. vivax malaria (10 patients) or P. falciparum malaria.  The primary end point was the parasite clearance time.  Results: The median parasite clearance time was 12 h in each cohort (interquartile range, 8 to 16 h in patients with P. vivax malaria and 10 to 16 h in those with P. falciparum malaria).  The median half-lives for parasite clearance were 0.95 h (range, 0.68 to 2.01; interquartile range, 0.85 to 1.14) in the patients with P. vivax malaria and 0.90 h (range, 0.68 to 1.64; interquartile range, 0.78 to 1.07) in those with P. falciparum malaria.  By comparison, only 19 of 5076 patients with P. falciparum malaria (<1%) who were treated with oral artesunate in Southeast Asia had a parasite clearance half-life of less than 1 h.  Adverse events were reported in 14 patients (67%), with nausea being the most common.  The adverse events were generally mild and did not lead to any discontinuations of the drug.  The mean terminal half-life for the elimination of KAE609 was 20.8 h (range, 11.3 to 37.6), supporting a once-daily oral dosing regimen.  Conclusions: KAE609, at dose of 30 mg daily for 3 days, cleared parasitemia rapidly in adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkg77w-ALxg7Vg90H21EOLACvtfcHk0lhVIfsEYBVUtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7vF&md5=a760f4182037c5e2c1834fddfaf21db9</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315860%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DRueangweerayut%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DJeeyapant%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DLefevre%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DSpiroindolone%2520KAE609%2520for%2520falciparum%2520and%2520vivax%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26issue%3D5%26spage%3D403%26epage%3D410%26doi%3D10.1056%2FNEJMoa1315860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flegg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span> <span> </span><span class="NLM_article-title">Standardizing the measurement of parasite clearance in <i>falciparum</i> malaria: the parasite clearance estimator</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-10-339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2F1475-2875-10-339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22074219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FmsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=339&author=J.+A.+Fleggauthor=P.+J.+Guerinauthor=N.+J.+Whiteauthor=K.+Stepniewska&title=Standardizing+the+measurement+of+parasite+clearance+in+falciparum+malaria%3A+the+parasite+clearance+estimator&doi=10.1186%2F1475-2875-10-339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator</span></div><div class="casAuthors">Flegg Jennifer A; Guerin Philippe J; White Nicholas J; Stepniewska Kasia</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A significant reduction in parasite clearance rates following artesunate treatment of falciparum malaria, and increased failure rates following artemisinin combination treatments (ACT), signaled emergent artemisinin resistance in Western Cambodia.  Accurate measurement of parasite clearance is therefore essential to assess the spread of artemisinin resistance in Plasmodium falciparum.  The slope of the log-parasitaemia versus time relationship is considered to be the most robust measure of anti-malarial effect.  However, an initial lag phase of numerical instability often precedes a steady exponential decline in the parasite count after the start of anti-malarial treatment.  This lag complicates the clearance estimation, introduces observer subjectivity, and may influence the accuracy and consistency of reported results.  METHODS:  To address this problem, a new approach to modelling clearance of malaria parasites from parasitaemia-time profiles has been explored and validated.  The methodology detects when a lag phase is present, selects the most appropriate model (linear, quadratic or cubic) to fit log-transformed parasite data, and calculates estimates of parasite clearance adjusted for this lag phase.  Departing from previous approaches, parasite counts below the level of detection are accounted for and not excluded from the calculation.  RESULTS:  Data from large clinical studies with frequent parasite counts were examined.  The effect of a lag phase on parasite clearance rate estimates is discussed, using individual patient data examples.  As part of the World Wide Antimalarial Resistance Network's (WWARN) efforts to make innovative approaches available to the malaria community, an automated informatics tool: the parasite clearance estimator has been developed.  CONCLUSIONS:  The parasite clearance estimator provides a consistent, reliable and accurate method to estimate the lag phase and malaria parasite clearance rate.  It could be used to detect early signs of emerging resistance to artemisinin derivatives and other compounds which affect ring-stage clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSXdhEejvf5WgRQsDqrjW_fW6udTcc2eYvxknhIMvBkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FmsVKgtQ%253D%253D&md5=4b11cba2c31cd4b7ea4abf0776b2689a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-10-339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-10-339%26sid%3Dliteratum%253Aachs%26aulast%3DFlegg%26aufirst%3DJ.%2BA.%26aulast%3DGuerin%26aufirst%3DP.%2BJ.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DStepniewska%26aufirst%3DK.%26atitle%3DStandardizing%2520the%2520measurement%2520of%2520parasite%2520clearance%2520in%2520falciparum%2520malaria%253A%2520the%2520parasite%2520clearance%2520estimator%26jtitle%3DMalar.%2520J.%26date%3D2011%26volume%3D10%26spage%3D339%26doi%3D10.1186%2F1475-2875-10-339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span> </span><span class="NLM_article-title">Safety of KAE609 in Adults With Uncomplicated <i>Plasmodium
falciparum</i> Malaria</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>. <span class="NLM_year" style="font-weight: bold;">2017</span>;  <span class="NLM_fpage">NCT03334747</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03334747?term=NCT03334747&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03334747?term=NCT03334747&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety+of+KAE609+in+Adults+With+Uncomplicated+Plasmodium%0Afalciparum+Malaria.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health.+2017%3B+NCT03334747%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03334747%3Fterm%3DNCT03334747%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DSafety%2520of%2520KAE609%2520in%2520Adults%2520With%2520Uncomplicated%2520Plasmodium%250Afalciparum%2520Malaria%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03334747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span> <span> </span><span class="NLM_article-title">Imidazolopiperazines: hit to lead optimization of new antimalarial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5116</span>– <span class="NLM_lpage">5130</span>, <span class="refDoi"> DOI: 10.1021/jm2003359</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003359" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5116-5130&issue=14&author=T.+Wuauthor=A.+Nagleauthor=K.+Kuhenauthor=K.+Gagaringauthor=R.+Borboaauthor=C.+Francekauthor=Z.+Chenauthor=D.+Plouffeauthor=A.+Gohauthor=S.+B.+Lakshminarayanaauthor=J.+Wuauthor=H.+Q.+Angauthor=P.+Zengauthor=M.+L.+Kangauthor=W.+Tanauthor=M.+Tanauthor=N.+Yeauthor=X.+Linauthor=C.+Caldwellauthor=J.+Ekauthor=S.+Skolnikauthor=F.+Liuauthor=J.+Wangauthor=J.+Changauthor=C.+Liauthor=T.+Hollenbeckauthor=T.+Tuntlandauthor=J.+Isbellauthor=C.+Fischliauthor=R.+Brunauthor=M.+Rottmannauthor=V.+Dartoisauthor=T.+Kellerauthor=T.+Diaganaauthor=E.+Winzelerauthor=R.+Glynneauthor=D.+C.+Tullyauthor=A.+K.+Chatterjee&title=Imidazolopiperazines%3A+hit+to+lead+optimization+of+new+antimalarial+agents&doi=10.1021%2Fjm2003359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents</span></div><div class="casAuthors">Wu, Tao; Nagle, Advait; Kuhen, Kelli; Gagaring, Kerstin; Borboa, Rachel; Francek, Caroline; Chen, Zhong; Plouffe, David; Goh, Anne; Lakshminarayana, Suresh B.; Wu, Jeanette; Ang, Hui Qing; Zeng, Peiting; Kang, Min Low; Tan, William; Tan, Maria; Ye, Nicole; Lin, Xuena; Caldwell, Christopher; Ek, Jared; Skolnik, Suzanne; Liu, Fenghua; Wang, Jianling; Chang, Jonathan; Li, Chun; Hollenbeck, Thomas; Tuntland, Tove; Isbell, John; Fischli, Christoph; Brun, Reto; Rottmann, Matthias; Dartois, Veronique; Keller, Thomas; Diagana, Thierry; Winzeler, Elizabeth; Glynne, Richard; Tully, David C.; Chatterjee, Arnab K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5116-5130</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from a hit series from a GNF compd. library collection and based on a cell-based proliferation assay of Plasmodium falciparum, a novel imidazolopiperazine scaffold was optimized.  SAR for this series of compds. is discussed, focusing on optimization of cellular potency against wild-type and drug resistant parasites and improvement of physiochem. and pharmacokinetic properties.  The lead compds. in this series showed good potencies in vitro and decent oral exposure levels in vivo.  In a Plasmodium berghei mouse infection model, one lead compd. lowered the parasitemia level by 99.4% after administration of 100 mg/kg single oral dose and prolonged mice survival by an av. of 17.0 days.  The lead compds. were also well-tolerated in the preliminary in vitro toxicity studies and represents an interesting lead for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaD1QipkA-QLVg90H21EOLACvtfcHk0lhSNK-WVNkIuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFags7s%253D&md5=eab02c18fda60302ffbcc581256cf149</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm2003359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003359%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DAng%26aufirst%3DH.%2BQ.%26aulast%3DZeng%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DM.%2BL.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DEk%26aufirst%3DJ.%26aulast%3DSkolnik%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DHollenbeck%26aufirst%3DT.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DDiagana%26aufirst%3DT.%26aulast%3DWinzeler%26aufirst%3DE.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DTully%26aufirst%3DD.%2BC.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26atitle%3DImidazolopiperazines%253A%2520hit%2520to%2520lead%2520optimization%2520of%2520new%2520antimalarial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D14%26spage%3D5116%26epage%3D5130%26doi%3D10.1021%2Fjm2003359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span> <span> </span><span class="NLM_article-title">Snapshot PK: a rapid rodent in vivo preclinical screening approach</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2007.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.drudis.2007.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=18405850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD1c3kslSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=360-367&author=B.+Liuauthor=J.+Changauthor=W.+P.+Gordonauthor=J.+Isbellauthor=Y.+Zhouauthor=T.+Tuntland&title=Snapshot+PK%3A+a+rapid+rodent+in+vivo+preclinical+screening+approach&doi=10.1016%2Fj.drudis.2007.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Snapshot PK: a rapid rodent in vivo preclinical screening approach</span></div><div class="casAuthors">Liu Bo; Chang Jonathan; Gordon William P; Isbell John; Zhou Yingyao; Tuntland Tove</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">360-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Described in this article are strategies implemented to increase the throughput of in vivo rodent pharmacokinetic (PK) studies using the snapshot PK study design and automated methods for compound submission, sample processing, data analysis and reporting.  Applying snapshot PK studies to categorize the oral exposure of >1300 discovery compounds as low, moderate or high resulted in an attrition rate of 86%.  The follow up full PK studies on the remaining compounds found that 98% of the compounds were predicted in the correct (69%) or adjacent (29%) oral exposure category by the snapshot PK studies.  These results demonstrate that the snapshot PK screen in rodents can serve as an effective and efficient in vivo tool in the compound selection process in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7lxjN22Wtb4xhnOQkIHOxfW6udTcc2eY4qnP6ysa7Drntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3kslSkuw%253D%253D&md5=2f0ca34fc2b06e13fc85fb28be221ffe</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2007.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2007.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26atitle%3DSnapshot%2520PK%253A%2520a%2520rapid%2520rodent%2520in%2520vivo%2520preclinical%2520screening%2520approach%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D360%26epage%3D367%26doi%3D10.1016%2Fj.drudis.2007.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbeck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isbell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alper, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span> <span> </span><span class="NLM_article-title">Imidazolopiperazines: lead optimization of the second-generation antimalarial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4244</span>– <span class="NLM_lpage">4273</span>, <span class="refDoi"> DOI: 10.1021/jm300041e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300041e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2kt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4244-4273&issue=9&author=A.+Nagleauthor=T.+Wuauthor=K.+Kuhenauthor=K.+Gagaringauthor=R.+Borboaauthor=C.+Francekauthor=Z.+Chenauthor=D.+Plouffeauthor=X.+Linauthor=C.+Caldwellauthor=J.+Ekauthor=S.+Skolnikauthor=F.+Liuauthor=J.+Wangauthor=J.+Changauthor=C.+Liauthor=B.+Liuauthor=T.+Hollenbeckauthor=T.+Tuntlandauthor=J.+Isbellauthor=T.+Chuanauthor=P.+B.+Alperauthor=C.+Fischliauthor=R.+Brunauthor=S.+B.+Lakshminarayanaauthor=M.+Rottmannauthor=T.+T.+Diaganaauthor=E.+A.+Winzelerauthor=R.+Glynneauthor=D.+C.+Tullyauthor=A.+K.+Chatterjee&title=Imidazolopiperazines%3A+lead+optimization+of+the+second-generation+antimalarial+agents&doi=10.1021%2Fjm300041e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazolopiperazines: Lead optimization of the second-generation antimalarial agents</span></div><div class="casAuthors">Nagle, Advait; Wu, Tao; Kuhen, Kelli; Gagaring, Kerstin; Borboa, Rachel; Francek, Caroline; Chen, Zhong; Plouffe, David; Lin, Xuena; Caldwell, Christopher; Ek, Jared; Skolnik, Suzanne; Liu, Fenghua; Wang, Jianling; Chang, Jonathan; Li, Chun; Liu, Bo; Hollenbeck, Thomas; Tuntland, Tove; Isbell, John; Chuan, Tiffany; Alper, Philip B.; Fischli, Christoph; Brun, Reto; Lakshminarayana, Suresh B.; Rottmann, Matthias; Diagana, Thierry T.; Winzeler, Elizabeth A.; Glynne, Richard; Tully, David C.; Chatterjee, Arnab K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4244-4273</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compds. involving changes in the core piperazine ring was synthesized to improve antimalarial properties.  These changes were carried out to further improve the potency and metabolic stability of the compds. by leveraging the outcome of a set of in vitro metabolic identification studies.  The optimized 8,8-di-Me imidazolopiperazine analogs I(R = 4-F, 4-Me, 3,4-F2) and II(R = 4-Me, 3-Cl-4-F) III(R = Me, F) exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice.  The optimized compds. were found to be more efficacious than the current antimalarials in a malaria mouse model.  They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonl3aXJKMqObVg90H21EOLACvtfcHk0lhSNK-WVNkIuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2kt7k%253D&md5=6c46f2f5ca76ae5a5089b542ec15e2ac</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm300041e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300041e%26sid%3Dliteratum%253Aachs%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DEk%26aufirst%3DJ.%26aulast%3DSkolnik%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHollenbeck%26aufirst%3DT.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DChuan%26aufirst%3DT.%26aulast%3DAlper%26aufirst%3DP.%2BB.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DTully%26aufirst%3DD.%2BC.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26atitle%3DImidazolopiperazines%253A%2520lead%2520optimization%2520of%2520the%2520second-generation%2520antimalarial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D9%26spage%3D4244%26epage%3D4273%26doi%3D10.1021%2Fjm300041e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenviaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graumans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vegte-Bolmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gemert, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebayang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patra, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinetz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">5060</span>– <span class="NLM_lpage">5067</span>, <span class="refDoi"> DOI: 10.1128/AAC.02727-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.02727-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24913172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5060-5067&issue=9&author=K.+L.+Kuhenauthor=A.+K.+Chatterjeeauthor=M.+Rottmannauthor=K.+Gagaringauthor=R.+Borboaauthor=J.+Buenviajeauthor=Z.+Chenauthor=C.+Francekauthor=T.+Wuauthor=A.+Nagleauthor=S.+W.+Barnesauthor=D.+Plouffeauthor=M.+C.+Leeauthor=D.+A.+Fidockauthor=W.+Graumansauthor=M.+van+de+Vegte-Bolmerauthor=G.+J.+van+Gemertauthor=G.+Wirjanataauthor=B.+Sebayangauthor=J.+Marfurtauthor=B.+Russellauthor=R.+Suwanaruskauthor=R.+N.+Priceauthor=F.+Nostenauthor=A.+Tungtaengauthor=M.+Gettayacaminauthor=J.+Sattabongkotauthor=J.+Taylorauthor=J.+R.+Walkerauthor=D.+Tullyauthor=K.+P.+Patraauthor=E.+L.+Flanneryauthor=J.+M.+Vinetzauthor=L.+Reniaauthor=R.+W.+Sauerweinauthor=E.+A.+Winzelerauthor=R.+J.+Glynneauthor=T.+T.+Diagana&title=KAF156+is+an+antimalarial+clinical+candidate+with+potential+for+use+in+prophylaxis%2C+treatment%2C+and+prevention+of+disease+transmission&doi=10.1128%2FAAC.02727-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">KAf156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission</span></div><div class="casAuthors">Kuhen, Kelli L.; Chatterjee, Arnab K.; Rottmann, Matthias; Gagaring, Kerstin; Borboa, Rachel; Buenviaje, Jennifer; Chen, Zhong; Francek, Carolyn; Wu, Tao; Nagle, Advait; Barnes, S. Whitney; Plouffe, David; Lee, Marcus C. S.; Fidock, David A.; Graumans, Wouter; van de Vegte-Bolmer, Marga; van Gemert, Geert J.; Wirjanata, Grennady; Sebayang, Boni; Marfurt, Jutta; Russell, Bruce; Suwanarusk, Rossarin; Price, Ric N.; Nosten, Francois; Tungtaeng, Anchalee; Gettayacamin, Montip; Sattabongkot, Jetsumon; Taylor, Jennifer; Walker, John R.; Tully, David; Patra, Kailash P.; Flannery, Erika L.; Vinetz, Joseph M.; Renia, Laurent; Sauerwein, Robert W.; Winzeler, Elizabeth A.; Glynne, Richard J.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5060-5067, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle.  We have previously reported the discovery of a novel class of antimalarial compds. in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria.  Consistent with the previously reported activity profile of this series, the clin. candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concns. of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99 % EDs of 0.6, 0.9, and 1.4 mg/kg, resp.  When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg.  Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo.  Collectively, our data suggest that KAF156, currently under evaluation in clin. trials, has the potential to treat, prevent, and block the transmission of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QluxrWtdq7Vg90H21EOLACvtfcHk0lixiYqyTUFpuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqs7fK&md5=c97e07e4832e871885546880084be5ca</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2FAAC.02727-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02727-13%26sid%3Dliteratum%253Aachs%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBuenviaje%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFrancek%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DGraumans%26aufirst%3DW.%26aulast%3Dvan%2Bde%2BVegte-Bolmer%26aufirst%3DM.%26aulast%3Dvan%2BGemert%26aufirst%3DG.%2BJ.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DSebayang%26aufirst%3DB.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTully%26aufirst%3DD.%26aulast%3DPatra%26aufirst%3DK.%2BP.%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DVinetz%26aufirst%3DJ.%2BM.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DKAF156%2520is%2520an%2520antimalarial%2520clinical%2520candidate%2520with%2520potential%2520for%2520use%2520in%2520prophylaxis%252C%2520treatment%252C%2520and%2520prevention%2520of%2520disease%2520transmission%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D9%26spage%3D5060%26epage%3D5067%26doi%3D10.1128%2FAAC.02727-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bopp, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borboa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettayacamin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattabongkot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">6061</span>),  <span class="NLM_fpage">1372</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1126/science.1211936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1211936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=22096101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=1372-1377&issue=6061&author=S.+Meisterauthor=D.+M.+Plouffeauthor=K.+L.+Kuhenauthor=G.+M.+Bonamyauthor=T.+Wuauthor=S.+W.+Barnesauthor=S.+E.+Boppauthor=R.+Borboaauthor=A.+T.+Brightauthor=J.+Cheauthor=S.+Cohenauthor=N.+V.+Dhariaauthor=K.+Gagaringauthor=M.+Gettayacaminauthor=P.+Gordonauthor=T.+Groesslauthor=N.+Katoauthor=M.+C.+Leeauthor=C.+W.+McNamaraauthor=D.+A.+Fidockauthor=A.+Nagleauthor=T.+G.+Namauthor=W.+Richmondauthor=J.+Rolandauthor=M.+Rottmannauthor=B.+Zhouauthor=P.+Froissardauthor=R.+J.+Glynneauthor=D.+Mazierauthor=J.+Sattabongkotauthor=P.+G.+Schultzauthor=T.+Tuntlandauthor=J.+R.+Walkerauthor=Y.+Zhouauthor=A.+Chatterjeeauthor=T.+T.+Diaganaauthor=E.+A.+Winzeler&title=Imaging+of+Plasmodium+liver+stages+to+drive+next-generation+antimalarial+drug+discovery&doi=10.1126%2Fscience.1211936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery</span></div><div class="casAuthors">Meister, Stephan; Plouffe, David M.; Kuhen, Kelli L.; Bonamy, Ghislain M. C.; Wu, Tao; Barnes, S. Whitney; Bopp, Selina E.; Borboa, Rachel; Bright, A. Taylor; Che, Jianwei; Cohen, Steve; Dharia, Neekesh V.; Gagaring, Kerstin; Gettayacamin, Montip; Gordon, Perry; Groessl, Todd; Kato, Nobutaka; Lee, Marcus C. S.; McNamara, Case W.; Fidock, David A.; Nagle, Advait; Nam, Tae-gyu; Richmond, Wendy; Roland, Jason; Rottmann, Matthias; Zhou, Bin; Froissard, Patrick; Glynne, Richard J.; Mazier, Dominique; Sattabongkot, Jetsumon; Schultz, Peter G.; Tuntland, Tove; Walker, John R.; Zhou, Yingyao; Chatterjee, Arnab; Diagana, Thierry T.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6061</span>),
    <span class="NLM_cas:pages">1372-1377</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Most malaria drug development focuses on parasite stages detected in red blood cells, even though, to achieve eradication, next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable.  We applied a multifactorial approach to a set of >4000 com. available compds. with previously demonstrated blood-stage activity (median inhibitory concn. < 1 micromolar) and identified chem. scaffolds with potent activity against both forms.  From this screen, we identified an imidazolopiperazine scaffold series that was highly enriched among compds. active against Plasmodium liver stages.  The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 mg/kg) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity.  The open-source chem. tools resulting from our effort provide starting points for future drug discovery programs, as well as opportunities for researchers to investigate the biol. of exo-erythrocytic forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyO41naZtcdrVg90H21EOLACvtfcHk0lixiYqyTUFpuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOjt7vN&md5=45b2993be36e36eabe1d9280c86c3db2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211936%26sid%3Dliteratum%253Aachs%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DBopp%26aufirst%3DS.%2BE.%26aulast%3DBorboa%26aufirst%3DR.%26aulast%3DBright%26aufirst%3DA.%2BT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DGettayacamin%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DNam%26aufirst%3DT.%2BG.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DRoland%26aufirst%3DJ.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFroissard%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DMazier%26aufirst%3DD.%26aulast%3DSattabongkot%26aufirst%3DJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DImaging%2520of%2520Plasmodium%2520liver%2520stages%2520to%2520drive%2520next-generation%2520antimalarial%2520drug%2520discovery%26jtitle%3DScience%26date%3D2011%26volume%3D334%26issue%3D6061%26spage%3D1372%26epage%3D1377%26doi%3D10.1126%2Fscience.1211936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the <i>Plasmodium falciparum</i> cyclic amine resistance locus (PfCARL) confer multidrug resistance</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e00696-16</span>, <span class="refDoi"> DOI: 10.1128/mBio.00696-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FmBio.00696-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27381290" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=e00696-16&author=G.+LaMonteauthor=M.+Y.+Limauthor=M.+Wreeauthor=C.+Reimerauthor=M.+Nachonauthor=V.+Coreyauthor=P.+Gedeckauthor=D.+Plouffeauthor=A.+Duauthor=N.+Figueroaauthor=B.+Yeungauthor=P.+Bifaniauthor=E.+A.+Winzeler&title=Mutations+in+the+Plasmodium+falciparum+cyclic+amine+resistance+locus+%28PfCARL%29+confer+multidrug+resistance&doi=10.1128%2FmBio.00696-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1128%2FmBio.00696-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00696-16%26sid%3Dliteratum%253Aachs%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DWree%26aufirst%3DM.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DA.%26aulast%3DFigueroa%26aufirst%3DN.%26aulast%3DYeung%26aufirst%3DB.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMutations%2520in%2520the%2520Plasmodium%2520falciparum%2520cyclic%2520amine%2520resistance%2520locus%2520%2528PfCARL%2529%2520confer%2520multidrug%2520resistance%26jtitle%3DmBio%26date%3D2016%26volume%3D7%26spage%3De00696-16%26doi%3D10.1128%2FmBio.00696-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magistrado, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title"><i>Plasmodium falciparum</i> cyclic amine resistance locus (PfCARL), a resistance mechanism for two distinct compound classes</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=816-826&issue=11&author=P.+A.+Magistradoauthor=V.+C.+Coreyauthor=A.+K.+Lukensauthor=G.+LaMonteauthor=E.+Sasakiauthor=S.+Meisterauthor=M.+Wreeauthor=E.+Winzelerauthor=D.+F.+Wirth&title=Plasmodium+falciparum+cyclic+amine+resistance+locus+%28PfCARL%29%2C+a+resistance+mechanism+for+two+distinct+compound+classes&doi=10.1021%2Facsinfecdis.6b00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium falciparum Cyclic Amine Resistance Locus (PfCARL), a Resistance Mechanism for Two Distinct Compound Classes</span></div><div class="casAuthors">Magistrado, Pamela A.; Corey, Victoria C.; Lukens, Amanda K.; LaMonte, Greg; Sasaki, Erika; Meister, Stephan; Wree, Melanie; Winzeler, Elizabeth; Wirth, Dyann F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">816-826</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MMV007564 is a novel antimalarial benzimidazolyl piperidine chemotype identified in cellular screens.  To identify the genetic determinant of MMV007564 resistance, parasites were cultured in the presence of the compd. to generate resistant lines.  Whole genome sequencing revealed distinct mutations in the gene named Plasmodium falciparum cyclic amine resistance locus (pfcarl), encoding a conserved protein of unknown function.  Mutations in pfcarl are strongly assocd. with resistance to a structurally unrelated class of compds., the imidazolopiperazines, including KAF156, currently in clin. trials.  Our data demonstrate that pfcarl mutations confer resistance to two distinct compd. classes, benzimidazolyl piperidines and imidazolopiperazines.  However, MMV007564 and the imidazolopiperazines, KAF156 and GNF179, have different timings of action in the asexual blood stage and different potencies against the liver and sexual blood stages.  These data suggest that pfcarl is a multidrug-resistance gene rather than a common target for benzimidazolyl piperidines and imidazolopiperazines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO2hqloBBVgbVg90H21EOLACvtfcHk0lixBqJew3gr7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCrsLo%253D&md5=099493350b8b85ee6363c844f9f325cf</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00025%26sid%3Dliteratum%253Aachs%26aulast%3DMagistrado%26aufirst%3DP.%2BA.%26aulast%3DCorey%26aufirst%3DV.%2BC.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DSasaki%26aufirst%3DE.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DWree%26aufirst%3DM.%26aulast%3DWinzeler%26aufirst%3DE.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DPlasmodium%2520falciparum%2520cyclic%2520amine%2520resistance%2520locus%2520%2528PfCARL%2529%252C%2520a%2520resistance%2520mechanism%2520for%2520two%2520distinct%2520compound%2520classes%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26issue%3D11%26spage%3D816%26epage%3D826%26doi%3D10.1021%2Facsinfecdis.6b00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjahjadi, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span> <span> </span><span class="NLM_article-title">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16166</span>, <span class="refDoi"> DOI: 10.1038/nmicrobiol.2016.166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnmicrobiol.2016.166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27642791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16166&author=M.+Y.+Limauthor=G.+LaMonteauthor=M.+C.+Leeauthor=C.+Reimerauthor=B.+H.+Tanauthor=V.+Coreyauthor=B.+F.+Tjahjadiauthor=A.+Chuaauthor=M.+Nachonauthor=R.+Wintjensauthor=P.+Gedeckauthor=B.+Malleretauthor=L.+Reniaauthor=G.+M.+Bonamyauthor=P.+C.+Hoauthor=B.+K.+Yeungauthor=E.+D.+Chowauthor=L.+Limauthor=D.+A.+Fidockauthor=T.+T.+Diaganaauthor=E.+A.+Winzelerauthor=P.+Bifani&title=UDP-galactose+and+acetyl-CoA+transporters+as+Plasmodium+multidrug+resistance+genes&doi=10.1038%2Fnmicrobiol.2016.166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span></div><div class="casAuthors">Lim, Michelle Yi-Xiu; La Monte, Gregory; Lee, Marcus C. S.; Reimer, Christin; Tan, Bee Huat; Corey, Victoria; Tjahjadi, Bianca F.; Chua, Adeline; Nachon, Marie; Wintjens, Rene; Gedeck, Peter; Malleret, Benoit; Renia, Laurent; Bonamy, Ghislain M. C.; Ho, Paul Chi-Lui; Yeung, Bryan K. S.; Chow, Eric D.; Lim, Liting; Fidock, David A.; Diagana, Thierry T.; Winzeler, Elizabeth A.; Bifani, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">16166</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A mol. understanding of drug resistance mechanisms enables surveillance of the effectiveness of new antimicrobial therapies during development and deployment in the field.  We used conventional drug resistance selection as well as a regime of limiting diln. at early stages of drug treatment to probe 2 antimalarial imidazolopiperazines, KAF156 and GNF179.  The latter approach permits the isolation of low-fitness mutants that might otherwise be out-competed during selection.  Whole-genome sequencing of 24 independently derived resistant Plasmodium falciparum clones revealed 4 parasites with mutations in the known cyclic amine resistance locus (pfcarl) and a further 20 with mutations in 2 previously unreported P. falciparum drug resistance genes, an acetyl-CoA transporter (pfact) and a UDP-galactose transporter (pfugt).  Mutations were validated both in vitro by CRISPR editing in P. falciparum and in vivo by evolution of resistant Plasmodium berghei mutants.  Both PfACT and PfUGT were localized to the endoplasmic reticulum by fluorescence microscopy.  As mutations in pfact and pfugt conveyed resistance against addnl. unrelated chem. scaffolds, these genes are probably involved in broad mechanisms of antimalarial drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWucZl9WjFw7Vg90H21EOLACvtfcHk0lixBqJew3gr7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D&md5=c87d57996e20bb94d7d44c556553daf4</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnmicrobiol.2016.166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmicrobiol.2016.166%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DTjahjadi%26aufirst%3DB.%2BF.%26aulast%3DChua%26aufirst%3DA.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DMalleret%26aufirst%3DB.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%26aulast%3DHo%26aufirst%3DP.%2BC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DChow%26aufirst%3DE.%2BD.%26aulast%3DLim%26aufirst%3DL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DBifani%26aufirst%3DP.%26atitle%3DUDP-galactose%2520and%2520acetyl-CoA%2520transporters%2520as%2520Plasmodium%2520multidrug%2520resistance%2520genes%26jtitle%3DNat.%2520Microbiol.%26date%3D2016%26volume%3D1%26spage%3D16166%26doi%3D10.1038%2Fnmicrobiol.2016.166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catoire, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flarakos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangold, J. B.</span></span> <span> </span><span class="NLM_article-title">Utilization of stable isotope labeling to facilitate the identification of polar metabolites of KAF156, an antimalarial agent</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.072108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1124%2Fdmd.116.072108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27486238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyls77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1697-1708&issue=10&author=S.+E.+Huskeyauthor=R.+R.+Forsethauthor=H.+Liauthor=Z.+Jianauthor=A.+Catoireauthor=J.+Zhangauthor=T.+Rayauthor=H.+Heauthor=J.+Flarakosauthor=J.+B.+Mangold&title=Utilization+of+stable+isotope+labeling+to+facilitate+the+identification+of+polar+metabolites+of+KAF156%2C+an+antimalarial+agent&doi=10.1124%2Fdmd.116.072108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Utilization of stable isotope labeling to facilitate the identification of polar metabolites of KAF156, an antimalarial agent</span></div><div class="casAuthors">Huskey, Su-Er W.; Forseth, Ry R.; Li, Hongmei; Jian, Zhigang; Catoire, Alexandre; Zhang, Jin; Ray, Tapan; He, Handan; Flarakos, Jimmy; Mangold, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1697-1708</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Identification of polar metabolites of drug candidates during development is often challenging.  Several prominent polar metabolites of 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone ([14C]KAF156), an antimalarial agent, were detected in rat urine from an absorption, distribution, metab., and excretion study but could not be characterized by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) because of low ionization efficiency.  In such instances, a strategy often chosen by investigators is to use a radiolabeled compd. with high specific activity, having an isotopic mass ratio (i.e., [12C]/[14C]) and mass difference that serve as the basis for a mass filter using accurate mass spectrometry.  Unfortunately, [14C]KAF156-1 was uniformly labeled (n = 1-6) with the mass ratio of ∼0.1.  This ratio was insufficient to be useful as a mass filter despite the high specific activity (120 μCi/mg).  At this stage in development, stable isotope labeled [13C6]KAF156-1 was available as the internal std. for the quantification of KAF156.  We were thus able to design an oral dose as a mixt. of [14C]KAF156-1 (specific activity 3.65 μCi/mg) and [13C6]KAF156-1 with a mass ratio of [12C]/[13C6] as 0.9 and the mass difference as 6.0202.  By using this mass filter strategy, four polar metabolites were successfully identified in rat urine.  Subsequently, using a similar dual labeling approach, [14C]KAF156-2 and [13C2]KAF156-2 were synthesized to allow the detection of any putative polar metabolites that may have lost labeling during biotransformations using the previous [14C]KAF156-1.  Three polar metabolites were thereby identified and M43, a less polar metabolite, was proposed as the key intermediate metabolite leading to the formation of a total of seven polar metabolites.  Overall this dual labeling approach proved practical and valuable for the identification of polar metabolites by LC-MS/MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGG9TzGB-u_bVg90H21EOLACvtfcHk0ljOEJHLsduBkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyls77I&md5=7035911a24a04a39ac4251e70bc9b3c2</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072108%26sid%3Dliteratum%253Aachs%26aulast%3DHuskey%26aufirst%3DS.%2BE.%26aulast%3DForseth%26aufirst%3DR.%2BR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DJian%26aufirst%3DZ.%26aulast%3DCatoire%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DRay%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DFlarakos%26aufirst%3DJ.%26aulast%3DMangold%26aufirst%3DJ.%2BB.%26atitle%3DUtilization%2520of%2520stable%2520isotope%2520labeling%2520to%2520facilitate%2520the%2520identification%2520of%2520polar%2520metabolites%2520of%2520KAF156%252C%2520an%2520antimalarial%2520agent%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D10%26spage%3D1697%26epage%3D1708%26doi%3D10.1124%2Fdmd.116.072108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6437</span>– <span class="NLM_lpage">6443</span>, <span class="refDoi"> DOI: 10.1128/AAC.03478-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.03478-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25136017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=6437-6443&issue=11&author=F.+J.+Leongauthor=R.+Zhaoauthor=S.+Zengauthor=B.+Magnussonauthor=T.+T.+Diaganaauthor=P.+Pertel&title=A+first-in-human+randomized%2C+double-blind%2C+placebo-controlled%2C+single-+and+multiple-ascending+oral+dose+study+of+novel+Imidazolopiperazine+KAF156+to+assess+its+safety%2C+tolerability%2C+and+pharmacokinetics+in+healthy+adult+volunteers&doi=10.1128%2FAAC.03478-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers</span></div><div class="casAuthors">Leong, F. Joel; Zhao, Rong; Zeng, Shuqi; Magnusson, Baldur; Diagana, Thierry T.; Pertel, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6437-6443, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">KAF156 belongs to a new class of antimalarial, the imidazolopiperazines, and is currently in clin. development for the treatment of uncomplicated malaria.  This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers detd. the max. oral dose of KAF156 tolerated by healthy adults and derived pharmacokinetic data including preliminary food effect to enable dose calcns. for malaria patients.  KAF156 was studied in single-dose cohorts 10 to 1,200 mg, including one 400-mg food effect cohort 4 to 10 subjects/cohort, and in multiple-dose cohorts 60 to 600 mg once daily for 3 days; 8 subjects/cohort.  The follow-up period was 6 to 14 days after the last dose.  KAF156 was tolerated, with self-limited mild to moderate gastrointestinal and neurol. adverse events.  In treated subjects after single doses, headache n = 4; 11.1%, diarrhea n = 3; 8.3%, dizziness n = 3; 8.3%, and abdominal pain n = 2; 5.6% were the most common adverse events.  Headache n = 4; 16.7%, nausea n = 3; 12.5%, upper respiratory tract infection n = 3; 12.5%, and dizziness n = 2; 8.3% were the most common adverse events following multiple doses.  KAF156 time to max. concn. (Tmax) was between 1.0 and 6.0 h.  Both the area under the concn.-time curve (AUC) and max. concn. (Cmax) increased more than dose-proportionally in both single- and multiple-ascending-dose cohorts terminal half-life, 42.5 to 70.7 h.  There was no significant accumulation over 3-day repeated administration.  The extent of absorption was not significantly affected by food at a single dose of 400 mg, while mean Cmax decreased from 778 ng/mL to 627 ng/mL and Tmax was delayed from a median of 3.0 h under fasting conditions to 6.0 h under fed conditions.  Renal elimination is a minor route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHd497-XrpVbVg90H21EOLACvtfcHk0ljOEJHLsduBkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjE&md5=e533daf63d5a0f60db93f12e592a1a0a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1128%2FAAC.03478-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03478-14%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26atitle%3DA%2520first-in-human%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520single-%2520and%2520multiple-ascending%2520oral%2520dose%2520study%2520of%2520novel%2520Imidazolopiperazine%2520KAF156%2520to%2520assess%2520its%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D11%26spage%3D6437%26epage%3D6443%26doi%3D10.1128%2FAAC.03478-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. S.</span></span> <span> </span><span class="NLM_article-title">A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/s12936-017-2162-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-017-2162-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29304859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Ogsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=7&author=F.+J.+Leongauthor=J.+P.+Jainauthor=Y.+Fengauthor=B.+Goswamiauthor=D.+S.+Stein&title=A+phase+1+evaluation+of+the+pharmacokinetic%2Fpharmacodynamic+interaction+of+the+anti-malarial+agents+KAF156+and+piperaquine&doi=10.1186%2Fs12936-017-2162-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine</span></div><div class="casAuthors">Leong, F. Joel; Jain, Jay Prakash; Feng, Yiyan; Goswami, Budhaditya; Stein, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7/1-7/11</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages.  Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are CYP3A4 substrates and inhibitors.  Potential combination effects on the QT interval were also assessed.  Methods: This was an open-label, parallel-group, single-dose study in healthy volunteers randomized to three parallel arms (1:1:1) of 800 mg KAF156 + 1280 mg PPQ, 800 mg KAF156 alone and 1280 mg PPQ alone.  Triplicate ECGs were done up to 48 h post-dose.  Routine safety and pharmacokinetic assessments were carried out up to 61 days.  Results: Of the 72 healthy male subjects recruited, 68 completed the study.  Co-administration of PPQ and KAF156 had no overall effect on AUC of either compd., but the Cmax values of both KAF156 (∼ 23%) and piperaquine (∼ 70%) increased.  Both drugs given alone or in combination were well tolerated with no deaths or serious adverse events (SAEs).  AEs were obsd. at the frequency of 87.5, 79.2 and 58.3% resp. for KAF156 + PPQ, PPQ and KAF156 arms.  The most common AEs were nausea and headache.  There were no Grade 3 or 4 events.  There were no ECG related AEs, no QTcF interval > 480 ms and no QTcF interval increase from baseline > 60 ms.  There was a pos. ΔQTcF trend in the KAF156 + PPQ arm when either KAF156 or piperaquine concn. increases, but there was no significant difference between the combination arm and other arms in max. ΔQTcF.  Conclusions: No safety/cardiac risk or drug interaction was identified which would preclude use of a KAF156 and PPQ combination in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx6g-lwFLSVLVg90H21EOLACvtfcHk0ljOEJHLsduBkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Ogsb4%253D&md5=0f95442418a2b9571498dac188486bba</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1186%2Fs12936-017-2162-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-017-2162-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26aulast%3DJain%26aufirst%3DJ.%2BP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DGoswami%26aufirst%3DB.%26aulast%3DStein%26aufirst%3DD.%2BS.%26atitle%3DA%2520phase%25201%2520evaluation%2520of%2520the%2520pharmacokinetic%252Fpharmacodynamic%2520interaction%2520of%2520the%2520anti-malarial%2520agents%2520KAF156%2520and%2520piperaquine%26jtitle%3DMalar.%2520J.%26date%3D2018%26volume%3D17%26spage%3D7%26doi%3D10.1186%2Fs12936-017-2162-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthaisin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuthasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of KAF156 in falciparum and vivax malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1056%2FNEJMoa1602250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=27653565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1152-1160&issue=12&author=N.+J.+Whiteauthor=T.+T.+Duongauthor=C.+Uthaisinauthor=F.+Nostenauthor=A.+P.+Phyoauthor=B.+Hanboonkunupakarnauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chuthasmitauthor=M.+S.+Cheungauthor=Y.+Fengauthor=R.+Liauthor=B.+Magnussonauthor=M.+Sultanauthor=D.+Wieserauthor=X.+Xunauthor=R.+Zhaoauthor=T.+T.+Diaganaauthor=P.+Pertelauthor=F.+J.+Leong&title=Antimalarial+activity+of+KAF156+in+falciparum+and+vivax+malaria&doi=10.1056%2FNEJMoa1602250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of KAF156 in falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Duong, Tran T.; Uthaisin, Chirapong; Nosten, Francois; Phyo, Aung P.; Hanboonkunupakarn, Borimas; Pukrittayakamee, Sasithon; Jittamala, Podjanee; Chuthasmit, Kittiphum; Cheung, Ming S.; Feng, Yiyan; Li, Ruobing; Magnusson, Baldur; Sultan, Marc; Wieser, Daniela; Xun, Xiaolei; Zhao, Rong; Diagana, Thierry T.; Pertel, Peter; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1152-1160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.  METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria.  Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a sep. cohort of patients with falciparum malaria who received a single dose (800 mg).  RESULTS: Median parasite clearance times were 45 h (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 h (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 h (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.  Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84).  The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 h.  There were no serious adverse events in this small study.  The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia.  Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose.  More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts.  CONCLUSIONS: KAF156 showed antimalarial activity without evident safety concerns in a small no. of adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHzWNldN2RLbVg90H21EOLACvtfcHk0lgdcQ4nNUWJwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN&md5=24d0943da6d583f8c0fe4fe9f380ec99</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602250%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DUthaisin%26aufirst%3DC.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChuthasmit%26aufirst%3DK.%26aulast%3DCheung%26aufirst%3DM.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DSultan%26aufirst%3DM.%26aulast%3DWieser%26aufirst%3DD.%26aulast%3DXun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DAntimalarial%2520activity%2520of%2520KAF156%2520in%2520falciparum%2520and%2520vivax%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D12%26spage%3D1152%26epage%3D1160%26doi%3D10.1056%2FNEJMoa1602250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bout, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, W. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandeur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Bras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barale, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span> <span> </span><span class="NLM_article-title">A molecular marker of artemisinin-resistant <i>Plasmodium falciparum</i> malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>505</i></span> (<span class="NLM_issue">7481</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/nature12876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature12876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24352242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2014&pages=50-55&issue=7481&author=F.+Arieyauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=J.+Beghainauthor=A.+C.+Langloisauthor=N.+Khimauthor=S.+Kimauthor=V.+Duruauthor=C.+Bouchierauthor=L.+Maauthor=P.+Limauthor=R.+Leangauthor=S.+Duongauthor=S.+Srengauthor=S.+Suonauthor=C.+M.+Chuorauthor=D.+M.+Boutauthor=S.+Menardauthor=W.+O.+Rogersauthor=B.+Gentonauthor=T.+Fandeurauthor=O.+Miottoauthor=P.+Ringwaldauthor=J.+Le+Brasauthor=A.+Berryauthor=J.+C.+Baraleauthor=R.+M.+Fairhurstauthor=F.+Benoit-Vicalauthor=O.+Mercereau-Puijalonauthor=D.+Menard&title=A+molecular+marker+of+artemisinin-resistant+Plasmodium+falciparum+malaria&doi=10.1038%2Fnature12876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular marker of artemisinin-resistant Plasmodium falciparum malaria</span></div><div class="casAuthors">Ariey Frederic; Beghain Johann; Barale Jean-Christophe; Witkowski Benoit; Khim Nimol; Kim Saorin; Duru Valentine; Amaratunga Chanaki; Langlois Anne-Claire; Bouchier Christiane; Ma Laurence; Lim Pharath; Leang Rithea; Duong Socheat; Sreng Sokunthea; Suon Seila; Chuor Char Meng; Bout Denis Mey; Menard Sandie; Berry Antoine; Rogers William O; Genton Blaise; Fandeur Thierry; Miotto Olivo; Ringwald Pascal; Le Bras Jacques; Fairhurst Rick M; Benoit-Vical Francoise; Mercereau-Puijalon Odile; Menard Didier</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">7481</span>),
    <span class="NLM_cas:pages">50-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide.  To monitor the spread of artemisinin resistance, a molecular marker is urgently needed.  Here, using whole-genome sequencing of an artemisinin-resistant parasite line from Africa and clinical parasite isolates from Cambodia, we associate mutations in the PF3D7_1343700 kelch propeller domain ('K13-propeller') with artemisinin resistance in vitro and in vivo.  Mutant K13-propeller alleles cluster in Cambodian provinces where resistance is prevalent, and the increasing frequency of a dominant mutant K13-propeller allele correlates with the recent spread of resistance in western Cambodia.  Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance.  K13-propeller polymorphism constitutes a useful molecular marker for large-scale surveillance efforts to contain artemisinin resistance in the Greater Mekong Subregion and prevent its global spread.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTg24yBOxa0oSjiVMCqkKxVfW6udTcc2eZFxNrcPLWwhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D&md5=e25f4dcc9ccc361de4c35e650391b7ca</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fnature12876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12876%26sid%3Dliteratum%253Aachs%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DBeghain%26aufirst%3DJ.%26aulast%3DLanglois%26aufirst%3DA.%2BC.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DBouchier%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DLeang%26aufirst%3DR.%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DBout%26aufirst%3DD.%2BM.%26aulast%3DMenard%26aufirst%3DS.%26aulast%3DRogers%26aufirst%3DW.%2BO.%26aulast%3DGenton%26aufirst%3DB.%26aulast%3DFandeur%26aufirst%3DT.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DLe%2BBras%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DA.%26aulast%3DBarale%26aufirst%3DJ.%2BC.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DMenard%26aufirst%3DD.%26atitle%3DA%2520molecular%2520marker%2520of%2520artemisinin-resistant%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DNature%26date%3D2014%26volume%3D505%26issue%3D7481%26spage%3D50%26epage%3D55%26doi%3D10.1038%2Fnature12876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadani, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urnov, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Drug resistance. K13-propeller mutations confer artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span> (<span class="NLM_issue">6220</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1126/science.1260867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscience.1260867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25502314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=428-431&issue=6220&author=J.+Straimerauthor=N.+F.+Gnadigauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=V.+Duruauthor=A.+P.+Ramadaniauthor=M.+Dacheuxauthor=N.+Khimauthor=L.+Zhangauthor=S.+Lamauthor=P.+D.+Gregoryauthor=F.+D.+Urnovauthor=O.+Mercereau-Puijalonauthor=F.+Benoit-Vicalauthor=R.+M.+Fairhurstauthor=D.+Menardauthor=D.+A.+Fidock&title=Drug+resistance.+K13-propeller+mutations+confer+artemisinin+resistance+in+Plasmodium+falciparum+clinical+isolates&doi=10.1126%2Fscience.1260867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates</span></div><div class="casAuthors">Straimer, Judith; Gnaedig, Nina F.; Witkowski, Benoit; Amaratunga, Chanaki; Duru, Valentine; Ramadani, Arba Pramundita; Dacheux, Melanie; Khim, Nimol; Zhang, Lei; Lam, Stephen; Gregory, Philip D.; Urnov, Fyodor D.; Mercereau-Puijalon, Odile; Benoit-Vical, Francoise; Fairhurst, Rick M.; Menard, Didier; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6220</span>),
    <span class="NLM_cas:pages">428-431</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The emergence of artemisinin resistance in Southeast Asia imperils efforts to reduce the global malaria burden.  We genetically modified the Plasmodium falciparum K13 locus using zinc-finger nucleases and measured ring-stage survival rates after drug exposure in vitro; these rates correlate with parasite clearance half-lives in artemisinin-treated patients.  With isolates from Cambodia, where resistance first emerged, survival rates decreased from 13 to 49% to 0.3 to 2.4% after the removal of K13 mutations.  Conversely, survival rates in wild-type parasites increased from ≤0.6% to 2 to 29% after the insertion of K13 mutations.  These mutations conferred elevated resistance to recent Cambodian isolates compared with that of ref. lines, suggesting a contemporary contribution of addnl. genetic factors.  Our data provide a conclusive rationale for worldwide K13-propeller sequencing to identify and eliminate artemisinin-resistant parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Ml-eUMKETLVg90H21EOLACvtfcHk0lhe4Fuq1cJx2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D&md5=5776238fb78428d16bcaed8d16fa73af</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1126%2Fscience.1260867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1260867%26sid%3Dliteratum%253Aachs%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DRamadani%26aufirst%3DA.%2BP.%26aulast%3DDacheux%26aufirst%3DM.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26aulast%3DUrnov%26aufirst%3DF.%2BD.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DDrug%2520resistance.%2520K13-propeller%2520mutations%2520confer%2520artemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520clinical%2520isolates%26jtitle%3DScience%26date%3D2015%26volume%3D347%26issue%3D6220%26spage%3D428%26epage%3D431%26doi%3D10.1126%2Fscience.1260867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roepe, P. D.</span></span> <span> </span><span class="NLM_article-title">Functional comparison of 45 naturally occurring isoforms of the <i>Plasmodium falciparum</i> chloroquine resistance transporter (PfCRT)</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">5083</span>– <span class="NLM_lpage">5094</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1agsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=5083-5094&issue=32&author=P.+S.+Callaghanauthor=M.+R.+Hassettauthor=P.+D.+Roepe&title=Functional+comparison+of+45+naturally+occurring+isoforms+of+the+Plasmodium+falciparum+chloroquine+resistance+transporter+%28PfCRT%29&doi=10.1021%2Facs.biochem.5b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Comparison of 45 Naturally Occurring Isoforms of the Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT)</span></div><div class="casAuthors">Callaghan, Paul S.; Hassett, Matthew R.; Roepe, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5083-5094</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">At least 53 distinct isoforms of Plasmodium falciparum chloroquine resistance transporter (PfCRT) protein are expressed in strains or isolates of P. falciparum malarial parasites from around the globe.  These parasites exhibit a range of sensitivities to chloroquine (CQ) and other drugs.  Mutant PfCRT is believed to confer cytostatic CQ resistance (CQRCS) by transporting CQ away from its DV target (free heme released upon Hb digestion).  One theory is that variable CQ transport catalyzed by these different PfCRT isoforms is responsible for the range of CQ sensitivities now found for P. falciparum.  Alternatively, addnl. mutations in drug-selected parasites, or addnl. functions of PfCRT, might complement PfCRT-mediated CQ transport in conferring the range of obsd. resistance phenotypes.  To distinguish between these possibilities, we recently optimized a convenient method for measuring PfCRT-mediated CQ transport, involving heterologous expression in Saccharomyces cerevisiae.  Here, we use this method to quantify drug transport activity for 45 of 53 of the naturally occurring PfCRT isoforms.  Data show that variable levels of CQR likely depend upon either addnl. PfCRT functions or addnl. genetic events, including perhaps changes that influence DV membrane potential.  The data also suggest that the common K76T PfCRT mutation that is often used to distinguish a P. falciparum CQR phenotype is not, in and of itself, a fully reliable indicator of CQR status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoP3eVuSL3frVg90H21EOLACvtfcHk0lhe4Fuq1cJx2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1agsrjE&md5=ea0a066cfcbab062341ed57f9addd188</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00412%26sid%3Dliteratum%253Aachs%26aulast%3DCallaghan%26aufirst%3DP.%2BS.%26aulast%3DHassett%26aufirst%3DM.%2BR.%26aulast%3DRoepe%26aufirst%3DP.%2BD.%26atitle%3DFunctional%2520comparison%2520of%252045%2520naturally%2520occurring%2520isoforms%2520of%2520the%2520Plasmodium%2520falciparum%2520chloroquine%2520resistance%2520transporter%2520%2528PfCRT%2529%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26issue%3D32%26spage%3D5083%26epage%3D5094%26doi%3D10.1021%2Facs.biochem.5b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlemann, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valderramos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valderramos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Decreasing pfmdr1 copy number in <i>Plasmodium falciparum</i> malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>194</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1086/507115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1086%2F507115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=16845638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BD28vit1alug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2006&pages=528-535&issue=4&author=A.+B.+Sidhuauthor=A.+C.+Uhlemannauthor=S.+G.+Valderramosauthor=J.+C.+Valderramosauthor=S.+Krishnaauthor=D.+A.+Fidock&title=Decreasing+pfmdr1+copy+number+in+Plasmodium+falciparum+malaria+heightens+susceptibility+to+mefloquine%2C+lumefantrine%2C+halofantrine%2C+quinine%2C+and+artemisinin&doi=10.1086%2F507115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin</span></div><div class="casAuthors">Sidhu Amar Bir Singh; Uhlemann Anne-Catrin; Valderramos Stephanie G; Valderramos Juan-Carlos; Krishna Sanjeev; Fidock David A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">528-35</span>
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    </div><div class="casAbstract">The global dissemination of drug-resistant Plasmodium falciparum is spurring intense efforts to implement artemisinin (ART)-based combination therapies for malaria, including mefloquine (MFQ)-artesunate and lumefantrine (LUM)-artemether.  Clinical studies have identified an association between an increased risk of MFQ, MFQ-artesunate, and LUM-artemether treatment failures and pfmdr1 gene amplification.  To directly address the contribution that pfmdr1 copy number makes to drug resistance, we genetically disrupted 1 of the 2 pfmdr1 copies in the drug-resistant FCB line, which resulted in reduced pfmdr1 mRNA and protein expression.  These knockdown clones manifested a 3-fold decrease in MFQ IC(50) values, compared with that for the FCB line, verifying the role played by pfmdr1 expression levels in mediating resistance to MFQ.  These clones also showed increased susceptibility to LUM, halofantrine, quinine, and ART.  No change was observed for chloroquine.  These results highlight the importance of pfmdr1 copy number in determining P. falciparum susceptibility to multiple agents currently being used to combat malaria caused by multidrug-resistant parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1o6ybd2Dyzo2y4bB4mnvYfW6udTcc2eaRQLBaHeEKEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vit1alug%253D%253D&md5=630ecb75857529bfcbf4e6db1fa3d779</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1086%2F507115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F507115%26sid%3Dliteratum%253Aachs%26aulast%3DSidhu%26aufirst%3DA.%2BB.%26aulast%3DUhlemann%26aufirst%3DA.%2BC.%26aulast%3DValderramos%26aufirst%3DS.%2BG.%26aulast%3DValderramos%26aufirst%3DJ.%2BC.%26aulast%3DKrishna%26aufirst%3DS.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DDecreasing%2520pfmdr1%2520copy%2520number%2520in%2520Plasmodium%2520falciparum%2520malaria%2520heightens%2520susceptibility%2520to%2520mefloquine%252C%2520lumefantrine%252C%2520halofantrine%252C%2520quinine%252C%2520and%2520artemisinin%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2006%26volume%3D194%26issue%3D4%26spage%3D528%26epage%3D535%26doi%3D10.1086%2F507115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span> </span><span class="NLM_article-title">Efficacy and Safety of KAF156 in Combination
With LUM-SDF in Adults
and Children With Uncomplicated <i>Plasmodium falciparum</i> Malaria</span>.  <i>ClinicalTrials.gov</i>: <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2019</span>;  <span class="NLM_fpage">NCT03167242</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03167242?term=NCT03167242&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03167242?term=NCT03167242&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy+and+Safety+of+KAF156+in+Combination%0AWith+LUM-SDF+in+Adults%0Aand+Children+With+Uncomplicated+Plasmodium+falciparum+Malaria.+ClinicalTrials.gov%3A+U.S.+National+Institutes+of+Health%2C+2019%3B+NCT03167242%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03167242%3Fterm%3DNCT03167242%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520KAF156%2520in%2520Combination%250AWith%2520LUM-SDF%2520in%2520Adults%250Aand%2520Children%2520With%2520Uncomplicated%2520Plasmodium%2520falciparum%2520Malaria%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2019%26spage%3DNCT03167242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span> <i>2018—A Triumph of Partnerships</i>; <span class="NLM_publisher-name">Medicines
for Malaria Venture</span>, 19 Dec <span class="NLM_year">2018</span>; <a href="http://www.mmv.org/newsroom/news/2018-triumph-partnerships" class="extLink">www.mmv.org/newsroom/news/2018-triumph-partnerships</a> (accessed
Jul. 10 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2018%E2%80%94A+Triumph+of+Partnerships%3B+Medicines%0Afor+Malaria+Venture%2C+19+Dec+2018%3B+www.mmv.org%2Fnewsroom%2Fnews%2F2018-triumph-partnerships+%28accessed%0AJul.+10+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2018%25E2%2580%2594A%2520Triumph%2520of%2520Partnerships%26pub%3DMedicines%250Afor%2520Malaria%2520Venture%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy</span>. <i>Infect. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.2174/187152610791163336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.2174%2F187152610791163336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=20334617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1egtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=226-239&author=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Plasmodium+dihydroorotate+dehydrogenase%3A+a+promising+target+for+novel+anti-malarial+chemotherapy&doi=10.2174%2F187152610791163336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy</span></div><div class="casAuthors">Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">226-239</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Malaria remains a globally prevalent infectious disease that leads to significant morbidity and mortality.  While there are a no. of drugs approved for its treatment, drug resistance has compromised most of them, making the development of new drugs for the treatment and prevention of malaria essential.  The completion of the Plasmodium falciparum genome and a growing understanding of parasite biol. are fueling the search for novel drug targets.  Despite this, few targets have been chem. validated in vivo.  The pyrimidine biosynthetic pathway illustrates one of the best examples of successful identification of anti-malarial drug targets.  This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum. dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery.  Several chem. scaffolds have been identified by high throughput screening as potent inhibitors of PfDHODH and these show strong selectivity for the material enzyme over that from the human host.  Potent activity against parasites in whole cell models with good correlation between activity on the enzyme and the parasite have also been obsd. for a no. of the identified series.  Lead optimization of a triazolopyrimidine-based series has identified an analog with prolonged plasma exposure, that is orally bioavailable, and which shows good efficacy against the in vivo mouse model of the disease.  These data provide strong evidence that PfDHODH is a validated target for the identification of new antimalarial chemotherapy.  The challenge remains to identify compds. with the necessary combination of potency and metabolic stability to allow identification of a clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-GwvHVLyauLVg90H21EOLACvtfcHk0lijmZf7L--6fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1egtLw%253D&md5=71abaa02fc1f5ccc9d44a138f5ce357b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.2174%2F187152610791163336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152610791163336%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DPlasmodium%2520dihydroorotate%2520dehydrogenase%253A%2520a%2520promising%2520target%2520for%2520novel%2520anti-malarial%2520chemotherapy%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2010%26volume%3D10%26spage%3D226%26epage%3D239%26doi%3D10.2174%2F187152610791163336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase with antimalarial activity in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3935</span>– <span class="NLM_lpage">3949</span>, <span class="refDoi"> DOI: 10.1021/jm200265b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200265b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3935-3949&issue=11&author=R.+Gujjarauthor=F.+El+Mazouniauthor=K.+L.+Whiteauthor=J.+Whiteauthor=S.+Creasonauthor=D.+M.+Shacklefordauthor=X.+Dengauthor=W.+N.+Charmanauthor=I.+Bathurstauthor=J.+Burrowsauthor=D.+M.+Floydauthor=D.+Matthewsauthor=F.+S.+Bucknerauthor=S.+A.+Charmanauthor=M.+A.+Phillipsauthor=P.+K.+Rathod&title=Lead+optimization+of+aryl+and+aralkyl+amine-based+triazolopyrimidine+inhibitors+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+with+antimalarial+activity+in+mice&doi=10.1021%2Fjm200265b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice</span></div><div class="casAuthors">Gujjar, Ramesh; El Mazouni, Farah; White, Karen L.; White, John; Creason, Sharon; Shackleford, David M.; Deng, Xiaoyi; Charman, William N.; Bathurst, Ian; Burrows, Jeremy; Floyd, David M.; Matthews, David; Buckner, Frederick S.; Charman, Susan A.; Phillips, Margaret A.; Rathod, Pradipsinh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3935-3949</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.  We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development.  Active compds. from the series contained a triazolopyrimidine ring attached to an arom. group through a bridging nitrogen atom.  Herein, we describe systematic efforts to optimize the arom. functionality with the goal of improving potency and in vivo properties of compds. from the series.  These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4-CF3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compds. from the series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh3es6zVLa3bVg90H21EOLACvtfcHk0lijmZf7L--6fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWmsbw%253D&md5=a04f0a93af71a83c7c8b4cd6932abb87</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm200265b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200265b%26sid%3Dliteratum%253Aachs%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DCreason%26aufirst%3DS.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBathurst%26aufirst%3DI.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DFloyd%26aufirst%3DD.%2BM.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26atitle%3DLead%2520optimization%2520of%2520aryl%2520and%2520aralkyl%2520amine-based%2520triazolopyrimidine%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520with%2520antimalarial%2520activity%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D11%26spage%3D3935%26epage%3D3949%26doi%3D10.1021%2Fjm200265b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujjar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marwaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1864</span>– <span class="NLM_lpage">1872</span>, <span class="refDoi"> DOI: 10.1021/jm801343r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801343r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlenuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1864-1872&issue=7&author=R.+Gujjarauthor=A.+Marwahaauthor=F.+El+Mazouniauthor=J.+Whiteauthor=K.+L.+Whiteauthor=S.+Creasonauthor=D.+M.+Shacklefordauthor=J.+Baldwinauthor=W.+N.+Charmanauthor=F.+S.+Bucknerauthor=S.+Charmanauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Identification+of+a+metabolically+stable+triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitor+with+antimalarial+activity+in+mice&doi=10.1021%2Fjm801343r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Metabolically Stable Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Antimalarial Activity in Mice</span></div><div class="casAuthors">Gujjar, Ramesh; Marwaha, Alka; El Mazouni, Farah; White, John; White, Karen L.; Creason, Sharon; Shackleford, David M.; Baldwin, Jeffrey; Charman, William N.; Buckner, Frederick S.; Charman, Susan; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1864-1872</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Plasmodium falciparum causes 1-2 million deaths annually.  Yet current drug therapies are compromised by resistance.  We previously described potent and selective triazolopyrimidine-based inhibitors of P. falciparum dihydroorotate dehydrogenase (PfDHODH) that inhibited parasite growth in vitro; however, they showed no activity in vivo.  Here we show that lack of efficacy against P. berghei in mice resulted from a combination of poor plasma exposure and reduced potency against P. berghei DHODH.  For compds. contg. naphthyl (DSM1) or anthracenyl (DSM2), plasma exposure was reduced upon repeated dosing.  Phenyl-substituted triazolopyrimidines were synthesized leading to identification of analogs with low predicted metab. in human liver microsomes and which showed prolonged exposure in mice.  Compd. 21 (DSM74), contg. p-trifluoromethylphenyl, suppressed growth of P. berghei in mice after oral administration.  This study provides the first proof of concept that DHODH inhibitors can suppress Plasmodium growth in vivo, validating DHODH as a new target for antimalarial chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKZ374sKZfCrVg90H21EOLACvtfcHk0lijmZf7L--6fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlenuro%253D&md5=773ca17ea78a4f833c092c211c90c199</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fjm801343r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801343r%26sid%3Dliteratum%253Aachs%26aulast%3DGujjar%26aufirst%3DR.%26aulast%3DMarwaha%26aufirst%3DA.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCreason%26aufirst%3DS.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DCharman%26aufirst%3DS.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520of%2520a%2520metabolically%2520stable%2520triazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520with%2520antimalarial%2520activity%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D7%26spage%3D1864%26epage%3D1872%26doi%3D10.1021%2Fjm801343r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine modulates species selectivity in the triazolopyrimidine class of <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5381</span>– <span class="NLM_lpage">5394</span>, <span class="refDoi"> DOI: 10.1021/jm500481t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500481t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5381-5394&issue=12&author=X.+Dengauthor=S.+Kokkondaauthor=F.+El+Mazouniauthor=J.+Whiteauthor=J.+N.+Burrowsauthor=W.+Kaminskyauthor=S.+A.+Charmanauthor=D.+Matthewsauthor=P.+K.+Rathodauthor=M.+A.+Phillips&title=Fluorine+modulates+species+selectivity+in+the+triazolopyrimidine+class+of+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors&doi=10.1021%2Fjm500481t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors</span></div><div class="casAuthors">Deng, Xiaoyi; Kokkonda, Sreekanth; El Mazouni, Farah; White, John; Burrows, Jeremy N.; Kaminsky, Werner; Charman, Susan A.; Matthews, David; Rathod, Pradipsinh K.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5381-5394</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most serious global infectious diseases.  The pyrimidine biosynthetic enzyme Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) is an important target for antimalarial chemotherapy.  The authors describe a detailed anal. of protein-ligand interactions between DHODH and a triazolopyrimidine-based inhibitor series to explore the effects of fluorine on affinity and species selectivity.  The authors show that increasing fluorination dramatically increases binding to mammalian DHODHs, leading to a loss of species selectivity.  Triazolopyrimidines bind Plasmodium and mammalian DHODHs in overlapping but distinct binding sites.  Key hydrogen-bond and stacking interactions underlying strong binding to PfDHODH are absent in the mammalian enzymes.  Increasing fluorine substitution leads to an increase in the entropic contribution to binding, suggesting that strong binding to mammalian DHODH is a consequence of an enhanced hydrophobic effect upon binding to an apolar pocket.  The authors conclude that hydrophobic interactions between fluorine and hydrocarbons provide significant binding energy to protein-ligand interactions.  The authors' studies define the requirements for species-selective binding to PfDHODH and show that the triazolopyrimidine scaffold can alternatively be tuned to inhibit human DHODH, an important target for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFg5a-YaPFpLVg90H21EOLACvtfcHk0liJztb9Kr4bLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Chs74%253D&md5=abfc8df6c8510665049e65338732acf0</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjm500481t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500481t%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DFluorine%2520modulates%2520species%2520selectivity%2520in%2520the%2520triazolopyrimidine%2520class%2520of%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D12%26spage%3D5381%26epage%3D5394%26doi%3D10.1021%2Fjm500481t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselden, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louttit, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickham, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gahagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirsalis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathhurst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">296</span>),  <span class="NLM_fpage">296ra111</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa6645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscitranslmed.aaa6645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26180101" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=296ra111&issue=296&author=M.+A.+Phillipsauthor=J.+Lothariusauthor=K.+Marshauthor=J.+Whiteauthor=A.+Dayanauthor=K.+L.+Whiteauthor=J.+W.+Njorogeauthor=F.+El+Mazouniauthor=Y.+Laoauthor=S.+Kokkondaauthor=D.+R.+Tomchickauthor=X.+Dengauthor=T.+Lairdauthor=S.+N.+Bhatiaauthor=S.+Marchauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=S.+Wittlinauthor=M.+Lafuente-Monasterioauthor=F.+J.+Benitoauthor=L.+M.+Alonsoauthor=M.+S.+Martinezauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=J.+N.+Haseldenauthor=J.+Louttitauthor=Y.+Cuiauthor=A.+Sridharauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=R.+Sauerweinauthor=K.+Decheringauthor=V.+M.+Averyauthor=S.+Duffyauthor=M.+Delvesauthor=R.+Sindenauthor=A.+Rueckerauthor=K.+S.+Wickhamauthor=R.+Rochfordauthor=J.+Gahagenauthor=L.+Iyerauthor=E.+Riccioauthor=J.+Mirsalisauthor=I.+Bathhurstauthor=T.+Rueckleauthor=X.+Dingauthor=B.+Campoauthor=D.+Leroyauthor=M.+J.+Rogersauthor=P.+K.+Rathodauthor=J.+N.+Burrowsauthor=S.+A.+Charman&title=A+long-duration+dihydroorotate+dehydrogenase+inhibitor+%28DSM265%29+for+prevention+and+treatment+of+malaria&doi=10.1126%2Fscitranslmed.aaa6645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa6645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa6645%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDayan%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DNjoroge%26aufirst%3DJ.%2BW.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLao%26aufirst%3DY.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLaird%26aufirst%3DT.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DMarch%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DBenito%26aufirst%3DF.%2BJ.%26aulast%3DAlonso%26aufirst%3DL.%2BM.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DHaselden%26aufirst%3DJ.%2BN.%26aulast%3DLouttit%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DSauerwein%26aufirst%3DR.%26aulast%3DDechering%26aufirst%3DK.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DDelves%26aufirst%3DM.%26aulast%3DSinden%26aufirst%3DR.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DWickham%26aufirst%3DK.%2BS.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DGahagen%26aufirst%3DJ.%26aulast%3DIyer%26aufirst%3DL.%26aulast%3DRiccio%26aufirst%3DE.%26aulast%3DMirsalis%26aufirst%3DJ.%26aulast%3DBathhurst%26aufirst%3DI.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DRogers%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520long-duration%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520%2528DSM265%2529%2520for%2520prevention%2520and%2520treatment%2520of%2520malaria%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D296%26spage%3D296ra111%26doi%3D10.1126%2Fscitranslmed.aaa6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span> </span><span class="NLM_article-title">Efficacy, Safety, Tolerability and Pharmacokinetics
of KAF156 in
Adult Patients With Acute, Uncomplicated <i>Plasmodium falciparum</i> or <i>vivax</i> Malaria Mono-infection</span>.  <i>Clinical trials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2015</span>;  <span class="NLM_fpage">NCT01753323</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT01753323?term=NCT01753323&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01753323?term=NCT01753323&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy%2C+Safety%2C+Tolerability+and+Pharmacokinetics%0Aof+KAF156+in%0AAdult+Patients+With+Acute%2C+Uncomplicated+Plasmodium+falciparum+or+vivax+Malaria+Mono-infection.+Clinical+trials.gov%3B+U.S.+National%0AInstitutes+of+Health%2C+2015%3B+NCT01753323%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01753323%3Fterm%3DNCT01753323%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%252C%2520Safety%252C%2520Tolerability%2520and%2520Pharmacokinetics%250Aof%2520KAF156%2520in%250AAdult%2520Patients%2520With%2520Acute%252C%2520Uncomplicated%2520Plasmodium%2520falciparum%2520or%2520vivax%2520Malaria%2520Mono-infection%26jtitle%3DClinical%2520trials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2015%26spage%3DNCT01753323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiegand, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span> <span> </span><span class="NLM_article-title">In vitro resistance selections for <i>Plasmodium falciparum</i> dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">17980</span>– <span class="NLM_lpage">17995</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.558353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1074%2Fjbc.M114.558353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24782313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=17980-17995&issue=26&author=L.+S.+Rossauthor=F.+J.+Gamoauthor=M.+J.+Lafuente-Monasterioauthor=O.+M.+Singhauthor=P.+Rowlandauthor=R.+C.+Wiegandauthor=D.+F.+Wirth&title=In+vitro+resistance+selections+for+Plasmodium+falciparum+dihydroorotate+dehydrogenase+inhibitors+give+mutants+with+multiple+point+mutations+in+the+drug-binding+site+and+altered+growth&doi=10.1074%2Fjbc.M114.558353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Resistance Selections for Plasmodium Falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered Growth</span></div><div class="casAuthors">Ross, Leila S.; Gamo, Francisco Javier; Lafuente-Monasterio, Maria Jose; Singh, Onkar M. P.; Rowland, Paul; Wiegand, Roger C.; Wirth, Dyann F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">17980-17995</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Malaria is a preventable and treatable disease; yet half of the world's population lives at risk of infection, and an estd. 660,000 people die of malaria-related causes every year.  Rising drug resistance threatens to make malaria untreatable, necessitating both the discovery of new antimalarial agents and the development of strategies to identify and suppress the emergence and spread of drug resistance.  We focused on in-development dihydroorotate dehydrogenase (DHODH) inhibitors.  Characterizing resistance pathways for antimalarial agents not yet in clin. use will increase our understanding of the potential for resistance.  We identified resistance mechanisms of Plasmodium falciparum (Pf) DHODH inhibitors via in vitro resistance selections.  We found 11 point mutations in the PfDHODH target.  Target gene amplification and unknown mechanisms also contributed to resistance, albeit to a lesser extent.  These mutant parasites were often hypersensitive to other PfDHODH inhibitors, which immediately suggested a novel combination therapy approach to preventing resistance.  Indeed, a combination of wild-type and mutant-type selective inhibitors led to resistance far less often than either drug alone.  The effects of point mutations in PfDHODH were corroborated with purified recombinant wild-type and mutant-type PfDHODH proteins, which showed the same trends in drug response as the cognate cell lines.  Comparative growth assays demonstrated that two mutant parasites grew less robustly than their wild-type parent, and the purified protein of those mutants showed a decrease in catalytic efficiency, thereby suggesting a reason for the diminished growth rate.  Co-crystallog. of PfDHODH with three inhibitors suggested that hydrophobic interactions are important for drug binding and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro56dX8r--uLVg90H21EOLACvtfcHk0liYxCtq8iMv1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGjsL%252FO&md5=35ea613c4223241c76a7bc0436cf9adb</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.558353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.558353%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DL.%2BS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DSingh%26aufirst%3DO.%2BM.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DWiegand%26aufirst%3DR.%2BC.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26atitle%3DIn%2520vitro%2520resistance%2520selections%2520for%2520Plasmodium%2520falciparum%2520dihydroorotate%2520dehydrogenase%2520inhibitors%2520give%2520mutants%2520with%2520multiple%2520point%2520mutations%2520in%2520the%2520drug-binding%2520site%2520and%2520altered%2520growth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D26%26spage%3D17980%26epage%3D17995%26doi%3D10.1074%2Fjbc.M114.558353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhingra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afanador, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span> <span> </span><span class="NLM_article-title">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in <i>Plasmodium falciparum</i> that confer in vitro resistance to the clinical candidate DSM265</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00211</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00211" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=90-101&issue=1&author=J.+Whiteauthor=S.+K.+Dhingraauthor=X.+Dengauthor=F.+El+Mazouniauthor=M.+C.+S.+Leeauthor=G.+A.+Afanadorauthor=A.+Lawongauthor=D.+R.+Tomchickauthor=C.+L.+Ngauthor=J.+Bathauthor=P.+K.+Rathodauthor=D.+A.+Fidockauthor=M.+A.+Phillips&title=Identification+and+mechanistic+understanding+of+dihydroorotate+dehydrogenase+point+mutations+in+Plasmodium+falciparum+that+confer+in+vitro+resistance+to+the+clinical+candidate+DSM265&doi=10.1021%2Facsinfecdis.8b00211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in vitro resistance to the clinical candidate DSM265</span></div><div class="casAuthors">White, John; Dhingra, Satish K.; Deng, Xiaoyi; El Mazouni, Farah; Lee, Marcus C. S.; Afanador, Gustavo A.; Lawong, Aloysus; Tomchick, Diana R.; Ng, Caroline L.; Bath, Jade; Rathod, Pradipsinh K.; Fidock, David A.; Phillips, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-101</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Malaria is one of the most challenging human infectious diseases, and both prevention and control have been hindered by the development of Plasmodium falciparum resistance to existing therapies.  Several new compds. with novel mechanisms are in clin. development for the treatment of malaria, including DSM265, an inhibitor of Plasmodium dihydroorotate dehydrogenase.  To explore the mechanisms by which resistance might develop to DSM265 in the field, we selected for DSM265-resistant P. falciparum parasites in vitro.  Any of five different amino acid changes led to reduced efficacy on the parasite and to decreased DSM265 binding to P. falciparum DHODH.  The DSM265-resistant parasites retained full sensitivity to atovaquone.  All but one of the obsd. mutations were in the DSM265 binding site, and the remaining C276F was in the adjacent flavin cofactor site.  The C276F mutation was previously identified in a recrudescent parasite during a Phase IIa clin. study.  We confirmed that this mutation (and the related C276Y) accounted for the full level of obsd. DSM265 resistance by regenerating the mutation using CRISPR/Cas9 genome editing.  X-ray structure anal. of the C276F mutant enzyme showed that conformational changes of nearby residues were required to accommodate the larger F276 residue, which in turn led to a restriction in the size of the DSM265 binding pocket.  These findings underscore the importance of developing DSM265 as part of a combination therapy with other agents for successful use against malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQMMzkCwd_zrVg90H21EOLACvtfcHk0liYxCtq8iMv1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVarurzN&md5=6b9001020d2332016c7f189a6dbe9380</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00211%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DDhingra%26aufirst%3DS.%2BK.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DAfanador%26aufirst%3DG.%2BA.%26aulast%3DLawong%26aufirst%3DA.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26atitle%3DIdentification%2520and%2520mechanistic%2520understanding%2520of%2520dihydroorotate%2520dehydrogenase%2520point%2520mutations%2520in%2520Plasmodium%2520falciparum%2520that%2520confer%2520in%2520vitro%2520resistance%2520to%2520the%2520clinical%2520candidate%2520DSM265%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26issue%3D1%26spage%3D90%26epage%3D101%26doi%3D10.1021%2Facsinfecdis.8b00211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacRae, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creek, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, A. P.</span></span> <span> </span><span class="NLM_article-title">Stage-specific changes in Plasmodium metabolism required for differentiation and adaptation to different host and vector environments</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e1006094</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1006094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.ppat.1006094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28027318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVyisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1006094&issue=12&author=A.+Srivastavaauthor=N.+Philipauthor=K.+R.+Hughesauthor=K.+Georgiouauthor=J.+I.+MacRaeauthor=M.+P.+Barrettauthor=D.+J.+Creekauthor=M.+J.+McConvilleauthor=A.+P.+Waters&title=Stage-specific+changes+in+Plasmodium+metabolism+required+for+differentiation+and+adaptation+to+different+host+and+vector+environments&doi=10.1371%2Fjournal.ppat.1006094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Stage-specific changes in Plasmodium metabolism required for differentiation and adaptation to different host and vector environments</span></div><div class="casAuthors">Srivastava, Anubhav; Philip, Nisha; Hughes, Katie R.; Georgiou, Konstantina; MacRae, James I.; Barrett, Michael P.; Creek, Darren J.; McConville, Malcolm J.; Waters, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1006094/1-e1006094/30</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Malaria parasites (Plasmodium spp.) encounter markedly different (nutritional) environments during their complex life cycles in the mosquito and human hosts.  Adaptation to these different host niches is assocd. with a dramatic rewiring of metab., from a highly glycolytic metab. in the asexual blood stages to increased dependence on tricarboxylic acid (TCA) metab. in mosquito stages.  Here we have used stable isotope labeling, targeted metabolomics and reverse genetics to map stage-specific changes in Plasmodium berghei carbon metab. and det. the functional significance of these changes on parasite survival in the blood and mosquito stages.  We show that glutamine serves as the predominant input into TCA metab. in both asexual and sexual blood stages and is important for complete male gametogenesis.  Glutamine catabolism, as well as key reactions in intermediary metab. and CoA synthesis are also essential for ookinete to oocyst transition in the mosquito.  These data extend our knowledge of Plasmodium metab. and point towards possible targets for transmission-blocking intervention strategies.  Furthermore, they highlight significant metabolic differences between Plasmodium species which are not easily anticipated based on genomics or transcriptomics studies and underline the importance of integration of metabolomics data with other platforms in order to better inform drug discovery and design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2vX-n_xTKWrVg90H21EOLACvtfcHk0liYxCtq8iMv1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVyisLk%253D&md5=1a8476606b4e89170d4521992546d123</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006094%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%26aulast%3DPhilip%26aufirst%3DN.%26aulast%3DHughes%26aufirst%3DK.%2BR.%26aulast%3DGeorgiou%26aufirst%3DK.%26aulast%3DMacRae%26aufirst%3DJ.%2BI.%26aulast%3DBarrett%26aufirst%3DM.%2BP.%26aulast%3DCreek%26aufirst%3DD.%2BJ.%26aulast%3DMcConville%26aufirst%3DM.%2BJ.%26aulast%3DWaters%26aufirst%3DA.%2BP.%26atitle%3DStage-specific%2520changes%2520in%2520Plasmodium%2520metabolism%2520required%2520for%2520differentiation%2520and%2520adaptation%2520to%2520different%2520host%2520and%2520vector%2520environments%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26issue%3D12%26spage%3De1006094%26doi%3D10.1371%2Fjournal.ppat.1006094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Mazouni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomchick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjalanagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazaga, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossignol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span> <span> </span><span class="NLM_article-title">A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">957</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=945-957&issue=12&author=M.+A.+Phillipsauthor=K.+L.+Whiteauthor=S.+Kokkondaauthor=X.+Dengauthor=J.+Whiteauthor=F.+El+Mazouniauthor=K.+Marshauthor=D.+R.+Tomchickauthor=K.+Manjalanagaraauthor=K.+R.+Rudraauthor=G.+Wirjanataauthor=R.+Noviyantiauthor=R.+N.+Priceauthor=J.+Marfurtauthor=D.+M.+Shacklefordauthor=F.+C.+Chiuauthor=M.+Campbellauthor=M.+B.+Jimenez-Diazauthor=S.+F.+Bazagaauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=M.+Lafuente-Monasterioauthor=W.+Kaminskyauthor=K.+Silueauthor=A.+M.+Zeemanauthor=C.+Kockenauthor=D.+Leroyauthor=B.+Blascoauthor=E.+Rossignolauthor=T.+Rueckleauthor=D.+Matthewsauthor=J.+N.+Burrowsauthor=D.+Watersonauthor=M.+J.+Palmerauthor=P.+K.+Rathodauthor=S.+A.+Charman&title=A+triazolopyrimidine-based+dihydroorotate+dehydrogenase+inhibitor+with+improved+drug-like+properties+for+treatment+and+prevention+of+malaria&doi=10.1021%2Facsinfecdis.6b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria</span></div><div class="casAuthors">Phillips, Margaret A.; White, Karen L.; Kokkonda, Sreekanth; Deng, Xiaoyi; White, John; El Mazouni, Farah; Marsh, Kennan; Tomchick, Diana R.; Manjalanagara, Krishne; Rudra, Kakali Rani; Wirjanata, Grennady; Noviyanti, Rintis; Price, Ric N.; Marfurt, Jutta; Shackleford, David M.; Chiu, Francis C. K.; Campbell, Michael; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Inigo; Martinez, Maria Santos; Lafuente-Monasterio, Maria; Kaminsky, Werner; Silue, Kigbafori; Zeeman, Anne-Marie; Kocken, Clemens; Leroy, Didier; Blasco, Benjamin; Rossignol, Emilie; Rueckle, Thomas; Matthews, Dave; Burrows, Jeremy N.; Waterson, David; Palmer, Michael J.; Rathod, Pradipsinh K.; Charman, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">945-957</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistant malaria parasites continues to hamper efforts to control this lethal disease.  Dihydroorotate dehydrogenase has recently been validated as a new target for the treatment of malaria and a selective inhibitor I of the Plasmodium enzyme is currently in clin. development.  With the goal of identifying a backup compd. to I, the authors explored replacement of the SF5-aniline moiety of I with a series of CF3-pyridinyls, while maintaining the core triazolopyrimidine scaffold.  This effort led to the identification of II, which has improved soly., lower intrinsic clearance and increased plasma exposure after oral dosing compared to I, while maintaining a long predicted human half-life.  Its improved phys. and chem. properties will allow it to be formulated more readily than I.  II showed excellent efficacy in the SCID mouse model of P. falciparum malaria that supports the prediction of a low human dose (<200 mg).  Importantly II showed equal activity against both P. falciparum and P. vivax field isolates, while I was more active on P. falciparum.  II has the potential to be developed as a single dose cure or once-weekly chemopreventative for both P. falciparum and P. vivax malaria leading to its advancement as a preclin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE-Pm5_CT2LrVg90H21EOLACvtfcHk0lj89VrpznTG0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWmtbjJ&md5=df58b9d21b75ad84d6181d42a2341e60</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00144%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DKokkonda%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DEl%2BMazouni%26aufirst%3DF.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DTomchick%26aufirst%3DD.%2BR.%26aulast%3DManjalanagara%26aufirst%3DK.%26aulast%3DRudra%26aufirst%3DK.%2BR.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DChiu%26aufirst%3DF.%2BC.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DBazaga%26aufirst%3DS.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%26aulast%3DKaminsky%26aufirst%3DW.%26aulast%3DSilue%26aufirst%3DK.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DKocken%26aufirst%3DC.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DRossignol%26aufirst%3DE.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DMatthews%26aufirst%3DD.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26atitle%3DA%2520triazolopyrimidine-based%2520dihydroorotate%2520dehydrogenase%2520inhibitor%2520with%2520improved%2520drug-like%2520properties%2520for%2520treatment%2520and%2520prevention%2520of%2520malaria%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2016%26volume%3D2%26issue%3D12%26spage%3D945%26epage%3D957%26doi%3D10.1021%2Facsinfecdis.6b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span> <span> </span><span class="NLM_article-title">DSM265 400 mg clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with <i>Plasmodium falciparum</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e01837-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.01837-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01837-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=30858218" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e01837-18&author=K.+A.+Collinsauthor=T.+Ruckleauthor=S.+Elliottauthor=L.+Marquartauthor=E.+Ballardauthor=S.+Chalonauthor=P.+Griffinauthor=J.+J.+Mohrleauthor=J.+S.+McCarthy&title=DSM265+400+mg+clears+asexual+stage+parasites+but+not+mature+gametocytes+from+the+blood+of+healthy+subjects+experimentally+infected+with+Plasmodium+falciparum&doi=10.1128%2FAAC.01837-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1128%2FAAC.01837-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01837-18%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DK.%2BA.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DBallard%26aufirst%3DE.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26atitle%3DDSM265%2520400%2520mg%2520clears%2520asexual%2520stage%2520parasites%2520but%2520not%2520mature%2520gametocytes%2520from%2520the%2520blood%2520of%2520healthy%2520subjects%2520experimentally%2520infected%2520with%2520Plasmodium%2520falciparum%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De01837-18%26doi%3D10.1128%2FAAC.01837-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Díaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibáñez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Doval, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo-Viola, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Improved murine model of malaria using <i>Plasmodium falciparum</i> competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4533</span>– <span class="NLM_lpage">4536</span>, <span class="refDoi"> DOI: 10.1128/AAC.00519-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.00519-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=19596869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=4533-4536&issue=10&author=M.+B.+Jim%C3%A9nez-D%C3%ADazauthor=T.+Muletauthor=S.+Vieraauthor=V.+G%C3%B3mezauthor=H.+Garutiauthor=J.+Ib%C3%A1%C3%B1ezauthor=A.+Alvarez-Dovalauthor=L.+D.+Shultzauthor=A.+Mart%C3%ADnezauthor=D.+Gargallo-Violaauthor=I.+Angulo-Barturen&title=Improved+murine+model+of+malaria+using+Plasmodium+falciparum+competent+strains+and+non-myelodepleted+NOD-scid+IL2Rgammanull+mice+engrafted+with+human+erythrocytes&doi=10.1128%2FAAC.00519-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes</span></div><div class="casAuthors">Jimenez-Diaz, Maria Belen; Mulet, Teresa; Viera, Sara; Gomez, Vanessa; Garuti, Helen; Ibanez, Javier; Alvarez-Doval, Angela; Shultz, Leonard D.; Martinez, Antonio; Gargallo-Viola, Domingo; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4533-4536</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Plasmodium falciparum malaria may become crucial tools in drug discovery.  Here we show that non-myelodepleted NOD-scid IL2Rγnull mice engrafted with human erythrocytes support an infectious burden up to tenfold higher than that supported by engrafted NOD-scid β2microglobulinnull mice.  The new model was validated for drug discovery and was used to assess the therapeutic efficacy of 4-pyridones, selective inhibitors of P. falciparum cytochrome bc1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoGw5NKfthdbVg90H21EOLACvtfcHk0liAV5CssSrpfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KkurbO&md5=df25f5f7382b0b422a9e9b2137a66093</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1128%2FAAC.00519-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00519-09%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-D%25C3%25ADaz%26aufirst%3DM.%2BB.%26aulast%3DMulet%26aufirst%3DT.%26aulast%3DViera%26aufirst%3DS.%26aulast%3DG%25C3%25B3mez%26aufirst%3DV.%26aulast%3DGaruti%26aufirst%3DH.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DJ.%26aulast%3DAlvarez-Doval%26aufirst%3DA.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DGargallo-Viola%26aufirst%3DD.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DImproved%2520murine%2520model%2520of%2520malaria%2520using%2520Plasmodium%2520falciparum%2520competent%2520strains%2520and%2520non-myelodepleted%2520NOD-scid%2520IL2Rgammanull%2520mice%2520engrafted%2520with%2520human%2520erythrocytes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26issue%3D10%26spage%3D4533%26epage%3D4536%26doi%3D10.1128%2FAAC.00519-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haworth, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. J.</span></span> <span> </span><span class="NLM_article-title">Physiologically based pharmacokinetic modeling in lead optimization. 1. Evaluation and adaptation of GastroPlus to predict bioavailability of Medchem series</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00972</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00972" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=821-830&issue=3&author=P.+R.+Dagaauthor=M.+B.+Bolgerauthor=I.+S.+Haworthauthor=R.+D.+Clarkauthor=E.+J.+Martin&title=Physiologically+based+pharmacokinetic+modeling+in+lead+optimization.+1.+Evaluation+and+adaptation+of+GastroPlus+to+predict+bioavailability+of+Medchem+series&doi=10.1021%2Facs.molpharmaceut.7b00972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series</span></div><div class="casAuthors">Daga, Pankaj R.; Bolger, Michael B.; Haworth, Ian S.; Clark, Robert D.; Martin, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">821-830</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">When medicinal chemists need to improve bioavailability (%F) within a chem. series during lead optimization, they synthesize new series members with systematically modified properties mainly by following experience and general rules of thumb.  More quant. models that predict %F of proposed compds. from chem. structure alone have proven elusive.  Global empirical %F quant. structure-property (QSPR) models perform poorly, and projects have too little data to train local %F QSPR models.  Mechanistic oral absorption and physiol. based pharmacokinetic (PBPK) models simulate the dissoln., absorption, systemic distribution, and clearance of a drug in preclin. species and humans.  Attempts to build global PBPK models based purely on calcd. inputs have not achieved the <2-fold av. error needed to guide lead optimization.  In this work, local GastroPlus PBPK models are instead customized for individual medchem series.  The key innovation was building a local QSPR for a numerically fitted effective intrinsic clearance (CLloc).  All inputs are subsequently computed from structure alone, so the models can be applied in advance of synthesis.  Training CLloc on the first 15-18 rat %F measurements gave adequate predictions, with clear improvements up to about 30 measurements, and incremental improvements beyond that.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTTUNr32xw1bVg90H21EOLACvtfcHk0liAV5CssSrpfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsw%253D%253D&md5=c7b89c1733fcb755e16a67ef3843a596</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00972%26sid%3Dliteratum%253Aachs%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DBolger%26aufirst%3DM.%2BB.%26aulast%3DHaworth%26aufirst%3DI.%2BS.%26aulast%3DClark%26aufirst%3DR.%2BD.%26aulast%3DMartin%26aufirst%3DE.%2BJ.%26atitle%3DPhysiologically%2520based%2520pharmacokinetic%2520modeling%2520in%2520lead%2520optimization.%25201.%2520Evaluation%2520and%2520adaptation%2520of%2520GastroPlus%2520to%2520predict%2520bioavailability%2520of%2520Medchem%2520series%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26issue%3D3%26spage%3D821%26epage%3D830%26doi%3D10.1021%2Facs.molpharmaceut.7b00972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruwende, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allsopp, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peschu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newbold, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. V. S.</span></span> <span> </span><span class="NLM_article-title">Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">6537</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1038/376246a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2F376246a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=7617034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADyaK2MXntFSmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=246-249&issue=6537&author=C.+Ruwendeauthor=S.+C.+Khooauthor=R.+W.+Snowauthor=S.+N.+Yatesauthor=D.+Kwiatkowskiauthor=S.+Guptaauthor=P.+Warnauthor=C.+E.+Allsoppauthor=S.+C.+Gilbertauthor=N.+Peschuauthor=C.+I.+Newboldauthor=B.+M.+Greenwoodauthor=K.+Marshauthor=A.+V.+S.+Hill&title=Natural+selection+of+hemi-+and+heterozygotes+for+G6PD+deficiency+in+Africa+by+resistance+to+severe+malaria&doi=10.1038%2F376246a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria</span></div><div class="casAuthors">Ruwende, C.; Khoo, S. C.; Snow, R. W.; Yates, S. N. R.; Kwiatkowski, D.; Gupta, S.; Warn, P.; Allsopp, C. E. M.; Gilbert, S. C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6537</span>),
    <span class="NLM_cas:pages">246-9</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common enzymopathy of humans, affects over 400 million people.  The geog. correlation of its distribution with the historical endemicity of malaria suggests that this disorder has risen in frequency through natural selection by malaria.  However, attempts to confirm that G6PD deficiency is protective in case-control studies of malaria have yielded conflicting results.  Hence, for this X-linked disorder, it is unclear whether both male hemizygotes and female heterozygotes are protected or, as frequently suggested, only females.  Furthermore, how much protection may be afforded is unknown.  Here the authors report that, in two large case-control studies of over 2,000 African children, the common African form of G6PD deficiency (G6PD A-) is assocd. with a 46-58% redn. in risk of severe malaria for both female heterozygotes and male hemizygotes.  A math. model incorporating the measured selective advantage against malaria suggests that a counterbalancing selective disadvantage, assocd. with this enzyme deficiency, has retarded its rise in frequency in malaria-endemic regions.  Although G6PD deficiency is now regarded as a generally benign disorder, in earlier environmental conditions it could have been significantly disadvantageous.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEDjI_LQJXE7Vg90H21EOLACvtfcHk0liAV5CssSrpfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntFSmu74%253D&md5=489a3ff9129219acd7010536069b1553</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2F376246a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376246a0%26sid%3Dliteratum%253Aachs%26aulast%3DRuwende%26aufirst%3DC.%26aulast%3DKhoo%26aufirst%3DS.%2BC.%26aulast%3DSnow%26aufirst%3DR.%2BW.%26aulast%3DYates%26aufirst%3DS.%2BN.%26aulast%3DKwiatkowski%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DWarn%26aufirst%3DP.%26aulast%3DAllsopp%26aufirst%3DC.%2BE.%26aulast%3DGilbert%26aufirst%3DS.%2BC.%26aulast%3DPeschu%26aufirst%3DN.%26aulast%3DNewbold%26aufirst%3DC.%2BI.%26aulast%3DGreenwood%26aufirst%3DB.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DA.%2BV.%2BS.%26atitle%3DNatural%2520selection%2520of%2520hemi-%2520and%2520heterozygotes%2520for%2520G6PD%2520deficiency%2520in%2520Africa%2520by%2520resistance%2520to%2520severe%2520malaria%26jtitle%3DNature%26date%3D1995%26volume%3D376%26issue%3D6537%26spage%3D246%26epage%3D249%26doi%3D10.1038%2F376246a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotharius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekuloski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebrevska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30171-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2817%2930171-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28363636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=626-635&issue=6&author=J.+S.+McCarthyauthor=J.+Lothariusauthor=T.+Ruckleauthor=S.+Chalonauthor=M.+A.+Phillipsauthor=S.+Elliottauthor=S.+Sekuloskiauthor=P.+Griffinauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=L.+Marquartauthor=N.+S.+Williamsauthor=N.+Gobeauauthor=L.+Bebrevskaauthor=M.+Rosarioauthor=K.+Marshauthor=J.+J.+Mohrle&title=Safety%2C+tolerability%2C+pharmacokinetics%2C+and+activity+of+the+novel+long-acting+antimalarial+DSM265%3A+a+two-part+first-in-human+phase+1a%2F1b+randomised+study&doi=10.1016%2FS1473-3099%2817%2930171-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study</span></div><div class="casAuthors">McCarthy, James S.; Lotharius, Julie; Ruckle, Thomas; Chalon, Stephan; Phillips, Margaret A.; Elliott, Suzanne; Sekuloski, Silvana; Griffin, Paul; Ng, Caroline L.; Fidock, David A.; Marquart, Louise; Williams, Noelle S.; Gobeau, Nathalie; Bebrevska, Lidiya; Rosario, Maria; Marsh, Kennan; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis.  We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity.  Healthy participants aged 18-55 years were enrolled in a two-part study: part 1, a single ascending dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised, active-comparator controlled study, in which participants were inoculated with Plasmodium falciparum induced blood-stage malaria (IBSM) and treated with DSM265 (150 mg) or mefloquine (10 mg/kg).  Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics.  Randomisation lists were created using a validated, automated system.  Both parts were registered with the Australian New Zealand Clin. Trials Registry, no. ACTRN12613000522718 (part 1) and no. ACTRN12613000527763 (part 2).  In part 1, 73 participants were enrolled between Apr. 12, 2013, and July 14, 2015 (DSM265, n = 55; placebo, n = 18).  In part 2, nine participants were enrolled between Sept 30 and Nov 25, 2013 (150 mg DSM265, n = 7; 10 mg/kg mefloquine, n = 2).  In part 1, 117 adverse events were reported; no drug-related serious or severe events were reported.  The most common drug-related adverse event was headache.  The mean DSM265 peak plasma concn. (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1.5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.  In part 2, the log10 parasite redn. ratio at 48 h in the DSM265 (150 mg) group was 1.55 (95% CI 1.42-1.67) and in the mefloquine (10 mg/kg) group was 2.34 (2.17-2.52), corresponding to a parasite clearance half-life of 9.4 h (8.7-10.2) and 6.2 h (5.7-6.7), resp.  The median min. inhibitory concn. of DSM265 in blood was estd. as 1040 ng/mL (range 552-1500), resulting in a predicted single efficacious dose of 340 mg.  Parasite clearance was significantly faster in participants who received mefloquine than in participants who received DSM265 (p<0.0001).  The good safety profile, long elimination half-life, and antimalarial effect of DSM265 supports its development as a partner drug in a single-dose antimalarial combination treatment.  Wellcome Trust, UK Department for International Development, Global Health Innovative Technol. Fund, Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc6SKwiEAKqbVg90H21EOLACvtfcHk0lhIwm7ReO4I3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmur8%253D&md5=144cece3cf70a64af921f7f37df7c72d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930171-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930171-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26aulast%3DLotharius%26aufirst%3DJ.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DSekuloski%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DN.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DBebrevska%26aufirst%3DL.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520activity%2520of%2520the%2520novel%2520long-acting%2520antimalarial%2520DSM265%253A%2520a%2520two-part%2520first-in-human%2520phase%25201a%252F1b%2520randomised%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26issue%3D6%26spage%3D626%26epage%3D635%26doi%3D10.1016%2FS1473-3099%2817%2930171-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekuloski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peatey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenholme, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humberstone, A. J.</span></span> <span> </span><span class="NLM_article-title">A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e21914</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0021914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1371%2Fjournal.pone.0021914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21887214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFyrs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21914&issue=8&author=J.+S.+McCarthyauthor=S.+Sekuloskiauthor=P.+M.+Griffinauthor=S.+Elliottauthor=N.+Douglasauthor=C.+Peateyauthor=R.+Rockettauthor=P.+O%E2%80%99Rourkeauthor=L.+Marquartauthor=C.+Hermsenauthor=S.+Duparcauthor=J.+Mohrleauthor=K.+R.+Trenholmeauthor=A.+J.+Humberstone&title=A+pilot+randomised+trial+of+induced+blood-stage+Plasmodium+falciparum+infections+in+healthy+volunteers+for+testing+efficacy+of+new+antimalarial+drugs&doi=10.1371%2Fjournal.pone.0021914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs</span></div><div class="casAuthors">McCarthy, James S.; Sekuloski, Silvana; Griffin, Paul M.; Elliott, Suzanne; Douglas, Nanette; Peatey, Chris; Rockett, Rebecca; O'Rourke, Peter; Marquart, Louise; Hermsen, Cornelius; Duparc, Stephan; Mohrle, Jorg; Trenholme, Katharine R.; Humberstone, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e21914</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Crit. to the development of new drugs for treatment of malaria is the capacity to safely evaluate their activity in human subjects.  The approach that has been most commonly used is testing in subjects with natural malaria infection, a methodol. that may expose symptomatic subjects to the risk of ineffective treatment.  Here we describe the development and pilot testing of a system to undertake exptl. infection using blood stage Plasmodium falciparum parasites (BSP).  The objectives of the study were to assess the feasibility and safety of induced BSP infection as a method for assessment of efficacy of new drug candidates for the treatment of P. falciparum infection.  Methods and Findings: A prospective, unblinded, Phase IIa trial was undertaken in 19 healthy, malaria-naive, male adult volunteers who were infected with BSP and followed with careful clin. and lab. observation, including a sensitive, quant. malaria PCR assay.  Volunteers were randomly allocated to treatment with either of two licensed antimalarial drug combinations, artemether-lumefantrine (A/L) or atovaquone-proguanil (A/P).  In the first cohort (n = 6) where volunteers received ∼360 BSP, none reached the target parasitemia of 1,000 before the day designated for antimalarial treatment (day 6).  In the second and third cohorts, 13 volunteers received 1,800 BSP, with all reaching the target parasitemia before receiving treatment (A/L, n = 6; A/P, n = 7).  The study demonstrated safety in the 19 volunteers tested, and a significant difference in the clearance kinetics of parasitemia between the drugs in the 13 evaluable subjects, with mean parasite redn. ratios of 759 for A/L and 17 for A/P (95% CI 120-4786 and 7-40 resp.; p<0.01).  Conclusions: This system offers a flexible and safe approach to testing the in vivo activity of novel antimalarials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpydB01EN7H4bVg90H21EOLACvtfcHk0lhIwm7ReO4I3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFyrs73I&md5=7673c39450a9daadb2ab7781fa94295e</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021914%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DJ.%2BS.%26aulast%3DSekuloski%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%2BM.%26aulast%3DElliott%26aufirst%3DS.%26aulast%3DDouglas%26aufirst%3DN.%26aulast%3DPeatey%26aufirst%3DC.%26aulast%3DRockett%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DP.%26aulast%3DMarquart%26aufirst%3DL.%26aulast%3DHermsen%26aufirst%3DC.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMohrle%26aufirst%3DJ.%26aulast%3DTrenholme%26aufirst%3DK.%2BR.%26aulast%3DHumberstone%26aufirst%3DA.%2BJ.%26atitle%3DA%2520pilot%2520randomised%2520trial%2520of%2520induced%2520blood-stage%2520Plasmodium%2520falciparum%2520infections%2520in%2520healthy%2520volunteers%2520for%2520testing%2520efficacy%2520of%2520new%2520antimalarial%2520drugs%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D8%26spage%3De21914%26doi%3D10.1371%2Fjournal.pone.0021914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llanos-Cuentas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casapia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuquiyauri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinojosa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toovey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arch, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenberg, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooft
van Huijsduijnen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araeipour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated <i>Plasmodium falciparum</i> or <i>Plasmodium vivax</i> malaria infection: a proof-of-concept, open-label, phase 2a study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30309-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2818%2930309-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29909069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=874-883&issue=8&author=A.+Llanos-Cuentasauthor=M.+Casapiaauthor=R.+Chuquiyauriauthor=J.+C.+Hinojosaauthor=N.+Kerrauthor=M.+Rosarioauthor=S.+Tooveyauthor=R.+H.+Archauthor=M.+A.+Phillipsauthor=F.+D.+Rozenbergauthor=J.+Bathauthor=C.+L.+Ngauthor=A.+N.+Cowellauthor=E.+A.+Winzelerauthor=D.+A.+Fidockauthor=M.+Bakerauthor=J.+J.+Mohrleauthor=R.+Hooft%0Avan+Huijsduijnenauthor=N.+Gobeauauthor=N.+Araeipourauthor=N.+Andenmattenauthor=T.+Ruckleauthor=S.+Duparc&title=Antimalarial+activity+of+single-dose+DSM265%2C+a+novel+plasmodium+dihydroorotate+dehydrogenase+inhibitor%2C+in+patients+with+uncomplicated+Plasmodium+falciparum+or+Plasmodium+vivax+malaria+infection%3A+a+proof-of-concept%2C+open-label%2C+phase+2a+study&doi=10.1016%2FS1473-3099%2818%2930309-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study</span></div><div class="casAuthors">Llanos-Cuentas, Alejandro; Casapia, Martin; Chuquiyauri, Raul; Hinojosa, Juan-Carlos; Kerr, Nicola; Rosario, Maria; Toovey, Stephen; Arch, Robert H.; Phillips, Margaret A.; Rozenberg, Felix D.; Bath, Jade; Ng, Caroline L.; Cowell, Annie N.; Winzeler, Elizabeth A.; Fidock, David A.; Baker, Mark; Mohrle, Jorg J.; Hooft van Huijsduijnen, Rob; Gobeau, Nathalie; Araeipour, Nada; Andenmatten, Nicole; Ruckle, Thomas; Duparc, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">874-883</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum.  This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection.  This proof-of-concept, open-label, phase 2a study was conducted at the Asociacio´n Civil Selva Amazo´nica in Iquitos, Peru.  Patients aged 18-70 years, weighing 45-90 kg, who had clin. malaria (P falciparum or P vivax monoinfection) and fever within the previous 24 h were eligible.  Exclusion criteria were clin. or lab. signs of severe malaria, inability to take oral medicine, and use of other antimalarial treatment in the preceding 14 days.  Patients were divided into cohorts of those with P falciparum (cohort a) or P vivax (cohort b) infection.  Two initial cohorts received single oral doses of 400 mg DSM265.  Patients were followed up for efficacy for 28 days and safety for 35 days.  Further cohorts received escalated or de-escalated doses of DSM265, after safety and efficacy assessment of the initial dose.  The primary endpoints were the proportion of patients achieving PCR-adjusted adequate clin. and parasitol. response (ACPR) by day 14 for patients infected with P falciparum and the proportion of patients achieving a crude cure by day 14 for those infected with P vivax.  Cohort success, the criteria for dose escalation, was defined as ACPR (P falciparum) or crude cure (P vivax) in at least 80% of patients in the cohort.  The primary anal. was done in the intention-to-treat population (ITT) and the per-protocol population, and safety analyses were done in all patients who received the study drug.  This study is registered at ClinicalTrials.gov (NCT02123290).  Between Jan 12, 2015, and Dec 2, 2015, 45 Peruvian patients (24 with P falciparum [cohort a] and 21 with P vivax [cohort b] infection) were sequentially enrolled.  For patients with P falciparum malaria in the per-protocol population, all 11 (100%) in the 400 mg group and eight (80%) of ten in the 250 mg group achieved ACPR on day 14.  In the ITT anal., 11 (85%) of 13 in the 400 mg group and eight (73%) of 11 in the 250 mg group achieved ACPR at day 14.  For the patients with P vivax malaria, the primary endpoint was not met.  In the per-protocol anal., none of four patients who had 400 mg, three (50%) of six who had 600 mg, and one (25%) of four who had 800 mg DSM265 achieved crude cure at day 14.  In the ITT anal., none of five in the 400 mg group, three (33%) of nine in the 600 mg group, and one (14%) of seven in the 800 mg group achieved crude cure at day 14.  During the 28-day extended observation of P falciparum patients, a resistance-assocd. mutation in the gene encoding the DSM265 target DHODH was obsd. in two of four recurring patients.  DSM265 was well tolerated.  The most common adverse events were pyrexia (20 [44%] of 45) and headache (18 [40%] of 45), which are both common symptoms of malaria, and no patients had any treatment-related serious adverse events or adverse events leading to study discontinuation.  After a single dose of DSM265, P falciparum parasitemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics.  Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies.  The Global Health Innovative Technol. Fund, the Bill & Melinda Gates Foundation, the National Institutes of Health (R01 AI103058), the Wellcome Trust, and the UK Department of International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgJbUWoNq8m7Vg90H21EOLACvtfcHk0lhIwm7ReO4I3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqurnI&md5=05eacd75b07eee65fca20ec28ea3c1c4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930309-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930309-8%26sid%3Dliteratum%253Aachs%26aulast%3DLlanos-Cuentas%26aufirst%3DA.%26aulast%3DCasapia%26aufirst%3DM.%26aulast%3DChuquiyauri%26aufirst%3DR.%26aulast%3DHinojosa%26aufirst%3DJ.%2BC.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DRosario%26aufirst%3DM.%26aulast%3DToovey%26aufirst%3DS.%26aulast%3DArch%26aufirst%3DR.%2BH.%26aulast%3DPhillips%26aufirst%3DM.%2BA.%26aulast%3DRozenberg%26aufirst%3DF.%2BD.%26aulast%3DBath%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DCowell%26aufirst%3DA.%2BN.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DHooft%2Bvan%2BHuijsduijnen%26aufirst%3DR.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DAraeipour%26aufirst%3DN.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DDuparc%26aufirst%3DS.%26atitle%3DAntimalarial%2520activity%2520of%2520single-dose%2520DSM265%252C%2520a%2520novel%2520plasmodium%2520dihydroorotate%2520dehydrogenase%2520inhibitor%252C%2520in%2520patients%2520with%2520uncomplicated%2520Plasmodium%2520falciparum%2520or%2520Plasmodium%2520vivax%2520malaria%2520infection%253A%2520a%2520proof-of-concept%252C%2520open-label%252C%2520phase%25202a%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26issue%3D8%26spage%3D874%26epage%3D883%26doi%3D10.1016%2FS1473-3099%2818%2930309-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span> </span><span class="NLM_article-title">DSM265
Phase IIa Investigation Treating <i>Plasmodium falciparum</i> or <i>vivax</i></span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2014</span>;  <span class="NLM_fpage">NCT02123290</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02123290?term=NCT02123290&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02123290?term=NCT02123290&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DSM265%0APhase+IIa+Investigation+Treating+Plasmodium+falciparum+or+vivax.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%2C+2014%3B+NCT02123290%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02123290%3Fterm%3DNCT02123290%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DDSM265%250APhase%2520IIa%2520Investigation%2520Treating%2520Plasmodium%2520falciparum%2520or%2520vivax%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2014%26spage%3DNCT02123290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rangel, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanjee, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw-Saliba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascarenhas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chery, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duraisingh, M. T.</span></span> <span> </span><span class="NLM_article-title">Enhanced ex vivo <i>Plasmodium vivax</i> intraerythrocytic enrichment and maturation for rapid and sensitive parasite growth assays</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e02519-17</span>, <span class="refDoi"> DOI: 10.1128/AAC.02519-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.02519-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29378713" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e02519-17&author=G.+W.+Rangelauthor=M.+A.+Clarkauthor=U.+Kanjeeauthor=C.+Limauthor=K.+Shaw-Salibaauthor=M.+J.+Menezesauthor=A.+Mascarenhasauthor=L.+Cheryauthor=E.+Gomesauthor=P.+K.+Rathodauthor=M.+U.+Ferreiraauthor=M.+T.+Duraisingh&title=Enhanced+ex+vivo+Plasmodium+vivax+intraerythrocytic+enrichment+and+maturation+for+rapid+and+sensitive+parasite+growth+assays&doi=10.1128%2FAAC.02519-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1128%2FAAC.02519-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02519-17%26sid%3Dliteratum%253Aachs%26aulast%3DRangel%26aufirst%3DG.%2BW.%26aulast%3DClark%26aufirst%3DM.%2BA.%26aulast%3DKanjee%26aufirst%3DU.%26aulast%3DLim%26aufirst%3DC.%26aulast%3DShaw-Saliba%26aufirst%3DK.%26aulast%3DMenezes%26aufirst%3DM.%2BJ.%26aulast%3DMascarenhas%26aufirst%3DA.%26aulast%3DChery%26aufirst%3DL.%26aulast%3DGomes%26aufirst%3DE.%26aulast%3DRathod%26aufirst%3DP.%2BK.%26aulast%3DFerreira%26aufirst%3DM.%2BU.%26aulast%3DDuraisingh%26aufirst%3DM.%2BT.%26atitle%3DEnhanced%2520ex%2520vivo%2520Plasmodium%2520vivax%2520intraerythrocytic%2520enrichment%2520and%2520maturation%2520for%2520rapid%2520and%2520sensitive%2520parasite%2520growth%2520assays%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De02519-17%26doi%3D10.1128%2FAAC.02519-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Perez, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legarda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballester, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moncunill, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cistero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zita, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhamuave, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Basteiro, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunasekera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aponte, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinovart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonijoan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, P. L.</span></span> <span> </span><span class="NLM_article-title">Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved <i>Plasmodium falciparum</i> sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">306</span>, <span class="refDoi"> DOI: 10.1186/s12936-015-0817-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-015-0817-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=26245196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC287gtFGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=306&author=G.+P.+Gomez-Perezauthor=A.+Legardaauthor=J.+Munozauthor=B.+K.+Simauthor=M.+R.+Ballesterauthor=C.+Dobanoauthor=G.+Moncunillauthor=J.+J.+Campoauthor=P.+Cisteroauthor=A.+Jimenezauthor=D.+Barriosauthor=B.+Mordmullerauthor=J.+Pardosauthor=M.+Navarroauthor=C.+J.+Zitaauthor=C.+A.+Nhamuaveauthor=A.+L.+Garcia-Basteiroauthor=A.+Sanzauthor=M.+Aldeaauthor=A.+Manojauthor=A.+Gunasekeraauthor=P.+F.+Billingsleyauthor=J.+J.+Aponteauthor=E.+R.+Jamesauthor=C.+Guinovartauthor=R.+M.+Antonijoanauthor=P.+G.+Kremsnerauthor=S.+L.+Hoffmanauthor=P.+L.+Alonso&title=Controlled+human+malaria+infection+by+intramuscular+and+direct+venous+inoculation+of+cryopreserved+Plasmodium+falciparum+sporozoites+in+malaria-naive+volunteers%3A+effect+of+injection+volume+and+dose+on+infectivity+rates&doi=10.1186%2Fs12936-015-0817-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates</span></div><div class="casAuthors">Gomez-Perez Gloria P; Legarda Almudena; Munoz Jose; Dobano Carlota; Moncunill Gemma; Campo Joseph J; Cistero Pau; Jimenez Alfons; Barrios Diana; Pardos Josefina; Navarro Mireia; Garcia-Basteiro Alberto L; Sanz Ariadna; Aldea Marta; Aponte John J; Guinovart Caterina; Alonso Pedro L; Gomez-Perez Gloria P; Sim B Kim Lee; Manoj Anita; Gunasekera Anusha; Billingsley Peter F; James Eric R; Hoffman Stephen L; Ballester Maria Rosa; Antonijoan Rosa M; Ballester Maria Rosa; Antonijoan Rosa M; Campo Joseph J; Mordmuller Benjamin; Kremsner Peter G; Zita Cecilia Justino; Nhamuave Carlos Arlindo; Garcia-Basteiro Alberto L; Aldea Marta; Alonso Pedro L</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">306</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Controlled human malaria infection (CHMI) by mosquito bite is a powerful tool for evaluation of vaccines and drugs against Plasmodium falciparum malaria.  However, only a small number of research centres have the facilities required to perform such studies.  CHMI by needle and syringe could help to accelerate the development of anti-malaria interventions by enabling centres worldwide to employ CHMI.  METHODS:  An open-label CHMI study was performed with aseptic, purified, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) in 36 malaria naive volunteers.  In part A, the effect of the inoculation volume was assessed: 18 participants were injected intramuscularly (IM) with a dose of 2,500 PfSPZ divided into two injections of 10 μL (n = 6), 50 μL (n = 6) or 250 μL (n = 6), respectively.  In part B, the injection volume that resulted in highest infectivity rates in part A (10 μL) was used to formulate IM doses of 25,000 PfSPZ (n = 6) and 75,000 PfSPZ (n = 6) divided into two 10-μL injections.  Results from a parallel trial led to the decision to add a positive control group (n = 6), each volunteer receiving 3,200 PfSPZ in a single 500-μL injection by direct venous inoculation (DVI).  RESULTS:  Four/six participants in the 10-μL group, 1/6 in the 50-μL group and 2/6 in the 250-μL group developed parasitaemia.  Geometric mean (GM) pre-patent periods were 13.9, 14.0 and 15.0 days, respectively.  Six/six (100%) participants developed parasitaemia in the 25,000 and 75,000 PfSPZ IM and 3,200 PfSPZ DVI groups.  GM pre-patent periods were 12.2, 11.4 and 11.4 days, respectively.  Injection of PfSPZ Challenge was well tolerated and safe in all groups.  CONCLUSIONS:  IM injection of 75,000 PfSPZ and DVI injection of 3,200 PfSPZ resulted in infection rates and pre-patent periods comparable to the bite of five PfSPZ-infected mosquitoes.  Remarkably, it required 23.4-fold more PfSPZ administered IM than DVI to achieve the same parasite kinetics.  These results allow for translation of CHMI from research to routine use, and inoculation of PfSPZ by IM and DVI regimens.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT01771848.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwVVux3zYjKRdUSIfHIn4FfW6udTcc2ebYpVltK4yhEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287gtFGmtA%253D%253D&md5=b1cdda3548bcf9921a59681bbe3d4c96</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1186%2Fs12936-015-0817-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-015-0817-x%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Perez%26aufirst%3DG.%2BP.%26aulast%3DLegarda%26aufirst%3DA.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DB.%2BK.%26aulast%3DBallester%26aufirst%3DM.%2BR.%26aulast%3DDobano%26aufirst%3DC.%26aulast%3DMoncunill%26aufirst%3DG.%26aulast%3DCampo%26aufirst%3DJ.%2BJ.%26aulast%3DCistero%26aufirst%3DP.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DBarrios%26aufirst%3DD.%26aulast%3DMordmuller%26aufirst%3DB.%26aulast%3DPardos%26aufirst%3DJ.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DZita%26aufirst%3DC.%2BJ.%26aulast%3DNhamuave%26aufirst%3DC.%2BA.%26aulast%3DGarcia-Basteiro%26aufirst%3DA.%2BL.%26aulast%3DSanz%26aufirst%3DA.%26aulast%3DAldea%26aufirst%3DM.%26aulast%3DManoj%26aufirst%3DA.%26aulast%3DGunasekera%26aufirst%3DA.%26aulast%3DBillingsley%26aufirst%3DP.%2BF.%26aulast%3DAponte%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DE.%2BR.%26aulast%3DGuinovart%26aufirst%3DC.%26aulast%3DAntonijoan%26aufirst%3DR.%2BM.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DAlonso%26aufirst%3DP.%2BL.%26atitle%3DControlled%2520human%2520malaria%2520infection%2520by%2520intramuscular%2520and%2520direct%2520venous%2520inoculation%2520of%2520cryopreserved%2520Plasmodium%2520falciparum%2520sporozoites%2520in%2520malaria-naive%2520volunteers%253A%2520effect%2520of%2520injection%2520volume%2520and%2520dose%2520on%2520infectivity%2520rates%26jtitle%3DMalar.%2520J.%26date%3D2015%26volume%3D14%26spage%3D306%26doi%3D10.1186%2Fs12936-015-0817-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Perez, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ospina Salazar, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joanny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamsfus Calle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohr, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalremruata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunasekera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legarda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonijoan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballester, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span> <span> </span><span class="NLM_article-title">Direct venous inoculation of <i>Plasmodium falciparum</i> sporozoites for controlled human malaria infection: a dose-finding trial in two centres</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">117</span>, <span class="refDoi"> DOI: 10.1186/s12936-015-0628-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1186%2Fs12936-015-0628-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=25889522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A280%3ADC%252BC2MjlvVSlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=117&author=B.+Mordmullerauthor=C.+Supanauthor=K.+L.+Simauthor=G.+P.+Gomez-Perezauthor=C.+L.+Ospina+Salazarauthor=J.+Heldauthor=S.+Bolteauthor=M.+Esenauthor=S.+Tschanauthor=F.+Joannyauthor=C.+Lamsfus+Calleauthor=S.+J.+Lohrauthor=A.+Lalremruataauthor=A.+Gunasekeraauthor=E.+R.+Jamesauthor=P.+F.+Billingsleyauthor=A.+Richmanauthor=S.+Chakravartyauthor=A.+Legardaauthor=J.+Munozauthor=R.+M.+Antonijoanauthor=M.+R.+Ballesterauthor=S.+L.+Hoffmanauthor=P.+L.+Alonsoauthor=P.+G.+Kremsner&title=Direct+venous+inoculation+of+Plasmodium+falciparum+sporozoites+for+controlled+human+malaria+infection%3A+a+dose-finding+trial+in+two+centres&doi=10.1186%2Fs12936-015-0628-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres</span></div><div class="casAuthors">Mordmuller Benjamin; Supan Christian; Ospina Salazar Carmen Lucelly; Held Jana; Bolte Stefanie; Esen Meral; Tschan Serena; Joanny Fanny; Lamsfus Calle Carlos; Lohr Sascha J Z; Lalremruata Albert; Kremsner Peter G; Sim Kim Lee; Gunasekera Anusha; James Eric R; Billingsley Peter F; Richman Adam; Chakravarty Sumana; Hoffman Stephen L; Gomez-Perez Gloria P; Legarda Almudena; Munoz Jose; Alonso Pedro L; Antonijoan Rosa M; Ballester Maria Rosa; Antonijoan Rosa M; Ballester Maria Rosa</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Controlled human malaria infection (CHMI) accelerates development of anti-malarial interventions.  So far, CHMI is done by exposure of volunteers to bites of five mosquitoes carrying Plasmodium falciparum sporozoites (PfSPZ), a technique available in only a few centres worldwide.  Mosquito-mediated CHMI is logistically complex, exact PfSPZ dosage is impossible and live mosquito-based interventions are not suitable for further clinical development.  METHODS:  An open-labelled, randomized, dose-finding study in 18-45 year old, healthy, malaria-naive volunteers was performed to assess if intravenous (IV) injection of 50 to 3,200 aseptic, purified, cryopreserved PfSPZ is safe and achieves infection kinetics comparable to published data of mosquito-mediated CHMI.  An independent study site verified the fully infectious dose using direct venous inoculation of PfSPZ.  Parasite kinetics were assessed by thick blood smear microscopy and quantitative real time PCR.  RESULTS:  IV inoculation with 50, 200, 800, or 3,200 PfSPZ led to parasitaemia in 1/3, 1/3, 7/9, and 9/9 volunteers, respectively.  The geometric mean pre-patent period (GMPPP) was 11.2 days (range 10.5-12.5) in the 3,200 PfSPZ IV group.  Subsequently, six volunteers received 3,200 PfSPZ by direct venous inoculation at an independent investigational site.  All six developed parasitaemia (GMPPP: 11.4 days, range: 10.4-12.3).  Inoculation of PfSPZ was safe.  Infection rate and pre-patent period depended on dose, and injection of 3,200 PfSPZ led to a GMPPP similar to CHMI with five PfSPZ-infected mosquitoes.  The infectious dose of PfSPZ predicted dosage of radiation-attenuated PfSPZ required for successful vaccination.  CONCLUSIONS:  IV inoculation of PfSPZ is safe, well tolerated and highly reproducible.  It shall further accelerate development of anti-malarial interventions through standardization and facilitation of CHMI.  Beyond this, rational dose selection for whole PfSPZ-based immunization and complex study designs are now possible.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT01624961 and NCT01771848 .</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNVDU3Wimq3LHHuJhbyicZfW6udTcc2eZoJIrNd9CDOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjlvVSlug%253D%253D&md5=cb2d519863b13b859152e2a9b696e13c</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2Fs12936-015-0628-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12936-015-0628-0%26sid%3Dliteratum%253Aachs%26aulast%3DMordmuller%26aufirst%3DB.%26aulast%3DSupan%26aufirst%3DC.%26aulast%3DSim%26aufirst%3DK.%2BL.%26aulast%3DGomez-Perez%26aufirst%3DG.%2BP.%26aulast%3DOspina%2BSalazar%26aufirst%3DC.%2BL.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DBolte%26aufirst%3DS.%26aulast%3DEsen%26aufirst%3DM.%26aulast%3DTschan%26aufirst%3DS.%26aulast%3DJoanny%26aufirst%3DF.%26aulast%3DLamsfus%2BCalle%26aufirst%3DC.%26aulast%3DLohr%26aufirst%3DS.%2BJ.%26aulast%3DLalremruata%26aufirst%3DA.%26aulast%3DGunasekera%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DE.%2BR.%26aulast%3DBillingsley%26aufirst%3DP.%2BF.%26aulast%3DRichman%26aufirst%3DA.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DLegarda%26aufirst%3DA.%26aulast%3DMunoz%26aufirst%3DJ.%26aulast%3DAntonijoan%26aufirst%3DR.%2BM.%26aulast%3DBallester%26aufirst%3DM.%2BR.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DAlonso%26aufirst%3DP.%2BL.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26atitle%3DDirect%2520venous%2520inoculation%2520of%2520Plasmodium%2520falciparum%2520sporozoites%2520for%2520controlled%2520human%2520malaria%2520infection%253A%2520a%2520dose-finding%2520trial%2520in%2520two%2520centres%26jtitle%3DMalar.%2520J.%26date%3D2015%26volume%3D14%26spage%3D117%26doi%3D10.1186%2Fs12936-015-0628-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murbeth, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samec, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calle, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granados, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguetse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalremruata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, B. K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">DSM265 for <i>Plasmodium falciparum</i> chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30139-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2FS1473-3099%2817%2930139-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28363637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=636-644&issue=6&author=M.+Sulyokauthor=T.+Ruckleauthor=A.+Rothauthor=R.+E.+Murbethauthor=S.+Chalonauthor=N.+Kerrauthor=S.+S.+Samecauthor=N.+Gobeauauthor=C.+L.+Calleauthor=J.+Ibanezauthor=Z.+Sulyokauthor=J.+Heldauthor=T.+Gebruauthor=P.+Granadosauthor=S.+Brucknerauthor=C.+Nguetseauthor=J.+Mengueauthor=A.+Lalremruataauthor=B.+K.+L.+Simauthor=S.+L.+Hoffmanauthor=J.+J.+Mohrleauthor=P.+G.+Kremsnerauthor=B.+Mordmuller&title=DSM265+for+Plasmodium+falciparum+chemoprophylaxis%3A+a+randomised%2C+double+blinded%2C+phase+1+trial+with+controlled+human+malaria+infection&doi=10.1016%2FS1473-3099%2817%2930139-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection</span></div><div class="casAuthors">Sulyok, Mihaly; Rueckle, Thomas; Roth, Alexandra; Muerbeth, Raymund E.; Chalon, Stephan; Kerr, Nicola; Samec, Sonia Schnieper; Gobeau, Nathalie; Calle, Carlos Lamsfus; Ibanez, Javier; Sulyok, Zita; Held, Jana; Gebru, Tamirat; Granados, Patricia; Brueckner, Sina; Nguetse, Christian; Mengue, Juliana; Lalremruata, Albert; Sim, Kim Lee; Hoffman, Stephen L.; Moehrle, Joerg J.; Kremsner, Peter G.; Mordmueller, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-644</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substantially advance malaria control.  DSM265 is an exptl. antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase.  DSM265 shows in vitro activity against liver and blood stages of P falciparum.  We assessed the prophylactic activity of DSM265 against controlled human malaria infection (CHMI).  At the Institute of Tropical Medicine, Eberhard Karls University (Tubingen, Germany), healthy, malaria-naive adults were allocated to receive 400 mg DSM265 or placebo either 1 day (cohort 1A) or 7 days (cohort 2) before CHMI by direct venous inoculation (DVI) of 3200 aseptic, purified, cryopreserved P falciparum sporozoites (PfSPZ Challenge; Sanaria Inc, Rockville, MD, USA).  An addnl. group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1 day before CHMI (cohort 1B).  Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an interactive web response system.  Allocation to cohort 1A and 1B was open-label, within cohorts 1A and 2, allocation to DSM265 and placebo was double-blinded.  All treatments were given orally.  Volunteers were treated with an antimalarial on day 28, or when parasitemic, as detected by thick blood smear (TBS) microscopy.  The primary efficacy endpoint was time-to-parasitemia, assessed by TBS.  All participants receiving at least one dose of chemoprophylaxis or placebo were considered for safety, those receiving PfSPZ Challenge for efficacy analyzes.  Log-rank test was used to compare time-to-parasitemia between interventions.  The trial was registered with ClinicalTrials.gov, no. NCT02450578.22 participants were enrolled between Oct 23, 2015, and Jan 18, 2016.  Five participants received 400 mg DSM265 and two participants received placebo 1 day before CHMI (cohort 1A), six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and six participants received 400 mg DSM265 and two participants received placebo 7 days before CHMI (cohort 2).  Five of five participants receiving DSM265 1 day before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas placebo recipients (two of two) developed malaria on days 11 and 14.  When given 7 days before CHMI, three of six volunteers receiving DSM265 became TBS pos. on days 11, 13, and 24.  The remaining three DSM265-treated, TBS-neg. participants of cohort 2 developed transient submicroscopic parasitemia.  Both participants receiving placebo 7 days before CHMI became TBS pos. on day 11.  The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin in one participant.  A single dose of 400 mg DSM265 was well tolerated and had causal prophylactic activity when given 1 day before CHMI.  Future trials are needed to investigate further the use of DSM265 for the prophylaxis of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Qz_g361v_rVg90H21EOLACvtfcHk0li1aUQRTqgdaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlWmtbY%253D&md5=17e414f86bbefda108b858930ae28bfc</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930139-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930139-1%26sid%3Dliteratum%253Aachs%26aulast%3DSulyok%26aufirst%3DM.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%26aulast%3DMurbeth%26aufirst%3DR.%2BE.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DSamec%26aufirst%3DS.%2BS.%26aulast%3DGobeau%26aufirst%3DN.%26aulast%3DCalle%26aufirst%3DC.%2BL.%26aulast%3DIbanez%26aufirst%3DJ.%26aulast%3DSulyok%26aufirst%3DZ.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DGebru%26aufirst%3DT.%26aulast%3DGranados%26aufirst%3DP.%26aulast%3DBruckner%26aufirst%3DS.%26aulast%3DNguetse%26aufirst%3DC.%26aulast%3DMengue%26aufirst%3DJ.%26aulast%3DLalremruata%26aufirst%3DA.%26aulast%3DSim%26aufirst%3DB.%2BK.%2BL.%26aulast%3DHoffman%26aufirst%3DS.%2BL.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DDSM265%2520for%2520Plasmodium%2520falciparum%2520chemoprophylaxis%253A%2520a%2520randomised%252C%2520double%2520blinded%252C%2520phase%25201%2520trial%2520with%2520controlled%2520human%2520malaria%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26issue%3D6%26spage%3D636%26epage%3D644%26doi%3D10.1016%2FS1473-3099%2817%2930139-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seilie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbaugher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VonGoedert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappe, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcsisin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andenmatten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueckle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kublin, J. G.</span></span> <span> </span><span class="NLM_article-title">A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic <i>Plasmodium falciparum</i> infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1093%2Finfdis%2Fjix613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29216395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2018&pages=693-702&issue=5&author=S.+C.+Murphyauthor=E.+R.+Dukeauthor=K.+J.+Shipmanauthor=R.+L.+Jensenauthor=Y.+Fongauthor=S.+Fergusonauthor=H.+E.+Janesauthor=K.+Gillespieauthor=A.+M.+Seilieauthor=A.+E.+Hanronauthor=L.+Rinnauthor=M.+Fishbaugherauthor=T.+VonGoedertauthor=E.+Fritzenauthor=S.+H.+Kappeauthor=M.+Changauthor=J.+C.+Sousaauthor=S.+R.+Marcsisinauthor=S.+Chalonauthor=S.+Duparcauthor=N.+Kerrauthor=J.+J.+Mohrleauthor=N.+Andenmattenauthor=T.+Rueckleauthor=J.+G.+Kublin&title=A+randomized+trial+evaluating+the+prophylactic+activity+of+DSM265+against+preerythrocytic+Plasmodium+falciparum+infection+during+controlled+human+malarial+infection+by+mosquito+bites+and+direct+venous+inoculation&doi=10.1093%2Finfdis%2Fjix613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic Plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation</span></div><div class="casAuthors">Murphy, Sean C.; Duke, Elizabeth R.; Shipman, Kelly J.; Jensen, Ryan L.; Fong, Youyi; Ferguson, Sue; Janes, Holly E.; Gillespie, Kevin; Seilie, Annette M.; Hanron, Amelia E.; Rinn, Laurie; Fishbaugher, Matthew; VonGoedert, Tracie; Fritzen, Emma; Kappe, Stefan H.; Chang, Ming; Sousa, Jason C.; Marcsisin, Sean R.; Chalon, Stephan; Duparc, Stephan; Kerr, Nicola; Mohrle, Jorg J.; Andenmatten, Nicole; Rueckle, Thomas; Kublin, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">693-702</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  DSM265 is a selective inhibitor of Plasmodium dihydroorotate dehydrogenase that fully protected against controlled human malarial infection (CHMI) by direct venous inoculation of Plasmodium falciparum sporozoites when administered 1 day before challenge and provided partial protection when administered 7 days before challenge.  Methods.  A double-blinded, randomized, placebo-controlled trial was performed to assess safety, tolerability, pharmacokinetics, and efficacy of 1 oral dose of 400 mg of DSM265 before CHMI.  Three cohorts were studied, with DSM265 administered 3 or 7 days before direct venous inoculation of sporozoites or 7 days before 5 bites from infected mosquitoes.  Results.  DSM265-related adverse events consisted of mild-to-moderate headache and gastrointestinal symptoms.  DSM265 concns. were consistent with pharmacokinetic models (mean area under the curve extrapolated to infinity, 1707 μg*h/mL).  Placebo-treated participants became pos. by quant. reverse transcription-polymerase chain reaction (qRT-PCR) and were treated 7-10 days after CHMI.  Among DSM265-treated subjects, 2 of 6 in each cohort were sterilely protected.  DSM265-treated recipients had longer times to development of parasitemia than placebo-treated participants (P < .004).  Conclusions.  This was the first CHMI study of a novel antimalarial compd. to compare direct venous inoculation of sporozoites and mosquito bites.  Times to qRT-PCR positivity and treatment were comparable for both routes.  DSM265 given 3 or 7 days before CHMI was safe and well tolerated but sterilely protected only one third of participants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMZHT578xgCrVg90H21EOLACvtfcHk0lgIr5UmiV7oGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsFGlsL8%253D&md5=09ad9e8ac99393967ca57e475f2f52bb</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix613%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DS.%2BC.%26aulast%3DDuke%26aufirst%3DE.%2BR.%26aulast%3DShipman%26aufirst%3DK.%2BJ.%26aulast%3DJensen%26aufirst%3DR.%2BL.%26aulast%3DFong%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DS.%26aulast%3DJanes%26aufirst%3DH.%2BE.%26aulast%3DGillespie%26aufirst%3DK.%26aulast%3DSeilie%26aufirst%3DA.%2BM.%26aulast%3DHanron%26aufirst%3DA.%2BE.%26aulast%3DRinn%26aufirst%3DL.%26aulast%3DFishbaugher%26aufirst%3DM.%26aulast%3DVonGoedert%26aufirst%3DT.%26aulast%3DFritzen%26aufirst%3DE.%26aulast%3DKappe%26aufirst%3DS.%2BH.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DSousa%26aufirst%3DJ.%2BC.%26aulast%3DMarcsisin%26aufirst%3DS.%2BR.%26aulast%3DChalon%26aufirst%3DS.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DKerr%26aufirst%3DN.%26aulast%3DMohrle%26aufirst%3DJ.%2BJ.%26aulast%3DAndenmatten%26aufirst%3DN.%26aulast%3DRueckle%26aufirst%3DT.%26aulast%3DKublin%26aufirst%3DJ.%2BG.%26atitle%3DA%2520randomized%2520trial%2520evaluating%2520the%2520prophylactic%2520activity%2520of%2520DSM265%2520against%2520preerythrocytic%2520Plasmodium%2520falciparum%2520infection%2520during%2520controlled%2520human%2520malarial%2520infection%2520by%2520mosquito%2520bites%2520and%2520direct%2520venous%2520inoculation%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D217%26issue%3D5%26spage%3D693%26epage%3D702%26doi%3D10.1093%2Finfdis%2Fjix613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P. F.</span></span> <span> </span><span class="NLM_article-title">The design and application of target-focused compound libraries</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.2174/138620711795767802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.2174%2F138620711795767802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=21521154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=521-531&author=C.+J.+Harrisauthor=R.+D.+Hillauthor=D.+W.+Sheppardauthor=M.+J.+Slaterauthor=P.+F.+Stouten&title=The+design+and+application+of+target-focused+compound+libraries&doi=10.2174%2F138620711795767802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The design and application of target-focused compound libraries</span></div><div class="casAuthors">Harris, C. John; Hill, Richard D.; Sheppard, David W.; Slater, Martin J.; Stouten, Pieter F. W.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">521-531</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Target-focused compd. libraries are collections of compds. which are designed to interact with an individual protein target or, frequently, a family of related targets (such as kinases, voltage-gated ion channels, serine/cysteine proteases).  They are used for screening against therapeutic targets in order to find hit compds. that might be further developed into drugs.  The design of such libraries generally utilizes structural information about the target or family of interest.  In the absence of such structural information, a chemogenomic model that incorporates sequence and mutagenesis data to predict the properties of the binding site can be employed.  A third option, usually pursued when no structural data are available, utilizes knowledge of the ligands of the target from' which focused libraries can be developed via scaffold hopping.  Consequently, the methods used for the design of target-focused libraries vary according to the quantity and quality of structural or ligand data that is available for each target family.  This article describes examples of each of these design approaches and illustrates them with case studies, which highlight some of the issues and successes obsd. when screening target-focused libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKS2t0qb2xBbVg90H21EOLACvtfcHk0lgIr5UmiV7oGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVSmu70%253D&md5=9070e45f5b842fccfee38c15e6cb6127</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.2174%2F138620711795767802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620711795767802%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DHill%26aufirst%3DR.%2BD.%26aulast%3DSheppard%26aufirst%3DD.%2BW.%26aulast%3DSlater%26aufirst%3DM.%2BJ.%26aulast%3DStouten%26aufirst%3DP.%2BF.%26atitle%3DThe%2520design%2520and%2520application%2520of%2520target-focused%2520compound%2520libraries%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2011%26volume%3D14%26spage%3D521%26epage%3D531%26doi%3D10.2174%2F138620711795767802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez
Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabiulla, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">8860</span>– <span class="NLM_lpage">8871</span>, <span class="refDoi"> DOI: 10.1021/jm401278d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401278d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFygurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8860-8871&issue=21&author=Y.+Younisauthor=F.+Douelleauthor=D.+Gonzalez%0ACabreraauthor=C.+Le+Manachauthor=A.+T.+Nchindaauthor=T.+Paquetauthor=L.+J.+Streetauthor=K.+L.+Whiteauthor=K.+M.+Zabiullaauthor=J.+T.+Josephauthor=S.+Bashyamauthor=D.+Watersonauthor=M.+J.+Wittyauthor=S.+Wittlinauthor=S.+A.+Charmanauthor=K.+Chibale&title=Structure-activity-relationship+studies+around+the+2-amino+group+and+pyridine+core+of+antimalarial+3%2C5-diarylaminopyridines+lead+to+a+novel+series+of+pyrazine+analogues+with+oral+in+vivo+activity&doi=10.1021%2Fjm401278d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity-Relationship Studies around the 2 Amino Group and Pyridine Core of Antimalarial 3,5-Diarylaminopyridines Lead to a Novel Series of Pyrazine Analogues with Oral in Vivo Activity</span></div><div class="casAuthors">Younis, Yassir; Douelle, Frederic; Gonzalez Cabrera, Diego; Le Manach, Claire; Nchinda, Aloysius T.; Paquet, Tanya; Street, Leslie J.; White, Karen L.; Zabiulla, K. Mohammed; Joseph, Jayan T.; Bashyam, Sridevi; Waterson, David; Witty, Michael J.; Wittlin, Sergio; Charman, Susan A.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8860-8871</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Replacement of the pyridine core of antimalarial 3,5-diaryl-2-aminopyridines led to the identification of a novel series of pyrazine analogs with potent oral antimalarial activity.  However, other changes to the pyridine core and replacement or substitution of the 2-amino group led to loss of antimalarial activity.  The 3,5-diaryl-2-aminopyrazine series showed impressive in vitro antiplasmodial activity against the K1 (multidrug resistant) and NF54 (sensitive) strains of Plasmodium falciparum in the nanomolar IC50 range of 6-94 nM while also demonstrating good in vitro metabolic stability in human liver microsomes.  In the Plasmodium berghei mouse model, this series generally exhibited good efficacy at low oral doses.  One of the frontrunner compds., (I), displayed potent in vitro antiplasmodial activity with IC50 values of 8.4 and 10 nM against the K1 and NF54 strains, resp.  When evaluated in P. berghei-infected mice, compd. I was completely curative at an oral dose of 4×10 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVhf8mhQH0rVg90H21EOLACvtfcHk0lgIr5UmiV7oGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFygurbF&md5=5ad6dd7f13247c70182bed236dbedaa3</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm401278d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401278d%26sid%3Dliteratum%253Aachs%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DDouelle%26aufirst%3DF.%26aulast%3DGonzalez%2BCabrera%26aufirst%3DD.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DZabiulla%26aufirst%3DK.%2BM.%26aulast%3DJoseph%26aufirst%3DJ.%2BT.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DStructure-activity-relationship%2520studies%2520around%2520the%25202-amino%2520group%2520and%2520pyridine%2520core%2520of%2520antimalarial%25203%252C5-diarylaminopyridines%2520lead%2520to%2520a%2520novel%2520series%2520of%2520pyrazine%2520analogues%2520with%2520oral%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D21%26spage%3D8860%26epage%3D8871%26doi%3D10.1021%2Fjm401278d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez
Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashyam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabiulla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botha, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nondaba, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Identification of a potential antimalarial drug candidate from a series of 2-aminopyrazines by optimization of aqueous solubility and potency across the parasite life cycle</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9890</span>– <span class="NLM_lpage">9905</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01265</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01265" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ylurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9890-9905&issue=21&author=C.+Le+Manachauthor=A.+T.+Nchindaauthor=T.+Paquetauthor=D.+Gonzalez%0ACabreraauthor=Y.+Younisauthor=Z.+Hanauthor=S.+Bashyamauthor=M.+Zabiullaauthor=D.+Taylorauthor=N.+Lawrenceauthor=K.+L.+Whiteauthor=S.+A.+Charmanauthor=D.+Watersonauthor=M.+J.+Wittyauthor=S.+Wittlinauthor=M.+E.+Bothaauthor=S.+H.+Nondabaauthor=J.+Readerauthor=L.+M.+Birkholtzauthor=M.+B.+Jimenez-Diazauthor=M.+S.+Martinezauthor=S.+Ferrerauthor=I.+Angulo-Barturenauthor=S.+Meisterauthor=Y.+Antonova-Kochauthor=E.+A.+Winzelerauthor=L.+J.+Streetauthor=K.+Chibale&title=Identification+of+a+potential+antimalarial+drug+candidate+from+a+series+of+2-aminopyrazines+by+optimization+of+aqueous+solubility+and+potency+across+the+parasite+life+cycle&doi=10.1021%2Facs.jmedchem.6b01265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle</span></div><div class="casAuthors">Le Manach, Claire; Nchinda, Aloysius T.; Paquet, Tanya; Gonzalez Cabrera, Diego; Younis, Yassir; Han, Ze; Bashyam, Sridevi; Zabiulla, Mohammed; Taylor, Dale; Lawrence, Nina; White, Karen L.; Charman, Susan A.; Waterson, David; Witty, Michael J.; Wittlin, Sergio; Botha, Mariette E.; Nondaba, Sindisiswe H.; Reader, Janette; Birkholtz, Lyn-Marie; Jimenez-Diaz, Maria Belen; Martinez, Maria Santos; Ferrer, Santiago; Angulo-Barturen, Inigo; Meister, Stephan; Antonova-Koch, Yevgeniya; Winzeler, Elizabeth A.; Street, Leslie J.; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9890-9905</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Introduction of water-solubilizing groups on the 5-Ph ring of a 2-aminopyrazine series led to the identification of highly potent compds. against the blood life-cycle stage of the human malaria parasite Plasmodium falciparum.  Several compds. displayed high in vivo efficacy in two different mouse models for malaria, P. berghei-infected mice and P. falciparum-infected NOD-scid IL-2Rγnull mice.  One of the front runners, compd. I, was identified to also have good pharmacokinetics, and addnl., very potent activity against the liver and gametocyte parasite life-cycle stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlhtTctb-IjbVg90H21EOLACvtfcHk0lh2j2nPRf3D-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ylurzK&md5=8841bac4d21b51a9b88c0fe844ca8ba0</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01265%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DGonzalez%2BCabrera%26aufirst%3DD.%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DBashyam%26aufirst%3DS.%26aulast%3DZabiulla%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DBotha%26aufirst%3DM.%2BE.%26aulast%3DNondaba%26aufirst%3DS.%2BH.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520a%2520potential%2520antimalarial%2520drug%2520candidate%2520from%2520a%2520series%2520of%25202-aminopyrazines%2520by%2520optimization%2520of%2520aqueous%2520solubility%2520and%2520potency%2520across%2520the%2520parasite%2520life%2520cycle%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9890%26epage%3D9905%26doi%3D10.1021%2Facs.jmedchem.6b01265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschwig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Cabrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nchinda, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herreros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coetzer, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Watt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silue, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">UCT943, a next-generation <i>Plasmodium falciparum</i> PI4K inhibitor preclinical candidate for the treatment of malaria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e00012-18</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1128/AAC.01941-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1128%2FAAC.01941-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=29941635" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00012-18-18&issue=9&author=C.+Brunschwigauthor=N.+Lawrenceauthor=D.+Taylorauthor=E.+Abayauthor=M.+Njorogeauthor=G.+S.+Basarabauthor=C.+Le+Manachauthor=T.+Paquetauthor=D.+Gonzalez-Cabreraauthor=A.+T.+Nchindaauthor=C.+de+Kockauthor=L.+Wiesnerauthor=P.+Dentiauthor=D.+Watersonauthor=B.+Blascoauthor=D.+Leroyauthor=M.+J.+Wittyauthor=C.+Doniniauthor=J.+Duffyauthor=S.+Wittlinauthor=K.+L.+Whiteauthor=S.+A.+Charmanauthor=M.+B.+Jimenez-Diazauthor=I.+Angulo-Barturenauthor=E.+Herrerosauthor=F.+J.+Gamoauthor=R.+Rochfordauthor=D.+Mancamaauthor=T.+L.+Coetzerauthor=M.+E.+van+der+Wattauthor=J.+Readerauthor=L.+M.+Birkholtzauthor=K.+C.+Marshauthor=S.+M.+Solapureauthor=J.+E.+Burkeauthor=J.+A.+McPhailauthor=M.+Vanaerschotauthor=D.+A.+Fidockauthor=P.+V.+Fishauthor=P.+Sieglauthor=D.+A.+Smithauthor=G.+Wirjanataauthor=R.+Noviyantiauthor=R.+N.+Priceauthor=J.+Marfurtauthor=K.+D.+Silueauthor=L.+J.+Streetauthor=K.+Chibale&title=UCT943%2C+a+next-generation+Plasmodium+falciparum+PI4K+inhibitor+preclinical+candidate+for+the+treatment+of+malaria&doi=10.1128%2FAAC.01941-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1128%2FAAC.01941-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01941-18%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschwig%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DAbay%26aufirst%3DE.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DGonzalez-Cabrera%26aufirst%3DD.%26aulast%3DNchinda%26aufirst%3DA.%2BT.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DWiesner%26aufirst%3DL.%26aulast%3DDenti%26aufirst%3DP.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DBlasco%26aufirst%3DB.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DDonini%26aufirst%3DC.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DHerreros%26aufirst%3DE.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DMancama%26aufirst%3DD.%26aulast%3DCoetzer%26aufirst%3DT.%2BL.%26aulast%3Dvan%2Bder%2BWatt%26aufirst%3DM.%2BE.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DSolapure%26aufirst%3DS.%2BM.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DFish%26aufirst%3DP.%2BV.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DSilue%26aufirst%3DK.%2BD.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DUCT943%252C%2520a%2520next-generation%2520Plasmodium%2520falciparum%2520PI4K%2520inhibitor%2520preclinical%2520candidate%2520for%2520the%2520treatment%2520of%2520malaria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26issue%3D9%26spage%3De00012-18%26epage%3D18%26doi%3D10.1128%2FAAC.01941-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manary, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagaring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haasen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tully, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenreider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Plasmodium PI(4)K to eliminate malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span> (<span class="NLM_issue">7479</span>),  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/nature12782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1038%2Fnature12782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=24284631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFaqsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=248-253&issue=7479&author=C.+W.+McNamaraauthor=M.+C.+Leeauthor=C.+S.+Limauthor=S.+H.+Limauthor=J.+Rolandauthor=O.+Simonauthor=B.+K.+Yeungauthor=A.+K.+Chatterjeeauthor=S.+L.+McCormackauthor=M.+J.+Manaryauthor=A.+M.+Zeemanauthor=K.+J.+Decheringauthor=T.+S.+Kumarauthor=P.+P.+Henrichauthor=K.+Gagaringauthor=M.+Ibanezauthor=N.+Katoauthor=K.+L.+Kuhenauthor=C.+Fischliauthor=A.+Nagleauthor=M.+Rottmannauthor=D.+M.+Plouffeauthor=B.+Bursulayaauthor=S.+Meisterauthor=L.+Ramehauthor=J.+Trappeauthor=D.+Haasenauthor=M.+Timmermanauthor=R.+W.+Sauerweinauthor=R.+Suwanaruskauthor=B.+Russellauthor=L.+Reniaauthor=F.+Nostenauthor=D.+C.+Tullyauthor=C.+H.+Kockenauthor=R.+J.+Glynneauthor=C.+Bodenreiderauthor=D.+A.+Fidockauthor=T.+T.+Diaganaauthor=E.+A.+Winzeler&title=Targeting+Plasmodium+PI%284%29K+to+eliminate+malaria&doi=10.1038%2Fnature12782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Plasmodium PI(4)K to eliminate malaria</span></div><div class="casAuthors">McNamara, Case W.; Lee, Marcus C. S.; Lim, Chek Shik; Lim, Siau Hoi; Roland, Jason; Nagle, Advait; Simon, Oliver; Yeung, Bryan K. S.; Chatterjee, Arnab K.; McCormack, Susan L.; Manary, Micah J.; Zeeman, Anne-Marie; Dechering, Koen J.; Kumar, T. R. Santha; Henrich, Philipp P.; Gagaring, Kerstin; Ibanez, Maureen; Kato, Nobutaka; Kuhen, Kelli L.; Fischli, Christoph; Rottmann, Matthias; Plouffe, David M.; Bursulaya, Badry; Meister, Stephan; Rameh, Lucia; Trappe, Joerg; Haasen, Dorothea; Timmerman, Martijn; Sauerwein, Robert W.; Suwanarusk, Rossarin; Russell, Bruce; Renia, Laurent; Nosten, Francois; Tully, David C.; Kocken, Clemens H. M.; Glynne, Richard J.; Bodenreider, Christophe; Fidock, David A.; Diagana, Thierry T.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">7479</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Achieving the goal of malaria elimination will depend on targeting Plasmodium pathways essential across all life stages.  Here the authors identify a lipid kinase, phosphatidylinositol-4-OH kinase (PI(4)K), as the target of imidazopyrazines, a new antimalarial compd. class that inhibits the intracellular development of multiple Plasmodium species at each stage of infection in the vertebrate host.  Imidazopyrazines demonstrate potent preventive, therapeutic, and transmission-blocking activity in rodent malaria models, are active against blood-stage field isolates of the major human pathogens P. falciparum and P. vivax, and inhibit liver-stage hypnozoites in the simian parasite P. cynomolgi.  The authors show that imidazopyrazines exert their effect through inhibitory interaction with the ATP-binding pocket of PI(4)K, altering the intracellular distribution of phosphatidylinositol-4-phosphate.  Collectively, the authors' data define PI(4)K as a key Plasmodium vulnerability, opening up new avenues of target-based discovery to identify drugs with an ideal activity profile for the prevention, treatment and elimination of malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTOmMeWluIubVg90H21EOLACvtfcHk0ljBvy1Tqc3sjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFaqsLzP&md5=9ed8f3e41d257bb4535b4c813abd54cf</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnature12782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12782%26sid%3Dliteratum%253Aachs%26aulast%3DMcNamara%26aufirst%3DC.%2BW.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DLim%26aufirst%3DC.%2BS.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DRoland%26aufirst%3DJ.%26aulast%3DSimon%26aufirst%3DO.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DMcCormack%26aufirst%3DS.%2BL.%26aulast%3DManary%26aufirst%3DM.%2BJ.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DKumar%26aufirst%3DT.%2BS.%26aulast%3DHenrich%26aufirst%3DP.%2BP.%26aulast%3DGagaring%26aufirst%3DK.%26aulast%3DIbanez%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DKuhen%26aufirst%3DK.%2BL.%26aulast%3DFischli%26aufirst%3DC.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DHaasen%26aufirst%3DD.%26aulast%3DTimmerman%26aufirst%3DM.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DTully%26aufirst%3DD.%2BC.%26aulast%3DKocken%26aufirst%3DC.%2BH.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DBodenreider%26aufirst%3DC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DTargeting%2520Plasmodium%2520PI%25284%2529K%2520to%2520eliminate%2520malaria%26jtitle%3DNature%26date%3D2013%26volume%3D504%26issue%3D7479%26spage%3D248%26epage%3D253%26doi%3D10.1038%2Fnature12782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Manach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrich, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagborough, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakutansky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeeman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackleford, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morizzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungtaeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witty, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenreider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkholtz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocken, C. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span> <span> </span><span class="NLM_article-title">Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">387</span>),  <span class="NLM_fpage">eaad9735</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1126%2Fscitranslmed.aad9735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=28446690" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaad9735&issue=387&author=T.+Paquetauthor=C.+Le+Manachauthor=D.+G.+Cabreraauthor=Y.+Younisauthor=P.+P.+Henrichauthor=T.+S.+Abrahamauthor=M.+C.+S.+Leeauthor=R.+Basakauthor=S.+Ghidelli-Disseauthor=M.+J.+Lafuente-Monasterioauthor=M.+Bantscheffauthor=A.+Rueckerauthor=A.+M.+Blagboroughauthor=S.+E.+Zakutanskyauthor=A.+M.+Zeemanauthor=K.+L.+Whiteauthor=D.+M.+Shacklefordauthor=J.+Mannilaauthor=J.+Morizziauthor=C.+Scheurerauthor=I.+Angulo-Barturenauthor=M.+S.+Martinezauthor=S.+Ferrerauthor=L.+M.+Sanzauthor=F.+J.+Gamoauthor=J.+Readerauthor=M.+Bothaauthor=K.+J.+Decheringauthor=R.+W.+Sauerweinauthor=A.+Tungtaengauthor=P.+Vanachayangkulauthor=C.+S.+Limauthor=J.+Burrowsauthor=M.+J.+Wittyauthor=K.+C.+Marshauthor=C.+Bodenreiderauthor=R.+Rochfordauthor=S.+M.+Solapureauthor=M.+B.+Jimenez-Diazauthor=S.+Wittlinauthor=S.+A.+Charmanauthor=C.+Doniniauthor=B.+Campoauthor=L.+M.+Birkholtzauthor=K.+K.+Hansonauthor=G.+Drewesauthor=C.+H.+M.+Kockenauthor=M.+J.+Delvesauthor=D.+Leroyauthor=D.+A.+Fidockauthor=D.+Watersonauthor=L.+J.+Streetauthor=K.+Chibale&title=Antimalarial+efficacy+of+MMV390048%2C+an+inhibitor+of+Plasmodium+phosphatidylinositol+4-kinase&doi=10.1126%2Fscitranslmed.aad9735"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9735%26sid%3Dliteratum%253Aachs%26aulast%3DPaquet%26aufirst%3DT.%26aulast%3DLe%2BManach%26aufirst%3DC.%26aulast%3DCabrera%26aufirst%3DD.%2BG.%26aulast%3DYounis%26aufirst%3DY.%26aulast%3DHenrich%26aufirst%3DP.%2BP.%26aulast%3DAbraham%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DBasak%26aufirst%3DR.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DBlagborough%26aufirst%3DA.%2BM.%26aulast%3DZakutansky%26aufirst%3DS.%2BE.%26aulast%3DZeeman%26aufirst%3DA.%2BM.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMannila%26aufirst%3DJ.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DScheurer%26aufirst%3DC.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DReader%26aufirst%3DJ.%26aulast%3DBotha%26aufirst%3DM.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DTungtaeng%26aufirst%3DA.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DC.%2BS.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DWitty%26aufirst%3DM.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DBodenreider%26aufirst%3DC.%26aulast%3DRochford%26aufirst%3DR.%26aulast%3DSolapure%26aufirst%3DS.%2BM.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonini%26aufirst%3DC.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DBirkholtz%26aufirst%3DL.%2BM.%26aulast%3DHanson%26aufirst%3DK.%2BK.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DKocken%26aufirst%3DC.%2BH.%2BM.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWaterson%26aufirst%3DD.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DAntimalarial%2520efficacy%2520of%2520MMV390048%252C%2520an%2520inhibitor%2520of%2520Plasmodium%2520phosphatidylinositol%25204-kinase%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26issue%3D387%26spage%3Deaad9735%26doi%3D10.1126%2Fscitranslmed.aad9735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=10.1016%2Fj.ejmech.2013.05.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=23811093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SkurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=314-323&author=K.+Singhauthor=H.+Kaurauthor=K.+Chibaleauthor=J.+Balzarini&title=Synthesis+of+4-aminoquinoline-pyrimidine+hybrids+as+potent+antimalarials+and+their+mode+of+action+studies&doi=10.1016%2Fj.ejmech.2013.05.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies</span></div><div class="casAuthors">Singh, Kamaljit; Kaur, Hardeep; Chibale, Kelly; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">314-323</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">One of the most viable options to tackle the growing resistance to the antimalarial drugs such as artemisinin is to resort to synthetic drugs.  The multi-target strategy involving the use of hybrid drugs has shown promise.  In line with this, new hybrids of quinoline with pyrimidine I were synthesized and evaluated for their antiplasmodial activity against both CQS and CQR strains of Plasmodium falciparum.  These depicted activity in nanomolar range and were found to bind to heme and AT rich pUC18 DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OBIjVzVXubVg90H21EOLACvtfcHk0li6bGMnAmpedQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SkurvK&md5=0dd9abed47c0494cf6f29eb76ef47ad9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.046%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DKaur%26aufirst%3DH.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%25204-aminoquinoline-pyrimidine%2520hybrids%2520as%2520potent%2520antimalarials%2520and%2520their%2520mode%2520of%2520action%2520studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D314%26epage%3D323%26doi%3D10.1016%2Fj.ejmech.2013.05.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Quinoline–pyrimidine hybrids: Synthesis, antiplasmodial activity, SAR, and mode of action studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1021/jm4014778</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4014778" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=435-448&issue=2&author=K.+Singhauthor=H.+Kaurauthor=P.+Smithauthor=C.+de+Kockauthor=K.+Chibaleauthor=J.+Balzarini&title=Quinoline%E2%80%93pyrimidine+hybrids%3A+Synthesis%2C+antiplasmodial+activity%2C+SAR%2C+and+mode+of+action+studies&doi=10.1021%2Fjm4014778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Quinoline-Pyrimidine Hybrids: Synthesis, Antiplasmodial Activity, SAR, and Mode of Action Studies</span></div><div class="casAuthors">Singh, Kamaljit; Kaur, Hardeep; Smith, Peter; de Kock, Carmen; Chibale, Kelly; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">435-448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">For the treatment of malaria which affects nearly 200 million people each year and the continued exacerbation by the emergence of drug resistance to most of the available antimalarials, the "covalent bitherapy" suggests hybrid mols. to be the next-generation antimalarial drugs.  In this investigation, new hybrids of 4-aminoquinoline and pyrimidine moieties, e.g., I [A = (CH2)3, "X" = O; X-rays single crystal structure shown], that show antiplasmodial activity in the nM range against chloroquine-resistant as well as chloroquine-sensitive strains of Plasmodium falciparum have been prepd.  Compd. I [A = (CH2)3, "X" = CH2] was found to be the most potent.  Cytotoxicity evaluation and mode of action of most potent hybrid mol. have been conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbZNA9D1VDZ7Vg90H21EOLACvtfcHk0li6bGMnAmpedQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKqtLzL&md5=b233c8922f87a3bc2aa0bd679552660b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fjm4014778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4014778%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DKaur%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DChibale%26aufirst%3DK.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DQuinoline%25E2%2580%2593pyrimidine%2520hybrids%253A%2520Synthesis%252C%2520antiplasmodial%2520activity%252C%2520SAR%252C%2520and%2520mode%2520of%2520action%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D2%26spage%3D435%26epage%3D448%26doi%3D10.1021%2Fjm4014778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span> </span><span class="NLM_article-title">Phase I Study of Ascending Doses of MMV390048
in Healthy Adult Volunteers</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>, <span class="NLM_year" style="font-weight: bold;">2014</span>;  <span class="NLM_fpage">NCT02230579</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02230579?term=NCT02230579&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02230579?term=NCT02230579&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+I+Study+of+Ascending+Doses+of+MMV390048%0Ain+Healthy+Adult+Volunteers.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%2C+2014%3B+NCT02230579%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02230579%3Fterm%3DNCT02230579%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%2520I%2520Study%2520of%2520Ascending%2520Doses%2520of%2520MMV390048%250Ain%2520Healthy%2520Adult%2520Volunteers%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2014%26spage%3DNCT02230579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2C88" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2C88','PDB','2C88'); return false;">PDB: 2C88</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RX0','PDB','4RX0'); return false;">PDB: 4RX0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ENE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ENE','PDB','3ENE'); return false;">PDB: 3ENE</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00761&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00761%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-23" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00761" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a342e38db3dd7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
